FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Clark, CT Sit, DK Driscoll, K Eng, HF Confer, AL Luther, JF Wisniewski, SR Wisner, KL AF Clark, Crystal T. Sit, Dorothy K. Y. Driscoll, Kara Eng, Heather F. Confer, Andrea L. Luther, James F. Wisniewski, Stephen R. Wisner, Katherine L. TI DOES SCREENING WITH THE MDQ AND EPDS IMPROVE IDENTIFICATION OF BIPOLAR DISORDER IN AN OBSTETRICAL SAMPLE? SO DEPRESSION AND ANXIETY LA English DT Article DE postpartum; depression; bipolar; screening; manic-depressive; postnatal ID POSTNATAL DEPRESSION SCALE; POSTPARTUM DEPRESSION; PERINATAL DEPRESSION; QUESTIONNAIRE MDQ; SPECTRUM DISORDER; MOOD; VALIDATION; WOMEN; PREVALENCE; SYMPTOMS AB BackgroundWomen with bipolar disorder (BD) are at high risk for postpartum affective episodes and psychosis. Although validated screening tools are available for postpartum unipolar depression, few screening tools for hypomania/mania exist. Screening tools for BD in the postpartum period are essential for improving detection and planning appropriate treatment. We evaluated whether adding the Mood Disorders Questionnaire (MDQ) to the Edinburgh Postnatal Depression Scale (EPDS) increased the identification of BD in the early postpartum period. MethodsWomen (N = 1,279) who delivered a live infant and screened positive on the EPDS and/or MDQ at 4-6 weeks postbirth were invited to undergo an in-home Structured Clinical Interview for DSM-IV (SCID). ResultsPositive EPDS and/or MDQ screens occurred in 12% of the sample (n = 155). In home SCID diagnostic interviews were completed in 93 (60%) of the mothers with positive screens. BD was the primary diagnosis in 37% (n = 34). Women with BD screened positive on the EPDS and/or MDQ as follows: EPDS+/MDQ+ (n = 14), EPDS+/MDQ- (n = 17), and EPDS-/MDQ+ (n = 3). The MDQ identified 50% (17/34) of the women with BD and 6 additional cases of BD when the MDQ question regarding how impaired the mother perceived herself was excluded from the screen criterion. ConclusionAddition of the MDQ to the EPDS improved the distinction of unipolar depression from bipolar depression at the level of screening in 50% of women with traditional MDQ scoring and by nearly 70% when the MDQ was scored without the impairment criterion. (C) 2015 Wiley Periodicals, Inc. C1 [Clark, Crystal T.; Driscoll, Kara; Wisner, Katherine L.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Asher Ctr Study & Treatment Depress Disorders, Chicago, IL 60611 USA. [Sit, Dorothy K. Y.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Eng, Heather F.; Luther, James F.; Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Epidemiol Data Ctr, Pittsburgh, PA USA. [Confer, Andrea L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Clark, CT (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat, Asher Ctr Study & Treatment Depress Disorders, 676 St Clair,Suite 1000, Chicago, IL 60611 USA. EM crystal.clark@northwestern.edu OI Wisniewski, Stephen/0000-0002-3877-9860 FU Eunice Kennedy Shriver National Institute of Child Health & Human Development [K12 HD055884]; [R01MH071825] FX This work was supported by R01MH071825, Identification and Therapy of Postpartum Depression, Katherine L. Wisner, P.I. Drs. Katherine L. Wisner and Steve Wisniewski, James Luther and Heather Eng had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Crystal Clark is supported in part by Grant Number K12 HD055884 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The authors would like to acknowledge Emily Pinheiro and Stephanie Schuette who arranged the references for this manuscript. NR 48 TC 7 Z9 7 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUL PY 2015 VL 32 IS 7 BP 518 EP 526 DI 10.1002/da.22373 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CL9WZ UT WOS:000357330700007 PM 26059839 ER PT J AU Mueller, AE Segal, DL Gavett, B Marty, MA Yochim, B June, A Coolidge, FL AF Mueller, Anne E. Segal, Daniel L. Gavett, Brandon Marty, Meghan A. Yochim, Brian June, Andrea Coolidge, Frederick L. TI Geriatric Anxiety Scale: item response theory analysis, differential item functioning, and creation of a ten-item short form (GAS-10) SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE geriatric; anxiety assessment; anxiety; item response theory; short form ID OLDER-ADULTS; PSYCHOMETRIC PROPERTIES; GENDER-DIFFERENCES; DEPRESSION; DISORDERS; INVENTORY; LIFE; ASSOCIATION; PREVALENCE; SYMPTOMS AB Background: The Geriatric Anxiety Scale (GAS; Segal et al. (Segal, D. L., June, A., Payne, M., Coolidge, F. L. and Yochim, B. (2010). Journal of Anxiety Disorders, 24, 709-714. doi: 10.1016/j.janxdis.2010.05.002) is a self-report measure of anxiety that was designed to address unique issues associated with anxiety assessment in older adults. This study is the first to use item response theory (IRT) to examine the psychometric properties of a measure of anxiety in older adults. Method: A large sample of older adults (n = 581; mean age = 72.32 years, SD = 7.64 years, range = 60 to 96 years; 64% women; 88% European American) completed the GAS. IRT properties were examined. The presence of differential item functioning (DIF) or measurement bias by age and sex was assessed, and a ten-item short form of the GAS (called the GAS-10) was created. Results: All GAS items had discrimination parameters of 1.07 or greater. Items from the somatic subscale tended to have lower discrimination parameters than items on the cognitive or affective subscales. Two items were flagged for DIF, but the impact of the DIF was negligible. Women scored significantly higher than men on the GAS and its subscales. Participants in the young-old group (60 to 79 years old) scored significantly higher on the cognitive subscale than participants in the old-old group (80 years old and older). Conclusions: Results from the IRT analyses indicated that the GAS and GAS-10 have strong psychometric properties among older adults. We conclude by discussing implications and future research directions. C1 [Mueller, Anne E.] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, Washington, DC USA. [Segal, Daniel L.; Gavett, Brandon; Yochim, Brian; Coolidge, Frederick L.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80918 USA. [Marty, Meghan A.] Transit Profess Ctr, Portland, OR USA. [Yochim, Brian] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, VA Palo Alto Hlth Care Syst, Stanford, CA 94305 USA. [June, Andrea] Cent Connecticut State Univ, Dept Psychol Sci, New Britain, CT 06050 USA. RP Segal, DL (reprint author), Univ Colorado, Dept Psychol, Colorado Springs, CO 80918 USA. EM dsegal@uccs.edu OI Gavett, Brandon/0000-0003-1938-1854 NR 35 TC 3 Z9 3 U1 3 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD JUL PY 2015 VL 27 IS 7 SI SI BP 1099 EP 1111 DI 10.1017/S1041610214000210 PG 13 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA CL5TW UT WOS:000357025400006 PM 24576589 ER PT J AU Reddy, A Pollack, CE Asch, DA Canamucio, A Werner, RM AF Reddy, Ashok Pollack, Craig E. Asch, David A. Canamucio, Anne Werner, Rachel M. TI The Effect of Primary Care Provider Turnover on Patient Experience of Care and Ambulatory Quality of Care SO JAMA INTERNAL MEDICINE LA English DT Article ID MEDICAL HOME; HEALTH-CARE; CONTINUITY; ORGANIZATIONS; SATISFACTION; VETERANS AB IMPORTANCE Primary care provider (PCP) turnover is common and can disrupt patient continuity of care. Little is known about the effect of PCP turnover on patient care experience and quality of care. OBJECTIVE To measure the effect of PCP turnover on patient experiences of care and ambulatory care quality. DESIGN, SETTING, AND PARTICIPANTS Observational, retrospective cohort study of a nationwide sample of primary care patients in the Veterans Health Administration (VHA). We included all patients enrolled in primary care at the VHA between 2010 and 2012 included in 1 of 2 national data sets used to measure our outcome variables: 326 374 patients in the Survey of Healthcare Experiences of Patients (SHEP; used to measure patient experience of care) associated with 8441 PCPs and 184 501 patients in the External Peer Review Program (EPRP; used to measure ambulatory care quality) associated with 6973 PCPs. EXPOSURES Whether a patient experienced PCP turnover, defined as a patient whose provider (physician, nurse practitioner, or physician assistant) had left the VHA (ie, had no patient encounters for 12 months). MAIN OUTCOMES AND MEASURES Five patient care experience measures (from SHEP) and 11 measures of quality of ambulatory care (from EPRP). RESULTS Nine percent of patients experienced a PCP turnover in our study sample. Primary care provider turnover was associated with a worse rating in each domain of patient care experience. Turnover was associated with a reduced likelihood of having a positive rating of their personal physician of 68.2% vs 74.6%(adjusted percentage point difference, -5.3; 95% CI, -6.0 to -4.7) and a reduced likelihood of getting care quickly of 36.5% vs 38.5%(adjusted percentage point difference, -1.1; 95% CI, -2.1 to -0.1). In contrast, PCP turnover was not associated with lower quality of ambulatory care except for a lower likelihood of controlling blood pressure of 78.7% vs 80.4%(adjusted percentage point difference, -1.44; 95% CI, -2.2 to -0.7). In 9 measures of ambulatory care quality, the difference between patients who experienced no PCP turnover and those who had a PCP turnover was less than 1 percentage point. These effects were moderated by the patients' continuity with their PCP prior to turnover, with a larger detrimental effect of PCP turnover among those with higher continuity prior to the turnover. CONCLUSIONS AND RELEVANCE Primary care provider turnover was associated with worse patient experiences of care but did not have a major effect on ambulatory care quality. C1 [Reddy, Ashok; Asch, David A.; Canamucio, Anne; Werner, Rachel M.] Philadelphia VA Med Ctr, VISN Ctr Evaluat PACT 4, Philadelphia, PA USA. [Reddy, Ashok; Asch, David A.; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Reddy, Ashok; Asch, David A.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Reddy, Ashok; Asch, David A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Pollack, Craig E.] Johns Hopkins Sch Med, Baltimore, MD USA. RP Reddy, A (reprint author), Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Perelman Sch Med, Blockley Hall 1303,423 Guardian Dr, Philadelphia, PA 19104 USA. EM ashokr@upenn.edu FU Robert Wood Johnson Foundation Clinical Scholars Program; National Institutes of Health career development award [K07CA151910] FX Dr Reddy was supported by the Robert Wood Johnson Foundation Clinical Scholars Program. Dr Pollack was supported by a National Institutes of Health career development award (K07CA151910). NR 21 TC 6 Z9 6 U1 1 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2015 VL 175 IS 7 BP 1157 EP 1162 DI 10.1001/jamainternmed.2015.1853 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CM3SM UT WOS:000357604400023 PM 25985320 ER PT J AU Ornstein, KA Leff, B Covinsky, KE Ritchie, CS Federman, AD Roberts, L Kelley, AS Siu, AL Szanton, SL AF Ornstein, Katherine A. Leff, Bruce Covinsky, Kenneth E. Ritchie, Christine S. Federman, Alex D. Roberts, Laken Kelley, Amy S. Siu, Albert L. Szanton, Sarah L. TI Epidemiology of the Homebound Population in the United States SO JAMA INTERNAL MEDICINE LA English DT Article ID HOME-BASED PRIMARY; LATE-LIFE DISABILITY; OF-CARE STANDARDS; OLDER PERSONS; HEALTH-CARE; ADULTS; PROGRAM; PREVALENCE; CAREGIVERS; DEPRESSION AB IMPORTANCE Increasing numbers of older, community-dwelling adults have functional impairments that prevent them from leaving their homes. It is uncertain how many people who live in the United States are homebound. OBJECTIVES To develop measures of the frequency of leaving and ability to leave the home and to use these measures to estimate the size of the homebound population in the US population. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional data from the National Health and Aging Trends Study collected in 2011 in the contiguous United States. Participants were a nationally representative sample of 7603 noninstitutionalized Medicare beneficiaries 65 years and older. MAIN OUTCOMES AND MEASURES We defined homebound persons as those who never (completely homebound) or rarely (mostly homebound) left the home in the last month. We defined semihomebound persons as those who only left the home with assistance or had difficulty or needed help leaving the home. We compared demographic, clinical, and health care utilization characteristics across different homebound status categories. RESULTS In 2011, the prevalence of homebound individuals was 5.6%(95% CI, 5.1%-6.2%), including an estimated 395 422 people who were completely homebound and 1 578 984 people who were mostly homebound. Among semihomebound individuals, the prevalence of those who never left home without personal assistance was 3.3%(95% CI, 2.8%-3.8%), and the prevalence of those who required help or had difficulty was 11.7%(95% CI, 10.9%-12.6%). Completely homebound individuals were more likely to be older (83.2 vs 74.3 years, P < .001), female (67.9% vs 53.4%, P < .006), and of nonwhite race (34.1% vs 17.6%, P < .001) and have less education and income than nonhomebound individuals. They also had more chronic conditions (4.9 vs 2.5) and were more likely to have been hospitalized in the last 12 months (52.1% vs 16.2%) (P < .001 for both). Only 11.9% of completely homebound individuals reported receiving primary care services at home. CONCLUSIONS AND RELEVANCE In total, 5.6% of the elderly, community-dwelling Medicare population (approximately 2 million people) were completely or mostly homebound in 2011. Our findings can inform improvements in clinical and social services for these individuals. C1 [Ornstein, Katherine A.; Kelley, Amy S.; Siu, Albert L.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Ornstein, Katherine A.] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA. [Ornstein, Katherine A.; Federman, Alex D.] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA. [Leff, Bruce] Johns Hopkins Univ, Dept Med, Div Geriatr Med, Baltimore, MD USA. [Leff, Bruce; Roberts, Laken; Szanton, Sarah L.] Johns Hopkins Univ, Dept Community & Publ Hlth, Sch Nursing, Baltimore, MD USA. [Leff, Bruce; Szanton, Sarah L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Covinsky, Kenneth E.; Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Kelley, Amy S.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Ornstein, KA (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, POB 1070,1 Gustave L Levy Pl, New York, NY 10029 USA. EM katherine.ornstein@mssm.edu FU National Institute on Aging [NIA U01AG32947, K01AG047923, 1K23AG040774-01A1]; National Palliative Care Research Center; American Federation for Aging Research; Robert Wood Johnson Foundation Nurse Faculty Scholars [69351] FX The National Health and Aging Trends Study is sponsored by grant NIA U01AG32947 from the National Institute on Aging. Dr Ornstein was supported by grant K01AG047923 from the National Institute on Aging and by the National Palliative Care Research Center. Dr Kelley was supported by grant 1K23AG040774-01A1 from the National Institute on Aging and by the American Federation for Aging Research. Dr Szanton was supported by program 69351 from the Robert Wood Johnson Foundation Nurse Faculty Scholars. NR 36 TC 17 Z9 17 U1 1 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2015 VL 175 IS 7 BP 1180 EP 1186 DI 10.1001/jamainternmed.2015.1849 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CM3SM UT WOS:000357604400028 PM 26010119 ER PT J AU Wierman, ME AF Wierman, Margaret E. TI Risks of Different Testosterone Preparations Too Much, Too Little, Just Right SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID THERAPY; MEN C1 [Wierman, Margaret E.] Univ Colorado, Dept Med, Sch Med, Aurora, CO 80045 USA. [Wierman, Margaret E.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO USA. RP Wierman, ME (reprint author), Univ Colorado, Dept Med, Sch Med, 12801 E 17th St,Bldg RC1S,Mail Stop 8106, Aurora, CO 80045 USA. EM margaret.wierman@ucdenver.edu NR 6 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2015 VL 175 IS 7 BP 1197 EP 1198 DI 10.1001/jamainternmed.2015.1580 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CM3SM UT WOS:000357604400030 PM 25961437 ER PT J AU Austin, CA Mohottige, D Sudore, RL Smith, AK Hanson, LC AF Austin, C. Adrian Mohottige, Dinushika Sudore, Rebecca L. Smith, Alexander K. Hanson, Laura C. TI Tools to Promote Shared Decision Making in Serious Illness A Systematic Review SO JAMA INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CARDIOPULMONARY-RESUSCITATION VIDEO; MECHANICAL VENTILATION; CONSORT STATEMENT; FEEDING OPTIONS; CANCER-PATIENTS; INTENSIVE-CARE; BREAST-CANCER; SUPPORT TOOL; AID AB IMPORTANCE Serious illness impairs function and threatens survival. Patients facing serious illness value shared decision making, yet few decision aids address the needs of this population. OBJECTIVE To perform a systematic review of evidence about decision aids and other exportable tools that promote shared decision making in serious illness, thereby (1) identifying tools relevant to the treatment decisions of seriously ill patients and their caregivers, (2) evaluating the quality of evidence for these tools, and (3) summarizing their effect on outcomes and accessibility for clinicians. EVIDENCE REVIEW We searched PubMed, CINAHL, and PsychInfo from January 1, 1995, through October 31, 2014, and identified additional studies from reference lists and other systematic reviews. Clinical trials with random or nonrandom controls were included if they tested print, video, or web-based tools for advance care planning (ACP) or decision aids for serious illness. We extracted data on the study population, design, results, and risk for bias using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. Each tool was evaluated for its effect on patient outcomes and accessibility. FINDINGS Seventeen randomized clinical trials tested decision tools in serious illness. Nearly all the trials were of moderate or high quality and showed that decision tools improve patient knowledge and awareness of treatment choices. The available tools address ACP, palliative care and goals of care communication, feeding options in dementia, lung transplant in cystic fibrosis, and truth telling in terminal cancer. Five randomized clinical trials provided further evidence that decision tools improve ACP documentation, clinical decisions, and treatment received. CONCLUSIONS AND RELEVANCE Clinicians can access and use evidence-based tools to engage seriously ill patients in shared decision making. This field of research is in an early stage; future research is needed to develop novel decision aids for other serious diagnoses and key decisions. Health care delivery organizations should prioritize the use of currently available tools that are evidence based and effective. C1 [Austin, C. Adrian; Hanson, Laura C.] Univ N Carolina, Ctr Aging & Hlth, Div Geriatr, Chapel Hill, NC 27599 USA. [Mohottige, Dinushika] Duke Univ, Dept Med, Durham, NC USA. [Sudore, Rebecca L.; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Sudore, Rebecca L.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hanson, Laura C.] Univ N Carolina, Palliat Care Program, Chapel Hill, NC 27599 USA. RP Hanson, LC (reprint author), Univ N Carolina, Ctr Aging & Hlth, Div Geriatr, 5003 Old Clin Bldg,Campus Box 7550, Chapel Hill, NC 27599 USA. EM laura_hanson@med.unc.edu FU National Institute on Aging [R01AG037483] FX This study was supported by grant R01AG037483 from the National Institute on Aging (principal investigator, Dr Hanson). NR 53 TC 10 Z9 10 U1 11 U2 39 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2015 VL 175 IS 7 BP 1213 EP 1221 DI 10.1001/jamainternmed.2015.1679 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CM3SM UT WOS:000357604400033 PM 25985438 ER PT J AU LaVela, SL Landers, K Etingen, B Karalius, VP Miskevics, S AF LaVela, Sherri L. Landers, Kelsie Etingen, Bella Karalius, Vytas P. Miskevics, Scott TI Factors related to caregiving for individuals with spinal cord injury compared to caregiving for individuals with other neurologic conditions SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Caregiving; Spinal cord injury; Sleep; Coronary heart disease; Obesity ID QUALITY-OF-LIFE; CORONARY-HEART-DISEASE; TRAUMATIC BRAIN-INJURY; SHORT-SLEEP DURATION; FAMILY CAREGIVERS; SPOUSAL CAREGIVERS; HEALTH; DEPRESSION; PEOPLE; BURDEN AB Context/objective: To compare outcomes among caregivers of adults with spinal cord injuries (SCIs) to caregivers of adults with other neurological conditions, and determine if caregiving for SCI is associated with poor health status and chronic conditions. Design: Secondary data analysis of 2009/2010 Behavioral Risk Factor Surveillance System survey. Participants: Informal caregivers of adults with neurological conditions. Outcome measures: Sociodemographics, caregiving factors (e.g. role, emotional support, life satisfaction), lifestyle behaviors, chronic conditions, and health status. Results: Demographics and lifestyle behaviors did not differ in caregivers of adults with SCI vs. caregivers of adults with other neurological conditions (except younger age of SCI caregivers). Greater proportions of caregivers of adults with SCI had coronary heart disease (CHD) (12% vs. 6%, P = 0.06) and were obese (43% vs. 28%, P = 0.03). Frequent physical distress was reported by 20% of caregivers of persons with SCI (vs. 12% of other caregivers, P = 0.09), but mental health did not differ between caregiver groups. A greater proportion of caregivers of adults with SCI experienced insufficient sleep (47% vs. 30%, P = 0.008) and more days without enough sleep (13 vs. 9 days, P = 0.008). Odds of being younger, caregiver of a spouse, having CHD, and being obese were associated with being a caregiver of an adult with SCI. Conclusion: Caregivers of adults with SCI report similar mental health status, but more poor sleep, and have increased odds of CHD and obesity. Interventions to address physical distress, improve sleep, and address CHD and obesity are needed in this cohort. C1 [LaVela, Sherri L.; Landers, Kelsie; Etingen, Bella; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res & Dev, Hines, IL 60141 USA. [LaVela, Sherri L.; Etingen, Bella; Karalius, Vytas P.; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat S, Hines, IL 60141 USA. [LaVela, Sherri L.; Landers, Kelsie; Etingen, Bella; Miskevics, Scott] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Evaluat Practices & Experiences Patient Ctr C, Hines, IL 60141 USA. [LaVela, Sherri L.] Northwestern Univ, Ctr Healthcare Studies, Inst Publ Hlth & Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Karalius, Vytas P.] Loyola Univ, Dept Publ Hlth Sci, Stritch Sch Med, Maywood, IL 60153 USA. RP Etingen, B (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hlth Serv Res & Dev, 151-H,Bldg 1,Off D 322,5th Ave & Roosevelt Rd, Hines, IL 60141 USA. EM Bella.Etingen@va.gov FU Veterans Health Administration, Health Services Research and Development (HSRD) Service [LIP 42-125] FX This work was supported by the Veterans Health Administration, Health Services Research and Development (HSR&D) Service (LIP 42-125). NR 54 TC 0 Z9 0 U1 3 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD JUL PY 2015 VL 38 IS 4 BP 505 EP 514 DI 10.1179/2045772314Y.0000000240 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA CL4RS UT WOS:000356941800013 PM 24993244 ER PT J AU Matsushita, K Coresh, J Sang, YY Chalmers, J Fox, C Guallar, E Jafar, T Jassal, SK Landman, GWD Muntner, P Roderick, P Sairenchi, T Schottker, B Shankar, A Shlipak, M Tonelli, M Townend, J van Zuilen, A Yamagishi, K Yamashita, K Gansevoort, R Sarnak, M Warnock, DG Woodward, M Arnlov, J AF Matsushita, Kunihiro Coresh, Josef Sang, Yingying Chalmers, John Fox, Caroline Guallar, Eliseo Jafar, Tazeen Jassal, Simerjot K. Landman, Gijs W. D. Muntner, Paul Roderick, Paul Sairenchi, Toshimi Schoettker, Ben Shankar, Anoop Shlipak, Michael Tonelli, Marcello Townend, Jonathan van Zuilen, Arjan Yamagishi, Kazumasa Yamashita, Kentaro Gansevoort, Ron Sarnak, Mark Warnock, David G. Woodward, Mark Arnlov, Johan CA CKD Prognosis Consortium TI Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; ARTERY-DISEASE; CYSTATIN C; RISK; CREATININE; MORTALITY; HEART; CKD; ASSOCIATION; EQUATION AB Background The usefulness of estimated glomerular filtration rate (eGFR) and albuminuria for prediction of cardiovascular outcomes is controversial. We aimed to assess the addition of creatinine-based eGFR and albuminuria to traditional risk factors for prediction of cardiovascular risk with a meta-analytic approach. Methods We meta-analysed individual-level data for 637 315 individuals without a history of cardiovascular disease from 24 cohorts (median follow-up 4.2-19.0 years) included in the Chronic Kidney Disease Prognosis Consortium. We assessed C statistic difference and reclassification improvement for cardiovascular mortality and fatal and non-fatal cases of coronary heart disease, stroke, and heart failure in a 5 year timeframe, contrasting prediction models for traditional risk factors with and without creatinine-based eGFR, albuminuria (either albumin-to-creatinine ratio [ACR] or semi-quantitative dipstick proteinuria), or both. Findings The addition of eGFR and ACR significantly improved the discrimination of cardiovascular outcomes beyond traditional risk factors in general populations, but the improvement was greater with ACR than with eGFR, and more evident for cardiovascular mortality (C statistic difference 0.0139 [95% CI 0.0105- 0.0174] for ACR and 0.0065 [0.0042-0.0088] for eGFR) and heart failure (0.0196 [0.0108-0.0284] and 0.0109 [0.0059-0.0159]) than for coronary disease (0.0048 [0.0029-0.0067] and 0.0036 [0.0019-0.0054]) and stroke (0.0105 [0.0058-0.0151]and 0.0036 [0.0004-0.0069]). Dipstick proteinuria showed smaller improvement than ACR. The discrimination improvement with eGFR or ACR was especially evident in individuals with diabetes or hypertension, but remained significant with ACR for cardiovascular mortality and heart failure in those without either of these disorders. In individuals with chronic kidney disease, the combination of eGFR and ACR for risk discrimination outperformed most single traditional predictors; the C statistic for cardiovascular mortality fell by 0.0227 (0.0158-0.0296) after omission of eGFR and ACR compared with less than 0.007 for any single modifiable traditional predictor. Interpretation Creatinine-based eGFR and albuminuria should be taken into account for cardiovascular prediction, especially when these measures are already assessed for clinical purpose or if cardiovascular mortality and heart failure are outcomes of interest. ACR could have particularly broad implications for cardiovascular prediction. In populations with chronic kidney disease, the simultaneous assessment of eGFR and ACR could facilitate improved classification of cardiovascular risk, supporting current guidelines for chronic kidney disease. Our results lend some support to also incorporating eGFR and ACR into assessments of cardiovascular risk in the general population. C1 [Matsushita, Kunihiro; Coresh, Josef; Sang, Yingying; Guallar, Eliseo; Woodward, Mark] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Chalmers, John; Woodward, Mark] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia. [Fox, Caroline] NHLBI, Framingham Heart Study & Ctr Populat Studies, Framingham, MA USA. [Jafar, Tazeen] Duke NUS Grad Med Sch, Singapore, Singapore. [Jassal, Simerjot K.] VA San Diego Healthcare, San Diego, CA USA. [Jassal, Simerjot K.] Univ Calif San Diego, San Diego, CA 92103 USA. [Landman, Gijs W. D.] Isala Hosp, Diabet Ctr Zwolle, Zwolle, Netherlands. [Muntner, Paul; Warnock, David G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Roderick, Paul] Univ Southampton, Fac Med, Primary Care & Populat Sci, Southampton SO9 5NH, Hants, England. [Sairenchi, Toshimi] Dokkyo Med Univ, Sch Med, Dept Publ Hlth, Shimotsuga, Tochigi, Japan. [Schoettker, Ben] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Shlipak, Michael] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA. [Shlipak, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada. [Townend, Jonathan] Queen Elizabeth Hosp, Dept Cardiol, Birmingham B15 2TH, W Midlands, England. [van Zuilen, Arjan] Univ Utrecht, Med Ctr, Dept Hypertens & Nephrol, Utrecht, Netherlands. [Yamagishi, Kazumasa] Univ Tsukuba, Fac Med, Dept Publ Hlth Med, Tsukuba, Ibaraki, Japan. [Yamashita, Kentaro] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4648601, Japan. [Gansevoort, Ron] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands. [Sarnak, Mark] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England. [Arnlov, Johan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Studies, Falun, Sweden. RP Coresh, J (reprint author), Data Coordinating Ctr, Chron Kidney Dis Prognosis Consortium, Baltimore, MD 21205 USA. EM ckdpc@jhmi.edu RI ; Wetzels, Jack/A-1720-2014; Woodward, Mark/D-8492-2015; Tonelli, Marcello/B-3028-2009; Brenner, Hermann/B-4627-2017; Moyes, Simon/D-2574-2017; Stengel, Benedicte/G-5730-2015 OI yamagishi, kazumasa/0000-0003-3301-5519; Brenner, Hermann/0000-0002-6129-1572; Moyes, Simon/0000-0001-9580-1545; Emberson, Jonathan/0000-0001-7792-9422; Grams, Morgan/0000-0002-4430-6023; Kenealy, Timothy/0000-0001-6002-4766 FU US National Kidney Foundation; National Institute of Diabetes and Digestive and Kidney Diseases FX US National Kidney Foundation, National Institute of Diabetes and Digestive and Kidney Diseases. NR 33 TC 58 Z9 59 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD JUL PY 2015 VL 3 IS 7 BP 514 EP 525 DI 10.1016/S2213-8587(15)00040-6 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CM1DC UT WOS:000357419500027 PM 26028594 ER PT J AU Kelly, VE Johnson, CO McGough, EL Shumway-Cook, A Horak, FB Chung, KA Espay, AJ Revilla, FJ Devoto, J Wood-Siverio, C Factor, SA Cholerton, B Edwards, KL Peterson, AL Quinn, JF Montine, TJ Zabetian, CP Leverenz, JB AF Kelly, V. E. Johnson, C. O. McGough, E. L. Shumway-Cook, A. Horak, F. B. Chung, K. A. Espay, A. J. Revilla, F. J. Devoto, J. Wood-Siverio, C. Factor, S. A. Cholerton, B. Edwards, K. L. Peterson, A. L. Quinn, J. F. Montine, T. J. Zabetian, C. P. Leverenz, J. B. TI Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Cognition; Executive function; Balance; Gait; Freezing of gait ID RATING-SCALE; DEMENTIA; IMPAIRMENT; GAIT; DYSFUNCTION; FEATURES; COHORT AB Introduction: Research suggests an association between global cognition and postural instability/gait disturbance (PIGD) in Parkinson disease (PD), but the relationship between specific cognitive domains and PIGD symptoms is not clear. This study examined the association of cognition (global and specific cognitive domains) with PIGD symptoms in a large, well-characterized sample of individuals with PD. Methods: Cognitive function was measured with a detailed neuropsychological assessment, including global cognition, executive function, memory, visuospatial function, and language. PIGD symptoms were measured using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, Motor Examination subscale. Multiple linear regression analyses were performed to assess the relationship between cognition and PIGD symptoms with models adjusting for age, sex, education, enrollment site, disease duration, and motor symptom severity. Results: The analysis included 783 participants, with mean (standard deviation) age of 67.3 (9.7) years and median (interquartile range) MDS-UPDRS Motor Subscale score of 26 (17, 35). Deficits in global cognition, executive function, memory, and phonemic fluency were associated with more severe PIGD symptoms. Deficits in executive function were associated with impairments in gait, freezing, and postural stability, while visuospatial impairments were associated only with more severe freezing, and poorer memory function was associated only with greater postural instability. Discussion: While impairments in global cognition and aspects of executive functioning were associated with more severe PIGD symptoms, specific cognitive domains were differentially related to distinct PIGD components, suggesting the presence of multiple neural pathways contributing to associations between cognition and PIGD symptoms in persons with PD. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Kelly, V. E.; McGough, E. L.; Shumway-Cook, A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Johnson, C. O.; Edwards, K. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Horak, F. B.; Chung, K. A.; Peterson, A. L.; Quinn, J. F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Horak, F. B.; Chung, K. A.; Peterson, A. L.] Portland VA Med Ctr, Portland, OR USA. [Espay, A. J.; Revilla, F. J.; Devoto, J.] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA. [Revilla, F. J.] Greenville Hlth Syst, Div Neurol, Greenville, SC USA. [Revilla, F. J.] Univ S Carolina, Sch Med, Greenville, SC USA. [Wood-Siverio, C.; Factor, S. A.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Cholerton, B.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Cholerton, B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Edwards, K. L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. [Montine, T. J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Zabetian, C. P.] Vet Affairs Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, C. P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, J. B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. RP Kelly, VE (reprint author), 1959 NE Pacific St,Box 356490, Seattle, WA USA. EM vekelly@u.washington.edu; johnsoco@uw.edu; emcg@uw.edu; ashumway@uw.edu; horakf@ohsu.edu; chungka@ohsu.edu; alberto.espay@uc.edu; fredy.revilla@uc.edu; devotoj@ucmail.uc.edu; cwoodsi@emory.edu; sfactor@emory.edu; bchol@uw.edu; kedwardl@uci.edu; peterami@ohsu.edu; quinnj@ohsu.edu; tmontine@uw.edu; zabetian@u.washington.edu; leverej@ccf.org OI Kelly, Valerie E./0000-0002-0099-9219 FU Department of Veterans Affairs from American Parkinson Disease Association; National Institutes of Health [P50 NS062684, R01 NS065070]; Consolidated Anti-Aging Foundation; Jane and Lee Seidman Fund FX This work was supported by the Department of Veterans Affairs, grants from the American Parkinson Disease Association, National Institutes of Health (P50 NS062684 and R01 NS065070), Consolidated Anti-Aging Foundation, and the Jane and Lee Seidman Fund. The funding sources did not provide scientific input for this study. NR 28 TC 15 Z9 15 U1 4 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JUL PY 2015 VL 21 IS 7 BP 692 EP 697 DI 10.1016/j.parkreldis.2015.04.002 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CM0HW UT WOS:000357360000004 PM 25943529 ER PT J AU Begum, G Yuan, H Kahle, KT Li, LL Wang, SX Shi, YJ Shmukler, BE Yang, SS Lin, SH Alper, SL Sun, DD AF Begum, Gulnaz Yuan, Hui Kahle, Kristopher T. Li, Liaoliao Wang, Shaoxia Shi, Yejie Shmukler, Boris E. Yang, Sung-Sen Lin, Shih-Hua Alper, Seth L. Sun, Dandan TI Inhibition of WNK3 Kinase Signaling Reduces Brain Damage and Accelerates Neurological Recovery After Stroke SO STROKE LA English DT Article DE bumetanide; KCC2 cotransporter; NKCC1 cotransporter; OSR1 kinase; SPAK Kinase ID FOCAL CEREBRAL-ISCHEMIA; K+-CL-COTRANSPORTER; NA-K-2CL COTRANSPORTER; BLOOD-PRESSURE; CELL-VOLUME; MEDIATED EXCITOTOXICITY; MOLECULAR PHYSIOLOGY; NA+/CA2+ EXCHANGER; ARTERY OCCLUSION; PROTEIN-KINASES AB Background and Purpose WNK kinases, including WNK3, and the associated downstream Ste20/SPS1-related proline-alanine-rich protein kinase (SPAK) and oxidative stress responsive 1 (OSR1) kinases, comprise an important signaling cascade that regulates the cation-chloride cotransporters. Ischemia-induced stimulation of the bumetanide-sensitive Na+-K+-Cl- cotransporter (NKCC1) plays an important role in the pathophysiology of experimental stroke, but the mechanism of its regulation in this context is unknown. Here, we investigated the WNK3-SPAK/OSR1 pathway as a regulator of NKCC1 stimulation and their collective role in ischemic brain damage. Method Wild-type WNK3 and WNK3 knockout mice were subjected to ischemic stroke via transient middle cerebral artery occlusion. Infarct volume, brain edema, blood brain barrier damage, white matter demyelination, and neurological deficits were assessed. Total and phosphorylated forms of WNK3 and SPAK/OSR1 were assayed by immunoblotting and immunostaining. In vitro ischemia studies in cultured neurons and immature oligodendrocytes were conducted using the oxygen-glucose deprivation/reoxygenation method. Results WNK3 knockout mice exhibited significantly decreased infarct volume and axonal demyelination, less cerebral edema, and accelerated neurobehavioral recovery compared with WNK3 wild-type mice subjected to middle cerebral artery occlusion. The neuroprotective phenotypes conferred by WNK3 knockout were associated with a decrease in stimulatory hyperphosphorylations of the SPAK/OSR1 catalytic T-loop and of NKCC1 stimulatory sites Thr(203)/Thr(207)/Thr(212), as well as with decreased cell surface expression of NKCC1. Genetic inhibition of WNK3 or small interfering RNA knockdown of SPAK/OSR1 increased the tolerance of cultured primary neurons and oligodendrocytes to in vitro ischemia. Conclusions These data identify a novel role for the WNK3-SPAK/OSR1-NKCC1 signaling pathway in ischemic neuroglial injury and suggest the WNK3-SPAK/OSR1 kinase pathway as a therapeutic target for neuroprotection after ischemic stroke. C1 [Begum, Gulnaz; Yuan, Hui; Li, Liaoliao; Wang, Shaoxia; Shi, Yejie; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Kahle, Kristopher T.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA USA. [Kahle, Kristopher T.] Harvard Univ, Sch Med, Manton Ctr Orphan Dis, Boston, MA USA. [Shmukler, Boris E.; Alper, Seth L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Shmukler, Boris E.; Alper, Seth L.] Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA. [Shmukler, Boris E.; Alper, Seth L.] Beth Israel Deaconess Med Ctr, Vasc Biol Ctr, Boston, MA 02215 USA. [Yang, Sung-Sen; Lin, Shih-Hua] Natl Def Med Ctr, Triserv Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Sun, DD (reprint author), Univ Pittsburgh, Dept Neurol, S-598 S Biomed Sci Tower BST,3500 Terranc St, Pittsburgh, PA 15213 USA. EM sund@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU National Institute of Health [R01 NS038118, R01 HL07765, R25]; Manton Center for Orphan Disease Research; Harvard-MIT Basic Neuroscience Award; Ministry of Science and Technology, Taiwan FX This study was supported by the National Institute of Health Grants R01 NS038118 (Dr Sun) and R01 HL07765 (Dr Alper) and R25 (Dr Kahle), and the Manton Center for Orphan Disease Research (Dr Kahle), and a Harvard-MIT Basic Neuroscience Award (Dr Kahle), and the Ministry of Science and Technology, Taiwan (Dr Yang). NR 54 TC 10 Z9 10 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD JUL PY 2015 VL 46 IS 7 BP 1956 EP 1965 DI 10.1161/STROKEAHA.115.008939 PG 10 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CL0ZY UT WOS:000356672800030 PM 26069258 ER PT J AU Liebeskind, DS Albers, GW Crawford, K Derdeyn, CP George, MS Palesch, YY Toga, AW Warach, S Zhao, WL Brott, TG Sacco, RL Khatri, P Saver, JL Cramer, SC Wolf, SL Broderick, JP Wintermark, M AF Liebeskind, David S. Albers, Gregory W. Crawford, Karen Derdeyn, Colin P. George, Mark S. Palesch, Yuko Y. Toga, Arthur W. Warach, Steven Zhao, Wenle Brott, Thomas G. Sacco, Ralph L. Khatri, Pooja Saver, Jeffrey L. Cramer, Steven C. Wolf, Steven L. Broderick, Joseph P. Wintermark, Max TI Imaging in StrokeNet Realizing the Potential of Big Data SO STROKE LA English DT Article DE collateral circulation; diagnostic imaging; stroke ID ACUTE ISCHEMIC-STROKE; TRIALS; REPERFUSION; COLLATERALS; DIFFUSION; STANDARDS; DISEASE; PROFILE; DEFUSE C1 [Liebeskind, David S.] Univ Calif Los Angeles, Neurovasc Imaging Res Core, Los Angeles, CA 90095 USA. [Liebeskind, David S.; Saver, Jeffrey L.] Univ Calif Los Angeles, Geffen Sch Med, Comprehens Stroke Ctr, Dept Neurol, Los Angeles, CA 90095 USA. [Albers, Gregory W.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA. [Wintermark, Max] Stanford Univ, Dept Radiol, Palo Alto, CA 94304 USA. [Crawford, Karen; Toga, Arthur W.] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Lab Neuro Imaging, Los Angeles, CA 90033 USA. [Derdeyn, Colin P.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Dept Neurol, St Louis, MO 63110 USA. [Derdeyn, Colin P.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Dept Neurol Surg, St Louis, MO 63110 USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat Radiol & Neurosci, Charleston, SC 29425 USA. [Palesch, Yuko Y.; Zhao, Wenle] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Warach, Steven] Univ Texas SW Med Ctr Dallas, Austin, TX USA. [Brott, Thomas G.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Coral Gables, FL 33124 USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Human Genet, Coral Gables, FL 33124 USA. [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Dept Neurosurg, Coral Gables, FL 33124 USA. [Khatri, Pooja; Broderick, Joseph P.] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45221 USA. [Cramer, Steven C.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA. [Wolf, Steven L.] Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA 30322 USA. [Wolf, Steven L.] Atlanta VA Med Ctr, Ctr Visual & Cognit Neurorehabil, Atlanta, GA USA. RP Liebeskind, DS (reprint author), Univ Calif Los Angeles, Dept Neurol, Neurovasc Imaging Res Core, Neurosci Res Bldg,635 Charles E Young Dr S, Los Angeles, CA 90095 USA. EM davidliebeskind@yahoo.com OI Derdeyn, Colin/0000-0002-5932-2683 FU National Institutes of Health-National Institute of Neurological Disorders and Stroke [U01NS087748, K24NS072272, R01NS077706, R13NS089280] FX This work has been funded by National Institutes of Health-National Institute of Neurological Disorders and Stroke awards U01NS087748, K24NS072272, R01NS077706, and R13NS089280. NR 25 TC 3 Z9 3 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD JUL PY 2015 VL 46 IS 7 BP 2000 EP 2006 DI 10.1161/STROKEAHA.115.009479 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA CL0ZY UT WOS:000356672800039 PM 26045600 ER PT J AU Meredith, ME Salameh, TS Banks, WA AF Meredith, M. Elizabeth Salameh, Therese S. Banks, William A. TI Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases SO AAPS JOURNAL LA English DT Review DE blood-brain barrier; cognition; intranasal; memory ID GALANIN-LIKE PEPTIDE; BLOOD-BRAIN-BARRIER; GLUCAGON-LIKE PEPTIDE-1; CYCLASE-ACTIVATING POLYPEPTIDE; MILD COGNITIVE IMPAIRMENT; CENTRAL-NERVOUS-SYSTEM; NASAL DRUG-DELIVERY; ADENYLATE-CYCLASE; ALZHEIMERS-DISEASE; ACETYLCHOLINE-RELEASE AB The blood-brain barrier (BBB) is a major impediment to the therapeutic delivery of peptides and proteins to the brain. Intranasal delivery often provides a non-invasive means to bypass the BBB. Advantages of using intranasal delivery include minimizing exposure to peripheral organs and tissues, thus reducing systemic side effects. It also allows substances that typically have rapid degradation in the blood time to exert their effect. Intranasal delivery provides the ability to target proteins and peptides to specific regions of the brain when administered with substrates like cyclodextrins. In this review, we examined the use of intranasal delivery of various proteins and peptides that have implications in the treatment of neurodegenerative diseases, focusing especially on albumin, exendin/GLP-1, GALP, insulin, leptin, and PACAP. We have described their rationale for use, distribution in the brain after intranasal injection, how intranasal administration differed from other modes of delivery, and their use in clinical trials, if applicable. Intranasal delivery of drugs, peptides, and other proteins could be very useful in the future for the prevention or treatment of brain related diseases. C1 [Meredith, M. Elizabeth] Univ Washington, Dept Pathol, Seattle, WA 98108 USA. [Meredith, M. Elizabeth; Salameh, Therese S.; Banks, William A.] Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med,VAPSHCS, Seattle, WA 98108 USA. [Meredith, M. Elizabeth; Salameh, Therese S.; Banks, William A.] Univ Washington, Geriatr Res Educ & Clin Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Banks, WA (reprint author), Univ Washington, Sch Med, Div Gerontol & Geriatr Med, Dept Med,VAPSHCS, 1660S Columbian Way,810A Bldg 1, Seattle, WA 98108 USA. EM bankswa@slu.edu FU NIA NIH HHS [T32 AG000057] NR 73 TC 13 Z9 14 U1 6 U2 26 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1550-7416 J9 AAPS J JI AAPS J. PD JUL PY 2015 VL 17 IS 4 BP 780 EP 787 DI 10.1208/s12248-015-9719-7 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CL0DV UT WOS:000356610300002 PM 25801717 ER PT J AU Patel, MS AF Patel, Mitesh S. TI Health Policy in Medical Education: A Renewed Look at a Timely and Achievable Imperative Reply SO ACADEMIC MEDICINE LA English DT Letter ID STUDENT PERCEPTIONS C1 [Patel, Mitesh S.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Patel, MS (reprint author), Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 3 TC 0 Z9 0 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD JUL PY 2015 VL 90 IS 7 BP 838 EP 838 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CL6QZ UT WOS:000357093500003 PM 26414047 ER PT J AU Zhang, YJ Chee, A Shi, P Wang, R Moss, I Chen, EY He, TC An, HS AF Zhang, Yejia Chee, Ana Shi, Peng Wang, Rui Moss, Isaac Chen, Er-Yun He, Tong-Chuan An, Howard S. TI Allogeneic Articular Chondrocyte Transplantation Downregulates Interleukin 8 Gene Expression in the Degenerating Rabbit Intervertebral Disk In Vivo SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Cell Therapy; Inflammation; Intervertebral Disk; Articular Chondrocytes ID MESENCHYMAL STEM-CELLS; NUCLEUS PULPOSUS CELLS; BONE MORPHOGENETIC PROTEINS; EXTRACELLULAR-MATRIX; CLINICAL-EXPERIENCE; SOX9 OVEREXPRESSION; CANINE MODEL; SAND RAT; REPAIR; INJECTION AB Objective The aim of this study was to investigate whether repopulating the degenerating intervertebral disk (IVD) with articular chondrocytes will decrease inflammation in the degenerating rabbit IVD. Design This was a biologic study in a rabbit IVD-injury model in vivo. Dual cell tracking methods (infrared dye labeling and adenovirus transduction) were used to demonstrate the viability of allogeneic articular chondrocytes injected into degenerating rabbit IVDs. Interleukin 8 gene expression was determined via real-time polymerase chain reaction. Infiltrating inflammatory cells (macrophages, T cells, or neutrophils) were examined with immunohistochemistry. The IVDs were also examined by routine histology. Results Articular chondrocytes labeled with infrared dye were detected in the degenerating IVDs at both 2 and 8 wks after injection. At the 2-wk time point, interleukin 8 gene expression was comparable in IVDs injected with chondrocytes and in intact disks as control (P = 0.647), whereas its expression in IVDs injected with saline increased 50-fold (P = 0.028). Transgene expression of red fluorescent protein, -galactosidase, and human bone morphogenetic protein 7 diminished at 8 wks after injection. IVDs injected with chondrocytes overexpressing human bone morphogenetic protein 7 did not show lower interleukin 8 gene expression or improved histology. Macrophages were consistently detected by immunohistochemistry in the cartilage formed around the needle insertion sites in both the saline and chondrocyte groups, whereas neither T cells nor neutrophils were detected. Conclusions Allogeneic rabbit articular chondrocyte survived in the degenerating rabbit IVDs for at least 8 wks. Cell treatment resulted in reduced IVD inflammation but did not significantly improve IVD structure. C1 [Zhang, Yejia; Chee, Ana; Shi, Peng; Wang, Rui; An, Howard S.] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA. [Zhang, Yejia] Vet Affairs Med Ctr, Philadelphia, PA 19146 USA. [Zhang, Yejia] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19146 USA. [Moss, Isaac] Univ Connecticut, Ctr Hlth, Dept Orthoped Surg, Hartford, CT 06112 USA. [Chen, Er-Yun] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [He, Tong-Chuan] Univ Chicago, Dept Orthopaed Surg & Rehabil Med, Chicago, IL 60637 USA. RP Zhang, YJ (reprint author), Vet Affairs Med Ctr, 1800 Lombard St,1st Floor, Philadelphia, PA 19146 USA. FU Cervical Spine Research Society (CSRS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1K08 HD049598] FX Supported, in part, by a research grant from the Cervical Spine Research Society (CSRS).; Yejia Zhang, MD, PhD, is supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 1K08 HD049598). Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. NR 37 TC 5 Z9 5 U1 5 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JUL PY 2015 VL 94 IS 7 BP 530 EP 538 DI 10.1097/PHM.0000000000000194 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK8NA UT WOS:000356493700004 PM 25133623 ER PT J AU Grady, CD Dehlendorf, C Cohen, ED Schwarz, EB Borrero, S AF Grady, Cynthia D. Dehlendorf, Christine Cohen, Elan D. Schwarz, E. Bimla Borrero, Sonya TI Racial and ethnic differences in contraceptive use among women who desire no future children, 2006-2010 National Survey of Family Growth SO CONTRACEPTION LA English DT Article DE Contraception; Disparities; Race/ethnicity; Unwanted pregnancy ID UNITED-STATES; UNINTENDED PREGNANCY; INTENTION; DISPARITIES; PATTERNS; BIRTHS; NONUSE; RISK AB Objective: To evaluate racial/ethnic differences in contraceptive use among women who do not desire future pregnancy. Study Design: We used the 2006-2010 National Survey of Family Growth to examine the associations between race/ethnicity and 1) use of any contraceptive method at last heterosexual intercourse and 2) effectiveness of contraceptive method used among women who stated that they did not desire any (more) children. We conducted multivariable logistic regression to assess the independent effect of race/ethnicity on these outcomes, adjusting for socio-demographic factors, reproductive characteristics, and indicators of healthcare access and utilization. Results: The study sample consisted of 2900 women, aged 15-44 years. The vast majority of women (91.2%) used contraception at last sex, although this varied significantly by race/ethnicity (p<.01). In the fully adjusted model controlling for demographic and reproductive characteristics as well as healthcare access, compared to whites, black women were significantly less likely to use any contraception at last sex (OR: 0.43; 95% CI: 0.27-0.73), while there was no significant difference for Hispanic women (OR: 0.95; 95% CI: 0.52-1.72). Among women who used a method at last sex, the type of contraceptive method varied significantly by race/ethnicity in bivariate analysis (p<.01), although most women (59%) used a highly effective method. In the fully adjusted model, racial/ethnic differences were no longer significant. Conclusions: In this nationally representative cohort of women who report that they do not desire (more) children, black women were significantly less likely than white women to use any contraception at last intercourse; this difference did not appear to be due to differential access to health care. Published by Elsevier Inc. C1 [Grady, Cynthia D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94110 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94110 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. [Cohen, Elan D.] Univ Pittsburgh, Hlth Care Data Ctr, Res Ctr, Pittsburgh, PA 15213 USA. [Schwarz, E. Bimla] Univ Calif Davis, Sch Med, Div Gen Internal Med, Sacramento, CA 95817 USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. RP Borrero, S (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu FU Eunice Kennedy Shriver National Institute of Child Health & Human Development [1R21HD068736-01A1, K23HD067197]; University of Pittsburgh Clinical Scientist Training Program, (CSTP) [UL1 TL1TR000005] FX This work was supported by Grant Numbers 1R21HD068736-01A1 (S.B.) and K23HD067197 (C.D.) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and from the University of Pittsburgh Clinical Scientist Training Program, (CSTP) UL1 TL1TR000005 (C.G.). NR 45 TC 0 Z9 0 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD JUL PY 2015 VL 92 IS 1 BP 62 EP 70 DI 10.1016/j.contraception.2015.03.017 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CL5IG UT WOS:000356992400010 PM 25863228 ER PT J AU Ma, B Khazali, A Wells, A AF Ma, Bo Khazali, Ahmad Wells, Alan TI CXCR3 in carcinoma progression SO HISTOLOGY AND HISTOPATHOLOGY LA English DT Review DE Chemokines; Cancer; CXCR3; CXCR3-A; CXCR3-B ID CHEMOKINE RECEPTOR CXCR3; RENAL-CELL CARCINOMA; METASTATIC BREAST-CANCER; ACTIVATED T-LYMPHOCYTES; LUNG-CANCER; UP-REGULATION; OVARIAN CANCERS; LIGAND-BINDING; MURINE MODEL; LYMPH-NODES AB CXCR3 is a G-protein coupled receptor which binds to ELR-negative CXC chemokines that have been found to impact immune responses, vascular develop, and wound repair. More recently, CXCR3 has been examined in the context of cancer and increased expression in many human tumors has been correlated with poor prognosis in breast, melanoma, colon and renal cancer patients. Three variants of CXCR3 are identified so far (CXCR3-A, CXCR3-B and CXCR3-alt) with the two primary ones, CXCR3-A and CXCR3-B, considered to induce opposite physiological functions. Generally, CXCR3-A, the predominant form in hematopoietic cells, appears to mediate tumor "go" signaling via promoting cell proliferation, survival, chemotaxis, invasion and metastasis; while CXCR3-B, the main form on formed elements including epithelial cells, appears to mediate tumor "stop" signaling via promoting growth suppression, apoptosis and vascular involution. Thus, aberrant expression of the isoforms CXCR3-A and CXCR3-B could affect tumor progression. In this review, we have discussed the profiles of CXCR3 variants and related signaling, as well as the role of CXCR3 variants in cancer. C1 [Wells, Alan] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. EM wellsa@upmc.edu OI Wells, Alan/0000-0002-1637-8150 FU VA Merit Program; DoD CDMRP in Breast and Prostate Cancer; NIH [UH2 TR000496] FX This study was supported by grants from the VA Merit Program and the DoD CDMRP in Breast and Prostate Cancer, and the NIH UH2 TR000496. NR 72 TC 4 Z9 5 U1 1 U2 8 PU F HERNANDEZ PI MURCIA PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN SN 0213-3911 EI 1699-5848 J9 HISTOL HISTOPATHOL JI Histol. Histopath. PD JUL PY 2015 VL 30 IS 7 BP 781 EP 792 DI 10.14670/HH-11-594 PG 12 WC Cell Biology; Pathology SC Cell Biology; Pathology GA CL2XN UT WOS:000356811200003 PM 25663474 ER PT J AU Walker, RJ Lynch, CP Williams, JS Voronca, D Egede, LE AF Walker, Rebekah J. Lynch, Cheryl P. Williams, Joni Strom Voronca, Delia Egede, Leonard E. TI Meaning of illness and quality of life in patients with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Meaning of illness; Diabetes; Quality of life; Physical health; Mental health ID QUESTIONNAIRE; RELIABILITY; VALIDITY; SCALE AB Background: Investigations into personal factors influencing quality of life are important for those developing strategies to support patients with diabetes. This study aimed to investigate the influence of meaning of illness on quality of life in patients with type 2 diabetes. Methods: Veterans from primary care clinics in the southeastern United States completed a questionnaire including questions from the validated 5-scale Meaning of Illness Questionnaire (MIQ). Unadjusted and adjusted linear regression models investigated the physical and mental components of quality of life with the 5 MIQ factors. Results: The sample comprised 302 Black and White veterans. The physical component of quality of life (PCS) was positively associated with type of stress/attitude of harm (beta = 2.43, CI: 0.94 to 3.93) and challenge/motivation/hope (beta = 3.02, CI: 0.40 to 5.64) after adjustment, whereas the mental component of quality of life (MCS) was positively associated with the degree of stress/change in commitment (beta = 2.58, CI: 0.78 to 438), and negatively associated with challenge/motivation/hope (beta = -2.55, CI: -4.99 to -0.11). Conclusion: Attitudes of challenge, motivation and hope had opposite effects on mental and physical components of quality of life in this sample of veterans. Additionally, whereas, the type of stress and attitude towards harm or loss was associated with the physical component, the degree of stress and change in commitments was associated with the mental component This suggests addressing the meaning of an illness may be complex but is an important consideration in improving both physical and mental components of quality of life in patients with type 2 diabetes. Published by Elsevier Inc. C1 [Walker, Rebekah J.; Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Walker, Rebekah J.; Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Lynch, Cheryl P.; Williams, Joni Strom; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU VHA Health Services Research and Development (HSRD) program [TRP 04-038] FX This study was supported by grant #TRP 04-038 (PI: Leonard Egede) funded by the VHA Health Services Research and Development (HSR&D) program. NR 19 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JUL PY 2015 VL 29 IS 5 BP 665 EP 669 DI 10.1016/j.jdiacomp.2015.04.006 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CL4EW UT WOS:000356906400010 PM 25934437 ER PT J AU Wallace, ML Iyengar, S Bramoweth, AD Frank, E Germain, A AF Wallace, Meredith L. Iyengar, Satish Bramoweth, Adam D. Frank, Ellen Germain, Anne TI Clarifying Heterogeneity of Daytime and Nighttime Symptoms of Posttraumatic Stress in Combat Veterans With Insomnia SO MILITARY PSYCHOLOGY LA English DT Article DE chronic insomnia; clustering; personalized medicine; PTSD; sleep ID SLEEP QUALITY INDEX; COGNITIVE-PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; ADMINISTERED PTSD SCALE; MENTAL-HEALTH PROBLEMS; PSYCHOMETRIC PROPERTIES; BEHAVIORAL THERAPY; PROLONGED EXPOSURE; MILITARY VETERANS; DISORDER AB Daytime and nighttime symptoms of posttraumatic stress disorder (PTSD) are common among combat veterans and military service members. However, there is a great deal of heterogeneity in how symptoms are expressed. Clarifying the heterogeneity of daytime and nighttime PTSD symptoms through exploratory clustering may generate hypotheses regarding ways to optimally match evidence-based treatments to PTSD symptom profiles. We used mixture modeling to reveal clusters based on 6 daytime and nighttime symptoms of 154 combat veterans with insomnia and varying levels of PTSD symptoms. Three clusters with increasing symptom severity were identified (n1 = 50, n2 = 70, n3 = 34). These results suggest that, among veterans with insomnia, PTSD symptoms tend to exist on a continuum of severity, rather than as a categorical PTSD diagnosis. Hypotheses regarding possible targeted treatment strategies for veterans within each identified cluster, as well as ways to generalize these methods to other groups within the military, are discussed. C1 [Wallace, Meredith L.; Frank, Ellen; Germain, Anne] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Iyengar, Satish] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15260 USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. RP Wallace, ML (reprint author), 3811 OHara St, Pittsburgh, PA 15213 USA. EM lotzmj@upmc.edu FU VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC), VA Pittsburgh Healthcare System; [K01 MH096944]; [PR054093]; [PT073961]; [MH080696]; [MH083035]; [Log11293006] FX Drs. Wallace, Iyengar, Bramoweth, and Germain have no conflicts of interest. Dr. Frank has the following conflicts of interest: (a) American Psychiatric Press, Editorial Consultant; (b) Psychiatric Assessments Inc, Stockholder; (c) American Psychological Association Press and Guilford Press, Royalties; (d) Servier International, Advisory Board. The contents of this article do not represent the views of the Department of the Veterans Affairs of the United States Government. This research was supported by Grants K01 MH096944 (PI: Wallace) and PR054093, PT073961, MH080696, MH083035, and Log11293006 (PI: Germain). Dr. Bramoweth is supported by funds from the VISN 4 Mental Illness Research, Education, and Clinical Center (MIRECC, Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. NR 60 TC 1 Z9 1 U1 2 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD JUL PY 2015 VL 27 IS 4 BP 212 EP 222 DI 10.1037/mil0000077 PG 11 WC Psychology, Multidisciplinary SC Psychology GA CL5BS UT WOS:000356975400002 PM 26457001 ER PT J AU Zhao, Y Olonisakin, TF Xiong, Z Hulver, M Sayeed, S Yu, MT Gregory, AD Kochman, EJ Chen, BB Mallampalli, RK Sun, M Silverstein, RL Stolz, DB Shapiro, SD Ray, A Ray, P Lee, JS AF Zhao, Y. Olonisakin, T. F. Xiong, Z. Hulver, M. Sayeed, S. Yu, M. T. Gregory, A. D. Kochman, E. J. Chen, B. B. Mallampalli, R. K. Sun, M. Silverstein, R. L. Stolz, D. B. Shapiro, S. D. Ray, A. Ray, P. Lee, J. S. TI Thrombospondin-1 restrains neutrophil granule serine protease function and regulates the innate immune response during Klebsiella pneumoniae infection SO MUCOSAL IMMUNOLOGY LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; BINDING COMPETITIVE INHIBITOR; IMPAIRED HOST-DEFENSE; ACUTE LUNG INJURY; CATHEPSIN-G; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; ELASTASE; CELLS; ACTIVATION AB Neutrophil elastase (NE) and cathepsin G (CG) contribute to intracellular microbial killing but, if left unchecked and released extracellularly, promote tissue damage. Conversely, mechanisms that constrain neutrophil serine protease activity protect against tissue damage but may have the untoward effect of disabling the microbial killing arsenal. The host elaborates thrombospondin-1 (TSP-1), a matricellular protein released during inflammation, but its role during neutrophil activation following microbial pathogen challenge remains uncertain. Mice deficient in TSP-1 (thbs1(-/-)) showed enhanced lung bacterial clearance, reduced splenic dissemination, and increased survival compared with wildtype (WT) controls during intrapulmonary Klebsiella pneumoniae infection. More effective pathogen containment was associated with reduced burden of inflammation in thbs1(-/-) mouse lungs compared with WT controls. Lung NE activity was increased in thbs1(-/-) mice following K. pneumoniae challenge, and thbs1(-/-) neutrophils showed enhanced intracellular microbial killing that was abrogated with recombinant TSP-1 administration or WT serum. Thbs1(-/-) neutrophils exhibited enhanced NE and CG enzymatic activity, and a peptide corresponding to amino-acid residues 793-801 within the type-III repeat domain of TSP-1 bridled neutrophil proteolytic function and microbial killing in vitro. Thus, TSP-1 restrains proteolytic action during neutrophilic inflammation elicited by K. pneumoniae, providing a mechanism that may regulate the microbial killing arsenal. C1 [Zhao, Y.; Olonisakin, T. F.; Xiong, Z.; Hulver, M.; Sayeed, S.; Yu, M. T.; Gregory, A. D.; Kochman, E. J.; Chen, B. B.; Mallampalli, R. K.; Shapiro, S. D.; Ray, A.; Ray, P.; Lee, J. S.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA. [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Sun, M.; Stolz, D. B.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA. [Sun, M.; Stolz, D. B.] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA USA. [Silverstein, R. L.] Blood Ctr SE Wisconsin Inc, Dept Med, Med Coll Wisconsin, Milwaukee, WI 53233 USA. [Silverstein, R. L.] Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53233 USA. [Lee, J. S.] Univ Pittsburgh, Dept Med, Vasc Med Inst, Pittsburgh, PA USA. RP Lee, JS (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA. EM leejs3@upmc.edu FU Flight Attendant Medical Research Institute; Pilot Project Program in Hemostasis and Vascular Biology (University of Pittsburgh CTSI) [UL1 RR024153, UL1 TR000005]; Vascular Medicine Institute; Hemophilia Center of Western Pennsylvania; Institute for Transfusion Medicine; Merit Review Award from the US Department of Veterans Affairs; [R01 HL086884]; [P01 HL114453] FX Funding sources include R01 HL086884 (J.S.L.), Flight Attendant Medical Research Institute (J.S.L.), Pilot Project Program in Hemostasis and Vascular Biology through UL1 RR024153 and UL1 TR000005 (University of Pittsburgh CTSI), the Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania, Institute for Transfusion Medicine (J.S.L.), P01 HL114453 (R.K.M., P.R.), and a Merit Review Award from the US Department of Veterans Affairs (R.K.M.). NR 51 TC 6 Z9 6 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1933-0219 EI 1935-3456 J9 MUCOSAL IMMUNOL JI Mucosal Immunol. PD JUL PY 2015 VL 8 IS 4 BP 896 EP 905 DI 10.1038/mi.2014.120 PG 10 WC Immunology SC Immunology GA CL3QP UT WOS:000356865700018 PM 25492474 ER PT J AU Scherzer, R Shlipak, MG AF Scherzer, Rebecca Shlipak, Michael G. TI Individual assessment of CKD risk in HIV-positive patients SO NATURE REVIEWS NEPHROLOGY LA English DT News Item ID KIDNEY-DISEASE RISK; TENOFOVIR; INFECTION AB Despite reductions in morbidity and mortality owing to widespread use of highly effective antiretroviral therapy (ART), HIV-positive patients remain at high risk of chronic kidney disease (CKD) and end-stage renal disease. A new report provides a HIV-specific CKD risk score to balance the potential benefits and harms of nephrotoxic ART. C1 [Scherzer, Rebecca; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu FU NIAID NIH HHS [R01 AI098472] NR 10 TC 2 Z9 2 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 EI 1759-507X J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD JUL PY 2015 VL 11 IS 7 BP 392 EP 393 DI 10.1038/nrneph.2015.75 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA CL2UT UT WOS:000356801900003 PM 25963593 ER PT J AU Fink, KR Benjert, JL AF Fink, Kathleen R. Benjert, Jayson L. TI Imaging of Nontraumatic Neuroradiology Emergencies SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Subarachnoid hemorrhage; Vasogenic edema; Hydrocephalus; Neurologic abnormalities ID RADIOLOGIC-PATHOLOGICAL CORRELATION; CEREBRAL VASOCONSTRICTION SYNDROME; ENCEPHALOPATHY SYNDROME PRES; OF-THE-LITERATURE; SUBARACHNOID HEMORRHAGE; PERIMESENCEPHALIC HEMORRHAGE; INTRACEREBRAL HEMORRHAGE; CT ANGIOGRAPHY; BRAIN-ABSCESS; AMYLOID ANGIOPATHY AB Imaging of acute neurologic disease in the emergency department can be challenging because of the wide range of possible causes and the overlapping imaging appearance of many of these entities on nonenhanced computed tomography (CT). The key to formulating a succinct, pertinent differential diagnosis includes characterizing the pattern of abnormalities on CT and identifying key features that suggest a particular diagnosis. This article divides neurologic emergencies into 5 scenarios based on the CT findings, including subarachnoid hemorrhage, intraparenchymal hemorrhage, vasogenic edema without and with underlying mass lesion, and acute hydrocephalus. Specific common or important diagnoses in each category are discussed. C1 [Fink, Kathleen R.] Univ Washington, Dept Radiol, Seattle, WA 98104 USA. [Benjert, Jayson L.] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Fink, KR (reprint author), Univ Washington, Dept Radiol, Box 359728,325 9th Ave, Seattle, WA 98104 USA. EM ktozer@u.washington.edu NR 59 TC 1 Z9 1 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD JUL PY 2015 VL 53 IS 4 BP 871 EP + DI 10.1016/j.rcl.2015.02.004 PG 21 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CL5GF UT WOS:000356987100015 PM 26046515 ER PT J AU Hoo, GWS Lin, HK Junaid, I Klaustermeyer, WB AF Hoo, Guy W. Soo Lin, Henry K. Junaid, Imran Klaustermeyer, William B. TI Angiotensin-converting Enzyme Inhibitor Angioedema Requiring Admission to an Intensive Care Unit SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Angioedema; Angiotensin-converting enzyme inhibitor; Respiratory failure ID EMERGENCY-DEPARTMENT; CLINICAL-EXPERIENCE; RISK; HOSPITALIZATIONS; STATES; DRUGS AB OBJECTIVE: The purpose of this study was to review consecutive cases of angiotensin-converting enzyme (ACE) inhibitor angioedema admitted to an intensive care unit. METHODS: Fifty subjects with ACE-inhibitor angioedema admitted from 1998-2011 were reviewed. RESULTS: All 50 subjects were men, 62.8 +/- 8.4 years of age, 76% African Americans. Fifteen (30%) required ventilatory support and 2 (4%) required tracheostomy. Over half (56%) had taken ACE inhibitors for over a year. Logistic regression identified dyspnea and tongue involvement with the need for ventilatory support (P < .01). Hypercapnia (PaCO2 +/- 45.2 +/- 6.7; P < 0.046) also identified patients needing ventilatory support. CONCLUSIONS: Ventilatory support was provided for about one-third of those with ACE inhibitorassociated angioedema. Angioedema can occur even after extended use. Dyspnea and tongue involvement identified patients requiring ventilatory support. Published by Elsevier Inc. C1 [Hoo, Guy W. Soo] Univ Calif Los Angeles, Pulm & Crit Care Sect, Los Angeles, CA USA. [Lin, Henry K.; Junaid, Imran; Klaustermeyer, William B.] Univ Calif Los Angeles, Allergy & Immunol Sect, Dept Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lin, Henry K.; Junaid, Imran; Klaustermeyer, William B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Hoo, GWS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Pulm & Crit Care Sect, 11301 Wilshire Blvd W111Q, Los Angeles, CA 90073 USA. EM guy.soohoo@va.gov NR 19 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD JUL PY 2015 VL 128 IS 7 BP 785 EP 789 DI 10.1016/j.amjmed.2015.02.006 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CK6WS UT WOS:000356370000036 ER PT J AU Streblow, DN Hwee, YK Kreklywich, CN Andoh, T Denton, M Smith, P Hart, E Broekel, R Pallett, C Rogers, K Streblow, AD Chuop, M Perry, A Slifka, M Messaoudi, I Orloff, SL AF Streblow, D. N. Hwee, Y. K. Kreklywich, C. N. Andoh, T. Denton, M. Smith, P. Hart, E. Broekel, R. Pallett, C. Rogers, K. Streblow, A. D. Chuop, M. Perry, A. Slifka, M. Messaoudi, I. Orloff, S. L. TI Rat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naive Recipients of Infected Donor Allograft Hearts SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; TRANSPLANT VASCULAR SCLEROSIS; CELL IMMUNE RECONSTITUTION; GLYCOPROTEIN-B VACCINE; CD8(+) T-CELLS; SMALL-BOWEL; PREEMPTIVE THERAPY; CARDIAC ALLOGRAFTS; VIRUS-VACCINE; RESPONSES AB Cytomegalovirus accelerates transplant vascular sclerosis (TVS) and chronic rejection (CR) in solid organ transplants; however, the mechanisms involved are unclear. We determined the efficacy of a CMV vaccine in preventing CMV-accelerated rat cardiac allograft rejection in naive recipients of CMV+ donor hearts. F344 donor rats were infected with RCMV 5 days prior to heterotopic cardiac transplantation into CMV-naive or H2O2-inactivated RCMV-vaccinated Lewis recipients. Recipients of RCMV-infected donor hearts rejected at POD59, whereas vaccinated recipients exhibited a significantly prolonged time to rejection-POD97, similar to recipients of uninfected donor hearts (POD108). Although all of the donor hearts were preinfected, the vaccinated recipients had lower graft and PBMC viral loads at POD 7 compared to unvaccinated controls. Adoptive T cell and passive antibody transfers from vaccinated Lewis rats into naive recipients demonstrate that both T-cell and B-cell arms of the adaptive immune response provide protection against CMV-accelerated rejection. Similar findings were obtained when testing three different adjuvants in passive transfer experiments. We have determined that the timing of the vaccine prior to transplantation and the specific adjuvant play critical roles in mediating anti-viral responses and promoting graft survival. CMV vaccination prior to transplantation may effectively increase graft survival. C1 [Streblow, D. N.; Perry, A.; Slifka, M.; Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Streblow, D. N.; Kreklywich, C. N.; Denton, M.; Smith, P.; Hart, E.; Broekel, R.; Pallett, C.; Rogers, K.; Streblow, A. D.; Chuop, M.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR USA. [Hwee, Y. K.; Kreklywich, C. N.; Andoh, T.; Orloff, S. L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA. [Andoh, T.; Orloff, S. L.] Portland VA Med Ctr, Portland, OR USA. [Slifka, M.] Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR USA. [Messaoudi, I.] Univ Calif Riverside, Sch Med, Div Biomed Sci, Riverside, CA 92521 USA. RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. EM streblow@ohsu.edu FU National Institutes of Health [HL083194, HL 66238-01] FX This work was supported by research grants from the National Institutes of Health to D.N.S. (HL083194) and S.L.O. (HL 66238-01). NR 44 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUL PY 2015 VL 15 IS 7 BP 1805 EP 1816 DI 10.1111/ajt.13188 PG 12 WC Surgery; Transplantation SC Surgery; Transplantation GA CK8NF UT WOS:000356494300016 PM 25766876 ER PT J AU Safdar, N Perencevich, E AF Safdar, Nasia Perencevich, Eli TI Crossing the quality chasm for Clostridium difficile infection prevention SO BMJ QUALITY & SAFETY LA English DT Editorial Material ID CARE; HOSPITALS C1 [Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med, Infect Dis Sect,William S Middleton Mem Vet Hosp, Madison, WI USA. [Perencevich, Eli] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. [Perencevich, Eli] Iowa City VA Healthcare Syst, Iowa City, IA USA. RP Safdar, N (reprint author), Univ Wisconsin Hosp & Clin, 1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU AHRQ HHS [R03HS023791, R03 HS023791, R18 HS024039] NR 17 TC 1 Z9 1 U1 1 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD JUL PY 2015 VL 24 IS 7 BP 409 EP 411 DI 10.1136/bmjqs-2015-004344 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CK9EI UT WOS:000356543000001 PM 25979001 ER PT J AU Sacks, GD Shannon, EM Dawes, AJ Rollo, JC Nguyen, DK Russell, MM Ko, CY Maggard-Gibbons, MA AF Sacks, Greg D. Shannon, Evan M. Dawes, Aaron J. Rollo, Johnathon C. Nguyen, David K. Russell, Marcia M. Ko, Clifford Y. Maggard-Gibbons, Melinda A. TI Teamwork, communication and safety climate: a systematic review of interventions to improve surgical culture SO BMJ QUALITY & SAFETY LA English DT Review ID RANDOMIZED-CONTROLLED-TRIAL; OPERATING-ROOM BRIEFINGS; INTERRUPTED TIME-SERIES; PATIENT SAFETY; TRAINING-PROGRAM; CHECKLIST; THEATER; PERFORMANCE; SURGERY; CARE AB Objectives To define the target domains of culture-improvement interventions, to assess the impact of these interventions on surgical culture and to determine whether culture improvements lead to better patient outcomes and improved healthcare efficiency. Background Healthcare systems are investing considerable resources in improving workplace culture. It remains unclear whether these interventions, when aimed at surgical care, are successful and whether they are associated with changes in patient outcomes. Methods PubMed, Cochrane, Web of Science and Scopus databases were searched from January 1980 to January 2015. We included studies on interventions that aimed to improve surgical culture, defined as the interpersonal, social and organisational factors that affect the healthcare environment and patient care. The quality of studies was assessed using an adapted tool to focus the review on higher-quality studies. Due to study heterogeneity, findings were narratively reviewed. Findings The 47 studies meeting inclusion criteria (4 randomised trials and 10 moderate-quality observational studies) reported on interventions that targeted three domains of culture: teamwork (n=28), communication (n=26) and safety climate (n=19); several targeted more than one domain. All moderate-quality studies showed improvements in at least one of these domains. Two studies also demonstrated improvements in patient outcomes, such as reduced postoperative complications and even reduced postoperative mortality (absolute risk reduction 1.7%). Two studies reported improvements in healthcare efficiency, including fewer operating room delays. These findings were supported by similar results from low-quality studies. Conclusions The literature provides promising evidence for various strategies to improve surgical culture, although these approaches differ in terms of the interventions employed as well as the techniques used to measure culture. Nevertheless, culture improvement appears to be associated with other positive effects, including better patient outcomes and enhanced healthcare efficiency. C1 [Sacks, Greg D.; Dawes, Aaron J.; Rollo, Johnathon C.; Nguyen, David K.; Russell, Marcia M.; Ko, Clifford Y.; Maggard-Gibbons, Melinda A.] Univ Calif Los Angeles, David Geffen Sch Med, Surg, Los Angeles, CA 90095 USA. [Shannon, Evan M.] UCSF Sch Med, San Francisco, CA USA. [Russell, Marcia M.; Ko, Clifford Y.; Maggard-Gibbons, Melinda A.] VA Greater Los Angeles Healthcare Syst, Gen Surg, Los Angeles, CA USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Surg, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 NR 73 TC 12 Z9 12 U1 2 U2 30 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD JUL PY 2015 VL 24 IS 7 BP 458 EP 467 DI 10.1136/bmjqs-2014-003764 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CK9EI UT WOS:000356543000012 PM 26002946 ER PT J AU Toosi, KK Hogaboom, NS Oyster, ML Boninger, ML AF Toosi, Kevin K. Hogaboom, Nathan S. Oyster, Michelle L. Boninger, Michael L. TI Computer keyboarding biomechanics and acute changes in median nerve indicative of carpal tunnel syndrome SO CLINICAL BIOMECHANICS LA English DT Article DE Carpal tunnel syndrome; Computer keyboarding biomechanics; Ultrasound; Ergonomics ID FOREARM POSTURES; CANAL PRESSURES; WRIST; DIAGNOSIS; SONOGRAPHY; ULTRASOUND; MOVEMENT; WORKERS; USERS AB Background: Carpal tunnel syndrome is a common and costly peripheral neuropathy. Occupations requiring repetitive, forceful motions of the hand and wrist may play a role in the development of carpal tunnel syndrome. Computer keyboarding is one such task, and has been associated with upper-extremity musculoskeletal disorder development. The purpose of this study was to determine whether continuous keyboarding can cause acute changes in the median nerve and whether these changes correlate with wrist biomechanics during keyboarding. Methods: A convenience sample of 37 healthy individuals performed a 60-minute typing task. Ultrasound images were collected at baseline, after 30 and 60 min of typing, then after 30 min of rest. Kinematic data were collected during the typing task. Variables of interest were median nerve cross-sectional area, flattening ratio, and swelling ratio at the pisiform; subject characteristics (age, gender, BMI, wrist circumference, typing speed) and wrist joint angles. Findings: Cross-sectional area and swelling ratio increased after 30 and 60 min of typing, and then decreased to baseline after 30 min of rest. Peak ulnar deviation contributed to changes in cross-sectional area after 30 min of typing. Interpretation: Results from this study confirmed a typing task causes changes in the median nerve, and changes are influenced by level of ulnar deviation. Furthermore, changes in the median nerve are present until cessation of the activity. While it is unclear if these changes lead to long-term symptoms or nerve injury, their existence adds to the evidence of a possible link between carpal tunnel syndrome and keyboarding. Published by Elsevier Ltd. C1 [Toosi, Kevin K.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Toosi, Kevin K.; Hogaboom, Nathan S.; Oyster, Michelle L.; Boninger, Michael L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Hogaboom, Nathan S.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Oyster, Michelle L.; Boninger, Michael L.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Boninger, ML (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Hogaboom, Nathan/0000-0002-0601-5751; Boninger, Michael/0000-0001-6966-919X FU U.S. Department of Veterans Affairs [B3142C]; National Institutes of Health [T32HD049307] FX This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. This study was supported by the U.S. Department of Veterans Affairs (B3142C) and the National Institutes of Health (T32HD049307). NR 30 TC 0 Z9 0 U1 2 U2 15 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0268-0033 EI 1879-1271 J9 CLIN BIOMECH JI Clin. Biomech. PD JUL PY 2015 VL 30 IS 6 BP 546 EP 550 DI 10.1016/j.clinbiomech.2015.04.008 PG 5 WC Engineering, Biomedical; Orthopedics; Sport Sciences SC Engineering; Orthopedics; Sport Sciences GA CK9FI UT WOS:000356545600004 PM 25933812 ER PT J AU Oliveira, SEH Esteves, FG Pereira, EG Carvalho, M Boyd, JE AF Oliveira, Sandra E. H. Esteves, Francisco G. Pereira, Edgar G. Carvalho, Marina Boyd, Jennifer E. TI The Internalized Stigma of Mental Illness: Cross-Cultural Adaptation and Psychometric Properties of the Portuguese Version of the ISMI Scale SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE ISMI; Self-stigma; Portuguese; Mental disorders; Diagnosis ID SCHIZOPHRENIA SPECTRUM DISORDERS; SELF-STIGMA; PERCEIVED DISCRIMINATION; EUROPEAN COUNTRIES; GAMIAN-EUROPE; PEOPLE; CONSEQUENCES; EMPOWERMENT; EXPERIENCES; OUTPATIENTS AB This study examined the psychometric properties of the Portuguese version of the ISMI scale in a sample of 253 adult psychiatric outpatients. The exploratory factor analysis replicated the five factor structure of the scale. The results revealed good internal consistency. Criterion-related validity supported the variability in response to stigma across clinical diagnoses. Thus, the Portuguese version of the ISMI scale can be considered appropriate to measure and differentiate between stigmatization experiences. Also, in order to design more focused approaches aimed to reduce the negative effects of internalized stigma, its use in institutional and in community-based mental health services is recommended. C1 [Oliveira, Sandra E. H.; Esteves, Francisco G.] Inst Univ Lisboa ISCTE IUL, CIS IUL, P-1649026 Lisbon, Portugal. [Pereira, Edgar G.; Carvalho, Marina] Univ Lusofona Humanidades & Tecnol, Fac Psicol, Lisbon, Portugal. [Carvalho, Marina] CHBA, Serv Psiquiatria, Algarve, Portugal. [Boyd, Jennifer E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Boyd, Jennifer E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Oliveira, SEH (reprint author), Inst Univ Lisboa ISCTE IUL, CIS IUL, Av Forcas Armadas, P-1649026 Lisbon, Portugal. EM seholiveira@gmail.com NR 44 TC 4 Z9 4 U1 2 U2 10 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD JUL PY 2015 VL 51 IS 5 BP 606 EP 612 DI 10.1007/s10597-015-9828-x PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA CK9DX UT WOS:000356541900013 PM 25612794 ER PT J AU Edelman, EJ Tate, JP Fiellin, DA Brown, ST Bryant, K Gandhi, N Gibert, CL Goetz, MB Gordon, KS Rodriguez-Barradas, MC Braithwaite, RS Rimland, D Justice, AC AF Edelman, E. J. Tate, J. P. Fiellin, D. A. Brown, S. T. Bryant, K. Gandhi, N. Gibert, C. L. Goetz, M. B. Gordon, K. S. Rodriguez-Barradas, M. C. Braithwaite, R. S. Rimland, D. Justice, A. C. TI Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system SO HIV MEDICINE LA English DT Article DE community viral load; epidemiological methods; HIV; population surveillance; quality of health care ID OF-VETERANS-AFFAIRS; MEDICAL-CARE; COHORT; INFORMATION; ENGAGEMENT; MORTALITY; INDEX AB ObjectivesCommunity viral load (CVL) estimates vary based on analytic methods. We extended the CVL concept and used data from the Veterans Health Administration (VA) to determine trends in the health care system viral load (HSVL) and its sensitivity to varying definitions of the clinical population and assumptions regarding missing data. MethodsWe included HIV-infected patients in the Veterans Aging Cohort Study, 2000-2010, with at least one documented CD4 count, HIV-1 RNA or antiretroviral prescription (n=37318). We created 6-month intervals including patients with at least one visit in the past 2 years. We assessed temporal trends in clinical population size, patient clinical status and mean HSVL and explored the impact of varying definitions of the clinical population and assumptions about missing viral load. ResultsThe clinical population size varied by definition, increasing from 16000-19000 patients in 2000 to 23000-26000 in 2010. The proportion of patients with suppressed HIV-1 RNA increased over time. Over 20% of patients had no viral load measured in a given interval or the past 2 years. Among patients with a current HIV-1 RNA, mean HSVL decreased from 97800 HIV-1 RNA copies/mL in 2000 to 2000 copies/mL in 2010. When current HIV-1 RNA data were unavailable and the HSVL was recalculated using the last available HIV-1 RNA, HSVL decreased from 322300 to 9900 copies/mL. HSVL was underestimated when using only current data in each interval. ConclusionsThe CVL concept can be applied to a health care system, providing a measure of health care quality. Like CVL, HSVL estimates depend on definitions of the clinical population and assumptions about missing data. C1 [Edelman, E. J.; Tate, J. P.; Fiellin, D. A.; Justice, A. C.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Edelman, E. J.; Fiellin, D. A.; Justice, A. C.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Tate, J. P.; Gordon, K. S.; Justice, A. C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brown, S. T.] James J Peters VA Med Ctr, Bronx, NY USA. [Brown, S. T.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Bryant, K.] NIAAA, Bethesda, MD USA. [Gandhi, N.] Emory Rollins Sch Publ Hlth, Atlanta, GA USA. [Gandhi, N.; Rimland, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Gibert, C. L.] Washington DC VA Med Ctr, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Sch Med, Washington, DC USA. [Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, M. B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Braithwaite, R. S.] NYU, Sch Med, New York, NY USA. [Rimland, D.] Atlanta Vet Affairs Med Ctr, Decatur, GA USA. RP Edelman, EJ (reprint author), Yale Univ, Sch Med, Gen Internal Med, POB 208025, New Haven, CT 06520 USA. EM ejennifer.edelman@yale.edu OI Goetz, Matthew/0000-0003-4542-992X; Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU NIAAA NIH HHS [U01 AA020790, U01-AA020790, U10 AA013566, U10-AA13566, U24 AA020794, U24-AA020794]; NIAID NIH HHS [K24 AI114444, P30AI050409]; NIDA NIH HHS [K12 DA033312, K12DA033312-01A1]; PHS HHS [K24114444-01] NR 38 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-2662 EI 1468-1293 J9 HIV MED JI HIV Med. PD JUL PY 2015 VL 16 IS 6 BP 346 EP 354 DI 10.1111/hiv.12219 PG 9 WC Infectious Diseases SC Infectious Diseases GA CK9XL UT WOS:000356592700003 PM 25688937 ER PT J AU Barron, DS Eickhoff, SB Clos, M Fox, PT AF Barron, Daniel S. Eickhoff, Simon B. Clos, Mareike Fox, Peter T. TI Human pulvinar functional organization and connectivity SO HUMAN BRAIN MAPPING LA English DT Article DE pulvinar; functional anatomy; fMRI; cognitive neuroscience; attention ID ACTIVATION-BASED PARCELLATION; HUMAN BRAIN; INFERIOR PULVINAR; ATTENTION SYSTEM; MEDIAL PULVINAR; CEREBRAL-CORTEX; HUMAN AMYGDALA; HUMAN THALAMUS; METAANALYSIS; NETWORKS AB The human pulvinar is the largest thalamic area in terms of size and cortical connectivity. Although much is known about regional pulvinar structural anatomy, relatively little is known about pulvinar functional anatomy in humans. Cooccurrence of experimentally induced brain activity is a traditional metric used to establish interregional brain connectivity and forms the foundation of functional neuroimaging connectivity analyses. Because functional neuroimaging studies report task-related coactivations within a standardized space, meta-analysis of many whole-brain studies can define the brain's interregional coactivation across many tasks. Such an analysis can also detect and define variations in functional coactivations within a particular region. Here we use coactivation profiles reported in approximate to 7,700 functional neuroimaging studies to parcellate and define the pulvinar's functional anatomy. Parcellation of the pulvinar's coactivation profile identified five clusters per pulvinar of distinct functional coactivation. These clusters showed a high degree of symmetry across hemispheres and correspondence with the human pulvinar's cytoarchitecture. We investigated the functional coactivation profiles of each resultant pulvinar cluster with meta-analytic methods. By referencing existent neuroimaging and lesion-deficit literature, these profiles make a case for regional pulvinar specialization within the larger human attention-controlling network. Reference to this literature also informs specific hypotheses that can be tested in subsequent studies in healthy and clinical populations. Hum Brain Mapp 36:2417-2431, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Barron, Daniel S.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT USA. [Eickhoff, Simon B.] Res Ctr Julich, INM 1, Julich, Germany. [Clos, Mareike] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.; Clos, Mareike] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, Hamburg, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China. [Fox, Peter T.] Shenzhen Univ, Neuroimaging Lab, Sch Med, Shenzhen, Peoples R China. RP Fox, PT (reprint author), 8407 Floyd Curl Dr, San Antonio, TX 78229 USA. EM fox@uthscsa.edu RI Eickhoff, Simon/K-2061-2013 OI Eickhoff, Simon/0000-0001-6363-2759 FU National Institute of Neurological Disorder Stroke [1-F31-NS083160-01]; National Institute of Mental Health [RO1-MH074457]; Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology (Human Brain Model); DFG [IRTG 1328] FX Contract grant sponsor: National Institute of Neurological Disorder & Stroke; Contract grant number: 1-F31-NS083160-01(D.S.B.); Contract grant sponsor: National Institute of Mental Health; Contract grant sponsor: RO1-MH074457 (P.T.F.), Contract grant sponsor: Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Systems Biology (Human Brain Model) (S.B.E. and M.C.); Contract grant sponsor: DFG; Contract grant number: IRTG 1328 (S.B.E.) NR 62 TC 4 Z9 4 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JUL PY 2015 VL 36 IS 7 BP 2417 EP 2431 DI 10.1002/hbm.22781 PG 15 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CL1QP UT WOS:000356719200001 PM 25821061 ER PT J AU Xu, M Wang, TF Chen, SP Fox, PT Tan, LH AF Xu, Min Wang, Tianfu Chen, Siping Fox, Peter T. Tan, Li Hai TI Effective connectivity of brain regions related to visual word recognition: An fMRI study of Chinese reading SO HUMAN BRAIN MAPPING LA English DT Article DE connectivity; functional magnetic resonance imaging; reading; Chinese reading; dynamic causal modeling; ventral pathway; dorsal pathway; writing systems ID VENTRAL OCCIPITOTEMPORAL CORTEX; INFERIOR PREFRONTAL CORTEX; DEVELOPMENTAL DYSLEXIA; FUNCTIONAL SPECIALIZATION; ALPHABETIC WORDS; NEURAL SYSTEMS; WRITTEN WORDS; CHARACTERS; LANGUAGE; METAANALYSIS AB Past neuroimaging studies have focused on identifying specialized functional brain systems for processing different components of reading, such as orthography, phonology, and semantics. More recently, a few experiments have been performed to look into the integration and interaction of distributed neural systems for visual word recognition, suggesting that lexical processing in alphabetic languages involves both ventral and dorsal neural pathways originating from the visual cortex. In the present functional magnetic resonance imaging study, we tested the multiple pathways model with Chinese character stimuli and examined how the neural systems interacted in reading Chinese. Using dynamic causal modeling, we demonstrated that visual word recognition in Chinese engages the ventral pathway from the visual cortex to the left ventral occipitotemporal cortex, but not the dorsal pathway from the visual cortex to the left parietal region. The ventral pathway, however, is linked to the superior parietal lobule and the left middle frontal gyrus (MFG) so that a dynamic neural network is formed, with information flowing from the visual cortex to the left ventral occipitotemporal cortex to the parietal lobule and then to the left MFG. The findings suggest that cortical dynamics is constrained by the differences in how visual orthographic symbols in writing systems are linked to spoken language. Hum Brain Mapp 36:2580-2591, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Xu, Min; Wang, Tianfu; Chen, Siping; Fox, Peter T.; Tan, Li Hai] Shenzhen Univ, Sch Med, Dept Biomed Engn, Shenzhen 518060, Peoples R China. [Xu, Min; Wang, Tianfu; Chen, Siping; Tan, Li Hai] Guangdong Key Lab Biomed Informat Detect & Ultras, Shenzhen, Peoples R China. [Xu, Min] Univ Hong Kong, Sch Humanities, Hong Kong, Hong Kong, Peoples R China. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Tan, LH (reprint author), Shenzhen Univ, Sch Med, Dept Biomed Engn, Shenzhen 518060, Peoples R China. EM fox@uthscsa.edu; tanlh@szu.edu.cn FU National Strategic Basic Research Program ("973" Program) of the Ministry of Science and Technology of China [2012CB720701]; National Natural Science Foundation of China [61372006] FX Contract grant sponsor: National Strategic Basic Research Program ("973" Program) of the Ministry of Science and Technology of China; Contract grant number: 2012CB720701; Contract grant sponsor: National Natural Science Foundation of China; Contract grant number: 61372006. NR 74 TC 3 Z9 3 U1 14 U2 56 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD JUL PY 2015 VL 36 IS 7 BP 2580 EP 2591 DI 10.1002/hbm.22792 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CL1QP UT WOS:000356719200012 PM 25788100 ER PT J AU Kaminetzky, CP Nelson, KM AF Kaminetzky, Catherine P. Nelson, Karin M. TI In the Office and In-Between: The Role of Panel Management in Primary Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID HEALTH; OUTCOMES C1 [Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, Seattle, WA 98108 USA. [Kaminetzky, Catherine P.; Nelson, Karin M.] Univ Washington, Sch Med, Div Gen Internal Med, Seattle, WA USA. [Nelson, Karin M.] VA Puget Sound Hlth Care Syst, VA Hlth Serv Res & Dev, Seattle, WA 98108 USA. RP Kaminetzky, CP (reprint author), VA Puget Sound Hlth Care Syst, Ctr Educ & Dev, 1660 South Columbian Way, Seattle, WA 98108 USA. EM catherine.kaminetzky@va.gov NR 12 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2015 VL 30 IS 7 BP 876 EP 877 DI 10.1007/s11606-015-3310-x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CK8AL UT WOS:000356459400005 PM 25851305 ER PT J AU Liu, QL Rehman, H Krishnasamy, Y Schnellmann, RG Lemasters, JJ Zhong, Z AF Liu, Qinlong Rehman, Hasibur Krishnasamy, Yasodha Schnellmann, Rick G. Lemasters, John J. Zhong, Zhi TI Improvement of liver injury and survival by JNK2 and iNOS deficiency in liver transplants from cardiac death mice SO JOURNAL OF HEPATOLOGY LA English DT Article DE c-Jun N-terminal kinase; Inducible nitric oxide synthase; Liver transplantation; Mitochondrial permeability transition; Non-heart-beating donors; Primary non-function; Sab ID MITOCHONDRIAL PERMEABILITY TRANSITION; NITRIC-OXIDE SYNTHASE; HEART-BEATING DONORS; N-TERMINAL KINASE; HEPATIC ISCHEMIA-REPERFUSION; GRAFT INJURY; ISCHEMIA/REPERFUSION INJURY; SIGNALING PATHWAYS; OXIDATIVE STRESS; INHIBITION AB Background & Aims: Inclusion of liver grafts from cardiac death donors (CDD) would increase the availability of donor livers but is hampered by a higher risk of primary non-function. Here, we seek to determine mechanisms that contribute to primary non-function of liver grafts from CDD with the goal to develop strategies for improved function and outcome, focusing on c-Jun-N-terminal kinase (JNK) activation and mitochondrial depolarization, two known mediators of graft failure. Methods: Livers explanted from wild-type, inducible nitric oxide synthase knockout (iNOS(-/-)), JNK1(-/-) or JNK2(-/-) mice after 45-min aorta clamping were implanted into wild-type recipients. Mitochondrial depolarization was detected by intravital confocal microscopy in living recipients. Results: After transplantation of wild-type CDD livers, graft iNOS expression and 3-nitrotyrosine adducts increased, but hepatic endothelial NOS expression was unchanged. Graft injury and dysfunction were substantially higher in CDD grafts than in non-CDD grafts. iNOS deficiency and inhibition attenuated injury and improved function and survival of CDD grafts. JNK1/2 and apoptosis signal-regulating kinase-1 activation increased markedly in wild-type CDD grafts, which was blunted by iNOS deficiency. JNK inhibition and JNK2 deficiency, but not JNK1 deficiency, decreased injury and improved function and survival of CDD grafts. Mitochondrial depolarization and binding of phospho-JNK2 to Sab, a mitochondrial protein linked to the mitochondrial permeability transition, were higher in CDD than in non-CDD grafts. iNOS deficiency, JNK inhibition and JNK2 deficiency all decreased mitochondrial depolarization and blunted ATP depletion in CDD grafts. JNK inhibition and deficiency did not decrease 3-nitrotyrosine adducts in CDD grafts. Conclusion: The iNOS-JNK2-Sab pathway promotes CDD graft failure via increased mitochondrial depolarization, and is an attractive target to improve liver function and survival in CDD liver transplantation recipients. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha; Schnellmann, Rick G.; Lemasters, John J.; Zhong, Zhi] Med Univ S Carolina, Dept Drug Discovery & Biol Sci, Charleston, SC 29425 USA. [Liu, Qinlong] Dalian Med Univ, Affiliated Hosp 2, Dalian, Liaoning, Peoples R China. [Lemasters, John J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA. RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biol Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM zhong@musc.edu FU National Institute of Health [DK70844, DK037034]; Chinese National Natural Foundation [81470878] FX This study was supported, in part, by Grant DK70844 and DK037034 from the National Institute of Health and Grant #81470878 from Chinese National Natural Foundation. NR 49 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD JUL PY 2015 VL 63 IS 1 BP 68 EP 74 DI 10.1016/j.jhep.2015.02.017 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CK6CC UT WOS:000356314400011 PM 25703084 ER PT J AU Peterson, DS Fling, BW Mancini, M Cohen, RG Nutt, JG Horak, FB AF Peterson, Daniel S. Fling, Brett W. Mancini, Martina Cohen, Rajal G. Nutt, John G. Horak, Fay B. TI Dual-task interference and brain structural connectivity in people with Parkinson's disease who freeze SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID PROGRESSIVE SUPRANUCLEAR PALSY; PEDUNCULOPONTINE NUCLEUS; BASAL GANGLIA; GAIT; NETWORK; MOTOR AB Background Freezing of gait in people with Parkinson's disease (PD) is likely related to attentional control (ie, ability to divide and switch attention). However, the neural pathophysiology of altered attentional control in individuals with PD who freeze is unknown. Structural connectivity of the pedunculopontine nucleus has been related to freezing and may play a role in altered attentional control; however, this relationship has not been investigated. We measured whether dual-task interference, defined as the reduction in gait performance during dual-task walking, is more pronounced in individuals with PD who freeze, and whether dual-task interference is associated with structural connectivity and/or executive function in this population. Methods We measured stride length in 13 people with PD with and 12 without freezing of gait during normal and dual-task walking. We also assessed asymmetry of pedunculopontine nucleus structural connectivity via diffusion tensor imaging and performance on cognitive tests assessing inhibition and set-shifting, cognitive domains related to freezing. Results Although stride length was not different across groups, change in stride length between normal and dual-task gait (ie, dual-task interference) was more pronounced in people with PD who freeze compared to non-freezers. Further, in people with PD who freeze, dual-task interference was correlated with asymmetry of pedunculopontine nucleus structural connectivity, Go-NoGo target accuracy (ability to release a response) and simple reaction time. Conclusions These results support the hypothesis that freezing is related to altered attentional control during gait, and suggest that differences in pedunculopontine nucleus connectivity contribute to poorer attentional control in people with PD who freeze. C1 [Peterson, Daniel S.; Fling, Brett W.; Mancini, Martina; Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA. [Peterson, Daniel S.; Fling, Brett W.; Horak, Fay B.] Portland VA Med Ctr, Portland, OR USA. [Cohen, Rajal G.] Univ Idaho, Dept Psychol & Commun Studies, Moscow, ID 83843 USA. RP Peterson, DS (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM petedani@ohsu.edu OI Peterson, Daniel/0000-0002-4639-6544 FU National Institutes of Health via the Morris K. Udall Center for Excellence in Parkinson's Disease Research at the University of Washington; Portland Veterans Affairs Medical Center (VA Merit Award) [E1075-R]; NIH [AG006457]; Medical Research Foundation of Oregon FX This work was supported by grants from National Institutes of Health via the Morris K. Udall Center for Excellence in Parkinson's Disease Research at the University of Washington, Portland Veterans Affairs Medical Center (VA Merit Award: E1075-R), NIH (AG006457) and the Medical Research Foundation of Oregon. NR 39 TC 14 Z9 14 U1 7 U2 23 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD JUL PY 2015 VL 86 IS 7 BP 786 EP 792 DI 10.1136/jnnp-2014-308840 PG 7 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA CK4FU UT WOS:000356179000016 PM 25224677 ER PT J AU Friedlander, AH Chang, TI Hazboun, RC Aghazadehsanai, N AF Friedlander, Arthur H. Chang, Tina I. Hazboun, Renna C. Aghazadehsanai, Nona TI Critique of American Dental Association Council on Scientific Affairs Clinical Practice Guideline: Use of Prophylactic Antibiotics Before Dental Procedures in Patients With Prosthetic Joints SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Editorial Material ID INFECTIONS C1 [Friedlander, Arthur H.] Vet Affairs Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. [Friedlander, Arthur H.; Chang, Tina I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Chang, Tina I.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA 90073 USA. [Hazboun, Renna C.; Aghazadehsanai, Nona] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Sect, Dent Serv, Los Angeles, CA 90073 USA. RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 5 TC 1 Z9 1 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD JUL PY 2015 VL 73 IS 7 BP 1242 EP 1243 DI 10.1016/j.joms.2015.03.052 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CK5ZI UT WOS:000356306900007 PM 25896570 ER PT J AU Busch, RA Curtis, CS Leverson, GE Kudsk, KA AF Busch, Rebecca A. Curtis, Caitlin S. Leverson, Glen E. Kudsk, Kenneth A. TI Use of Piggyback Electrolytes for Patients Receiving Individually Prescribed vs Premixed Parenteral Nutrition SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; nutrition; parenteral formulas; compounding; outcomes research; quality; nutrition support practice; reimbursement ID BLOOD-STREAM INFECTIONS; OUTBREAK AB Background: Parenteral nutrition (PN) is available as individualized prescriptions frequently prepared with an automated compounding device or as commercially prepared premixed solutions. Our institution exclusively used individualized PN until an amino acid shortage forced a temporary switch to premixed solutions. In general, premixed solutions contain lower electrolyte levels than individualized formulations prescribed for patients with normal organ function. We aimed to quantify supplemental intravenous piggyback (IVPB) electrolyte use in adult patients receiving individualized and premixed PN and to quantify any effect on difference in the cost of therapy. Methods: We compared use of supplemental IVPB electrolytes administered to patients receiving PN during consecutive periods prior to and during the amino acid shortage. Electrolyte IVPBs tabulated were potassium chloride, 10 and 20 mEq; magnesium sulfate, 2 g and 4 g; potassium phosphate, 7.5 and 15 mmol; and sodium phosphate, 7.5 and 15 mmol IVPB. Results: There was no statistical difference in the number of PN formulations administered per day during each period (14.7 +/- 3.9 vs 14.0 +/- 2.6, individualized vs premixed, respectively). Total IVPB electrolytes prescribed per day increased significantly from the individualized PN period to the premixed PN period (7.03 +/- 3.8 vs 13.8 +/- 6.8; P < .0001). The additional IVPB electrolyte supplementation required in patients receiving premixed PN was associated with an additional $11,855.74 cost per 30 days of therapy compared with those who received individualized PN. Conclusion: Inpatient use of premixed PN results in a significant increase in IVPB electrolyte supplementation and cost compared with individualized PN use. C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Busch, Rebecca A.; Leverson, Glen E.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI 53792 USA. [Curtis, Caitlin S.] Univ Wisconsin Hosp & Clin, Dept Pharm, Madison, WI 53792 USA. RP Kudsk, KA (reprint author), Univ Wisconsin, G5-341 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Surgical Oncology Research Training Program [T32CA090217-13] FX The project described was supported by the Surgical Oncology Research Training Program (grant number T32CA090217-13). NR 17 TC 3 Z9 3 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JUL PY 2015 VL 39 IS 5 BP 586 EP 590 DI 10.1177/0148607113518583 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CK8SE UT WOS:000356507600010 PM 24390715 ER PT J AU Horan, WP Reise, SP Kern, RS Lee, J Penn, DL Green, MF AF Horan, William P. Reise, Steven P. Kern, Robert S. Lee, Junghee Penn, David L. Green, Michael F. TI Structure and correlates of self-reported empathy in schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Schizophrenia; Empathy; Social functioning; Social cognition; QCAE ID SOCIAL NEUROSCIENCE MEASURES; EMOTION REGULATION; COGNITIVE EMPATHY; CLINICAL-TRIALS; ACCURACY; PERSPECTIVE; SUPPRESSION; COMPETENCE; PSYCHOSIS; DEFICITS AB Research on empathy in schizophrenia has relied on dated self-report scales that do not conform to contemporary social neuroscience models of empathy. The current study evaluated the structure and correlates of the recently-developed Questionnaire of Cognitive and Affective Empathy (QCAE) in schizophrenia. This measure, whose structure and validity was established in healthy individuals, includes separate scales to assess the two main components of empathy: Cognitive Empathy (assessed by two subscales) and Affective Empathy (assessed by three subscales). Stable outpatients with schizophrenia (n = 145) and healthy individuals (n = 45) completed the QCAE, alternative measures of empathy, and assessments of clinical symptoms, neurocognition, and functional outcome. Exploratory and confirmatory factor analyses provided consistent support for a two-factor solution in the schizophrenia group, justifying the use of separate cognitive and affective empathy scales in this population. However, one of the three Affective Empathy subscales was not psychometrically sound and was excluded from further analyses. Patients reported significantly lower Cognitive Empathy but higher Affective Empathy than controls. Among patients, the QCAE scales showed significant correlations with an alternative self-report empathy scale, but not with performance on an empathic accuracy task. The QCAE Cognitive Empathy subscales also showed significant, though modest, correlations with negative symptoms and functional outcome. These findings indicate that structure of self-reported empathy is similar in people with schizophrenia and healthy subjects, and can be meaningfully compared between groups. They also contribute to emerging evidence that some aspects of empathy may be intact or hyper-responsive in schizophrenia. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Horan, William P.; Kern, Robert S.; Lee, Junghee; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Horan, William P.; Kern, Robert S.; Lee, Junghee; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Reise, Steven P.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Penn, David L.] Univ N Carolina, Chapel Hill, NC USA. [Penn, David L.] Australian Catholic Univ, Melbourne, Vic, Australia. RP Horan, WP (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC 210A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU National Institute of Mental Health [MH087618, MH043292, MH065707] FX National Institute of Mental Health (MH087618, MH043292, and MH065707 to M.F.G.) NR 51 TC 7 Z9 7 U1 2 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JUL-AUG PY 2015 VL 66-67 BP 60 EP 66 DI 10.1016/j.jpsychires.2015.04.016 PG 7 WC Psychiatry SC Psychiatry GA CL2AT UT WOS:000356746700008 PM 25985922 ER PT J AU Tsai, J Armour, C Southwick, SM Pietrzak, RH AF Tsai, Jack Armour, Cherie Southwick, Steven M. Pietrzak, Robert H. TI Dissociative subtype of DSM-5 posttraumatic stress disorder in US veterans SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; Dissociation; Veterans; Substance abuse ID QUALITY-OF-LIFE; AFGHANISTAN VETERANS; NATIONAL-HEALTH; LATENT PROFILE; PTSD TREATMENT; IRAQ; RESILIENCE; DEPRESSION; VALIDATION; HOSTILITY AB The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) formally introduced a dissociative subtype of posttraumatic stress disorder (PTSD). This study examined the proportion of U.S. veterans with DSM-5 PTSD that report dissociative symptoms; and compared veterans with PTSD with and without the dissociative subtype and trauma-exposed controls on sociodemographics, clinical characteristics, and quality of life. Multivariable analyses were conducted on a nationally representative sample of 1484 veterans from the National Health and Resilience in Veterans Study (second baseline survey conducted September October, 2013). Of the 12.0% and 5.2% of veterans who screened positive for lifetime and past-month DSM-5 PTSD, 19.2% and 16.1% screened positive for the dissociative subtype, respectively. Among veterans with PTSD, those with the dissociative subtype reported more severe PTSD symptoms, comorbid depressive and anxiety symptoms, alcohol use problems, and hostility than those without the dissociative subtype. Adjusting for PTSD symptom severity, those with the dissociative subtype continued to report more depression and alcohol use problems. These results underscore the importance of assessing, monitoring, and treating the considerable proportion of veterans with PTSD and dissociative symptoms. Published by Elsevier Ltd. C1 [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland. [Southwick, Steven M.; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. RP Tsai, J (reprint author), 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM jack.Tsai@yale.edu OI Tsai, Jack/0000-0002-0329-648X; Armour, Cherie/0000-0001-7649-3874 FU U.S. Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder; U.S. Department of Veterans Affairs, Health Services Research and Development FX This work received no specific grant from any funding agency, commercial or not-for-profit sectors. This work was supported by the U.S. Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder and the U.S. Department of Veterans Affairs, Health Services Research and Development. The views presented here are those of the authors alone and do not represent the position of the United States Government. NR 52 TC 5 Z9 5 U1 7 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JUL-AUG PY 2015 VL 66-67 BP 67 EP 74 DI 10.1016/j.jpsychires.2015.04.017 PG 8 WC Psychiatry SC Psychiatry GA CL2AT UT WOS:000356746700009 PM 25969340 ER PT J AU Nair, A Gan, J Bush-Joseph, C Verma, N Tetreault, MW Saha, K Margulis, A Fogg, L Scanzello, CR AF Nair, A. Gan, J. Bush-Joseph, C. Verma, N. Tetreault, M. W. Saha, K. Margulis, A. Fogg, L. Scanzello, C. R. TI Synovial chemokine expression and relationship with knee symptoms in patients with meniscal tears SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Osteoarthritis; Synovitis; Relative expression; Knee disability; KOOS ID GENE-EXPRESSION; CARTILAGE LOSS; OSTEOARTHRITIS; PAIN; INFLAMMATION; PROGRESSION; BIOMARKERS; FEATURES; SURGERY; INJURY AB Objective: In patients with knee OA, synovitis is associated with knee pain and symptoms. We previously identified synovial mRNA expression of a set of chemokines (CCL19, IL-8, CCL5, XCL-1, CCR7) associated with synovitis in patients with meniscal tears but without radiographic OA. CCL19 and CCR7 were also associated with knee symptoms. This study sought to validate expression of these chemokines and association with knee symptoms in more typical patients presenting for meniscal arthroscopy, many who have pre-existing OA. Design: Synovial fluid (SF) and biopsies were collected from patients undergoing meniscal arthroscopy. Synovial mRNA expression was measured using quantitative RT-PCR. The Knee Injury and Osteoarthritis Outcome Score (KOOS) was administered preoperatively. Regression analyses determined if associations between chemokine mRNA levels and KOOS scores were independent of other factors including radiographic OA. CCL19 in SF was measured by ELISA, and compared to patients with advanced knee OA and asymptomatic organ donors. Results: 90% of patients had intra-operative evidence of early cartilage degeneration. CCL19, IL-8, CCL5, XCL1, CCR7 transcripts were detected in all patients. Synovial CCL19 mRNA levels independently correlated with KOOS Activities of Daily Living (ADL) scores (95% CI [-8.071, -0.331], P = 0.036), indicating higher expression was associated with more knee-related dysfunction. SF CCL19 was detected in 7 of 10 patients, compared to 4 of 10 asymptomatic donors. Conclusion: In typical patients presenting for meniscal arthroscopy, synovial CCL19 mRNA expression was associated with knee-related difficulty with ADL, independent of other factors including presence of radiographic knee OA. (C) 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Nair, A.; Gan, J.; Saha, K.] Rush Univ, Med Ctr, Div Rheumatol, Chicago, IL 60612 USA. [Bush-Joseph, C.; Verma, N.; Tetreault, M. W.] Rush Univ, Med Ctr, Dept Orthoped, Chicago, IL 60612 USA. [Margulis, A.] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Fogg, L.] Rush Univ, Med Ctr, Dept Community Syst & Mental Hlth Nursing, Chicago, IL 60612 USA. [Scanzello, C. R.] Univ Penn, Perelman Sch Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Scanzello, C. R.] Univ Penn, Perelman Sch Med, Dept Orthoped, Philadelphia, PA 19104 USA. [Scanzello, C. R.] Philadelphia Vet Affairs Med Ctr, Dept Med, Rheumatol Sect, Philadelphia, PA USA. RP Scanzello, CR (reprint author), Univ Penn, Perelman Sch Med, Div Rheumatol, 3400 Spruce St,8th Floor Penn Tower, Philadelphia, PA 19104 USA. EM cscanz@upenn.edu OI Tetreault, Matthew/0000-0003-3584-9285 FU NIAMS NIH HHS [K08 AR057859, K08AR057859] NR 32 TC 4 Z9 4 U1 2 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD JUL PY 2015 VL 23 IS 7 BP 1158 EP 1164 DI 10.1016/j.joca.2015.02.016 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA CK7WM UT WOS:000356446300017 PM 25724256 ER PT J AU Maher, TM Piper, A Song, YL Restrepo, MI Eves, ND AF Maher, Toby M. Piper, Amanda Song, Yuanlin Restrepo, Marcos I. Eves, Neil D. TI Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease SO RESPIROLOGY LA English DT Review DE acute respiratory distress syndrome; bronchiectasis; interstitial lung disease; lung function; obstructive sleep apnoea ID IDIOPATHIC PULMONARY-FIBROSIS; POSITIVE AIRWAY PRESSURE; THORACIC GAS-COMPRESSION; OBESITY HYPOVENTILATION SYNDROME; MESENTERIC FAT THICKNESS; NON-CF BRONCHIECTASIS; SERUM CYSTATIN-C; HEART-FAILURE; TRANSBRONCHIAL CRYOBIOPSY; NONINVASIVE VENTILATION C1 [Maher, Toby M.] Royal Brompton Hosp, Natl Inst Hlth Res, Resp Biomed Res Unit, London SW3 6LY, England. [Maher, Toby M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart Lung Inst, Ctr Leukocyte Biol, Fibrosis Res Grp, London SW7 2AZ, England. [Piper, Amanda] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia. [Piper, Amanda] Univ Sydney, Woolcock Inst Med Res, Circadian Grp, Sydney, NSW 2006, Australia. [Song, Yuanlin] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200433, Peoples R China. [Song, Yuanlin] Fudan Univ, Qingpu Branch, Shanghai 200433, Peoples R China. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Eves, Neil D.] Univ British Columbia, Sch Hlth & Exercise Sci, Fac Hlth & Social Dev, Ctr Heart Lung & Vasc Hlth, Kelowna, BC, Canada. RP Maher, TM (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart Lung Inst, Ctr Leukocyte Biol, Fibrosis Res Grp, Sir Alexander Fleming Bldg, London SW7 2AZ, England. EM t.maher@imperial.ac.uk FU National Heart, Lung, and Blood Institute [K23HL096054] FX M.I.R.'s time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health, nor the Department of Veteran Affairs. NR 117 TC 1 Z9 1 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD JUL PY 2015 VL 20 IS 5 BP 834 EP 845 DI 10.1111/resp.12532 PG 12 WC Respiratory System SC Respiratory System GA CK6XH UT WOS:000356371600023 PM 25824415 ER PT J AU Almli, LM Stevens, JS Smith, AK Kilaru, V Meng, Q Flory, J Abu-Amara, D Hammamieh, R Yang, RT Mercer, KB Binder, EB Bradley, B Hamilton, S Jett, M Yehuda, R Marmar, CR Ressler, KJ AF Almli, Lynn M. Stevens, Jennifer S. Smith, Alicia K. Kilaru, Varun Meng, Qian Flory, Janine Abu-Amara, Duna Hammamieh, Rasha Yang, Ruoting Mercer, Kristina B. Binder, Elizabeth B. Bradley, Bekh Hamilton, Steven Jett, Marti Yehuda, Rachel Marmar, Charles R. Ressler, Kerry J. TI A genome-wide identified risk variant for PTSD is a methylation quantitative trait locus and confers decreased cortical activation to fearful faces SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE GWAS; PTSD; fMRI; meQTL; epigenetic ID POSTTRAUMATIC-STRESS-DISORDER; DNA METHYLATION; ASSOCIATION; SYMPTOMS; AMYGDALA; POLYMORPHISM; POPULATION; EXPRESSION; INVENTORY; RECEPTOR AB Genetic factors appear to be highly relevant to predicting differential risk for the development of post-traumatic stress disorder (PTSD). In a discovery sample, we conducted a genome-wide association study (GWAS) for PTSD using a small military cohort (Systems Biology PTSD Biomarkers Consortium; SBPBC, N=147) that was designed as a case-controlled sample of highly exposed, recently returning veterans with and without combat-related PTSD. A genome-wide significant single nucleotide polymorphism (SNP), rs717947, at chromosome 4p15 (N=147, =31.34, P=1.28x10(-8)) was found to associate with the gold-standard diagnostic measure for PTSD (the Clinician Administered PTSD Scale). We conducted replication and follow-up studies in an external sample, a larger urban community cohort (Grady Trauma Project, GTP, N=2006), to determine the robustness and putative functionality of this risk variant. In the GTP replication sample, SNP rs717947 associated with PTSD diagnosis in females (N=2006, P=0.005), but not males. SNP rs717947 was also found to be a methylation quantitative trait locus (meQTL) in the GTP replication sample (N=157, P=0.002). Further, the risk allele of rs717947 was associated with decreased medial and dorsolateral cortical activation to fearful faces (N=53, P<0.05) in the GTP replication sample. These data identify a genome-wide significant polymorphism conferring risk for PTSD, which was associated with differential epigenetic regulation and with differential cortical responses to fear in a replication sample. These results may provide new insight into understanding genetic and epigenetic regulation of PTSD and intermediate phenotypes that contribute to this disorder. (c) 2015 Wiley Periodicals, Inc. C1 [Almli, Lynn M.; Stevens, Jennifer S.; Smith, Alicia K.; Kilaru, Varun; Mercer, Kristina B.; Binder, Elizabeth B.; Bradley, Bekh; Ressler, Kerry J.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Meng, Qian] Univ Med Ctr, Dept Psychiat, New York, NY USA. [Flory, Janine; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY USA. [Flory, Janine; Yehuda, Rachel] Traumat Stress Studies Div, New York, NY USA. [Abu-Amara, Duna; Marmar, Charles R.] NYU, Dept Psychiat, Steven & Alexandra Cohen Vet Ctr Posttraumat Stre, New York, NY 10016 USA. [Hammamieh, Rasha; Jett, Marti] US Army Ctr Environm Hlth Res, Integrat Syst Biol, Ft Detrick, MD USA. [Yang, Ruoting] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Adv Biomed Comp Ctr, Frederick, MD USA. [Binder, Elizabeth B.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, D-80804 Munich, Germany. [Bradley, Bekh] Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Atlanta, GA USA. [Hamilton, Steven] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Ressler, Kerry J.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP Ressler, KJ (reprint author), Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. EM kressle@emory.edu FU National Institutes of Mental Health [MH071537, MH096764]; Department of Defense [W81XWH-09-2-0044, W911NF-09-1-0298]; Emory and Grady Memorial Hospital General Clinical Research Center; NIH National Centers for Research Resources [M01RR00039]; Howard Hughes Medical Institute; Steven and Alexandra Cohen Foundation; National Center for Advancing Translational Sciences [UL1TR000067] FX Grant sponsor: National Institutes of Mental Health; Grant numbers: MH071537, MH096764; Grant sponsor: Department of Defense; Grant numbers: W81XWH-09-2-0044, W911NF-09-1-0298; Grant sponsor: Emory and Grady Memorial Hospital General Clinical Research Center; Grant sponsor: NIH National Centers for Research Resources; Grant number: M01RR00039; Grant sponsor: Howard Hughes Medical Institute; Grant sponsor: Steven and Alexandra Cohen Foundation; Grant sponsor: National Center for Advancing Translational Sciences; Grant number: #UL1TR000067. NR 43 TC 12 Z9 12 U1 2 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD JUL PY 2015 VL 168 IS 5 BP 327 EP 336 DI 10.1002/ajmg.b.32315 PG 10 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA CK2XW UT WOS:000356079700002 PM 25988933 ER PT J AU Dey, N Bera, A Das, F Ghosh-Choudhury, N Kasinath, BS Choudhury, GG AF Dey, Nirmalya Bera, Amit Das, Falguni Ghosh-Choudhury, Nandini Kasinath, Balakuntalam S. Choudhury, Goutam Ghosh TI High glucose enhances microRNA-26a to activate mTORC1 for mesangial cell hypertrophy and matrix protein expression SO CELLULAR SIGNALLING LA English DT Article DE MicroRNA; Diabetic nephropathy; mTOR; Mesangial cell pathology ID INDUCED COLLAGEN EXPRESSION; MESSENGER-RNA TRANSLATION; TUBULAR EPITHELIAL-CELLS; NF-KAPPA-B; DIABETIC-NEPHROPATHY; PTEN EXPRESSION; TENSIN HOMOLOG; AKT KINASE; TARGETING PHOSPHATASE; DOWN-REGULATION AB High glucose milieu inhibits PTEN expression to activate Akt kinase and induces glomerular mesangial cell hypertrophy and matrix protein expression in diabetic nephropathy. Specific mechanism by which high glucose inhibits PTEN expression is not clear. We found that high glucose increased the expression of the microRNA-26a (miR-26a) in mesangial cells. Using a sensor plasmid with 3'UTR-driven luciferase, we showed PTEN as a target of miR-26a in response to high glucose. Overexpression of miR-26a reduced the PTEN protein levels resulting in increased Akt kinase activity similar to high glucose treatment. In contrast, anti-miR-26a reversed high glucose-induced suppression of PTEN with concomitant inhibition of Akt kinase activity. Akt-mediated phosphorylation of tuberin and PRAS40 regulates mTORC1, which is necessary for mesangial cell hypertrophy and matrix protein expression. Inhibition of high glucose-induced miR-26a blocked phosphorylation of tuberin and PRAS40, which lead to suppression of phosphorylation of S6 kinase and 4EBP-1, two substrates of mTORC1. Furthermore, we show that expression of miR-26a induced mesangial cell hypertrophy and increased fibronectin and collagen I (alpha 2) expression similar to that observed with the cells incubated with high glucose. Anti-miR-26a inhibited these phenomena in response to high glucose. Together our results provide the first evidence for the involvement of miR-26a in high glucose-induced mesangial cell hypertrophy and matrix protein expression. These data indicate the potential therapeutic utility of anti-miR-26a for the complications of diabetic kidney disease. Published by Elsevier Inc. C1 [Dey, Nirmalya; Bera, Amit; Das, Falguni; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU NIH [RO1 DK50190]; VA Research Service Merit Review [5I01BX000926]; VA Senior Research Career Scientist Award; VA Merit Review grants [5I01BX000150, 5I01BX001340] FX This work was supported by the NIH RO1 DK50190 and VA Research Service Merit Review 5I01BX000926 grants to GGC. GGC is a recipient of VA Senior Research Career Scientist Award. NGC AND BSK are supported by VA Merit Review grants 5I01BX000150 and 5I01BX001340, respectively. NR 55 TC 11 Z9 12 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD JUL PY 2015 VL 27 IS 7 BP 1276 EP 1285 DI 10.1016/j.cellsig.2015.03.007 PG 10 WC Cell Biology SC Cell Biology GA CK0HY UT WOS:000355887500002 PM 25797045 ER PT J AU Ozieh, MN Dismuke, CE Lynch, CP Egede, LE AF Ozieh, Mukoso N. Dismuke, Clara E. Lynch, Cheryl P. Egede, Leonard E. TI Medical care expenditures associated with chronic kidney disease in adults with diabetes: United States 2011 SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Diabetes; Chronic kidney disease; Cost; MEPS ID COMPLICATIONS; MORTALITY; MELLITUS; BURDEN; COSTS AB Objective: Approximately 1 in 3 adults with diabetes have CKD. However, there are no recent national estimates of the association of CKD with medical care expenditures in individuals with diabetes. Our aim is to assess the association of CKD with total medical expenditures in US adults with diabetes using a national sample and novel cost estimation methodology. Research design and methods: Data on 2,053 adults with diabetes in the 2011 Medical Expenditure Panel Survey (MEPS) was analyzed. Individuals with CKD were identified based on self-report. Adjusted mean health services expenditures per person in 2011 were estimated using a two-part model after adjusting for demographic and clinical covariates. Results: Of the 2,053 individuals with diabetes, approximately 9.7% had self-reported CKD. Unadjusted mean expenditures for individuals with CKD were $ 20,726 relative to $ 9,689.49 for no CKD. Adjusted mean expenditures from the 2-part model for individuals with CKD were $ 8473 higher relative to individuals without CKD. Additional significant covariates were Hispanic/other race, uninsured, urban dwellers, CVD, stroke, high cholesterol, arthritis, and asthma. The estimated unadjusted total expenditures for individuals with CKD were estimated to be in excess of $ 43 billion in 2011. Conclusions: We showed that CKD is a significant contributor to the financial burden among individuals with diabetes, and that minorities and the uninsured with CKD may experience barriers in access to care. Our study also provides a baseline national estimate of CKD cost in Diabetes by which future studies can be used for comparison. Published by Elsevier Ireland Ltd. C1 [Ozieh, Mukoso N.] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Ozieh, Mukoso N.; Dismuke, Clara E.; Lynch, Cheryl P.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Dismuke, Clara E.; Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699] FX This study was supported by Grant K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 17 TC 13 Z9 13 U1 3 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 EI 1872-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD JUL PY 2015 VL 109 IS 1 BP 185 EP 190 DI 10.1016/j.diabres.2015.04.011 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CK4YA UT WOS:000356228100026 PM 25935258 ER PT J AU Goldman, SM Umbach, DM Kamel, F Tanner, CM AF Goldman, S. M. Umbach, D. M. Kamel, F. Tanner, C. M. TI Head injury, alpha-synuclein Rep1 and Parkinson's disease: a meta-analytic view of gene-environment interaction SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Letter DE alpha-synuclein; epidemiology; gene-environment interaction; genetic association study; Parkinson's disease; traumatic brain injury C1 [Goldman, S. M.; Tanner, C. M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Goldman, S. M.; Tanner, C. M.] Univ Calif San Francisco, Neurol, San Francisco, CA 94143 USA. [Umbach, D. M.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA. [Kamel, F.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. RP Goldman, SM (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 127-P, San Francisco, CA 94121 USA. EM samuel.goldman@ucsf.edu OI Kamel, Freya/0000-0001-5052-6615 NR 3 TC 1 Z9 1 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD JUL PY 2015 VL 22 IS 7 BP E75 EP E75 DI 10.1111/ene.12694 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CK3BP UT WOS:000356090800002 PM 26060929 ER PT J AU Mashmoushi, AK Oates, JC AF Mashmoushi, Ahmad K. Oates, Jim C. TI Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1 alpha and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Podocyte; Toll-like receptor 4; Nitric oxide; Superoxide; Lipopolysaccharide; Hypoxia-inducible factor 1 alpha; Cell division control protein 42; Ras-related C3 botulinum toxin substrate 1; Inducible nitric oxide synthase; Lupus nephritis; Peroxynitrite Free radicals ID TOLL-LIKE RECEPTORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IN-VIVO; AUTOIMMUNE-DISEASE; NEPHROTIC SYNDROME; MRL/LPR MICE; EXPRESSION; KIDNEY; NEPHRITIS; INJURY AB Urine protein loss in immune complex-mediated diseases such as lupus nephritis is associated with podocyte foot process effacement (podocytopathy) but is not always dependent on glomerular immune complex deposition. Several murine and human studies have associated lupus nephritis with inducible nitric oxide synthase (iNOS) expression in what appear to be podocytes. This study was conducted to determine mechanisms of immune-complex-independent and iNOS-dependent podocyte dysfunction. Conditionally immortalized podocytes were Cultured with lipopolysaccharide (LPS) and nitric oxide (NO), superoxide (SO), or peroxynitrite donors in the presence or absence of inhibitors of iNOS, reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase or monocyte chemotactic protein 1 (MCP-1), or with sepiapterin to increase coupling of iNOS homodimers. Podocyte NO, SO, and MCP-1 production and nitrotyrosine modifications were determined. The podocytopathy phenotype was determined by measuring cell Motility and membrane permeability to albumin. This study determined that NO produced by iNOS is sufficient and necessary to induce podocytopathy. NO probably induces this phenotype via hypoxia-inducible factor, its and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathways. With LPS stimulation, neither SO nor peroxynitrite produced by uncoupled iNOS or NADPH oxidase nor MCP-1 was sufficient to induce the full phenotype. This study supports the notion that iNOS may induce autocrine podocyte dysfunction. Thus, targeting iNOS or the pathways of its induction may have therapeutic benefit. Published by Elsevier Inc. C1 [Mashmoushi, Ahmad K.; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Oates, Jim C.] Ralph H Johnson VA Med Ctr, Rheumatol Sect, Med Serv, Charleston, SC 29401 USA. RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU Veterans Affairs Administration [5I01CX000218]; National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR045476] FX We give special thanks to Dr. Jeffery Kopp at the National Institute of Diabetes, Digestive, and Kidney Diseases in Bethesda, Maryland, for generously providing the conditionally immortalized podocytes. Thanks go to Dr. Julie Chao for technical assistance with the lucigenin assay protocol and Ms. May Amria for assistance with the transepithelial resistance assay. This work was funded by grants from the Veterans Affairs Administration (VA Merit Project 5I01CX000218) and the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR045476). None of these funding agencies played a role in the design, conduct, or reporting of this study. NR 57 TC 3 Z9 3 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JUL PY 2015 VL 84 BP 185 EP 195 DI 10.1016/j.freeradbiomed.2015.02.031 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CK0LK UT WOS:000355896500017 PM 25765888 ER PT J AU Yoong, SL Hall, A Williams, CM Skelton, E Oldmeadow, C Wiggers, J Karimkhani, C Boyers, LN Dellavalle, RP Hilton, J Wolfenden, L AF Yoong, Sze Lin Hall, Alix Williams, Christopher M. Skelton, Eliza Oldmeadow, Christopher Wiggers, John Karimkhani, Chante Boyers, Lindsay N. Dellavalle, Robert P. Hilton, John Wolfenden, Luke TI Alignment of systematic reviews published in the Cochrane Database of Systematic Reviews and the Database of Abstracts and Reviews of Effectiveness with global burden-of-disease data: a bibliographic analysis SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Review ID HEALTH-CARE; ASSOCIATION AB Background Systematic reviews of high-quality evidence are used to inform policy and practice. To improve community health, the production of such reviews should align with burden of disease. This study aims to assess if the volume of research output from systematic reviews proportionally aligns with burden of disease assessed using percentages of mortality and disability-adjusted life years (DALYs). Methods A cross-sectional audit of reviews published between January 2012 and August 2013 in the Cochrane Database of Systematic Reviews (CDSR) and Database of Abstracts of Reviews of Effects (DARE) was undertaken. Percentages of mortality and DALYs were obtained from the 2010 Global Burden of Disease study. Standardised residual differences (SRD) based on percentages of mortality and DALYs were calculated, where conditions with SRD of more than or less than three were considered overstudied or understudied, respectively. Results 1029 reviews from CDSR and 1928 reviews from DARE were examined. There was a significant correlation between percentage DALYs and systematic reviews published in CDSR and DARE databases (CDSR: r=0.68, p=0.001; DARE: r=0.60, p<0.001). There was no significant correlation between percentage mortality and number of systematic reviews published in either database (CDSR: r=0.34, p=0.14; DARE: r=0.22, p=0.34). Relative to percentage of mortality, mental and behavioural disorders, musculoskeletal conditions and other non-communicable diseases were overstudied. Maternal disorders were overstudied relative to percentages of mortality and DALYs in CDSR. Conclusions The focus of systematic reviews is moderately correlated with DALYs. A number of conditions may be overstudied relative to percentage of mortality particularly in the context of health and medical reviews. C1 [Yoong, Sze Lin; Williams, Christopher M.; Wiggers, John; Wolfenden, Luke] Hunter New England Populat Hlth, Wallsend, NSW 2287, Australia. [Yoong, Sze Lin; Hall, Alix; Williams, Christopher M.; Skelton, Eliza; Oldmeadow, Christopher; Wiggers, John; Wolfenden, Luke] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia. [Yoong, Sze Lin; Hall, Alix; Williams, Christopher M.; Oldmeadow, Christopher; Wiggers, John; Wolfenden, Luke] Hunter Med Res Inst, New Lambton, NSW, Australia. [Oldmeadow, Christopher] George Inst Global Hlth, Sydney, NSW, Australia. [Karimkhani, Chante] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Dellavalle, Robert P.] Dermatol Serv, US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Hilton, John] Cochrane Collaborat, Cochrane Editorial Unit, London, England. RP Yoong, SL (reprint author), Hunter New England Populat Hlth, Locked Bag 10, Wallsend, NSW 2287, Australia. EM Serene.Yoong@hnehealth.nsw.gov.au OI Hilton, John/0000-0002-1607-3250; Wolfenden, Luke/0000-0002-6178-3868 FU Australian National and Medical Research Council Career Development Fellowship [APP1041867]; US Department of Veterans Affairs; Centers for Disease Control and Prevention [CDC 3U48DP001938-0451]; National Institutes of Health [NCI R21 CA173654] FX This work was supported by the Hunter Medical Research Institute and Hunter New England Population Health through providing infrastructure support. LW is supported by an Australian National and Medical Research Council Career Development Fellowship APP1041867. RPD is supported by a salary from the US Department of Veterans Affairs and grants from the Centers for Disease Control and Prevention (CDC 3U48DP001938-0451 (PI:Crane), and the National Institutes of Health (NCI R21 CA173654 (PI:Walkocz). JH is an employee of The Cochrane Collaboration which produces the Cochrane Database of Systematic Reviews. NR 32 TC 1 Z9 1 U1 2 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X EI 1470-2738 J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD JUL PY 2015 VL 69 IS 7 BP 708 EP 714 DI 10.1136/jech-2014-205389 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK4BS UT WOS:000356164200017 PM 25888595 ER PT J AU Bird, ER Gilmore, AK George, WH Lewis, MA AF Bird, E. R. Gilmore, A. K. George, W. H. Lewis, M. A. TI A CYCLE OF RISK? THE ROLE OF SOCIAL DRINKING FACTORS IN THE RELATIONSHIP BETWEEN INCAPACITATED SEXUAL ASSAULT AND DRINKING BEFORE SEX SO JOURNAL OF SEXUAL MEDICINE LA English DT Meeting Abstract C1 [Bird, E. R.; George, W. H.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Gilmore, A. K.] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98101 USA. [Lewis, M. A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD JUL PY 2015 VL 12 SU 4 SI SI MA 038 BP 285 EP 285 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CK2VJ UT WOS:000356071800034 ER PT J AU Linos, E Berger, T Chren, MM AF Linos, Eleni Berger, Timothy Chren, Mary-Margaret TI Point: Care of potential low-risk basal cell carcinomas (BCCs) at the end of life The key role of the dermatologist SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Editorial Material DE basal cell carcinoma; elders; end of life; skin cancer; squamous cell carcinoma ID SKIN-CANCER C1 [Linos, Eleni; Berger, Timothy; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Berger, Timothy; Chren, Mary-Margaret] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA. RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Room N421,Mail Code Box 0808, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700 FU NCATS NIH HHS [KL2TR000143]; NIA NIH HHS [P30AG044281]; NIAMS NIH HHS [5K24AR052667-09] NR 9 TC 6 Z9 6 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUL PY 2015 VL 73 IS 1 BP 158 EP 161 DI 10.1016/j.jaad.2015.02.005 PG 4 WC Dermatology SC Dermatology GA CK6BZ UT WOS:000356314100038 PM 26089051 ER PT J AU Yu, MK Katon, W Young, BA AF Yu, Margaret K. Katon, Wayne Young, Bessie A. TI Associations between sex and incident chronic kidney disease in a prospective diabetic cohort SO NEPHROLOGY LA English DT Article DE chronic renal insufficiency; diabetes mellitus; health disparity; vulnerable population; women's health ID GLOMERULAR-FILTRATION-RATE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SELF-CARE; DEPRESSION; CKD; NEPHROPATHY; DISPARITIES; MELLITUS; MDRD AB AimWomen with diabetes have a higher prevalence of chronic kidney disease (CKD) risk factors compared with men, but whether they are at higher risk for incident CKD remains uncertain. MethodsThis was a prospective, observational cohort study of 1464 patients with diabetes and normal renal function, recruited from primary care clinics at a vertically integrated healthcare system in Seattle, WA, USA. The primary predictor was sex. Incident CKD was defined by an estimated glomerular filtration rate (eGFR)<60mL/min per 1.73m(2) by Chronic Kidney Disease-Epidemiology equations or sex-specific microalbuminuria (urine albumin/creatinine ratio 25mg/g for women or 17mg/g for men). ResultsOf the 1464 patients (52.0% women), CKD incidence rates were 154.0 and 144.3 cases per 1000 patient-years for women and men, respectively. In the competing risks regression, women had an increased risk of incident CKD (sub-hazard ratio 1.37, 95% confidence interval (CI) 1.17, 1.60) compared with men after adjustment for demographics, baseline eGFR and duration of diabetes, which persisted after additional adjustment for CKD risk factors, depressive symptoms and diabetes self-care (sub-hazard ratio 1.35, 95% CI 1.15, 1.59). Sex differences in incident CKD were consistent across age groups and appeared to be driven by differences in the development of low eGFR rather than microalbuminuria. ConclusionWomen with diabetes had a higher risk of incident CKD compared with men, which could not be entirely explained by differences in biologic CKD risk factors, depression or diabetes self-care. Additional work is needed determine if these sex differences contribute to worse outcomes in women with diabetes. Summary at a Glance The authors have evaluated associations between sex and chronic kidney disease (CKD) incidence in a primary care population with diabetes using Chronic Kidney Disease-Epidemiology equations for estimating glomerular filtration rate (GFR) and sex-specific definitions of microalbuminuria. They found that women had an increased risk of incident CKD compared with men. They also found that this difference in incident CKD was primarily driven by differences in incident eGFR<60mL/min per 1.73m(2). C1 [Yu, Margaret K.; Young, Bessie A.] VA Puget Sound Hlth Care Syst, Ctr Innovat, VA Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Yu, Margaret K.; Young, Bessie A.] Univ Washington, Sch Med, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Katon, Wayne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Yu, Margaret K.; Young, Bessie A.] Kidney Res Inst, Seattle, WA USA. RP Yu, MK (reprint author), VA Puget Sound Hlth Care Syst, 1100 Olive Way Suite 1400, Seattle, WA 98101 USA. EM mkyu@uw.edu FU National Institutes of Health National Institute of Diabetes, Digestive, and Kidney Diseases [DK079745]; National Institute of Mental Health [MH41739, MH01643]; American Kidney Fund; VA Advanced Fellowship Program in Health Services Research and Development; American Kidney Fund's Clinical Scientist in Nephrology Program; VA Puget Sound Health Care System FX This work was supported by research grants by the National Institutes of Health National Institute of Diabetes, Digestive, and Kidney Diseases (DK079745) and National Institute of Mental Health (MH41739, MH01643) and the American Kidney Fund. Dr. Yu was supported by the VA Advanced Fellowship Program in Health Services Research and Development and the American Kidney Fund's Clinical Scientist in Nephrology Program. Dr. Young was supported by the VA Puget Sound Health Care System. The study sponsor had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. NR 32 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1320-5358 EI 1440-1797 J9 NEPHROLOGY JI Nephrology PD JUL PY 2015 VL 20 IS 7 BP 451 EP 458 DI 10.1111/nep.12468 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CK2ZK UT WOS:000356084100003 PM 25807970 ER PT J AU Sayer, NA Orazem, RJ Noorbaloochi, S Gravely, A Frazier, P Carlson, KF Schnurr, PP Oleson, H AF Sayer, Nina A. Orazem, Robert J. Noorbaloochi, Siamak Gravely, Amy Frazier, Patricia Carlson, Kathleen F. Schnurr, Paula P. Oleson, Heather TI Iraq and Afghanistan War Veterans with Reintegration Problems: Differences by Veterans Affairs Healthcare User Status SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Veterans; Healthcare service needs; Mental health; Posttraumatic stress disorder; Traumatic brain injury; Department of Veterans Affairs Healthcare ID TRAUMATIC BRAIN-INJURY; FREEDOM VETERANS; BINGE DRINKING; MEDICAL-CARE; DEPLOYMENT; MILITARY; SOLDIERS; DIAGNOSES; SERVICES; RISK AB We studied 1,292 Iraq and Afghanistan War veterans who participated in a clinical trial of expressive writing to estimate the prevalence of perceived reintegration difficulty and compare Veterans Affairs (VA) healthcare users to nonusers in terms of demographic and clinical characteristics. About half of participants perceived reintegration difficulty. VA users and nonusers differed in age and military background. Levels of mental and physical problems were higher in VA users. In multivariate analysis, military service variables and probable traumatic brain injury independently predicted VA use. Findings demonstrate the importance of research comparing VA users to nonusers to understand veteran healthcare needs. C1 [Sayer, Nina A.; Orazem, Robert J.; Noorbaloochi, Siamak; Gravely, Amy; Oleson, Heather] Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. [Sayer, Nina A.; Noorbaloochi, Siamak] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Frazier, Patricia] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Carlson, Kathleen F.] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR USA. [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA. [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Sayer, NA (reprint author), Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, One Vet Dr, Minneapolis, MN 55417 USA. EM nina.sayer@va.gov RI Sayer, Nina/E-3249-2016 FU Department of Veterans Affairs (VA); Health Services Research and Development (HSRD) Service [DHI-07-150]; Department of Defense (DoD) [08-2-0045] FX This research was supported by the Department of Veterans Affairs (VA), Health Services Research and Development (HSR&D) Service (Grant No. DHI-07-150) and the Department of Defense (DoD) (Grant No. 08-2-0045). The sponsors were not involved in any aspect of the study's design and conduct; data collection, management, analysis, or interpretation of data; or in the preparation, review or approval of the manuscript. The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the VA, HSR&D, or DoD. NR 39 TC 5 Z9 5 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD JUL PY 2015 VL 42 IS 4 BP 493 EP 503 DI 10.1007/s10488-014-0564-2 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CJ7EC UT WOS:000355656100012 PM 24913102 ER PT J AU Papesh, MA Billings, CJ Baltzell, LS AF Papesh, Melissa A. Billings, Curtis J. Baltzell, Lucas S. TI Background noise can enhance cortical auditory evoked potentials under certain conditions SO CLINICAL NEUROPHYSIOLOGY LA English DT Article DE Electroencephalography; Event related potential; Hearing; Human; Presentation rate; Speech ID STOCHASTIC RESONANCE; BINAURAL INTERACTION; NEUROMAGNETIC FIELDS; MIDDLE-LATENCY; COCHLEAR-NERVE; HEARING-LOSS; BRAIN-STEM; SPEECH; RESPONSES; STIMULATION AB Objective: To use cortical auditory evoked potentials (CAEPs) to understand neural encoding in background noise and the conditions under which noise enhances CAEP responses. Methods: CAEPs from 16 normal-hearing listeners were recorded using the speech syllable/ba/presented in quiet and speech-shaped noise at signal-to-noise ratios of 10 and 30 dB. The syllable was presented binaurally and monaurally at two presentation rates. Results: The amplitudes of N1 and N2 peaks were often significantly enhanced in the presence of low-level background noise relative to quiet conditions, while P1 and P2 amplitudes were consistently reduced in noise. P1 and P2 amplitudes were significantly larger during binaural compared to monaural presentations, while N1 and N2 peaks were similar between binaural and monaural conditions. Conclusions: Methodological choices impact CAEP peaks in very different ways. Negative peaks can be enhanced by background noise in certain conditions, while positive peaks are generally enhanced by binaural presentations. Significance: Methodological choices significantly impact CAEPs acquired in quiet and in noise. If CAEPs are to be used as a tool to explore signal encoding in noise, scientists must be cognizant of how differences in acquisition and processing protocols selectively shape CAEP responses. Published by Elsevier Ltd. on behalf of International Federation of Clinical Neurophysiology. C1 [Papesh, Melissa A.; Billings, Curtis J.; Baltzell, Lucas S.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97207 USA. [Billings, Curtis J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Papesh, MA (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM Melissa.Papesh@va.gov FU NIH-NIDCD [R03DC010914]; VA-RRD [CoE C4844C] FX This work was supported by NIH-NIDCD (R03DC010914) and VA-RR&D (CoE C4844C). These funding sources had no role in the design, interpretation, or publishing of this work. NR 43 TC 2 Z9 2 U1 3 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 EI 1872-8952 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD JUL PY 2015 VL 126 IS 7 BP 1319 EP 1330 DI 10.1016/j.clinph.2014.10.017 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CJ9QF UT WOS:000355836600008 PM 25453611 ER PT J AU Hall, DE Hanusa, BH Fine, MJ Arnold, RM AF Hall, Daniel E. Hanusa, Barbara H. Fine, Michael J. Arnold, Robert M. TI Do surgeons and patients discuss what they document on consent forms? SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Informed consent; Shared decision making; Ethics; Cholecystectomy; Herniorrhaphy ID INFORMED DECISION-MAKING; GENERAL-PRACTICE; HAWTHORNE; CONSULTATIONS; QUALITY; DOCTORS; BACK; TIME AB Background: Previous studies of surgeon behavior report that surgeons rarely meet basic standards of informed consent, raising concerns that current practice requires urgent remediation. We wondered if the Veterans Affairs Healthcare System's recent implementation of standardized, procedure-specific consent forms might produce a better practice of informed consent than has been reported previously. Our goal was to determine how the discussions shared between surgeons and patients correspond to the VA's standardized consent forms. Methods: We enrolled a prospective cohort of patients presenting for possible cholecystectomy or inguinal herniorrhaphy and the surgical providers for those patients. Audio recordings captured the clinical encounter(s) culminating in a decision to have surgery. Each patient's informed consent was documented using a standardized, computer-generated form. We abstracted and compared the information documented with the information discussed. Results: Of 75 consecutively enrolled patients, 37 eventually decided to have surgery and signed the standardized consent form. Patients and providers discussed 37% (95% confidence interval, 0.07-0.67) and 33% (95% confidence interval, 0.21-0.43) of the information found on the cholecystectomy and herniorrhaphy consent forms, respectively. However, the patienteprovider discussions frequently included relevant details nowhere documented on the standardized forms, culminating in discussions that included a median 27.5 information items for cholecystectomy and 20 items for herniorrhaphy. Fully, 80% of cholecystectomy discussions and 76% of herniorrhaphy discussions mentioned at least one risk, benefit or alternative, indication for, and description of the procedure. Conclusions: The patients and providers observed here collaborated in a detailed process of informed consent that challenges the initial reports suggesting the need to remediate surgeon's practice of informed consent. However, because the discrepancy between the information documented and discussed exposes legal and ethical liability, there is an opportunity to improve the iMed system so that it better reflects what surgeons discuss and more frequently includes all the information patients need. Published by Elsevier Inc. C1 [Hall, Daniel E.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Hanusa, Barbara H.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA 15240 USA. [Arnold, Robert M.] Univ Pittsburgh, UPMC Montefiore Hosp, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr 151C, Pittsburgh, PA 15240 USA. EM hallde@upmc.edu OI Hall, Daniel/0000-0001-6382-0522 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281]; VISN4 CPPF [XVA 72-057]; VA Center for Health Equity Research and Promotion [LIP 72-043] FX This research was supported by supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (CDA 08-281). It was also supported by the VISN4 CPPF (XVA 72-057) and the VA Center for Health Equity Research and Promotion (LIP 72-043). NR 26 TC 1 Z9 1 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JUL PY 2015 VL 197 IS 1 BP 67 EP 77 DI 10.1016/j.jss.2015.03.058 PG 11 WC Surgery SC Surgery GA CJ5UA UT WOS:000355554900012 PM 25891679 ER PT J AU Ventura, J Ered, A Gretchen-Doorly, D Subotnik, KL Horan, WP Hellemann, GS Nuechterlein, KH AF Ventura, J. Ered, A. Gretchen-Doorly, D. Subotnik, K. L. Horan, W. P. Hellemann, G. S. Nuechterlein, K. H. TI Theory of mind in the early course of schizophrenia: stability, symptom and neurocognitive correlates, and relationship with functioning SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Disorganization; early-course schizophrenia; functioning; neurocognition; theory of mind ID SOCIAL COGNITION; 1ST EPISODE; 1ST-EPISODE SCHIZOPHRENIA; INTENTIONAL MOVEMENT; ASPERGER-SYNDROME; ANIMATED SHAPES; MENTAL STATES; RATING-SCALE; METAANALYSIS; ATTRIBUTION AB Background. Numerous studies have reported links between theory of mind (ToM) deficits, neurocognition and negative symptoms with functional outcome in chronic schizophrenia patients. Although the ToM deficit has been observed in first-episode patients, fewer studies have addressed ToM as a possible trait marker, neurocognitive and symptom correlations longitudinally, and associations with later functioning. Method. Recent-onset schizophrenia patients (n = 77) were assessed at baseline after reaching medication stabilization, and again at 6 months (n = 48). Healthy controls (n = 21) were screened, and demographically comparable with the patients. ToM was assessed with a Social Animations Task (SAT), in which the participants' descriptions of scenes depicting abstract visual stimuli 'interacting' in three conditions (ToM, goal directed and random) were rated for degree of intentionality attributed to the figures and for appropriateness. Neurocognition, symptoms and role functioning were also assessed. Results. On the SAT, patients had lower scores than controls for both intentionality (p < 0.01) and appropriateness (p < 0.01) during the ToM condition, at baseline and 6 months. The ToM deficit was stable and present even in remitted patients. Analyses at baseline and 6 months indicated that for patients, ToM intentionality and appropriateness were significantly correlated with neurocognition, negative symptoms and role functioning. The relationship between ToM and role functioning was mediated by negative symptoms. Conclusions. The ToM deficit was found in recent-onset schizophrenia patients and appears to be moderately trait-like. ToM is also moderately correlated with neurocognition, negative and positive symptoms, and role functioning. ToM appears to influence negative symptoms which in turn makes an impact on role functioning. C1 [Ventura, J.; Ered, A.; Gretchen-Doorly, D.; Subotnik, K. L.; Horan, W. P.; Hellemann, G. S.; Nuechterlein, K. H.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Horan, W. P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. RP Ventura, J (reprint author), Univ Calif Los Angeles, Dept Psychiat, 300 Med Plaza,Room 2243, Los Angeles, CA 90095 USA. EM jventura@ucla.edu FU National Institute of Mental Health [MH37705, P50 MH066286]; Janssen Scientific Affairs, LLC. FX This research was supported in part by National Institute of Mental Health grants MH37705 (principal investigator K.H.N.) and P50 MH066286 (principal investigator K.H.N.), and supplemental support from an investigator-initiated grant from Janssen Scientific Affairs, LLC. The authors would like to thank the following research associates who worked on data collection: Sarah Wilson, Robin Kite, Rachel Wood, Sharon Birman, Jackie Hayata and Lilian Medina. NR 54 TC 10 Z9 10 U1 2 U2 17 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD JUL PY 2015 VL 45 IS 10 BP 2031 EP 2043 DI 10.1017/S0033291714003171 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CJ8MW UT WOS:000355757500003 PM 25647289 ER PT J AU Wilkinson, CW AF Wilkinson, Charles W. TI COMMENTARY ON A NEUROENDOCRINE APPROACH TO PATIENTS WITH TRAUMATIC BRAIN INJURY SO ENDOCRINE PRACTICE LA English DT Editorial Material ID PITUITARY DYSFUNCTION C1 [Wilkinson, Charles W.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Wilkinson, Charles W.] Washington Univ, Sch Med, Dept Psychiat & Behav Sci, St Louis, MO 63130 USA. RP Wilkinson, CW (reprint author), VA Puget Sound Hlth Care Syst, S-182 GRECC,1660 South Columbian Way, Seattle, WA 98108 USA. EM wilkinso@uw.edu FU RRD VA [I01 RX000509] NR 15 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUL PY 2015 VL 21 IS 7 BP 851 EP 853 DI 10.4158/EP15854.CO PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7LQ UT WOS:000377964500018 PM 26172130 ER PT J AU Lugea, A Waldron, RT Pandol, SJ AF Lugea, Aurelia Waldron, Richard T. Pandol, Stephen J. TI Pancreatic adaptive responses in alcohol abuse: Role of the unfolded protein response SO PANCREATOLOGY LA English DT Review DE Pancreas; Pancreatitis; Alcohol; Alcohol abuse; Unfolded protein response; ER stress AB The majority of those who drink excessive amounts of alcohol do not develop pancreatic disease. One over arching hypothesis is that alcohol abuse requires additional risk factors, either environmental or genetic, for disease to occur. However, another reason be a result of alcohol-induced activation of adaptive systems that protect the pancreas from the toxic effects of alcohol. We show that mechanisms within the unfolded protein response (UPR) of the endoplasmic reticulum(ER) that can lead to protection of the pancreas from pancreatic diseases with alcohol abuse. The remarkable ability of the pancreas to adapt its machinery to alcohol abuse using UPR systems and continue functioning is the likely reason that pancreatitis from alcohol abuse does not occur in the majority of heavy drinkers. These findings indicate that methods to enhance the protective responses of the UPR can provide opportunities for prevention and treatment of pancreatic diseases. Copyright (C) 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Pandol, Stephen J.] Cedars Sinai Med Ctr, 8730 Alden Dr,Thalians E222, Los Angeles, CA 90048 USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Pandol, SJ (reprint author), Cedars Sinai Med Ctr, 8730 Alden Dr,Thalians E222, Los Angeles, CA 90048 USA. EM stephen.pandol@cshs.org FU NIH [R01 AA019954, P50 AA11999, P01 CA163200, P01 DK098108]; Department of Veterans Affairs FX NIH grants: R01 AA019954 (to A.L.), P50 AA11999 (S.P.), P01 CA163200 (S.P.), P01 DK098108 (S.P.); and Department of Veterans Affairs (S.P.). NR 56 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD JUL PY 2015 VL 15 IS 4 SU S BP S1 EP S5 DI 10.1016/j.pan.2015.01.011 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V47YB UT WOS:000209986000001 PM 25736240 ER PT J AU Tsukamoto, H AF Tsukamoto, Hidekazu TI Metabolic reprogramming and cell fate regulation in alcoholic liver disease SO PANCREATOLOGY LA English DT Review DE M1 macrophage activation; Iron; Hepatic stellate cells; Morphogens; Wnt; MeCP2 AB Alcoholic liver disease (ALD) should be defined as a life-style metabolic disease. Its pathogenesis is driven by altered cell fate of both parenchymal and non-parenchymal liver cell types, contributing to different pathologic spectra. A critical turning point in progression of ALD is chronic alcoholic steatohepatitis (ASH) or alcoholic neutrophilic hepatitis (AH), which markedly predisposes patients to most devastating ALD sequela, cirrhosis and liver cancer. Results: Our research identifies the pivotal roles of unique metabolic reprogramming in M1 activation of hepatic macrophages (HM) and myofibroblastic activation (MF) of hepatic stellate cells (HSC) in the genesis of inflammation and fibrosis, the two key histological features of chronic ASH and neutrophilic AH. For M1 HM activation, heightened proinflammatory iron redox signaling in endosomes or caveosomes results from altered iron metabolism and storage, promoting IKK/NF-kB activation via interactive activation of p21ras, TAK1, and PI3K. For MF cell fate regulation of HSC, activation of the morphogen Wnt pathway caused by the nuclear protein NECDIN or the single-pass trans-membrane protein DLK1, reprograms lipid metabolism via MeCP2-mediated epigenetic repression of the key HSC quiescence gene Ppar-gamma. Conclusions: The findings from these studies re-enforce the importance of metabolic reprogramming in cell fate regulation required for the pathogenesis of ALD. Copyright (C) 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Tsukamoto, Hidekazu] Univ Southern Calif, Greater Los Angeles VA Healthcare Syst, Keck Sch Med, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. [Tsukamoto, Hidekazu] Univ Southern Calif, Greater Los Angeles VA Healthcare Syst, Keck Sch Med, Dept Pathol, Los Angeles, CA USA. RP Tsukamoto, H (reprint author), Univ Southern Calif, Southern Calif Res Ctr ALPD & Cirrhosis, Keck Sch Med, 1333 San Pablo St,MMR-402, Los Angeles, CA 90089 USA. EM htsukamo@med.usc.edu FU NIAAA [P50AA011999, R24AA012885, U01AA018663]; Medical Research Service of Department of Veterans Affairs (VA Merit Review) [1I01BX001991] FX The studies described in this review have been supported by NIAAA grants (P50AA011999, R24AA012885, U01AA018663) and Medical Research Service of Department of Veterans Affairs (VA Merit Review: 1I01BX001991 and senior research career scientist award). NR 40 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD JUL PY 2015 VL 15 IS 4 SU S BP S61 EP S65 DI 10.1016/j.pan.2015.03.003 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V47YB UT WOS:000209986000011 PM 25800177 ER PT J AU Davies, MR Ravishankar, B Laron, D Kim, HT Liu, XH Feeley, BT AF Davies, Michael R. Ravishankar, Bharat Laron, Dominique Kim, Hubert T. Liu, Xuhui Feeley, Brian T. TI Rat rotator cuff muscle responds differently from hindlimb muscle to a combined tendon-nerve injury SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE rotator cuff tear; fatty infiltration; sciatic nerve denervation; Akt; mTOR signaling; TGF- signaling ID FIBER-TYPE COMPOSITION; FATTY INFILTRATION; MODEL; TEAR; RECOVERY; ATROPHY; REPAIR; MTOR; SUPRASPINATUS; AUTOPHAGY AB Rotator cuff tears (RCTs) are among the most common musculoskeletal injuries seen by orthopaedic surgeons. Clinically, massive cuff tears lead to unique pathophysiological changes in rotator cuff muscle, including atrophy, and massive fatty infiltration, which are rarely seen in other skeletal muscles. Studies in a rodent model for RCT have demonstrated that these histologic findings are accompanied by activation of the Akt/mammalian target of rapamycin (mTOR) and transforming growth factor- (TGF-) pathways following combined tendon-nerve injury. The purpose of this study was to compare the histologic and molecular features of rotator cuff muscle and gastrocnemius musclea major hindlimb muscle, following combined tendon-nerve injury. Six weeks after injury, the rat gastrocnemius did not exhibit notable fatty infiltration compared to the rotator cuff. Likewise, the adipogenic markers SREBP-1 and PPAR as well as the TGF- canonical pathway were upregulated in the rotator cuff, but not the gastrocnemius. Our study suggests that the rat rotator cuff and hindlimb muscles differ significantly in their response to a combined tendon-nerve injury. Clinically, these findings highlight the unique response of the rotator cuff to injury, and may begin to explain the poor outcomes of massive RCTs compared to other muscle-tendon injuries. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:1046-1053, 2015. C1 [Davies, Michael R.; Ravishankar, Bharat; Laron, Dominique; Kim, Hubert T.; Liu, Xuhui; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94158 USA. [Ravishankar, Bharat; Kim, Hubert T.; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. RP Feeley, BT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 1500 Owens St, San Francisco, CA 94158 USA. EM feeleyb@orthosurg.ucsf.edu FU NIH [R03-AR060871]; OREF Career Development Award FX Grant sponsor: NIH; Grant number: R03-AR060871; Grant sponsor: OREF Career Development Award. NR 32 TC 4 Z9 4 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD JUL PY 2015 VL 33 IS 7 BP 1046 EP 1053 DI 10.1002/jor.22864 PG 8 WC Orthopedics SC Orthopedics GA CJ2SA UT WOS:000355333600015 PM 25974842 ER PT J AU Milekovic, T Truccolo, W Grun, S Riehle, A Brochier, T AF Milekovic, Tomislav Truccolo, Wilson Gruen, Sonja Riehle, Alexa Brochier, Thomas TI Local field potentials in primate motor cortex encode grasp kinetic parameters SO NEUROIMAGE LA English DT Article DE Macaque; Motor cortex; Kinetics; Grasping; Local field potentials; Movement planning ID CORTICO-MOTONEURONAL CELLS; DORSAL PREMOTOR CORTEX; SPIKING ACTIVITY; MACAQUE MONKEY; HIGH-FREQUENCY; REACH; SIGNALS; MOVEMENTS; TETRAPLEGIA; FORCE AB Reach and grasp kinematics are known to be encoded in the spiking activity of neuronal ensembles and in local field potentials (LFPs) recorded from primate motor cortex during movement planning and execution. However, little is known, especially in LFPs, about the encoding of kinetic parameters, such as forces exerted on the object during the same actions. We implanted two monkeys with microelectrode arrays in the motor cortical areas MI and PMd to investigate encoding of grasp-related parameters in motor cortical LFPs during planning and execution of reach-and-grasp movements. We identified three components of the LFP that modulated during grasps corresponding to low (0.3-7 Hz), intermediate(similar to 10-similar to 40 Hz) and high (similar to 80-250 Hz) frequency bands. We show that all three components can be used to classify not only grip types but also object loads during planning and execution of a grasping movement. In addition, we demonstrate that all three components recorded during planning or execution can be used to continuously decode finger pressure forces and hand position related to the grasping movement. Low and high frequency components provide similar classification and decoding accuracies, which were substantially higher than those obtained from the intermediate frequency component. Our results demonstrate that intended reach and grasp kinetic parameters are encoded in multiple LFP bands during both movement planning and execution. These findings also suggest that the LFP is a reliable signal for the control of parameters related to object load and applied pressure forces in brain-machine interfaces. (C) 2015 Elsevier Inc. All rights reserved. C1 [Milekovic, Tomislav] Univ Freiburg, Bernstein Ctr Freiburg, D-79106 Freiburg, Germany. [Milekovic, Tomislav] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England. [Milekovic, Tomislav] Univ London Imperial Coll Sci Technol & Med, Dept Elect & Elect Engn, London, England. [Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02912 USA. [Gruen, Sonja] Res Ctr Julich, Inst Neurosci & Med INM 6, Julich, Germany. [Gruen, Sonja] Res Ctr Julich, Inst Adv Simulat IAS 6, Julich, Germany. [Gruen, Sonja] Rhein Westfal TH Aachen, Theoret Syst Neurobiol, Aachen, Germany. [Gruen, Sonja; Riehle, Alexa] RIKEN, Brain Sci Inst, Wako, Saitama, Japan. [Riehle, Alexa; Brochier, Thomas] CNRS AMU, Inst Neurosci la Timone, Marseille, France. RP Milekovic, T (reprint author), Swiss Fed Inst Technol EPFL, EPFL SV UPCOURTINE, Ctr Neuroprosthet, Stn 19, CH-1015 Lausanne, Switzerland. EM tomislav.milekovic@epfl.ch; wilson_truccolo@brown.edu; s.gruen@fz-juelich.de; alexa.riehle@univ-amu.fr; thomas.brochier@univ-amu.fr RI Grun, Sonja/I-6321-2013 OI Grun, Sonja/0000-0003-2829-2220; Milekovic, Tomislav/0000-0001-6769-6506 FU German Federal Ministry of Education and Research (BMBF) [01GQ0830]; Imperial College London; IBRO InEurope Short Stay Grant program; RIKEN-CNRS Collaborative Research Agreement; ANR GRASP (France); BrainScaleS (EU) [269912]; Helmoltz portfolio theme "Supercomputing and modeling for the human brain" (SMHB); U.S. National Institute of Neurological Disorders and Stroke (NINDS) [NS057389]; Brown University FX This work was supported by the German Federal Ministry of Education and Research (BMBF) grant 01GQ0830 to BFNT Freiburg and Tubingen, Imperial College London, IBRO InEurope Short Stay Grant program, RIKEN-CNRS Collaborative Research Agreement, ANR GRASP (France), BrainScaleS (EU Grant 269912), Helmoltz portfolio theme "Supercomputing and modeling for the human brain" (SMHB), U.S. National Institute of Neurological Disorders and Stroke (NINDS) K01 Career Award NS057389, and the Pablo J. Salame '88 Goldman Sachs endowed Professorship in Computational Neuroscience, Brown University. NR 63 TC 4 Z9 4 U1 3 U2 20 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JUL 1 PY 2015 VL 114 BP 338 EP 355 DI 10.1016/j.neuroimage.2015.04.008 PG 18 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA CI8ES UT WOS:000355002900031 PM 25869861 ER PT J AU Freeman, MA Myaskovsky, L AF Freeman, Michael A. Myaskovsky, Larissa TI An overview of disparities and interventions in pediatric kidney transplantation worldwide SO PEDIATRIC NEPHROLOGY LA English DT Review DE Kidney transplantation; Minority health; Organ allocation; Racial disparities; Socioeconomic status ID STAGE RENAL-DISEASE; RACIAL DISPARITIES; ORGAN-TRANSPLANTATION; SOCIOECONOMIC-STATUS; MEDICATION ADHERENCE; REPLACEMENT THERAPY; ETHNIC DISPARITIES; UNITED-STATES; US CHILDREN; DONATION AB Despite the stated goals of the transplant community and the majority of organ allocation systems, persistent racial disparities in pediatric kidney transplantation exist throughout the world. These disparities are evident in both living and deceased donor kidney transplantation and are independent of any clinical differences between racial groups. The reasons for these persistent disparities are multifactorial, reflecting both patient and provider barriers to care. In this review, we examine the most current findings regarding disparities in pediatric kidney transplantation and consider interventions which may help reduce those disparities. C1 [Freeman, Michael A.] Penn State Hershey Childrens Hosp, Div Pediat Nephrol & Hypertens, Hershey, PA 17033 USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. RP Freeman, MA (reprint author), Penn State Hershey Childrens Hosp, Div Pediat Nephrol & Hypertens, Mail Code H085,500 Univ Dr, Hershey, PA 17033 USA. EM MFreeman3@hmc.psu.edu RI Freeman, Michael/O-1837-2016 OI Freeman, Michael/0000-0001-5022-4377 FU National Institute of Diabetes, Digestive and Kidney Disease [T32DKK091202, R01DK081325]; Veterans Affairs Health Services Research and Development Service [IIR 06-220, CIN 13-405] FX The data reported in the USRDS 2013 report were supplied by the USRDS. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government. The data and analyses reported in the 2011 and 2012 Annual Data Report of the U.S. Organ Procurement and Transplantation Network and the SRTR have been supplied by UNOS and the Minneapolis Medical Research Foundation under contract with the U.S. Department of Health and Human Services/Health Resources and Services Administration. The authors alone are responsible for reporting and interpreting these data; the views expressed herein are those of the authors and not necessarily those of the U.S. government. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The work of Dr. Freeman on this paper was supported by Grant #T32DKK091202 from the National Institute of Diabetes, Digestive and Kidney Disease and for Dr. Myaskovsky by Grant #R01DK081325 from the National Institute of Diabetes, Digestive and Kidney Disease, and Grants #IIR 06-220 and #CIN 13-405 from the Veterans Affairs Health Services Research and Development Service. NR 67 TC 5 Z9 5 U1 4 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0931-041X EI 1432-198X J9 PEDIATR NEPHROL JI Pediatr. Nephrol. PD JUL PY 2015 VL 30 IS 7 BP 1077 EP 1086 DI 10.1007/s00467-014-2879-3 PG 10 WC Pediatrics; Urology & Nephrology SC Pediatrics; Urology & Nephrology GA CJ0UD UT WOS:000355193100006 PM 25315177 ER PT J AU Pekarya, AE Sattin, A Lloyd, RL AF Pekarya, A. Eugene Sattin, Albert Lloyd, Robert L. TI Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats SO PEPTIDES LA English DT Article DE Depression; Anxiety; Limbic system; Neuroendocrine ID RAPID ANTIDEPRESSANT RESPONSE; RESISTANT MAJOR DEPRESSION; NMDA RECEPTOR BLOCKADE; D-ASPARTATE ANTAGONIST; INTRANASAL INSULIN; SUICIDAL IDEATION; HORMONE TRH; THYROTROPIN; ANXIETY; ANESTHESIA AB Major depression is the largest single healthcare burden with treatments of slow onset and often limited efficacy. Ketamine, a NMDA antagonist used extensively as a pediatric and veterinary anesthetic, has recently been shown to be a rapid acting antidepressant, making it a potential lifesaver for suicidal patients. Side effects and risk of abuse limit the chronic use of ketamine. More complete understanding of the neurobiochemical mechanisms of ketamine should lead to safer alternatives. Some of the physiological and pharmacological actions of ketamine are consistent with increased synthesis and release of TRH (pGlu-His-Pro-NH2), and TRH-like peptides (pGlu-X-Pro-NH2) where "X" can be any amino acid residue. Moreover, TRH-like peptides are themselves potential therapeutic agents for the treatment of major depression, anxiety, bipolar disorder, epilepsy, Alzheimer's and Parkinson's diseases. For these reasons, male Sprague-Dawley rats were anesthetized with 162 mg/kg ip ketamine and then infused intranasally with 20 mu l of sterile saline containing either 0 or 5 mg/ml Glu-TRH. One, 2 or 4 h later, the brain levels of TRH and TRH-like peptides were measured in various brain regions and peripheral tissues. At 1 h in brain following ketamine only, the levels of TRH and TRH-like peptides were significantly increased in 52 instances (due to increased biosynthesis and/or decreased release) or decreased in five instances. These changes, listed by brain region in order of decreasing number of significant increases (up arrow) and/or decreases (down arrow), were: hypothalamus (9 up arrow); piriform cortex (8 up arrow); entorhinal cortex (7 up arrow); nucleus accumbens (7 up arrow); posterior cingulate (5 up arrow); striatum (4 up arrow); frontal cortex (2 up arrow,3 down arrow); amygdala (3 up arrow); medulla oblongata (1 up arrow,2 down arrow); cerebellum (2 up arrow); hippocampus (2 up arrow); anterior cingulate (2 up arrow). The corresponding changes in peripheral tissues were: adrenals (8 up arrow); epididymis (4 up arrow); testis (1 up arrow,3 down arrow); pancreas (1 up arrow); prostate (1 up arrow). We conclude that TRH and TRH-like peptides may be downstream mediators of the rapid antidepressant actions of ketamine. Published by Elsevier Inc. C1 [Pekarya, A. Eugene; Sattin, Albert] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA 90073 USA. [Pekarya, A. Eugene] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90073 USA. [Sattin, Albert] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. [Pekarya, A. Eugene] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. [Lloyd, Robert L.] Univ Minnesota, Dept Psychol, Duluth, MN 55812 USA. RP Pekarya, AE (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Albert.Pekary@va.gov FU Department of Veterans Affairs Medical Research funds; Pekary Trust FX This work was supported by the Department of Veterans Affairs Medical Research funds (AEP and AS) and the Pekary Trust. NR 72 TC 4 Z9 4 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 EI 1873-5169 J9 PEPTIDES JI Peptides PD JUL PY 2015 VL 69 BP 66 EP 76 DI 10.1016/j.peptides.2015.04.003 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA CJ1AR UT WOS:000355214300009 PM 25882008 ER PT J AU Kennelty, KA Chewning, B Wise, M Kind, A Roberts, T Kreling, D AF Kennelty, Korey A. Chewning, Betty Wise, Meg Kind, Amy Roberts, Tonya Kreling, David TI Barriers and facilitators of medication reconciliation processes for recently discharged patients from community pharmacists' perspectives SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Community pharmacy; Medication reconciliation; Transitions of care; Qualitative methods ID SOCIAL DESIRABILITY BIAS; INFORMATION-TRANSFER; TRANSITIONAL CARE; PLANNED BEHAVIOR; REHOSPITALIZATION; QUESTIONNAIRE; INTERVENTION; CONTINUITY; EMERGENCY; OUTCOMES AB Background: Community pharmacists play a vital part in reconciling medications for patients transitioning from hospital to community care, yet their roles have not been fully examined in the extant literature. Objectives: The objectives of this study were to: 1) examine the barriers and facilitators community pharmacists face when reconciling medications for recently discharged patients; and 2) identify pharmacists' preferred content and modes of information transfer regarding updated medication information for recently discharged patients. Methods: Community pharmacists were purposively and conveniently sampled from the Wisconsin (U.S. state) pharmacist-based research network, Pharmacy Practice Enhancement and Action Research Link (PEARL Rx). Community pharmacists were interviewed face-to-face, and transcriptions from audio recordings were analyzed using directed content analysis. The Theory of Planned Behavior (TPB) guided the development of questions for the semi-structured interviews. Results: Interviewed community pharmacists (N = 10) described the medication reconciliation process to be difficult and time-consuming for recently discharged patients. In the context of the TPB, more barriers than facilitators of reconciling medications were revealed. Themes were categorized as organizational and individual-level themes. Major organizational-level factors affecting the medication reconciliation process included: pharmacy resources, discharge communication, and hospital resources. Major individual-level factors affecting the medication reconciliation process included: pharmacists' perceived responsibility, relationships, patient perception of pharmacist, and patient characteristics. Interviewed pharmacists consistently responded that several pieces of information items would be helpful when reconciling medications for recently discharged patients, including the hospital medication discharge list and stop-orders for discontinued medications. Conclusions: The TPB was useful for identifying barriers and facilitators of medication reconciliation for recently discharged patients from community pharmacists' perspectives. The elucidation of these specific facilitators and barriers suggest promising avenues for future research interventions to improve exchange of medication information between the community pharmacy, hospitals, and patients. Published by Elsevier Inc. C1 [Kennelty, Korey A.; Kind, Amy; Roberts, Tonya] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. [Kennelty, Korey A.; Chewning, Betty; Wise, Meg; Kreling, David] Univ Wisconsin, Sch Pharm, Sonderegger Res Ctr, Madison, WI 53706 USA. [Kind, Amy] Univ Wisconsin, Dept Med, Div Geriatr, Madison, WI USA. [Roberts, Tonya] Univ Wisconsin, Sch Nursing, Madison, WI USA. RP Kennelty, KA (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace,11-G, Madison, WI 53705 USA. EM kennelty@wisc.edu FU Agency for Healthcare Research and Quality (AHRQ) Health Services Research Dissertation Grant of the National Institutes of Health [1R36HS021984-01]; UW-Madison School of Pharmacy Sonderegger Research Center Dissertation Grant; Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; National Institute on Aging Beeson Career Development Award [K23AG034551]; National Institute on Aging; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Wisconsin Partnership Program New Investigator Award; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR)from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources [1UL1RR025011] FX Funding support: Research reported in this manuscript was supported by the Agency for Healthcare Research and Quality (AHRQ) Health Services Research Dissertation Grant of the National Institutes of Health under award number 1R36HS021984-01 [PI: Kennelty]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Research reported was also supported by the UW-Madison School of Pharmacy Sonderegger Research Center Dissertation Grant.; The project described was also supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427.; Dr. Kind is supported by a National Institute on Aging Beeson Career Development Award (K23AG034551 [PI: Kind], National Institute on Aging, The American Federation for Aging Research, The John A. Hartford Foundation, The Atlantic Philanthropies and The Starr Foundation). Additional support was provided by the Wisconsin Partnership Program New Investigator Award (PI: Kind) and Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (UW ICTR), grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources, National Institutes of Health. NR 47 TC 6 Z9 6 U1 4 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD JUL-AUG PY 2015 VL 11 IS 4 BP 517 EP 530 DI 10.1016/j.sapharm.2014.10.008 PG 14 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA CJ2UD UT WOS:000355339200004 PM 25586885 ER PT J AU Muller, LPD Sargoy, A Fernandez-Sanchez, L Rodriguez, A Liu, J Cuenca, N Brecha, N AF Mueller, Luis Perez de Sevilla Sargoy, Allison Fernandez-Sanchez, Laura Rodriguez, Allen Liu, Janelle Cuenca, Nicolas Brecha, Nicholas TI Expression and cellular localization of the voltage-gated calcium channel alpha(2)delta(3) in the rodent retina SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Review DE calcium channel; retina; alpha(2)delta(3) subunit; amacrine cell; ganglion cell; photoreceptor ID PHOTORECEPTOR RIBBON SYNAPSE; ACID TRANSPORTER EXPRESSION; TISSUE-SPECIFIC EXPRESSION; DISPLACED AMACRINE CELLS; DEVELOPING MOUSE RETINA; PIG HORIZONTAL CELLS; RNA-BINDING PROTEIN; MAMMALIAN RETINA; RAT RETINA; BIPOLAR CELLS AB High-voltage-activated calcium channels are hetero-oligomeric protein complexes that mediate multiple cellular processes, including the influx of extracellular Ca2+, neurotransmitter release, gene transcription, and synaptic plasticity. These channels consist of a primary (1) pore-forming subunit, which is associated with an extracellular (2) subunit and an intracellular auxiliary subunit, which alter the gating properties and trafficking of the calcium channel. The cellular localization of the (23) subunit in the mouse and rat retina is unknown. In this study using RT-PCR, a single band at approximate to 305 bp corresponding to the predicted size of the (23) subunit fragment was found in mouse and rat retina and brain homogenates. Western blotting of rodent retina and brain homogenates showed a single 123-kDa band. Immunohistochemistry with an affinity-purified antibody to the (23) subunit revealed immunoreactive cell bodies in the ganglion cell layer and inner nuclear layer and immunoreactive processes in the inner plexiform layer and the outer plexiform layer. (23) immunoreactivity was localized to multiple cell types, including ganglion, amacrine, and bipolar cells and photoreceptors, but not horizontal cells. The expression of the (23) calcium channel subunit to multiple cell types suggests that this subunit participates widely in Ca-channel-mediated signaling in the retina. J. Comp. Neurol. 523:1443-1460, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Mueller, Luis Perez de Sevilla; Sargoy, Allison; Rodriguez, Allen; Liu, Janelle; Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Sargoy, Allison; Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Sargoy, Allison; Brecha, Nicholas] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Fernandez-Sanchez, Laura; Cuenca, Nicolas] Univ Alicante, Physiol Genet & Microbiol, Alicante 03690, Spain. [Brecha, Nicholas] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Brecha, Nicholas] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Muller, LPD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med Los Angeles, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM luisperez@mednet.ucla.edu FU U.S. Army Medical Research & Materiel Command (USAMRMC); Telemedicine & Advanced Technology Research Center (TATRC) [W81XWH-10-2-0077]; National Institutes of Health [EY04067]; VA Merit Review FX Grant sponsor: U.S. Army Medical Research & Materiel Command (USAMRMC); Grant sponsor: Telemedicine & Advanced Technology Research Center (TATRC); Grant number: W81XWH-10-2-0077; Grant sponsor: National Institutes of Health; Grant number: EY04067; Grant sponsor: VA Merit Review (to N.B.). NR 110 TC 1 Z9 1 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9967 EI 1096-9861 J9 J COMP NEUROL JI J. Comp. Neurol. PD JUL 1 PY 2015 VL 523 IS 10 BP 1443 EP 1460 DI 10.1002/cne.23751 PG 18 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA CI4QQ UT WOS:000354737600001 ER PT J AU Kacimi, R Yenari, MA AF Kacimi, Rachid Yenari, Midori A. TI Pharmacologic Heat Shock Protein 70 Induction Confers Cytoprotection against Inflammation in Gliovascular Cells SO GLIA LA English DT Article DE cytoprotection; HSP70; HSP90; microglia; endothelial cells ID HEAT-SHOCK-PROTEIN; ISCHEMIA-REPERFUSION INJURY; OXYGEN-GLUCOSE DEPRIVATION; BLOOD-BRAIN-BARRIER; NF-KAPPA-B; MATRIX METALLOPROTEINASES; EXPERIMENTAL STROKE; HSP90 INHIBITORS; CLINICAL DEVELOPMENT; CEREBRAL-ISCHEMIA AB The inhibition of the 90-kDa heat shock protein (HSP90) leads to upregulation of the 70-kDa-inducible HSP70. HSP70 has been previously shown to be neuroprotective and anti-inflammatory. Geldanamycin (GA) and other HSP90 inhibitors have emerged as promising therapeutic agents in cancer, presumably owing to their ability to upregulate HSP70. However, the effects of HSP90 inhibition in brain inflammation are still unclear. We investigate the effect of a panel of HSP90 inhibitors on endotoxin-activated microglia and eventual protection from brain-derived endothelial cells. Prior studies have shown that GA protects brain cells from oxidative stress. We show here that when astrocytes or microglial BV2 cells were pretreated with GA or other HSP90 inhibitors, endotoxin-induced cell death was reduced in cocultures of BV2 microglia and brain-derived endothelial cells (bEND.3). Endotoxin-stimulated BV2 cells led to increased nitric oxide (NO) and inducible nitric oxide synthase which was prevented by treatment with all HSP90 inhibitors. HSP90 inhibitors also prevented lipopolysaccharide (LPS)-induced BV2 cell death. We also found that HSP90 inhibition blocked nuclear translocation of nuclear factor kappa B and attenuated IB degradation, and inhibited LPS-activated JAK-STAT phosphorylation. We show that pharmacologic inhibition of HSP90 with subsequent HSP70 induction protects cells that comprise the cerebral vasculature against cell death owing to proinflammatory stimuli. This approach may have therapeutic potential in neurological conditions with an inflammatory component. C1 [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, Neurol 127 VAMC 4150 Clement St, San Francisco, CA 94143 USA. EM yenari@alum.mit.edu FU National Institutes of Health [NS40516]; Veteran's Merit Award [BX000589]; Department of Defense [DAMD17-03-1-0532]; Northern California Institute for Research and Education, Resources of the Veterans Affairs Medical Center, San Francisco, California FX Grant sponsor: The National Institutes of Health; Grant number: NS40516; Grant sponsor: Veteran's Merit Award; Grant number: BX000589; Grant sponsor: The Department of Defense;; Grant number: DAMD17-03-1-0532; Grant sponsor: The Northern California Institute for Research and Education, Resources of the Veterans Affairs Medical Center, San Francisco, California. NR 42 TC 6 Z9 7 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-1491 EI 1098-1136 J9 GLIA JI Glia PD JUL PY 2015 VL 63 IS 7 BP 1200 EP 1212 DI 10.1002/glia.22811 PG 13 WC Neurosciences SC Neurosciences & Neurology GA CG6IC UT WOS:000353402100007 PM 25802219 ER PT J AU Horton, LE Tarbox, SI Olino, TM Haas, GL AF Horton, Leslie E. Tarbox, Sarah I. Olino, Thomas M. Haas, Gretchen L. TI Trajectories of premorbid childhood and adolescent functioning in schizophrenia-spectrum psychoses: A first-episode study SO PSYCHIATRY RESEARCH LA English DT Article DE Premorbid adjustment; Social amotivation; First-episode schizophrenia (FEP); Psychosis; Schizophrenia-spectrum ID NEGATIVE SYMPTOMS; NONAFFECTIVE PSYCHOSIS; EPISODE SCHIZOPHRENIA; UNTREATED PSYCHOSIS; ADJUSTMENT SCALE; DISORDERS; PATTERNS; ONSET; DETERIORATION; ANHEDONIA AB Evidence of social and behavioral problems preceding the onset of schizophrenia-spectrum psychoses is consistent with a neurodevelopmental model of these disorders. Here we predict that individuals with a first episode of schizophrenia-spectrum psychoses will evidence one of three patterns of premorbid adjustment: an early deficit, a deteriorating pattern, or adequate or good social adjustment. Participants were 164(38% female; 31% black) individuals ages 15-50 with a first episode of schizophrenia-spectrum psychoses. Premorbid adjustment was assessed using the Cannon-Spoor Premorbid Adjustment Scale. We compared the fit of a series of growth mixture models to examine premorbid adjustment trajectories, and found the following 3-class model provided the best fit with: a "stable-poor" adjustment class (54%), a "stable-good" adjustment class (39%), and a "deteriorating" adjustment class (7%). Relative to the "stable-good" class, the "stable-poor" class experienced worse negative symptoms at 1-year follow-up, particularly in the social amotivation domain. This represents the first known growth mixture modeling study to examine premorbid functioning patterns in first-episode schizophrenia-spectrum psychoses. Given that the stable-poor adjustment pattern was most prevalent, detection of social and academic maladjustment as early as childhood may help identify people at increased risk for schizophrenia-spectrum psychoses, potentially increasing feasibility of early interventions. Published by Elsevier Ireland Ltd. C1 [Horton, Leslie E.; Olino, Thomas M.; Haas, Gretchen L.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA. [Horton, Leslie E.; Haas, Gretchen L.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Tarbox, Sarah I.] Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, Dept Psychiat, New Haven, CT 06159 USA. [Olino, Thomas M.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA. RP Haas, GL (reprint author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM hortonle2@upmc.edu; sarah.tarbox@yale.edu; thomas.olino@temple.edu; haasgl@upmc.edu FU NIMH [MH48492]; NIH [UL1 RR024153, UL1 TR000005]; NIH/NCRR/GCRC [M01 RR00056] FX This publication was supported by funds received MH48492 (NIMH; PI: G L. Haas) and the NIH-funded UL1 RR024153, UL1 TR000005, and NIH/NCRR/GCRC Grant M01 RR00056. NR 58 TC 2 Z9 2 U1 2 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JUN 30 PY 2015 VL 227 IS 2-3 BP 339 EP 346 DI 10.1016/j.psychres.2015.02.013 PG 8 WC Psychiatry SC Psychiatry GA CK0GU UT WOS:000355884500033 PM 25829134 ER PT J AU Smucny, J Stevens, KE Olincy, A Tregellas, JR AF Smucny, J. Stevens, K. E. Olincy, A. Tregellas, J. R. TI Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation SO TRANSLATIONAL PSYCHIATRY LA English DT Review ID NICOTINIC ACETYLCHOLINE-RECEPTORS; DEFICIENT SENSORY INHIBITION; FREELY MOVING RATS; MEDIAL PREFRONTAL CORTEX; DRUG-INDUCED PSYCHOSIS; PURSUIT EYE-MOVEMENTS; PROOF-OF-CONCEPT; DBA/2 MICE; CIGARETTE-SMOKING; P50 SUPPRESSION AB Impaired gating of the auditory evoked P50 potential is one of the most pharmacologically well-characterized features of schizophrenia. This deficit is most commonly modeled in rodents by implanted electrode recordings from the hippocampus of the rodent analog of the P50, the P20-N40. The validity and effectiveness of this tool, however, has not been systematically reviewed. Here, we summarize findings from studies that have examined the effects of pharmacologic modulation on gating of the rodent hippocampal P20-N40 and the human P50. We show that drug effects on the P20-N40 are highly predictive of human effects across similar dose ranges. Furthermore, mental status (for example, anesthetized vs alert) does not appear to diminish the predictive capacity of these recordings. We then discuss hypothesized neuropharmacologic mechanisms that may underlie gating effects for each drug studied. Overall, this review supports continued use of hippocampal P20-N40 gating as a translational tool for schizophrenia research. C1 [Smucny, J.; Tregellas, J. R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Smucny, J.; Olincy, A.; Tregellas, J. R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Smucny, J.; Stevens, K. E.; Olincy, A.; Tregellas, J. R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus,Bldg 500,MS 546, Aurora, CO 80045 USA. EM jason.tregellas@ucdenver.edu FU VA Biomedical Laboratory and Clinical Science Research and Development Service; Brain and Behavior Foundation; Blowitz-Ridgeway Foundation [MH-086383-01, 1F31-MH102879-01A1] FX This work was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service, the Brain and Behavior Foundation, the Blowitz-Ridgeway Foundation, MH-086383-01 and 1F31-MH102879-01A1. NR 180 TC 4 Z9 5 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JUN 23 PY 2015 VL 5 AR e587 DI 10.1038/tp.2015.77 PG 13 WC Psychiatry SC Psychiatry GA DA2WZ UT WOS:000367659200002 PM 26101850 ER PT J AU Preiss, D Campbell, RT Murray, HM Ford, I Packard, CJ Sattar, N Rahimi, K Colhoun, HM Waters, DD LaRosa, JC Amarenco, P Pedersen, TR Tikkanen, MJ Koren, MJ Poulter, NR Sever, PS Ridker, PM MacFadyen, JG Solomon, SD Davis, BR Simpson, LM Nakamura, H Mizuno, K Marfisi, RM Marchioli, R Tognoni, G Athyros, VG Ray, KK Gotto, AM Clearfield, MB Downs, JR McMurray, JJ AF Preiss, David Campbell, Ross T. Murray, Heather M. Ford, Ian Packard, Chris J. Sattar, Naveed Rahimi, Kazem Colhoun, Helen M. Waters, David D. LaRosa, John C. Amarenco, Pierre Pedersen, Terje R. Tikkanen, Matti J. Koren, Michael J. Poulter, Neil R. Sever, Peter S. Ridker, Paul M. MacFadyen, Jean G. Solomon, Scott D. Davis, Barry R. Simpson, Lara M. Nakamura, Haruo Mizuno, Kyoichi Marfisi, Rosa M. Marchioli, Roberto Tognoni, Gianni Athyros, Vasilios G. Ray, Kausik K. Gotto, Antonio M. Clearfield, Michael B. Downs, John R. McMurray, John J. TI The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials SO EUROPEAN HEART JOURNAL LA English DT Article DE Statin; Heart failure; Randomized trial; Prevention; Meta-analysis ID AVERAGE CHOLESTEROL LEVELS; PLACEBO-CONTROLLED TRIAL; ACUTE CORONARY SYNDROMES; HIGH-DOSE ATORVASTATIN; PRIMARY PREVENTION; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; HYPERTENSIVE PATIENTS; VASCULAR EVENTS; LDL CHOLESTEROL AB Aims The effect of statins on risk of heart failure (HF) hospitalization and HF death remains uncertain. We aimed to establish whether statins reduce major HF events. Methods and results We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized controlled endpoint statin trials from 1994 to 2014. Collaborating trialists provided unpublished data from adverse event reports. We included primary- and secondary-prevention statin trials with >1000 participants followed for >1 year. Outcomes consisted of first on-fatal HF hospitalization, HF death and a composite of first non-fatal HF hospitalization or HF death. HF events occurring <30 days after within-trial myocardial infarction (MI) were excluded. We calculated risk ratios (RR) with fixed-effects meta-analyses. In up to 17 trials with 132 538 participants conducted over 4.3 [weighted standard deviation (SD) 1.4] years, statin therapy reduced LDL-cholesterol by 0.97 mmol/L (weighted SD 0.38 mmol/L). Statins reduced the numbers of patients experiencing non-fatal HF hospitalization (1344/66 238 vs. 1498/66 330; RR 0.90, 95% confidence interval, CI 0.84-0.97) and the composite HF outcome (1234/57 734 vs. 1344/57 836; RR 0.92, 95% CI 0.85-0.99) but not HF death (213/57 734 vs. 220/57 836; RR0.97,95% CI 0.80-1.17). The effect of statins on first non-fatal HF hospitalization was similar whether this was preceded by MI (RR 0.87, 95% CI 0.68-1.11) or not (RR 0.91, 95% CI 0.84-0.98). Conclusion In primary- and secondary-prevention trials, statins modestly reduced the risks of non-fatal HF hospitalization and a composite of non-fatal HF hospitalization and HF death with no demonstrable difference in risk reduction between those who suffered an MI or not. C1 [Preiss, David; Campbell, Ross T.; Sattar, Naveed; McMurray, John J.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland. [Murray, Heather M.; Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8TA, Lanark, Scotland. [Packard, Chris J.] Univ Glasgow, Western Infirm, Glasgow Clin Res Facil, Glasgow G11 6NT, Lanark, Scotland. [Rahimi, Kazem] Univ Oxford, George Inst Global Hlth, Oxford, England. [Colhoun, Helen M.] Univ Dundee, Med Res Inst, Dundee, Scotland. [Waters, David D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [LaRosa, John C.] SUNY Hlth Sci Ctr Brooklyn, New York, NY USA. [Amarenco, Pierre] Hop Xavier Bichat, Dept Neurol, Paris, France. [Amarenco, Pierre] Hop Xavier Bichat, Stroke Ctr, Paris, France. [Pedersen, Terje R.] Univ Oslo, Oslo, Norway. [Pedersen, Terje R.] Oslo Univ Hosp, Ctr Preventat Med, Oslo, Norway. [Tikkanen, Matti J.] Univ Helsinki, Helsinki, Finland. [Tikkanen, Matti J.] Univ Helsinki, Cent Hosp, Heart & Lung Ctr, Helsinki, Finland. [Tikkanen, Matti J.] Folkhalsan Res Ctr, Helsinki, Finland. [Koren, Michael J.] Jacksonville Ctr Clin Res, Jacksonville, FL USA. [Poulter, Neil R.; Sever, Peter S.; Ray, Kausik K.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England. [Ridker, Paul M.; MacFadyen, Jean G.; Solomon, Scott D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,Dept Med, Boston, MA USA. [Davis, Barry R.; Simpson, Lara M.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Nakamura, Haruo] Mitsukoshi Hlth & Welf Fdn, Shinjuku Ku, Tokyo, Japan. [Mizuno, Kyoichi] Nippon Med Sch, Dept Med, Bunkyo Ku, Tokyo 113, Japan. [Marfisi, Rosa M.; Marchioli, Roberto; Tognoni, Gianni] Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy. [Athyros, Vasilios G.] Aristotle Univ Thessaloniki, Hippokrat Hosp, Propedeut Dept Internal Med 2, Sch Med, GR-54006 Thessaloniki, Greece. [Gotto, Antonio M.] Weill Cornell Med Coll, New York, NY USA. [Clearfield, Michael B.] Touro Univ, Coll Osteopath Med, Vallejo, CA USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Downs, John R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Preiss, D (reprint author), Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, 126 Univ Pl, Glasgow G12 8TA, Lanark, Scotland. EM david.preiss@glasgow.ac.uk RI Rahimi, Kazem/Q-1279-2015 OI Rahimi, Kazem/0000-0002-4807-4610; Preiss, David/0000-0003-3139-1836; Colhoun, Helen/0000-0002-8345-3288; Sattar, Naveed/0000-0002-1604-2593; mcmurray, john/0000-0002-6317-3975 FU BHF project [PG/13/17/30050]; National Institute for Health Research Senior Investigator Awards; Biomedical Research Centre; British Heart Foundation Research Centre Excellence Award; National Institute for Health Research Career Development Fellowship; Oxford Biomedical Research Centre; Oxford Martin School FX This project was not supported by external funding. R.T.C. is funded by a BHF project grant (PG/13/17/30050). N.R.P. is supported by the National Institute for Health Research Senior Investigator Awards, Biomedical Research Centre funding, and the British Heart Foundation Research Centre Excellence Award. K.R. is supported by a National Institute for Health Research Career Development Fellowship and funding from the Oxford Biomedical Research Centre, and the Oxford Martin School. NR 38 TC 24 Z9 24 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD JUN 21 PY 2015 VL 36 IS 24 BP 1536 EP 1546 DI 10.1093/eurheartj/ehv072 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CM7LZ UT WOS:000357876100015 PM 25802390 ER PT J AU Kagan, VE Tyurina, YY Tyurin, VA Mohammadyani, D Angeli, JPF Baranov, SV Klein-Seetharaman, J Friedlander, RM Mallampalli, RK Conrad, M Bayir, H AF Kagan, Valerian E. Tyurina, Yulia Y. Tyurin, Vladimir A. Mohammadyani, Dariush Angeli, Jose Pedro Friedmann Baranov, Sergei V. Klein-Seetharaman, Judith Friedlander, Robert M. Mallampalli, Rama K. Conrad, Marcus Bayir, Huelya TI Cardiolipin Signaling Mechanisms: Collapse of Asymmetry and Oxidation SO ANTIOXIDANTS & REDOX SIGNALING LA English DT Review ID MASS-SPECTROMETRIC CHARACTERIZATION; HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; CYTOCHROME-C; BARTH-SYNDROME; CELL-DEATH; INDUCED APOPTOSIS; PHOSPHATIDYLSERINE PEROXIDATION; MITOCHONDRIAL CARDIOLIPIN; STRUCTURAL TRANSITIONS; ANIONIC PHOSPHOLIPIDS AB Significance: An ancient anionic phospholipid, cardiolipin (CL), ubiquitously present in prokaryotic and eukaryotic membranes, is essential for several structural and functional purposes. Recent Advances: The emerging role of CLs in signaling has become the focus of many studies. Critical Issues: In this work, we describe two major pathways through which mitochondrial CLs may fulfill the signaling functions via utilization of their (i) asymmetric distribution across membranes and translocations, leading to the surface externalization and (ii) ability to undergo oxidation reactions to yield the signature products recognizable by the executionary machinery of cells. Future Directions: We present a concept that CLs and their oxidation/hydrolysis products constitute a rich communication language utilized by mitochondria of eukaryotic cells for diversified regulation of cell physiology and metabolism as well as for inter-cellular interactions. Antioxid. Redox Signal. 22, 1667-1680. C1 [Kagan, Valerian E.; Tyurina, Yulia Y.; Tyurin, Vladimir A.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15219 USA. [Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15219 USA. [Kagan, Valerian E.] Univ Pittsburgh, Dept Radiat Oncol, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15219 USA. [Kagan, Valerian E.] Univ Pittsburgh, Dept Chem, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15219 USA. [Mohammadyani, Dariush] Univ Pittsburgh, Dept Chem, Dept Bioengn, Pittsburgh, PA 15219 USA. [Angeli, Jose Pedro Friedmann; Conrad, Marcus] German Res Ctr Environm Hlth, Inst Dev Genet, Helmholtz Zentrum Munchen, Neuherberg, Germany. [Baranov, Sergei V.; Friedlander, Robert M.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15219 USA. [Klein-Seetharaman, Judith] Univ Warwick, Sch Med, Div Metab & Vasc Hlth, Coventry CV4 7AL, W Midlands, England. [Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15219 USA. [Mallampalli, Rama K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15219 USA. RP Kagan, VE (reprint author), Univ Pittsburgh, Dept Environm & Occupat Hlth, Ctr Free Rad & Antioxidant Hlth, Bridgeside Point 100 Technol Dr, Pittsburgh, PA 15219 USA. EM kagan@pitt.edu RI Friedlander, Robert/A-2845-2016; Friedmann Angeli, Jose /C-9038-2014 OI Friedlander, Robert/0000-0003-4423-9219; Tyurin, Vladimir/0000-0002-3474-1697; Conrad, Marcus/0000-0003-1140-5612; Friedmann Angeli, Jose Pedro/0000-0001-7706-1379 FU NIH [PO1HL114453, CA165065, ES020693, U19AIO68021, NS076511, NS061817]; NIOSH [OH008282, HFSP-RGP0013/2014]; US Department of Veterans Affairs; Alexander von Humboldt Stiftung; Marie Curie Actions grant MPFP FP7-People-IIF [626470] FX This study was supported by NIH: PO1HL114453, CA165065, ES020693, U19AIO68021, NS076511, NS061817; NIOSH: OH008282, HFSP-RGP0013/2014, a Merit Review award from the US Department of Veterans Affairs and Alexander von Humboldt Stiftung (to AJPF) and Marie Curie Actions grant 626470 MPFP FP7-People-IIF. NR 104 TC 10 Z9 11 U1 0 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1523-0864 EI 1557-7716 J9 ANTIOXID REDOX SIGN JI Antioxid. Redox Signal. PD JUN 20 PY 2015 VL 22 IS 18 BP 1667 EP 1680 DI 10.1089/ars.2014.6219 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA CU9WA UT WOS:000363895900003 PM 25566681 ER PT J AU Suchankova, P Yan, J Schwandt, ML Stangl, BL Caparelli, EC Momenan, R Jerlhag, E Engel, JA Hodgkinson, CA Egli, M Lopez, MF Becker, HC Goldman, D Heilig, M Ramchandani, VA Leggio, L AF Suchankova, P. Yan, J. Schwandt, M. L. Stangl, B. L. Caparelli, E. C. Momenan, R. Jerlhag, E. Engel, J. A. Hodgkinson, C. A. Egli, M. Lopez, M. F. Becker, H. C. Goldman, D. Heilig, M. Ramchandani, V. A. Leggio, L. TI The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence SO TRANSLATIONAL PSYCHIATRY LA English DT Article ID POPULATION-BASED SAMPLE; VENTRAL TEGMENTAL AREA; FOOD-INTAKE; REWARD ANTICIPATION; GLP-1; POLYMORPHISM; EXENDIN-4; CORRELATE; SMOKING; ANALOG AB The hormone glucagon-like peptide-1 (GLP-1) regulates appetite and food intake. GLP-1 receptor (GLP-1R) activation also attenuates the reinforcing properties of alcohol in rodents. The present translational study is based on four human genetic association studies and one preclinical study providing data that support the hypothesis that GLP-1R may have a role in the pathophysiology of alcohol use disorder (AUD). Case-control analysis (N = 908) was performed on a sample of individuals enrolled in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) intramural research program. The Study of Addiction: Genetics and Environment (SAGE) sample (N = 3803) was used for confirmation purposes. Post hoc analyses were carried out on data from a human laboratory study of intravenous alcohol self-administration (IV-ASA; N = 81) in social drinkers and from a functional magnetic resonance imaging study in alcohol-dependent individuals (N = 22) subjected to a Monetary Incentive Delay task. In the preclinical study, a GLP-1R agonist was evaluated in a mouse model of alcohol dependence to demonstrate the role of GLP-1R for alcohol consumption. The previously reported functional allele 168Ser (rs6923761) was nominally associated with AUD (P = 0.004) in the NIAAA sample, which was partially replicated in males of the SAGE sample (P = 0.033). The 168Ser/Ser genotype was further associated with increased alcohol administration and breath alcohol measures in the IV-ASA experiment and with higher BOLD response in the right globus pallidus when receiving notification of outcome for high monetary reward. Finally, GLP-1R agonism significantly reduced alcohol consumption in a mouse model of alcohol dependence. These convergent findings suggest that the GLP-1R may be an attractive target for personalized pharmacotherapy treatment of AUD. C1 [Suchankova, P.; Leggio, L.] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA. [Suchankova, P.; Jerlhag, E.; Engel, J. A.] Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, Gothenburg, Sweden. [Yan, J.; Stangl, B. L.; Ramchandani, V. A.] NIAAA, Sect Human Psychopharmacol, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA. [Yan, J.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat, Richmond, VA USA. [Schwandt, M. L.; Heilig, M.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA. [Caparelli, E. C.; Leggio, L.] NIDA, Intramural Res Program, NIH, Baltimore, MD USA. [Momenan, R.] NIAAA, Sect Brain Electrophysiol & Imaging, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA. [Hodgkinson, C. A.; Goldman, D.] NIAAA, Lab Neurogenet, NIH, Bethesda, MD 20892 USA. [Egli, M.] NIAAA, Div Neurosci & Behav, Bethesda, MD 20892 USA. [Lopez, M. F.; Becker, H. C.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. [Becker, H. C.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Becker, H. C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Leggio, L.] Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Providence, RI 02912 USA. RP Leggio, L (reprint author), NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, Lab Clin & Translat Studies, 10 Ctr Dr 10CRC 15330 MSC 1108,Room 1-5429, Bethesda, MD 20892 USA. EM lorenzo.leggio@nih.gov RI Goldman, David/F-9772-2010; Schwandt, Melanie/L-9866-2016; Leggio, Lorenzo/M-2972-2016 OI Goldman, David/0000-0002-1724-5405; FU Division of Intramural Clinical and Biological Research of the National Institute on Alcohol Abuse and Alcoholism (NIAAA); Intramural Research Program of the National Institute on Drug Abuse (NIDA); NIAAA Extramural Division of Neuroscience and Behavior via the NIH/NIAAA contract 'Preclinical Medications Screening in Alcohol Dependence and Anxiety Models' [HHSN267200700038C]; Swedish Brain Foundation; LUA/ALF grant from the Sahlgrenska University Hospital [148251]; Indiana Alcohol Research Center [NIH P60 AA007611]; NIH Genes, Environment and Health Initiative (GEI) [U01HG004422]; Gene Environment Association Studies under GEI; NIH GEI [U01HG004438]; NIAAA; NIDA; NIH [HHSN268200782096C] FX This work was supported by the Division of Intramural Clinical and Biological Research of the National Institute on Alcohol Abuse and Alcoholism (NIAAA; PS, JY, MLS, BLS, RM, CAH, DG, MH, VAR, LL), the Intramural Research Program of the National Institute on Drug Abuse (NIDA; PS, ECC, LL). This work was also supported by the NIAAA Extramural Division of Neuroscience and Behavior via the NIH/NIAAA contract 'Preclinical Medications Screening in Alcohol Dependence and Anxiety Models' (HHSN267200700038C; ME, MFL, HCB), under which the compound AC3174 was provided to NIAAA for testing by Medical University of South Carolina (MUSC). AC3174 was manufactured by Amylin Pharmaceuticals and is now owned by MedImmune, LLC (a wholly owned subsidiary of AstraZeneca), whose staff reviewed and authorized the use of the data described in the 'Study 5'. In addition, this work was supported by the Swedish Brain Foundation (PS), and a LUA/ALF grant (no. 148251) from the Sahlgrenska University Hospital (PS, EJ, JAE). Development of the Computerized Alcohol Infusion System (CAIS) software used in the IV-ASA study was supported by the Indiana Alcohol Research Center (NIH P60 AA007611). Finally, funding support for the Study of Addiction: Genetics and Environment (SAGE; Study 2) was provided through the NIH Genes, Environment and Health Initiative (GEI; U01HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of data sets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), NIAAA, NIDA and the NIH contract 'High throughput genotyping for studying the genetic contributions to human disease' (HHSN268200782096C). The data sets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id = phs000092.v1.p1 through dbGaP accession number phs000092.v1.p. NR 50 TC 10 Z9 10 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JUN 16 PY 2015 VL 5 AR e583 DI 10.1038/tp.2015.68 PG 11 WC Psychiatry SC Psychiatry GA DA2WW UT WOS:000367658900004 PM 26080318 ER PT J AU Corrick, KL Stec, MJ Merritt, EK Windham, ST Thomas, SJ Cross, JM Bamman, MM AF Corrick, Katie L. Stec, Michael J. Merritt, Edward K. Windham, Samuel T. Thomas, Steven J. Cross, James M. Bamman, Marcas M. TI Serum from human burn victims impairs myogenesis and protein synthesis in primary myoblasts SO FRONTIERS IN PHYSIOLOGY LA English DT Article DE burn; inflammation; myogenesis; myoblast; myotube; muscle protein synthesis ID HUMAN SKELETAL-MUSCLE; INJURY; ACTIVATION; GROWTH; DIFFERENTIATION; REGENERATION; INFLAMMATION; CATABOLISM; EXPRESSION; CASPASE-3 AB The pathophysiological response to a severe burn injury involves a robust increase in circulating inflammatory/endocrine factors and a hypermetabolic state, both of which contribute to prolonged skeletal muscle atrophy. In order to characterize the role of circulating factors in muscle atrophy following a burn injury, human skeletal muscle satellite cells were grown in culture and differentiated to myoblasts/myotubes in media containing serum from burn patients or healthy, age, and sex-matched controls. While incubation in burn serum did not affect NF kappa B signaling, cells incubated in burn serum displayed a transient increase in STAT3 phosphorlyation (Tyr705) after 48 h of treatment with burn serum (approximate to + 70%; P < 0.01), with these levels returning to normal by 96 h. Muscle cells differentiated in burn serum displayed reduced myogenic fusion signaling (phospho-STAT6 (Tyr641), approximate to-75% ADAM12, approximate to-20% both P < 0.01), and reduced levels of myogenin (approximate to-75% P < 0.05). Concomitantly, myotubes differentiated in burn serum demonstrated impaired myogenesis (assessed by number of nuclei/myotube). Incubation in burn serum for 96 h did not increase proteolytic signaling (assessed via caspase-3 and ubiquitin levels), but reduced anabolic signaling [p-p70S6k (Ser421/Thr424), -30%; p-rpS6 (Ser240/244), approximate to -50%] and impaired protein synthesis (-24%) (P < 0.05). This resulted in a loss of total protein content (-18%) and reduced cell size (-33%) (P < 0.05). Overall, incubation of human muscle cells in serum from burn patients results in impaired myogenesis and reduced myotube size, indicating that circulating factors may play a significant role in muscle loss and impaired muscle recovery following burn injury. C1 [Corrick, Katie L.; Stec, Michael J.; Merritt, Edward K.; Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA. [Stec, Michael J.; Merritt, Edward K.; Windham, Samuel T.; Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL 35294 USA. [Windham, Samuel T.; Thomas, Steven J.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Cross, James M.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA. [Bamman, Marcas M.] Birmingham VA Med Ctr, Ctr Geriatr Res Educ & Clin, Birmingham, AL USA. RP Bamman, MM (reprint author), Univ Alabama Birmingham, UAB Ctr Exercise Med, Dept Cell Dev & Integrat Biol, MCLM 966,1720 2nd Ave South, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU VA Merit Review Grant [R01AG017896, F32AR060670, F31AG044109]; UAB Burn Center FX We are indebted to the subjects for their efforts and dedication. This work was supported by a VA Merit Review Grant (MB), R01AG017896 (MB), F32AR060670 (EM), F31AG044109 (MS), and the UAB Burn Center. NR 33 TC 5 Z9 5 U1 0 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PD JUN 16 PY 2015 VL 6 AR 184 DI 10.3389/fphys.2015.00184 PG 8 WC Physiology SC Physiology GA CM4UZ UT WOS:000357681800001 PM 26136691 ER PT J AU Driscoll, TP Cosgrove, BD Heo, SJ Shurden, ZE Mauck, RL AF Driscoll, Tristan P. Cosgrove, Brian D. Heo, Su-Jin Shurden, Zach E. Mauck, Robert L. TI Cytoskeletal to Nuclear Strain Transfer Regulates YAP Signaling in Mesenchymal Stem Cells SO BIOPHYSICAL JOURNAL LA English DT Article ID FOCAL ADHESION KINASE; MECHANICAL-PROPERTIES; VINCULIN RECRUITMENT; LOADING IMPROVES; DEPENDENT MANNER; ANNULUS FIBROSUS; K+ CHANNELS; TALIN ROD; MECHANOTRANSDUCTION; MECHANOSENSITIVITY AB Mechanical forces transduced to cells through the extracellular matrix are critical regulators of tissue development, growth, and homeostasis, and can play important roles in directing stem cell differentiation. In addition to force-sensing mechanisms that reside at the cell surface, there is growing evidence that forces transmitted through the cytoskeleton and to the nuclear envelope are important for mechanosensing, including activation of the Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) pathway. Moreover, nuclear shape, mechanics, and deformability change with differentiation state and have been likewise implicated in force sensing and differentiation. However, the significance of force transfer to the nucleus through the mechanosensing cytoskeletal machinery in the regulation of mesenchymal stem cell mechanobiologic response remains unclear. Here we report that actomyosin-generated cytoskeletal tension regulates nuclear shape and force transmission through the cytoskeleton and demonstrate the differential short- and long-term response of mesenchymal stem cells to dynamic tensile loading based on the contractility state, the patency of the actin cytoskeleton, and the connections it makes with the nucleus. Specifically, we show that while some mechanoactive signaling pathways (e.g., ERK signaling) can be activated in the absence of nuclear strain transfer, cytoskeletal strain transfer to the nucleus is essential for activation of the YAP/TAZ pathway with stretch. C1 [Driscoll, Tristan P.; Cosgrove, Brian D.; Heo, Su-Jin; Shurden, Zach E.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Driscoll, Tristan P.; Cosgrove, Brian D.; Heo, Su-Jin; Shurden, Zach E.; Mauck, Robert L.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. [Mauck, Robert L.] Univ Penn, Sch Engn & Appl Sci, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA. [Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu OI Driscoll, Tristan/0000-0002-2426-5551 FU National Institutes of Health [R01 EB02425, R01 AR056624, T32 AR007132]; University of Pennsylvania University Research Foundation Award; Montague Research Award at the Perelman School of Medicine; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was supported by the National Institutes of Health (grants No. R01 EB02425 and No. R01 AR056624). Additional support was provided from a University of Pennsylvania University Research Foundation Award, the Montague Research Award at the Perelman School of Medicine, a grant from the Penn Center for Musculoskeletal Disorders (No. P30 AR050950), and a training grant from the National Institutes of Health (No. T32 AR007132). NR 44 TC 17 Z9 18 U1 4 U2 36 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD JUN 16 PY 2015 VL 108 IS 12 BP 2783 EP 2793 DI 10.1016/j.bpj.2015.05.010 PG 11 WC Biophysics SC Biophysics GA CK6UO UT WOS:000356364000010 PM 26083918 ER PT J AU Harris, J Browne, KD Wolf, JA Smith, DH Duda, JE Cullen, DK AF Harris, James Browne, Kevin D. Wolf, John A. Smith, Douglas H. Duda, John E. Cullen, D. Kacy TI NEURONAL PLASMALEMMAL PERMEABILITY/DENDRITIC BEADING IN THE HIPPOCAMPUS FOLLOWING DIFFUSE BRAIN INJURY IN SWINE SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 33rd Annual National Neurotrauma Symposium CY JUN 28-JUL 01, 2015 CL Santa Fe, NM DE traumatic brain injury; biomechanics; plasma membrane; cell permeability C1 [Harris, James; Browne, Kevin D.; Wolf, John A.; Duda, John E.; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, Philadelphia, PA USA. [Harris, James; Browne, Kevin D.; Wolf, John A.; Smith, Douglas H.; Cullen, D. Kacy] Univ Penn, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA. [Duda, John E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 15 PY 2015 VL 32 IS 12 MA T1-13 BP A6 EP A6 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0OB UT WOS:000363949000014 ER PT J AU Koch, P Tekriwal, A Ulyanova, A Grovola, M Cullen, DK Wolf, J AF Koch, Paul Tekriwal, Anand Ulyanova, Alexandra Grovola, Micheal Cullen, D. Kacy Wolf, John TI CHRONIC NEUROPHYSIOLOGICAL RECORDING OF THE HIPPOCAMPUS IN AWAKE BEHAVING SWINE AFTER DIFFUSE BRAIN INJURY SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 33rd Annual National Neurotrauma Symposium CY JUN 28-JUL 01, 2015 CL Santa Fe, NM DE electrophysiology; behavior; rotational injury; mild TBI C1 [Koch, Paul; Tekriwal, Anand; Ulyanova, Alexandra; Grovola, Micheal; Cullen, D. Kacy; Wolf, John] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Grovola, Micheal; Cullen, D. Kacy; Wolf, John] Philadelphia VA Med Ctr, Dept Neurosurg, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 15 PY 2015 VL 32 IS 12 MA S10-02 BP A10 EP A10 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0OB UT WOS:000363949000023 ER PT J AU Osier, N Yan, HQ Ma, XC Mondello, S Empey, P Poloyac, S Feldman, K Wang, K Hayes, R Kochanek, PM Dixon, CE AF Osier, Nicole Yan, Hong Q. Ma, Xiecheng Mondello, Stefania Empey, Philip Poloyac, Samuel Feldman, Keri Wang, Kevin Hayes, Ronald Kochanek, Patrick M. Dixon, C. Edward TI EVALUATION OF KOLLIDON VA-64 IN THE CONTROLLED CORTICAL IMPACT MODEL OF TRAUMATIC BRAIN INJURY: AN OBTT CONSORTIUM STUDY SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 33rd Annual National Neurotrauma Symposium CY JUN 28-JUL 01, 2015 CL Santa Fe, NM DE traumatic brain injury; neuroprotection; consortium; rat C1 [Yan, Hong Q.; Ma, Xiecheng; Dixon, C. Edward] UPitt, Neurosurg, Pittsburgh, PA USA. [Osier, Nicole] UPitt, SON, Pittsburgh, PA USA. [Osier, Nicole; Yan, Hong Q.; Ma, Xiecheng; Feldman, Keri; Kochanek, Patrick M.] UPitt, SCRR, Pittsburgh, PA USA. [Empey, Philip; Poloyac, Samuel] UPitt, Pharm, Pittsburgh, PA USA. [Mondello, Stefania; Hayes, Ronald] Banyan Biomarker LLC, Alachua, FL USA. [Feldman, Keri; Kochanek, Patrick M.] UPitt, CCM, Pittsburgh, PA USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wang, Kevin] Univ Florida, Med, Gainesville, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 15 PY 2015 VL 32 IS 12 MA D8-19 BP A120 EP A120 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0OB UT WOS:000363949000326 ER PT J AU Ulyanova, A Lee, JH Brem, S Lucas, T O'Rourke, D Grovola, M Wang, JH Na, YJ Singh, J Smith, D Kim, J Eberwine, J Sul, JY Grady, S Wolf, J AF Ulyanova, Alexandra Lee, Jae-Hee Brem, Steven Lucas, Timothy O'Rourke, Donald Grovola, Michael Wang, Jinhui Na, Youngji Singh, Jennifer Smith, Douglas Kim, Junhyong Eberwine, James Sul, Jai-Yoon Grady, Sean Wolf, John TI ELECTROPHYSIOLOGICAL PHENOTYPING OF HUMAN NEURONS IN SLICES AND DISSOCIATED CULTURE SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 33rd Annual National Neurotrauma Symposium CY JUN 28-JUL 01, 2015 CL Santa Fe, NM DE TBI; adult human neurons; electrophysiology; single cell mRNA analysis C1 [Ulyanova, Alexandra; Brem, Steven; Lucas, Timothy; O'Rourke, Donald; Grovola, Michael; Smith, Douglas; Grady, Sean; Wolf, John] Univ Penn, Neurosurg, Philadelphia, PA 19104 USA. [Wolf, John] Philadelphia VA Med Ctr, Neurosurg, Philadelphia, PA USA. [Lee, Jae-Hee; Wang, Jinhui; Singh, Jennifer; Eberwine, James; Sul, Jai-Yoon] Univ Penn, Pharmacol, Philadelphia, PA 19104 USA. [Na, Youngji; Kim, Junhyong] Univ Penn, Biol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 15 PY 2015 VL 32 IS 12 MA C6-03 BP A85 EP A86 PG 2 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA CV0OB UT WOS:000363949000231 ER PT J AU Yuh, B Tate, J Butt, AA Crothers, K Freiberg, M Leaf, D Logeais, M Rimland, D Rodriguez-Barradas, MC Ruser, C Justice, AC AF Yuh, Bianca Tate, Janet Butt, Adeel A. Crothers, Kristina Freiberg, Matthew Leaf, David Logeais, Mary Rimland, David Rodriguez-Barradas, Maria C. Ruser, Christopher Justice, Amy C. TI Weight Change After Antiretroviral Therapy and Mortality SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; veterans; weight; antiretroviral therapy; BMI ID BODY-MASS INDEX; CORONARY-ARTERY-DISEASE; HIV-INFECTED PATIENTS; OBESITY PARADOX; MITOCHONDRIAL TOXICITY; HEART-FAILURE; COHORT; OUTCOMES; IMPACT; GAIN AB Background. Weight gain after antiretroviral therapy (ART) initiation is common, but its implication for mortality is unknown. We evaluated weight change in the first year after ART initiation and its association with subsequent mortality. Methods. Human immunodeficiency virus-infected patients from the Veterans Aging Cohort Study (VACS) who initiated ART between 2000 and 2008, with weight recorded at baseline and 1 year later, were followed another 5 years for mortality. Baseline body mass index (BMI) was classified as underweight (<18.5 kg/m(2)), normal (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)), and obese (>= 30 kg/m(2)). We used multivariable Cox models to assess mortality risk with adjustment for disease severity using the VACS Index. Results. The sample consisted of 4184 men and 127 women with a mean age of 47.9 +/- 10.0 years. After 1 year of ART, median weight change was 5.9 pounds (2.7 kg) (interquartile range, -2.9 to 17.0 pounds, -1.3 to 7.7 kg). Weight gain after ART initiation was associated with lower mortality among underweight and normal-weight patients. A minimum threshold of 10- to 19.9-pound (4.5 to 9.0 kg) weight gain was beneficial for normal-weight patients (hazard ratio, 0.56; 95% confidence interval, .41-.78), but there was no clear benefit to weight gain for overweight/obese patients. Baseline weight, CD4 cell count status, and hemoglobin level were strongly associated with weight gain. Risk for weight gain was higher among those with greater disease severity, regardless of weight at initiation. Conclusions. The survival benefits of weight gain after ART initiation are dependent on starting BMI. Weight gain after ART is associated with lower mortality for those who are not initially overweight. C1 [Yuh, Bianca; Tate, Janet; Ruser, Christopher; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Tate, Janet; Ruser, Christopher; Justice, Amy C.] Vet Affairs VA Connecticut Healthcare Syst, West Haven, CT USA. [Butt, Adeel A.; Freiberg, Matthew] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.; Freiberg, Matthew] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Crothers, Kristina] Univ Washington, Sch Med, Seattle, WA USA. [Leaf, David] UCLA Sch Med, San Francisco, CA USA. [Leaf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Logeais, Mary] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E Debakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. RP Tate, J (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06416 USA. EM janet.tate2@va.gov OI Butt, Adeel/0000-0002-1118-1826; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health (NIH): National Institute on Alcohol Abuse and Alcoholism [U10-AA13566]; National Heart, Lung, and Blood Institute [R01-HL095136, R01-HL090342, RCI-HL100347]; National Institute on Aging [R01-AG029154, K23 AG024896]; National Center for Advancing Translational Sciences of the NIH [TL1TR000141] FX This work was supported by the National Institutes of Health (NIH): National Institute on Alcohol Abuse and Alcoholism (grant number U10-AA13566), National Heart, Lung, and Blood Institute (grant number R01-HL095136, R01-HL090342, and RCI-HL100347), and National Institute on Aging (grant number R01-AG029154, K23 AG024896). Additional funding for this work includes the National Center for Advancing Translational Sciences of the NIH (grant number TL1TR000141 to B. Y.). NR 41 TC 11 Z9 12 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 15 PY 2015 VL 60 IS 12 BP 1852 EP 1859 DI 10.1093/cid/civ192 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CN0BC UT WOS:000358075800021 PM 25761868 ER PT J AU Arjomandi, M Wong, H Donde, A Frelinger, J Dalton, S Ching, W Power, K Balmes, JR AF Arjomandi, Mehrdad Wong, Hofer Donde, Aneesh Frelinger, Jessica Dalton, Sarah Ching, Wendy Power, Karron Balmes, John R. TI Exposure to medium and high ambient levels of ozone causes adverse systemic inflammatory and cardiac autonomic effects SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE ozone; inhalational exposure; heart rate variability; systemic inflammation; airway inflammation ID HEART-RATE-VARIABILITY; C-REACTIVE PROTEIN; AIR-POLLUTION; METABOLIC SYNDROME; VASCULAR DYSFUNCTION; MEXICO-CITY; EXERCISE; INHALATION; ASTHMA; HYPERRESPONSIVENESS AB Epidemiological evidence suggests that exposure to ozone increases cardiovascular morbidity. However, the specific biological mechanisms mediating ozone-associated cardiovascular effects are unknown. To determine whether short-term exposure to ambient levels of ozone causes changes in biomarkers of cardiovascular disease including heart rate variability (HRV), systemic inflammation, and coagulability, 26 subjects were exposed to 0, 100, and 200 ppb ozone in random order for 4 h with intermittent exercise. HRV was measured and blood samples were obtained immediately before (0 h), immediately after (4 h), and 20 h after (24 h) each exposure. Bronchoscopy with bronchoalveolar lavage (BAL) was performed 20 h after exposure. Regression modeling was used to examine dose-response trends between the endpoints and ozone exposure. Inhalation of ozone induced dose-dependent adverse changes in the frequency domains of HRV across exposures consistent with increased sympathetic tone [increase of (parameter estimate +/- SE) 0.4 +/- 0.2 and 0.3 +/- 0.1 in low-to high-frequency domain HRV ratio per 100 ppb increase in ozone at 4 h and 24 h, respectively (P = 0.02 and P = 0.01)] and a dosedependent increase in serum C-reactive protein (CRP) across exposures at 24 h [increase of 0.61 +/- 0.24 mg/l in CRP per 100 ppb increase in ozone (P = 0.01)]. Changes in HRV and CRP did not correlate with ozone-induced local lung inflammatory responses (BAL granulocytes, IL-6, or IL-8), but changes in HRV and CRP were associated with each other after adjustment for age and ozone level. Inhalation of ozone causes adverse systemic inflammatory and cardiac autonomic effects that may contribute to the cardiovascular mortality associated with short-term exposure. C1 [Arjomandi, Mehrdad; Wong, Hofer; Donde, Aneesh; Frelinger, Jessica; Power, Karron; Balmes, John R.] San Francisco Gen Hosp Med Ctr, Div Occupat & Environm Med, Human Exposure Lab, San Francisco, CA USA. [Arjomandi, Mehrdad; Frelinger, Jessica; Balmes, John R.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA. [Arjomandi, Mehrdad; Frelinger, Jessica; Dalton, Sarah; Ching, Wendy] San Francisco VA Med Ctr, Pulm Res Grp, San Francisco, CA USA. [Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Arjomandi, M (reprint author), Univ Calif San Francisco Corresponding, San Francisco Vet Affairs Med Ctr, Div Pulm & Crit Care Med, Bldg 203,Rm 3A-128,Mailstop 111-D,4150 Clement St, San Francisco, CA 94121 USA. EM mehrdad.arjomandi@ucsf.edu FU California Air Resources Board (CARB) [04-322]; National Institutes of Health [NIH/NHLBI K23 HL-083099]; Northern California Institute for Research and Education; University of California San Francisco Cardiovascular Research Institute Faculty Development Funds; NIH/NCRR/OD UCSF-CTSI [KL2 RR-024130, UL1 RR-024131] FX This work was supported by California Air Resources Board (CARB Contract No. 04-322); National Institutes of Health Grants NIH/NHLBI K23 HL-083099, NIH/NCRR/OD UCSF-CTSI Grant Number KL2 RR-024130, and UL1 RR-024131; Northern California Institute for Research and Education; and University of California San Francisco Cardiovascular Research Institute Faculty Development Funds. NR 51 TC 6 Z9 6 U1 0 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUN 15 PY 2015 VL 308 IS 12 BP H1499 EP H1509 DI 10.1152/ajpheart.00849.2014 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA CK5NZ UT WOS:000356273200005 PM 25862833 ER PT J AU Sheth, SA Iavarone, AT Liebeskind, DS Won, SJ Swanson, RA AF Sheth, Sunil A. Iavarone, Anthony T. Liebeskind, David S. Won, Seok Joon Swanson, Raymond A. TI Targeted Lipid Profiling Discovers Plasma Biomarkers of Acute Brain Injury SO PLOS ONE LA English DT Article ID FIBRILLARY ACIDIC PROTEIN; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; INFARCT VOLUME; WHITE-MATTER; SPHINGOLIPIDS; INTERVENTION; ASSOCIATION; GUIDELINES; PROGNOSIS AB Prior efforts to identify a blood biomarker of brain injury have relied almost exclusively on proteins; however their low levels at early time points and poor correlation with injury severity have been limiting. Lipids, on the other hand, are the most abundant molecules in the brain and readily cross the blood-brain barrier. We previously showed that certain sphingolipid (SL) species are highly specific to the brain. Here we examined the feasibility of using SLs as biomarkers for acute brain injury. A rat model of traumatic brain injury (TBI) and a mouse model of stroke were used to identify candidate SL species though our mass-spectrometry based lipid profiling approach. Plasma samples collected after TBI in the rat showed large increases in many circulating SLs following injury, and larger lesions produced proportionately larger increases. Plasma samples collected 24 hours after stroke in mice similarly revealed a large increase in many SLs. We constructed an SL score (sum of the two SL species showing the largest relative increases in the mouse stroke model) and then evaluated the diagnostic value of this score on a small sample of patients (n = 14) who presented with acute stroke symptoms. Patients with true stroke had significantly higher SL scores than patients found to have non-stroke causes of their symptoms. The SL score correlated with the volume of ischemic brain tissue. These results demonstrate the feasibility of using lipid biomarkers to diagnose brain injury. Future studies will be needed to further characterize the diagnostic utility of this approach and to transition to an assay method applicable to clinical settings. C1 [Sheth, Sunil A.; Liebeskind, David S.] Univ Calif Los Angeles, Comprehens Stroke Ctr, Los Angeles, CA 90095 USA. [Sheth, Sunil A.; Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Iavarone, Anthony T.] Univ Calif Berkeley, Chem Mass Spectrometry Facil QB3, Berkeley, CA 94720 USA. [Won, Seok Joon; Swanson, Raymond A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94143 USA. [Won, Seok Joon; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Sheth, SA (reprint author), Univ Calif Los Angeles, Comprehens Stroke Ctr, Los Angeles, CA 90095 USA. EM ssheth@post.harvard.edu FU NIH [NS041421]; Department of Defense (RAS) [W81XWH-13-2-0091]; Department of Veterans Affairs FX This study was supported by the NIH (NS041421), Department of Defense (RAS, grant W81XWH-13-2-0091) and the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 6 Z9 6 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 15 PY 2015 VL 10 IS 6 AR e0129735 DI 10.1371/journal.pone.0129735 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK6HU UT WOS:000356329900098 PM 26076478 ER PT J AU Toba, H Bras, LED Baicu, CF Zile, MR Lindsey, ML Bradshaw, AD AF Toba, Hiroe Bras, Lisandra E. de Castro Baicu, Catalin F. Zile, Michael R. Lindsey, Merry L. Bradshaw, Amy D. TI Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE secreted protein acidic and rich in cysteine; aging; heart; inflammation; macrophage ID CARDIOVASCULAR-DISEASE ENTERPRISES; EXTRACELLULAR-MATRIX; NEUTROPHIL RECRUITMENT; DIASTOLIC DYSFUNCTION; MATRICELLULAR PROTEIN; MAJOR SHAREHOLDERS; HEART-FAILURE; SPARC; FIBROSIS; EXPRESSION AB To investigate the role of secreted protein acidic and rich in cysteine (SPARC) in age-related cardiac inflammation, we studied six groups of mice: young (3-5 mo old), middle-aged (10-12 mo old), and old (18-29 mo old) C57BL/6 wild-type (WT) and SPARC-null (Null) mice (n = 7-10/group). Cardiac function and structure were determined by echocardiography. The left ventricle was used for cytokine gene array and macrophage quantification by immunohistochemistry. Macrophage infiltration increased with age in WT (n = 5-6/group, P < 0.05 for young vs. old), but not in Null. Proinflammatory markers (Ccl5, Cx3cl1, Ccr2, and Cxcr3) increased in middle-aged and old WT, whereas they were increased only in old Null compared with respective young (n = 5-6/group, P < 0.05 for all). These results suggest that SPARC deletion delayed age-related cardiac inflammation. To further assess how SPARC affects inflammation, we stimulated peritoneal macrophages with SPARC (n = 4). SPARC treatment increased expression of proinflammatory macrophage M1 markers and decreased anti-inflammatory M2 markers. Echocardiography (n = 7-10/group) revealed an age-related increase in wall thickness of the left ventricle in WT (0.76 +/- 0.02 mm in young vs. 0.91 +/- 0.03 mm in old; P < 0.05) but not in Null (0.78 +/- 0.01 mm in young vs. 0.84 +/- 0.02 mm in old). In conclusion, SPARC deletion delayed age-related increases in macrophage infiltration and proinflammatory cytokine expression in vivo and in vitro. SPARC acts as an important mediator of age-related cardiac inflammation by increasing the expression of macrophage M1 markers and decreasing M2 markers. C1 [Toba, Hiroe; Bras, Lisandra E. de Castro; Lindsey, Merry L.] Univ Mississippi, Med Ctr, Mississippi Ctr Heart Res, Jackson, MS 39216 USA. [Toba, Hiroe; Bras, Lisandra E. de Castro; Lindsey, Merry L.] Univ Mississippi, Med Ctr, San Antonio Cardiovasc Prote Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA. [Toba, Hiroe] Kyoto Pharmaceut Univ, Div Pathol Sci, Dept Clin Pharmacol, Kyoto 607, Japan. [Bras, Lisandra E. de Castro] E Carolina Univ, Dept Physiol, Greenville, NC USA. [Baicu, Catalin F.; Zile, Michael R.; Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Zile, Michael R.; Bradshaw, Amy D.] Med Ctr, Ralph H Johnson Dept Vet Affairs, Charleston, SC USA. [Lindsey, Merry L.] GV Sonny Montgomery Vet Affairs Med Ctr, Jackson, MS USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, 171 Ashley Ave, Charleston, SC 29425 USA. EM bradshad@musc.edu FU American Heart Association [14SDG1886005]; Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development [1I01BX001385, 5I01BX000505]; National Institutes of Health [268201000036C (N01-HV-00244), HL-075360, HL-051971, GM-104357] FX We acknowledge support from the American Heart Association for 14SDG1886005, from the Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development Awards 1I01BX001385 and 5I01BX000505, and from the National Institutes of Health for HHSN 268201000036C (N01-HV-00244) for the San Antonio Cardiovascular Proteomics Center, HL-075360, HL-051971, and GM-104357. NR 58 TC 4 Z9 4 U1 1 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 EI 1522-1563 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD JUN 15 PY 2015 VL 308 IS 12 BP C972 EP C982 DI 10.1152/ajpcell.00402.2014 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA CK5DI UT WOS:000356242000003 PM 25877699 ER PT J AU Zhang, YQ Fischer, KE Soto, V Liu, YH Sosnowska, D Richardson, A Salmon, AB AF Zhang, Yiqiang Fischer, Kathleen E. Soto, Vanessa Liu, Yuhong Sosnowska, Danuta Richardson, Arlan Salmon, Adam B. TI Obesity-induced oxidative stress, accelerated functional decline with age and increased mortality in mice SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Obesity; Rotarod; Longevity; Oxidation; Grip strength; Respirometry; Gait ID MN-SUPEROXIDE-DISMUTASE; INSULIN-RESISTANCE; LIFE-SPAN; COGNITIVE IMPAIRMENT; ADIPOSE-TISSUE; HEALTH; MUSCLE; OVEREXPRESSION; RESTRICTION; LONGEVITY AB Obesity is a serious chronic disease that increases the risk of numerous co-morbidities including metabolic syndrome, cardiovascular disease and cancer as well as increases risk of mortality, leading some to suggest this condition represents accelerated aging. Obesity is associated with significant increases in oxidative stress in vivo and, despite the well-explored relationship between oxidative stress and aging, the role this plays in the increased mortality of obese subjects remains an unanswered question. Here, we addressed this by undertaking a comprehensive, longitudinal study of a group of high fat-fed obese mice and assessed both their changes in oxidative stress and in their performance in physiological assays known to decline with aging. In female C57BL/6J mice fed a high-fat diet starting in adulthood, mortality was significantly increased as was oxidative damage in vivo. High fat-feeding significantly accelerated the decline in performance in several assays, including activity, gait, and rotarod. However, we also found that obesity had little effect on other markers of function and actually improved performance in grip strength, a marker of muscular function. Together, this first comprehensive assessment of longitudinal, functional changes in high fat-fed mice suggests that obesity may induce segmental acceleration of some of the aging process. Published by Elsevier Inc. C1 [Zhang, Yiqiang; Soto, Vanessa; Liu, Yuhong; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Zhang, Yiqiang] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Fischer, Kathleen E.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA. [Sosnowska, Danuta; Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK USA. [Sosnowska, Danuta; Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Salmon, AB (reprint author), 15355 Lambda Dr, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu FU American Federation for Aging Research; Biomedical Laboratory Research & Development Service of the Veteran's Affairs Office of Research and Development [1I01BX000547]; Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System FX Animal studies were performed in the Healthspan and Functional Assessment Core of the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. This research was supported in part by funding from the American Federation for Aging Research (Y.Z. and A.B.S.), the Biomedical Laboratory Research & Development Service of the Veteran's Affairs Office of Research and Development (1I01BX000547 to A.R.) and Geriatric Research Education and Clinical Center of the South Texas Veterans Healthcare System (A.B.S.). NR 45 TC 9 Z9 9 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 EI 1096-0384 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD JUN 15 PY 2015 VL 576 BP 39 EP 48 DI 10.1016/j.abb.2014.12.018 PG 10 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA CK3LQ UT WOS:000356118000006 PM 25558793 ER PT J AU Kwon, I Choi, S Mittman, B Bharmal, N Liu, HH Vickrey, B Song, S Araiza, D McCreath, H Seeman, T Oh, SM Trejo, L Sarkisian, C AF Kwon, Ivy Choi, Sarah Mittman, Brian Bharmal, Nazleen Liu, Honghu Vickrey, Barbara Song, Sarah Araiza, Daniel McCreath, Heather Seeman, Teresa Oh, Sang-Mi Trejo, Laura Sarkisian, Catherine TI Study protocol of "Worth the Walk": a randomized controlled trial of a stroke risk reduction walking intervention among racial/ethnic minority older adults with hypertension in community senior centers SO BMC NEUROLOGY LA English DT Article DE Seniors; Ethnic minority; Stroke; Primary prevention; Behavioral intervention; Clinical trial ID AMERICAN-HEART-ASSOCIATION; PHYSICAL-ACTIVITY; ETHNIC DISPARITIES; NORTHERN MANHATTAN; ISCHEMIC-STROKE; WARNING SIGNS; SHORT-FORM; HEALTH; KNOWLEDGE; DISEASE AB Background: Stroke disproportionately kills and disables ethnic minority seniors. Up to 30 % of ischemic strokes in the U.S. can be attributed to physical inactivity, yet most Americans, especially older racial/ethnic minorities, fail to participate in regular physical activity. We are conducting a randomized controlled trial (RCT) to test a culturally-tailored community-based walking intervention designed to reduce stroke risk by increasing physical activity among African American, Latino, Chinese, and Korean seniors with hypertension. We hypothesize that the intervention will yield meaningful changes in seniors' walking levels and stroke risk with feasibility to sustain and scale up across the aging services network. Methods/Design: In this randomized single-blind wait-list control study, high-risk ethnic minority seniors are enrolled at senior centers, complete baseline data collection, and are randomly assigned to receive the intervention "Worth the Walk" immediately (N = 120, intervention group) or in 90 days upon completion of follow-up data collection (N = 120, control group). Trained case managers employed by the senior centers implement hour-long intervention sessions twice weekly for four consecutive weeks to the intervention group. Research staff blinded to participants' group assignment collect outcome data from both intervention and wait-list control participants 1 and 3-months after baseline data collection. Primary outcome measures are mean steps/day over 7 days, stroke knowledge, and self-efficacy for reducing stroke risk. Secondary and exploratory outcome measures include selected biological markers of health, healthcare seeking, and health-related quality of life. Outcomes will be compared between the two groups using standard analytic methods for randomized trials. We will conduct a formal process evaluation to assess barriers and facilitators to successful integration of Worth the Walk into the aging services network and to calculate estimated costs to sustain and scale up the intervention. Data collection is scheduled to be completed in December 2016. Discussion: If this RCT demonstrates superior improvements in physical activity and stroke knowledge in the intervention group compared to the control group and is found to be sustainable and scalable, Worth the Walk could serve as a primary stroke prevention model for racial/ethnic communities across the nation. C1 [Kwon, Ivy; Araiza, Daniel; Seeman, Teresa; Sarkisian, Catherine] Univ Calif Los Angeles, Dept Med, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Choi, Sarah] Univ Calif Irvine, Nursing Sci, Coll Hlth Sci, Irvine, CA 92697 USA. [Mittman, Brian] VA Greater Angeles Healthcare Syst, Ctr Implementat Practice & Res Support, Sepulveda, CA 91343 USA. [Bharmal, Nazleen] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Bharmal, Nazleen] Univ Calif Los Angeles, Hlth Serv Res, Los Angeles, CA 90095 USA. [Liu, Honghu] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. [Vickrey, Barbara] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Song, Sarah] Rush Univ, Vasc Neurol, Chicago, IL 60612 USA. [McCreath, Heather] Univ Calif Los Angeles, Geriatr Res Ctr, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Oh, Sang-Mi] Amer Stroke Assoc, American Heart Assoc, San Jose, CA 95113 USA. [Trejo, Laura] City Los Angeles Dept Aging, Los Angeles, CA 90012 USA. [Sarkisian, Catherine] GRECC, VA Greater Angeles Healthcare Syst Geriatr, Los Angeles, CA 90073 USA. RP Kwon, I (reprint author), Univ Calif Los Angeles, Dept Med, Div Geriatr, David Geffen Sch Med, 10945 Conte Ave, Los Angeles, CA 90095 USA. EM IKwon@mednet.ucla.edu OI Kwon, Ivy/0000-0003-4160-6546 FU National Institute of Neurological Disorders and Stroke [1U54NS081764]; National Institute on Aging [1K24AG047899-01]; National Institute on Aging UCLA Older Americans Independence Center [P30AG028748]; National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III [P30AG021684] FX This work was supported by the National Institute of Neurological Disorders and Stroke [1U54NS081764] and the National Institute on Aging [1K24AG047899-01]. Additional sources of support for this project include the National Institute on Aging UCLA Older Americans Independence Center [P30AG028748] and National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III ([2] P30AG021684). NR 58 TC 3 Z9 3 U1 3 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD JUN 15 PY 2015 VL 15 AR 91 DI 10.1186/s12883-015-0346-9 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CK2KE UT WOS:000356038400001 PM 26072359 ER PT J AU Gosain, A Barlow-Anacker, AJ Erickson, CS Pierre, JF Heneghan, AF Epstein, ML Kudsk, KA AF Gosain, Ankush Barlow-Anacker, Amanda J. Erickson, Chris S. Pierre, Joseph F. Heneghan, Aaron F. Epstein, Miles L. Kudsk, Kenneth A. TI Impaired Cellular Immunity in the Murine Neural Crest Conditional Deletion of Endothelin Receptor-B Model of Hirschsprung's Disease SO PLOS ONE LA English DT Article ID ENTERIC NERVOUS-SYSTEM; PEYERS-PATCHES; INTESTINAL AGANGLIONOSIS; ANATOMICAL EVIDENCE; SURGICAL-CORRECTION; ULCERATIVE-COLITIS; CROHNS-DISEASE; L-SELECTIN; RAT MODEL; ENTEROCOLITIS AB Hirschsprung's disease (HSCR) is characterized by aganglionosis from failure of neural crest cell (NCC) migration to the distal hindgut. Up to 40% of HSCR patients suffer Hirschsprung's-associated enterocolitis (HAEC), with an incidence that is unchanged from the pre-operative to the post-operative state. Recent reports indicate that signaling pathways involved in NCC migration may also be involved in the development of secondary lymphoid organs. We hypothesize that gastrointestinal (GI) mucosal immune defects occur in HSCR that may contribute to enterocolitis. EdnrB was deleted from the neural crest (EdnrB(NCC-/-)) resulting in mutants with defective NCC migration, distal colonic aganglionosis and the development of enterocolitis. The mucosal immune apparatus of these mice was interrogated at post-natal day (P) 2124, prior to histological signs of enterocolitis. We found that EdnrB(NCC-/-) display lymphopenia of their Peyer's Patches, the major inductive site of GI mucosal immunity. EdnrB(NCC-/-) Peyer's Patches demonstrate decreased B-lymphocytes, specifically IgM(+)IgD(hi) (Mature) B-lymphocytes, which are normally activated and produce IgA following antigen presentation. EdnrB(NCC-/-) animals demonstrate decreased small intestinal secretory IgA, but unchanged nasal and bronchial airway secretory IgA, indicating a gut-specific defect in IgA production or secretion. In the spleen, which is the primary source of IgA-producing Mature B-lymphocytes, EdnrB(NCC-/-) animals display decreased B-lymphocytes, but an increase in Mature B-lymphocytes. EdnrB(NCC-/-) spleens are also small and show altered architecture, with decreased red pulp and a paucity of B-lymphocytes in the germinal centers and marginal zone. Taken together, these findings suggest impaired GI mucosal immunity in EdnrB(NCC-/-) animals, with the spleen as a potential site of the defect. These findings build upon the growing body of literature that suggests that intestinal defects in HSCR are not restricted to the aganglionic colon but extend proximally, even into the ganglionated small intestine and immune cells. C1 [Gosain, Ankush; Barlow-Anacker, Amanda J.; Erickson, Chris S.; Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. [Gosain, Ankush; Epstein, Miles L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosci, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Gosain, A (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. EM gosain@surgery.wisc.edu OI Gosain, Ankush/0000-0002-0428-1503 FU National Institutes of Health [NIDDK RO1DK081634, NIDDK K08DK098271]; Veteran's Affairs Office of Research and Development (Biomedical Laboratory Research & Development Award) [I01BX001672]; Central Surgical Association Foundation (Turcotte Award); American Pediatric Surgical Association Foundation Award FX This work was supported by the National Institutes of Health (NIDDK RO1DK081634) to MLE, the Veteran's Affairs Office of Research and Development (Biomedical Laboratory Research & Development Award I01BX001672) to KAK, the Central Surgical Association Foundation (2012 Turcotte Award) to AG, the American Pediatric Surgical Association Foundation Award to AG, and the National Institutes of Health (NIDDK K08DK098271) to AG. The contents of this article do not represent the views of the Veterans Affairs or the United States Government (KAK). NR 76 TC 11 Z9 11 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 10 PY 2015 VL 10 IS 6 AR e0128822 DI 10.1371/journal.pone.0128822 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK1PO UT WOS:000355979500100 PM 26061883 ER PT J AU O'Donovan, SM Hasselfeld, K Bauer, D Simmons, M Roussos, P Haroutunian, V Meador-Woodruff, JH McCullumsmith, RE AF O'Donovan, S. M. Hasselfeld, K. Bauer, D. Simmons, M. Roussos, P. Haroutunian, V. Meador-Woodruff, J. H. McCullumsmith, R. E. TI Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia SO TRANSLATIONAL PSYCHIATRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; ELDERLY-PATIENTS; RAT-BRAIN; DIFFERENTIAL EXPRESSION; TRANSCRIPT EXPRESSION; ASPARTATE TRANSPORTER; NEURONAL EXPRESSION; ABNORMAL EXPRESSION; ALZHEIMERS-DISEASE; EAAT2 POLYMORPHISM AB Dysregulation of the glutamate transporters EAAT1 and EAAT2 and their isoforms have been implicated in schizophrenia. EAAT1 and EAAT2 expression has been studied in different brain regions but the prevalence of astrocytic glutamate transporter expression masks the more subtle changes in excitatory amino acid transporters (EAATs) isoforms in neurons in the cortex. Using laser capture microdissection, pyramidal neurons were cut from the anterior cingulate cortex of postmortem schizophrenia (n = 20) and control (n = 20) subjects. The messenger RNA (mRNA) levels of EAAT1, EAAT2 and the splice variants EAAT1 exon9skipping, EAAT2 exon9skipping and EAAT2b were analyzed by real time PCR (RT-PCR) in an enriched population of neurons. Region-level expression of these transcripts was measured in postmortem schizophrenia (n = 25) and controls (n = 25). The relationship between selected EAAT polymorphisms and EAAT splice variant expression was also explored. Anterior cingulate cortex pyramidal cell expression of EAAT2b mRNA was increased (P<0.001; 67%) in schizophrenia subjects compared with controls. There was no significant change in other EAAT variants. EAAT2 exon9skipping mRNA was increased (P<0.05; 38%) at region level in the anterior cingulate cortex with no significant change in other EAAT variants at region level. EAAT2 single-nucleotide polymorphisms were significantly associated with changes in EAAT2 isoform expression. Haloperidol decanoate-treated animals, acting as controls for possible antipsychotic effects, did not have significantly altered neuronal EAAT2b mRNA levels. The novel finding that EAAT2b levels are increased in populations of anterior cingulate cortex pyramidal cells further demonstrates a role for neuronal glutamate transporter splice variant expression in schizophrenia. C1 [O'Donovan, S. M.; Hasselfeld, K.; McCullumsmith, R. E.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45267 USA. [Bauer, D.; McCullumsmith, R. E.] Wellesley Coll, Dept Neurosci, Wellesley, MA 02181 USA. [Simmons, M.; Meador-Woodruff, J. H.; McCullumsmith, R. E.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA. [Roussos, P.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Dept Psychiat, New York, NY 10029 USA. [Roussos, P.] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Roussos, P.] Mental Illness Res Educ & Clin Ctr, James J Peters VA Med Ctr, Bronx, NY USA. [Haroutunian, V.] Icahn Sch Med Mt Sinai, Dept Psychiat & Neurosci, New York, NY 10029 USA. RP McCullumsmith, RE (reprint author), Univ Cincinnati, Dept Psychiat & Behav Neurosci, CARE 5830,231 Albert Sabin Way Cincinnati, Cincinnati, OH 45267 USA. EM robert.mccullumsmith@uc.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239; O'Donovan, Sinead/0000-0003-3172-4952 FU NIH [MH074016, MH087752, MH094445]; Doris Duke Clinical Scientist Award; Lindsay Brinkmeyer Schizophrenia Research Fund FX This research was funded by NIH grant numbers: MH074016, MH087752, MH094445 and the Doris Duke Clinical Scientist Award (REM). This work was also supported by the Lindsay Brinkmeyer Schizophrenia Research Fund. We gratefully acknowledge Bronx VA and Mount Sinai Centre Brain Bank for providing tissue samples. NR 66 TC 3 Z9 3 U1 3 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JUN 9 PY 2015 VL 5 AR e579 DI 10.1038/tp.2015.74 PG 9 WC Psychiatry SC Psychiatry GA DA2WT UT WOS:000367658600003 PM 26057049 ER PT J AU Moledina, DG Parikh, CR Garg, AX Thiessen-Philbrook, H Koyner, JL Patel, UD Devarajan, P Shlipak, MG Coca, SG AF Moledina, Dennis G. Parikh, Chirag R. Garg, Amit X. Thiessen-Philbrook, Heather Koyner, Jay L. Patel, Uptal D. Devarajan, Prasad Shlipak, Michael G. Coca, Steven G. CA TRIBE-AKI Consortium TI Association of Perioperative Plasma Neutrophil Gelatinase-Associated Lipocalin Levels with 3-Year Mortality after Cardiac Surgery: A Prospective Observational Cohort Study SO PLOS ONE LA English DT Article ID ACUTE KIDNEY INJURY; GLOMERULAR-FILTRATION-RATE; ISCHEMIC RENAL INJURY; POOR OUTCOMES; BIOMARKERS; NGAL; DISEASE; AKI AB Background Higher levels of plasma neutrophil gelatinase-associated lipocalin (pNGAL) are an early marker of acute kidney injury and are associated with increased risk of short-term adverse outcomes. The independent association between pNGAL and long-term mortality is unknown. Methods In this prospective observational cohort study, we studied 1191 adults who underwent cardiac surgery between 2007 and 2009 at 6 centers in the TRIBE-AKI cohort. We measured the pNGAL on the pre-operative and first 3 post-operative days and assessed the relationship of peri-operative pNGAL concentrations with all-cause mortality. Results During a median follow-up of 3.0 years, 139 participants died (50/1000 person-years). Pre-operative levels of pNGAL were associated with 3-year mortality (unadjusted HR 1.96, 95% CI 1.34,2.85) and the association persisted after adjustment for pre-operative variables including estimated glomerular filtration rate (adjusted HR 1.48, 95% CI 1.04-2.12). After adjustment for pre- and intra-operative variables, including pre-operative NGAL levels, the highest tertiles of first post-operative and peak post-operative pNGAL were also independently associated with 3-year mortality risk (adjusted HR 1.31, 95% CI 1.0-1.7 and adjusted HR 1.78, 95% CI 1.2-2.7, respectively). However, after adjustment for peri-operative changes in serum creatinine, there was no longer an independent association between the first post-operative and peak post-operative pNGAL and long-term mortality (adjusted HR 0.98,95% CI 0.79-1.2 for first pNGAL and adjusted HR 1.19, 95% CI 0.87-1.61 for peak pNGAL). Conclusions Pre-operative pNGAL levels were independently associated with 3-year mortality after cardiac surgery. While post-operative pNGAL levels were also associated with 3-year mortality, this relationship was not independent of changes in serum creatinine. These findings suggest that while pre-operative pNGAL adds prognostic value for mortality beyond routinely available serum creatinine, post-operative pNGAL measurements may not be as useful for this purpose. C1 [Moledina, Dennis G.; Parikh, Chirag R.; Coca, Steven G.] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA. [Moledina, Dennis G.; Parikh, Chirag R.; Coca, Steven G.] VA CT Healthcare Syst, West Haven, CT USA. [Moledina, Dennis G.; Parikh, Chirag R.; Coca, Steven G.] Yale Univ, Sch Med, Program Appl Translat Res, New Haven, CT 06510 USA. [Garg, Amit X.; Thiessen-Philbrook, Heather] Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada. [Garg, Amit X.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Koyner, Jay L.] Univ Chicago, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. [Patel, Uptal D.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Devarajan, Prasad] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Parikh, CR (reprint author), Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA. EM chirag.parikh@yale.edu OI Moledina, Dennis/0000-0002-9537-9038 FU NIH [RO1HL085757, K24DK090203, U01DK082185]; Career Development Award from NIH [K23DK080132]; O'Brien Kidney Center Grant [P30 DK079310-07]; Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC); [R01DK096549] FX The study was supported by the NIH grant RO1HL085757 (CRP) to fund the TRIBE-AKI Consortium to study novel biomarkers of acute kidney injury in cardiac surgery. SGC has been supported by Career Development Award from the NIH (K23DK080132) and R01DK096549. CRP is also supported by NIH grant K24DK090203. CRP was supported by the P30 DK079310-07 O'Brien Kidney Center Grant. SGC, AXG, PD, and CRP are also members of the NIH-sponsored ASsess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185). The plasma NGAL assays were donated by Biosite. Biosite, Inc., did not participate in the protocol development, analysis, or interpretation of the results. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 21 TC 3 Z9 3 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 8 PY 2015 VL 10 IS 6 AR UNSP e0129619 DI 10.1371/journal.pone.0129619 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK1GM UT WOS:000355955300153 PM 26053382 ER PT J AU Guo, Y Hu, BF Huang, H Tsung, A Gaikwad, NW Xu, MS Jiang, MX Ren, SR Fan, J Billiar, TR Huang, M Xie, W AF Guo, Yan Hu, Bingfang Huang, Hai Tsung, Allan Gaikwad, Nilesh W. Xu, Meishu Jiang, Mengxi Ren, Songrong Fan, Jie Billiar, Timothy R. Huang, Min Xie, Wen TI Estrogen Sulfotransferase Is an Oxidative Stress-responsive Gene That Gender-specifically Affects Liver Ischemia/Reperfusion Injury SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ISCHEMIA-REPERFUSION INJURY; REDUCED-SIZE LIVER; NRF2 ACTIVATION; CELL-SURVIVAL; X-RECEPTOR; MICE; 17-BETA-ESTRADIOL; ANTIOXIDANT; MECHANISMS; INHIBITION AB Estrogen sulfotransferase (EST) regulates estrogen homeostasis by sulfonating and deactivating estrogens. Liver ischemia and reperfusion (I/R) involves both hypoxia during the ischemic phase and oxidative damage during the reperfusion phase. In this report, we showed that the expression of EST was markedly induced by I/R. Mechanistically, oxidative stress-induced activation of Nrf2 was responsible for the EST induction, which was abolished in Nrf2(-/-) mice. EST is a direct transcriptional target of Nrf2. In female mice, the I/R-responsive induction of EST compromised estrogen activity. EST ablation attenuated I/R injury as a result of decreased estrogen deprivation, whereas this benefit was abolished upon ovariectomy. The effect of EST ablation was sex-specific because the EST-/- males showed heightened I/R injury. Reciprocally, both estrogens and EST regulate the expression and activity of Nrf2. Estrogen deprivation by ovariectomy abolished the I/R-responsive Nrf2 accumulation, whereas the compromised estrogen deprivation in EST-/- mice was associated with increased Nrf2 accumulation. Our results suggested a novel I/R-responsive feedback mechanism to limit the activity of Nrf2 in which Nrf2 induces the expression of EST, which subsequently increases estrogen deactivation and limits the estrogen-responsive activation of Nrf2. Inhibition of EST, at least in females, may represent an effective approach to manage hepatic I/R injury. C1 [Guo, Yan; Hu, Bingfang; Xu, Meishu; Jiang, Mengxi; Ren, Songrong; Xie, Wen] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA. [Guo, Yan; Hu, Bingfang; Xu, Meishu; Jiang, Mengxi; Ren, Songrong; Xie, Wen] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Huang, Hai; Tsung, Allan; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA. [Xie, Wen] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Guo, Yan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai 200025, Peoples R China. [Hu, Bingfang; Huang, Min] Sun Yat Sen Univ, Inst Clin Pharmacol, Guangzhou 510275, Guangdong, Peoples R China. [Gaikwad, Nilesh W.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Gaikwad, Nilesh W.] Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA 15240 USA. RP Huang, M (reprint author), Sun Yat Sen Univ, Inst Clin Pharmacol, Guangzhou 510006, Guangdong, Peoples R China. EM huangmin@mail.sysu.edu.cn; wex6@pitt.edu RI Huang, Hai/F-4286-2012; Regan, Clinton/E-6250-2012; Xie, Wen/M-1768-2016 OI Huang, Hai/0000-0001-7430-0119; FU National Institutes of Health [HD073070, DK099232, ES023438]; Joseph Koslow Endowed Professorship; Visiting Scholar Foundation of Shanghai Municipal Education Commission; China Scholarship Council [201206380045] FX This work was supported, in whole or in part, by National Institutes of Health Grants HD073070, DK099232, and ES023438, and by the Joseph Koslow Endowed Professorship (to W. X.).; Supported by the Visiting Scholar Foundation of Shanghai Municipal Education Commission.; Supported by China Scholarship Council Scholarship 201206380045. NR 37 TC 6 Z9 6 U1 0 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 5 PY 2015 VL 290 IS 23 BP 14754 EP 14764 DI 10.1074/jbc.M115.642124 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CJ8MC UT WOS:000355754600044 PM 25922074 ER PT J AU Fogelgren, B Polgar, N Lui, VH Lee, AJ Tamashiro, KKA Napoli, JA Walton, CB Zuo, XF Lipschutz, JH AF Fogelgren, Ben Polgar, Noemi Lui, Vanessa H. Lee, Amanda J. Tamashiro, Kadee-Kalia A. Napoli, Josephine Andrea Walton, Chad B. Zuo, Xiaofeng Lipschutz, Joshua H. TI Urothelial Defects from Targeted Inactivation of Exocyst Sec10 in Mice Cause Ureteropelvic Junction Obstructions SO PLOS ONE LA English DT Article ID BLADDER UMBRELLA CELLS; YEAST SECRETORY PATHWAY; CADHERIN GENE PROMOTER; CHRONIC-RENAL-FAILURE; PRIMARY CILIOGENESIS; GENITOURINARY TRACT; URETER DEVELOPMENT; DEVELOPING KIDNEY; PLASMA-MEMBRANE; PROTEIN SEC8 AB Most cases of congenital obstructive nephropathy are the result of ureteropelvic junction obstructions, and despite their high prevalence, we have a poor understanding of their etiology and scarcity of genetic models. The eight-protein exocyst complex regulates polarized exocytosis of intracellular vesicles in a large variety of cell types. Here we report generation of a conditional knockout mouse for Sec10, a central component of the exocyst, which is the first conditional allele for any exocyst gene. Inactivation of Sec10 in ureteric bud-derived cells using Ksp1.3-Cre mice resulted in severe bilateral hydronephrosis and complete anuria in newborns, with death occurring 6-14 hours after birth. Sec10(FL/FL); Ksp-Cre embryos developed ureteropelvic junction obstructions between E17.5 and E18.5 as a result of degeneration of the urothelium and subsequent overgrowth by surrounding mesenchymal cells. The urothelial cell layer that lines the urinary tract must maintain a hydrophobic luminal barrier again urine while remaining highly stretchable. This barrier is largely established by production of uroplakin proteins that are transported to the apical surface to establish large plaques. By E16.5, Sec10(FL/FL); Ksp-Cre ureter and pelvic urothelium showed decreased uroplakin-3 protein at the luminal surface, and complete absence of uroplakin-3 by E17.5. Affected urothelium at the UPJ showed irregular barriers that exposed the smooth muscle layer to urine, suggesting this may trigger the surrounding mesenchymal cells to overgrow the lumen. Findings from this novel mouse model show Sec10 is critical for the development of the urothelium in ureters, and provides experimental evidence that failure of this urothelial barrier may contribute to human congenital urinary tract obstructions. C1 [Fogelgren, Ben; Polgar, Noemi; Lui, Vanessa H.; Lee, Amanda J.; Tamashiro, Kadee-Kalia A.; Napoli, Josephine Andrea] Univ Hawaii Manoa, John A Burns Sch Med, Dept Anat Biochem & Physiol, Honolulu, HI 96822 USA. [Walton, Chad B.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [Zuo, Xiaofeng; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. RP Fogelgren, B (reprint author), Univ Hawaii Manoa, John A Burns Sch Med, Dept Anat Biochem & Physiol, Honolulu, HI 96822 USA. EM fogelgre@hawaii.edu OI Polgar, Noemi/0000-0002-8400-162X FU National Institutes of Health [K01DK087852, R03DK100738, P20GM103457-06A1-8293, R01DK069909, R21DK070980]; United States Department of Veteran's Affairs [I01 BX000820]; Satellite Healthcare Norman S. Coplon Extramural Research Grant; Hawaii Community Foundation [12ADVC-51347]; University of Alabama at Birmingham Hepato/Renal Fibrocystic Diseases Core Center [5P30DK074038]; March of Dimes: Basil O'Connor Starter Scholar Research Award [5-FY14-56]; University of Hawaii at Manoa Research Centers in Minority Institute, BRIDGES program [5G12MD007601] FX This work was supported by 1) National Institutes of Health: Grant # K01DK087852 to BF; http://www.nih.gov/. 2) National Institutes of Health: Grant # R03DK100738 to BF; http://www.nih.gov/. 3) National Institutes of Health: Grant # P20GM103457-06A1-8293 to BF; http://www.nih.gov/. 4) National Institutes of Health: Grant # R01DK069909 to JL; http://www.nih.gov/. 5) National Institutes of Health: Grant # R21DK070980 to JL; http://www.nih.gov/. 6) United States Department of Veteran's Affairs: Merit Award # I01 BX000820 to JL; http://www.research.va.gov/funding/. 7) Satellite Healthcare Norman S. Coplon Extramural Research Grant to JL; http://www.satellitehealth.com/about_satellite/philanthropy/coplon_grant s/. 8) Hawaii Community Foundation: Grant # 12ADVC-51347 to BF; http://www.hawaiicommunityfoundation.org/. 9) University of Alabama at Birmingham Hepato/Renal Fibrocystic Diseases Core Center: Pilot Award # 5P30DK074038 to BF; http://www.uab.edu/medicine/hrfdcc/. 10) March of Dimes: Basil O'Connor Starter Scholar Research Award #5-FY14-56 to BF; http://www.marchofdimes.org/. 11) University of Hawaii at Manoa Research Centers in Minority Institute, BRIDGES program: Pilot Award # 5G12MD007601 to BF; http://rcmi-bridges.jabsom.hawaii.edu/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 73 TC 4 Z9 4 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 5 PY 2015 VL 10 IS 6 AR UNSP e0129346 DI 10.1371/journal.pone.0129346 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7CR UT WOS:000355652200154 PM 26046524 ER PT J AU Safdar, N Odden, A Abad, CL Thapa, R Saint, S AF Safdar, Nasia Odden, Andrew Abad, Cybele L. Thapa, Rameet Saint, Sanjay TI In Sight and Out of Mind SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID RUBELLA VACCINATION; MEASLES; POPULATION; CALIFORNIA; AUTISM; MUMPS C1 [Safdar, Nasia; Thapa, Rameet] Univ Wisconsin, Sch Med, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. [Safdar, Nasia; Thapa, Rameet] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Odden, Andrew; Saint, Sanjay] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Saint, Sanjay] Dept Vet Affairs Hlth Serv, Res & Dev Ctr Excellence, Ann Arbor, MI USA. [Abad, Cybele L.] Univ Philippines, Philippine Gen Hosp, Dept Med, Manila, Philippines. RP Safdar, N (reprint author), Univ Wisconsin, Div Infect Dis, 1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU Doximity; Jvion FX Dr. Saint reports receiving fees for board membership from Doximity and Jvion. No other potential conflict of interest relevant to this article was reported. NR 13 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 4 PY 2015 VL 372 IS 23 BP 2218 EP 2223 DI 10.1056/NEJMcps1413402 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CK1GK UT WOS:000355955100009 PM 26039603 ER PT J AU Wheeler, JM McMillan, PJ Hawk, M Iba, M Robinson, L Xu, GJ Dombroski, BA Jeong, D Dichter, MA Juul, H Loomis, E Raskind, M Leverenz, JB Trojanowski, JQ Lee, VMY Schellenberg, GD Kraemer, BC AF Wheeler, Jeanna M. McMillan, Pamela J. Hawk, Michele Iba, Michiyo Robinson, Linda Xu, George J. Dombroski, Beth A. Jeong, Doori Dichter, Marc A. Juul, Halvor Loomis, Elaine Raskind, Murray Leverenz, James B. Trojanowski, John Q. Lee, Virginia M. Y. Schellenberg, Gerard D. Kraemer, Brian C. TI High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Tau; Aggregation; Hyperphosphorylation; Tauopathy ID ALZHEIMERS-DISEASE; MOUSE MODEL; MEMORY DEFICITS; PROTEIN; AGGREGATION; AXONOPATHY; DEMENTIA; ISOFORMS; TANGLES; BRAIN AB Introduction: Accumulation of insoluble conformationally altered hyperphosphorylated tau occurs as part of the pathogenic process in Alzheimer's disease (AD) and other tauopathies. In most AD subjects, wild-type (WT) tau aggregates and accumulates in neurofibrillary tangles and dystrophic neurites in the brain; however, in some familial tauopathy disorders, mutations in the gene encoding tau cause disease. Results: We generated a mouse model, Tau4RTg2652, that expresses high levels of normal human tau in neurons resulting in the early stages of tau pathology. In this model, over expression of WT human tau drives pre-tangle pathology in young mice resulting in behavioral deficits. These changes occur at a relatively young age and recapitulate early pre-tangle stages of tau pathology associated with AD and mild cognitive impairment. Several features distinguish the Tau4RTg2652 model of tauopathy from previously described tau transgenic mice. Unlike other mouse models where behavioral and neuropathologic changes are induced by transgenic tau harboring MAPT mutations pathogenic for frontotemporal lobar degeneration (FTLD), the mice described here express the normal tau sequence. Conclusions: Features of Tau4RTg2652 mice distinguishing them from other established wild type tau overexpressing mice include very early phenotypic manifestations, non-progressive tau pathology, abundant pre-tangle and phosphorylated tau, sparse oligomeric tau species, undetectable fibrillar tau pathology, stability of tau transgene copy number/expression, and normal lifespan. These results suggest that Tau4RTg2652 animals may facilitate studies of tauopathy target engagement where WT tau is driving tauopathy phenotypes. C1 [Wheeler, Jeanna M.; McMillan, Pamela J.; Robinson, Linda; Loomis, Elaine; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [McMillan, Pamela J.; Raskind, Murray] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [McMillan, Pamela J.; Raskind, Murray; Kraemer, Brian C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Hawk, Michele; Iba, Michiyo; Xu, George J.; Dombroski, Beth A.; Jeong, Doori; Trojanowski, John Q.; Lee, Virginia M. Y.; Schellenberg, Gerard D.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Dichter, Marc A.; Juul, Halvor] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44195 USA. [Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. RP Schellenberg, GD (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. EM gerardsc@mail.med.UPENN.edu; kraemerb@uw.edu FU BLRD VA [I01 BX002619]; NIA NIH HHS [P50 AG005136, AG017586, P01 AG017586] NR 31 TC 3 Z9 3 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD JUN 4 PY 2015 VL 3 AR 33 DI 10.1186/s40478-015-0210-6 PG 13 WC Neurosciences SC Neurosciences & Neurology GA CP9WK UT WOS:000360245800001 PM 26041339 ER PT J AU Rostoker, R Abelson, S Genkin, I Ben-Shmuel, S Sachidanandam, R Scheinman, EJ Bitton-Worms, K Orr, ZS Caspi, A Tzukerman, M LeRoith, D AF Rostoker, Ran Abelson, Sagi Genkin, Inna Ben-Shmuel, Sarit Sachidanandam, Ravi Scheinman, Eyal J. Bitton-Worms, Keren Orr, Zila Shen Caspi, Avishay Tzukerman, Maty LeRoith, Derek TI CD24(+) cells fuel rapid tumor growth and display high metastatic capacity SO BREAST CANCER RESEARCH LA English DT Article ID CANCER STEM-CELLS; BREAST-CANCER; HETEROGENEITY; PROGRESSION; EXPRESSION; CARCINOMA; SURVIVAL; PROLIFERATION; TUMORIGENESIS; HIERARCHY AB Introduction: Breast tumors are comprised of distinct cancer cell populations which differ in their tumorigenic and metastatic capacity. Characterization of cell surface markers enables investigators to distinguish between cancer stem cells and their counterparts. CD24 is a well-known cell surface marker for mammary epithelial cells isolation, recently it was suggested as a potential prognostic marker in a wide variety of malignancies. Here, we demonstrate that CD24(+) cells create intra-tumor heterogeneity, and display highly metastatic properties. Methods: The mammary carcinoma Mvt1 cells were sorted into CD24(-) and CD24(+) cells. Both subsets were morphologically and phenotypically characterized, and tumorigenic capacity was assessed via orthotopic inoculation of each subset into the mammary fat pad of wild-type and MKR mice. The metastatic capacity of each subset was determined with the tail vein metastasis assay. The role of CD24 in tumorigenesis was further examined with shRNA technology. GFP-labeled cells were monitored in vivo for differentiation. The genetic profile of each subset was analyzed using RNA sequencing. Results: CD24(+) cells displayed a more spindle-like cytoplasm. The cells formed mammospheres in high efficiency and CD24(+) tumors displayed rapid growth in both WT and MKR mice, and were more metastatic than CD24(-) cells. Interestingly, CD24(-) KD in CD24(+) cells had no effect both in vitro and in vivo on the various parameters studied. Moreover, CD24(+) cells gave rise in vivo to the CD24(-) that comprised the bulk of the tumor. RNA-seq analysis revealed enrichment of genes and pathways of the extracellular matrix in the CD24(+) cells. Conclusion: CD24(+) cells account for heterogeneity in mammary tumors. CD24 expression at early stages of the cancer process is an indication of a highly invasive tumor. However, CD24 is not a suitable therapeutic target; instead we suggest here new potential targets accounting for early differentiated cancer cells tumorigenic capacity. C1 [Rostoker, Ran; Genkin, Inna; Ben-Shmuel, Sarit; Scheinman, Eyal J.; Bitton-Worms, Keren; Orr, Zila Shen; Caspi, Avishay; LeRoith, Derek] Technion Israel Inst Technol, Diabet & Metab Clin Res Ctr Excellence, Rambam Med Ctr, CRIR, IL-31096 Haifa, Israel. [Rostoker, Ran; Genkin, Inna; Ben-Shmuel, Sarit; Scheinman, Eyal J.; Bitton-Worms, Keren; Orr, Zila Shen; Caspi, Avishay; LeRoith, Derek] Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, IL-31096 Haifa, Israel. [Abelson, Sagi; Tzukerman, Maty] Technion Israel Inst Technol, Lab Mol Med, Rambam Hlth Care Campus, IL-31096 Haifa, Israel. [Abelson, Sagi; Tzukerman, Maty] Technion Israel Inst Technol, Rappaport Fac Med & Res Inst, IL-31096 Haifa, Israel. [Sachidanandam, Ravi] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA. [Sachidanandam, Ravi] James J Peters VA Med Ctr, New York, NY USA. [LeRoith, Derek] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. RP LeRoith, D (reprint author), Technion Israel Inst Technol, Diabet & Metab Clin Res Ctr Excellence, Rambam Med Ctr, CRIR, POB 9602, IL-31096 Haifa, Israel. EM derek.leroith@mssm.edu FU Diabetes and Metabolism Clinical Research Center of Excellence, Clinical Research Institute at Rambam; Israel Science Foundation; European Foundation for the Study of Diabetes and Cancer Program; Chesed Foundation New York; NCI [2R01CA128799-06A1] FX This work was supported by grants from the Diabetes and Metabolism Clinical Research Center of Excellence, Clinical Research Institute at Rambam (to DLR), the Israel Science Foundation grant (to DLR), the European Foundation for the Study of Diabetes and Cancer Program (to DLR), Chesed Foundation New York (DLR) and the NCI grant (Grant 2R01CA128799-06A1) to DLR. NR 50 TC 6 Z9 7 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-542X EI 1465-5411 J9 BREAST CANCER RES JI Breast Cancer Res. PD JUN 4 PY 2015 VL 17 AR 78 DI 10.1186/s13058-015-0589-9 PG 14 WC Oncology SC Oncology GA CL2KZ UT WOS:000356774000002 PM 26040280 ER PT J AU Gulati, T Won, SJ Ramanathan, DS Wong, CC Bodepudi, A Swanson, RA Ganguly, K AF Gulati, Tanuj Won, Seok Joon Ramanathan, Dhakshin S. Wong, Chelsea C. Bodepudi, Anitha Swanson, Raymond A. Ganguly, Karunesh TI Robust Neuroprosthetic Control from the Stroke Perilesional Cortex SO JOURNAL OF NEUROSCIENCE LA English DT Article DE brain-machine interface; electrophysiology; plasticity; stroke ID BRAIN-COMPUTER INTERFACES; PRIMARY MOTOR CORTEX; MACHINE INTERFACE; CORTICAL CONTROL; IPSILATERAL ARM; AREA V4; RECOVERY; MOVEMENTS; NEURONS; REHABILITATION AB Intracortical brain-machine interfaces (BMIs) may eventually restore function in those with motor disability after stroke. However, current research into the development of intracortical BMIs has focused on subjects with largely intact cortical structures, such as those with spinal cord injury. Although the stroke perilesional cortex (PLC) has been hypothesized as a potential site for a BMI, it remains unclear whether the injured motor cortical network can support neuroprosthetic control directly. Using chronic electrophysiological recordings in a rat stroke model, we demonstrate here the PLC's capacity for neuroprosthetic control and physiological plasticity. We initially found that the perilesional network demonstrated abnormally increased slow oscillations that also modulated neural firing. Despite these striking abnormalities, neurons in the perilesional network could be modulated volitionally to learn neuroprosthetic control. The rate of learning was surprisingly similar regardless of the electrode distance from the stroke site and was not significantly different from intact animals. Moreover, neurons achieved similar task-related modulation and, as an ensemble, formed cell assemblies with learning. Such control was even achieved in animals with poor motor recovery, suggesting that neuroprosthetic control is possible even in the absence of motor recovery. Interestingly, achieving successful control also reduced locking to abnormal oscillations significantly. Our results thus suggest that, despite the disrupted connectivity in the PLC, it may serve as an effective target for neuroprosthetic control in those with poor motor recovery after stroke. C1 [Gulati, Tanuj; Won, Seok Joon; Ramanathan, Dhakshin S.; Wong, Chelsea C.; Bodepudi, Anitha; Swanson, Raymond A.; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94158 USA. [Ramanathan, Dhakshin S.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA 94158 USA. [Gulati, Tanuj; Won, Seok Joon; Wong, Chelsea C.; Bodepudi, Anitha; Swanson, Raymond A.; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA. [Ramanathan, Dhakshin S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Neurol & Rehabil Serv, 1700 Owens St, San Francisco, CA 94158 USA. EM karunesh.ganguly@ucsf.edu FU Department of Veterans Affairs [B6674]; Burroughs Wellcome Fund [1009855]; American Heart/Stroke Association [0875016N]; SFVAMC; NCIRE; UCSF Department of Neurology; Advanced Research Fellowship from the VA FX This work is supported by the Department of Veterans Affairs (Grant B6674 to K.G.), the Burroughs Wellcome Fund (Grant 1009855 to K.G.), the American Heart/Stroke Association (Grant 0875016N to K.G.), and by start-up funds from the SFVAMC, NCIRE, and UCSF Department of Neurology; an Advanced Research Fellowship from the VA to D.R. NR 63 TC 6 Z9 6 U1 0 U2 7 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 3 PY 2015 VL 35 IS 22 BP 8653 EP 8661 DI 10.1523/JNEUROSCI.5007-14.2015 PG 9 WC Neurosciences SC Neurosciences & Neurology GA CN2JV UT WOS:000358247900025 PM 26041930 ER PT J AU Gold, PW Pavlatou, MG Michelson, D Mouro, CM Kling, MA Wong, ML Licinio, J Goldstein, SA AF Gold, P. W. Pavlatou, M. G. Michelson, D. Mouro, C. M. Kling, M. A. Wong, M-L Licinio, J. Goldstein, S. A. TI Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications SO TRANSLATIONAL PSYCHIATRY LA English DT Review ID SYMPATHETIC-NERVOUS-SYSTEM; SEROTONIN-REUPTAKE INHIBITORS; MINERAL DENSITY; MAJOR DEPRESSION; BIOCHEMICAL MANIFESTATIONS; WOMEN; RISK; INTERLEUKIN-6; NEUROBIOLOGY; FRACTURES AB Major depression and bipolar disorder are associated with decreased bone mineral density (BMD). Antidepressants such as imipramine (IMIP) and specific serotonin reuptake inhibitors (SSRIs) have been implicated in reduced BMD and/or fracture in older depressed patients. Moreover, anticonvulsants such as valproate (VAL) and carbamazepine (CBZ) are also known to increase fracture rates. Although BMD is a predictor of susceptibility to fracture, bone strength is a more sensitive predictor. We measured mechanical and geometrical properties of bone in 68 male Sprague Dawley rats on IMIP, fluoxetine (FLX), VAL, CBZ, CBZ vehicle and saline (SAL), given intraperitoneally daily for 8 weeks. Distinct regions were tested to failure by four-point bending, whereas load displacement was used to determine stiffness. The left femurs were scanned in a MicroCT system to calculate mid-diaphyseal moments of inertia. None of these parameters were affected by antidepressants. However, VAL resulted in a significant decrease in stiffness and a reduction in yield, and CBZ induced a decrease in stiffness. Only CBZ induced alterations in mechanical properties that were accompanied by significant geometrical changes. These data reveal that chronic antidepressant treatment does not reduce bone strength, in contrast to chronic anticonvulsant treatment. Thus, decreased BMD and increased fracture rates in older patients on antidepressants are more likely to represent factors intrinsic to depression that weaken bone rather than antidepressants per se. Patients with affective illness on anticonvulsants may be at particularly high risk for fracture, especially as they grow older, as bone strength falls progressively with age. C1 [Gold, P. W.; Pavlatou, M. G.] NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA. [Michelson, D.] Merck, Whitehouse Stn, NJ USA. [Mouro, C. M.; Goldstein, S. A.] Univ Michigan, Orthopaed Res Labs, Ann Arbor, MI 48109 USA. [Kling, M. A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Kling, M. A.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Wong, M-L; Licinio, J.] Australian Natl Univ, John Curtin Sch Med Res, Dept Translat Med, Canberra, ACT 2601, Australia. RP Gold, PW (reprint author), NIMH, Clin Neuroendocrinol Branch, NIH, 10 Ctr Dr,Room 2D46, Bethesda, MD 20892 USA. EM philipgold@mail.nih.gov OI Kling, Mitchel/0000-0002-2232-1409 FU Clinical Neuroendocrinology Branch, National Institute of Mental Health, NIH [AR34399]; Whittaker Foundation; National Institute of Aging, NIA [T32 AG00114]; GAANN FX We acknowledge the substantial contributions of Erica Smith and Cameron Mouro for conducting many of the MicroCT and mechanical tests. We also acknowledge Mark Stock and Rick Zanecki for their technical assistance. This work was supported by funding from the Clinical Neuroendocrinology Branch, National Institute of Mental Health, NIH AR34399, the Whittaker Foundation and a Multidisciplinary Research Training Grant in Aging from the National Institute of Aging, NIA T32 AG00114 and a GAANN Fellowship. NR 29 TC 0 Z9 0 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JUN 2 PY 2015 VL 5 AR e576 DI 10.1038/tp.2015.38 PG 6 WC Psychiatry SC Psychiatry GA DA2WQ UT WOS:000367658300003 PM 26035060 ER PT J AU Zheng, X Demirci, FY Barmada, MM Richardson, GA Lopez, OL Sweet, RA Kamboh, MI Feingold, E AF Zheng, X. Demirci, F. Y. Barmada, M. M. Richardson, G. A. Lopez, O. L. Sweet, R. A. Kamboh, M. I. Feingold, E. TI Genome-wide copy-number variation study of psychosis in Alzheimer's disease SO TRANSLATIONAL PSYCHIATRY LA English DT Article ID LAST 2 DECADES; PROTEIN PHOSPHATASE-2A; VARIATION ASSOCIATION; IDENTIFIES VARIANTS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; COMMON VARIANTS; BETA-CATENIN; ADULT BRAIN; ONSET AB About 40-60% of patients with late-onset Alzheimer's disease (AD) develop psychosis, which represents a distinct phenotype of more severe cognitive and functional deficits. The estimated heritability of AD+P is similar to 61%, which makes it a good target for genetic mapping. We performed a genome-wide copy-number variation (CNV) study on 496 AD cases with psychosis (AD+P), 639 AD subjects with intermediate psychosis (AD intermediate P) and 156 AD subjects without psychosis (AD - P) who were recruited at the University of Pittsburgh Alzheimer's Disease Research Center using over 1 million single-nucleotide polymorphisms (SNPs) and CNV markers. CNV load analysis found no significant difference in total and average CNV length and CNV number in the AD+P or AD intermediate P groups compared with the AD - P group. Our analysis revealed a marginally significant lower number of duplication events in AD+P cases compared with AD - P controls (P = 0.059) using multivariable regression model. The most interesting finding was the presence of a genome-wide significant duplication in the APC2 gene on chromosome 19, which was protective against developing AD+P (odds ratio = 0.42; P = 7.2E - 10). We also observed suggestive associations of duplications with AD+P in the SET (P = 1.95E - 06), JAG2 (P = 5.01E - 07) and ZFPM1 (P = 2.13E - 07) genes and marginal association of a deletion in CNTLN (P = 8.87E - 04). We have identified potential novel loci for psychosis in Alzheimer's disease that warrant follow-up in large-scale independent studies. C1 [Zheng, X.; Feingold, E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Zheng, X.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27514 USA. [Demirci, F. Y.; Barmada, M. M.; Kamboh, M. I.; Feingold, E.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Richardson, G. A.; Sweet, R. A.; Kamboh, M. I.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Richardson, G. A.; Kamboh, M. I.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Lopez, O. L.; Sweet, R. A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Lopez, O. L.; Sweet, R. A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Zheng, X (reprint author), Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27514 USA. EM xiaojinz@email.unc.edu OI Demirci, F. Yesim/0000-0001-6907-9843; Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460; Feingold, Eleanor/0000-0003-2898-6484 FU National Institute on Aging [AG030653, AG041718, AG005133, AG027224]; NIMH [T32 MH015169] FX This study was supported by the National Institute on Aging grants AG030653, AG041718 (MIK), AG005133 (OLL) and AG027224 (RAS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs or the United States Government. This work was conducted in partial fulfillment of requirements for the first author's doctoral degree, supported by NIMH Grant T32 MH015169 (GAR, Program Director). NR 66 TC 3 Z9 3 U1 4 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD JUN 2 PY 2015 VL 5 AR e574 DI 10.1038/tp.2015.64 PG 9 WC Psychiatry SC Psychiatry GA DA2WQ UT WOS:000367658300001 PM 26035058 ER PT J AU Leroy, P Tham, A Wong, H Tenney, R Chen, C Stiner, R Balmes, JR Paquet, AC Arjomandi, M AF Leroy, Pascale Tham, Andrea Wong, Hofer Tenney, Rachel Chen, Chun Stiner, Rachel Balmes, John R. Paquet, Agnes C. Arjomandi, Mehrdad TI Inflammatory and Repair Pathways Induced in Human Bronchoalveolar Lavage Cells with Ozone Inhalation SO PLOS ONE LA English DT Article ID LARGE GENE LISTS; AIRWAY INFLAMMATION; EPITHELIAL INJURY; APOPTOTIC CELLS; CROSS-LINKING; IN-VITRO; LUNG; OSTEOPONTIN; EXPOSURE; MICE AB Background Inhalation of ambient levels of ozone causes airway inflammation and epithelial injury. Methods To examine the responses of airway cells to ozone-induced oxidative injury, 19 subjects (7 with asthma) were exposed to clean air (0ppb), medium (100ppb), and high (200ppb) ambient levels of ozone for 4h on three separate occasions in a climate-controlled chamber followed by bronchoscopy with bronchoalveolar lavage (BAL) 24h later. BAL cell mRNA expression was examined using Affymetrix GeneChip Microarray. The role of a differentially expressed gene (DEG) in epithelial injury was evaluated in an in vitro model of injury [16HBE14o-cell line scratch assay]. Results Ozone exposure caused a dose-dependent up-regulation of several biologic pathways involved in inflammation and repair including chemokine and cytokine secretion, activity, and receptor binding; metalloproteinase and endopeptidase activity; adhesion, locomotion, and migration; and cell growth and tumorigenesis regulation. Asthmatic subjects had 1.7- to 3.8-fold higher expression of many DEGs suggestive of increased proinflammatory and matrix degradation and remodeling signals. The most highly up-regulated gene was osteopontin, the protein level of which in BAL fluid increased in a dose-dependent manner after ozone exposure. Asthmatic subjects had a disproportionate increase in non-polymerized osteopontin with increasing exposure to ozone. Treatment with polymeric, but not monomeric, osteopontin enhanced the migration of epithelial cells and wound closure in an alpha 9 beta 1 integrin-dependent manner. Conclusions Expression profiling of BAL cells after ozone exposure reveals potential regulatory genes and pathways activated by oxidative stress. One DEG, osteopontin, promotes epithelial wound healing in an in vitro model of injury. C1 [Leroy, Pascale; Tham, Andrea; Tenney, Rachel; Stiner, Rachel; Arjomandi, Mehrdad] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Wong, Hofer; Balmes, John R.; Arjomandi, Mehrdad] Univ Calif San Francisco, Div Occupat & Environm Med, Human Exposure Lab, San Francisco, CA 94143 USA. [Wong, Hofer; Balmes, John R.; Arjomandi, Mehrdad] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Immunol & Sleep Med, San Francisco, CA 94143 USA. [Chen, Chun] Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA. [Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Paquet, Agnes C.] CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France. RP Arjomandi, M (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM mehrdad.arjomandi@ucsf.edu FU National Institute of Health/NHLBI [K23 HL083099]; Stromedix, Inc.; Five Prime Therapeutics, Inc.; National Institute of Health/NCRR/OD UCSF-CTSI [KL2 RR024130, UL1 RR024131]; California Air Resources Board (CARB) [04-322]; Northern California Institute for Research and Education; University of California San Francisco Cardiovascular Research Institute Faculty Development Funds FX This work was supported by: 1) National Institute of Health/NHLBI K23 HL083099 (Arjomandi); 2) Stromedix, Inc. unrestricted research gift (Arjomandi); 3) Five Prime Therapeutics, Inc. investigator-initiated grant (Arjomandi); 4) National Institute of Health/NCRR/OD UCSF-CTSI Grant Number KL2 RR024130 and UL1 RR024131; 5) California Air Resources Board (CARB Contract # 04-322; Balmes); 6) Northern California Institute for Research and Education (Arjomandi); and 7) University of California San Francisco Cardiovascular Research Institute Faculty Development Funds (Arjomandi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 58 TC 2 Z9 2 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 2 PY 2015 VL 10 IS 6 AR e0127283 DI 10.1371/journal.pone.0127283 PG 28 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7SJ UT WOS:000355699100010 PM 26035830 ER PT J AU Schwartz, GG Abt, M Bao, W DeMicco, D Kallend, D Miller, M Mundl, H Olsson, AG AF Schwartz, Gregory G. Abt, Markus Bao, Weihang DeMicco, David Kallend, David Miller, Michael Mundl, Hardi Olsson, Anders G. TI Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE lipids; myocardial infarction; unstable angina ID DENSITY-LIPOPROTEIN-CHOLESTEROL; ACUTE MYOCARDIAL-INFARCTION; OF-FUNCTION MUTATIONS; HEART-DISEASE; NONFASTING TRIGLYCERIDES; CARDIOVASCULAR EVENTS; VASCULAR-DISEASE; RISK-FACTOR; TRIAL; WOMEN AB BACKGROUND Most patients with acute coronary syndrome (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins. It is uncertain whether triglycerides predict risk after ACS on a background of statin treatment. OBJECTIVES This study examined the relationship of fasting triglyceride levels to outcomes after ACS in patients treated with statins. METHODS Long-term and short-term relationships of triglycerides to risk after ACS were examined in the dal-OUTCOMES trial and atorvastatin arm of the MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering) trial, respectively. Analysis of dal-OUTCOMES included 15,817 patients (97% statin-treated) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib (a cholesteryl ester transfer protein inhibitor) or placebo and followed for a median 31 months. Analysis of MIRACL included 1,501 patients treated with atorvastatin 80 mg daily beginning 1 to 4 days after ACS and followed for 16 weeks. Fasting triglycerides at initial random assignment were related to risk of coronary heart disease death, nonfatal myocardial infarction, stroke, and unstable angina in models adjusted for age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass index. RESULTS Fasting triglyceride levels were associated with both long-term and short-term risk after ACS. In dalOUTCOMES, long-term risk increased across quintiles of baseline triglycerides (p < 0.001). The hazard ratio in the highest/lowest quintile (> 175/<= 80 mg/dl) was 1.50 (95% confidence interval: 1.05 to 2.15). There was no interaction of triglycerides and treatment assignment on the primary outcome. In the atorvastatin group of MIRACL, short-term risk increased across tertiles of baseline triglycerides (p = 0.03), with a hazard ratio of 1.51 (95% confidence interval: 1.05 to 2.15) in highest/lowest tertiles (>195/<= 135 mg/dl). The relationship of triglycerides to risk was independent of lowdensity lipoprotein cholesterol in both studies. CONCLUSIONS Among patients with ACS treated effectively with statins, fasting triglycerides predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy. (C) 2015 by the American College of Cardiology Foundation. C1 [Schwartz, Gregory G.] Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. [Schwartz, Gregory G.] Univ Colorado, Sch Med, Denver, CO 80202 USA. [Abt, Markus; Kallend, David; Mundl, Hardi] F Hoffmann La Roche, Pharma Dev, Basel, Switzerland. [Bao, Weihang; DeMicco, David] Pfizer Inc, New York, NY USA. [Miller, Michael] Univ Maryland, Sch Med, Div Cardiovasc Med, Baltimore, MD 21201 USA. [Olsson, Anders G.] Stockholm Heart Ctr, Stockholm, Sweden. [Olsson, Anders G.] Linkoping Univ, Linkoping, Sweden. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@va.gov RI 刘, 李陆/H-8469-2015 FU F. Hoffmann-La Roche Ltd.; Pfizer; Anthera; Resverlogix; Roche; Sanofi; Amgen; AstraZeneca; Karobio; Merck FX The dal-OUTCOMES trial was funded by F. Hoffmann-La Roche Ltd. The MIRACL trial was funded by Pfizer. Dr. Schwartz, through his institution, has received research grants from Anthera, Pfizer, Resverlogix, Roche, and Sanofi. Dr. Abt is an employee of F. Hoffmann-La Roche, Ltd. Drs. Bao and DeMicco are employees of Pfizer. Drs. Kallend and Mundl were employees of F. Hoffmann-La Roche at the time the dal-OUTCOMES study was performed and data collected. Dr. Miller has served as a consultant for Amarin, AstraZeneca, Pronova, and Zydus. Dr. Olsson has received research grants from Amgen, AstraZeneca, Karobio, Merck, Pfizer, Roche, and Sanofi; and has received consultation fees from AstraZeneca, Karobio, Merck, Pfizer, and Roche. Dr. Kallend is currently affiliated with The Medicines Company, Zurich, Switzerland. Dr. Mundl is currently affiliated with Bayer Pharmaceuticals, Berlin, Germany. NR 30 TC 39 Z9 40 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JUN 2 PY 2015 VL 65 IS 21 BP 2267 EP 2275 DI 10.1016/j.jacc.2015.03.544 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CJ0VH UT WOS:000355196300001 PM 26022813 ER PT J AU Menda, SA Lowry, EA Porco, TC Stamper, RL Rubin, MR Han, Y AF Menda, Shivali A. Lowry, Eugene A. Porco, Travis C. Stamper, Robert L. Rubin, Michel R. Han, Ying TI Ex-PRESS outcomes using mitomycin-C, Ologen alone, Ologen with 5-fluorouracil SO INTERNATIONAL OPHTHALMOLOGY LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; COLLAGEN MATRIX IMPLANTS; TRABECULECTOMY; GLAUCOMA; PHACOTRABECULECTOMY AB To compare the complication rate and effectiveness of mitomycin C (MMC), Ologen alone, and Ologen with 5-fluorouracil (5-FU) as adjunctives with Ex-PRESS mini shunt for medically uncontrolled glaucoma. Retrospective comparative study of 59 Ex-PRESS mini shunt trabeculectomy operations coupled with Ologen implantation alone, transient MMC application or Ologen implantation with 5-FU as adjunctive treatment. Eight eyes (7 patients) received Ologen alone, 37 eyes (34 patients) received MMC, and 14 eyes (14 patients) received Ologen with 5-FU as adjunctive therapy. Baseline characteristics, adjunctive used during operation, along with outcomes including intraocular pressure (IOP), number of anti-hypertensive drops, visual acuity, and complications were documented and compared. The primary outcome was IOP at 12 months. Variables were compared with r x c Fisher tests. The Ologen only group had a significantly higher IOP at 12 months (20.5 +/- A 10.23 mmHg) compared with Ologen combined with 5-FU (12.2 +/- A 1.47 mmHg) or MMC (13.8 +/- A 4.37 mmHg) (p = 0.015, linear mixed model). The Ologen only cohort also had a higher re-operation rate (p = 0.01, Fisher's Exact Test) and higher rate of bleb leak (p = 0.02, Fisher's Exact Test). Visual acuity was similar among all three groups. 5-FU with Ologen is as effective as MMC in maintaining IOP following Ex-PRESS shunt surgery at 1 year. However, Ologen alone may not be as effective as the other two adjunctive agents. C1 [Menda, Shivali A.; Lowry, Eugene A.; Porco, Travis C.; Stamper, Robert L.; Rubin, Michel R.; Han, Ying] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Porco, Travis C.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA. [Porco, Travis C.] UCSF, Div Prevent Med & Publ Hlth, Dept Epidemiol & Biostat, San Francisco, CA USA. [Han, Ying] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP Lowry, EA (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA. EM gene.lowry@ucsf.edu NR 17 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0165-5701 EI 1573-2630 J9 INT OPHTHALMOL JI Int. Ophthalmol. PD JUN PY 2015 VL 35 IS 3 BP 357 EP 363 DI 10.1007/s10792-014-9955-3 PG 7 WC Ophthalmology SC Ophthalmology GA CH2AZ UT WOS:000353827300008 PM 24920197 ER PT J AU Boyd, JE Juanamarga, J Hashemi, P AF Boyd, Jennifer E. Juanamarga, Josephine Hashemi, Parisa TI Stigma of Taking Psychiatric Medications Among Psychiatric Outpatient Veterans SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE social stigma; stigmatization; psychotropic drugs; outpatients; veterans ID ILLNESS ISMI SCALE; MENTAL-ILLNESS; INTERNALIZED STIGMA; MILITARY; DEPRESSION; PEOPLE AB Objective: Service members and veterans underutilize mental health services due to stigma. The study investigated stigma of taking psychiatric medications, and its relationship to internalized stigma of mental illness, gender, age, service era, duration of taking medications, and their perceived helpfulness. Method: Of the 200 veterans completing an anonymous questionnaire in an outpatient mental health waiting room, data are presented on the 159 who reported taking psychiatric medications. Results: Medication stigma was related to internalized stigma and was common: over one half reported feeling uncomfortable disclosing or feeling judged, and about one fifth reported feeling embarrassed. Medication stigma was not related to gender, duration, or helpfulness. Younger age was associated with feeling judged, and more recent service era was associated with shame. Conclusions and Implications for Practice: Medication stigma among veterans is common and warrants further study. Discomfort disclosing and feeling judged might be particularly worthy targets of discussion in shared decisions about medication. C1 [Boyd, Jennifer E.; Juanamarga, Josephine; Hashemi, Parisa] San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St 116A, San Francisco, CA 94121 USA. [Boyd, Jennifer E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Boyd, JE (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St 116A, San Francisco, CA 94121 USA. EM jennifer.boyd@va.gov NR 12 TC 2 Z9 2 U1 1 U2 6 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD JUN PY 2015 VL 38 IS 2 SI SI BP 132 EP 134 DI 10.1037/prj0000122 PG 3 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA DE1NE UT WOS:000370392900006 PM 25821981 ER PT J AU Harris, JI Farchmin, L Stull, L Boyd, J Schumacher, M Drapalski, AL AF Harris, J. Irene Farchmin, Leah Stull, Laura Boyd, Jennifer Schumacher, Marianne Drapalski, Amy L. TI Prediction of Changes in Self-Stigma Among Veterans Participating in Partial Psychiatric Hospitalization: The Role of Disability Status and Military Cohort SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE internalized stigma; research; Veterans; partial hospitalization; serious mental illness ID RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH PROBLEMS; INTERNALIZED STIGMA; REDUCE STIGMA; ILLNESS; SCHIZOPHRENIA; PEOPLE; RECOVERY; CONSEQUENCES; ASSOCIATIONS AB Objective: Interventions addressing internalized stigma are a new area of research, and it is important to identify the types of clientele who derive benefit from existing interventions. Method: Information was provided by 235 veterans attending a partial psychiatric hospitalization program, regarding their levels of internalized stigma on admission and discharge from a 3-week program that included interventions targeting internalized stigma. Results: Upon discharge, veterans receiving disability benefits demonstrated less reduction in internalized stigma than those not receiving disability benefits. Time of service moderated the relationship between disability status and change in internalized stigma, such that veterans serving in the more recent Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) cohort who received disability benefits had a more difficult time resolving internalized stigma. Further analyses suggested that OEF/OIF/OND cohort veterans receiving disability benefits have more difficulty developing effective stigma resistance, and more difficulty resolving stigma-related alienation, than other veterans. Conclusions and Implications for Practice: Based on this research, particular attention should be devoted to internalized stigma among OEF/OIF/OND veterans. C1 [Harris, J. Irene; Farchmin, Leah] Minneapolis Vet Affairs Hlth Care Syst, Mental & Behav Hlth VA, Minneapolis, MN 55417 USA. [Harris, J. Irene] Univ Minnesota, Counseling Psychol & Psychiat, Minneapolis, MN 55455 USA. [Farchmin, Leah] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Stull, Laura] Anderson Univ, Dept Psychol, Anderson, IN USA. [Boyd, Jennifer] San Francisco VA Med Ctr, Mental Hlth Serv VA, San Francisco, CA USA. [Boyd, Jennifer] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Schumacher, Marianne] Minneapolis Vet Affairs Hlth Care Syst, Mental & Behav Hlth, Minneapolis, MN USA. [Drapalski, Amy L.] Vet Affairs Capitol Hlth Care Network VISN 5, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. RP Harris, JI (reprint author), Minneapolis Vet Affairs Hlth Care Syst, Mental & Behav Hlth VA, Minneapolis, MN 55417 USA.; Harris, JI (reprint author), Minneapolis VA Hlth Cam Syst, Psychol, Mailstop 116B,One Vet Dr, Minneapolis, MN 55417 USA. EM jeanette.harris2@va.gov FU VISN 5 Mental Illness Research, Education, and Clinical Center; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Support for the manuscript was provided by the VISN 5 Mental Illness Research, Education, and Clinical Center. This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The contents of the publication/presentation do not represent the views of the Department of Veterans Affairs or the United States Government. NR 42 TC 2 Z9 2 U1 3 U2 8 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD JUN PY 2015 VL 38 IS 2 SI SI BP 179 EP 185 DI 10.1037/prj0000118 PG 7 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA DE1NE UT WOS:000370392900013 PM 25799300 ER PT J AU Haywood, C Lanzkron, S Hughes, M Brown, R Saha, S Beach, MC AF Haywood, Carlton, Jr. Lanzkron, Sophie Hughes, Mark Brown, Rochelle Saha, Somnath Beach, Mary Catherine TI The Association of Clinician Characteristics with their Attitudes Toward Patients with Sickle Cell Disease: Secondary Analyses of a Randomized Controlled Trial SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE Sickle cell disease; clinician attitudes; healthcare disparities ID HIGH HOSPITAL UTILIZATION; PAIN MANAGEMENT; HEALTH-CARE; PROVIDERS CONTRIBUTE; PHYSICIANS; TRUST; RACE; PERCEPTIONS; DISPARITIES; DEPENDENCE AB Background: A high level of evidence exists to suggest that negative attitudes held by clinicians toward persons with sickle cell disease serve as important barriers to the delivery of high quality care to this patient population. Little is known. though. about the characteristics of clinicians that may be predictive of these negative attitudes. Methods: During spring and summer 2009, we conducted a randomized controlled trial to test an intervenlion to improve clinician attitudes toward persons with sickle cell disease. Participating clinicians completed questionnaires regarding their demographic characteristics and their attitudes toward sic kle cell patienls. Principal clinician charac teristics of interest included their race, professio nal discipline (nurse/ physic ian), and the amount of their recent exposure to sickle cell patients in pain. Secondary analyses from this trial are presented here. Main Findings: Asian clinicians reported more negative allitudes towards these palients than did Black or White clinicians, nurses reported more negative altitudes lhan physicians. and clinicians w ith the greatest levels of recent exposure to sickle cell patients in pain reported more nega tive attitudes than did clinicians with lower levels of recent exposure. Conclusions: Our findings could facilitate the development of tailored educational resources needed to improve the quality of care delivered to persons with sickle cell disease, a national priority for sickle cell efforts. C1 [Haywood, Carlton, Jr.; Hughes, Mark; Beach, Mary Catherine] Johns Hopkins Sch Med, Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA. [Lanzkron, Sophie; Brown, Rochelle] Johns Hopkins Sch Med, Baltimore, MD USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Gen Internal Med Sect, Div Gen Internal Med & Geriatr, Portland, OR 97201 USA. RP Haywood, C (reprint author), Johns Hopkins Berman Inst Bioeth, 1809 Ashland Ave,Deering Hall,Room 210, Baltimore, MD 21205 USA. EM chaywoodjr@jhu.edu FU Osler Center for Excellence institutional award; Johns Hopkins Clinical Research Scholars Program [5KL2RR025006-03]; National Heart, Lung, and Blood Institute [1 KOI HL108832-01]; Agency for Healthcare Research and Quality [K08 HS013903-05]; Blaustein Scholars through the Johns Hopkins Berman Institute of Bioethics FX This work was supported by an Osler Center for Excellence institutional award. Dr. Haywood's effort on this project was supported by the Johns Hopkins Clinical Research Scholars Program (5KL2RR025006-03), as well as by a grant from the National Heart, Lung, and Blood Institute (1 KOI HL108832-01). Dr. Beach's effort on this project was supported by a grant from the Agency for Healthcare Research and Quality (K08 HS013903-05). Drs. Beach and Hughes were also supported as Blaustein Scholars through the Johns Hopkins Berman Institute of Bioethics. NR 44 TC 1 Z9 1 U1 4 U2 5 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 EI 1943-4693 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD JUN PY 2015 VL 107 IS 2 BP 89 EP 96 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DC4EX UT WOS:000369174400012 PM 27269495 ER PT J AU Huffman, KM Cohen, ME Ko, CY Hall, BL AF Huffman, Kristopher M. Cohen, Mark E. Ko, Clifford Y. Hall, Bruce Lee TI A Comprehensive Evaluation of Statistical Reliability in ACS NSQIP Profiling Models SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; hospital profiling; reliability; surgical quality ID HOSPITAL QUALITY MEASURE; SURGICAL QUALITY; RISK AB Objective: To assess statistical reliability of hospital profiling models in ACS NSQIP (American College of Surgeons' National Surgical Quality Improvement Program). Background: The ACS NSQIP January 2013 Semiannual Report provided risk-adjusted hospital quality assessments for 137 models. Methods: Median reliability and percentage of hospitals achieving acceptable reliability were computed for each model. Average median reliability was computed across models with common outcomes. Results: Median reliability varied across the 137 models, from a high of 0.91 for "All Cases Morbidity" to a low of 0.005 for "Procedure-Targeted Total Hip Arthroplasty Surgical Site Infection." Generally, reliability was greatest for models with larger sample sizes and higher outcome event rates. Among "Essentials" models, 72% attained a median reliability of 0.40 or more, and 24% of 0.70 or more. Among "Procedure-Targeted" models, 29% attained a median reliability of 0.40 or more, and 3% of 0.70 or more. Percentage of hospitals achieving an acceptable reliability of 0.40 ranged from 98% for "All Cases Morbidity" to 0% for "Procedure-Targeted Pancreatectomy Mortality." For Essentials models, average median reliability for each outcome, except mortality, was more than 0.40. However, for Procedure-Targeted models the average median was less than 0.40. Conclusions: For a large proportion of ACS NSQIP Essentials models, statistical reliability is adequate for assessing surgical quality and differentiating hospital performance. The Procedure-Targeted program is evolving in terms of statistical reliability, with promising results to date. These results also argue for broader discussions of statistical reliability in performance assessments for the profession. C1 [Huffman, Kristopher M.; Cohen, Mark E.; Ko, Clifford Y.; Hall, Bruce Lee] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce Lee] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce Lee] BJC Healthcare, St Louis, MO USA. RP Huffman, KM (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM khuffman@facs.org NR 11 TC 5 Z9 5 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUN PY 2015 VL 261 IS 6 BP 1108 EP 1113 DI 10.1097/SLA.0000000000000913 PG 6 WC Surgery SC Surgery GA DD0LN UT WOS:000369611600040 PM 25211276 ER PT J AU Merkow, RP Hall, BL Ko, CY AF Merkow, Ryan P. Hall, Bruce L. Ko, Clifford Y. TI Validity and Feasibility of the American College of Surgeons Colectomy Composite Outcome Quality Measure Reply SO ANNALS OF SURGERY LA English DT Letter ID SURGICAL QUALITY C1 [Merkow, Ryan P.; Hall, Bruce L.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Merkow, Ryan P.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Hall, Bruce L.] Washington Univ, Barnes Jewish Hosp, Sch Med, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. EM RMerkow@facs.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD JUN PY 2015 VL 261 IS 6 BP E158 EP E159 DI 10.1097/SLA.0000000000000405 PG 2 WC Surgery SC Surgery GA DD0LN UT WOS:000369611600012 PM 24263330 ER PT J AU Jeffery, AD AF Jeffery, Alvin D. TI Methodological Challenges in Examining the Impact of Healthcare Predictive Analytics on Nursing-Sensitive Patient Outcomes SO CIN-COMPUTERS INFORMATICS NURSING LA English DT Article DE Computer assisted; Clinical decision; Decision making; Models; Nursing; Research design; Statistical; Support systems ID DECISION-SUPPORT-SYSTEMS; PRACTITIONER PERFORMANCE; CLINICAL DETERIORATION; EXTERNAL VALIDATION; PRESSURE ULCERS; RISK-ASSESSMENT; BIG DATA; MODELS; TRIAL; INFECTIONS AB The expansion of real-time analytic abilities within current electronic health records has led to innovations in predictive modeling and clinical decision support systems. However, the ability of these systems to influence patient outcomes is currently unknown. Even though nurses are the largest profession within the healthcare workforce, little research has been performed to explore the impact of clinical decision support on their decisions and the patient outcomes associated with them. A scoping literature review explored the impact clinical decision support systems containing healthcare predictive analytics have on four nursing-sensitive patient outcomes (pressure ulcers, failure to rescue, falls, and infections). While many articles discussed variable selection and predictive model development/validation, only four articles examined the impact on patient outcomes. The novelty of predictive analytics and the inherent methodological challenges in studying clinical decision support impact are likely responsible for this paucity of literature. Major methodological challenges include (1) multilevel nature of intervention, (2) treatment fidelity, and (3) adequacy of clinicians' subsequent behavior. There is currently insufficient evidence to demonstrate efficacy of healthcare predictive analytics-enhanced clinical decision support systems on nursing-sensitive patient outcomes. Innovative research methods and a greater emphasis on studying this phenomenon are needed. C1 [Jeffery, Alvin D.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. [Jeffery, Alvin D.] Cincinnati Childrens Hosp Med Ctr, Ctr Profess Excellence, Cincinnati, OH 45229 USA. RP Jeffery, AD (reprint author), 3333 Burnet Ave,MLC 8006, Cincinnati, OH 45229 USA. EM alvinjeffery@gmail.com FU US Department of Veterans Affairs, Office of Academic Affiliations FX This work was supported, in part, by the US Department of Veterans Affairs, Office of Academic Affiliations. NR 34 TC 0 Z9 0 U1 5 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1538-2931 EI 1538-9774 J9 CIN-COMPUT INFORM NU JI CIN-Comput. Inform. Nurs. PD JUN PY 2015 VL 33 IS 6 BP 258 EP 264 DI 10.1097/CIN.0000000000000154 PG 7 WC Computer Science, Interdisciplinary Applications; Medical Informatics; Nursing SC Computer Science; Medical Informatics; Nursing GA DD0RV UT WOS:000369628000004 PM 25899442 ER PT J AU Greene, M Covinsky, KE Valcour, V Miao, YH Madamba, J Lampiris, H Cenzer, IS Martin, J Deeks, SG AF Greene, Meredith Covinsky, Kenneth E. Valcour, Victor Miao, Yinghui Madamba, Joy Lampiris, Harry Cenzer, Irena Stijacic Martin, Jeffrey Deeks, Steven G. TI Geriatric Syndromes in Older HIV-Infected Adults SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE aging; frailty; function ID IMMUNODEFICIENCY-VIRUS-INFECTION; INDEPENDENT RISK-FACTOR; DRUG-DRUG INTERACTIONS; ANTIRETROVIRAL THERAPY; HOMELESS ADULTS; PREVENTION TRIALS; FRAILTY; FALLS; IMPAIRMENT; PREVALENCE AB Background: Geriatric syndromes such as falls, frailty, and functional impairment are multifactorial conditions used to identify vulnerable older adults. Limited data exist on these conditions in older HIV-infected adults, and no studies have comprehensively examined these conditions. Methods: Geriatric syndromes including falls, urinary incontinence, functional impairment, frailty, sensory impairment, depression, and cognitive impairment were measured in a cross-sectional study of HIV-infected adults aged 50 years and older who had an undetectable viral load on antiretroviral therapy. We examined both HIV and nonHIV- related predictors of geriatric syndromes including sociodemographics, number of comorbidities and nonantiretroviral medications, and HIV-specific variables in multivariate analyses. Results: We studied 155 participants with a median age of 57 (interquartile range: 54-62) and 94% were men. Prefrailty (56%), difficulty with instrumental activities of daily living (46%), and cognitive impairment (47%) were the most frequent geriatric syndromes. Lower CD4 nadir incidence rate ratio [IRR: 1.16, 95% (confidence interval) CI: 1.06 to 1.26], non-white race (IRR: 1.38, 95% CI: 1.10 to 1.74), and increasing number of comorbidities (IRR: 1.09, 95% CI: 1.03 to 1.15) were associated with increased risk of having more geriatric syndromes. Conclusions: Geriatric syndromes are common in older HIVinfected adults. Treatment of comorbidities and early initiation of antiretroviral therapy may help to prevent development of these agerelated complications. Clinical care of older HIV-infected adults should consider incorporation of geriatric principles. C1 [Greene, Meredith; Covinsky, Kenneth E.; Valcour, Victor; Miao, Yinghui; Cenzer, Irena Stijacic] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Greene, Meredith; Covinsky, Kenneth E.; Miao, Yinghui; Cenzer, Irena Stijacic] San Francisco VA Med Ctr, Sect Geriatr & Palliat Med, San Francisco, CA USA. [Valcour, Victor] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Madamba, Joy; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, Div HIV AIDS, San Francisco, CA USA. [Lampiris, Harry] Univ Calif San Francisco, Div Infect Dis, Dept Med, San Francisco, CA USA. [Martin, Jeffrey] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lampiris, Harry] San Francisco VA Med Ctr, Infect Dis Sect, San Francisco, CA USA. RP Greene, M (reprint author), 4150 Clement St UC Box 181-G, San Francisco, CA 94121 USA. EM meredith.greene@ucsf.edu FU National Institutes of Health; University of California San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30-AI027763]; S.D. Bechtel Jr. Foundation Program for the Aging Century; NIAID [K24AI069994]; UCSF Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; CFAR Network of Integrated Systems [R24 AI067039]; National Institutes of Health [5-T32-AG000212] FX Supported by a grant from the National Institutes of Health, University of California San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research, P30-AI027763, the S.D. Bechtel Jr. Foundation Program for the Aging Century, NIAID (K24AI069994), the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131), and the CFAR Network of Integrated Systems (R24 AI067039). M.G. receives salary support from the National Institutes of Health (5-T32-AG000212). S.G.D., J.M., and K.E.C. each currently hold grants from the National Institutes of Health. V.V. currently holds grants from the National Institutes of Health and has served as a consultant and paid lecturer for IAS-USA. NR 53 TC 17 Z9 17 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2015 VL 69 IS 2 BP 161 EP 167 DI 10.1097/QAI.0000000000000556 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5GW UT WOS:000369250500012 PM 26009828 ER PT J AU Weisberg, DF Gordon, KS Barry, DT Becker, WC Crystal, S Edelman, EJ Gaither, J Gordon, AJ Goulet, J Kerns, RD Moore, BA Tate, J Justice, AC Fiellin, DA AF Weisberg, Daniel F. Gordon, Kirsha S. Barry, Declan T. Becker, William C. Crystal, Stephen Edelman, Eva J. Gaither, Julie Gordon, Adam J. Goulet, Joseph Kerns, Robert D. Moore, Brent A. Tate, Janet Justice, Amy C. Fiellin, David A. TI Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE opioid analgesics; benzodiazepines; HIV; pharmacoepidemiology; polypharmacy ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; VETERANS AGING COHORT; PROBLEM DRUG-USE; NONCANCER PAIN; NONMALIGNANT PAIN; PROPENSITY SCORES; OLDER-ADULTS; PRIMARY-CARE; ADMINISTRATIVE DATA AB Background: Increased long-term prescription of opioids and/or benzodiazepines necessitates evaluating risks associated with their receipt. We sought to evaluate the association between long-term opioids and/or benzodiazepines and mortality in HIV-infected patients receiving antiretroviral therapy and uninfected patients. Methods: Prospective analysis of all-cause mortality using multivariable methods and propensity score matching among HIV-infected patients receiving antiretroviral therapy and uninfected patients. Results: Of 64,602 available patients (16,989 HIV-infected and 47,613 uninfected), 27,128 (exposed and unexposed to long-term opioids and/or benzodiazepines) were 1: 1 matched by propensity score. The hazard ratio for death was 1.40 [95% confidence interval (CI): 1.22 to 1.61] for long-term opioid receipt, 1.26 (95% CI: 1.08 to 1.48) for long-term benzodiazepine receipt, and 1.56 (95% CI: 1.26 to 1.92) for long-term opioid and benzodiazepine receipt. There was an interaction (P = 0.01) between long-term opioid receipt and HIV status with mortality. For long-term opioid receipt, the hazard ratio was 1.46 (95% CI: 1.15 to 1.87) among HIV-infected patients, and 1.25 (95% CI: 1.05 to 1.49) among uninfected patients. Mortality risk was increased for patients receiving both long-term opioids and benzodiazepines when opioid doses were >= 20 mg morphine-equivalent daily dose and for patients receiving long-term opioids alone when doses were >= 50 mg morphine-equivalent daily dose. Conclusions: Long-term opioid receipt was associated with an increased risk of death; especially with long-term benzodiazepine receipt, higher opioid doses, and among HIV-infected patients. Long-term benzodiazepine receipt was associated with an increased risk of death regardless of opioid receipt. Strategies to mitigate risks associated with these medications, and caution when they are coprescribed, are needed particularly in HIV-infected populations. C1 [Weisberg, Daniel F.] Yale Univ, Sch Med, New Haven, CT 06510 USA. [Gordon, Kirsha S.; Goulet, Joseph; Kerns, Robert D.; Moore, Brent A.; Tate, Janet; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Barry, Declan T.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Becker, William C.; Edelman, Eva J.; Tate, Janet; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, ES Harkness Bldg A,367 Cedar St,Suite 406A, New Haven, CT 06510 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Edelman, Eva J.; Moore, Brent A.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA. [Gaither, Julie] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Goulet, Joseph; Kerns, Robert D.; Moore, Brent A.] VA Connecticut Healthcare Syst, Pain Res Informat Multimorbid & Educ PRIME Ctr, West Haven, CT USA. RP Fiellin, DA (reprint author), Yale Univ, Sch Med, Dept Internal Med, ES Harkness Bldg A,367 Cedar St,Suite 406A, New Haven, CT 06510 USA. EM david.fiellin@yale.edu RI Moore, Brent/O-4867-2015 OI Moore, Brent/0000-0003-0123-6616; Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502; Goulet, Joseph/0000-0002-0842-804X FU NIH [U01 AA020790, U24 AA020794, U10 AA 13566]; Office of Medical Student Research, Yale School of Medicine, New Haven, CT; Veterans Aging Cohort study - National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566] FX Supported by NIH Grants U01 AA020790; U24 AA020794; U10 AA 13566. Funding for this study was provided by the Office of Medical Student Research, Yale School of Medicine, New Haven, CT, and the Veterans Aging Cohort study, funded by the National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]. NR 77 TC 8 Z9 9 U1 4 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2015 VL 69 IS 2 BP 223 EP 233 DI 10.1097/QAI.0000000000000591 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5GW UT WOS:000369250500020 PM 26009831 ER PT J AU Marcus, EA Li, N Cheng, EY Wozniak, LJ Venick, RS Farmer, DG AF Marcus, Elizabeth A. Li, Ning Cheng, Elaine Y. Wozniak, Laura J. Venick, Robert S. Farmer, Douglas G. TI A Single Center Analysis of Reoperative Frequency Following Intestinal Transplantation. SO TRANSPLANTATION LA English DT Meeting Abstract CT 14th International Small Bowel Transplant Symposium (ISBTS) CY JUN 10-13, 2015 CL Univ Catolica Argentina, Buenos Aires, ARGENTINA HO Univ Catolica Argentina C1 [Marcus, Elizabeth A.; Wozniak, Laura J.; Venick, Robert S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Marcus, Elizabeth A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Li, Ning] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA USA. [Cheng, Elaine Y.; Venick, Robert S.; Farmer, Douglas G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUN PY 2015 VL 99 SU 1 MA 232 BP S43 EP S43 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DB6EC UT WOS:000368605200076 ER PT J AU Merlin, JS Westfall, AO Chamot, E Saag, M Walcott, M Ritchie, C Kertesz, S AF Merlin, Jessica S. Westfall, Andrew O. Chamot, Eric Saag, Michael Walcott, Melonie Ritchie, Christine Kertesz, Stefan TI Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID PATIENT-REPORTED OUTCOMES; SCREENING-TEST; CARE; VALIDATION; RECOMMENDATIONS; POPULATION; ADHERENCE; SCALE; SF-36 AB A method to rapidly identify the presence of chronic pain would enhance the care of HIV-infected individuals, but such an instrument has not been assessed in this population to date. We assessed the construct validity of the two-question Brief Chronic Pain Questionnaire (BCPQ) in HIV-infected patients by assessing the association between BCPQ responses and known correlates of chronic pain. Participants in the University of Alabama Center for AIDS Research Network of Integrated Clinical Systems cohort completed the BCPQ, along with the EuroQOL to assess physical function, the PHQ-9 to assess depression, and the PHQ-anxiety module to assess anxiety. Among 100 participants, 25% were female, the mean age was 45 (SD 12), 63% were African American, 27% were publicly insured, the median CD4(+) T cell count was 572 cells/mm(3) (IQR 307-788), and 82% had an undetectable viral load. Participants with chronic pain were more likely to have impaired mobility (43% vs. 12%, p=0.001), difficulty with usual activities (47% vs. 12%, p<0.001), lower overall health state (70 vs. 84, p=0.002), pain today (80% vs. 27%, p<0.001), depression (30% vs. 15%, p=0.10), and anxiety (43% vs. 10%, p<0.001) than those without chronic pain. This study provides preliminary evidence for the BCPQ as a brief questionnaire to identify the presence of chronic pain in HIV care settings. C1 [Merlin, Jessica S.; Westfall, Andrew O.; Saag, Michael; Walcott, Melonie] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Merlin, Jessica S.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Chamot, Eric] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Ritchie, Christine] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA. [Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. RP Merlin, JS (reprint author), BBRB 222,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jmerlin@uab.edu FU University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR; NIH funded program [P30 A1027767]; AHRQ [1K12HS02169401]; NIA [7K07AG031779]; Mary Fisher CARE Fund at UAB FX This research was supported by the University of Alabama at Birmingham (UAB) Center for AIDS Research CFAR, an NIH funded program (P30 A1027767) that was made possible by the following institutes: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR. J.S.M. is supported by 1K12HS02169401 (AHRQ). C.S.R. is supported by 7K07AG031779 (NIA). Funding was also provided by the Mary Fisher CARE Fund at UAB. NR 34 TC 0 Z9 0 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JUN 1 PY 2015 VL 31 IS 6 BP 623 EP 627 DI 10.1089/aid.2014.0362 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DB7LD UT WOS:000368695700009 PM 25693683 ER PT J AU Robinson, ES Werth, VP AF Robinson, E. S. Werth, V. P. TI The role of cytokines in the pathogenesis of cutaneous lupus erythematosus SO CYTOKINE LA English DT Article DE Cutaneous lupus erythematous; Ultraviolet light; Interferon; Interleukin; Tumor necrosis factor-alpha ID NECROSIS-FACTOR-ALPHA; PLASMACYTOID DENDRITIC CELLS; QUALITY-OF-LIFE; HUMAN KERATINOCYTES; TNF-ALPHA; ULTRAVIOLET-LIGHT; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; CLINICAL ACTIVITY; APOPTOTIC CELLS AB Cutaneous lupus erythematosus (CLE) is an inflammatory disease with a broad range of cutaneous manifestations that may be accompanied by systemic symptoms. The pathogenesis of CLE is complex, multifactorial and incompletely defined. Below we review the current understanding of the cytokines involved in these processes. Ultraviolet (UV) light plays a central role in the pathogenesis of CLE, triggering keratinocyte apoptosis, transport of nucleoprotein autoantigens to the keratinocyte cell surface and the release of inflammatory cytokines (including interferons (IFNs), tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, IL-6, IL-8, IL-10 and IL-17). Increased IFN, particularly type I IFN, is central to the development of CLE lesions. In CLE, type I IFN is produced in response to nuclear antigens, immune complexes and UV light. Type I IFN increases leukocyte recruitment to the skin via inflammatory cytokines, chemokines, and adhesion molecules, thereby inducing a cycle of cutaneous inflammation. Increased TNF alpha in CLE may also cause inflammation. However, decreasing TNF alpha with an anti-TNF alpha agent can induce CLE-like lesions. TNF alpha regulates B cells, increases the production of inflammatory molecules and inhibits the production of IFN-alpha. An increase in the inflammatory cytokines IL-1, IL-6, IL-10, 1L-17 and IL-18 and a decrease in the anti-inflammatory cytokine IL-12 also act to amplify inflammation in CLE. Specific gene mutations may increase the levels of these inflammatory cytokines in some CLE patients. New drugs targeting various aspects of these cytokine pathways are being developed to treat CLE and systemic lupus erythematosus (SLE). Published by Elsevier Ltd. C1 Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, Perelman Ctr Adv Med, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; VA Merit Review grant FX This material is supported by the Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and a VA Merit Review grant to VPW. NR 91 TC 7 Z9 9 U1 0 U2 4 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 EI 1096-0023 J9 CYTOKINE JI Cytokine PD JUN PY 2015 VL 73 IS 2 BP 326 EP 334 DI 10.1016/j.cyto.2015.01.031 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA DB2AB UT WOS:000368309600022 PM 25767072 ER PT J AU Zhuang, YH Heather, MB Leser, JS Clarke, P Tyler, KL AF Zhuang, Yonghua Heather, M. Berens Leser, J. Smith Clarke, Penny Tyler, Kenneth L. TI Mitochondrial apoptotic activity of P53 contributes to neuronal apoptosis and pathogenesis during reovirus encephalitis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 13th International Symposium on NeuroVirology CY JUN 02-06, 2015 CL San Diego, CA C1 [Zhuang, Yonghua; Heather, M. Berens; Leser, J. Smith; Clarke, Penny; Tyler, Kenneth L.] Univ Colorado Denver, Dept Neurol, Denver, CO USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Denver, CO USA. EM Yonghua.Zhuang@UCDenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD JUN PY 2015 VL 21 SU 1 MA P174 BP S81 EP S81 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA DA5ET UT WOS:000367826400175 ER PT J AU Ogawa, M LaRue, AC Mehrotra, M AF Ogawa, Makio LaRue, Amanda C. Mehrotra, Meenal TI Plasticity of hematopoietic stem cells SO BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY LA English DT Article DE Hematopoietic stem cells (HSCs); Plasticity; Stem cells; Tissue regeneration; Transplantation ID BONE-MARROW-CELLS; OSTEOGENESIS IMPERFECTA; IN-VIVO; MESENCHYMAL CELLS; ORIGIN; TRANSPLANTATION; MUSCLE; MICE; MYOFIBROBLASTS; CHILDREN AB Almost two decades ago, a number of cell culture and preclinical transplantation studies suggested the striking concept of the tissue-reconstituting ability of hematopoietic stem cells (HSCs). While this heralded an exciting time of radically new therapies for disorders of many organs and tissues, the concept was soon mired by controversy and remained dormant This chapter provides a brief review of evidence for HSC plasticity including our findings based on single HSC transplantation in mouse. These studies strongly support the concept that HSCs are pluripotent and may be the source for the majority, if not all, of the cell types in our body. (C) 2015 Published by Elsevier Ltd. C1 [Ogawa, Makio; LaRue, Amanda C.; Mehrotra, Meenal] Med Univ S Carolina, Charleston, SC 29425 USA. [LaRue, Amanda C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA. [LaRue, Amanda C.; Mehrotra, Meenal] Hollings Canc Ctr, Charleston, SC 29425 USA. RP Ogawa, M (reprint author), Med Univ S Carolina, 165 Ashley Ave,MSC 908, Charleston, SC 29425 USA. EM ogawam@musc.edu FU BLRD VA [I01 BX000333] NR 44 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6926 EI 1532-1924 J9 BEST PRACT RES CL HA JI Best Pract. Res. Clin. Haematol. PD JUN-SEP PY 2015 VL 28 IS 2-3 BP 73 EP 80 DI 10.1016/j.beha.2015.10.003 PG 8 WC Hematology SC Hematology GA CY0CQ UT WOS:000366074300002 PM 26590762 ER PT J AU Carson, PE Anand, IS Win, S Rector, T Haass, M Lopez-Sendon, J Miller, A Teerlink, JR White, M McKelvie, RS Komajda, M Zile, MR McMurray, JJ Massie, B AF Carson, Peter E. Anand, Inder S. Win, Sithu Rector, Thomas Haass, Markus Lopez-Sendon, Jose Miller, Alan Teerlink, John R. White, Michel McKelvie, Robert S. Komajda, Michel Zile, Michael R. McMurray, John J. Massie, Barry TI The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction) SO JACC-HEART FAILURE LA English DT Article DE heart failure; hospitalizations; preserved ejection fraction; prognosis ID VENTRICULAR SYSTOLIC FUNCTION; CLINICAL CHARACTERISTICS; SURVIVAL; POPULATION; MORBIDITY; OUTCOMES; PREVALENCE; MANAGEMENT; REGISTRY; DEATH AB OBJECTIVES The aim of this study was to investigate prognosis in patients with heart failure (HF) with preserved ejection fraction and the causes of hospitalization and post-hospitalization mortality. BACKGROUND Although hospitalizations in patients with HF with preserved ejection fraction are common, there are limited data from clinical trials on the causes of admission and the influence of hospitalizations on subsequent mortality risk. METHODS Patients (n = 4,128) with New York Heart Association functional class II to IV HF and left ventricular ejection fractions >45% were enrolled in I-PRESERVE (Irbesartan in Heart Failure and Preserved Ejection Fraction). A blinded events committee adjudicated cardiovascular hospitalizations and all deaths using predefined and standardized definitions. The risk for death after HF, any-cause, or non-HF hospitalization was assessed using time-dependent Cox proportional hazard models. RESULTS A total of 2,278 patients had 5,863 hospitalizations during the 49 months of follow-up, of which 3,585 (61%) were recurrent hospitalizations. For any-cause hospitalizations, 26.5% of patients died during follow-up, with an incident mortality rate of 11.1 deaths per 100 patient-years (PYs) and an adjusted hazard ratio of 5.32 (95% confidence interval: 4.21 to 6.23). Overall, 53.6% of hospitalizations were classified as cardiovascular and 43.7% as noncardiovascular, with 2.7% not classifiable. HF was the largest single cause of initial (17.6%) and overall (21.1%) hospitalizations, although, after HF hospitalization, a substantially higher proportion of readmissions were due to primary HF causes (40%). HF hospitalization occurred in 685 patients, with 41% deaths during follow-up, an incident mortality rate of 19.3 deaths per 100 PYs. The adjusted hazard ratio was 2.93 (95% confidence interval: 2.40 to 3.57) relative to patients who were not hospitalized for HF and was greater in those with longer durations of hospitalization. There were 1,593 patients with only non-HF hospitalizations, 21% of whom died during follow-up, with an incident mortality rate of 8.7 deaths per 100 PYs and an adjusted hazard ratio of 4.25 (95% confidence interval: 3.27 to 5.32). The risk for death was highest in the first 30 days and declined over time for all hospitalization categories. Patients not hospitalized for HF or for any cause had observed incident mortality rates of 3.8 and 1.3 deaths per 100 PYs, respectively. CONCLUSIONS In I-PRESERVE, HFpEF patients hospitalized for any reason, and especially for HF, were at high risk for subsequent death, particularly early. The findings support the need for careful attention in the post-discharge time period including attention to comorbid conditions. Among those hospitalized for HF, the high mortality rate and increased proportion of readmissions due to HF (highest during the first 30 days), suggest that this group would be an appropriate target for investigation of new interventions. (C) 2015 by the American College of Cardiology Foundation. C1 [Carson, Peter E.] Washington Vet Affairs Med Ctr, Washington, DC 20422 USA. [Carson, Peter E.] Georgetown Univ, Washington, DC USA. [Anand, Inder S.; Win, Sithu; Rector, Thomas; Haass, Markus] Vet Affairs Hlth Care Syst, Minneapolis, MN USA. [Anand, Inder S.; Win, Sithu; Rector, Thomas] Univ Minnesota, Minneapolis, MN USA. [Haass, Markus] Theresienkrankenhaus, Mannheim, Germany. [Lopez-Sendon, Jose] Hosp Gregorio Maranon, Madrid, Spain. [Miller, Alan] Univ Florida, Jacksonville, FL USA. [Teerlink, John R.; Massie, Barry] San Francisco VA Med Ctr, San Francisco, CA USA. [Teerlink, John R.; Massie, Barry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [White, Michel] Montreal Heart Inst Res Ctr, Montreal, PQ, Canada. [McKelvie, Robert S.] Populat Hlth Res Inst, Hamilton, ON, Canada. [McKelvie, Robert S.] McMaster Univ, Hamilton, ON, Canada. [Komajda, Michel] Univ Paris, Pitie Salpetriere Hosp, F-75252 Paris, France. [Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [McMurray, John J.] British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. RP Carson, PE (reprint author), Washington Vet Affairs Med Ctr, Dept Cardiol, 151D,50 Irving St NW, Washington, DC 20422 USA. EM peter.carson@med.va.gov OI mcmurray, john/0000-0002-6317-3975 FU I-PRESERVE trial; Minneapolis Veterans Affairs Health Care System FX Bristol-Myers Squibb sponsored the I-PRESERVE trial. The views expressed herein do not necessarily represent the views of the U.S. Department of Veterans Affairs or the U.S. government. Dr. Rector was supported by resources and facilities of the Minneapolis Veterans Affairs Health Care System. Drs. Carson, Anand, Haass, Lopez-Sendon, Miller, Teerlink, White, McKelvie, Komajda, Zile, McMurray, and Massie were consultants to Bristol-Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 31 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD JUN PY 2015 VL 3 IS 6 BP 429 EP 441 DI 10.1016/j.jchf.2014.12.017 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4ER UT WOS:000365652200001 PM 25982110 ER PT J AU Abraham, WT Zile, MR Weaver, FA Butter, C Ducharme, A Halbach, M Klug, D Lovett, EG Muller-Ehmsen, J Schafer, JE Senni, M Swarup, V Wachter, R Little, WC AF Abraham, William T. Zile, Michael R. Weaver, Fred A. Butter, Christian Ducharme, Anique Halbach, Marcel Klug, Didier Lovett, Eric G. Mueller-Ehmsen, Jochen Schafer, Jill E. Senni, Michele Swarup, Vijay Wachter, Rolf Little, William C. TI Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction SO JACC-HEART FAILURE LA English DT Article DE autonomic nervous system; baroreflex; device; heart failure; randomized controlled trial ID INHIBITION; METOPROLOL; SYSTEM; TRIAL; HF AB OBJECTIVES The objective of this clinical trial was to assess the safety and efficacy of carotid BAT in advanced HF. BACKGROUND Increased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Baroreflex activation therapy (BAT) results in centrally mediated reduction of sympathetic outflow and increased parasympathetic activity. METHODS Patients with New York Heart Association (NYHA) functional class III HF and ejection fractions <= 35% on chronic stable guideline-directed medical therapy (GDMT) were enrolled at 45 centers in the United States, Canada, and Europe. They were randomly assigned to receive ongoing GDMT alone (control group) or ongoing GDMT plus BAT (treatment group) for 6 months. The primary safety end point was system-and procedure-related major adverse neurological and cardiovascular events. The primary efficacy end points were changes in NYHA functional class, quality-of-life score, and 6-minute hall walk distance. RESULTS One hundred forty-six patients were randomized, 70 to control and 76 to treatment. The major adverse neurological and cardiovascular event-free rate was 97.2% (lower 95% confidence bound 91.4%). Patients assigned to BAT, compared with control group patients, experienced improvements in the distance walked in 6 min (59.6 +/- 14 m vs. 1.5 +/- 13.2 m; p = 0.004), quality-of-life score (-17.4 +/- 2.8 points vs. 2.1 +/- 3.1 points; p < 0.001), and NYHA functional class ranking (p = 0.002 for change in distribution). BAT significantly reduced N-terminal pro-brain natriuretic peptide (p = 0.02) and was associated with a trend toward fewer days hospitalized for HF (p = 0.08). CONCLUSIONS BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA functional class III HF. (C) 2015 by the American College of Cardiology Foundation. C1 [Abraham, William T.] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA. [Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA. [Zile, Michael R.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Weaver, Fred A.] Univ So Calif, Keck Sch Med, Div Vasc Surg & Endovasc Therapy, Los Angeles, CA 90033 USA. [Butter, Christian] Med Sch Brandenburg, Immanuel Heart Ctr Bernau, Dept Cardiol, Bernau, Germany. [Ducharme, Anique] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Halbach, Marcel] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany. [Klug, Didier] Univ Hosp, Dept Cardiol A, Lille, France. [Lovett, Eric G.] CVRx Inc, Dept Res, Minneapolis, MN USA. [Mueller-Ehmsen, Jochen] Asklepios Klin Altona, Dept Med, Hamburg, Germany. [Schafer, Jill E.] NAMSA Inc, Dept Stat, Minneapolis, MN USA. [Senni, Michele] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy. [Swarup, Vijay] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA. [Wachter, Rolf] Univ Med Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany. [Wachter, Rolf] German Cardiovasc Res Ctr, Gottingen, Germany. [Little, William C.] Univ Mississippi, Med Ctr, Div Cardiol, Jackson, MS 39216 USA. RP Abraham, WT (reprint author), Davis Heart & Lung Res Inst, Div Cardiovasc Med, 473 West 12th Ave,Room 110P, Columbus, OH 43210 USA. EM william.abraham@osumc.edu OI Wachter, Rolf/0000-0003-2231-2200 FU CVRx, Inc. (Minneapolis, Minnesota); CVRx FX This study was funded by CVRx, Inc. (Minneapolis, Minnesota). Drs. Abraham, Little, Weaver, and Zile have received consulting fees and speaking honoraria from CVRx and are members of the CVRx Heart Failure Executive Steering Committee. Dr. Butter has received research fees from CVRx. Dr. Ducharme has received research fees and consulting fees from CVRx. Dr. Halbach has received research fees and speaking honoraria from CVRx. Dr. Klug has received research fees from CVRx. Dr. Muller-Ehmsen has received research fees and speaking honoraria from CVRx. Dr. Senni has received research fees from CVRx. Dr. Swarup has received research fees from CVRx. Dr. Wachter has received research fees and consultant fees from CVRx. Ms. Schafer is a statistical consultant for CVRx. Dr. Lovett is an employee of CVRx. NR 19 TC 35 Z9 36 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD JUN PY 2015 VL 3 IS 6 BP 487 EP 496 DI 10.1016/j.jchf.2015.02.006 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4ER UT WOS:000365652200009 PM 25982108 ER PT J AU Lo Re, V Kallan, MJ Tate, JP Lim, JK Goetz, MB Klein, MB Rimland, D Rodriguez-Barradas, MC Butt, AA Gibert, CL Brown, ST Park, LS Dubrow, R Reddy, KR Kostman, JR Justice, AC Localio, AR AF Lo Re, Vincent, III Kallan, Michael J. Tate, Janet P. Lim, Joseph K. Goetz, Matthew Bidwell Klein, Marina B. Rimland, David Rodriguez-Barradas, Maria C. Butt, Adeel A. Gibert, Cynthia L. Brown, Sheldon T. Park, Lesley S. Dubrow, Robert Reddy, K. Rajender Kostman, Jay R. Justice, Amy C. Localio, A. Russell TI Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE end-stage liver disease; hepatic decompensation; HIV; hepatitis C; HIV/HCV coinfection ID SIMPLE NONINVASIVE INDEX; VETERANS AGING COHORT; NATIONAL DEATH INDEX; HEPATITIS-C; INFECTED VETERANS; HEPATOCELLULAR-CARCINOMA; SIGNIFICANT FIBROSIS; ANTIVIRAL THERAPY; PHARMACY RECORDS; HIV AB Background. End-stage liver disease (ESLD) is an important cause of morbidity among human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. Quantifying the risk of this outcome over time could help determine which coinfected patients should be targeted for risk factor modification and HCV treatment. We evaluated demographic, clinical, and laboratory variables to predict risk of ESLD in HIV/HCV-coinfected patients receiving antiretroviral therapy (ART). Methods. We conducted a retrospective cohort study among 6016 HIV/HCV-coinfected patients who received ART within the Veterans Health Administration between 1997 and 2010. The main outcome was incident ESLD, defined by hepatic decompensation, hepatocellular carcinoma, or liver-related death. Cox regression was used to develop prognostic models based on baseline demographic, clinical, and laboratory variables, including FIB-4 and aspartate aminotransferase-to-platelet ratio index, previously validated markers of hepatic fibrosis. Model performance was assessed by discrimination and decision curve analysis. Results. Among 6016 HIV/HCV patients, 532 (8.8%) developed ESLD over a median of 6.6 years. A model comprising FIB-4 and race had modest discrimination for ESLD (c-statistic, 0.73) and higher net benefit than alternative strategies of treating no or all coinfected patients at relevant risk thresholds. For FIB-4 > 3.25, ESLD risk ranged from 7.9% at 1 year to 26.0% at 5 years among non-blacks and from 2.4% at 1 year to 14.0% at 5 years among blacks. Conclusions. Race and FIB-4 provided important predictive information on ESLD risk among HIV/HCV patients. Estimating risk of ESLD using these variables could help direct HCV treatment decisions among HIV/HCV-coinfected patients. C1 [Lo Re, Vincent, III; Reddy, K. Rajender; Kostman, Jay R.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Kallan, Michael J.; Localio, A. Russell] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III; Kallan, Michael J.; Localio, A. Russell] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Philadelphia VA Med Ctr, Med Serv, Philadelphia, PA USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Tate, Janet P.; Lim, Joseph K.; Park, Lesley S.; Dubrow, Robert; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Klein, Marina B.] McGill Univ, Ctr Hlth, Chron Viral Illness Serv, Montreal, PQ, Canada. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington DC VA Med Ctr, Washington, DC 20037 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, New York, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Park, Lesley S.; Dubrow, Robert] Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, 836 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM vincentl@mail.med.upenn.edu OI Butt, Adeel/0000-0002-1118-1826; Justice, Amy/0000-0003-0139-5502 NR 41 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv109 PG 9 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500024 ER PT J AU Luks, AM Swenson, ER AF Luks, Andrew M. Swenson, Erik R. TI Evaluating the Risks of High Altitude Travel in Chronic Liver Disease Patients SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article DE altitude illness; cirrhosis; clinical hepatology; hepatopulmonary syndrome; hypoxia; portopulmonary hypertension ID ACUTE MOUNTAIN-SICKNESS; RIGHT PULMONARY-ARTERY; FACTOR-DEPENDENT PRODUCTION; HEPATIC TISSUE OXYGENATION; CONGENITAL HEART-DISEASE; CHRONIC KIDNEY-DISEASE; HEPATOPULMONARY SYNDROME; AIR-TRAVEL; PORTOPULMONARY HYPERTENSION; PROFIBROTIC MEDIATORS AB Luks, Andrew M., and Erik R. Swenson. Clinician's Corner: Evaluating the risks of high altitude travel in chronic liver disease patients. High Alt Med Biol 16:80-88, 2015.With improvements in the quality of health care, people with chronic medical conditions are experiencing better quality of life and increasingly participating in a wider array of activities, including travel to high altitude. Whenever people with chronic diseases travel to this environment, it is important to consider whether the physiologic responses to hypobaric hypoxia will interact with the underlying medical condition such that the risk of acute altitude illness is increased or the medical condition itself may worsen. This review considers these questions as they pertain to patients with chronic liver disease. While the limited available evidence suggests there is no evidence of liver injury or dysfunction in normal individuals traveling as high as 5000m, there is reason to suspect that two groups of cirrhosis patients are at increased risk for problems, hepatopulmonary syndrome patients, who are at risk for severe hypoxemia following ascent, and portopulmonary hypertension patients who may be at risk for high altitude pulmonary edema and acute right ventricular dysfunction. While liver transplant patients may tolerate high altitude exposure without difficulty, no information is available regarding the risks of long-term residence at altitude with chronic liver disease. All travelers with cirrhosis require careful pre-travel evaluation to identify conditions that might predispose to problems at altitude and develop risk mitigation strategies for these issues. Patients also require detailed counseling about recognition, prevention, and treatment of acute altitude illness and may require different medication regimens to prevent or treat altitude illness than used in healthy individuals. C1 [Luks, Andrew M.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA 98104 USA. [Swenson, Erik R.] VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA USA. RP Luks, AM (reprint author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, 325 Ninth Ave,Box 359762, Seattle, WA 98103 USA. EM aluks@u.washington.edu NR 93 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 EI 1557-8682 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD JUN 1 PY 2015 VL 16 IS 2 BP 80 EP 88 DI 10.1089/ham.2014.1122 PG 9 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA CU9YG UT WOS:000363902400003 PM 25844541 ER PT J AU Hao, K Di Narzo, AF Ho, L Luo, W Li, SY Chen, R Li, TB Dubner, L Pasinetti, GM AF Hao, Ke Di Narzo, Antonio Fabio Ho, Lap Luo, Wei Li, Shuyu Chen, Rong Li, Tongbin Dubner, Lauren Pasinetti, Giulio Maria TI Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes SO MOLECULAR ASPECTS OF MEDICINE LA English DT Review DE Alzheimer's disease; Type 2 diabetes; GWAS; Shared genomic component; eQTLs; Pathway ID METABOLIC SYNDROME; SUSCEPTIBILITY LOCI; SYNAPTIC PLASTICITY; SIGNALING PATHWAYS; INFLAMMATION; ASSOCIATION; ANNOTATION; INSIGHTS; COHORT; RISK AB Epidemiological evidence supports the observation that subjects with type 2 diabetes (T2D) are at higher risk to develop Alzheimer's disease (AD). However, whether and how these two conditions are causally linked is unknown. Possible mechanisms include shared genetic risk factors, which were investigated in this study based on recent genome wide association study (GWAS) findings. In order to achieve our goal, we retrieved single nucleotide polymorphisms (SNPs) associated with T2D and AD from large-scale GWAS metaanalysis consortia and tested for overlap among the T2D- and AD-associated SNPs at various p-value thresholds. We then explored the function of the shared T2D/AD GWAS SNPs by leveraging expressional quantitative trait loci, pathways, gene ontology data, and coexpression networks. We found 927 SNPs associated with both AD and T2D with p-value <= 0.01, an overlap significantly larger than random chance (overlapping p-value of 6.93E-28). Among these, 395 of the shared GWAS SNPs have the same risk allele for AD and T2D, suggesting common pathogenic mechanisms underlying the development of both AD and T2D. Genes influenced by shared T2D/AD SNPs with the same risk allele were first identified using a SNP annotation variation (ANNOVAR) software, followed by using Association Protein-Protein Link Evaluator (DAPPLE) software to identify additional proteins that are known to physically interact with the ANNOVAR gene annotations. We found that gene annotations from ANNOVAR and DAPPLE significantly enriched specific KEGG pathways pertaining to immune responses, cell signaling and neuronal plasticity, cellular processes in which abnormalities are known to contribute to both T2D and AD pathogenesis. Thus, our observation suggests that among T2D subjects with common genetic predispositions (e.g., SNPs with consistent risk alleles for T2D and AD), dysregulation of these pathogenic pathways could contribute to the elevated risks for AD in subjects. Interestingly, we found that 532 of the shared T2D/AD GWAS SNPs had divergent risk alleles in the two diseases. For individual shared T2D/AD SNPs with divergent alleles, one of the allelic forms may contribute to one of the diseases (e.g., T2D), but not necessarily to the other (e.g., AD), or vice versa. Collectively, our GWAS studies tentatively support the epidemiological observation of disease concordance between T2D and AD. Moreover, the studies provide the much needed information for the design of future novel therapeutic approaches, for a subpopulation of T2D subjects with genetic disposition to AD, that could benefit T2D and reduce the risk for subsequent development of AD. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Hao, Ke; Di Narzo, Antonio Fabio; Luo, Wei; Li, Shuyu; Chen, Rong] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Hao, Ke; Di Narzo, Antonio Fabio; Li, Shuyu; Chen, Rong] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Ho, Lap; Dubner, Lauren; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Luo, Wei] Huaqiao Univ, Coll Comp Sci & Technol, Xiamen 361021, Peoples R China. [Li, Tongbin] AccuraSci LLC, Johnston, IA USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Icahn School of Medicine at Mount Sinai; Altschul Foundation; National Natural Science Foundation of China [21477087]; CADgenomics grant of Leduqc Foundation [0266-2493]; Fujian Province Overseas Studying Fellowship FX This study was supported by discretionary funding from the Icahn School of Medicine at Mount Sinai to Dr. Giulio Pasinetti and in part by the Altschul Foundation. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this article do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Hao K is partially supported by National Natural Science Foundation of China (Grant No. 21477087). Hao K is also partially supported by CADgenomics grant of Leduqc Foundation (Grant #0266-2493) as co-Investigator. Luo W is partially supported by Fujian Province Overseas Studying Fellowship. NR 46 TC 7 Z9 8 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0098-2997 EI 1872-9452 J9 MOL ASPECTS MED JI Mol. Asp. Med. PD JUN-OCT PY 2015 VL 43-44 SI SI BP 66 EP 76 DI 10.1016/j.mam.2015.06.006 PG 11 WC Biochemistry & Molecular Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Research & Experimental Medicine GA CV4VC UT WOS:000364263600007 PM 26116273 ER PT J AU Moreno, G Mangione, CM Meza, CE Kwon, I Seeman, T Trejo, L Moore, M Sarkisian, CA AF Moreno, Gerardo Mangione, Carol M. Meza, Carlos E. Kwon, Ivy Seeman, Teresa Trejo, Laura Moore, Mignon Sarkisian, Catherine A. TI PERCEPTIONS FROM LATINO AND AFRICAN AMERICAN OLDER ADULTS ABOUT BIOLOGICAL MARKERS IN RESEARCH SO ETHNICITY & DISEASE LA English DT Article DE Aging; African Americans; Latinos; Biomarkers ID REACTIVE PROTEIN-LEVELS; PARTICIPATORY RESEARCH; CLINICAL-TRIALS; RISK PROFILES; COMMUNITY; STRATEGIES AB Although older adult minorities face disparities in health and health care, they continue to be underrepresented in health research. Studies with biological markers of health often lack representation of older minority adults. The purpose of this study was to describe perceptions of biomarkers among ethnic minority seniors who might participate in studies of biological markers of health and to document barriers and facilitators to acceptance of biomarkers. Six focus groups (3 of Spanish-speaking Latinos and 3 of African Americans) were conducted in three community senior service organizations (two senior centers and one church). Ten semi-structured interviews were conducted to support and augment focus group data. Seventy-two community-dwelling minority older adults aged 62 years and older and 10 community stakeholders participated. A community-based partnered research approach was used and two community partners participated in the analysis and interpretation of results. Standard qualitative content-analysis methods were used to identify and organize themes in domains. Focus group participants were 49% Latino and 51% African American. Results included barriers: 1) mistrust, 2) fear of specimen collection/storage, 3) perceived harms, 4) competing demands, and 5) costs. Older Latinos cited issues of language as barriers to awareness and acceptance of biomarkers. African Americans had concerns over perceived harms of biomarkers. Facilitators to acceptance of biomarkers were community engagement through church and community leaders. Older Latino and African Americans identified many barriers and facilitators to the collection and storage of biomarkers. Participants identified community-partnered recommendations to overcome barriers to the acceptance, collection, and storage of biomarkers. C1 [Moreno, Gerardo; Meza, Carlos E.] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90024 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Kwon, Ivy; Seeman, Teresa; Sarkisian, Catherine A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, Los Angeles, CA 90024 USA. [Trejo, Laura] City Los Angeles Dept Aging, Los Angeles, CA USA. [Moore, Mignon] Univ Calif Los Angeles, Dept Sociol, Los Angeles, CA 90024 USA. [Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Moreno, G (reprint author), 10880 Wilshire Blvd,Suite 1800, Los Angeles, CA 90024 USA. EM gemoreno@mednet.ucla.edu OI Kwon, Ivy/0000-0003-4160-6546 FU NIA [K23 AG042961]; NIH/NCATS/UCLA [UL1TR000124, P30-AG021684]; L.A. CAPRA Center [1RC4AG038182, P30 AG028748] FX Funding from the NIA K23 AG042961 Paul B. Beeson Career Development Award in Aging Research, NIH/NCATS/UCLA #UL1TR000124, P30-AG021684, L.A. CAPRA Center 1RC4AG038182, and P30 AG028748. NR 30 TC 0 Z9 0 U1 1 U2 2 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X EI 1945-0826 J9 ETHNIC DIS JI Ethn. Dis. PD SUM PY 2015 VL 25 IS 3 BP 355 EP 362 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CU7KW UT WOS:000363717800016 PM 26347148 ER PT J AU Lautz, J Pervan, CL Stubbs, EB AF Lautz, Jonathan Pervan, Cynthia Lynn Stubbs, Evan B. TI Transforming Growth Factor-beta 2 Attenuates Bradykinin B2 Receptor Expression in Human Trabecular Meshwork Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Lautz, Jonathan] Loyola Univ Chicago, Program Neurosci, Maywood, IL USA. [Lautz, Jonathan; Pervan, Cynthia Lynn; Stubbs, Evan B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Pervan, Cynthia Lynn; Stubbs, Evan B.] Loyola Univ Chicago, Ophthalmol, Maywood, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3293 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100164 ER PT J AU Pervan, CL Lautz, JD Blitzer, AL Stubbs, EB AF Pervan, Cynthia Lynn Lautz, Jonathan D. Blitzer, Andrea L. Stubbs, Evan B. TI Constitutive Expression and Release of TGF-beta 2 by Human Trabecular Meshwork Cells SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Pervan, Cynthia Lynn; Lautz, Jonathan D.; Blitzer, Andrea L.; Stubbs, Evan B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv 151, Hines, IL 60141 USA. [Pervan, Cynthia Lynn; Stubbs, Evan B.] Loyola Univ Chicago, Ophthalmol, Maywood, IL USA. [Lautz, Jonathan D.] Loyola Univ Chicago, Program Neurosci, Maywood, IL USA. [Blitzer, Andrea L.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3295 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891100166 ER PT J AU Schnabolk, G Bandyopadhyay, M Tomlinson, S Rohrer, B AF Schnabolk, Gloriane Bandyopadhyay, Mausumi Tomlinson, Stephen Rohrer, Baerbel TI New insights on complement inhibitor CD59 in mouse laser-induced choroidal neovascularization: reduced expression after injury and targeted delivery for protein replacement SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Schnabolk, Gloriane; Tomlinson, Stephen; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bandyopadhyay, Mausumi; Rohrer, Baerbel] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Med Univ S Carolina, Microbiol & Immunol, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 5459 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891105371 ER PT J AU Obert, E Ghatnekar, G Rohrer, B AF Obert, Elisabeth Ghatnekar, Gautam Rohrer, Baerbel TI Effects of the Act-1 Peptide on Retinal Pigment Epithelial Cell Integrity in Two Mouse Models of Age-Related Macular Degeneration SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Obert, Elisabeth; Rohrer, Baerbel] Med Univ S Carolina, Charleston, SC 29425 USA. [Ghatnekar, Gautam] FirstString Res, Mt Pleasant, SC USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2341 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205342 ER PT J AU Reardon, W Sharpe, RA Sharpe, E AF Reardon, Wade Sharpe, Robert Allan Sharpe, Elizabeth TI Retrospective analysis of resident-performed microinvasive glaucoma surgery with the iStent SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Reardon, Wade; Sharpe, Robert Allan; Sharpe, Elizabeth] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Sharpe, Elizabeth] Ralph H Johnson VA Med Ctr, Ophthalmol, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 2694 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882206263 ER PT J AU Rohrer, B Woodell, A Casey, S Williamson, T Jones, BW Tomlinson, S Atkinson, C AF Rohrer, Baerbel Woodell, Alex Casey, Sarah Williamson, Tucker Jones, Bryan W. Tomlinson, Stephen Atkinson, Carl TI Inhibition of the alternative pathway of complement accelerates recovery from smoke-induced functional and morphological ocular injury SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Rohrer, Baerbel; Woodell, Alex] Med Univ S Carolina, Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel; Tomlinson, Stephen] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Casey, Sarah; Williamson, Tucker; Tomlinson, Stephen; Atkinson, Carl] Med Univ S Carolina, Immunol, Charleston, SC 29425 USA. [Jones, Bryan W.] Univ Utah, Ophthalmol, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882205289 ER PT J AU Wahle, A Lee, KE Lee, K Zhang, L Bogunovic, H Harding, AT Scheetz, TE Sonka, M Klein, R Abramoff, MD AF Wahle, Andreas Lee, Kristine E. Lee, Kyungmoo Zhang, Li Bogunovic, Hrvoje Harding, Adam T. Scheetz, Todd E. Sonka, Milan Klein, Ronald Abramoff, Michael David TI Use of XNAT to generate phenotype data from OCT scans for use with genetic association analyses SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Wahle, Andreas; Lee, Kyungmoo; Zhang, Li; Bogunovic, Hrvoje; Sonka, Milan] Univ Iowa, Elect & Comp Engn, Iowa City, IA USA. [Lee, Kristine E.; Scheetz, Todd E.; Sonka, Milan; Klein, Ronald; Abramoff, Michael David] Univ Wisconsin, Ophthalmol & Visual Sci, Madison, WI USA. [Harding, Adam T.] Univ Iowa, Inst Clin & Translat Sci, Iowa City, IA USA. [Abramoff, Michael David] US Dept Vet Affairs, Iowa City, IA USA. RI Bogunovic, Hrvoje/J-3445-2014 OI Bogunovic, Hrvoje/0000-0002-9168-0894 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1261 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203170 ER PT J AU Teo, AR AF Teo, A. R. TI Developing a mental health research career: A review of early career opportunities in the US SO ASIA-PACIFIC PSYCHIATRY LA English DT Meeting Abstract C1 [Teo, A. R.] Portland VA Med Ctr, Portland, OR USA. [Teo, A. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1758-5864 EI 1758-5872 J9 ASIA-PAC PSYCHIAT JI Asia-Pac. Psychiatry PD JUN PY 2015 VL 7 SU 1 SI SI MA 60 BP 18 EP 19 PG 2 WC Psychiatry SC Psychiatry GA CT0SD UT WOS:000362505800028 ER PT J AU Teo, AR Fetters, MD Stufflebam, K Tateno, M Balhara, Y Choi, TY Kanba, S Mathews, CA Kato, TA AF Teo, A. R. Fetters, M. D. Stufflebam, K. Tateno, M. Balhara, Y. Choi, T. Y. Kanba, S. Mathews, C. A. Kato, T. A. TI A cross-national study of social withdrawal: Identification, diagnosis and psychosocial features of hikikomori in four countries SO ASIA-PACIFIC PSYCHIATRY LA English DT Meeting Abstract C1 [Teo, A. R.] Portland VA Med Ctr, Portland, OR USA. [Teo, A. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Fetters, M. D.] Univ Michigan, Japanese Family Hlth Program, Ann Arbor, MI 48109 USA. [Fetters, M. D.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Stufflebam, K.] FreshStart ClubHouse, Ann Arbor, MI USA. [Tateno, M.] Sapporo Med Univ, Sapporo Hana Dev Psychiat Clin, Ch Ku, Sapporo, Hokkaid, Japan. [Tateno, M.] Sapporo Med Univ, Dept Neuropsychiat, Ch Ku, Sapporo, Hokkaid, Japan. [Balhara, Y.] All India Inst Med Sci, Natl Drug Dependence Treatment Ctr, New Delhi, India. [Choi, T. Y.] Catholic Univ Daegu, Sch Med, Dept Psychiat, Daegu, South Korea. [Kanba, S.; Kato, T. A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan. [Mathews, C. A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kato, T. A.] Kyushu Univ, Innovat Ctr Med Redox Nav, Fukuoka 812, Japan. NR 0 TC 0 Z9 0 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1758-5864 EI 1758-5872 J9 ASIA-PAC PSYCHIAT JI Asia-Pac. Psychiatry PD JUN PY 2015 VL 7 SU 1 SI SI MA 61 BP 19 EP 19 PG 1 WC Psychiatry SC Psychiatry GA CT0SD UT WOS:000362505800029 ER PT J AU McFarland, LV AF McFarland, Lynne V. TI Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review SO ANTIBIOTICS-BASEL LA English DT Review DE probiotics; clostridium difficile infections; diarrhea; meta-analysis ID ANTIBIOTIC-ASSOCIATED DIARRHEA; PLACEBO-CONTROLLED TRIAL; LACTOBACILLUS-ACIDOPHILUS CL1285; SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; HOSPITALIZED-PATIENTS; PUBLICATION BIAS; CLINICAL-TRIAL; ADULT PATIENTS; DISEASE AB Clostridium difficile infections are a global clinical concern and are one of the leading causes of nosocomial outbreaks. Preventing these infections has benefited from multidisciplinary infection control strategies and new antibiotics, but the problem persists. Probiotics are effective in preventing antibiotic-associated diarrhea and may also be a beneficial strategy for C. difficile infections, but randomized controlled trials are scarce. This meta-analysis pools 21 randomized, controlled trials for primary prevention of C. difficile infections (CDI) and four trials for secondary prevention of C. difficile recurrences and assesses the efficacy of specific probiotic strains. Four probiotics significantly improved primary CDI prevention: (Saccharomyces boulardii, Lactobacillus casei DN114001, a mixture of L. acidophilus and Bifidobacterium bifidum, and a mixture of L. acidophilus, L. casei and L. rhamnosus). None of the tested probiotics significantly improved secondary prevention of CDI. More confirmatory randomized trials are needed to establish if probiotics are useful for preventing C. difficile infections. C1 Univ Washington, Dept Med Chem, VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. RP McFarland, LV (reprint author), Univ Washington, Dept Med Chem, VA Puget Sound Healthcare Syst, 1660 S Columbian Way,S-152, Seattle, WA 98108 USA. EM lvmcfarl@u.washington.edu FU Biocodex, France; Lallemand, France FX Lynne McFarland has received fees as a speaker (Biocodex, France and Lallemand, France) and is on the scientific advisory board of BioK+, Canada. NR 59 TC 11 Z9 13 U1 0 U2 6 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2079-6382 J9 ANTIBIOTICS-BASEL JI Antibiotics-Basel PD JUN PY 2015 VL 4 IS 2 BP 160 EP 178 DI 10.3390/antibiotics4020160 PG 19 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CS4UQ UT WOS:000362071900002 PM 27025619 ER PT J AU Busch, AC Hetzel, S Brown, RT AF Busch, A. C. Hetzel, S. Brown, R. T. TI PHARMACOTHERAPEUTIC INTERVENTION TO IMPROVE TREATMENT ENGAGEMENT AMONG ALCOHOL DEPENDENT VETERANS AFTER HOSPITAL DISCHARGE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Busch, A. C.; Hetzel, S.; Brown, R. T.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 260 BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100261 ER PT J AU Schrodek, E Pennington, DL Lasher, B Herbst, E Yohannes, S McDonald, J Schmeling, BL Wong, T Batki, SL AF Schrodek, E. Pennington, D. L. Lasher, B. Herbst, E. Yohannes, S. McDonald, J. Schmeling, B. L. Wong, T. Batki, S. L. TI AN EVALUATION OF TOPIRAMATE TREATMENT: SECONDARY HEALTH OUTCOMES FOR VETERANS WITH ALCOHOL USE DISORDER AND COMORBID PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 258 BP 76A EP 76A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100259 ER PT J AU Hutchison, D Possemato, K Lynch, KG Maisto, SA Oslin, DW AF Hutchison, D. Possemato, K. Lynch, K. G. Maisto, S. A. Oslin, D. W. TI CRAVINGS MEDIATE DECREASES IN DRINKING FOR VETERANS WHO USE NALTREXONE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Hutchison, D.; Possemato, K.; Lynch, K. G.; Maisto, S. A.; Oslin, D. W.] Univ Penn, Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 261 BP 77A EP 77A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100262 ER PT J AU Yohannes, S Pennington, DL Lasher, B Schrodek, E McDonald, J Schmeling, BL Wong, T Lee, I Batki, SL AF Yohannes, S. Pennington, D. L. Lasher, B. Schrodek, E. McDonald, J. Schmeling, B. L. Wong, T. Lee, I. Batki, S. L. TI PHARMACOTHERAPY CLINICAL TRIAL RECRUITMENT OF VETERANS WITH ALCOHOL USE DISORDER AND COMORBID PTSD/MTBI SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 San Francisco Vet Adm Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 273 BP 80A EP 80A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100274 ER PT J AU Pennington, DL Meyerhoff, D Schmidt, T Schmeling, B Lasher, B Schrodek, E Yohannes, S McDonald, J Herbst, E Wong, T Batki, SL AF Pennington, D. L. Meyerhoff, D. Schmidt, T. Schmeling, B. Lasher, B. Schrodek, E. Yohannes, S. McDonald, J. Herbst, E. Wong, T. Batki, S. L. TI COGNITIVE FUNCTION IN PATIENTS WITH ALCOHOL USE DISORDER WITH AND WITHOUT PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 290 BP 84A EP 84A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100291 ER PT J AU Schmeling, B Heinz, AJ Pennington, DL Cohen, N Lasher, BA Schrodek, E Yohannes, S McDonald, J Wong, T Batki, SL AF Schmeling, B. Heinz, A. J. Pennington, D. L. Cohen, N. Lasher, B. A. Schrodek, E. Yohannes, S. McDonald, J. Wong, T. Batki, S. L. TI AN EXAMINATION OF RELATIONS BETWEEN COGNITIVE FUNCTIONING AND ALCOHOL USE AND CRAVING AMONG VETERANS WITH ALCOHOL USE DISORDER AND TRAUMA EXPOSURE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Schmeling, B.; Heinz, A. J.; Pennington, D. L.; Cohen, N.; Lasher, B. A.; Schrodek, E.; Yohannes, S.; McDonald, J.; Wong, T.; Batki, S. L.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 293 BP 85A EP 85A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100294 ER PT J AU Buck, KJ Denmark, DL Walter, NAR AF Buck, K. J. Denmark, D. L. Walter, N. A. R. TI A SYSTEMS BIOLOGY APPROACH IMPLICATES OXIDATIVE HOMEOSTASIS IN ALCOHOL WITHDRAWAL VULNERABILITY SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland Alcohol Res Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 468 BP 128A EP 128A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637100468 ER PT J AU Oslin, DW Polusny, M Kehle-Forbes, S Van Horn, D Yusko, D Drapkin, ML Foa, E Ingram, I AF Oslin, D. W. Polusny, M. Kehle-Forbes, S. Van Horn, D. Yusko, D. Drapkin, M. L. Foa, E. Ingram, I. TI INTEGRATED VERSUS SEQUENTIAL TREATMENT FOR COMORBID PTSD/ADDICTION AMONG VETERANS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Penn, Philadelphia, PA USA. Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 524 BP 142A EP 142A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101047 ER PT J AU Goeke, CM Zhang, X Bhattacharyya, S York, JM Tobacman, JK Guizzetti, M AF Goeke, C. M. Zhang, X. Bhattacharyya, S. York, J. M. Tobacman, J. K. Guizzetti, M. TI ROLE OF N-ACETYL-GALACTOSAMINE-6-SULFATASE IN ETHANOL-INDUCED INHIBITION OF ASTROCYTE-MEDIATED HIPPOCAMPAL PYRAMIDAL NEURON NEURITE OUTGROWTH SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Univ Illinois, Coll Med, Chicago, IL 60612 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] OHSU, Portland, OR 97239 USA. [Goeke, C. M.; Zhang, X.; Bhattacharyya, S.; York, J. M.; Tobacman, J. K.; Guizzetti, M.] Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 839 BP 220A EP 220A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101361 ER PT J AU Rasmussen, DD Johanson, SS Kincaid, CL Froehlich, JC AF Rasmussen, D. D. Johanson, S. S. Kincaid, C. L. Froehlich, J. C. TI IN FEMALE P RATS, PRAZOSIN plus NALTREXONE DECREASES ALCOHOL DRINKING MORE EFFECTIVELY THAN EITHER DRUG ALONE, WITH MAXIMUM EFFECT ON INTERMITTENT DRINKING SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 905 BP 237A EP 237A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101427 ER PT J AU Rasmussen, DD Kincaid, CL Johanson, SS Froehlich, JC AF Rasmussen, D. D. Kincaid, C. L. Johanson, S. S. Froehlich, J. C. TI PRAZOSIN plus PROPRANOLOL plus NALTREXONE DECREASES ALCOHOL DRINKING IN FEMALE P RATS MORE EFFECTIVELY THAN THE INDIVIDUAL DRUGS OR TWO-DRUG COMBINATIONS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 906 BP 237A EP 237A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101428 ER PT J AU Simpson, TL Stappenbeck, CA Luterek, JA Rosenthal, CF Gurrad, B Kaysen, D AF Simpson, T. L. Stappenbeck, C. A. Luterek, J. A. Rosenthal, C. F. Gurrad, B. Kaysen, D. TI OUTCOMES OF AN RCT COMPARING TWO COPING SKILLS AMONG DUALLY DIAGNOSED INDIVIDUALS WITH ALCOHOL DEPENDENCE AND PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Simpson, T. L.; Stappenbeck, C. A.; Luterek, J. A.; Rosenthal, C. F.; Gurrad, B.; Kaysen, D.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 200 BP 299A EP 299A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637102084 ER PT J AU Lau, MK Meier, JL Gasper, W Lovett, DH Velez, PM Owens, CD AF Lau, Marcos K. Meier, Joy L. Gasper, Warren Lovett, David H. Velez, Pauline M. Owens, Christopher D. TI Renal Progression in the Advanced Chronic Kidney Disease Populations: Creation of the ESRD Prediction Scorecard SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting CY 2015 CL Chicago, IL C1 [Meier, Joy L.] VA Northern Calif Hlth Care Syst, Martinez, CA USA. [Gasper, Warren; Lovett, David H.; Owens, Christopher D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Velez, Pauline M.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 SU S MA RR15 BP 195S EP 195S PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CS2FS UT WOS:000361884200360 ER PT J AU Neuwelt, E Doolittle, N Knight, K Lindemulder, S AF Neuwelt, Edward Doolittle, Nancy Knight, Kristin Lindemulder, Susan TI USE OF IV N-ACETYLCYSTEINE IN COMBINATION WITH SODIUM THIOSULFATE FOR PREVENTION OF OTOTOXICITY IN PEDIATRIC PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 3rd Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research CY MAY 07-08, 2015 CL San Diego, CA C1 [Neuwelt, Edward; Doolittle, Nancy; Knight, Kristin; Lindemulder, Susan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Neuwelt, Edward] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD JUN PY 2015 VL 17 SU 3 MA TR-15 BP 40 EP 40 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CR4LV UT WOS:000361304800161 ER PT J AU Boyko, EJ Trone, DW Peterson, AV Jacobson, IG Littman, AJ Maynard, C Seelig, AD Crum-Cianflone, NF Bricker, JB AF Boyko, Edward J. Trone, Daniel W. Peterson, Arthur V. Jacobson, Isabel G. Littman, Alyson J. Maynard, Charles Seelig, Amber D. Crum-Cianflone, Nancy F. Bricker, Jonathan B. TI Longitudinal Investigation of Smoking Initiation and Relapse Among Younger and Older US Military Personnel SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; READJUSTMENT RATING-SCALE; DEPARTMENT-OF-DEFENSE; TOBACCO USE; CIGARETTE-SMOKING; UNITED-STATES; PROSPECTIVE COHORT; MILLENNIUM COHORT; SERVICE MEMBERS; BODY-WEIGHT AB Objectives. We examined whether military service, including deployment and combat experience, were related to smoking initiation and relapse. Methods. We included older (panel 1) and younger (panel 2) participants in the Millennium Cohort Study. Never smokers were followed for 3 to 6 years for smoking initiation, and former smokers were followed for relapse. Complementary log-log regression models estimated the relative risk (RR) of initiation and relapse by military exposure while adjusting for demographic, health, and lifestyle factors. Results. Deployment with combat experience predicted higher initiation rate (panel 1: RR = 1.44; 95% confidence interval [CI] = 1.28, 1.62; panel 2: RR = 1.26; 95% CI = 1.04, 1.54) and relapse rate (panel 1 only: RR = 1.48; 95% CI = 1.36, 1.62). Depending on the panel, previous mental health disorders, life stressors, and other military and nonmilitary characteristics independently predicted initiation and relapse. Conclusions. Deployment with combat experience and previous mental disorder may identify military service members in need of intervention to prevent smoking initiation and relapse. C1 [Boyko, Edward J.; Littman, Alyson J.; Seelig, Amber D.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Maynard, Charles] VA Eastern Colorado, VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev,VA Puget Sound Hlth Care Syst, Denver, CO USA. [Trone, Daniel W.; Jacobson, Isabel G.] Naval Hlth Res Ctr, Dept Def Ctr Deployment Hlth Res, San Diego, CA USA. [Crum-Cianflone, Nancy F.] Naval Med Ctr, San Diego, CA USA. [Peterson, Arthur V.; Bricker, Jonathan B.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Boyko, EJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,MS-152E, Seattle, WA 98108 USA. EM Edward.Boyko@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814; Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs Clinical Science Research and Development Program; Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command (Fort Detrick, MD); Career Development Award from the VA Rehabilitation Research and Development Program [CDA 6982]; VA Puget Sound Health Care System FX This study was funded by a Merit Review Award from the Department of Veterans Affairs Clinical Science Research and Development Program. The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the US Army Medical Research and Materiel Command (Fort Detrick, MD). A. J. Littman is supported by a Career Development Award from the VA Rehabilitation Research and Development Program (CDA 6982). The VA Puget Sound Health Care System provided support for C. Maynard's participation in this research. NR 38 TC 6 Z9 6 U1 2 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1220 EP 1229 DI 10.2105/AJPH.2014.302538 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800040 PM 25880953 ER PT J AU Godwin, BD Drake, FT Simianu, VV Shriki, JE Hippe, DS Dighe, M Bastawrous, S Cuevas, C Flum, D Bhargava, P AF Godwin, Benjamin D. Drake, Frederick T. Simianu, Vlad V. Shriki, Jabi E. Hippe, Daniel S. Dighe, Manjiri Bastawrous, Sarah Cuevas, Carlos Flum, David Bhargava, Puneet TI A Novel Reporting System to Improve Accuracy in Appendicitis Imaging SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE appendectomy; appendicitis; CT; standardized reporting ID LOWER QUADRANT PAIN; SUSPECTED ACUTE APPENDICITIS; COMPUTED-TOMOGRAPHY; HELICAL CT; NEGATIVE APPENDECTOMY; CLINICAL-OUTCOMES; DIAGNOSIS; CONTRAST; PERFORMANCE; PATIENT AB OBJECTIVE. The purpose of this study was to ascertain if standardized radiologic reporting for appendicitis imaging increases diagnostic accuracy. MATERIALS AND METHODS. We developed a standardized appendicitis reporting system that includes objective imaging findings common in appendicitis and a certainty score ranging from 1 (definitely not appendicitis) through 5 (definitely appendicitis). Four radiologists retrospectively reviewed the preoperative CT scans of 96 appendectomy patients using our reporting system. The presence of appendicitis-specific imaging findings and certainty scores were compared with final pathology. These comparisons were summarized using odds ratios (ORs) and the AUC. RESULTS. The appendix was visualized on CT in 89 patients, of whom 71 (80%) had pathologically proven appendicitis. Imaging findings associated with appendicitis included appendiceal diameter (odds ratio [OR] = 14 [> 10 vs < 6 mm]; p = 0.002), periappendiceal fat stranding (OR = 8.9; p < 0.001), and appendiceal mucosal hyperenhancement (OR = 8.7; p < 0.001). Of 35 patients whose initial clinical findings were reported as indeterminate, 28 (80%) had appendicitis. In this initially indeterminate group, using the standardized reporting system, radiologists assigned higher certainty scores (4 or 5) in 21 of the 28 patients with appendicitis (75%) and lower scores (1 or 2) in five of the seven patients without appendicitis (71%) (AUC = 0.90; p = 0.001). CONCLUSION. Standardized reporting and grading of objective imaging findings correlated well with postoperative pathology and may decrease the number of CT findings reported as indeterminate for appendicitis. Prospective evaluation of this reporting system on a cohort of patients with clinically suspected appendicitis is currently under way. C1 [Godwin, Benjamin D.; Shriki, Jabi E.; Hippe, Daniel S.; Dighe, Manjiri; Bastawrous, Sarah; Cuevas, Carlos; Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Drake, Frederick T.; Simianu, Vlad V.; Flum, David] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Shriki, Jabi E.; Bastawrous, Sarah] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Bhargava, P (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,UW Mailbox 357115, Seattle, WA 98195 USA. EM bhargp@uw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases training grant [5T32DK070555] FX V. V. Simianu and F. T. Drake are supported by a National Institute of Diabetes and Digestive and Kidney Diseases training grant (5T32DK070555). The Surgical Care and Outcomes Assessment Program (SCOAP) is a Coordinated Quality Improvement Program of the Foundation for Health Care Quality (FHCQ). NR 38 TC 1 Z9 1 U1 0 U2 0 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD JUN PY 2015 VL 204 IS 6 BP 1212 EP 1219 DI 10.2214/AJR.14.13512 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CQ2ZU UT WOS:000360472100033 PM 26001230 ER PT J AU Rivera-Barrios, AE Brown, S Reid, CM Hassanein, AH Coimbra, R Dobke, M Herrera, FA AF Rivera-Barrios, Angel E. Brown, Satara Reid, Christopher M. Hassanein, Aladdin H. Coimbra, Raul Dobke, Marek Herrera, Fernando A., Jr. TI Craniofacial Fracture Patterns in All Terrain Vehicle Injuries SO ANNALS OF PLASTIC SURGERY LA English DT Article; Proceedings Paper CT 57th Annual Meeting of the South6eastern-Society-of-Plastic-and-Reconstructive-Surgeons CY JUN 08-12, 2014 CL Nassau, BAHAMAS SP SE Soc Plast & Reconstruct Surg ID ACCIDENTS; CHILDREN AB Background A multicenter, retrospective study was conducted to determine the frequency and distribution of craniofacial fractures sustained from all terrain vehicle (ATV) accidents. Methods Medical records of all patients presenting to 2 trauma centers with ATV-related craniofacial trauma from 2001 to 2013 were reviewed. Patient notes and radiographic images were analyzed for detailed craniofacial injury data. The identified fractures were classified as: frontal/skullbase, naso-orbital, maxilla/zygoma, and mandible. In addition, patient demographic information, length of stay, airway status, intensive care unit stay, Glasgow coma scale, use of safety equipment, associated traumatic brain injury, and surgical intervention were compiled. Results One hundred fifty-six patients with craniofacial fractures secondary to ATV accidents presented from 2001 to 2013. The incidence of craniofacial fractures found in patients with ATV injuries was 12.2%. Sixty-one patients (39.1%) suffered frontal/skullbase fractures, 98 (62.8%) naso-orbital fractures, 62 (39.7%) maxillary/zygoma fractures, and 35 (22.4%) mandibular fractures. Forty-one patients (26.3%) required surgical intervention to correct their craniofacial injuries. Conclusions The most common craniofacial fractures experienced in ATV injuries are naso-orbital fractures. The correlation of nonuse of safety equipment and associated traumatic brain injuries displays the importance of using helmets when operating ATVs. Future studies can be conducted examining ATV-related upper extremity injuries, among others. C1 [Rivera-Barrios, Angel E.; Brown, Satara; Reid, Christopher M.; Hassanein, Aladdin H.; Coimbra, Raul; Dobke, Marek; Herrera, Fernando A., Jr.] Med Univ S Carolina, Ralph Johnson VA Med Ctr, Charleston, SC 29425 USA. [Rivera-Barrios, Angel E.; Brown, Satara; Reid, Christopher M.; Hassanein, Aladdin H.; Coimbra, Raul; Dobke, Marek; Herrera, Fernando A., Jr.] Univ Calif San Diego, San Diego, CA 92103 USA. RP Herrera, FA (reprint author), Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. EM herreraf@musc.edu NR 10 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-7043 EI 1536-3708 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD JUN PY 2015 VL 74 SU 4 BP S229 EP S230 DI 10.1097/SAP.0000000000000445 PG 2 WC Surgery SC Surgery GA CQ4IC UT WOS:000360567200011 PM 25695451 ER PT J AU Jackevicius, CA Co, MJ Warner, AL AF Jackevicius, Cynthia A. Co, Mary Joana Warner, Alberta L. TI Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome SO INTERNATIONAL JOURNAL OF PHARMACY PRACTICE LA English DT Article DE anaemia; anaemia of chronic kidney disease; congestive heart failure; CRAS; kidney failure ID CONGESTIVE-HEART-FAILURE; CHRONIC-RENAL-FAILURE; SUBCUTANEOUS ERYTHROPOIETIN; INTRAVENOUS IRON; UNITED-STATES; PATTERNS; DISEASE; HOSPITALIZATIONS; MEDICATIONS; MANAGEMENT AB Objectives Chronic kidney disease (CKD) and anemia are common in patients with heart failure (HF) - these 3 conditions have been coined the Cardiorenal Anemia Sydrome (CRAS). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines do not specifically address patients with CRAS, creating uncertainty in erythropoietin (EPO) prescribing. We sought to determine predictors of EPO use in patients with CRAS. Methods We conducted a retrospective cohort study at the Veteran's Affairs Greater Los Angeles Healthcare System (VAGLAHS), a 300+ bed facility that provides primary and tertiary inpatient, and ambulatory care services, between January 1, 2003 to December 31, 2006. A multiple logistic regression model was constructed to identify predictors of EPO use among CRAS patients. Key findings Of 2058 patients with CRAS, 213 (10.3%) were prescribed EPO. There were significant differences in baseline characteristics between the EPO and non-EPO groups. The following predictors were found to be associated with EPO prescription: iron supplementation (odds ratio [OR] 52.70, 95% confidence interval [CI] 11.70-237.46), renal clinic appointment (OR 2.60, 95% CI 1.79-3.76), malignancy (OR 1.52, 95% CI 1.07-2.16) and use of hydralazine/nitrates (OR 1.41, 95% CI 1.03-1.92). There was an inverse association found between EPO prescription and baseline hemoglobin (OR 0.61, 95% CI 0.53-0.70) and eGFR (OR 0.96, 95% CI 0.94-0.97). Conclusion A small proportion of patients eligible for EPO therapy according to guidelines at the time of the study were prescribed the indicated therapy. Markers of declining renal function or those suggesting need for anemia therapy were identified as EPO predictors. C1 [Jackevicius, Cynthia A.; Co, Mary Joana] Western Univ Hlth Sci, Pharm Practice & Adm Dept, Pomona, CA 91766 USA. [Jackevicius, Cynthia A.; Warner, Alberta L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Warner, Alberta L.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. [Co, Mary Joana] Providence St Joseph Med Ctr, Dept Pharm, Burbank, CA USA. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. RP Jackevicius, CA (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM cjackevicius@westernu.edu NR 28 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0961-7671 EI 2042-7174 J9 INT J PHARM PRACT JI Int. J. Pharm. Pract. PD JUN PY 2015 VL 23 IS 3 BP 199 EP 204 DI 10.1111/ijpp.12133 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CP2OS UT WOS:000359717300006 PM 24990704 ER PT J AU Klein, E AF Klein, Eran TI Eloquent Brain, Ethical Challenges: Functional Brain Mapping in Neurosurgery SO SEMINARS IN ULTRASOUND CT AND MRI LA English DT Article ID LOW-GRADE GLIOMAS; SURGERY; AREAS AB Functional brain mapping is an increasingly relied upon tool in presurgical planning and intraoperative decision making. Mapping allows personalization of structure-function relationships when surgical or other treatment of pathology puts eloquent functioning like language or vision at risk As an innovative technology, functional brain mapping holds great promise but also raises important ethical questions. In this article, recent work in neuroethics on functional imaging and functional neurosurgery is explored and applied to functional brain mapping. Specific topics discussed in this article are incidental findings, responsible innovation, and informed consent. (C) 2015 Elsevier Inc. All rights reserved. C1 [Klein, Eran] Portland VA Med Ctr, Neurol Serv, Portland, OR USA. [Klein, Eran] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Klein, Eran] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA. RP Klein, E (reprint author), Dept Vet Affairs, Med Ctr, Portland Div, 3710 SW US Vet Hosp Rd,POB 1034,P3 Neuro, Portland, OR 97207 USA. EM kleine@ohsu.edu NR 28 TC 1 Z9 1 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0887-2171 EI 1558-5034 J9 SEMIN ULTRASOUND CT JI Semin. Ultrasound CT MRI PD JUN PY 2015 VL 36 IS 3 BP 291 EP 295 DI 10.1053/j.sult.2015.05.009 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CO7IL UT WOS:000359332700008 PM 26233862 ER PT J AU Zwaan, L Singh, H AF Zwaan, Laura Singh, Hardeep TI The challenges in defining and measuring diagnostic error SO DIAGNOSIS LA English DT Article DE clinical decision-making; cognitive errors; diagnostic error; judgment; patient safety ID ADVERSE EVENTS; CELIAC-DISEASE; HEALTH-CARE; OVERDIAGNOSIS; MEDICINE; HINDSIGHT; RESPECT; TRENDS; CLAIMS; TIME AB Diagnostic errors have emerged as a serious patient safety problem but they are hard to detect and complex to define. At the research summit of the 2013 Diagnostic Error in Medicine 6th International Conference, we convened a multidisciplinary expert panel to discuss challenges in defining and measuring diagnostic errors in real-world settings. In this paper, we synthesize these discussions and outline key research challenges in operationalizing the definition and measurement of diagnostic error. Some of these challenges include 1) difficulties in determining error when the disease or diagnosis is evolving over time and in different care settings, 2) accounting for a balance between underdiagnosis and overaggressive diagnostic pursuits, and 3) determining disease diagnosis likelihood and severity in hindsight. We also build on these discussions to describe how some of these challenges can be addressed while conducting research on measuring diagnostic error. C1 [Zwaan, Laura] Erasmus MC, Inst Med Educ Res Rotterdam, Rotterdam, Netherlands. [Zwaan, Laura] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Singh, Hardeep] Baylor Coll Med, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Zwaan, L (reprint author), Erasmus MC, Inst Med Educ Res Rotterdam, Rotterdam, Netherlands. EM L.zwaan@erasmusmc.nl RI Zwaan, Laura/I-6473-2015 FU AHRQ HHS [R13 HS021774, R01 HS022087]; NCI NIH HHS [K23 CA125585] NR 41 TC 13 Z9 13 U1 2 U2 8 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD JUN PY 2015 VL 2 IS 2 BP 97 EP 103 DI 10.1515/dx-2014-0069 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CL9FD UT WOS:000357280400004 PM 26955512 ER PT J AU Kopacz, MS Hoffmire, CA Morley, SW Vance, CG AF Kopacz, Marek S. Hoffmire, Claire A. Morley, Sybil W. Vance, C. Garland TI Using a Spiritual Distress Scale to Assess Suicide Risk in Veterans: An Exploratory Study SO PASTORAL PSYCHOLOGY LA English DT Article DE Veterans; Chaplaincy services; Moral injury; Suicide ID INTERVENTION; COMBAT AB This exploratory study (1) examined the ability of a spiritual distress scale used by chaplains to identify Veterans with certain suicide risk factors and (2) provided an initial assessment of the reliability and validity of this scale to screen for Veterans at increased risk of suicide based on the presence of these risk factors. The scale consisted of five questions examining the presence or absence of guilt, sadness or grief, anger or resentment, despair or hopelessness, and feeling that life has no meaning or purpose. The scale was analyzed using Chronbach's alpha-coefficient, factor analysis, Student's t-tests, and logistic regression. Cut-off values were determined using the maximum Youden statistic. The five questions had a high level of internal consistency(alpha =0.88). Factor analysis suggested the presence of a common underlying factor, with correlations ranging from 0.42 to 0.78. Those identified with a suicide risk factor had significantly higher mean composite scores on this scale. Further, scores were significantly associated with increased odds of being identified with a suicide risk factor. A score >= 10 may be best suited for differentiating between individuals with and without certain suicide risk factors. This scale shows promise for identifying Veterans who may be at increased risk of suicide. C1 [Kopacz, Marek S.; Hoffmire, Claire A.; Morley, Sybil W.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Vance, C. Garland] US Dept Vet Affairs, Charles George VA Med Ctr, Asheville, NC 28805 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 28 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-2789 EI 1573-6679 J9 PASTOR PSYCHOL JI Pastor. Psychol. PD JUN PY 2015 VL 64 IS 3 BP 381 EP 390 DI 10.1007/s11089-014-0633-1 PG 10 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA CH8VV UT WOS:000354315100007 ER PT J AU Ricci, KA Griffin, AR Heslin, KC Kranke, D Dobalian, A AF Ricci, Karen A. Griffin, Anne R. Heslin, Kevin C. Kranke, Derrick Dobalian, Aram TI Evacuate or Shelter-in-place? The Role of Corporate Memory and Political Environment in Hospital-evacuation Decision Making SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE disasters; hospital evacuation; organizational culture; organizational decision making ID PUBLIC-HEALTH; DISASTERS; LESSONS; SANDY; CARE AB Problem: Hospital-evacuation decisions are rarely straightforward in protracted advance-warning events. Previous work provides little insight into the decision-making process around evacuation. This study was conducted to identify factors that most heavily influenced the decisions to evacuate the US Department of Veterans Affairs (VA) New York Harbor Healthcare System's (NYHHS; New York USA) Manhattan Campus before Hurricane Irene in 2011 and before Superstorm Sandy in 2012. Methods: Semi-structured interviews with 11 senior leaders were conducted on the processes and factors that influenced the evacuation decisions prior to each event. Results: The most influential factor in the decision to evacuate the Manhattan Campus before Hurricane Irene was New York City's (NYC's) hospital-evacuation mandate. As a federal facility, the Manhattan VA medical center (VAMC) was exempt from the city's order, but decision makers felt compelled to comply. In the case of Superstorm Sandy, corporate memory of a similar 1992 storm that crippled the Manhattan facility drove the decision to evacuate before the storm hit. Conclusions: Results suggest that hospital-evacuation decisions are confounded by political considerations and are influenced by past disaster experience. Greater shared situational awareness among at-risk hospitals, along with a more coordinated approach to evacuation decision making, could reduce pressure on hospitals to make these high-stakes decisions. Systematic mechanisms for collecting, documenting, and sharing lessons learned from past disasters are sorely needed at the institutional, local, and national levels. Ricci KA, Griffin AR, Heslin KC, Kranke D, Dobalian A. Evacuate or shelter-in-place? The role of corporate memory and political environment in hospital-evacuation decision making. C1 [Ricci, Karen A.; Griffin, Anne R.; Kranke, Derrick; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr VEMEC, North Hills, CA USA. [Ricci, Karen A.] RAND Corp, Santa Monica, CA USA. [Heslin, Kevin C.] US Dept HHS, Ctr Delivery Org & Markets CDOM, Agcy Healthcare Res & Qual, Rockville, MD USA. [Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Dobalian, A (reprint author), Vet Emergency Management Evaluat Ctr VEMEC, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. EM Aram.Dobalian@va.gov NR 27 TC 2 Z9 2 U1 7 U2 10 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD JUN PY 2015 VL 30 IS 3 BP 233 EP 238 DI 10.1017/S1049023X15000229 PG 6 WC Emergency Medicine SC Emergency Medicine GA CN4OP UT WOS:000358410000004 PM 25783663 ER PT J AU Reddy, A Canamucio, A Werner, RM AF Reddy, Ashok Canamucio, Anne Werner, Rachel M. TI Impact of the Patient-Centered Medical Home on Veterans' Experience of Care SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID QUALITY-OF-CARE; HEALTH-CARE; OUTCOMES; TRANSFORMATION; COMMUNICATION; SATISFACTION; SYSTEMS; COSTS AB Objectives: A core tenet of the patient-centered medical home is improving patient experiences of care, but evidence is limited on the impact of medical home adoption on patient experiences of care. Study Design: We conducted a repeated cross-sectional, patient-level analysis in 1 region of the Veterans Health Administration (VHA), which includes 56 primary care sites. Methods: Our primary outcomes include 5 domains of patient care experience from the Survey of Healthcare Experiences of Patients (SHEP). We used a linear probability model to test whether changes in medical home implementation are associated with changes in patient experience of care. Results: During the study period, 30,849 SHEP respondents received care. We observed significant increase in medical home implementation: a 10-fold increase in percentage of primary care providers who were part of a medical home, a 7-fold increase in 8 out of 9 structural measures of the medical home, and an increase in overall quality of medical home implementation. Yet, we found no association between medical home adoption and 5 domains of patient experience of care. For example, patients assigned to a medical home provider had a 0.51 percentage point (95% CI, -1.8 to 2.8) higher response in how well they communicate with their provider compared with patients not assigned to a medical provider and with patients in the pre-medical home period. Conclusions: Despite wide implementation of the medical home, we did not see an improvement in patient experiences of care in the VHA. As we focus on primary care transformation, we need to find ways to incorporate the patient's voice and input into these transitions. C1 [Reddy, Ashok; Canamucio, Anne; Werner, Rachel M.] Philadelphia VA Med Ctr, PACT, VISN Ctr Evaluat 4, Philadelphia, PA USA. [Reddy, Ashok; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Reddy, Ashok; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Reddy, Ashok] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. RP Reddy, A (reprint author), Univ Penn, Perelman Sch Med, Blockley Hall 1303,423 Guardian Dr, Philadelphia, PA 19104 USA. EM ashokr@upenn.edu FU Robert Wood Johnson Foundation Clinical Scholars Program; VA Office of Patient Care Services FX This work was supported by the Robert Wood Johnson Foundation Clinical Scholars Program. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. NR 30 TC 2 Z9 2 U1 5 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JUN PY 2015 VL 21 IS 6 BP 413 EP + PG 19 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN8BS UT WOS:000358662700008 PM 26168062 ER PT J AU Yin, SY Jin, WP De Salles, A AF Yin, Shaoya Jin, Weipeng De Salles, Antonio TI Occipital-device-related pain as a complication of deep brain stimulation SO BRITISH JOURNAL OF NEUROSURGERY LA English DT Article DE complication; deep brain stimulation; essential tremor; occipital pain; Parkinson's disease; reposition ID HARDWARE COMPLICATIONS; SURGERY; IMPLANTATION AB Deep brain stimulation is an established treatment for movement disorders. We reported 4 patients (1.3%) of postoperative occipital headache related to the placement of the connection among 309 patients from 1998 to 2008. The patients were treated successfully by repositioning the connector into a groove created in the bone. C1 [Yin, Shaoya; De Salles, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA. [Yin, Shaoya; De Salles, Antonio] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yin, Shaoya] Tianjin Huanhu Hosp, Neurol Cent Hosp Tianjin, Dept Neurosurg, Tianjin, Peoples R China. [Jin, Weipeng] Tianjin Med Univ, Hosp 2, Dept Neurosurg, Tianjin, Peoples R China. RP Yin, SY (reprint author), Dept Neurosurg, Neurosurg, 122 Qixiangtai Rd, Tianjin 300060, Peoples R China. EM yinsy@163.com NR 14 TC 0 Z9 0 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0268-8697 EI 1360-046X J9 BRIT J NEUROSURG JI Br. J. Neurosurg. PD JUN PY 2015 VL 29 IS 3 BP 340 EP 342 DI 10.3109/02688697.2014.1003031 PG 3 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CN7OY UT WOS:000358625100007 PM 25659960 ER PT J AU Dick, AW Pacula, RL Gordon, AJ Sorbero, M Burns, RM Leslie, D Stein, BD AF Dick, Andrew W. Pacula, Rosalie L. Gordon, Adam J. Sorbero, Mark Burns, Rachel M. Leslie, Douglas Stein, Bradley D. TI Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11 SO HEALTH AFFAIRS LA English DT Article ID SUBSTANCE-ABUSE TREATMENT; OFFICE-BASED TREATMENT; UNITED-STATES; USE DISORDER; ADDICTION TREATMENT; DEPENDENT PATIENTS; COST-EFFECTIVENESS; OPIATE ADDICTION; RISK BEHAVIORS; NONMEDICAL USE AB Opioid use disorders are a significant public health problem, affecting two million people in the United States. Treatment with buprenorphine, methadone, or both is predominantly offered in methadone clinics, yet many people do not receive the treatment they need. In 2002 the Food and Drug Administration approved buprenorphine for prescription by physicians who completed a course and received a waiver from the Drug Enforcement Administration, exempting them from requirements in the Controlled Substances Act. To determine the waiver program's impact on the availability of opioid agonist treatment, we analyzed data for the period 2002-11 to identify counties with opioid treatment shortages. We found that the percentage of counties with a shortage of waivered physicians fell sharply, from 98.9 percent in 2002 to 46.8 percent in 2011. As a result, the percentage of the US population residing in what we classified as opioid treatment shortage counties declined from 48.6 percent in 2002 to 10.4 percent in 2011. These findings suggest that the increase in waivered physicians has dramatically increased potential access to opioid agonist treatment. Policy makers should focus their efforts on further increasing the number and geographical distribution of physicians, particularly in more rural counties, where prescription opioid misuse is rapidly growing. C1 [Dick, Andrew W.] RAND Corp, Boston, MA 02116 USA. [Pacula, Rosalie L.] RAND, Santa Monica, CA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Med, Pittsburgh, PA 15260 USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sorbero, Mark; Burns, Rachel M.; Stein, Bradley D.] RAND, Pittsburgh, PA USA. [Leslie, Douglas] Penn State Coll Med, Publ Hlth Sci & Psychiat, Pittsburgh, PA USA. [Stein, Bradley D.] Univ Pittsburgh, Sch Med, Psychiat, Pittsburgh, PA 15260 USA. RP Dick, AW (reprint author), RAND Corp, Boston, MA 02116 USA. EM stein@rand.org FU National Institute on Drug Abuse of the National Institutes of Health [1R01DA032881-01A1] FX An earlier version on this article was presented at the Addiction Health Services Research conference in Portland, Oregon, October 23-25, 2013. Bradley Stein was previously an employee of Community Care Behavioral Health Organization, a nonprofit organization that manages behavioral health services for Medicaid enrollees in Pennsylvania. Stein has also served on an advisory board for Otsuka Pharmaceuticals. Adam Gordon receives royalties from Cambridge University Press and UptoDate for work unrelated to the topic of this article. The authors are indebted to Steve Mason of the Substance Abuse and Mental Health Services Administration for assistance with the Buprenorphine Waiver Notification System data; Mary Vaiana, Sebastian Bauhoff, Carrie Farmer, and Todd Mandell for review and Feedback on earlier versions of the manuscript; and Gina Boyd for research assistance The National Institute on Drug Abuse of the National Institutes of Health supported this study (Grant No 1R01DA032881-01A1). NR 57 TC 10 Z9 10 U1 5 U2 8 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUN PY 2015 VL 34 IS 6 BP 1028 EP 1034 DI 10.1377/hlthaff.2014.1205 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CN5EY UT WOS:000358453800018 PM 26056209 ER PT J AU McCormack, S Johnson, B Saunders, RH Jacobsen, PL Siegel, MA Friedlander, AH DeLuke, DM AF McCormack, Steve Johnson, Bart Saunders, Ralph H. Jacobsen, Peter L. Siegel, Michael A. Friedlander, Arthur H. DeLuke, Dean M. TI PROPHYLACTIC ANTIBIOTICS SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Editorial Material C1 [Johnson, Bart] Swedish Gen Practice Residency, Seattle, WA USA. [Saunders, Ralph H.] Univ Rochester, Eastman Inst Oral Hlth, Rochester, NY USA. [Jacobsen, Peter L.] Univ Pacific, San Francisco, CA USA. [Siegel, Michael A.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [DeLuke, Dean M.] Virginia Commonwealth Univ, Sch Dent, Richmond, VA USA. [DeLuke, Dean M.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JUN PY 2015 VL 146 IS 6 BP 357 EP 358 DI 10.1016/j.adaj.2015.04.019 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CN6CZ UT WOS:000358522500002 ER PT J AU Wilson, PC Fitzgibbon, WR Garrett, SM Jaffa, AA Luttrell, LM Brands, MW El-Shewy, HM AF Wilson, Parker C. Fitzgibbon, Wayne R. Garrett, Sara M. Jaffa, Ayad A. Luttrell, Louis M. Brands, Michael W. El-Shewy, Hesham M. TI Inhibition of Sphingosine Kinase 1 Ameliorates Angiotensin II-Induced Hypertension and Inhibits Transmembrane Calcium Entry via Store-Operated Calcium Channel SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; CA2+ ENTRY; CELL-PROLIFERATION; SIGNALING PATHWAYS; BASILAR ARTERIES; VASCULAR-TONE; IN-VITRO; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; 1-PHOSPHATE AB Angiotensin II (AngII) plays a critical role in the regulation of vascular tone and blood pressure mainly via regulation of Ca2+ mobilization. Several reports have implicated sphingosine kinase 1 (SK1)/sphingosine 1-phosphate (S1P) in the mobilization of intracellular Ca2+ through a yet-undefined mechanism. Here we demonstrate that AngII-induces biphasic calcium entry in vascular smooth muscle cells, consisting of an immediate peak due to inositol tris-phosphate-dependent release of intracellular calcium, followed by a sustained transmembrane Ca2+ influx through store-operated calcium channels (SOCs). Inhibition of SK1 attenuates the second phase of transmembrane Ca2+ influx, suggesting a role for SK1 in AngII-dependent activation of SOC. Intracellular S1P triggers SOC-dependent Ca2+ influx independent of S1P receptors, whereas external application of S1P stimulated S1P receptor-dependent Ca2+ influx that is insensitive to inhibitors of SOCs, suggesting that the SK1/S1P axis regulates store-operated calcium entry via intracellular rather than extracellular actions. Genetic deletion of SK1 significantly inhibits both the acute hypertensive response to AngII in anaesthetized SK1 knockout mice and the sustained hypertensive response to continuous infusion of AngII in conscious animals. Collectively these data implicate SK1 as the missing link that connects the angiotensin AT1A receptor to transmembrane Ca2+ influx and identify SOCs as a potential intracellular target for SK1. C1 [Wilson, Parker C.] Yale New Haven Med Ctr, Dept Pathol, New Haven, CT 06510 USA. [Fitzgibbon, Wayne R.; Garrett, Sara M.; Jaffa, Ayad A.; Luttrell, Louis M.; El-Shewy, Hesham M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Dept Res Serv, Charleston, SC 29401 USA. [Brands, Michael W.] Georgia Hlth Sci Univ, Dept Physiol, Med Coll Georgia, Augusta, GA 30912 USA. [Jaffa, Ayad A.] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut 1136044, Lebanon. RP El-Shewy, HM (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St,MSC 776, Charleston, SC 29425 USA. EM elshewy@musc.edu FU National Institutes of Health COBRE in Lipidomics and Pathobiology at Medical University of South Carolina; National Institutes of Health [DK55524, S10 RR027777, HL077192, HL087986]; Dialysis Clinics Inc Grant FX This work was supported by National Institutes of Health COBRE in Lipidomics and Pathobiology at Medical University of South Carolina (to H.M.E.), National Institutes of Health Grants DK55524, S10 RR027777 (to L.M.L.), HL077192, and HL087986 (to A.A.J.), and Dialysis Clinics Inc Grant (to W.R.F.). NR 49 TC 4 Z9 4 U1 0 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD JUN PY 2015 VL 29 IS 6 BP 896 EP 908 DI 10.1210/me.2014-1388 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN6HA UT WOS:000358534000010 PM 25871850 ER PT J AU Demirjian, A Lucas, CE Garrison, LE Kozak-Muiznieks, NA States, S Brown, EW Wortham, JM Beaudoin, A Casey, ML Marriott, C Ludwig, AM Sonel, AF Muder, RR Hicks, LA AF Demirjian, Alicia Lucas, Claressa E. Garrison, Laurel E. Kozak-Muiznieks, Natalia A. States, Stanley Brown, Ellen W. Wortham, Jonathan M. Beaudoin, Amanda Casey, Megan L. Marriott, Chandra Ludwig, Alison M. Sonel, Ali F. Muder, Robert R. Hicks, Lauri A. TI The Importance of Clinical Surveillance in Detecting Legionnaires' Disease Outbreaks: A Large Outbreak in a Hospital With a Legionella Disinfection System-Pennsylvania, 2011-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Legionnaires' disease; Legionella pneumophila; healthcare-acquired infection; disinfectants; infection control ID COPPER-SILVER IONIZATION; SEQUENCE-BASED SCHEME; WATER; PNEUMOPHILA; CONSTRUCTION; EXPERIENCE; PNEUMONIA; FOUNTAIN; IONS; GENE AB Background. Healthcare-associated Legionnaires' disease (LD) is a preventable pneumonia with a 30% case fatality rate. The Centers for Disease Control and Prevention guidelines recommend a high index of suspicion for the diagnosis of healthcare-associated LD. We characterized an outbreak and evaluated contributing factors in a hospital using copper-silver ionization for prevention of Legionella growth in water. Methods. Through medical records review at a large, urban tertiary care hospital in November 2012, we identified patients diagnosed with LD during 2011-2012. Laboratory-confirmed cases were categorized as definite, probable, and not healthcare associated based on time spent in the hospital during the incubation period. We performed an environmental assessment of the hospital, including collection of samples for Legionella culture. Clinical and environmental isolates were compared by genotyping. Copper and silver ion concentrations were measured in 11 water samples. Results. We identified 5 definite and 17 probable healthcare-associated LD cases; 6 case patients died. Of 25 locations (mostly potable water) where environmental samples were obtained for Legionella-specific culture, all but 2 showed Legionella growth; 11 isolates were identical to 3 clinical isolates by sequence-based typing. Mean copper and silver concentrations were at or above the manufacturer's recommended target for Legionella control. Despite this, all samples where copper and silver concentrations were tested showed Legionella growth. Conclusions. This outbreak was linked to the hospital's potable water system and highlights the importance of maintaining a high index of suspicion for healthcare-associated LD, even in the setting of a long-term disinfection program. C1 [Demirjian, Alicia; Wortham, Jonathan M.; Beaudoin, Amanda; Ludwig, Alison M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30309 USA. [Demirjian, Alicia; Lucas, Claressa E.; Garrison, Laurel E.; Kozak-Muiznieks, Natalia A.; Brown, Ellen W.; Wortham, Jonathan M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30309 USA. [States, Stanley] Pittsburgh Water & Sewer Author, Pittsburgh, PA USA. [Beaudoin, Amanda] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Casey, Megan L.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA. [Marriott, Chandra] Penn Dept Hlth, Pittsburgh, PA USA. [Ludwig, Alison M.] VA Off Publ Hlth Surveillance & Res, Palo Alto, CA USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Demirjian, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30309 USA. EM alicia.demirjian@post.harvard.edu NR 32 TC 16 Z9 16 U1 2 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1596 EP 1602 DI 10.1093/cid/civ153 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500007 PM 25722201 ER PT J AU Seremwe, M Schnellmann, RG Bollag, WB AF Seremwe, Mutsa Schnellmann, Rick G. Bollag, Wendy B. TI Calpain-10 Activity Underlies Angiotensin II-Induced Aldosterone Production in an Adrenal Glomerulosa Cell Model SO ENDOCRINOLOGY LA English DT Article ID SKELETAL-MUSCLE; SECRETION; CALCIUM; INHIBITOR; SYSTEM; DYSFUNCTION; EXPRESSION; INFLUX; LINES AB Aldosterone is a steroid hormone important in the regulation of blood pressure. Aberrant production of aldosterone results in the development and progression of diseases including hypertension and congestive heart failure; therefore, a complete understanding of aldosterone production is important for developing more effective treatments. Angiotensin II (AngII) regulates steroidogenesis, in part through its ability to increase intracellular calcium levels. Calcium can activate calpains, proteases classified as typical or atypical based on the presence or absence of penta-EF-hands, which are involved in various cellular responses. We hypothesized that calpain, in particular calpain-10, is activated by AngII in adrenal glomerulosa cells and underlies aldosterone production. Our studies showed that pan-calpain inhibitors reduced AngII-induced aldosterone production in 2 adrenal glomerulosa cell models, primary bovine zona glomerulosa and human adrenocortical carcinoma (HAC15) cells, as well as CYP11B2 expression in the HAC15 cells. Although AngII induced calpain activation in these cells, typical calpain inhibitors had no effect on AngII-elicited aldosterone production, suggesting a lack of involvement of classical calpains in this process. However, an inhibitor of the atypical calpain, calpain-10, decreased AngII-induced aldosterone production. Consistent with this result, small interfering RNA (siRNA)-mediated knockdown of calpain-10 inhibited aldosterone production and CYP11B2 expression, whereas adenovirus-mediated overexpression of calpain-10 resulted in increased AngII-induced aldosterone production. Our results indicate that AngII-induced activation of calpain-10 in glomerulosa cells underlies aldosterone production and identify calpain-10 or its downstream pathways as potential targets for the development of drug therapies for the treatment of hypertension. C1 [Bollag, Wendy B.] Charlie Norwood Vet Adm Med Ctr, Augusta, GA 30904 USA. [Seremwe, Mutsa; Bollag, Wendy B.] Georgia Regents Univ, Dept Physiol, Augusta, GA 30912 USA. [Bollag, Wendy B.] Georgia Regents Univ, Dermatol Sect, Dept Med, Augusta, GA 30912 USA. [Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Bollag, WB (reprint author), Georgia Regents Univ, Med Coll Georgia, Dept Physiol, 1120 15th St, Augusta, GA 30912 USA. EM WB@gru.edu FU National Institutes of Health [HL070046, GM084147, ES012239]; Veterans Affairs Merit Review Award [BX001344, BX000851] FX This work was supported in part by the National Institutes of Health Grant HL070046 and Veterans Affairs Merit Review Award BX001344 (to W.B.B.) and by National Institutes of Health Grants GM084147 and ES012239 and Veterans Affairs Merit Review Award BX000851 (to R.G.S.). W.B.B. is also supported by a Veterans Affairs Research Career Scientist award. NR 34 TC 0 Z9 0 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JUN PY 2015 VL 156 IS 6 BP 2138 EP 2149 DI 10.1210/en.2014-1866 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CN4YB UT WOS:000358435400022 PM 25836666 ER PT J AU Restrepo, MI Keyt, H Reyes, LF AF Restrepo, Marcos I. Keyt, Holly Reyes, Luis F. TI Aerosolized Antibiotics SO RESPIRATORY CARE LA English DT Article DE aerosols; antibacterial agents; cystic fibrosis (CF); bronchiectasis; ventilator-associated pneumonia (VAP) ID VENTILATOR-ASSOCIATED PNEUMONIA; CYSTIC FIBROSIS BRONCHIECTASIS; INHALED AZTREONAM LYSINE; TOBRAMYCIN INHALATION POWDER; CHRONIC BRONCHIAL INFECTION; INTENSIVE-CARE-UNIT; PSEUDOMONAS-AERUGINOSA; ACQUIRED PNEUMONIA; RESPIRATORY-TRACT; NEBULIZED CEFTAZIDIME AB Administration of medications via aerosolization is potentially an ideal strategy to treat airway diseases. This delivery method ensures high concentrations of the medication in the targeted tissues, the airways, with generally lower systemic absorption and systemic adverse effects. Aerosolized antibiotics have been tested as treatment for bacterial infections in patients with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and ventilator-associated pneumonia (VAP). The most successful application of this to date is treatment of infections in patients with CF. It has been hypothesized that similar success would be seen in NCFB and in difficult-to-treat hospital-acquired infections such as VAP. This review summarizes the available evidence supporting the use of aerosolized antibiotics and addresses the specific considerations that clinicians should recognize when prescribing an aerosolized antibiotic for patients with CF, NCFB, and VAP. C1 [Restrepo, Marcos I.; Keyt, Holly; Reyes, Luis F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Reyes, Luis F.] Univ La Sabana, Bogota, Colombia. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, 11C6,7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu FU National Institutes of Health Grant from the National Heart, Lung, and Blood Institute [K23HL096054] FX Dr Restrepo was partially supported by National Institutes of Health Grant K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The funding agencies had no role in the preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 72 TC 2 Z9 3 U1 0 U2 8 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUN PY 2015 VL 60 IS 6 BP 762 EP 771 DI 10.4187/respcare.04208 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CM8IY UT WOS:000357944400002 PM 26070573 ER PT J AU Menatti, AR DeBoer, LBH Weeks, JW Heimberg, RG AF Menatti, Andrew R. DeBoer, Lindsey B. Hopkins Weeks, Justin W. Heimberg, Richard G. TI Social anxiety and associations with eating psychopathology: Mediating effects of fears of evaluation SO BODY IMAGE LA English DT Article DE Social anxiety; Eating disorders; Fear of negative evaluation; Fear of positive evaluation; Social-evaluative concerns; Body image ID NEGATIVE-EVALUATION-SCALE; POSITIVE EVALUATION SCALE; PSYCHOMETRIC EVALUATION; BULIMIA-NERVOSA; PHOBIA SCALE; DISORDERS; COMORBIDITY; VALIDATION; PREVALENCE; ANOREXIA AB Recent work suggests unique relations among features of social anxiety disorder and eating disorder pathology. Thus, it may be important to determine specific facets of social anxiety that account for the relation between it and eating disorders. Given the similarities in social-evaluative concerns in both sets of symptoms, we hypothesized that fears of both positive and negative evaluation would each independently account for the relationship between social anxiety symptoms and eating pathology among college females (N=167). Results were partially supportive of hypotheses. Fear of negative evaluation independently accounted for a significant portion of the relationship between social anxiety and each domain of eating pathology that was tested, which included Drive for Thinness, Body Dissatisfaction, and Bulimic Symptoms. Body mass index appeared to play a moderating role on the relationship between fear of negative evaluation and body dissatisfaction, but not drive for thinness or bulimia symptoms. Clinical implications including diagnostic and treatment considerations will be discussed. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Menatti, Andrew R.; Weeks, Justin W.] Ohio Univ, Ctr Evaluat & Treatment Anxiety, Athens, OH 45701 USA. [DeBoer, Lindsey B. Hopkins] San Francisco VA Med Ctr, San Francisco, CA USA. [Heimberg, Richard G.] Temple Univ, Philadelphia, PA 19122 USA. RP Weeks, JW (reprint author), 200 Porter Hall, Athens, OH USA. EM weeksj@ohio.edu RI Hopkins, Lindsey/D-4408-2015 OI Hopkins, Lindsey/0000-0002-0577-2961 NR 56 TC 5 Z9 5 U1 3 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1740-1445 EI 1873-6807 J9 BODY IMAGE JI Body Image PD JUN PY 2015 VL 14 BP 20 EP 28 DI 10.1016/j.bodyim.2015.02.003 PG 9 WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary SC Psychology; Psychiatry GA CL8MJ UT WOS:000357228500004 PM 25867525 ER PT J AU Muir, ER Chandra, SB De La Garza, BH Velagapudi, C Abboud, HE Duong, TQ AF Muir, Eric R. Chandra, Saurav B. De La Garza, Bryan H. Velagapudi, Chakradhar Abboud, Hanna E. Duong, Timothy Q. TI Layer-Specific Manganese-Enhanced MRI of the Diabetic Rat Retina in Light and Dark Adaptation at 11.7 Tesla SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE ultra high-resolution MRI; high field; MRI contrast agents; light and dark adaptation; visual stimulation; manganese; MEMRI; photoreceptors; diabetic retinopathy ID CHOROIDAL BLOOD-FLOW; MOUSE MODEL; OXYGEN-CONSUMPTION; FUNCTIONAL MRI; OUTER RETINA; CAT RETINA; RETINOPATHY; DYSFUNCTION; METABOLISM; RESOLUTION AB PURPOSE. To employ high-resolution manganese-enhanced MRI (MEMRI) to study abnormal calcium activity in different cell layers in streptozotocin-induced diabetic rat retinas, and to determine whether MEMRI detects changes at earlier time points than previously reported. METHODS. Sprague-Dawley rats were studied 14 days (n = 8) and 30 days (n = 5) after streptozotocin (STZ) or vehicle (n = 7) injection. Manganese-enhanced MRI at 20 x 20 x 700 mu m, in which contrast is based on manganese as a calcium analogue and an MRI contrast agent, was obtained in light and dark adaptation of the retina in the same animals in which one eye was covered and the fellow eye was not. The MEMRI activity encoding of the light and dark adaptation was achieved in awake conditions and imaged under anesthesia. RESULTS. Manganese-enhanced MRI showed three layers, corresponding to the inner retina, outer retina, and the choroid. In normal animals, the outer retina showed higher MEMRI activity in dark compared to light; the inner retina displayed lower activity in dark compared to light; and the choroid showed no difference in activity. Manganese-enhanced MRI activity changed as early as 14 days after hyperglycemia and decreased with duration of hyperglycemia in the outer retina in dark relative to light adaptation. The choroid also had altered MEMRI activity at 14 days, which returned to normal by 30 days. No differences in MEMRI activity were detected in the inner retina. CONCLUSIONS. Manganese-enhanced MRI detects progressive reduction in calcium activity with duration of hyperglycemia in the outer retina as early as 14 days after hyperglycemia, earlier than any other time point reported in the literature. C1 [Muir, Eric R.; Chandra, Saurav B.; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [Velagapudi, Chakradhar; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu FU National Institutes of Health/National Eye Institute [R01 EY014211, EY018855, EY021173]; MERIT Award from the Department of Veterans Affairs; Clinical Translational Science Award (CTSA) [UL1 TR001120] FX Supported in part by the National Institutes of Health/National Eye Institute (R01 EY014211, EY018855, and EY021173), a MERIT Award from the Department of Veterans Affairs, and a Pilot Award, Translational Technology Research Award from the Clinical Translational Science Award (CTSA, Parent Grant UL1 TR001120). NR 34 TC 3 Z9 3 U1 0 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 6 BP 4006 EP 4012 DI 10.1167/iovs.14-16128 PG 7 WC Ophthalmology SC Ophthalmology GA CM5PJ UT WOS:000357740200066 PM 26098468 ER PT J AU Gleason, CE Dowling, NM Wharton, W Manson, JE Miller, VM Atwood, CS Brinton, EA Cedars, MI Lobo, RA Merriam, GR Neal-Perry, G Santoro, NF Taylor, HS Black, DM Budoff, MJ Hodis, HN Naftolin, F Harman, SM Asthana, S AF Gleason, Carey E. Dowling, N. Maritza Wharton, Whitney Manson, JoAnn E. Miller, Virginia M. Atwood, Craig S. Brinton, Eliot A. Cedars, Marcelle I. Lobo, Rogerio A. Merriam, George R. Neal-Perry, Genevieve Santoro, Nanette F. Taylor, Hugh S. Black, Dennis M. Budoff, Matthew J. Hodis, Howard N. Naftolin, Frederick Harman, S. Mitchell Asthana, Sanjay TI Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study SO PLOS MEDICINE LA English DT Article ID CONJUGATED EQUINE ESTROGENS; MINI-MENTAL-STATE; HEALTH INITIATIVE MEMORY; PROGESTERONE-INDUCED NEUROPROTECTION; ANDROGEN REPLACEMENT THERAPY; SURGICALLY MENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; CONTROLLED-TRIAL; PLUS PROGESTIN; MEDROXYPROGESTERONE ACETATE AB Background Menopausal hormone therapy (MHT) reportedly increases the risk of cognitive decline in women over age 65 y. It is unknown whether similar risks exist for recently postmenopausal women, and whether MHT affects mood in younger women. The ancillary Cognitive and Affective Study (KEEPS-Cog) of the Kronos Early Estrogen Prevention Study (KEEPS) examined the effects of up to 4 y of MHT on cognition and mood in recently postmenopausal women. Methods and Findings KEEPS, a randomized, double-blinded, placebo-controlled clinical trial, was conducted at nine US academic centers. Of the 727 women enrolled in KEEPS, 693 (95.3%) participated in the ancillary KEEPS-Cog, with 220 women randomized to receive 4 y of 0.45 mg/d oral conjugated equine estrogens (o-CEE) plus 200 mg/d micronized progesterone (m-P) for the first 12 d of each month, 211 women randomized to receive 50 mu g/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the first 12 d of each month, and 262 women randomized to receive placebo pills and patches. Primary outcomes included the Modified Mini-Mental State examination; four cognitive factors: verbal learning/memory, auditory attention/working memory, visual attention/executive function, and speeded language/mental flexibility; and a mood measure, the Profile of Mood States (POMS). MHT effects were analyzed using linear mixed-effects (LME) models, which make full use of all available data from each participant, including those with missing data. Data from those with and without full data were compared to assess for potential biases resulting from missing observations. For statistically significant results, we calculated effect sizes (ESs) to evaluate the magnitude of changes. On average, participants were 52.6 y old, and 1.4 y past their last menstrual period. By month 48, 169 (24.4%) and 158 (22.8%) of the 693 women who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cognitive factors) and mood evaluations (POMS), respectively. However, because LME models make full use all available data, including data from women with missing data, 95.5% of participants were included in the final analysis (n = 662 in cognitive analyses, and n = 661 in mood analyses). To be included in analyses, women must have provided baseline data, and data from at least one post-baseline visit. The mean length of follow-up was 2.85 y (standard deviation [SD] = 0.49) for cognitive outcomes and 2.76 (SD = 0.57) for mood outcomes. No treatment-related benefits were found on cognitive outcomes. For mood, model estimates indicated that women treated with o-CEE showed improvements in depression and anxiety symptoms over the 48 mo of treatment, compared to women on placebo. The model estimate for the depression subscale was -5.36 x 10(-2) (95% CI, -8.27 x 10(-2) to -2.44 x 10(-2); ES = 0.49, p < 0.001) and for the anxiety subscale was -3.01 x 10(-2) (95% CI, -5.09 x 10(-2) to -9.34 x 10(-3); ES = 0.26, p < 0.001). Mood outcomes for women randomized to t-E2 were similar to those for women on placebo. Importantly, the KEEPS-Cog results cannot be extrapolated to treatment longer than 4 y. Conclusions The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. However, beneficial mood effects with small to medium ESs were noted with 4 y of o-CEE, but not with 4 y of t-E2. The generalizability of these findings is limited to recently postmenopausal women with low cardiovascular risk profiles. C1 [Gleason, Carey E.; Dowling, N. Maritza; Wharton, Whitney; Atwood, Craig S.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Gleason, Carey E.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Gleason, Carey E.; Dowling, N. Maritza; Atwood, Craig S.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Wharton, Whitney] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Wharton, Whitney] Emory Alzheimers Dis Res Ctr, Atlanta, GA USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Prevent Med, Sch Med, Boston, MA 02115 USA. [Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA. [Brinton, Eliot A.] Utah Fdn Biomed Res, Salt Lake City, UT USA. [Cedars, Marcelle I.] Univ Calif San Francisco, Obstet & Gynecol, San Francisco, CA 94143 USA. [Lobo, Rogerio A.] Columbia Univ Coll Phys & Surg, Obstet & Gynecol, New York, NY 10032 USA. [Merriam, George R.] VA Puget Sound Hlth Care Syst, Tacoma, WA USA. [Merriam, George R.] Univ Washington, Div Metab Endocrinol & Nutr, Tacoma, WA USA. [Neal-Perry, Genevieve] Albert Einstein Coll Med, Neurosci & Obstet & Gynecol, Bronx, NY 10467 USA. [Santoro, Nanette F.] Univ Colorado, Sch Med, Obstet & Gynecol, Aurora, CO USA. [Taylor, Hugh S.] Yale Univ, Sch Med, Obstet & Gynecol, New Haven, CT USA. [Black, Dennis M.] Univ Calif San Francisco, Epidemiol & Biostat, San Francisco, CA 94143 USA. [Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Cardiol, Torrance, CA 90509 USA. [Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA. [Naftolin, Frederick] NYU, Sch Med, Obstet & Gynecol, New York, NY USA. [Harman, S. Mitchell] Kronos Longev Res Inst, Phoenix, AZ USA. [Harman, S. Mitchell] Phoenix VA Med Ctr, Div Endocrinol, Phoenix, AZ USA. RP Gleason, CE (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM ceg@medicine.wisc.edu FU National Institutes of Health (NIH) from the Clinical and Translational Science Award (CTSA) program of the NIH National Center for Research Resources [R01 AG029624, P50AG033514, R01AG031790, 1UL1RR025011]; Wisconsin National Primate Research Center base grant, NIH [NCRR000167]; Aurora Foundation; National Institutes of Health (NIH) [HL90639]; Einstein College of Medicine; CTSA [UL1 RR025750, KL2 RR025749, TL1 RR025748, UL1 RR024139]; Mayo CTSA [1 UL1 RR024150]; Mayo Foundation; Brigham and Women's Hospital/Harvard Medical School CTSA; UCSF CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024131]; NIH Roadmap for Medical Research; Madison VA; VA Puget Sound Health Care System FX The KEEPS-Cog project was supported by grants from the National Institutes of Health (NIH) R01 AG029624, P50AG033514, R01AG031790, grant 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the NIH National Center for Research Resources and the Wisconsin National Primate Research Center base grant, NIH NCRR000167. The Parent KEEPS trial was funded by grants from the Aurora Foundation to the Kronos Longevity Research Institute, National Institutes of Health (NIH) HL90639 to VMM, Einstein College of Medicine, CTSA UL1 RR025750, KL2 RR025749 and TL1 RR025748, Mayo CTSA 1 UL1 RR024150, the Mayo Foundation, Brigham and Women's Hospital/Harvard Medical School CTSA, CTSA UL1 RR024139 and UCSF CTSA UL1 RR024131 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Additional support provided by resources and facilities of the Madison VA, and the VA Puget Sound Health Care System. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov. Bayer HealthCare Pharmaceuticals, Inc. supplied the CLIMARA estradiol and placebo patches and Abbott Laboratories (formerly Solvay Pharmaceuticals) provided the micronized progesterone (PROMETRIUM) and placebo capsules. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 78 TC 43 Z9 44 U1 2 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JUN PY 2015 VL 12 IS 6 AR e1001833 DI 10.1371/journal.pmed.1001833 PG 25 WC Medicine, General & Internal SC General & Internal Medicine GA CM0UY UT WOS:000357395500002 PM 26035291 ER PT J AU Kerlikowske, K Gard, CC Sprague, BL Tice, JA Miglioretti, DL AF Kerlikowske, Karla Gard, Charlotte C. Sprague, Brian L. Tice, Jeffrey A. Miglioretti, Diana L. CA Breast Canc Surveillance Consortiu TI One versus Two Breast Density Measures to Predict 5-and 10-Year Breast Cancer Risk SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID MAMMOGRAPHIC DENSITY; SCREENING MAMMOGRAPHY; WOMEN; MODEL; RECLASSIFICATION; REPRODUCIBILITY; VALIDATION; REDUCTION; CHOICE; MARKER AB Background: One measure of Breast Imaging Reporting and Data System (BI-RADS) breast density improves 5-year breast cancer risk prediction, but the value of sequential measures is unknown. We determined whether two BI-RADS density measures improve the predictive accuracy of the Breast Cancer Surveillance Consortium 5-year risk model compared with one measure. Methods: We included 722,654 women of ages 35 to 74 years with two mammograms with BI-RADS density measures on average 1.8 years apart; 13,715 developed invasive breast cancer. We used Cox regression to estimate the relative hazards of breast cancer for age, race/ethnicity, family history of breast cancer, history of breast biopsy, and one or two density measures. We developed a risk prediction model by combining these estimates with 2000-2010 Surveillance, Epidemiology, and End Results incidence and 2010 vital statistics for competing risk of death. Results: The two-measure density model had marginally greater discriminatory accuracy than the one-measure model (AUC, 0.640 vs. 0.635). Of 18.6% of women (134,404 of 722,654) who decreased density categories, 15.4% (20,741 of 134,404) of women whose density decreased from heterogeneously or extremely dense to a lower density category with one other risk factor had a clinically meaningful increase in 5-year risk from <1.67% with the one-density model to >= 1.67% with the two-density model. Conclusion: The two-density model has similar overall discrimination to the one-density model for predicting 5-year breast cancer risk and improves risk classification for women with risk factors and a decrease in density. Impact: A two-density model should be considered for women whose density decreases when calculating breast cancer risk. (C)2015 AACR. C1 [Kerlikowske, Karla; Tice, Jeffrey A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla; Tice, Jeffrey A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Gard, Charlotte C.] New Mexico State Univ, Dept Econ Appl Stat & Int Business, Las Cruces, NM 88003 USA. [Sprague, Brian L.] Univ Vermont, Dept Surg, Burlington, VT 05405 USA. [Sprague, Brian L.] Univ Vermont, Vermont Canc Ctr, Burlington, VT USA. [Miglioretti, Diana L.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Miglioretti, Diana L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Karla.Kerlikowske@ucsf.edu FU National Cancer Institute [P01 CA154292, HHSN261201100031C, U54 CA163303] FX This work was supported by the National Cancer Institute-funded Breast Cancer Surveillance Consortium (P01 CA154292 and HHSN261201100031C to K. Kerlikowske, B.L. Sprague, and D.L. Miglioretti) and U54 CA163303 to B.L. Sprague. The collection of cancer data used in this study was supported, in part, by several state public health departments and cancer registries throughout the U.S. For a full description of these sources, please see: http://breastscreening.cancer.gov/work/acknowledgement.html. NR 37 TC 1 Z9 1 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JUN PY 2015 VL 24 IS 6 BP 889 EP 897 DI 10.1158/1055-9965.EPI-15-0035 PG 9 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CM1FB UT WOS:000357425200001 PM 25824444 ER PT J AU Douketis, J Spyropoulos, A Kaatz, S Caprini, J Dunn, A Garcia, D Jacobson, A Jaffer, A Kindzelski, A Schulman, S Turpie, AG Becker, R Clark, NP Conti, B Ellsworth, S Harrison, RW Kong, D Johnson, G Krishnamoorthy, A Palmeri, S Parker, W Saucedo, J Schoch, P Tallman, D Witt, D Hasselblad, V Ortel, TL AF Douketis, J. Spyropoulos, A. Kaatz, S. Caprini, J. Dunn, A. Garcia, D. Jacobson, A. Jaffer, A. Kindzelski, A. Schulman, S. Turpie, A. G. Becker, R. Clark, N. P. Conti, B. Ellsworth, S. Harrison, R. W. Kong, D. Johnson, G. Krishnamoorthy, A. Palmeri, S. Parker, W. Saucedo, J. Schoch, P. Tallman, D. Witt, D. Hasselblad, V Ortel, T. L. CA BRIDGE Study Investigators TI Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial) SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Douketis, J.] St Josephs Healthcare, Hamilton, ON, Canada. [Douketis, J.; Turpie, A. G.] McMaster Univ, Hamilton, ON, Canada. [Spyropoulos, A.; Ortel, T. L.] Lenox Hill Hosp, North Shore LIJ Hlth Syst, Hofstra North Shore LIJ Sch Med, New York, NY 10021 USA. [Kaatz, S.; Ortel, T. L.] Hurley Med Ctr, Flint, MI USA. [Caprini, J.] North Shore Univ Hlth Syst, New York, NY USA. [Dunn, A.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Garcia, D.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Jacobson, A.] VA Loma Linda Healthcare Syst, Loma Linda, CA USA. [Jaffer, A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Kindzelski, A.] NHLBI, Bethesda, MD 20892 USA. [Schulman, S.] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada. [Becker, R.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Clark, N. P.] Kaiser Permanente Colorado, Lafayette, CO USA. [Conti, B.] Owen Sound Family Hlth Team, Owen Sound, ON, Canada. [Ellsworth, S.] Henry Ford Hosp, Detroit, MI 48202 USA. [Harrison, R. W.; Kong, D.; Krishnamoorthy, A.; Parker, W.; Hasselblad, V] Duke Univ, Durham, NC USA. [Johnson, G.] Univ Minnesota, Minneapolis, MN USA. [Palmeri, S.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Saucedo, J.] NorthShore Univ HealthSyst, New York, NY USA. [Schoch, P.] US Dept Vet Affairs, Washington, DC USA. [Witt, D.] Univ Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA LB002 BP 83 EP 84 PG 2 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901228 ER PT J AU Miravitlles, M Anzueto, A AF Miravitlles, Marc Anzueto, Antonio TI Antibiotic prophylaxis in COPD: Why, when, and for whom? SO PULMONARY PHARMACOLOGY & THERAPEUTICS LA English DT Article DE COPD; Bronchial colonization; Antibiotics; Prophylaxis; macrolides; Quinolones ID OBSTRUCTIVE PULMONARY-DISEASE; CONTROLLED-TRIAL; EXACERBATIONS; PREVENTION; INFECTION; AIRWAY; AZITHROMYCIN; ERYTHROMYCIN; THERAPY; MOXIFLOXACIN AB One of the main goals of treatment of chronic obstructive pulmonary disease (COPD) is the prevention of exacerbations. Bronchodilators and anti-inflammatories are the first line therapy for treatment of COPD; however, these drugs are not effective in suppressing all infective exacerbations. In fact, the use of inhaled corticosteroids in patients with COPD and chronic bronchial infection may even increase the bacterial load in the airways and increase the risk of pneumonia. In this context, the use of long-term or intermittent antibiotic treatment has shown to prevent COPD exacerbations and hospitalizations. These effects may be achieved by reducing bacterial load in the airways in stable state and/or bronchial inflammation. The drugs more extensively studied are macrolides, followed by quinolones. The long-term use of antibiotics is associated with an increased risk of potentially serious adverse events and development of bacterial resistance. Therefore, the indication of long-term antibiotic therapy must be determined on a case by case basis taking into account the potential risks and benefits. In general, this treatment may be indicated in patients with severe or very severe COPD with frequent or severe exacerbations despite optimal pharmacological and non pharmacological treatment. These patients should be carefully monitored based on clinical and microbiological assessments. The most appropriate drug and regime administration, as well as the optimal duration of therapy are issues that still require further investigation. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Miravitlles, Marc] Hosp Univ Vall dHebron, Dept Pneumol, ES-08035 Barcelona, Spain. [Miravitlles, Marc] Ciber Enfermedades Resp CIBERES, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, San Antonio, TX USA. RP Miravitlles, M (reprint author), Hosp Univ Vall dHebron, Dept Pneumol, P Vall dHebron 119-129, ES-08035 Barcelona, Spain. EM mmiravitlles@vhebron.net OI Miravitlles, Marc/0000-0002-9850-9520 NR 42 TC 3 Z9 3 U1 1 U2 7 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1094-5539 J9 PULM PHARMACOL THER JI Pulm. Pharmacol. Ther. PD JUN PY 2015 VL 32 BP 119 EP 123 DI 10.1016/j.pupt.2014.05.002 PG 5 WC Pharmacology & Pharmacy; Respiratory System SC Pharmacology & Pharmacy; Respiratory System GA CL5HL UT WOS:000356990300015 PM 24825753 ER PT J AU Jotwani, V Shlipak, MG Scherzer, R Parekh, RS Kao, WHL Bennett, M Cohen, MH Nowicki, M Sharma, A Young, M Tien, PC Parikh, CR Estrella, MM AF Jotwani, Vasantha Shlipak, Michael G. Scherzer, Rebecca Parekh, Rulan S. Kao, W. H. Linda Bennett, Michael Cohen, Mardge H. Nowicki, Marek Sharma, Anjali Young, Mary Tien, Phyllis C. Parikh, Chirag R. Estrella, Michelle M. TI APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE APOL1 genotype; risk variant; risk allele; G1 allele; G2 allele; single-nucleotide polymorphism (SNP); albumin-creatinine ratio (ACR); proteinuria; tubular injury biomarker; apolipoprotein L1; kidney disease; renal function; glomerular injury; African American; Women's Interagency HIV Study (WIHS) ID STAGE RENAL-DISEASE; GENOME-WIDE ASSOCIATION; ALL-CAUSE MORTALITY; L1 GENE VARIANTS; AFRICAN-AMERICANS; APOLIPOPROTEIN L1; INTERAGENCY HIV; RISK VARIANTS; CARDIOVASCULAR-DISEASE; INFECTED INDIVIDUALS AB Background: APOL1 genotype is associated with advanced kidney disease in African Americans, but the pathogenic mechanisms are unclear. Here, associations of APOL1 genotype with urine biomarkers of glomerular and tubular injury and kidney function decline were evaluated. Study Design: Observational study. Setting & Participants: 431 human immunodeficiency virus (HIV)-infected African American women enrolled in Women's Interagency HIV Study (WIHS). Predictor: APOL1 genotype. Outcomes: Albumin-creatinine ratio (ACR), 4 tubular injury biomarkers (interleukin 18 [IL-18], kidney injury molecule 1 [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL], and alpha(1)-microglobulin [A1M]), and kidney function estimated using the CKD-EPI cystatin C equation. Measurements: Participants were genotyped for APOL1 single-nucleotide polymorphisms rs73885319 (G1 allele) and rs71785313 (G2 allele). Urine biomarkers were measured using stored samples from 1999-2000. Cystatin C was measured using serum collected at baseline and 4- and 8-year follow-ups. Results: At baseline, ACRs were higher among 47 women with 2 APOL1 risk alleles versus 384 women with 0/1 risk allele (median, 24 vs 11 mg/g; P < 0.001). Compared with women with 0/1 risk allele, women with 2 risk alleles had 104% higher ACRs (95% CI, 29-223 mg/g) and 2-fold greater risk of ACR. 30 (95% CI, 1.17-3.44) mg/g after multivariable adjustment. APOL1 genotype showed little association with urine IL-18: Cr ratio, KIM-1: Cr ratio, and NGAL: Cr ratio (estimates of -5% [95% CI, -24% to 18%], -20% [95% CI, -36% to -1%], and 10% [95% CI, -26% to 64%], respectively) or detectable urine A1M (prevalence ratio, 1.13; 95% CI, 0.65-1.97) in adjusted analyses. Compared with women with 0/1 allele, women with 2 risk alleles had faster eGFR decline, by 1.2 (95% CI, 0.2 to 2.2) mL/min/1.73 m(2) per year, and 1.7- and 3.4-fold greater rates of incident chronic kidney disease (95% CI, 1.1 to 2.5) and 10% annual eGFR decline (95% CI, 1.7 to 6.7), respectively, with minimal attenuation after adjustment for glomerular and tubular injury biomarker levels. Limitations: Results may not be generalizable to men. Conclusions: Among HIV-infected African American women, APOL1-associated kidney injury appears to localize to the glomerulus, rather than the tubules. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Jotwani, Vasantha; Shlipak, Michael G.; Scherzer, Rebecca; Tien, Phyllis C.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Jotwani, Vasantha; Shlipak, Michael G.; Scherzer, Rebecca] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Parekh, Rulan S.] Hosp Sick Children, Univ Healthy Network, Toronto, ON M5G 1X8, Canada. [Parekh, Rulan S.] Univ Toronto, Toronto, ON, Canada. [Parekh, Rulan S.; Kao, W. H. Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Bennett, Michael] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Cohen, Mardge H.] Stroger Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Nowicki, Marek] Univ So Calif, Dept Med, Los Angeles, CA USA. [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Div Infect Dis, Brooklyn, NY 11203 USA. [Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis & Travel Med, Washington, DC 20007 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Sect Nephrol, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. RP Jotwani, V (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM vasantha.jotwani@ucsf.edu FU NCATS NIH HHS [UL1 TR000004, UL1 TR000454, UL1-TR000004, UL1-TR000454]; NIA NIH HHS [R01 AG034853]; NIAID NIH HHS [U01-AI-103401, P30 AI027763, U01 AI031834, U01 AI034989, U01 AI034993, U01 AI034994, U01 AI035004, U01 AI042590, U01 AI103390, U01 AI103397, U01 AI103401, U01 AI103408, U01-AI-031834, U01-AI-034989, U01-AI-034993, U01-AI-034994, U01-AI-035004, U01-AI-042590, U01-AI-103390, U01-AI-103397, U01-AI-103408]; NICHD NIH HHS [U01 HD032632, U01-HD-032632]; NIDDK NIH HHS [1 K23DK08131, F32 DK103451, K23 DK081317] NR 51 TC 5 Z9 5 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUN PY 2015 VL 65 IS 6 BP 889 EP 898 DI 10.1053/j.ajkd.2015.02.329 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA CL1TP UT WOS:000356728000013 PM 25921719 ER PT J AU Bangen, KJ Gu, YA Gross, AL Schneider, BC Skinner, JC Benitez, A Sachs, BC Shih, R Sisco, S Schupf, N Mayeux, R Manly, JJ Luchsinger, JA AF Bangen, Katherine J. Gu, Yian Gross, Alden L. Schneider, Brooke C. Skinner, Jeannine C. Benitez, Andreana Sachs, Bonnie C. Shih, Regina Sisco, Shannon Schupf, Nicole Mayeux, Richard Manly, Jennifer J. Luchsinger, Jose A. TI Relationship Between Type 2 Diabetes Mellitus and Cognitive Change in a Multiethnic Elderly Cohort SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE diabetes mellitus; cognition; aging; vascular risk factors ID VASCULAR RISK-FACTORS; ALZHEIMERS-DISEASE NEUROPATHOLOGY; OLDER-ADULTS; DEMENTIA; IMPAIRMENT; DECLINE; POPULATION; ASSOCIATION; CHOLESTEROL; DYSFUNCTION AB ObjectivesTo examine the association between diabetes mellitus and cognitive functioning at baseline and cognitive change over time in a large, ethnically diverse sample of older adults. DesignProspective cohort study. SettingWashington Heights-Inwood Columbia Aging Project, a community-based, prospective study of risk factors for dementia in northern Manhattan, New York City. ParticipantsHispanic, non-Hispanic black, and non-Hispanic white men and women aged 65 and older without dementia at baseline (N=1,493). MeasurementsParticipants underwent baseline and follow-up cognitive and health assessments approximately every 18months. Generalized estimating equations were used to examine the longitudinal association between diabetes mellitus and cognition. ResultsDiabetes mellitus was associated with poorer baseline cognitive performance in memory, language, processing speed and executive functioning, and visuospatial abilities. After adjusting for age, education, sex, race and ethnicity, and apolipoprotein-epsilon 4, participants with diabetes mellitus performed significantly worse at baseline than those without in language and visuospatial abilities. There were no differences between those with and without diabetes mellitus in terms of rate of cognitive change over a mean follow-up time of 6years. ConclusionThe rate of cognitive change in elderly persons with and without diabetes mellitus is similar, although cognitive performance is poorer in persons with diabetes mellitus. These findings suggest that cognitive changes may occur early during the diabetes mellitus process and highlight the need for studies to follow participants beginning at least in midlife, before the typical later-life onset of dementia. C1 [Bangen, Katherine J.] Vet Affairs San Diego Healthcare Syst, Res Serv, San Diego, CA USA. [Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Gu, Yian; Schupf, Nicole; Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. [Gross, Alden L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Schneider, Brooke C.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Skinner, Jeannine C.] Vanderbilt Univ, Med Ctr, Vanderbilt Memory & Alzheimers Ctr, Dept Neurol, Nashville, TN USA. [Benitez, Andreana] Med Univ S Carolina, Dept Radiol & Radiol Sci, Ctr Biomed Imaging, Charleston, SC 29425 USA. [Sachs, Bonnie C.] Virginia Commonwealth Univ, Dept Neurol, Sch Med, Richmond, VA 23284 USA. [Shih, Regina] RAND Corp, Arlington, VA USA. [Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Schupf, Nicole; Mayeux, Richard; Luchsinger, Jose A.] Columbia Univ, Dept Epidemiol, Joseph P Mailman Sch Publ Hlth, New York, NY USA. [Schupf, Nicole; Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA. [Mayeux, Richard] Columbia Univ, Dept Psychiat, New York, NY USA. [Mayeux, Richard; Manly, Jennifer J.] Columbia Univ, Dept Neurol, New York, NY USA. [Luchsinger, Jose A.] Columbia Univ, Coll Phys & Surg, Coll Med, New York, NY USA. RP Luchsinger, JA (reprint author), Columbia Univ, Med Ctr, 630 West 168th St, New York, NY 10032 USA. EM jal94@cumc.columbia.edu FU National Institute on Aging [AG026413, AG037212, AG030995, K99AG042483]; National Institute on Mental Health [T32 MH 19934-17]; National Institute on Minority Health and Health Disparities [P60 MD000206] FX K. Bangen, Y. Gu, N. Schupf, R. Mayeux, J. Manly, and J. Luchsinger receive funding from the National Institutes of Health. This study was funded by grants from the National Institute on Aging (AG026413, AG037212, AG030995, K99AG042483), National Institute on Mental Health (T32 MH 19934-17), and National Institute on Minority Health and Health Disparities (P60 MD000206). J. Luchsinger has been a consultant to Nutricia, Inc. and has received royalties from Springer Publishing for a book he edited entitled Diabetes and the Brain. NR 50 TC 7 Z9 7 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1075 EP 1083 DI 10.1111/jgs.13441 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500003 PM 26096383 ER PT J AU Genther, DJ Betz, J Pratt, S Martin, KR Harris, TB Satterfield, S Bauer, DC Newman, AB Simonsick, EM Lin, FR AF Genther, Dane J. Betz, Joshua Pratt, Sheila Martin, Kathryn R. Harris, Tamara B. Satterfield, Suzanne Bauer, Douglas C. Newman, Anne B. Simonsick, Eleanor M. Lin, Frank R. CA Hlth Aging Body Composition Study TI Association Between Hearing Impairment and Risk of Hospitalization in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hearing impairment; hospitalization; older adults; epidemiology ID QUICK DIAGNOSIS UNITS; ELDER LIFE PROGRAM; HEALTH-CARE USE; INCIDENT DEMENTIA; BODY-COMPOSITION; SOCIAL-ISOLATION; AGE; STATES; DISEASE; ADMISSION AB ObjectivesTo determine the association between hearing impairment (HI) and risk and duration of hospitalization in community-dwelling older adults in the United States. DesignProspective observational study. SettingHealth, Aging and Body Composition Study. ParticipantsWell-functioning community-dwelling white and black Medicare beneficiaries aged 70 to 79 at study enrollment in 1997-98 were followed for a median of 12years. MeasurementsIncidence, annual rate, and duration of hospitalization were the primary outcomes. Hearing was defined as the pure-tone average (PTA) of hearing thresholds in decibels re: hearing level (dB HL) at octave frequencies from 0.5 to 4.0kHz. Mild HI was defined as a PTA from 25 to 40dB HL, and moderate or greater HI was defined as a PTA greater than 40dB HL. ResultsOf the 2,148 participants included in the analysis, 1,801 (83.5%) experienced one or more hospitalizations, with 7,007 adjudicated hospitalization events occurring during the study period. Eight hundred eighty-two (41.1%) participants had normal hearing, 818 (38.1%) had mild HI, and 448 (20.9%) had moderate or greater HI. After adjusting for demographic characteristics and cardiovascular comorbidities, persons with mild HI experienced a 16% (hazard ratio (HR)=1.16, 95% confidence interval (CI) =1.04-1.29) greater risk of incident hospitalization and a 17% (incidence rate ratio (IRR)=1.17, 95% CI=1.04-1.32) greater annual rate of hospitalization, and those with moderate or greater HI experienced a 21% (HR=1.21, 95% CI=1.06-1.38) greater risk of incident hospitalization and a 19% (IRR=1.19, 95% CI=1.04-1.38) greater annual rate of hospitalization than persons with normal hearing. There was no significant association between HI and mean duration of hospitalization. ConclusionHearing-impaired older adults experience a greater incidence and annual rate of hospitalization than those with normal hearing. Investigating whether rehabilitative therapies could affect the risk of hospitalization in older adults requires further study. C1 [Genther, Dane J.; Lin, Frank R.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA. [Genther, Dane J.; Betz, Joshua; Lin, Frank R.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21287 USA. [Betz, Joshua] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21287 USA. [Pratt, Sheila] Univ Pittsburgh, Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Pratt, Sheila] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Martin, Kathryn R.; Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Martin, Kathryn R.] Univ Aberdeen, Sch Med & Dent, Epidemiol Grp, Aberdeen, Scotland. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Bauer, Douglas C.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Simonsick, Eleanor M.; Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. [Simonsick, Eleanor M.] Johns Hopkins Univ, NIA, Intramural Res Program, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA. RP Genther, DJ (reprint author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St,Suite 6210, Baltimore, MD 21287 USA. EM dgenthe2@jhmi.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150; Genther, Dane/0000-0002-7925-012X; Betz, Joshua/0000-0003-4488-9799 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050, K24AG031155]; National Institute of Nursing Research [R01-NR012459]; National Institutes of Health [T32DC000027]; National Institute on Deafness and Other Communication Disorders [K23DC011279]; Intramural Research Program of the NIA; Triological Society and American College of Surgeons through the Clinician Scientist Award; Eleanor Schwartz Charitable Foundation FX This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106; NIA Grant R01-AG028050; and National Institute of Nursing Research Grant R01-NR012459. This study was further supported in part by National Institutes of Health Grant T32DC000027, NIA grant K24AG031155, National Institute on Deafness and Other Communication Disorders Grant K23DC011279, Intramural Research Program of the NIA, Triological Society and American College of Surgeons through the Clinician Scientist Award, and Eleanor Schwartz Charitable Foundation. Dr. Pratt was supported in part with resources and the use of facilities at the Department of Veterans Affairs Pittsburgh Healthcare System, although the contents do not represent the views of the Department of Veterans Affairs or the U.S. government. This work was presented as a poster display as part of the American Auditory Society Scientific and Technology Meeting, March 6-8, 2014, Scottsdale, Arizona. NR 42 TC 3 Z9 3 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1146 EP 1152 DI 10.1111/jgs.13456 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500012 PM 26096388 ER PT J AU Dougherty, M Harris, PS Teno, J Corcoran, AM Douglas, C Nelson, J Way, D Harrold, JE Casarett, DJ AF Dougherty, Meredith Harris, Pamela S. Teno, Joan Corcoran, Amy M. Douglas, Cindy Nelson, Jackie Way, Deborah Harrold, Joan E. Casarett, David J. TI Hospice Care in Assisted Living Facilities Versus at Home: Results of a Multisite Cohort Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE assisted living; hospice; palliative care ID LIFE; END AB ObjectivesTo compare residents of assisted living facilities receiving hospice with people receiving hospice care at home. DesignElectronic health record-based retrospective cohort study. SettingNonprofit hospices in the Coalition of Hospices Organized to Investigate Comparative Effectiveness network. ParticipantsIndividuals admitted to hospice between January 1, 2008, and May 15, 2012 (N=85,581; 7,451 (8.7%) assisted living facility, 78,130 (91.3%) home). MeasurementsHospice length of stay, use of opioids for pain, and site of death. ResultsThe assisted living population was more likely than the home hospice population to have a diagnosis of dementia (23.5% vs 4.7%; odds ratio (OR)=13.3, 95% confidence interval (CI) =12.3-14.4; P<.001) and enroll in hospice closer to death (median length of stay 24 vs 29days). Assisted living residents were less likely to receive opioids for pain (18.1% vs 39.7%; OR=0.33, 95% CI=0.29-0.39, P<.001) and less likely to die in an inpatient hospice unit (9.3% vs 16.1%; OR=0.53, 95% CI=0.49-0.58, P<.001) or a hospital (1.3% vs 7.6%; OR=0.16, 95% CI=0.13-0.19, P<.001). ConclusionThree are several differences between residents of assisted living receiving hospice care and individuals living at home receiving hospice care. A better understanding of these differences could allow hospices to develop guidelines for better coordination of end-of-life care for the assisted living population. C1 [Dougherty, Meredith; Casarett, David J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Harris, Pamela S.] Kansas City Hospice & Palliat Care, Kansas City, MO USA. [Teno, Joan] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA. [Corcoran, Amy M.] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA. [Douglas, Cindy] Faith Presbyterian Hospice, Dallas, TX USA. [Nelson, Jackie] Arbor Hospice, Ann Arbor, MI USA. [Way, Deborah] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Harrold, Joan E.] Hospice & Community Care, Lancaster, PA USA. RP Casarett, DJ (reprint author), Univ Penn, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 13 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2015 VL 63 IS 6 BP 1153 EP 1157 DI 10.1111/jgs.13429 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CL1CG UT WOS:000356679500013 PM 26096389 ER PT J AU Graff, JN Beer, TM AF Graff, Julie N. Beer, Tomasz M. TI Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer SO ONCOLOGY-NEW YORK LA English DT Review ID PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; ZOLEDRONIC ACID; INCREASED SURVIVAL; MULTIPLE-MYELOMA; BONE METASTASES; ENZALUTAMIDE; MEN; BISPHOSPHONATES; CHEMOTHERAPY AB Skeletal-related events contribute substantially to morbidity, mortality and cost in men with metastatic castration-resistant prostate cancer (mCRPC). There are five agents available for treatment in mCRPC that reduce skeletal-related events. Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223. We include data on and a discussion of duration of treatment with zoledronic acid and denosumab, the only two of these agents that do not have a clinically proven anticancer effect. Finally, we review the available data regarding the cost of denosumab compared with that of zoledronic acid. C1 [Graff, Julie N.; Beer, Tomasz M.] Portland VA Med Ctr, Portland, OR USA. [Graff, Julie N.; Beer, Tomasz M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. RP Graff, JN (reprint author), Knight Canc Inst, 3303 SW Bond Ave,MC CH14R, Portland, OR 97239 USA. EM graffj@ohsu.edu FU Astellas Pharma Global; Bayer; Medivation; Janssen FX Dr. Graff receives research funding from Astellas Pharma Global, Bayer, and Medivation. Dr. Beer receives research funding from Astellas Pharma Global, Janssen, and Medivation; he receives consulting fees from Astellas Pharma Global and Bayer. NR 41 TC 3 Z9 3 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD JUN PY 2015 VL 29 IS 6 BP 416 EP 423 PG 8 WC Oncology SC Oncology GA CL3HY UT WOS:000356842200002 PM 26091674 ER PT J AU Frank, JW Carey, EP Fagan, KM Aron, DC Todd-Stenberg, J Moore, BA Kerns, RD Au, DH Ho, PM Kirsh, SR AF Frank, Joseph W. Carey, Evan P. Fagan, Katherine M. Aron, David C. Todd-Stenberg, Jeff Moore, Brent A. Kerns, Robert D. Au, David H. Ho, P. Michael Kirsh, Susan R. TI Evaluation of a Telementoring Intervention for Pain Management in the Veterans Health Administration SO PAIN MEDICINE LA English DT Article DE Telehealth; Pain Management; Primary Care; Anticonvulsants; Antidepressants; Opioids and Physical Therapy ID CHRONIC OPIOID THERAPY; CHRONIC NONCANCER PAIN; PRIMARY-CARE CLINICIAN; PROJECT ECHO; UNITED-STATES; MEDICAL-CENTERS; SPECIALTY CARE; MENTAL-HEALTH; HEPATITIS-C; ACCESS AB ObjectiveHalf of all Veterans experience chronic pain yet many face geographical barriers to specialty pain care. In 2011, the Veterans Health Administration (VHA) launched the Specialty Care Access Network-ECHO (SCAN-ECHO), which uses telehealth technology to provide primary care providers with case-based specialist consultation and pain management education. Our objective was to evaluate the pilot SCAN-ECHO pain management program (SCAN-ECHO-PM). Design and SettingThis was a longitudinal observational evaluation of SCAN-ECHO-PM in seven regional VHA healthcare networks. MethodsWe identified the patient panels of primary care providers who submitted a consultation to one or more SCAN-ECHO-PM sessions. We constructed multivariable Cox proportional hazards models to assess the association between provider SCAN-ECHO-PM consultation and 1) delivery of outpatient care (physical medicine, mental health, substance use disorder, and pain medicine) and 2) medication initiation (antidepressants, anticonvulsants, and opioid analgesics). ResultsPrimary care providers (N = 159) who presented one or more SCAN-ECHO-PM sessions had patient panels of 22,454 patients with chronic noncancer pain (CNCP). Provider consultation to SCAN-ECHO-PM was associated with utilization of physical medicine [hazard ratio (HR) 1.10, 95% confidence interval (CI) 1.05-1.14] but not mental health (HR 0.99, 95% CI 0.93-1.05), substance use disorder (HR 0.93, 95% CI 0.84-1.03) or specialty pain clinics (HR 1.01, 95% CI 0.94-1.08). SCAN-ECHO-PM consultation was associated with initiation of an antidepressant (HR 1.09, 95% CI 1.02-1.15) or anticonvulsant medication (HR 1.13, 95% CI 1.06-1.19) but not an opioid analgesic (HR 1.05, 0.99-1.10). ConclusionsSCAN-ECHO-PM was associated with increased utilization of physical medicine services and initiation of nonopioid medications among patients with CNCP. SCAN-ECHO-PM may provide a novel means of building pain management competency among primary care providers. C1 [Frank, Joseph W.; Carey, Evan P.; Fagan, Katherine M.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [Frank, Joseph W.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Aron, David C.; Kirsh, Susan R.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Aron, David C.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA. [Todd-Stenberg, Jeff; Au, David H.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Moore, Brent A.; Kerns, Robert D.] Yale Univ, Sch Med, New Haven, CT USA. [Moore, Brent A.; Kerns, Robert D.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Ho, P. Michael] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Kirsh, Susan R.] Vet Hlth Adm, Off Specialty Care, Washington, DC USA. RP Frank, JW (reprint author), VA Eastern Colorado Hlth Care Syst, Ambulatory Care, 1055 Clermont St, Denver, CO 80220 USA. EM joseph.frank@va.gov RI Moore, Brent/O-4867-2015 OI Moore, Brent/0000-0003-0123-6616 NR 40 TC 8 Z9 8 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUN PY 2015 VL 16 IS 6 BP 1090 EP 1100 DI 10.1111/pme.12715 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CL1SG UT WOS:000356724000008 PM 25716075 ER PT J AU Michalek, AK Kan, D Prochaska, J AF Michalek, Anne Kathryn Kan, David Prochaska, Judith TI Engaging veterans with substance abuse disorders into a research trial: success with study branding, networking, and presence SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Veteran health administration; Recruitment; Retention; Multiple-risk behavior change; Methods research ID CLINICAL-TRIALS; SUCCESSFUL RECRUITMENT; RETENTION STRATEGIES; PARTICIPANTS; SMOKERS; INTERVENTION; INFORMATION; PREVALENCE; QUALITY; PEOPLE AB Recruiting and retaining clients in health interventions can be challenging especially when targeting multiple behavior change in high-risk populations. To inform the methods of trials working with similarly complex clinical populations, we describe multi-pronged efforts to recruit and retain a representative sample. In a two-group RCT, veterans were recruited from a Veteran Affairs Medical Center. The goal was to enroll 200 participants over a 25-month period, and to exceed 70 % follow-up for all treatment arms. To meet these goals, a four-pronged strategy was developed: branding, outreach/networking, onsite presence, and incentives. In month 1, 32 % of the proposed sample size was met (n=64), and by month 2, 45 % (n=90); the recruitment goal (n=200) was achieved 13 months ahead of schedule. Retention exceeds 90% at all time points out to 18 months. The multipronged recruitment and retention plan was efficient, cost effective, and may generalize to other health promotion initiatives. C1 [Michalek, Anne Kathryn] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kan, David] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Prochaska, Judith] Stanford Prevent Res Ctr, Stanford, CA 94305 USA. RP Prochaska, J (reprint author), Stanford Prevent Res Ctr, Med Sch Off Bldg,X316,1265 Welch Rd, Stanford, CA 94305 USA. EM jpro@stanford.edu FU National Institutes of Health [P50DA09253] FX We wish to acknowledge the clinical team that provided valuable treatment referrals and support throughout the duration of the trial, including Peter Banys, MD; Steven Batki, MD; Ricky Chen, RN; William Clift, AT; Ellen Herbst, MD; Patricia Lane, RN; and Rebecca Young, RN. We acknowledge Pro-Change Behavior Systems Inc., which developed the multiple risk behavior change intervention evaluated in this trial. We also acknowledge the contributions of research staff Carson Benowitz-Fredericks and Erin Dougherty who worked with participants in this trial. Study supported by the National Institutes of Health grant #P50DA09253 NR 37 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD JUN PY 2015 VL 5 IS 2 BP 167 EP 176 DI 10.1007/s13142-014-0302-z PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2QI UT WOS:000356788700006 PM 26029279 ER PT J AU Mani, SK Kern, CB Kimbrough, D Addy, B Kasiganesan, H Rivers, WT Patel, RK Chou, JC Spinale, FG Mukherjee, R Menick, DR AF Mani, Santhosh K. Kern, Christine B. Kimbrough, Denise Addy, Benjamin Kasiganesan, Harinath Rivers, William T. Patel, Risha K. Chou, James C. Spinale, Francis G. Mukherjee, Rupak Menick, Donald R. TI Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and-9 expression and preserves LV function postmyocardial infarction SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE myocardial infarction; histone deacetylase; matrix metalloproteinases; transcriptional regulation; macrophages; LV remodeling ID NF-KAPPA-B; EXPERIMENTAL MYOCARDIAL-INFARCTION; CARDIAC-HYPERTROPHY; TARGETED DELETION; MATRIX-METALLOPROTEINASE-9 EXPRESSION; GENE-EXPRESSION; CARDIOMYOCYTE HYPERTROPHY; ISCHEMIA-REPERFUSION; HYPERTENSIVE-RATS; TRANSCRIPTION AB Left ventricular (LV) remodeling, after myocardial infarction (MI), can result in LV dilation and LV pump dysfunction. Post-MI induction of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, have been implicated as causing deleterious effects on LV and extracellular matrix remodeling in the MI region and within the initially unaffected remote zone. Histone deacetylases (HDACs) are a class of enzymes that affect the transcriptional regulation of genes during pathological conditions. We assessed the efficacy of both class I/IIb- and class I-selective HDAC inhibitors on MMP-2 and MMP-9 abundance and determined if treatment resulted in the attenuation of adverse LV and extracellular matrix remodeling and improved LV pump function post-MI. MI was surgically induced in MMP-9 promoter reporter mice and randomized for treatment with a class I/IIb HDAC inhibitor for 7 days post-MI. After MI, LV dilation, LV pump dysfunction, and activation of the MMP-9 gene promoter were significantly attenuated in mice treated with either the class I/IIb HDAC inhibitor tichostatin A or suberanilohydroxamic acid (voronistat) compared with MI-only mice. Immunohistological staining and zymographic levels of MMP-2 and MMP-9 were reduced with either tichostatin A or suberanilohydroxamic acid treatment. Class I HDAC activity was dramatically increased post-MI. Treatment with the selective class I HDAC inhibitor PD-106 reduced post-MI levels of both MMP-2 and MMP-9 and attenuated LV dilation and LV pump dysfunction post-MI, similar to class I/IIb HDAC inhibition. Taken together, these unique findings demonstrate that selective inhibition of class I HDACs may provide a novel therapeutic means to attenuate adverse LV remodeling post-MI. C1 [Mani, Santhosh K.; Kimbrough, Denise; Addy, Benjamin; Kasiganesan, Harinath; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Kern, Christine B.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Rivers, William T.; Patel, Risha K.; Mukherjee, Rupak] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Chou, James C.] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA. [Menick, Donald R.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Spinale, Francis G.] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC USA. RP Menick, DR (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM menickd@musc.edu FU American Heart Association (AHA); National Institutes of Health (NIH) [R01-HL-095696, UL1-TR-000062]; Veterans Affairs Health Administration; NIH [R01-HL-121382, 5-P20-RR-016434, HL-057952, HL-059165]; AHA Scientist Development Grant; NIH Postdoctoral Fellowship Grant [T32-HL-07260]; AHA Predoctoral Fellowship FX This work was supported by an American Heart Association (AHA) grant-in-aid, National Institutes of Health (NIH) Grants R01-HL-095696 and UL1-TR-000062, a merit award from the Veterans Affairs Health Administration, and a gift from Mr. and Mrs. Robert Tarr (to D.R. Menick). C.B. Kern was supported by NIH Grants R01-HL-121382 and 5-P20-RR-016434 and an AHA Scientist Development Grant. F.G. Spinale was supported by NIH Grants HL-057952 and HL-059165 and a merit award from the Veterans Affairs Health Administration. D. Kimbrough was supported by NIH Postdoctoral Fellowship Grant T32-HL-07260 and an AHA Predoctoral Fellowship. NR 61 TC 8 Z9 8 U1 2 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUN 1 PY 2015 VL 308 IS 11 BP H1391 EP H1401 DI 10.1152/ajpheart.00390.2014 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA CK5MS UT WOS:000356269600010 PM 25795711 ER PT J AU Wecht, JM Weir, JP Galea, M Martinez, S Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Galea, Marinella Martinez, Stephanie Bauman, William A. TI Prevalence of Abnormal Systemic Hemodynamics in Veterans With and Without Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Hypertension; Hypotension; Orthostatic hypotension; Rehabilitation; Tachycardia ID HYPOTENSION PREDICTS MORTALITY; ELEVATED HEART-RATE; REMAINING AUTONOMIC FUNCTION; POPULATION HEALTH SURVEY; PULSE-WAVE VELOCITY; LOW BLOOD-PRESSURE; MIDDLE-AGED MEN; ORTHOSTATIC HYPOTENSION; INTERNATIONAL STANDARDS; CARDIOVASCULAR-DISEASE AB Objective: Increased prevalence of heart rate and blood pressure abnormalities are evident in persons with spinal cord injury (SCI), but age, comorbid medical conditions, and prescription medication use may contribute. To determine differences in the prevalence of cardiac acceleration (heart rate >= 80 beats per minute), hypotension (blood pressure <= 110/70mmHg), orthostatic hypotension (OH) (-20/-10mmHg with upright positioning), and hypertension (HTN) (blood pressure >= 140/90mmHg) in veterans with and without SCI. Design: Observational trial. Setting: Medical center. Participants: Subjects included veterans with SCI (n=62; cervical: tetraplegia, C3-8; high thoracic, T1-5; low thoracic, T7-L2) and veterans without SCI (n=160). Interventions: None. Main Outcome Measures: We assessed medical history, prescription medication use, and heart rate and blood pressure during a routine clinical visit. Prevalence rates of cardiac acceleration, hypotension, OH, and HTN were calculated using binary logistic regression analysis with 95% confidence intervals. The influence of SCI status, age, smoking status, cardiovascular diagnoses, and use of prescribed antihypertensive medications on the prevalence of abnormal heart rate and blood pressure recordings was determined. Results: The diagnosis of HTN was reduced in the high thoracic and tetraplegia groups compared with the non-SCI and low thoracic groups. Use of antihypertensive medications was increased in the low thoracic group compared with the other 3 groups and was increased in the non-SCI group compared with the tetraplegia group. The prevalence of cardiac acceleration was reduced, and the prevalence of systolic hypotension was increased in the tetraplegia group. The prevalence of diastolic hypotension was increased in all SCI groups compared with the non-SCI group. For all analyses, increased prevalence of abnormal heart rate and blood pressure recordings was not further explained by the covariates, with the exception of age, cardiovascular diagnoses, and antihypertensive medications in the cardiac acceleration model; however, SCI status remained significant and was the dominant predictor variable. Conclusions: Our data suggest that SCI status contributes to the prevalence of cardiac acceleration and systolic and diastolic hypotension regardless of cardiovascular medical conditions or prescription antihypertensive medication use. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Wecht, Jill M.; Martinez, Stephanie; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Galea, Marinella; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. [Galea, Marinella; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Med Serv, Bronx, NY USA. RP Wecht, JM (reprint author), James J Peters Vet Affairs Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Room 7A-13,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B9212C, B6999R] FX Supported by the Veterans Affairs Rehabilitation Research and Development Service (grants nos. B9212C and B6999R). NR 62 TC 0 Z9 0 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUN PY 2015 VL 96 IS 6 BP 1071 EP 1079 DI 10.1016/j.apmr.2015.01.018 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK7FM UT WOS:000356398200014 PM 25660005 ER PT J AU Pham, PMT Pham, PAT Pham, SV Pham, PTT Pham, PTT Pham, PCT AF Pham, Phuong-Mai T. Pham, Phuong-Anh T. Pham, Son V. Pham, Phuong-Truc T. Pham, Phuong-Thu T. Pham, Phuong-Chi T. TI Correction of hyponatremia and osmotic demyelinating syndrome: have we neglected to think intracellularly? SO CLINICAL AND EXPERIMENTAL NEPHROLOGY LA English DT Article DE Hypophosphatemia; Hypokalemia; Hypomagnesemia; Hypoglycemia; Thiamine; Folate ID CENTRAL PONTINE MYELINOLYSIS; CELL-VOLUME REGULATION; EXTRAPONTINE MYELINOLYSIS; HYPOGLYCEMIA; ENCEPHALOPATHY; HYPERNATREMIA; POTASSIUM; DISEASE; OSMOLES; WATER AB Osmotic demyelination syndrome (ODS) is a complication generally associated with overly rapid correction of hyponatremia. Traditionally, nephrologists have been trained to focus solely on limiting the correction rate. However, there is accumulating evidence to suggest that the prevention of ODS is beyond achieving slow correction rates. We (1) reviewed the literature for glial intracellular protective alterations during hyperosmolar stress, a state presumed equivalent to the rapid correction of hyponatremia, and (2) analyzed all available hyponatremia-associated ODS cases from PubMed for possible contributing factors including correction rates and concurrent metabolic disturbances involving hypokalemia, hypophosphatemia, hypomagnesemia, and/or hypoglycemia. In response to acute hyperosmolar stress, glial cells undergo immediate extracellular free water shift, followed by active intracellular Na+, K+ and amino acid uptake, and eventual idiogenic osmoles synthesis. At minimum, protective mechanisms require K+, Mg2+, phosphate, amino acids, and glucose. There were 158 cases of hyponatremia-associated ODS where both correction rates and other metabolic factors were documented. Compared with the rapid correction group (> 0.5 mmol/L/h), the slow correction group (a parts per thousand currency sign0.5 mmol/L/h) had a greater number of cases with concurrent hypokalemia (49.4 vs. 33.3 %, p = 0.04), and a greater number of cases with any concurrent metabolic derangements (55.8 vs. 38.3 %, p = 0.03). Glial cell minimizes volume changes and injury in response to hyperosmolar stress via mobilization and/or utilization of various electrolytes and metabolic factors. The prevention of ODS likely requires both minimization of correction rate and optimization of intracellular response during the correction phase when a sufficient supply of various factors is necessary. C1 [Pham, Phuong-Mai T.] Greater Los Angeles Vet Adm, Sepulveda, CA 91343 USA. [Pham, Phuong-Anh T.] Vet Affairs Cent Calif Hlth Care Syst, Fresno, CA 93703 USA. [Pham, Son V.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Pham, Son V.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Pham, Phuong-Truc T.] Penn State Worthington Scranton, Dunmore, PA 18512 USA. [Pham, Phuong-Thu T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Pham, Phuong-Chi T.] Olive View UCLA Med Ctr, Div Nephrol & Hypertens, Sylmar, CA 91342 USA. RP Pham, PCT (reprint author), Olive View UCLA Med Ctr, Div Nephrol & Hypertens, 14445 Olive View Dr,2B-182, Sylmar, CA 91342 USA. EM Phuong-Mai.Pham@va.gov; Phuong-Anh.Pham@va.gov; PhamS@uthscsa.edu; PTP2@psu.edu; PPham@mednet.ucla.edu; Pham.PChi@ucla.edu NR 39 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1342-1751 EI 1437-7799 J9 CLIN EXP NEPHROL JI Clin. Exp. Nephrol. PD JUN PY 2015 VL 19 IS 3 BP 489 EP 495 DI 10.1007/s10157-014-1021-y PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CK5FZ UT WOS:000356249700022 PM 25150510 ER PT J AU Gilmore-Bykovskyi, AL Roberts, TJ Bowers, BJ Brown, RL AF Gilmore-Bykovskyi, Andrea L. Roberts, Tonya J. Bowers, Barbara J. Brown, Roger L. TI Caregiver Person-Centeredness and Behavioral Symptoms in Nursing Home Residents with Dementia: A Timed-Event Sequential Analysis SO GERONTOLOGIST LA English DT Article DE Person-centered interaction; Caregiver task-centeredness; Mealtime interactions ID CLUSTER-RANDOMIZED-TRIAL; CARE; AGITATION; ASSISTANTS AB Purpose: Evidence suggests that person-centered caregiving approaches may reduce dementia-related behavioral symptoms; however, little is known about the sequential and temporal associations between specific caregiver actions and behavioral symptoms. The aim of this study was to identify sequential associations between caregiver person-centered actions, task-centered actions, and resident behavioral symptoms and the temporal variation within these associations. Design and Methods: Videorecorded observations of naturally occurring interactions (N = 33; 724 min) between 12 nursing home (NH) residents with dementia and eight certified nursing assistants were coded for caregiver person-centered actions, task-centered actions, and resident behavioral symptoms and analyzed using timed-event sequential analysis. Results: Although caregiver actions were predominantly person-centered, we found that resident behavioral symptoms were significantly more likely to occur following task-centered caregiver actions than person-centered actions. Implications: Findings suggest that the person-centeredness of caregivers is sequentially and temporally related to behavioral symptoms in individuals with dementia. Additional research examining the temporal structure of these relationships may offer valuable insights into the utility of caregiver person-centeredness as a low-cost strategy for improving behavioral symptom management in the NH setting. C1 [Gilmore-Bykovskyi, Andrea L.; Roberts, Tonya J.] US Dept Vet Affairs, William S Middleton Hosp, Geriatr Res Educ & Clin, Madison, WI USA. [Gilmore-Bykovskyi, Andrea L.; Roberts, Tonya J.; Bowers, Barbara J.; Brown, Roger L.] Univ Wisconsin, Madison Sch Nursing, Madison, WI 53705 USA. RP Gilmore-Bykovskyi, AL (reprint author), Univ Wisconsin, Madison Sch Nursing, 5136 Cooper Hall,701 Highland Ave, Madison, WI 53705 USA. EM algilmore@wisc.edu OI Bowers, Barbara/0000-0002-3226-0718 FU National Hartford Centers of Gerontological Nursing Excellence; American Nurses Foundation Virginia Stone Research Grant in Clinical Gerontology; Nurses Foundation of Wisconsin; University of Wisconsin-Madison School of Nursing Eckburg Research Award; Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX This work was supported by the National Hartford Centers of Gerontological Nursing Excellence Patricia G. Archbold Scholar Program and Claire M. Fagin Postdoctoral Fellowship Program, the American Nurses Foundation Virginia Stone Research Grant in Clinical Gerontology, the Nurses Foundation of Wisconsin and the University of Wisconsin-Madison School of Nursing Eckburg Research Award. This work is also support, in part by the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (1UL1RR025011). NR 13 TC 1 Z9 1 U1 4 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD JUN PY 2015 VL 55 SU 1 BP S61 EP S66 DI 10.1093/geront/gnu164 PG 6 WC Gerontology SC Geriatrics & Gerontology GA CK4ZJ UT WOS:000356231600006 PM 26055782 ER PT J AU Varela, JC Tomlinson, S AF Varela, Juan Carlos Tomlinson, Stephen TI Complement An Overview for the Clinician SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Complement system; Complement activation; Complement regulation; Complement function; Inflammation; Immune response ID DECAY-ACCELERATING FACTOR; MEMBRANE-ATTACK COMPLEX; C-REACTIVE PROTEIN; CA2+-DEPENDENT ANIMAL LECTINS; VASCULAR ENDOTHELIAL-CELLS; SITE-DIRECTED MUTAGENESIS; HEMOLYTIC-UREMIC SYNDROME; INNATE IMMUNITY; T-CELLS; MICROVASCULAR THROMBOSIS AB The complement system is an essential component of the immune system. It is a highly integrative system and has a number of functions, including host defense, removal of injured cells and debris, modulation of metabolic and regenerative processes, and regulation of adaptive immunity. Complement is activated via different pathways and it is regulated tightly by several mechanisms to prevent host injury. Imbalance between complement activation and regulation can manifest in disease and injury to self. This article provides an outline of complement activation pathways, regulatory mechanisms, and normal physiologic functions of the system. C1 [Varela, Juan Carlos] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol,Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. EM tomlinss@musc.edu FU BLRD VA [I01 BX001218]; NCI NIH HHS [R01 CA158179]; NHLBI NIH HHS [R01 HL086576]; RRD VA [I01 RX001141] NR 102 TC 2 Z9 2 U1 2 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD JUN PY 2015 VL 29 IS 3 BP 409 EP + DI 10.1016/j.hoc.2015.02.001 PG 20 WC Oncology; Hematology SC Oncology; Hematology GA CK9EX UT WOS:000356544500002 PM 26043382 ER PT J AU Stone, GW Maehara, A Muller, JE Rizik, DG Shunk, KA Ben-Yehuda, O Genereux, P Dressler, O Parvataneni, R Madden, S Shah, P Brilakis, ES Kini, AS AF Stone, Gregg W. Maehara, Akiko Muller, James E. Rizik, David G. Shunk, Kendrick A. Ben-Yehuda, Ori Genereux, Philippe Dressler, Ovidiu Parvataneni, Rupa Madden, Sean Shah, Priti Brilakis, Emmanouil S. Kini, Annapoorna S. CA CANARY Investigators TI Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE atherosclerosis; distal protection; embolization; myocardial infarction; near-infrared spectroscopy ID LIPID-CORE PLAQUES; INTRAPROCEDURAL THROMBOTIC EVENTS; EXPERT CONSENSUS DOCUMENT; INTRAVASCULAR ULTRASOUND; UNIVERSAL DEFINITION; ADVERSE OUTCOMES; ISCHEMIC EVENTS; ELEVATION; REVASCULARIZATION; SPECTROSCOPY AB OBJECTIVES This study sought to determine whether pre-percutaneous coronary intervention (PCI) plaque characterization using near-infrared spectroscopy identifies lipid-rich plaques at risk of periprocedural myonecrosis and whether these events may be prevented by the use of a distal protection filter during PCI. BACKGROUND Lipid-rich plaques may be prone to distal embolization and periprocedural myocardial infarction (MI) in patients undergoing PCI. METHODS Patients undergoing stent implantation of a single native coronary lesion were enrolled in a multicenter, prospective trial. Near-infrared spectroscopy and intravascular ultrasound were performed at baseline, and lesions with a maximal lipid core burden index over any 4-mm length (maxLCBI(4mm)) >= 600 were randomized to PCI with versus without a distal protection filter. The primary endpoint was periprocedural MI, defined as troponin or a creatine kinase-myocardial band increase to 3 or more times the upper limit of normal. RESULTS Eighty-five patients were enrolled at 9 U.S. sites. The median (interquartile range) maxLCBI(4mm) was 448.4 (274.8 to 654.4) pre-PCI and decreased to 156.0 (75.6 to 312.6) post-PCI (p < 0.0001). Periprocedural MI developed in 21 patients (24.7%). The maxLCBI(4mm) was higher in patients with versus without MI (481.5 [425.6 to 679.6] vs. 371.5 [228.9 to 611.6], p = 0.05). Among 31 randomized lesions with maxLCBI(4mm) >= 600, there was no difference in the rates of periprocedural MI with versus without the use of a distal protection filter (35.7% vs. 23.5%, respectively; relative risk: 1.52; 95% confidence interval: 0.50 to 4.60, p = 0.69). CONCLUSIONS Plaque characterization by near-infrared spectroscopy identifies lipid-rich lesions with an increased likelihood of periprocedural MI after stent implantation, presumably due to distal embolization. However, in this pilot randomized trial, the use of a distal protection filter did not prevent myonecrosis after PCI of lipid-rich plaques. (C) 2015 by the American College of Cardiology Foundation. C1 [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori] Columbia Univ, Med Ctr, New York, NY 10022 USA. [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori] New York Presbyterian Hosp, New York, NY USA. [Stone, Gregg W.; Maehara, Akiko; Ben-Yehuda, Ori; Genereux, Philippe; Dressler, Ovidiu; Parvataneni, Rupa] Cardiovasc Res Fdn, New York, NY USA. [Muller, James E.; Madden, Sean; Shah, Priti] InfraReDx Inc, Burlington, MA USA. [Rizik, David G.] Scottsdale Healthcare, Scottsdale, AZ USA. [Shunk, Kendrick A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Genereux, Philippe] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada. [Brilakis, Emmanouil S.] North Texas Vet Affairs Med Ctr, Dallas, TX USA. [Kini, Annapoorna S.] Mt Sinai Hosp, New York, NY 10029 USA. RP Stone, GW (reprint author), Columbia Univ, Med Ctr, Cardiovasc Res Fdn, 111 E 59th St,11th Floor, New York, NY 10022 USA. EM gs2184@columbia.edu FU St. Jude Medical; Guerbet; InfraReDx FX The names of the investigators, institutions, and research organizations participating in the CANARY trial are provided in Online Appendix 1. Dr. Stone is a past consultant for Boston Scientific, Volcano, and InfraReDx. Dr. Maehara is a consultant for Boston Scientific and ACIST; and has received speaker fees from St. Jude Medical. Drs. Muller and Madden and Ms. Shah are full-time employees of InfraReDx. Dr. Brilakis has served as a consultant and has received speaker honoraria from St. Jude, Terumo, Asahi, Abbott Vascular, Elsevier, Somahlution, and Boston Scientific; has received research support from Guerbet and InfraReDx; and that his spouse is an employee of Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 25 TC 14 Z9 14 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2015 VL 8 IS 7 BP 927 EP 936 DI 10.1016/j.jcin.2015.01.032 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK5YJ UT WOS:000356303900014 PM 26003018 ER PT J AU Feldman, MD Phipps, JE AF Feldman, Marc D. Phipps, Jennifer E. TI Can Multimodal Invasive Imaging Be Used to Predict Periprocedural Myocardial Infarctions? SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE atherosclerosis; coronary artery disease; distal protection; embolization; fibrous cap thickness; intravascular imaging; myocardial infarction; near-infrared spectroscopy; percutaneous coronary intervention ID OPTICAL COHERENCE TOMOGRAPHY; THIN-CAP FIBROATHEROMA; NEAR-INFRARED SPECTROSCOPY; ACUTE CORONARY SYNDROME; LIPID-CORE PLAQUES; INTRAVASCULAR ULTRASOUND; HIGH-RISK; ARTERY; FREQUENCY; INTRACORONARY C1 [Feldman, Marc D.; Phipps, Jennifer E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Cardiol, 7703 Floyd Curl Dr,MSC 7872, San Antonio, TX 78229 USA. EM feldmanm@uthscsa.edu NR 18 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD JUN PY 2015 VL 8 IS 7 BP 946 EP 948 DI 10.1016/j.jcin.2015.04.002 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CK5YJ UT WOS:000356303900016 PM 26088512 ER PT J AU Oresanya, L Zhao, SJ Gan, SQ Fries, BE Goodney, PP Covinsky, KE Conte, MS Finlayson, E AF Oresanya, Lawrence Zhao, Shoujun Gan, Siqi Fries, Brant E. Goodney, Philip P. Covinsky, Kenneth E. Conte, Michael S. Finlayson, Emily TI Functional Outcomes After Lower Extremity Revascularization in Nursing Home Residents A National Cohort Study SO JAMA INTERNAL MEDICINE LA English DT Article ID CRITICAL LIMB ISCHEMIA; INFRAINGUINAL BYPASS-SURGERY; AMBULATORY FUNCTION; ELDERLY ADULTS; SALVAGE; MDS AB IMPORTANCE Lower extremity revascularization often seeks to allow patients with peripheral arterial disease to maintain the ability to walk, a key aspect of functional independence. Surgical outcomes in patients with high levels of functional dependence are poorly understood. OBJECTIVE To determine functional status trajectories, changes in ambulatory status, and survival after lower extremity revascularization in nursing home residents. DESIGN Using full Medicare claims data for 2005 to 2009, we identified nursing home residents who underwent lower extremity revascularization. With the Minimum Data Set for Nursing Homes activities of daily living summary score, we examined changes in their ambulatory and functional status after surgery. We identified patient and surgery characteristics associated with a composite measure of clinical and functional failure-death or nonambulatory status 1 year after surgery. SETTING All nursing homes in the United States participating in Medicare or Medicaid. PARTICIPANTS Nursing home residents who underwent lower extremity revascularization. MAIN OUTCOMES AND MEASURES Functional status, ambulatory status, and death. RESULTS During the study period, 10 784 long-term nursing home residents underwent lower extremity revascularization. Prior to surgery, 75% of the residents were not walking; 40% had experienced functional decline. One year after surgery, 51% of patients had died, 28% were nonambulatory, and 32% had sustained functional decline. Among 1672 residents who were ambulatory before surgery, 63% had died or were nonambulatory at 1 year; among 7188 who were nonambulatory, 89% had died or were nonambulatory. After multivariate adjustment, factors independently associated with death or nonambulatory status were 80 years or older (adjusted hazard ratio [AHR], 1.28; 95% CI, 1.16-1.40), cognitive impairment (AHR, 1.23; 95% CI, 1.18-1.29), congestive heart failure (AHR, 1.16; 95% CI, 1.11-1.22), renal failure (AHR, 1.09; 95% CI, 1.04-1.14), emergent surgery (AHR, 1.29; 95% CI, 1.23-1.35), nonambulatory status before surgery (AHR, 1.88; 95% CI, 1.78-1.99), and decline in activities of daily living before surgery (AHR, 1.23; 95% CI, 1.18-1.28). CONCLUSIONS AND RELEVANCE Of nursing home residents in the United States who undergo lower extremity revascularization, few are alive and ambulatory 1 year after surgery. Most who were still alive had gained little, if any, function. C1 [Oresanya, Lawrence; Zhao, Shoujun; Conte, Michael S.; Finlayson, Emily] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Gan, Siqi] Univ Calif San Francisco, Fielding Sch Publ Hlth, San Francisco, CA 94143 USA. [Fries, Brant E.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. [Fries, Brant E.] Univ Michigan, Ann Arbor, MI 48109 USA. [Fries, Brant E.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Goodney, Philip P.] Geisel Sch Med Dartmouth, Dept Surg, Hanover, NH USA. [Goodney, Philip P.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Goodney, Philip P.] VA Outcomes Grp, White River Jct, VT USA. [Covinsky, Kenneth E.; Finlayson, Emily] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Finlayson, Emily] Univ Calif San Francisco, Phillip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. RP Finlayson, E (reprint author), Philip R Lee Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94118 USA. EM emily.finlayson@ucsf.edu FU National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging [K08AG028965]; University of California, San Francisco, Claude D. Pepper Older Americans Independence Center FX Dr Finlayson was supported by a National Institute on Aging/Paul B. Beeson Clinical Scientist Development Award in Aging (K08AG028965) and the University of California, San Francisco, Claude D. Pepper Older Americans Independence Center. NR 21 TC 5 Z9 5 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 951 EP 957 DI 10.1001/jamainternmed.2015.0486 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400020 PM 25844523 ER PT J AU Wong, SSPY Kreuter, W Curtis, JR Hall, YN O'Hare, AM AF Wong, Susan P. Y. Kreuter, William Curtis, J. Randall Hall, Yoshio N. O'Hare, Ann M. TI Trends in In-Hospital Cardiopulmonary Resuscitation and Survival in Adults Receiving Maintenance Dialysis SO JAMA INTERNAL MEDICINE LA English DT Article ID LONG-TERM SURVIVAL; OF-LIFE CARE; CARDIAC-ARREST; HEALTH-CARE; HEMODIALYSIS-PATIENTS; PATIENTS PREFERENCES; ADVANCE DIRECTIVES; UNITED-STATES; OUTCOMES; END AB IMPORTANCE Understanding cardiopulmonary resuscitation (CPR) practices and outcomes can help to support advance care planning in patients receiving maintenance dialysis. OBJECTIVE To characterize patterns and outcomes of in-hospital CPR in US adults receiving maintenance dialysis. DESIGN, SETTING, AND PARTICIPANTS This national retrospective cohort study studied 663 734 Medicare beneficiaries 18 years or older from a comprehensive national registry for end-stage renal disease who initiated maintenance dialysis from January 1, 2000, through December 31, 2010. EXPOSURES Receipt of in-hospital CPR from 91 days after dialysis initiation through the time of death, first kidney transplantation, or end of follow-up on December 31, 2011. MAIN OUTCOMES AND MEASURES Incidence of CPR and survival after the first episode of CPR recorded in Medicare claims during follow-up. RESULTS The annual incidence of CPR for the overall cohort was 1.4 events per 1000 in-hospital days (95% CI, 1.3-1.4). A total of 21.9% CPR recipients (95% CI, 21.4%-22.3%) survived to hospital discharge, with a median postdischarge survival of 5.0 months (interquartile range, 0.7-16.8 months). Among patients who died in the hospital, 14.9%(95% CI, 14.8%-15.1%) received CPR during their terminal admission. From 2000 to 2011, there was an increase in the incidence of CPR (1.0 events per 1000 in-hospital days; 95% CI, 0.9-1.1; to 1.6 events per 1000 in-hospital days; 95% CI, 1.6-1.7; P for trend <. 001), the proportion of CPR recipients who survived to discharge (15.2%; 95% CI, 11.1%-20.5%; to 28%; 95% CI, 26.7%-29.4%; P for trend <. 001), and the proportion of in-hospital deaths preceded by CPR (9.5%; 95% CI, 8.4%-10.8%; to 19.8%; 95% CI, 19.2%-20.4%; P for trend <. 001), with no substantial change in duration of postdischarge survival. CONCLUSIONS AND RELEVANCE Among a national cohort of patients receiving maintenance dialysis, the incidence of CPR was higher and long-term survival worse than reported for other populations. C1 [Wong, Susan P. Y.; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Wong, Susan P. Y.; Curtis, J. Randall; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA. [Wong, Susan P. Y.; Curtis, J. Randall; Hall, Yoshio N.; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Kreuter, William] Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA. [Hall, Yoshio N.; O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. [O'Hare, Ann M.] Grp Hlth Res Inst, Seattle, WA USA. RP Wong, SSPY (reprint author), Univ Washington, Kidney Res Inst, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU Beeson Career Development Award; National Institute on Aging [U01-DK102105]; Clinical Scientist in Nephrology Award from the American Kidney Fund [T32DK746730] FX This study was supported by a Beeson Career Development Award and grant U01-DK102105 from the National Institute on Aging (Dr O'Hare) and by grant T32DK746730 and the Clinical Scientist in Nephrology Award from the American Kidney Fund (DrWong). NR 45 TC 14 Z9 14 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2015 VL 175 IS 6 BP 1028 EP 1035 DI 10.1001/jamainternmed.2015.0406 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CK4GD UT WOS:000356180400034 PM 25915762 ER PT J AU Choby, GW Kim, J Ling, DC Abberbock, S Mandal, R Kim, S Ferris, RL Duvvuri, U AF Choby, Garret W. Kim, Jeehong Ling, Diane C. Abberbock, Shira Mandal, Rajarsi Kim, Seungwon Ferris, Robert L. Duvvuri, Umamaheswar TI Transoral Robotic Surgery Alone for Oropharyngeal Cancer Quality-of-Life Outcomes SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; FUNCTIONAL OUTCOMES; ASSISTED SURGERY; NECK; HEAD; IMPACT AB IMPORTANCE Few studies have examined quality-of-life (QOL) outcomes in patients who undergo transoral robotic surgery (TORS) alone (ie, without adjuvant radiotherapy or chemoradiotherapy). OBJECTIVE To report QOL outcomes of patients with oropharyngeal squamous cell carcinoma who receive only TORS. DESIGN, SETTING, AND PARTICIPANTS Medical records for all patients undergoing TORS for treatment of primary oropharyngeal squamous cell carcinoma from May 1, 2010, to March 31, 2014, at a tertiary care academic cancer center were examined from June through September 2014. Thirty-four patients who did not receive adjuvant therapy after TORS were included in the study. INTERVENTION Primary surgical resection via TORS. MAIN OUTCOMES AND MEASURES The University of Washington Quality of Life, version 4, questionnaire was completed by patients preoperatively and at 1-, 6-, 12-, and 24-month intervals after TORS. Demographic, clinicopathologic, and follow-up data were collected. RESULTS Mean follow-up time was 14 months (May 1, 2010, to April 30, 2014). Most patients had T1 (20 [59%]) or T2 (13 [38%]) and N0 (13 [38%]) or N1 (16 [47%]) disease. Statistically significant improvement in QOL outcomes was noted in the following postoperative domains: chewing from 1 month (median, 50 [IQR, 50-100]) to 12 months (100 [IQR, 100-100]; P = .048), swallowing from 1 month (70 [IQR, 30-85]) to 6 months (100 [IQR, 70-100]; P = .047) and 1 to 24 months (100 [IQR, 70-100]; P = .048), pain from 1 month (38 [IQR, 25-75]) to 6 months (88 [IQR, 75-100]; P = .006) and 1 to 12 months after surgery (100 [IQR, 75-100]; P = .01), and activity from 1 month (63 [IQR, 50-88]) to 24 months (100 [IQR, 75-100]; P = .03). Two participants (6%) died during the follow-up period: 1 because of disease and 1 because of amyocardial infarction. Two patients (6%) required temporary gastrostomy tube placement, but none required tracheostomy. CONCLUSIONS AND RELEVANCE Appropriately selected patients who undergo TORS alone for oropharyngeal squamous cell carcinoma experience acceptable short-and long-term QOL outcomes. C1 [Choby, Garret W.; Mandal, Rajarsi; Kim, Seungwon; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Kim, Jeehong; Ling, Diane C.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Abberbock, Shira] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Eye & Ear Inst 500, 200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs Career Development Award; PNC Foundation FX This work was funded in part by the Department of Veterans Affairs Career Development Award and the PNC Foundation (Dr Duvvuri). NR 19 TC 10 Z9 10 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD JUN PY 2015 VL 141 IS 6 BP 499 EP 504 DI 10.1001/jamaoto.2015.0347 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CK8AC UT WOS:000356458300001 PM 25834991 ER PT J AU Beaber, EF Kim, JJ Schapira, MM Tosteson, ANA Zauber, AG Geiger, AM Kamineni, A Weaver, DL Tiro, JA AF Beaber, Elisabeth F. Kim, Jane J. Schapira, Marilyn M. Tosteson, Anna N. A. Zauber, Ann G. Geiger, Ann M. Kamineni, Aruna Weaver, Donald L. Tiro, Jasmin A. CA Population-Based Res Optimizing TI Unifying Screening Processes Within the PROSPR Consortium: A Conceptual Model for Breast, Cervical, and Colorectal Cancer Screening SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID SERVICES TASK-FORCE; COMMON DATA ELEMENTS; TIMELY FOLLOW-UP; RECOMMENDATION STATEMENT; PERSONALIZED REGIMENS; RESEARCH PERSPECTIVE; SOCIETY GUIDELINES; MULTILEVEL FACTORS; CARE CONTINUUM; TISSUE-BANK AB General frameworks of the cancer screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one cancer site to other sites. We present a trans-organ conceptual model that incorporates a single screening episode for breast, cervical, and colorectal cancers into a unified framework based on clinical guidelines and protocols; the model concepts could be expanded to other organ sites. The model covers four types of care in the screening process: risk assessment, detection, diagnosis, and treatment. Interfaces between different provider teams (eg, primary care and specialty care), including communication and transfer of responsibility, may occur when transitioning between types of care. Our model highlights across each organ site similarities and differences in steps, interfaces, and transitions in the screening process and documents the conclusion of a screening episode. This model was developed within the National Cancer Institute-funded consortium Population-based Research Optimizing Screening through Personalized Regimens (PROSPR). PROSPR aims to optimize the screening process for breast, cervical, and colorectal cancer and includes seven research centers and a statistical coordinating center. Given current health care reform initiatives in the United States, this conceptual model can facilitate the development of comprehensive quality metrics for cancer screening and promote trans-organ comparative cancer screening research. PROSPR findings will support the design of interventions that improve screening outcomes across multiple cancer sites. C1 [Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Kim, Jane J.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Schapira, Marilyn M.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Tosteson, Anna N. A.] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Dept Med, Lebanon, NH USA. [Tosteson, Anna N. A.] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Geiger, Ann M.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. [Kamineni, Aruna] Grp Hlth Res Inst, Seattle, WA USA. [Weaver, Donald L.] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. [Weaver, Donald L.] Univ Vermont, Ctr Canc, Burlington, VT USA. [Tiro, Jasmin A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. RP Beaber, EF (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-A306,POB 19024, Seattle, WA 98109 USA. EM ebeaber@fredhutch.org OI Tiro, Jasmin/0000-0001-8300-0441 FU NCI NIH HHS [U54 CA164336, U54CA163308, U54 CA163261, U54 CA163303, U54CA163303, U54CA163262, U54 CA163262, P30 CA008748, U54CA163307, U54CA163308-04S1, P30 CA023108, 54CA163262-04S1, U54 CA163307, U01CA163304, U54CA163261-04S1, U54 CA163313, U01 CA163304, U54CA164336, U54 CA163308, U54CA163261, U54CA163313] NR 67 TC 6 Z9 6 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv120 DI 10.1093/jnci/djv120 PG 8 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500019 PM 25957378 ER PT J AU Tomer, Y Dolan, LM Kahaly, G Divers, J D'Agostino, RB Imperatore, G Dabelea, D Marcovina, S Black, MH Pihoker, C Hasham, A Hammerstad, SS Greenberg, DA Lotay, V Zhang, WJ Monti, MC Matheis, N AF Tomer, Yaron Dolan, Lawrence M. Kahaly, George Divers, Jasmin D'Agostino, Ralph B., Jr. Imperatore, Giuseppina Dabelea, Dana Marcovina, Santica Black, Mary Helen Pihoker, Catherine Hasham, Alia Hammerstad, Sara Salehi Greenberg, David A. Lotay, Vaneet Zhang, Weijia Monti, Maria Cristina Matheis, Nina CA SEARCH Diabet Youth Study TI Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Type 1 diabetes; Graves' disease; Hashimoto's thyroiditis; Gene; HLA ID HASHIMOTOS-THYROIDITIS; RISK LOCI; SUSCEPTIBILITY; DISEASE; ASSOCIATION; FAMILIES; GENETICS; CHILDREN; MELLITUS; COMMON AB Autoimmune thyroid diseases (AITD) and Type 1 diabetes (T1D) frequently occur in the same individual pointing to a strong shared genetic susceptibility. Indeed, the co-occurrence of T1D and AITD in the same individual is classified as a variant of the autoimmune polyglandular syndrome type 3 (designated APS3v). Our aim was to identify new genes and mechanisms causing the co-occurrence of T1D AITD (APS3v) in the same individual using a genome-wide approach. For our discovery set we analyzed 346 Caucasian APS3v patients and 727 gender and ethnicity matched healthy controls. Genotyping was performed using the Illumina Human660W-Quad.v1. The replication set included 185 APS3v patients and 340 controls. Association analyses were performed using the PLINK program, and pathway analyses were performed using the MAGENTA software. We identified multiple signals within the HLA region and conditioning studies suggested that a few of them contributed independently to the strong association of the HLA locus with APS3v. Outside the HLA region, variants in GPR103, a gene not suggested by previous studies of APS3v, T1D, or AITD, showed genolne-wide significance (p < 5 x 10(-8)). In addition, a locus on 1p13 containing the PTPN22 gene showed genome-wide significant associations. Pathway analysis demonstrated that cell cycle, B-cell development, CD40, and CTLA-4 signaling were the major pathways contributing to the pathogenesis of APS3v. These findings suggest that complex mechanisms involving T-cell and B-cell pathways are involved in the strong genetic association between AITD and T1D. Published by Elsevier Ltd. C1 [Tomer, Yaron; Hasham, Alia; Hammerstad, Sara Salehi] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Endocrinol, Cincinnati, OH 45229 USA. [Kahaly, George; Matheis, Nina] Johannes Gutenberg Univ Mainz, Med Ctr, Thyroid Res Lab, D-55122 Mainz, Germany. [Divers, Jasmin; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Dabelea, Dana] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Marcovina, Santica] Univ Washington, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Black, Mary Helen] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Greenberg, David A.] Nationwide Childrens Hosp, Battelle Ctr Math Med, Columbus, OH USA. [Lotay, Vaneet; Zhang, Weijia] Icahn Sch Med Mt Sinai, Dept Med Bioinformat Core, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Monti, Maria Cristina] Univ Pavia, Dept Publ Hlth Neurosci Expt & Forens Med, I-27100 Pavia, Italy. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395; Monti, Maria Cristina/0000-0003-1586-527X FU NIH-NIDDK [DK61659, DK067555, DK073681]; Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai; Andrea and Charles Bronfman Philanthropies; Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR) [UL1RR029882]; Seattle Children's Hospital (NIH CTSA) of the University of Washington [UL1 TR00423]; University of Colorado Pediatric Clinical and Translational Research Center (CTRC) [UL1 TR000154]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [8 UL1 TR000077] FX We thank the Human Biological Data Interchange (Philadelphia, PA) for assisting with the recruitment of the replication set. This work was supported in part by grants DK61659, DK067555 & DK073681 from NIH-NIDDK (to YT). This study was also supported in part by the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai with funding provided by the Andrea and Charles Bronfman Philanthropies.; Grant Support: SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases.; Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Seattle Children's Hospital (NIH CTSA Grant UL1 TR00423 of the University of Washington); University of Colorado Pediatric Clinical and Translational Research Center (CTRC) (Grant Number UL1 TR000154) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8 UL1 TR000077; and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 40 TC 14 Z9 15 U1 1 U2 9 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD JUN PY 2015 VL 60 BP 32 EP 39 DI 10.1016/j.jaut.2015.03.006 PG 8 WC Immunology SC Immunology GA CK9JX UT WOS:000356557500004 PM 25936594 ER PT J AU Dain, AS Bradley, EH Hurzeler, R Aldridge, MD AF Dain, Aleksandra S. Bradley, Elizabeth H. Hurzeler, Rosemary Aldridge, Melissa D. TI Massage, Music, and Art Therapy in Hospice: Results of a National Survey SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hospice; complementary and alternative medicine; massage therapy; art therapy; music therapy ID ALTERNATIVE MEDICINE; PALLIATIVE CARE; FOR-PROFIT; MORTALITY; CANCER; COMPLEMENTARY; PATTERNS; QUALITY; ILLNESS; NURSES AB Context. Complementary and alternative medicine (CAM) provides clinical benefits to hospice patients, including decreased pain and improved quality of life. Yet little is known about the extent to which U.S. hospices employ CAM therapists. Objectives. To report the most recent national data regarding the inclusion of art, massage, and music therapists on hospice interdisciplinary teams and how CAM therapist staffing varies by hospice characteristics. Methods. A national cross-sectional survey of a random sample of hospices (n = 591; 84% response rate) from September 2008 to November 2009. Results. Twenty-nine percent of hospices (169 of 591) reported employing an art, massage, or music therapist. Of those hospices, 74% employed a massage therapist, 53% a music therapist, and 22% an art therapist, and 42% expected the therapist to attend interdisciplinary staff meetings, indicating a significant role for these therapists on the patient's care team. In adjusted analyses, larger hospices compared with smaller hospices had significantly higher odds of employing a CAM therapist (adjusted odds ratio 6.38; 95% CI 3.40, 11.99) and for-profit hospices had lower odds of employing a CAM therapist compared with nonprofit hospices (adjusted odds ratio 0.52; 95% CI 0.32, 0.85). Forty-four percent of hospices in the Mountain/Pacific region reported employing a CAM therapist vs. 17% in the South Central region. Conclusion. Less than one-third of U.S. hospices employ art, massage, or music therapists despite the benefits these services may provide to patients and families. A higher proportion of large hospices, nonprofit hospices, and hospices in the Mountain/Pacific region employ CAM therapists, indicating differential access to these important services. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Dain, Aleksandra S.; Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dain, Aleksandra S.] James J Peters VA, Bronx, NY USA. [Bradley, Elizabeth H.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. [Hurzeler, Rosemary] John Thompson Hosp Inst Educ Training & Res Inc, Branford, CT USA. RP Aldridge, MD (reprint author), Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM Melissa.Aldridge@mssm.edu FU National Cancer Institute [1R01CA116398]; National Institute of Nursing Research [5R01NR013499]; John D. Thompson Foundation; American Federation for Aging Research and Medical Student Training in Aging Research FX This study was supported by the National Cancer Institute 1R01CA116398 (Bradley); National Institute of Nursing Research 5R01NR013499 (Aldridge); the John D. Thompson Foundation (Bradley); and the American Federation for Aging Research and Medical Student Training in Aging Research (Dain). The authors declare no conflicts of interest. NR 36 TC 2 Z9 2 U1 7 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD JUN PY 2015 VL 49 IS 6 BP 1035 EP 1041 DI 10.1016/j.jpainsymman.2014.11.295 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CL0BY UT WOS:000356604700012 PM 25555445 ER PT J AU Vaid, M Katiyar, SK AF Vaid, Mudit Katiyar, Santosh K. TI Grape seed proanthocyanidins inhibit cigarette smoke condensate-induced lung cancer cell migration through inhibition of NADPH oxidase and reduction in the binding of p22(phox) and p47(phox) proteins SO MOLECULAR CARCINOGENESIS LA English DT Article DE cigarette smoke condensate; oxidative stress; lung cancer cells; proanthocyanidins; cancer cell migration; NADPH oxidase ID SKH-1 HAIRLESS MICE; OXIDATIVE STRESS; MESENCHYMAL TRANSITION; LIPID-PEROXIDATION; NITRIC-OXIDE; IN-VITRO; ACTIVATION; EXTRACT; PHOSPHORYLATION; PEROXYNITRITE AB Cigarette smoking is the major cause of lung cancer. It is therefore important to develop effective strategies that target molecular abnormalities induced by cigarette smoke condensate (CSC). Cigarette smoking increases oxidative stress particularly via activation of NADPH oxidase (NOX), a key source of superoxide anion production. Here, we report that grape seed proanthocyanidins (GSPs) exert an inhibitory effect on the CSC-induced migration of non-small cell lung cancer (NSCLC) cells (A549, H460, and H1299). Using an in vitro invasion assay, we found that treatment of NSCLC cells with CSC increased NSCLC cell migration by enhancing NOX mediated-oxidative stress. Treatment of NSCLC cells with GSPs inhibited the CSC-induced cell migration through reduction in oxidative stress levels and a reduction in the epithelial-to-mesenchymal transition. To identify the molecular targets of GSPs, we examined the effects of GSPs on CSC-induced alterations in the levels of key NOX components, namely p22(phox) and p47(phox) proteins, using A549 cells. We also determined the effect of GSPs on CSC-induced interaction/binding between these proteins, which is a key event in NOX activation. We found that treatment of A549 cells with GSPs not only inhibited the CSC-induced increase in the expression levels of p22(phox) and p47(phox), but also reduced the binding of p22(phox) to p47(phox) proteins. This new insight into the anti-lung cancer cell migration activity of GSPs could serve as a basis for development of improved chemopreventive or therapeutic strategies for lung cancer. (c) 2014 Wiley Periodicals, Inc. C1 [Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670,Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. FU Veterans Administration Merit Review Award [1I01BX001410-01] FX Grant sponsor: Veterans Administration Merit Review Award; Grant number: 1I01BX001410-01 NR 39 TC 5 Z9 5 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0899-1987 EI 1098-2744 J9 MOL CARCINOGEN JI Mol. Carcinog. PD JUN PY 2015 VL 54 SU 1 SI SI BP E61 EP E71 DI 10.1002/mc.22173 PG 11 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA CK8UG UT WOS:000356513600008 PM 24798688 ER PT J AU Mamikonyan, E Xie, SX Melvin, E Weintraub, D AF Mamikonyan, Eugenia Xie, Sharon X. Melvin, Emilie Weintraub, Daniel TI Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study SO MOVEMENT DISORDERS LA English DT Article DE clinical trials randomized controlled; mild cognitive impairment; Parkinson's disease; cholinesterase inhibitor; class I ID DEMENTIA RATING-SCALE; QUALITY-OF-LIFE; NONMOTOR SYMPTOMS; DIAGNOSTIC-CRITERIA; MATTIS DEMENTIA; DOUBLE-BLIND; DISABILITY; DONEPEZIL; VALIDITY; TRIAL AB Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n=28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal patch. The primary outcome measure was the Alzheimer's Disease Cooperative StudyClinical Global Impression of Change (ADCS-CGIC). Secondary outcomes included the Montreal Cognitive Assessment (MoCA), Dementia Rating Scale-2 (DRS-2), Neurotrax computerized cognitive battery, the Everyday Cognition Battery (ECB), and the Parkinson's Disease Questionnaire (PDQ-8). Twenty-six participants (92.9%) completed both study phase assessments, and 23 (82.1%) completed both phases on study medication. The CGIC response rate demonstrated a trend effect in favor of rivastigmine (regression coefficient for interaction term in linear mixed-effects model=0.44, F[df]=3.01 [1, 24], P=0.096). For secondary outcomes, a significant rivastigmine effect on the ECB (regression coefficient=-2.41, F[df]=5.81 [1, 22.05], P=0.03) was seen, but no treatment effect was found on any cognitive measures. Trend effects also occurred in favor of rivastigmine on the PDQ-8 (regression coefficient=4.55, F[df]=3.93 [1, 14. 79], P=0.09) and the State Anxiety Inventory (regression coefficient=-1.24, F[df]=3.17 [1, 33], P=0.08). Rivastigmine in PD-MCI showed a trend effect for improvements on a global rating of cognition, disease-related health status, and anxiety severity, and significant improvement on a performance-based measure of cognitive abilities. (c) 2015 International Parkinson and Movement Disorder Society C1 [Mamikonyan, Eugenia; Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Melvin, Emilie] Duke Univ, Durham, NC USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Educ & Clin Ctr PADRECC & MIRECC, Parkinsons Dis & Mental Illness Res, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU Novartis Pharmaceuticals FX Novartis Pharmaceuticals provided financial support as well as drug supply (rivastigmine and placebo patch) for this investigator initiated clinical trial. NR 46 TC 24 Z9 24 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 912 EP 918 DI 10.1002/mds.26236 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600009 PM 25914281 ER PT J AU Weintraub, D Simuni, T Caspell-Garcia, C Coffey, C Lasch, S Siderowf, A Aarsland, D Barone, P Burn, D Chahine, LM Eberling, J Espay, AJ Foster, ED Leverenz, JB Litvan, I Richard, I Troyer, MD Hawkins, KA AF Weintraub, Daniel Simuni, Tanya Caspell-Garcia, Chelsea Coffey, Christopher Lasch, Shirley Siderowf, Andrew Aarsland, Dag Barone, Paolo Burn, David Chahine, Lama M. Eberling, Jamie Espay, Alberto J. Foster, Eric D. Leverenz, James B. Litvan, Irene Richard, Irene Troyer, Matthew D. Hawkins, Keith A. CA Parkinson's Progression Markers In TI Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE anxiety; apathy; cognition; depression; impulse control disorder; Parkinson's disease; psychosis ID IMPULSE CONTROL DISORDERS; NONMOTOR SYMPTOMS; RATING-SCALE; DEPRESSION SCALE; MOTOR SUBTYPE; IMPAIRMENT; DEMENTIA; INCIDENT; COHORT; SPECTRUM AB This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). BackgroundBoth CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS. MethodsParkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy. ResultsBaseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P<0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P<0.001) and apathy (P<0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P=0.51). ConclusionsApproximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS. (c) 2015 International Parkinson and Movement Disorder Society C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Chahine, Lama M.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Caspell-Garcia, Chelsea; Coffey, Christopher; Foster, Eric D.] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. [Lasch, Shirley] IND, New Haven, CT USA. [Lasch, Shirley] MNI, New Haven, CT USA. [Siderowf, Andrew] Avid Radiopharmaceut, Philadelphia, PA USA. [Aarsland, Dag] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Aarsland, Dag] Karolinska Inst, Alzheimer Dis Res Ctr, Stockholm, Sweden. [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway. [Barone, Paolo] Univ Salerno, Dept Med, Neurosci Sect, Neurodegenerat Dis Ctr, Salerno, Italy. [Burn, David] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Eberling, Jamie] Michael J Fox Fdn Parkinsons Res, New York, NY USA. [Espay, Alberto J.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH USA. [Leverenz, James B.] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Litvan, Irene] Univ Calif San Diego, Dept Neurosci, UCSD Movement Disorder Ctr, San Diego, CA 92103 USA. [Richard, Irene] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [Richard, Irene] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Troyer, Matthew D.] Medivation Inc, San Francisco, CA USA. [Hawkins, Keith A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, Psychiat & Neurol, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu RI Rowe, Dominic/B-6661-2011 OI Rowe, Dominic/0000-0003-0912-2146; Aarsland, Dag/0000-0001-6314-216X; Standaert, David/0000-0003-2921-8348; Litvan, Irene/0000-0002-3485-3445 FU Michael J. Fox Foundation (MJFF) FX The study is funded by the Michael J. Fox Foundation (MJFF). The MJFF designed the study and is overseeing its conduct at the study sites but is not involved in data analysis. The Foundation reviewed and approved this manuscript for submission. Details regarding MJFF's Parkinson Progression Marker Initiative (PPMI) have been previously published (Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95:629-35). NR 44 TC 37 Z9 39 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 919 EP 927 DI 10.1002/mds.26170 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600010 PM 25737166 ER PT J AU Bekris, LM Tsuang, DW Peskind, ER Yu, CE Montine, TJ Zhang, J Zabetian, CP Leverenz, JB AF Bekris, Lynn M. Tsuang, Debby W. Peskind, Elaine R. Yu, Chang E. Montine, Thomas J. Zhang, Jing Zabetian, Cyrus P. Leverenz, James B. TI Cerebrospinal fluid A(42) levels and APP processing pathway genes in Parkinson's disease SO MOVEMENT DISORDERS LA English DT Article DE APP; ADAM10; BACE1; BACE2; PSEN1; PSEN2; PEN2; NCSTN; APH1B; Parkinson's disease; cerebrospinal fluid ID GAMMA-SECRETASE COMPLEX; CSF AMYLOID-BETA; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ALPHA-SECRETASE; DOWN-SYNDROME; LEWY BODIES; PLAQUE-FORMATION; SENILE PLAQUES; TAU PROTEINS AB BackgroundOf recent interest is the finding that certain cerebrospinal fluid (CSF) biomarkers traditionally linked to Alzheimer's disease (AD), specifically amyloid beta protein (A), are abnormal in PD CSF. The aim of this exploratory investigation was to determine whether genetic variation within the amyloid precursor protein (APP) processing pathway genes correlates with CSF A(42) levels in Parkinson's disease (PD). MethodsParkinson's disease (n=86) and control (n=161) DNA were genotyped for 19 regulatory region tagging single-nucleotide polymorphisms (SNPs) within nine genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN, and APH1B) involved in the cleavage of APP. The SNP genotypes were tested for their association with CSF biomarkers and PD risk while adjusting for age, sex, and APOE 4 status. ResultsSignificant correlation with CSF A(42) levels in PD was observed for two SNPs, (APP rs466448 and APH1B rs2068143). Conversely, significant correlation with CSF A(42) levels in controls was observed for three SNPs (APP rs214484, rs2040273, and PSEN1 rs362344). ConclusionsIn addition, results of this exploratory investigation suggest that an APP SNP and an APH1B SNP are marginally associated with PD CSF A(42) levels in APOE 4 noncarriers. Further hypotheses generated include that decreased CSF A(42) levels are in part driven by genetic variation in APP processing genes. Additional investigation into the relationship between these findings and clinical characteristics of PD, including cognitive impairment, compared with other neurodegenerative diseases, such as AD, are warranted. (c) 2015 International Parkinson and Movement Disorder Society C1 [Bekris, Lynn M.] Cleveland Clin Fdn, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA. [Yu, Chang E.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Yu, Chang E.] Univ Washington, Dept Med, Seattle, WA USA. [Tsuang, Debby W.; Peskind, Elaine R.; Montine, Thomas J.; Zhang, Jing] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr MIRECC, Northwest Network Mental Illness Res, Seattle, WA USA. [Tsuang, Debby W.; Peskind, Elaine R.; Montine, Thomas J.; Zhang, Jing] Univ Washington, Sch Med, Psychiat & Behav Sci, Seattle, WA USA. [Montine, Thomas J.; Zhang, Jing; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Montine, Thomas J.; Zhang, Jing; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr PADRECC, Northwest Network Parkinsons Dis Res, Seattle, WA USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. RP Bekris, LM (reprint author), Cleveland Clin Fdn, Lerner Res Inst, Genom Med Inst, 9500 Euclid Ave,Mailstop NE-50, Cleveland, OH 44195 USA. EM bekrisl@ccf.org RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program; Biomedical Laboratory Research Program; NIH [P50AG005136, P50NS062684, K99AG034214/4R00AG034214]; University of Washington Alzheimer's Disease Research Center NIH [P50-AB005136]; Jane and Lee Seidman Fund, Joseph Hahn MD Endowed Chair FX This work is supported in part by the U.S. Department of Veterans Affairs, Office of Research and Development Clinical Research and Development Program, the Biomedical Laboratory Research Program and NIH Grants P50AG005136, P50NS062684, K99AG034214/4R00AG034214. Additional support includes University of Washington Alzheimer's Disease Research Center NIH P50-AB005136 and the Jane and Lee Seidman Fund, Joseph Hahn MD Endowed Chair. NR 66 TC 1 Z9 2 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD JUN PY 2015 VL 30 IS 7 BP 936 EP 944 DI 10.1002/mds.26172 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CK9YD UT WOS:000356594600012 PM 25808939 ER PT J AU Martinez-Martin, P Rodriguez-Blazquez, C Forjaz, MJ Frades-Payo, B Agueera-Ortiz, L Weintraub, D Riesco, A Kurtis, MM Chaudhuri, KR AF Martinez-Martin, Pablo Rodriguez-Blazquez, Carmen Forjaz, Maria Joao Frades-Payo, Belen Agueera-Ortiz, Luis Weintraub, Daniel Riesco, Ana Kurtis, Monica M. Chaudhuri, Kallol Ray TI Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Parkinson's disease; Caregiver burden; Neuropsychiatric symptoms ID QUALITY-OF-LIFE; PSYCHOSIS; DISABILITY; DEMENTIA; DISORDER; STRESS AB Introduction: In Parkinson's disease (PD), neuropsychiatric symptoms (NPS) can be particularly burdensome for caregivers. The main goal of this study was to assess the impact of NPS, assessed by means of a new specific scale, on caregiver burden. Methods: A sample of 584 pairs of PD patients and their primary caregivers was studied. Patients' NPS were measured with the Scale for Evaluation of Neuropsychiatric Disorders in PD (SEND-PD), and the Zarit Caregiver Burden Inventory was used to quantify caregiver burden. Three linear regression models were built to check factors associated with caregiver burden, one for the total sample and two for subgroups stratified by the presence of dementia. Results: The most frequent NPS were depression (in 66% of the sample), anxiety (65%) and mental fatigue (57%). Patients with dementia (n = 94; 16% of sample) consistently presented more NPS than patients without dementia (p < 0.001). On linear regression models, the main determinants of caregiver burden (for the total sample and the sample of patients without dementia) were SEND-PD dimensions mood/apathy and psychosis, PD-related disability and disease duration. For patients with dementia, the only significant caregiver burden determinants were SEND-PD psychosis and mood/apathy subscale scores. Conclusions: NPS in PD are highly associated with and are determinants of caregiver burden, and are more prevalent and burdensome in patients with dementia. Detailed assessment and specific interventions aimed at NPS could alleviate caregiver burden. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen] Carlos III Inst Hlth, Natl Ctr Epidemiol, Madrid, Spain. [Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen] Carlos III Inst Hlth, CIBERNED, Madrid, Spain. [Forjaz, Maria Joao] Carlos III Inst Hlth, Natl Sch Publ Hlth, Madrid, Spain. [Forjaz, Maria Joao] Carlos III Inst Hlth, REDISSEC, Madrid, Spain. [Frades-Payo, Belen; Agueera-Ortiz, Luis; Riesco, Ana] Carlos III Inst Hlth, Res Unit, Alzheimer Ctr Reina Sofia Fdn, Madrid, Spain. [Agueera-Ortiz, Luis] Carlos III Inst Hlth, CIBERSAM, Madrid, Spain. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Kurtis, Monica M.] Hosp Ruber Int, Dept Neurol, Madrid, Spain. [Chaudhuri, Kallol Ray] Kings Coll Hosp London, Dept Neurol, Natl Parkinson Fdn Ctr Excellence, London, England. [Chaudhuri, Kallol Ray] Kings Hlth Partners, London, England. RP Martinez-Martin, P (reprint author), Natl Ctr Epidemiol, Av Monforte Lemos 3, Madrid 28029, Spain. EM pmartinez@isciii.es RI Rodriguez-Blazquez, Carmen/K-6447-2012 OI Rodriguez-Blazquez, Carmen/0000-0003-3829-0675; Aguera-Ortiz, Luis/0000-0003-2410-2880; Ray Chaudhuri, K/0000-0003-2815-0505; Forjaz, Maria Joao/0000-0003-3935-962X NR 30 TC 16 Z9 16 U1 2 U2 9 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD JUN PY 2015 VL 21 IS 6 BP 629 EP 634 DI 10.1016/j.parkreldis.2015.03.024 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA CK3GX UT WOS:000356105700014 PM 25892660 ER PT J AU Taber, DJ Gebregziabher, MG Srinivas, TR Chavin, KD Baliga, PK Egede, LE AF Taber, David J. Gebregziabher, Mulugeta G. Srinivas, Titte R. Chavin, Kenneth D. Baliga, Prabhakar K. Egede, Leonard E. TI African-American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients SO PHARMACOTHERAPY LA English DT Article DE kidney transplantation; African-American; tacrolimus; therapeutic drug monitoring; acute rejection ID SOLID-ORGAN TRANSPLANTATION; WHOLE-BLOOD CONCENTRATIONS; RENAL-TRANSPLANTATION; IMMUNOSUPPRESSION; RISK; PHARMACOKINETICS; SIROLIMUS; CYP3A5; POLYMORPHISMS; CYCLOSPORINE AB Study ObjectiveTo determine the effect of tacrolimus trough concentrations on clinical outcomes in kidney transplantation, while assessing if African-American (AA) race modifies these associations. DesignRetrospective longitudinal cohort study of solitary adult kidney transplants. SettingLarge tertiary care transplant center. PatientsAdult solitary kidney transplant recipients (n=1078) who were AA (n=567) or non-AA (n=511). ExposureMean and regressed slope of tacrolimus trough concentrations. Subtherapeutic concentrations were lower than 8ng/ml. Measurements and Main ResultsAA patients were 1.7 times less likely than non-AA patients to achieve therapeutic tacrolimus concentrations (8ng/ml or higher) during the first year after kidney transplant (35% vs 21%, respectively, p<0.001). AAs not achieving therapeutic concentrations were 2.4 times more likely to have acute cellular rejection (ACR) as compared with AAs achieving therapeutic concentrations (20.8% vs 8.5%, respectively, p<0.01) and 2.5 times more likely to have antibody-mediated rejection (AMR; 8.9% vs 3.6%, respectively, p<0.01). Rates of ACR (8.3% vs 6.7%) and AMR (2.0% vs 0.9% p=0.131) were similar in non-AAs compared across tacrolimus concentration groups. Multivariate modeling confirmed these findings and demonstrated that AAs with low tacrolimus exposure experienced a mild protective effect for the development of interstitial fibrosis/tubular atrophy (IF/TA; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.47-1.32) with the opposite demonstrated in non-AAs (HR 2.2, 95% CI 0.90-5.1). ConclusionIn contradistinction to non-AAs, AAs who achieve therapeutic tacrolimus concentrations have substantially lower acute rejection rates but are at risk of developing IF/TA. These findings may reflect modifiable time-dependent racial differences in the concentration-effect relationship of tacrolimus. Achievement of therapeutic tacrolimus trough concentrations, potentially through genotyping and more aggressive dosing and monitoring, is essential to minimize the risk of acute rejection in AA kidney transplant recipients. C1 [Taber, David J.; Chavin, Kenneth D.; Baliga, Prabhakar K.] Med Univ S Carolina, Div Transplant Surg, Coll Med, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Gebregziabher, Mulugeta G.] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Srinivas, Titte R.] Med Univ S Carolina, Coll Med, Div Transplant Nephrol, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440, T35 DK007431] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Numbers K23DK099440 and T35 DK007431. NR 34 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUN PY 2015 VL 35 IS 6 BP 569 EP 577 DI 10.1002/phar.1591 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CL0DZ UT WOS:000356610700007 PM 26011276 ER PT J AU Dicianno, BE Mahajan, H Cooper, RA AF Dicianno, Brad E. Mahajan, Harshal Cooper, Rory A. TI Advanced Joystick Algorithms for Computer Access Tasks SO PM&R LA English DT Article ID WHEELCHAIR DRIVING PERFORMANCE; SPASTICITY; INJURY; PEOPLE AB Objective: To compare 2 correction algorithms and 2 joysticks (a conventional movement-sensing joystick and a custom-designed isometric joystick) in computer access tasks. Design: Repeated-measures, within-subject. Setting: National Veterans Wheelchair Games. Participants: Fifteen participants with various diagnoses including multiple sclerosis, spinal cord injury, traumatic brain injury, Wilson disease, and Parkinson disease. Methods: A computer access test scenario was used to evaluate the effects of applying proportional integral derivative (PID)-based and least means-based algorithms to suppress unintentional cursor motions by users with upper extremity spasticity. Main Outcome Measures: Trial completion time, reaction time, and trajectory-based measures: movement offset, movement variability, and percentage of out-of-path motion on test tracks. Results: The quantitative outcome measures showed a high correlation with clinical measures for spasticity and functional independence. On small test tracks, compared to when no correction algorithms were used, both algorithms performed equally well in suppressing unintentional cursor motions. On longer test tracks, participants navigated most accurately while using the PID algorithm. Participants moved the cursor more accurately using the isometric joystick compared to the movement-sensing joystick, with only a slight increase in the task completion times. Conclusions: The joysticks and the advanced correction algorithms show promise for use in wide-ranging applications as control interfaces. C1 [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh HealthCare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Mahajan, Harshal; Cooper, Rory A.] VA Pittsburgh HealthCare Syst, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. [Dicianno, Brad E.; Mahajan, Harshal] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), VA Pittsburgh HealthCare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400,Bakery Sq, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu FU Rehabilitation Medicine Scientist Training Program National Institutes of Health (NIH) K12 Award [K12HD01097] FX Funding was provided by the Rehabilitation Medicine Scientist Training Program National Institutes of Health (NIH) K12 Award (K12HD01097). This material is the result of work supported with resources and the use of facilities at the Human Engineering Research Laboratories, VA Pittsburgh Healthcare System. The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. This study does not involve a Food and Drug Administration-regulated medical device. NR 30 TC 1 Z9 1 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD JUN PY 2015 VL 7 IS 6 BP 555 EP 561 DI 10.1016/j.pmrj.2014.12.009 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CK2PO UT WOS:000356053400001 PM 25595664 ER PT J AU Creswell, KG Wright, AGC Troxel, WM Ferrell, RE Flory, JD Manuck, SB AF Creswell, Kasey G. Wright, Aidan G. C. Troxel, Wendy M. Ferrell, Robert E. Flory, Janine D. Manuck, Stephen B. TI OXTR polymorphism predicts social relationships through its effects on social temperament SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE oxytocin; OXTR; social support; personality; genetics ID OXYTOCIN RECEPTOR GENE; ENVIRONMENTAL CONTRIBUTIONS; SUPPORT; STRESS; BEHAVIOR; HUMANS; INTERACT; ASSOCIATION; PERSONALITY; LONELINESS AB Humans have a fundamental need for strong interpersonal bonds, yet individuals differ appreciably in their degree of social integration. That these differences are also substantially heritable has spurred interest in biological mechanisms underlying the quality and quantity of individuals' social relationships. We propose that polymorphic variation in the oxytocin receptor gene (OXTR) associates with complex social behaviors and social network composition through intermediate effects on negative affectivity and the psychological processing of socially relevant information. We tested a hypothesized social cascade from the molecular level (OXTR variation) to the social environment, through negative affectivity and inhibited sociality, in a sample of 1295 men and women of European American (N = 1081) and African American (N = 214) ancestry. Compared to European Americans having any T allele of rs1042778, individuals homozygous for the alternate G allele reported significantly lower levels of negative affectivity and inhibited sociality, which in turn predicted significantly higher levels of social support and a larger/more diverse social network. Moreover, the effect of rs1042778 variation on social support was fully accounted for by associated differences in negative affectivity and inhibited sociality. Results replicated in the African American sample. Findings suggest that OXTR variation modulates levels of social support via proximal impacts on individual temperament. C1 [Creswell, Kasey G.] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA. [Wright, Aidan G. C.; Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Troxel, Wendy M.] RAND Corp, Behav & Policy Sci, Pittsburgh, PA USA. [Ferrell, Robert E.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA. [Flory, Janine D.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Flory, Janine D.] James J Peters VAMC, New York, NY USA. RP Creswell, KG (reprint author), Carnegie Mellon Univ, Dept Psychol, 5000 Forbes Ave,Baker Hall 342c, Pittsburgh, PA 15213 USA. EM kasey@andrew.cmu.edu OI Wright, Aidan/0000-0002-2369-0601 FU NHLBI NIH HHS [HL093220, K23 HL093220, P01 HL040962, R01 HL065137]; NIMH NIH HHS [T32MH018269, F32 MH097325, F32MH097325, T32 MH018269] NR 77 TC 3 Z9 3 U1 2 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD JUN PY 2015 VL 10 IS 6 BP 869 EP 876 DI 10.1093/scan/nsu132 PG 8 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA CK5NV UT WOS:000356272800013 PM 25326040 ER PT J AU Forrest, GN Bhalla, P DeBess, EE Winthrop, KL Lockhart, SR Mohammadi, J Cieslak, PR AF Forrest, G. N. Bhalla, P. DeBess, E. E. Winthrop, K. L. Lockhart, S. R. Mohammadi, J. Cieslak, P. R. TI Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Cryptococcus gattii; organ transplantation; antifungals; immunosuppression ID CALCINEURIN-INHIBITOR AGENTS; INVASIVE FUNGAL-INFECTIONS; PACIFIC-NORTHWEST; PRACTICE GUIDELINES; BRITISH-COLUMBIA; UNITED-STATES; IN-VITRO; NEOFORMANS; MANAGEMENT; DISEASE AB Cryptococcus gattii was recognized as an emerging infection in the Pacific Northwest in 2004. Out of 62 total infections in Oregon since the outbreak, 11 were in solid organ transplant (SOT) recipients. SOT recipients were more likely to have disseminated disease and higher mortality than normal hosts, who mostly had isolated mass lesions. The median time from transplantation to C.gattii diagnosis was 17.8months. The primary sites of infection were lung (n=4), central nervous system (n=3), or both (n=4). The Oregon-endemic strain, VGII (subtypes IIa and IIc) was present in 10 of 11 patients; the median fluconazole minimum inhibitory concentration (MIC) was 12g/mL (range 2-32g/mL) for this strain. We found C.gattii infection among organ transplant recipients was disseminated at diagnosis, had low cerebrospinal fluid cryptococcal antigen titers, and was associated with an elevated fluconazole MIC and high attributable mortality. C1 [Forrest, G. N.; Mohammadi, J.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Bhalla, P.; Winthrop, K. L.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Bhalla, P.; DeBess, E. E.; Cieslak, P. R.] Oregon Hlth Author, Publ Hlth Div, Acute & Communicable Dis Prevent, Portland, OR USA. [Lockhart, S. R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Oregon Health Authority; Epidemiology and Laboratory Capacity Cooperative Agreement [5U50CK000218]; Centers for Disease Control and Prevention (CDC) FX The study was conducted under the auspices of the Oregon Health Authority. This publication was supported by the Epidemiology and Laboratory Capacity Cooperative Agreement (number 5U50CK000218) with the Centers for Disease Control and Prevention (CDC). NR 25 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2015 VL 17 IS 3 BP 467 EP 476 DI 10.1111/tid.12370 PG 10 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CK2YW UT WOS:000356082600021 PM 25677448 ER PT J AU Gorin, Y Cavaglieri, RC Khazim, K Lee, DY Bruno, F Thakur, S Fanti, P Szyndralewiez, C Barnes, JL Block, K Abboud, HE AF Gorin, Yves Cavaglieri, Rita C. Khazim, Khaled Lee, Doug-Yoon Bruno, Francesca Thakur, Sachin Fanti, Paolo Szyndralewiez, Cedric Barnes, Jeffrey L. Block, Karen Abboud, Hanna E. TI Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE diabetic nephropathy; NADPH oxidase; Nox1/Nox4 inhibitor ID INDUCED OXIDATIVE STRESS; KIDNEY-DISEASE; PREVENTS GLOMERULOSCLEROSIS; PHARMACOLOGICAL INHIBITION; CARDIOVASCULAR-SYSTEM; PODOCYTE INJURY; DB/DB MICE; IN-VIVO; NEPHROPATHY; NOX4 AB Reactive oxygen species (ROS) generated by Nox NADPH oxidases may play a critical role in the pathogenesis of diabetic nephropathy (DN). The efficacy of the Nox1/Nox4 inhibitor GKT137831 on the manifestations of DN was studied in OVE26 mice, a model of type 1 diabetes. Starting at 4-5 mo of age, OVE26 mice were treated with GKT137831 at 10 or 40 mg/kg, once-a-day for 4 wk. At both doses, GKT137831 inhibited NADPH oxidase activity, superoxide generation, and hydrogen peroxide production in the renal cortex from diabetic mice without affecting Nox1 or Nox4 protein expression. The increased expression of fibronectin and type IV collagen was reduced in the renal cortex, including glomeruli, of diabetic mice treated with GKT137831. GKT137831 significantly reduced glomerular hypertrophy, mesangial matrix expansion, urinary albumin excretion, and podocyte loss in OVE26 mice. GKT137831 also attenuated macrophage infiltration in glomeruli and tubulointerstitium. Collectively, our data indicate that pharmacological inhibition of Nox1/4 affords broad renoprotection in mice with preexisting diabetes and established kidney disease. This study validates the relevance of targeting Nox4 and identifies GKT137831 as a promising compound for the treatment of DN in type 1 diabetes. C1 [Gorin, Yves; Cavaglieri, Rita C.; Khazim, Khaled; Lee, Doug-Yoon; Bruno, Francesca; Thakur, Sachin; Fanti, Paolo; Barnes, Jeffrey L.; Block, Karen; Abboud, Hanna E.] Univ Texas San Antonio, Dept Med, Hlth Sci Ctr, San Antonio, TX 78229 USA. [Fanti, Paolo; Barnes, Jeffrey L.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Audie Leon Murphy Mem Hosp Div, San Antonio, TX USA. [Szyndralewiez, Cedric] Genkyotex SA, Geneva, Switzerland. RP Gorin, Y (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gorin@uthscsa.edu FU Juvenile Diabetes Research Foundation; National Center for Advancing Translational Sciences; National Institutes of Health (NIH) [UL1 TR001120, RO1 DK 079996, RO1 CA 131272, RO1 DK 78971]; Department of Veterans Affairs; Juvenile Diabetes Research Foundation [GKT137831] FX This work was supported by Juvenile Diabetes Research Foundation Multiproject Grants (Y. Gorin, K. Block, J. L. Barnes, and H. E. Abboud), the National Center for Advancing Translational Sciences, the National Institutes of Health (NIH) through Grants UL1 TR001120 (Y. Gorin), RO1 DK 079996 (Y. Gorin), RO1 CA 131272 (K. Block), RO1 DK 78971 (H. E. Abboud), and the Department of Veterans Affairs (K. Block, J. L. Barnes, and H. E. Abboud). GKT137831 was provided by Genkyotex through funds from Juvenile Diabetes Research Foundation Multiproject Grants. NR 49 TC 32 Z9 33 U1 4 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUN 1 PY 2015 VL 308 IS 11 BP F1276 EP F1287 DI 10.1152/ajprenal.00396.2014 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA CK5BN UT WOS:000356237200011 PM 25656366 ER PT J AU Goff, KL Karimkhani, C Boyers, LN Weinstock, MA Lott, JP Hay, RJ Coffeng, LE Norton, SA Naldi, L Dunnick, C Armstrong, AW Dellavalle, RP AF Goff, K. L. Karimkhani, C. Boyers, L. N. Weinstock, M. A. Lott, J. P. Hay, R. J. Coffeng, L. E. Norton, S. A. Naldi, L. Dunnick, C. Armstrong, A. W. Dellavalle, R. P. TI The global burden of psoriatic skin disease SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID SYSTEMATIC ANALYSIS; GBD 2010; PREVALENCE; INJURIES; LIFE C1 [Goff, K. L.] Univ S Carolina, Sch Med, Columbia, SC USA. [Karimkhani, C.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, L. N.] Georgetown Univ, Sch Med, Washington, DC USA. [Weinstock, M. A.] VA Med Ctr Providence, Dermatoepidemiol Unit, Providence, RI USA. [Weinstock, M. A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA. [Weinstock, M. A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, M. A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Lott, J. P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. [Lott, J. P.] Connecticut Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, West Haven, CT USA. [Hay, R. J.] Kings Coll Hosp NHS Trust, Dept Dermatol, London, England. [Coffeng, L. E.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Norton, S. A.] Childrens Natl Med Ctr, Dermatol Div, Washington, DC 20010 USA. [Naldi, L.] Azienda Osped Papa Giovanni XXIII, Dept Dermatol, Bergamo, Italy. [Dunnick, C.; Armstrong, A. W.; Dellavalle, R. P.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA. [Dellavalle, R. P.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Dunnick, C.; Armstrong, A. W.; Dellavalle, R. P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. EM robert.dellavalle@ucdenver.edu RI Naldi, Luigi/K-6343-2016 OI Naldi, Luigi/0000-0002-3160-2835 NR 15 TC 6 Z9 6 U1 4 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JUN PY 2015 VL 172 IS 6 BP 1665 EP 1668 DI 10.1111/bjd.13715 PG 4 WC Dermatology SC Dermatology GA CK2LR UT WOS:000356042500043 PM 25645671 ER PT J AU Bansal, N Shlipak, MG AF Bansal, Nisha Shlipak, Michael G. TI Should Hemoglobin A1C Be Routinely Measured in Patients with CKD? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR RISK; GLYCEMIC CONTROL; AVERAGE GLUCOSE; ASSOCIATION; OUTCOMES; ADULTS; MODEL C1 [Bansal, Nisha] Univ Washington, Kidney Res Inst, Div Nephrol, Seattle, WA 98195 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Med, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM Michael.Shlipak@ucsf.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUN PY 2015 VL 10 IS 6 BP 914 EP 916 DI 10.2215/CJN.04200415 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA CJ8XV UT WOS:000355787700002 PM 25979974 ER PT J AU Murugan, R Wen, XY Keener, C Pike, F Palevsky, PM Unruh, M Finkel, K Vijayan, A Elder, M Chen, YF Kellum, JA AF Murugan, Raghavan Wen, Xiaoyan Keener, Christopher Pike, Francis Palevsky, Paul M. Unruh, Mark Finkel, Kevin Vijayan, Anitha Elder, Michele Chen, Yi-Fan Kellum, John A. CA Biol Markers Recovery Kidney TI Associations between Intensity of RRT, Inflammatory Mediators, and Outcomes SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID RENAL-REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; MARKERS; SEPSIS; PNEUMONIA; MORTALITY; CYTOKINE; FAILURE AB Background and objectives Critically ill patients requiring RRT have higher circulating plasma concentrations of inflammatory and apoptosis markers that are associated with subsequent RRT dependence and death. Whether intensive dosing of RRT is associated with changes in specific mediators is unknown. Design, setting, participants, & measurements A multicenter, prospective, cohort study of 817 critically ill patients receiving RRT ancillary to the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network study was conducted between November 2003 and July 2007. Plasma inflammatory (IL-6, IL-8, IL-10, IL-18, and macrophage migration inhibitory factor) and apoptosis (TNF receptor-I [TNFR-I] TNFR-II, and death receptor-5) biomarkers on days 1 and 8 were examined after initiation of intensive RRT. Whether intensive RRT, given day 1 biomarkers, is associated with RRT independence and lower mortality at day 60 was also examined. Results Overall, no differences were found in day 8 biomarker concentrations between intensive and less-intensive RRT groups. When adjusted for day 1 biomarkers and clinical variables, intensive RRT was not associated with renal recovery (adjusted odds ratio [OR], 0.80; 95% confidence interval, 0.56 to 1.14) or mortality (adjusted OR, 1.15; 95% confidence interval, 0.81 to 1.64). Use of intensive RRT, however, was associated with lower day 8 concentrations when day 1 plasma IL-6, macrophage migration inhibitory factor, and TNFR-I concentrations were high (interaction P value for all markers, <0.01). In contrast, day 8 marker concentrations were higher when day 1 levels were low (P<0.01). Elevated biomarker concentrations on day 8 among 476 participants were associated with lower renal recovery (adjusted OR range, 0.19-0.87) and higher mortality (adjusted OR range, 1.26-3.18). Conclusions Among critically ill patients receiving RRT, intensive dosing of RRT has variable association with biomarker concentration and no association with renal recovery and mortality. However, elevated concentrations of inflammatory and apoptosis markers on day 8 of RRT were associated with RRT dependence and death. C1 [Murugan, Raghavan; Wen, Xiaoyan; Keener, Christopher; Pike, Francis; Palevsky, Paul M.; Elder, Michele; Kellum, John A.] Univ Pittsburgh, Sch Med, Ctr Crit Care Nephrol, Pittsburgh, PA USA. [Murugan, Raghavan; Wen, Xiaoyan; Keener, Christopher; Pike, Francis; Palevsky, Paul M.; Unruh, Mark; Elder, Michele; Chen, Yi-Fan; Kellum, John A.] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness Ctr, Dept Crit Care Med, Pittsburgh, PA USA. [Keener, Christopher; Pike, Francis; Chen, Yi-Fan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Unruh, Mark] Univ New Mexico, Dept Internal Med, Div Nephrol, Albuquerque, NM 87131 USA. [Finkel, Kevin] Univ Texas Med Sch Houston, Div Renal Dis & Hypertens, Houston, TX USA. [Vijayan, Anitha] Washington Univ, Div Renal Dis, St Louis, MO USA. RP Kellum, JA (reprint author), Ctr Crit Care Nephrol, Crit Care Med, Translat Sci & Bioengn, 608 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK070910]; National Center For Advancing Translational Sciences of the National Institutes of Health [KL2-TR000146]; Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP) [530]; NIDDK [Y1-DK-3508] FX The BioMaRK study was conducted by the BioMaRK investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grant no. R01-DK070910) and the National Center For Advancing Translational Sciences of the National Institutes of Health (award no. KL2-TR000146). The Veterans Affairs/National Institutes of Health ATN study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development (CSP no. 530) and by NIDDK by an interagency agreement (no. Y1-DK-3508). NR 18 TC 5 Z9 5 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUN PY 2015 VL 10 IS 6 BP 926 EP 933 DI 10.2215/CJN.04560514 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA CJ8XV UT WOS:000355787700006 PM 25862777 ER PT J AU Fried, LF Lewis, J AF Fried, Linda F. Lewis, Julia TI Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC RENAL-INSUFFICIENCY; TYPE-2 DIABETES-MELLITUS; CHRONIC KIDNEY-DISEASE; SURROGATE END-POINTS; BLOOD-PRESSURE CONTROL; CLINICAL-TRIALS; NEPHROPATHY; PROGRESSION; EFFICACY; CHOLESTEROL AB Albuminuria is a risk factor for progression of kidney disease. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers slow the progression to ESRD, an effect that is correlated with reduction in albuminuria. This has led to the hypothesis that albuminuria should be a target for therapy. This work argues that there are issues with this hypothesis. The previously reported studies were not designed to test the hypothesis that achieving a specific albuminuria target would be beneficial in and of itself irrespective the mechanism used to achieve that goal. One cannot assume that the beneficial effect observed was causally related to the effect on albuminuria or that it would extend to other interventions. Most importantly, it is not known if the approach of maximizing therapy to reduce proteinuria is safe. Recent studies have shown that combining renin-angiotensin system therapies decreases albuminuria without significant clinical benefit but with increased risk of adverse events. More studies are needed, but at this time, albuminuria has not jumped the hurdle needed to be accepted as a surrogate end point or target for treatment. Primum non nocere, first do no harm. C1 [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Lewis, Julia] Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol & Hypertens, Nashville, TN 37212 USA. RP Fried, LF (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 47 TC 14 Z9 14 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUN PY 2015 VL 10 IS 6 BP 1089 EP 1093 DI 10.2215/CJN.10681014 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA CJ8XV UT WOS:000355787700024 PM 25887070 ER PT J AU Fried, LF Lewis, J AF Fried, Linda F. Lewis, Julia TI Rebuttal of the Pro View: Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID DIABETIC-NEPHROPATHY; END-POINTS; TYPE-2; TRIAL; PROTEINURIA; ALISKIREN; LOSARTAN; OUTCOMES C1 [Fried, Linda F.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Lewis, Julia] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Fried, LF (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Univ Dr,Mailstop 111F-U, Pittsburgh, PA 15240 USA. EM Linda.Fried@va.gov NR 13 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD JUN PY 2015 VL 10 IS 6 BP 1095 EP 1098 DI 10.2215/CJN.01610215 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA CJ8XV UT WOS:000355787700025 PM 25887072 ER PT J AU Baca, CB Pieters, HC Iwaki, TJ Mathern, GW Vickrey, BG AF Baca, Christine B. Pieters, Huibrie C. Iwaki, Tomoko J. Mathern, Gary W. Vickrey, Barbara G. TI "A journey around the world": Parent narratives of the journey to pediatric resective epilepsy surgery and beyond SO EPILEPSIA LA English DT Article DE Epilepsy surgery; Pediatric; Access to care; Parent ID TEMPORAL-LOBE EPILEPSY; MEDICALLY REFRACTORY EPILEPSY; UNITED-STATES; RACIAL DISPARITIES; IMPROVED OUTCOMES; CHILDREN; HEMISPHERECTOMY; RECOMMENDATIONS; NEUROLOGISTS; ACCEPTANCE AB ObjectiveAlthough shorter time to pediatric resective epilepsy surgery is strongly associated with greater disease severity, other nonclinical diagnostic and sociodemographic factors also play a role. We aimed to examine parent-reported barriers to timely receipt of pediatric epilepsy surgery. MethodsWe conducted 37 interviews of parents of children who previously had resective epilepsy surgery at University of California Los Angeles (UCLA; 2006-2011). Interviews were audio-recorded, transcribed, and systematically coded using thematic analysis by two independent coders, and subsequently checked for agreement. Clinical data, including time to surgery (age of epilepsy onset to surgery) were abstracted from medical records. ResultsThe mean time to surgery was 5.3years (standard deviation [SD] 3.8); surgery types included 32% hemispherectomy, 43% lobar/focal, and 24% multilobar. At surgery, parents were on average 38.4years (SD 6.6) and children were on average 8.2years (SD 4.7). The more arduous and longer aspect of the journey to surgery was perceived by parents to be experienced prior to presurgical referral. The time from second antiepileptic drug failure to presurgical referral was 1year in 64% of children. Thematic analysis revealed four themes (with subthemes) along the journey to surgery and beyond: (1) recognitionsomething is wrong (unfamiliarity with epilepsy, identification of medical emergency); (2) searching and findinga circuitous journey (information seeking, finding the right doctors, multiple medications, insurance obstacles, parental stress); (3) surgery is a viable optionthe right spot (surgery as last resort, surgery as best option, hoping for candidacy); and (4) life nowwe took the steps we needed to (a new life, giving back). SignificanceMultipronged interventions targeting parent-, provider-, and system-based barriers should focus on the critical presurgical referral period; such interventions are needed to remediate delays and improve access to subspecialty care for children with medically refractory epilepsy and potentially eligible for surgery. C1 [Baca, Christine B.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Pieters, Huibrie C.; Iwaki, Tomoko J.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Mathern, Gary W.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,C-239, Los Angeles, CA 90095 USA. EM cbower@mednet.ucla.edu FU Epilepsy Foundation of America [20111278]; National Institute of Neurological Diseases and Stroke (NINDS) [R01 NS38992] FX This study was supported by grants from the Epilepsy Foundation of America (20111278 - PI Baca) and the National Institute of Neurological Diseases and Stroke (NINDS; R01 NS38992 PI - Mathern). We thank Frances Barry for her assistance with statistical programming. NR 40 TC 4 Z9 4 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD JUN PY 2015 VL 56 IS 6 BP 822 EP 832 DI 10.1111/epi.12988 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CK1DU UT WOS:000355946900005 PM 25894906 ER PT J AU Maust, DT Chen, SH Benson, A Mavandadi, S Streim, JE DiFilippo, S Snedden, TM Oslin, DW AF Maust, Donovan T. Chen, Shirley H. Benson, Amy Mavandadi, Shahrzad Streim, Joel E. DiFilippo, Suzanne Snedden, Thomas M. Oslin, David W. TI Older adults recently started on psychotropic medication: where are the symptoms? SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE psychotropic medication; primary care; older adults ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; ANXIETY DISORDERS; RISK; MANAGEMENT; PEOPLE; BENZODIAZEPINE; POPULATION; IMPAIRMENT AB Objective: The objective of this study is to understand the characteristics of older adults on newly prescribed psychotropic medication with minimal psychiatric symptoms. Methods: Naturalistic cohort study of non-institutionalized older adults in Pennsylvania participating in the Pharmaceutical Assistance Contract for the Elderly. Persons newly prescribed antidepressant or anxiolytic monotherapy or combination therapy were contacted for clinical assessment by a telephone-based behavioral health service. The initial assessment included standardized mental health screening instruments and scales including the Blessed Orientation-Memory-Concentration test, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Medical Outcomes Survey (SF-12). In addition, patients were asked for their understanding of the prescription indication. Results: Of the 254 participants who met minimal symptom criteria (Patient Health Questionnaire 9<5 and Generalized AnxietyDisorder-7<5), women comprised slightly more of the anxiolytic compared with antidepressant monotherapy group (88.9% vs. 76.7%, p = 0.04). The most common self-reported reason for prescription of an antidepressant or anxiolytic was depression or anxiety, respectively, despite near-absence of these symptoms on clinical assessment. Comparing monotherapy to combination therapy groups, those with combination therapy were more likely to report a history of depression (12.6% vs. 1.8%, p< 0.001) and also report depression as the reason for the prescription (40.2% vs. 21.0%, p< 0.01). Conclusions: In this sample of older adults on new psychotropic medication with minimal psychiatric symptoms, there are few patient characteristics that distinguish those on antidepressant versus anxiolytic monotherapy or those on monotherapy versus combination therapy. While quality of care in late-life mental health has focused on improving detection and treatment, there should be further attention to low-symptom patients potentially receiving inappropriate pharmacotherapy. Copyright (C) 2014 John Wiley & Sons, Ltd. C1 [Maust, Donovan T.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Maust, Donovan T.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. [Chen, Shirley H.; Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chen, Shirley H.; Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Philadelphia, PA USA. [Benson, Amy; Mavandadi, Shahrzad; Streim, Joel E.; DiFilippo, Suzanne; Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Snedden, Thomas M.] Penn Dept Aging, PACE Program, Harrisburg, PA USA. RP Maust, DT (reprint author), Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. EM maustd@umich.edu FU PACE Program of the Pennsylvania Department of Aging FX This work was funded by the PACE Program of the Pennsylvania Department of Aging. Mr Snedden directs the PACE Program. The authors have no further disclosures to report. NR 36 TC 2 Z9 2 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JUN PY 2015 VL 30 IS 6 BP 580 EP 586 DI 10.1002/gps.4187 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CK1RT UT WOS:000355985600005 PM 25116369 ER PT J AU Almeida, RP Schultz, SA Austin, BP Boots, EA Dowling, NM Gleason, CE Bendlin, BB Sager, MA Hermann, BP Zetterberg, H Carlsson, CM Johnson, SC Asthana, S Okonkwo, OC AF Almeida, Rodrigo P. Schultz, Stephanie A. Austin, Benjamin P. Boots, Elizabeth A. Dowling, N. Maritza Gleason, Carey E. Bendlin, Barbara B. Sager, Mark A. Hermann, Bruce P. Zetterberg, Henrik Carlsson, Cynthia M. Johnson, Sterling C. Asthana, Sanjay Okonkwo, Ozioma C. TI Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease SO JAMA NEUROLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; PHYSICAL-ACTIVITY; FDG-PET; EDUCATION; DEMENTIA; BRAIN AB IMPORTANCE Although advancing age is the strongest risk factor for the development of symptomatic Alzheimer disease (AD), recent studies have shown that there are individual differences in susceptibility to age-related alterations in the biomarkers of AD pathophysiology. OBJECTIVE To investigate whether cognitive reserve (CR) modifies the adverse influence of age on key cerebrospinal fluid (CSF) biomarkers of AD. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional cohort of 268 individuals (211 in a cognitively normal group and 57 in a cognitively impaired group) from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center participated in this study. They underwent lumbar puncture for collection of CSF samples, from which A beta 42, total tau (t-tau), and phosphorylated tau (p-tau) were immunoassayed. In addition, we computed t-tau/A beta 42 and p-tau/A beta 42 ratios. Cognitive reserve was indexed by years of education, with 16 or more years taken to confer high reserve. Covariate-adjusted regression analyses were used to test whether the effect of age on CSF biomarkers was modified by CR. The study dates were March 5, 2010, to February 13, 2013. MAIN OUTCOMES AND MEASURES Cerebrospinal fluid levels of A beta 42, t-tau, p-tau, t-tau/A beta 42, and p-tau/A beta 42. RESULTS There were significant age x CR interactions for CSF t-tau (beta [SE] = -6.72 [2.84], P = .02), p-tau (beta [SE] = -0.71 [0.27], P = .01), t-tau/A beta 42 (beta [SE] = -0.02 [0.01], P = .02), and p-tau/A beta 42 (beta [SE] = -0.002 [0.001], P = .004). With advancing age, individuals with high CR exhibited attenuated adverse alterations in these CSF biomarkers compared with individuals with low CR. This attenuation of age effects by CR tended to be more pronounced in the cognitively impaired group compared with the cognitively normal group. There was evidence of a dose-response relationship such that the effect of age on the biomarkers was progressively attenuated given additional years of schooling. CONCLUSIONS AND RELEVANCE In a sample composed of a cognitively normal group and a cognitively impaired group, higher CR was associated with a diminution of age-related alterations in CSF biomarkers of AD. This suggests one pathway through which CR might favorably alter lifetime risk for symptomatic AD. C1 [Almeida, Rodrigo P.; Schultz, Stephanie A.; Austin, Benjamin P.; Boots, Elizabeth A.; Gleason, Carey E.; Bendlin, Barbara B.; Carlsson, Cynthia M.; Johnson, Sterling C.; Asthana, Sanjay; Okonkwo, Ozioma C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Almeida, Rodrigo P.; Schultz, Stephanie A.; Boots, Elizabeth A.; Bendlin, Barbara B.; Sager, Mark A.; Hermann, Bruce P.; Johnson, Sterling C.; Asthana, Sanjay; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Almeida, Rodrigo P.; Schultz, Stephanie A.; Austin, Benjamin P.; Boots, Elizabeth A.; Dowling, N. Maritza; Gleason, Carey E.; Bendlin, Barbara B.; Sager, Mark A.; Hermann, Bruce P.; Carlsson, Cynthia M.; Johnson, Sterling C.; Asthana, Sanjay; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53792 USA. [Dowling, N. Maritza; Hermann, Bruce P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI 53792 USA. [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Molndal, Sweden. [Zetterberg, Henrik] Univ London, Inst Neurol, London, England. RP Okonkwo, OC (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA. EM ozioma@medicine.wisc.edu OI Schultz, Stephanie/0000-0001-8460-4415 FU National Institute on Aging [K23 AG045957, R01 AG031790, R01 AG021155, R01 AG027161, P50 AG033514]; Clinical and Translational Science Award [UL1RR025011]; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Extendicare Foundation; US Department of Veterans Affairs; Coordination for the Improvement of Higher Education Personnel (CAPES) Foundation FX This work was supported by grants K23 AG045957 (Dr Okonkwo), R01 AG031790 (Dr Carlsson), R01 AG021155 and R01 AG027161 (Dr Johnson), and P50 AG033514 (Dr Asthana) from the National Institute on Aging and by Clinical and Translational Science Award UL1RR025011 to the University of Wisconsin, Madison. Portions of this research were supported by the Wisconsin Alumni Research Foundation, Helen Bader Foundation, Northwestern Mutual Foundation, and Extendicare Foundation, as well as by the US Department of Veterans Affairs, including facilities and resources at the Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison. Mr Almeida's yearlong study abroad at the University of Wisconsin, Madison, was funded by a scholarship from the Coordination for the Improvement of Higher Education Personnel (CAPES) Foundation. NR 43 TC 13 Z9 13 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JUN PY 2015 VL 72 IS 6 BP 699 EP 706 DI 10.1001/jamaneurol.2015.0098 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CK1BC UT WOS:000355939400015 PM 25893879 ER PT J AU Nagiel, A Sadda, SR Sarraf, D AF Nagiel, Aaron Sadda, SriniVas R. Sarraf, David TI A Promising Future for Optical Coherence Tomography Angiography SO JAMA OPHTHALMOLOGY LA English DT Editorial Material C1 [Nagiel, Aaron; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA. [Sarraf, David] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu OI Nagiel, Aaron/0000-0001-7275-6980 NR 7 TC 26 Z9 27 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD JUN PY 2015 VL 133 IS 6 BP 629 EP 630 DI 10.1001/jamaophthalmol.2015.0668 PG 2 WC Ophthalmology SC Ophthalmology GA CK2MI UT WOS:000356044400009 PM 25856444 ER PT J AU Ruben, MA Hall, JA Curtin, EM Blanch-Hartigan, D Ship, AN AF Ruben, Mollie A. Hall, Judith A. Curtin, Elizabeth M. Blanch-Hartigan, Danielle Ship, Amy N. TI Discussion increases efficacy when training accurate perception of patients' affect SO JOURNAL OF APPLIED SOCIAL PSYCHOLOGY LA English DT Article ID CLINICIAN; SATISFACTION; RECOGNITION; SKILLS AB Patients benefit when their healthcare providers accurately recognize their affect. The efficacy of three short-term training components, practice, practice with feedback, and discussion with practice and feedback, to improve accuracy for judging patients' affect was experimentally assessed. Undergraduate participants were randomly assigned in pairs to one of the training conditions or an untrained control condition and the effect of training was measured using the Test of Accurate Perception of Patients' Affect (TAPPA). Participants were significantly more accurate on the TAPPA in the discussion with feedback and practice condition compared with the control condition. There was a significant linear trend in accuracy across training elements. Results suggest that a 40-min discussion with feedback and practice training can significantly improve interpersonal accuracy. C1 [Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, Boston, MA 02130 USA. [Hall, Judith A.] Northeastern Univ, Psychol Dept, Boston, MA USA. [Curtin, Elizabeth M.] Arbour Counseling Serv, Allston, MA USA. [Blanch-Hartigan, Danielle] Bentley Univ, Nat & Appl Sci, Bentley, WA, Australia. [Ship, Amy N.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA. [Ship, Amy N.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Ruben, MA (reprint author), US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, 150 South Huntington Ave,Bldg 9, Boston, MA 02130 USA. EM Mollie.Ruben@va.gov FU Agency for Healthcare Research and Quality FX Funded by a grant from the Agency for Healthcare Research and Quality. NR 30 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9029 EI 1559-1816 J9 J APPL SOC PSYCHOL JI J. Appl. Soc. Psychol. PD JUN PY 2015 VL 45 IS 6 BP 355 EP 362 DI 10.1111/jasp.12301 PG 8 WC Psychology, Social SC Psychology GA CJ8FR UT WOS:000355736100005 ER PT J AU Fisher, MB Henning, EA Soegaard, N Bostrom, M Esterhai, JL Mauck, RL AF Fisher, Matthew B. Henning, Elizabeth A. Soeegaard, Nicole Bostrom, Marc Esterhai, John L. Mauck, Robert L. TI Engineering meniscus structure and function via multi-layered mesenchymal stem cell-seeded nanofibrous scaffolds SO JOURNAL OF BIOMECHANICS LA English DT Article DE Tissue engineering; Meniscus; Nanofibrous scaffold; Electrospinning; Mechanical properties ID MEDIAL MENISCUS; POLYURETHANE SCAFFOLD; PARTIAL MENISCECTOMY; ANNULUS FIBROSUS; KNEE MENISCUS; JOINT; REGENERATION; MECHANICS; MODEL; REPLACEMENT AB Despite complex macroscopic and microscopic structural features of native tissue, including the circumferentially and radially aligned collagen bundles essential for mechanical function. To mimic this structural hierarchy, this study developed multi-lamellar mesenchymal stem cell (MSC)-seeded nanofibrous constructs. Bovine MSCs were seeded onto nanofibrous scaffolds comprised of poly(e-caprolactone) with fibers aligned in a single direction (0 degrees or 90 degrees to the scaffold long axis) or circumferentially aligned (C). Multi-layer groups (0 degrees/0 degrees/0 degrees, 90 degrees/90 degrees/90 degrees, 0 degrees/90 degrees/0 degrees, 90 degrees/0 degrees/90 degrees, and C/C/C) were created and cultured for a total of 6 weeks under conditions favoring fibrocartilaginous tissue formation. Tensile testing showed that 0 degrees and C single layer constructs had stiffness values several fold higher than 90 degrees constructs. For multi-layer groups, the stiffness of 0 degrees/0 degrees/0 degrees constructs was higher than all other groups, while 90 degrees/90 degrees/90 degrees constructs had the lowest values. Data for collagen content showed a general positive interactive effect for multi-layers relative to single layer constructs, while a positive interaction for stiffness was found only for the C/C/C group. Collagen content and cell infiltration occurred independent of scaffold alignment, and newly formed collagenous matrix followed the scaffold fiber direction. Structural hierarchies within multi-lamellar constructs dictated biomechanical properties, and only the C/C/C constructs with non-orthogonal alignment within layers featured positive mechanical reinforcement as a consequence of the layered construction. These multi-layer constructs may serve as functional substitutes for the meniscus as well as test beds to understand the complex mechanical principles that enable meniscus function. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Fisher, Matthew B.; Henning, Elizabeth A.; Soeegaard, Nicole; Bostrom, Marc; Esterhai, John L.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Fisher, Matthew B.; Henning, Elizabeth A.; Esterhai, John L.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. [Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Fisher, Matthew B.] Univ N Carolina, Dept Biomed Engn, Chapel Hill, NC 27599 USA. [Fisher, Matthew B.] N Carolina State Univ, Raleigh, NC 27695 USA. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu RI Fisher, Matthew/M-5809-2016 OI Fisher, Matthew/0000-0002-3212-0870 FU National Institutes of Health [R01 AR056624]; Department of Veterans' Affairs [I01 RX000174]; NIH Post-Doctoral National Research Service Award [F32 AR062971]; NIH sponsored Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was supported by the National Institutes of Health (R01 AR056624) and the Department of Veterans' Affairs (I01 RX000174). Additional support was provided by an NIH Post-Doctoral National Research Service Award (F32 AR062971) and the NIH sponsored Penn Center for Musculoskeletal Disorders (P30 AR050950). Study sponsors had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication. NR 44 TC 8 Z9 8 U1 5 U2 31 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD JUN 1 PY 2015 VL 48 IS 8 SI SI BP 1412 EP 1419 DI 10.1016/j.jbiomech.2015.02.036 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA CK3MK UT WOS:000356120000012 PM 25817333 ER PT J AU Minzenberg, MJ Lesh, T Niendam, T Yoon, JH Cheng, YA Rhoades, R Carter, CS AF Minzenberg, Michael J. Lesh, Tyler Niendam, Tara Yoon, Jong H. Cheng, Yaoan Rhoades, Remy Carter, Cameron S. TI Conflict-related anterior cingulate functional connectivity is associated with past suicidal ideation and behavior in recent-onset schizophrenia SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Schizophrenia; Conflict-monitoring; Suicidal ideation; Suicidal behavior; Anterior cingulate; Functional connectivity ID MAJOR DEPRESSIVE DISORDER; PREFRONTAL CORTEX DYSFUNCTION; POSITRON-EMISSION-TOMOGRAPHY; 1ST EPISODE PSYCHOSIS; COGNITIVE CONTROL; BIPOLAR DISORDER; WORST-POINT; BRAIN; RISK; TASK AB Suicide is highly prevalent in schizophrenia (SZ), yet it remains unclear how suicide risk factors such as past suicidal ideation or behavior relate to brain function. Circuits modulated by the prefrontal cortex (PFC) are altered in SZ, including in dorsal anterior cingulate cortex (dACC) during conflict-monitoring (an important component of cognitive control), and dACC changes are observed in post-mortem studies of heterogeneous suicide victims. We tested whether conflict-related dACC functional connectivity is associated with past suicidal ideation and behavior in SZ. 32 patients with recent-onset of DSM-IV-TR-deflned SZ were evaluated with the Columbia Suicide Severity Rating Scale and functional MRI during cognitive control (AX-CPT) task performance. Group-level regression models relating past history of suicidal ideation or behavior to dACC-seeded functional connectivity during conflict-monitoring controlled for severity of depression, psychosis and impulsivity. Past suicidal ideation was associated with relatively higher functional connectivity of the dACC with the precuneus during conflict-monitoring. Intensity of worst-point past suicidal ideation was associated with relatively higher dACC functional connectivity in medial parietal lobe and striato-thalamic nuclei. In contrast, among those with past suicidal ideation (n = 17), past suicidal behavior was associated with lower conflict-related dACC connectivity with multiple lateral and medial PFC regions, parietal and temporal cortical regions. This study provides unique evidence that recent-onset schizophrenia patients with past suicidal ideation or behavior show altered dACC-based circuit function during conflict-monitoring. Suicidal ideation and suicidal behavior have divergent patterns of associated dACC functional connectivity, suggesting a differing pattern of conflict-related brain dysfunction with these two distinct features of suicide phenomenology. Published by Elsevier Ltd. C1 [Minzenberg, Michael J.; Cheng, Yaoan] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Lesh, Tyler; Niendam, Tara; Carter, Cameron S.] Univ Calif Davis, Sch Med, Dept Psychiat, Sacramento, CA 95817 USA. [Yoon, Jong H.; Rhoades, Remy] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA. [Carter, Cameron S.] Stanford Sch Med, Dept Psychiat, Palo Alto, CA USA. RP Minzenberg, MJ (reprint author), San Francisco VA Med Ctr, Outpatient Mental Hlth, 116C,4150 Clement St, San Francisco, CA 94121 USA. EM Michael.minzenberg@ucsf.edu RI Niendam, Tara/K-8475-2015 OI Niendam, Tara/0000-0003-2285-5002; Cheng, Yaoan/0000-0001-5858-6161 FU American Foundation for Suicide Prevention Young Investigator Award; Doris Duke Charitable Foundation [2009045, MH059883] FX This work was supported by an American Foundation for Suicide Prevention Young Investigator Award, and the Doris Duke Charitable Foundation Grant # 2009045, both to MJM, and MH059883 to CSC. NR 58 TC 5 Z9 5 U1 4 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JUN PY 2015 VL 65 BP 95 EP 101 DI 10.1016/j.jpsychires.2015.04.002 PG 7 WC Psychiatry SC Psychiatry GA CK3NR UT WOS:000356123300013 PM 25891474 ER PT J AU Piel, J Finkle, MJ Giske, M Leong, GB AF Piel, Jennifer Finkle, Michael J. Giske, Megan Leong, Gregory B. TI Determining a Criminal Defendant's Competency to Proceed With an Extradition Hearing SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID TRIAL AB When a criminal defendant flees from one state (often referred to as the requesting state) to another (often referred to as the asylum state), the requesting state can demand that the asylum state return the defendant through a process called extradition. Only a handful of states have considered a fugitive's right to be competent to proceed with an extradition hearing. Those states fall into three categories. Some states apply the same standard as in criminal trial competency cases. Others apply a more limited competency standard. Two have found that a fugitive has no right to be competent to proceed in an extradition hearing. The particular legal test adopted affects the nature and scope of the competency evaluation conducted by the psychiatrist or psychologist in the extradition hearing. In addition, we are not aware of any state that has considered what happens to the fugitive if he is ultimately found not competent to proceed. Legislation, either state by state or through amendments to the Uniform Criminal Extradition Act, can provide the legal and psychiatric communities with guidance in assessing competency initially and in taking appropriate steps if the fugitive is ultimately found not competent. C1 [Piel, Jennifer] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Piel, Jennifer] Univ Washington, Seattle, WA 98195 USA. [Finkle, Michael J.] King Cty Dist Court, King County, WA USA. [Finkle, Michael J.] Seattle Univ, Sch Law, Law, Seattle, WA 98122 USA. [Giske, Megan] King Cty Dept Publ Def, Northwest Defenders Div, Seattle, WA USA. [Leong, Gregory B.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. RP Piel, J (reprint author), 1660 South Columbian Way,MS-116, Seattle, WA 98108 USA. EM jennifer.piel@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD JUN 1 PY 2015 VL 43 IS 2 BP 201 EP 209 PG 9 WC Law; Psychiatry SC Government & Law; Psychiatry GA CK4FB UT WOS:000356175700011 PM 26071510 ER PT J AU Bancroft, LW Kransdorf, MI Adler, R Appel, M Beaman, FD Bernard, SA Bruno, MA Dempsey, ME Fries, IB Khoury, V Khurana, B Mosher, TJ Roberts, CC Tuite, MJ Ward, RJ Zoga, AC Weissman, BN AF Bancroft, Laura W. Kransdorf, Mark I. Adler, Ronald Appel, Marc Beaman, Francesca D. Bernard, Stephanie A. Bruno, Michael A. Dempsey, Molly E. Fries, Ian B. Khoury, Viviane Khurana, Bharti Mosher, Timothy J. Roberts, Catherine C. Tuite, Michael J. Ward, Robert J. Zoga, Adam C. Weissman, Barbara N. TI ACR Appropriateness Criteria Acute Trauma to the Foot SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness Criteria; acute trauma; foot trauma; Ottawa Rules; adult; child ID OTTAWA ANKLE RULES; CLINICAL-PREDICTION RULES; TISSUE FOREIGN-BODIES; LISFRANC LIGAMENT; SOFT-TISSUE; PROSPECTIVE VALIDATION; ANATOMIC CORRELATION; SURGICAL CORRELATION; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-ACCURACY AB This ACR Appropriateness Criteria article offers imaging triage guidance for several variants of patients presenting with acute foot trauma. Patients meeting inclusion criteria for the Ottawa Rules should undergo a 3-view radiographic series. Diabetic patients with peripheral neuropathy should undergo radiography, even though they do not meet the Ottawa Rules inclusion criteria. Patients with suspected midfoot and/or Lisfranc injury should undergo 3-view radiographs with weight bearing on at least the anterior posterior view. Patients with suspected Lisfranc injury and normal radiographs should be considered for MRI and CT on a case-by-case basis. MRI or ultrasound could confirm cases of suspected acute tendon rupture. Radiography is the initial imaging modality for suspected plantar plate injury after metatarsal phalangeal joint injury. Weight-bearing anterior posterior, lateral, and sesamoid axial views may detect proximal migration of the hallux sesamoids. Ultrasound or MRI can directly evaluate the capsuloligamentous complex, specifically the plantar plate. Radiography can detect radiopaque penetrating foreign bodies, and ultrasound can be helpful in detecting those that are nonradiopaque. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures, by the panel. In instances in which evidence is lacking or is not definitive, expert opinion may be used to recommend imaging and treatment. C1 [Bancroft, Laura W.] Radiol Specialists Florida, Maitland, FL 32751 USA. [Kransdorf, Mark I.; Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA. [Adler, Ronald] NYU, Ctr Musculoskeletal Care, New York, NY USA. [Appel, Marc] James J Peters VA Med Ctr, Bronx, NY USA. [Appel, Marc; Fries, Ian B.] Amer Acad Orthopaed Surg, Rosemont, IL USA. [Beaman, Francesca D.] Univ Kentucky, Lexington, KY USA. [Bernard, Stephanie A.; Bruno, Michael A.; Mosher, Timothy J.] Penn State Milton S Hershey Med Ctr, Hershey, PA USA. [Dempsey, Molly E.] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA. [Khoury, Viviane] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Khurana, Bharti; Weissman, Barbara N.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Tuite, Michael J.] Univ Wisconsin Hosp, Madison, WI USA. [Ward, Robert J.] Tufts Med Ctr, Boston, MA USA. [Zoga, Adam C.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. RP Bancroft, LW (reprint author), Radiol Specialists Florida, 900 Winderley Pl Ste 1100, Maitland, FL 32751 USA. EM laura.bancroft@flhosp.org RI Mosher, Timothy/J-5146-2015 OI Mosher, Timothy/0000-0001-8573-3614; Bancroft, Laura/0000-0002-3997-5759 FU Medical Metrics; Kensey Nash Corporation FX Timothy J. Mosher, MD, is a paid consultant for Medical Metrics, a paid consultant for Kensey Nash Corporation, and a stockholder with Johnson and Johnson. NR 52 TC 1 Z9 1 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2015 VL 12 IS 6 BP 575 EP 581 DI 10.1016/j.jacr.2015.02.018 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CK1IM UT WOS:000355961000011 PM 25935824 ER PT J AU Morey, JM Haney, NM Schoppe, K Hawkins, CM AF Morey, Jose M. Haney, Nora M. Schoppe, Kurt Hawkins, C. Matthew TI Adding Value as Young Radiologists: Challenges and Opportunities, Part 2 SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID SOCIAL MEDIA; IMPACT C1 [Morey, Jose M.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Morey, Jose M.] US Dept Vet Affairs, Hampton, VA USA. [Haney, Nora M.] Tulane Univ, Sch Med, New Orleans, LA 70130 USA. [Schoppe, Kurt] Radiol Associates North Texas, Arlington, TX USA. [Hawkins, C. Matthew] Emory Univ, Sch Med, Atlanta, GA USA. RP Haney, NM (reprint author), Tulane Univ, Sch Med, 929 Washington Ave, New Orleans, LA 70130 USA. EM nhaney@tulane.edu NR 24 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2015 VL 12 IS 6 BP 641 EP 644 DI 10.1016/j.jacr.2015.02.004 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CK1IM UT WOS:000355961000026 PM 25935823 ER PT J AU Stahlman, S Javanbakht, M Cochran, S Hamilton, AB Shoptaw, S Gorbach, PM AF Stahlman, Shauna Javanbakht, Marjan Cochran, Susan Hamilton, Alison B. Shoptaw, Steven Gorbach, Pamina M. TI Mental Health and Substance Use Factors Associated With Unwanted Sexual Contact Among US Active Duty Service Women SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; RECENT VICTIMS; MILITARY; VETERANS; ASSAULT; TRAUMA; RAPE; HARASSMENT; DRINKING AB Many U.S. military women are exposed to unwanted sexual contact during military service, which can have important implications for mental health. Using data from the 2008 Department of Defense Survey of Health Related Behaviors, we employed multiple logistic regression methods to examine whether unwanted sexual contact was associated with stress, screening positive for mental disorders, or substance use, among active duty service women. The sample included 7,415 female military personnel, of whom 13.4% reported unwanted sexual contact (including any touching of genitals) since entering the military. After adjusting for potentially confounding variables, factors independently associated with unwanted sexual contact included military-related stress (adjusted odds ratio [AOR] = 2.44), family/personal life-related stress (AOR = 1.78), and gender-related stress (AOR = 1.98) in the past 12 months. In addition, screening positive for depression, anxiety, posttraumatic stress disorder, or psychological distress, and suicidal ideation or attempt were associated with unwanted sexual contact (AOR = 1.57-2.11). For drug/alcohol use, only misuse of tranquilizers/muscle relaxers (past 12 months) was associated with report of unwanted sexual contact (AOR = 1.35). Given the prevalence of unwanted sexual contact and corresponding adverse health outcomes in this sample of active duty women, strategies to create military structural/cultural changes and reduce gender-related stress and sexism are needed. Resumen `Muchas mujeres militares estan expuestas a contacto sexual no deseado durante el servicio militar, lo cual puede tener implicancias importantes para la salud mental. Utilizando informacion de la Encuesta del Departamento de Defensa sobre Conductas relacionadas con la salud del 2008, utilizamos multiples metodos de regresion logistica para examinar si el contacto sexual no deseado se asocio con estres, tamizaje positivo para trastornos mentales, o uso de sustancias entre mujeres en servicio activo. La muestra incluyo 7.415 militares femeninas, de las cuales el 13,4% reporto contacto sexual no deseado (incluyendo cualquier contacto de genitales) desde su entrada como militar. Despues del ajuste de variables potencialmente confundidoras, los factores asociados independientemente con contacto sexual no deseado incluyeron estres relacionado a la actividad militar (AOR:2.44), estres relacionado a la vida personal/familiar (AOR: 1.78), y estres relacionado a genero (AOR:1.98) en los ultimos 12 meses. Ademas, el tamizaje positivo para depresion, ansiedad, TEPT, distress psicologico, e ideacion o intento suicida fueron asociados con contacto sexual no deseado (AOR:1.57-2.11). En relacion al uso de drogas/alcohol, solo el mal uso de tranquilizantes/relajantes musculares (ultimos 12 meses) estuvo asociado con el reporte de contacto sexual no deseado (AOR: 1.35). Dada la prevalencia de contacto sexual no deseado y las correspondientes consecuencias adversas en la salud en la muestra de mujeres en servicio activo, son necesarias estrategias para crear cambios en la estructura/cultura militar y reducir el estres relacionado al genero y machismo. Traditional and Simplified Chinese Abstracts by AsianSTSS ?? : ??????????????????????????? ??: ?????????????????????,?????????????????????2008?????????????????,??????????????????????????????????????????????????7415????,13.4%?????????????(?????????)?????????????,???????????????????12?????????(???????[AOR] = 2.44)?????????????(AOR = 1.78)????????(AOR = 1.98)???,???????????????????????????????????????????(AOR = 1.57 ? 2.11)??????????,????12??????????????????????????(AOR = 1.35)????????????????????????????????,?????????????????,??????????????? ?? : ??????????????????????????? ??: ????????????????????,?????????????????????2008?????????????????,??????????????????????????????????????????????????7415????,13.4%?????????????(?????????)?????????????,???????????????????12?????????(???????[AOR] = 2.44)?????????????(AOR = 1.78)????????(AOR = 1.98)???,???????????????????????????????????????????(AOR = 1.57 ? 2.11)??????????,????12??????????????????????????(AOR = 1.35)????????????????????????????????,?????????????????,??????????????? C1 [Stahlman, Shauna; Javanbakht, Marjan; Cochran, Susan; Gorbach, Pamina M.] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA. RP Stahlman, S (reprint author), Univ Calif Los Angeles, Dept Epidemiol, Box 951772, Los Angeles, CA 90095 USA. EM sstahlman@ucla.edu OI Stahlman, Shauna/0000-0003-2861-7734 FU UCLA; NIMH [P30 MH58107] FX This research was supported by funds from the UCLA Dr. Ursula Mandel Scholarship (Stahlman), the 2013-2014 Fellowship in Epidemiology (Stahlman), and NIMH research grant P30 MH58107 (Shoptaw and Gorbach). The views expressed in this article are those of the authors and do not reflect the official policy or position of the U.S. Department of Defense, U.S. Department of Veterans Affairs, or the U.S. government. The funding organizations had no role in the design and conduct of the study; collection, analysis, or preparation of the data; or preparation, review, or approval of the manuscript. Shauna Stahlman had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 44 TC 1 Z9 1 U1 4 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2015 VL 28 IS 3 BP 167 EP 173 DI 10.1002/jts.22009 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CK2XZ UT WOS:000356080100001 PM 25976935 ER PT J AU Paul, LA Felton, JW Adams, ZW Welsh, K Miller, S Ruggiero, KJ AF Paul, Lisa A. Felton, Julia W. Adams, Zachary W. Welsh, Kyleen Miller, Stephanie Ruggiero, Kenneth J. TI Mental Health Among Adolescents Exposed to a Tornado: The Influence of Social Support and Its Interactions With Sociodemographic Characteristics and Disaster Exposure SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC STRESS SYMPTOMS; HURRICANE KATRINA; RISK-FACTORS; LIFE EVENTS; DEPRESSION; CHILDREN; PREVALENCE; PTSD; PSYCHOPATHOLOGY; DISTRESS AB Approximately 25% of youths experience a natural disaster and many experience disaster-related distress, including symptoms of posttraumatic stress disorder (PTSD) and depression. This study contributes to the literature by examining PTSD and depressive symptoms among 2,000 adolescents (50.9% female, 70.5% White) assessed after exposure to tornadoes in 2011. The authors hypothesized that greater tornado exposure, female sex, and younger age would be associated with distress, and that social support would interact with these associations. Analyses showed that PTSD symptoms were associated with lower levels of social support ( = -.28, p < .001), greater tornado exposure ( = .14, p < .001), lower household income ( = -.06, p = .013, female sex ( = -.10, p < .001), and older age ( = .07, p = .002), with a 3-way interaction between tornado exposure, sex, and social support ( = -.06, p = .017). For boys, the influence of tornado exposure on PTSD symptoms increased as social support decreased. Regardless of level of tornado exposure, low social support was related to PTSD symptoms for girls; depressive symptom results were similar. These findings were generally consistent with the literature and provide guidance for intervention development focused on strengthening social support at the individual, family, and community levels. Resumen Aproximadamente un 25% de los jovenes experimentan desastres naturales y muchos sufren estres relacionado con los desastres, incluyendo sintomas de Trastorno por Estres Postraumatico (TEPT) y Depresion. Este estudio contribuye a la literatura investigando sintomas de Trastorno por Estres Postraumatico y Depresion en 2.000 adolescentes (50,9% mujeres; 70,5% de raza blanca), evaluados, despues de un tornado en el 2011. Los autores plantearon la hipotesis que la exposicion a un gran tornado, en personas jovenes y de sexo femenino podrian tener asociacion con estres y que el apoyo social podria interactuar con estas asociaciones. El analisis mostro que escaso apoyo social (B = - .28, p < .001), exposicion a un gran tornado (B = - .14, p< .001), bajos ingresos familiares (B = -.06, p< .013) sexo femenino (B = -.10, P<.001) y edades mayores (B = .07, p< .002) predijeron sintomas de TEPT con una interaccion de 3 vias, la exposicion al tornado, sexo y apoyo social (B = -.06, p< .017). En varones, la influencia de la exposicion a un tornado aumenta los sintomas de TEPT cuando el apoyo social es menor. En ninas, independientemente del nivel de exposicion a un tornado, el escaso apoyo social estuvo relacionado con sintomas de TEPT. Estos resultados fueron similares para los sintomas depresivos. Estos hallazgos son consistentes con la literatura y provee un referente de desarrollo de intervencion focalizado en fortalecer el apoyo social tanto a nivel individual, familiar y comunitario. Traditional and Simplified Chinese Abstracts by AsianSTSS ?? : ???????????????????????????????????? ??: ?25%?????????????,????????????,????????(PTSD)????????????2000????(50.9% ??, 70.5% ??)?2011????????????PTSD?????,????????????????????????????????????,?????????????????????PTSD???????????( = -.28, p < .001)????????( = .14, p < .001)???????( = -.06, p = .013)??????( = -.10, p < .001)?????( = .07, p = .002)???,?????????????????????????( = -.06, p = .017)?????,????????,??????PTSD???????????????????,??????????PTSD????;??????????????????????,????????????????????????????????? ?? : ?????????????????????????????????? ??: ?25%????????????,???????????,????????(PTSD)????????????2000????(50.9% ??, 70.5% ??)?2011???????????PTSD?????,???????????????????????????????????,?????????????????????PTSD???????????( = -.28, p < .001)???????( = .14, p < .001)???????( = -.06, p = .013)??????( = -.10, p < .001)?????( = .07, p = .002)???,????????????????????????( = -.06, p = .017)?????,????????,?????PTSD???????????????????,??????????PTSD????;??????????????????????,????????????????????????????????? C1 [Paul, Lisa A.] Univ Illinois, Dept Psychol, De Kalb, IL USA. [Felton, Julia W.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA. [Adams, Zachary W.; Miller, Stephanie; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Welsh, Kyleen; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Ruggiero, KJ (reprint author), Med Univ S Carolina, 67 President St,MSC 861, Charleston, SC 29425 USA. EM ruggierk@musc.edu FU National Institute of Mental Health [R01-MH081056]; [T32-MH018869] FX The National Institute of Mental Health (Grant R01-MH081056 to KJR) supported this study as well as the team of collaborators (T32-MH018869 sponsoring LAP and ZWA). We thank the many families affected by the spring 2011 tornado outbreak for participating in this study. NR 42 TC 0 Z9 0 U1 5 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD JUN PY 2015 VL 28 IS 3 BP 232 EP 239 DI 10.1002/jts.22012 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CK2XZ UT WOS:000356080100009 PM 26031997 ER PT J AU McCarty, TP Baddley, JW Walsh, TJ Alexander, BD Kontoyiannis, DP Perl, TM Walker, R Patterson, TF Schuster, MG Lyon, GM Wingard, JR Andes, DR Park, BJ Brandt, ME Pappas, PG AF McCarty, Todd P. Baddley, John W. Walsh, Thomas J. Alexander, Barbara D. Kontoyiannis, Dimitrios P. Perl, Trish M. Walker, Randall Patterson, Thomas F. Schuster, Mindy G. Lyon, G. Marshall Wingard, John R. Andes, David R. Park, Benjamin J. Brandt, Mary E. Pappas, Peter G. CA TRANSNET Investigators TI Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET) SO MEDICAL MYCOLOGY LA English DT Article DE phaeohyphomycosis; dematiaceous mold; Alternaria; Exserohilum ID VITRO ANTIFUNGAL SUSCEPTIBILITY; INVASIVE FUNGAL-INFECTIONS; METHYLPREDNISOLONE INJECTIONS; CEREBRAL PHEOHYPHOMYCOSIS; VORICONAZOLE; DIAGNOSIS AB Transplant recipients are at a high risk for developing invasive fungal infections. The agents of phaeohyphomycosis are environmental molds found worldwide, and they cause a broad spectrum of disease including skin and subcutaneous lesions, pneumonia, central nervous system disease, fungemia, and disseminated disease. Using data from the Transplant Associated Infection Surveillance Network (TRANSNET), we evaluated patients with proven and probable phaeohyphomycosis. Centers collected data on demographics, co-morbid conditions, clinical features, treatment, and three-month mortality. Fifty-six patients with phaeohyphomycosis were identified from 15 centers, comprising 26 stem cell transplant (SCT) and 30 solid organ transplant (SOT) recipients. Median time to diagnosis post-transplant was 358 days (SCT 100 days; SOT 685 days; P = <.001). The most frequent pathogen was Alternaria species (32%). Disseminated disease was found in 55.4%. Cutaneous infection was more common in SOT (53.3% vs 23.1%; P = .021), while pulmonary disease was more common in SCT (57.7 vs. 26.7; P = .019). Voriconazole (44.6%) and amphotericin B preparations (37.5%) were the most common antifungal therapies. Overall mortality was 25% and was higher in SCT than in SOT (42% vs 10%; P = <.001). A wide variety of organisms encompass phaeohyphomycosis contributing to varying types of infection in transplant recipients. Site of infection, time to disease, and mortality varies significantly between SCT and SOT recipients. Lipid formulations of amphotericin B and voriconazole were the most common antifungals used to treat this disorder. C1 [McCarty, Todd P.; Baddley, John W.; Pappas, Peter G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Med, New York, NY USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Pediat, New York, NY USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Microbiol & Immunol, New York, NY USA. [Alexander, Barbara D.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Epidemiol, Baltimore, MD 21287 USA. [Walker, Randall] Mayo Clin, Dept Med, Rochester, MN USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Schuster, Mindy G.] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA. [Lyon, G. Marshall] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Wingard, John R.] Univ Florida, Dept Med, Gainesville, FL USA. [Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Park, Benjamin J.; Brandt, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP McCarty, TP (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. EM tmccarty@uabmc.edu FU Centers for Disease Control and Prevention [5U01CI000286-05]; Merck Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Enzon Pharmaceuticals, Inc.; Vicuron Pharmaceuticals FX Funding was provided by the Centers for Disease Control and Prevention (Grant 5U01CI000286-05) and grants from Merck & Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Enzon Pharmaceuticals, Inc.; and Vicuron Pharmaceuticals. NR 22 TC 8 Z9 8 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1369-3786 EI 1460-2709 J9 MED MYCOL JI Med. Mycol. PD JUN PY 2015 VL 53 IS 5 BP 440 EP 446 DI 10.1093/mmy/myv018 PG 7 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA CK5GA UT WOS:000356249800002 PM 25908651 ER PT J AU Sieverdes, JC Nemeth, LS Magwood, GS Baliga, PK Chavin, KD Ruggiero, KJ Treiber, FA AF Sieverdes, John C. Nemeth, Lynne S. Magwood, Gayenell S. Baliga, Prabhakar K. Chavin, Kenneth D. Ruggiero, Ken J. Treiber, Frank A. TI African American kidney transplant patients' perspectives on challenges in the living donation process SO PROGRESS IN TRANSPLANTATION LA English DT Article ID STAGE RENAL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; RACIAL DISPARITIES; ORGAN DONATION; UNITED-STATES; LONG-TERM; DONOR; BARRIERS; CANDIDATES AB Context-The increasing shortage of deceased donor kidneys suitable for African Americans highlights the critical need to increase living donations among African Americans. Little research has addressed African American transplant recipients' perspectives on challenges and barriers related to the living donation process. Objective-To understand the perspectives of African American recipients. of deceased and living donor kidney transplants on challenges, barriers, and educational needs related to pursuing such transplants. Participants and Design-A mixed-method design involved 27 African American kidney recipients (13 male) in 4 focus groups (2 per recipient type: 16 African American deceased donor and 11 living donor recipients) and questionnaires. Focus group transcripts were evaluated with NVivo 10.0 (QSR, International) by using inductive and deductive qualitative methods along with crystallization to develop themes, of underlying bathers to the living donor kidney transplant process and were compared with the questionnaires. Results-Four main themes were identified from groups: concerns, knowledge and learning, expectations of support, and communication. Many concerns for the donor were identified (eg, process too difficult, financial burden, effect on relationships). A general lack of knowledge about the donor process and lack of behavioral skills on how to approach others was noted. The latter was especially evident among deceased donor recipients. Findings from the questionnaires On myths and perceptions supported the lack of knowledge in a variety of domains, including donors' surgical outcomes risks, costs of surgery, and impact on future health. Participants thought that an educational program led by an African American recipient of a living donor kidney transplant, including practice in approaching others, would increase the likelihood of transplant-eligible patients pursuing living donor kidney transplant. (C) 2015 NATCO, The Organization far Transplant Professionals C1 [Sieverdes, John C.; Nemeth, Lynne S.; Magwood, Gayenell S.; Baliga, Prabhakar K.; Chavin, Kenneth D.; Ruggiero, Ken J.; Treiber, Frank A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Ruggiero, Ken J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Treiber, FA (reprint author), Med Univ S Carolina, Coll Nursing, 1002 Harbor View Off Tower,19 Hagood Ave, Charleston, SC 29425 USA. EM treiberf@musc.edu OI Nemeth, Lynne/0000-0001-8691-1400 FU National Institutes of Health (NIH) [DK 098777]; South Carolina Clinical and Translational Research Institute; Medical University of South Carolina, Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS) [UL1RR029882] FX This publication was supported with funding from National Institutes of Health (NIH) grant DK 098777 and the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina, Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS), grant UL1RR029882. The content does not represent the official views of the NIH or the NCATS. NR 45 TC 2 Z9 2 U1 0 U2 4 PU NATCO-THE ORGANIZATION FOR TRANSPLANT PROFESSIONALS SN 1526-9248 EI 2164-6708 J9 PROG TRANSPLANT JI Prog. Transplant. PD JUN PY 2015 VL 25 IS 2 BP 164 EP 175 DI 10.7182/pit2015852 PG 12 WC Surgery; Transplantation SC Surgery; Transplantation GA CK3GS UT WOS:000356105200011 PM 26107278 ER PT J AU Sankari, A Martin, JL Badr, M AF Sankari, A. Martin, J. L. Badr, M. TI A retrospective review of sleep-disordered breathing, hypertenstion and cardiovascular diseases in spinal cord injury patients SO SPINAL CORD LA English DT Letter ID BLOOD-PRESSURE C1 [Sankari, A.; Badr, M.] John D Dingell VA Med Ctr, Dept Med, Detroit, MI 48201 USA. [Sankari, A.; Badr, M.] Wayne State Univ, Sch Med, Detroit, MI USA. [Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA USA. [Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Sankari, A (reprint author), John D Dingell VA Med Ctr, Dept Med, Detroit, MI 48201 USA. EM abdulghani.sankari@va.gov FU CSRD VA [I01 CX001040, IK2 CX000547] NR 3 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD JUN PY 2015 VL 53 IS 6 BP 496 EP 497 DI 10.1038/sc.2015.16 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CK1DP UT WOS:000355946300017 PM 25665540 ER PT J AU Fortenbaugh, FC VanVleet, TM Silver, MA Robertson, LC AF Fortenbaugh, Francesca C. VanVleet, Thomas M. Silver, Michael A. Robertson, Lynn C. TI Spatial distortions in localization and midline estimation in hemianopia and normal vision SO VISION RESEARCH LA English DT Article DE Hemianopia; Hemianopic Line Bisection Error; Pseudoneglect; Bisection; Space perception; Peripheral localization ID VISUAL-FIELD DEFECTS; VIEWING PERCEPTUAL ASYMMETRIES; IN-LINE BISECTION; STRIATE CORTEX; INDIVIDUAL VARIABILITY; ATTENTIONAL BIASES; NORMAL OBSERVERS; SIZE PERCEPTION; FILLING-IN; TEST SCORE AB Studies have shown that individuals with hemianopia tend to bisect a line toward their blind, contralesional visual field, termed the hemianopic line bisection error (HLBE). One theory proposes that the HLBE is a perceptual distortion resulting from expansion of the central region of visual space. If true, perceptual expansions of the central regions in the intact hemifield should also be present and observable across different tasks. We tested this hypothesis using a peripheral localization task to assess localization and midpoint estimation along the horizontal axis of the visual field. In this task, participants judged the location of a target dot presented inside a Goldmann perimeter relative to their perceived visual field boundary. In Experiment 1, we tested neurologically healthy participants on the peripheral localization task as well as a novel midpoint assessment task in which participants reported their perceived midpoint along the horizontal axis of their left and right visual fields. The results revealed consistency in individual biases across the two tasks. We then used the peripheral localization task to test whether two patients with hemianopia showed a selective expansion of central visual space. For these patients, three axes were tested: the spared temporal horizontal axis and the upper and lower vertical axes. The results support the notion that the HLBE is due to expansion of perceived space along the spared temporal axis. Together, the results of both experiments validate the use of these novel paradigms for exploring perceptual asymmetries in both healthy individuals and patients with visual field loss. Published by Elsevier Ltd. C1 [Fortenbaugh, Francesca C.; VanVleet, Thomas M.; Robertson, Lynn C.] US Dept Vet Affairs, Martinez, CA USA. [Fortenbaugh, Francesca C.; Robertson, Lynn C.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. [VanVleet, Thomas M.] Brain Plast Inc, San Francisco, CA USA. [Silver, Michael A.] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA. [Silver, Michael A.; Robertson, Lynn C.] Univ Calif Berkeley, Vis Sci Grad Grp, Berkeley, CA 94720 USA. [Silver, Michael A.; Robertson, Lynn C.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. RP Robertson, LC (reprint author), Univ Calif Berkeley, Dept Psychol, 4143 Tolman Hall 5050, Berkeley, CA 94720 USA. EM lynnrob@berkeley.edu FU Veterans Administration; National Institutes of Health [R01-EY016975]; Chancellor's Faculty Partnership Fund from the University of California Berkeley; NEI [EY003176]; Veterans Administration in the VA Clinical Sciences Research Service, Department of Veterans Affairs Medical Center, Martinez, CA FX The authors would especially like to thank the patients for participating in the current study. This research was partially supported by the Veterans Administration as well as National Institutes of Health Grant R01-EY016975 (L.C.R.), the Chancellor's Faculty Partnership Fund from the University of California Berkeley (M.A.S. and L.C.R.), and NEI Core grant EY003176 (L.C.R. and M.A.S). L.C.R. has a Senior Research Career Scientist award from the Veterans Administration in the VA Clinical Sciences Research Service, Department of Veterans Affairs Medical Center, Martinez, CA. The contents within do not represent the views of the Department of Veterans Affairs of the United States government. NR 66 TC 3 Z9 3 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0042-6989 EI 1878-5646 J9 VISION RES JI Vision Res. PD JUN PY 2015 VL 111 BP 1 EP 12 DI 10.1016/j.visres.2015.03.022 PN A PG 12 WC Neurosciences; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA CK2FW UT WOS:000356027200001 PM 25872177 ER PT J AU Parekh, PK Ozburn, AR McClung, CA AF Parekh, Puja K. Ozburn, Angela R. McClung, Colleen A. TI Circadian clock genes: Effects on dopamine, reward and addiction SO ALCOHOL LA English DT Article DE Circadian; Dopamine; Alcohol; Addiction ID ALCOHOL-SEEKING BEHAVIOR; MEDIAL PREFRONTAL CORTEX; NUCLEUS-ACCUMBENS; SUPRACHIASMATIC NUCLEUS; ACTIVITY RHYTHMS; ETHANOL WITHDRAWAL; COCAINE REWARD; TYROSINE-HYDROXYLASE; SYNAPTIC PLASTICITY; LOCOMOTOR-ACTIVITY AB Addiction is a widespread public health issue with social and economic ramifications. Substance abuse disorders are often accompanied by disruptions in circadian rhythms including sleep/wake cycles, which can exacerbate symptoms of addiction and dependence. Additionally, genetic disturbance of circadian molecular mechanisms can predispose some individuals to substance abuse disorders. In this review, we will discuss how circadian genes can regulate midbrain dopaminergic activity and subsequently, drug intake and reward. We will also suggest future directions for research on circadian genes and drugs of abuse. (C) 2015 Elsevier Inc. All rights reserved. C1 [Parekh, Puja K.; Ozburn, Angela R.; McClung, Colleen A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15219 USA. [Ozburn, Angela R.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA. [Ozburn, Angela R.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. RP McClung, CA (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, 450 Technology Dr,Suite 223, Pittsburgh, PA 15219 USA. EM mcclungca@upmc.edu FU NIDA [DA023988]; NIMH [MH082876]; NIAAA [AA020452]; NARSAD FX Studies from our group were supported by NIDA (DA023988 to CAM), NIMH (MH082876 to CAM), NIAAA (AA020452 to ARO), and NARSAD Young Investigator Award (to ARO). The authors declare no conflict of interest. NR 112 TC 12 Z9 12 U1 2 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD JUN PY 2015 VL 49 IS 4 SI SI BP 341 EP 349 DI 10.1016/j.alcohol.2014.09.034 PG 9 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA CJ8YC UT WOS:000355788400005 PM 25641765 ER PT J AU Cherrier, MM Anderson, K Shofer, J Millard, S Matsumoto, AM AF Cherrier, M. M. Anderson, K. Shofer, J. Millard, S. Matsumoto, A. M. TI Testosterone Treatment of Men With Mild Cognitive Impairment and Low Testosterone Levels SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE mild cognitive impairment; testosterone treatment; verbal memory; cognition; quality of life; low serum testosterone ID HEALTHY OLDER MEN; ALZHEIMERS-DISEASE; BIOAVAILABLE TESTOSTERONE; ELDERLY-MEN; SERUM TESTOSTERONE; CLINICAL-TRIALS; ALTERNATE FORMS; VERBAL MEMORY; RISK; PERFORMANCE AB Introduction: This study investigated the effects of testosterone (T) treatment on cognition, mood, and quality of life in men with mild cognitive impairment (MCI) and low serum T levels. Methods: A total of 351 community-dwelling men were screened, and 37 men evidenced both MCI and low T of whom 27 agreed for further screening. Twenty-two met all the study inclusion/exclusion criteria and enrolled in a 6-month randomized, double-blind, placebo-controlled study. Results: Total T levels significantly increased in the T treatment group. No significant changes were observed in measures of cognition, mood, or quality of life other than improvement in 1 objective measure of verbal memory (P < .05) and decreased depression symptoms (P < .02) in the treatment group. Conclusions: Testosterone treatment may modestly improve verbal memory and depression symptoms in men with both MCI and low T. C1 [Cherrier, M. M.; Anderson, K.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Shofer, J.; Millard, S.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Matsumoto, A. M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Cherrier, MM (reprint author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. EM cherrier@uw.edu FU NIA [AG027156]; VA Puget Sound Health Care System, Seattle, WA; University of Washington, Seattle, WA; Abbott Laboratories FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Supported in part by NIA # AG027156. This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, WA as well as the University of Washington, Seattle, WA. The study was also supported by Abbott Laboratories who provided study medication, but did not participate in study design, analyzing data or preparing the manuscript. We would also like to acknowledge the administrative support of Christina Bradic and Ashley Holder. NR 48 TC 7 Z9 7 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD JUN PY 2015 VL 30 IS 4 BP 421 EP 430 DI 10.1177/1533317514556874 PG 10 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA CJ6RK UT WOS:000355620900014 PM 25392187 ER PT J AU Garvey, WT AF Garvey, W. Timothy TI The conundrum of whole foods versus macronutrient composition in assessing effects on insulin sensitivity SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Editorial Material ID HIGH-CARBOHYDRATE DIET; RESISTANCE; FAT; OBESITY; GLUCOSE; RISK C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 616,1675 Univ Boulevard, Birmingham, AL 35294 USA. EM garveyt@uab.edu FU NIDDK NIH HHS [DK-083562, P30 DK079626, P60-DK079626, DK-038765] NR 12 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUN PY 2015 VL 101 IS 6 BP 1109 EP 1110 DI 10.3945/ajcn.115.112292 PG 2 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CJ6YU UT WOS:000355641900002 PM 25971718 ER PT J AU McCoy, KJM AF McCoy, Karin J. M. TI Clinical Neuropsychology: A Pocket Handbook for Assessment, 3rd edition SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Book Review C1 [McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP McCoy, KJM (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM Karin.McCoy@va.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD JUN PY 2015 VL 30 IS 4 BP 356 EP 357 DI 10.1093/arclin/acv023 PG 2 WC Psychology, Clinical; Psychology SC Psychology GA CJ6VF UT WOS:000355632300007 PM 25948292 ER PT J AU Wecht, JM Cirnigliaro, CM Azarelo, F Bauman, WA Kirshblum, SC AF Wecht, Jill M. Cirnigliaro, Christopher M. Azarelo, Frank Bauman, William A. Kirshblum, Steven C. TI Orthostatic responses to anticholinesterase inhibition in spinal cord injury SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Pyridostigmine; Hypotension; Blood pressure; Heart rate; Tetraplegia ID LOW BLOOD-PRESSURE; CONTINGENT NEGATIVE-VARIATION; ACETYLCHOLINESTERASE INHIBITION; DEPRESSIVE SYMPTOMS; COGNITIVE PERFORMANCE; HYPOTENSION; POPULATION; ASSOCIATION; TETRAPLEGIA; COMMUNITY AB Acetylcholine (Ach) is the pre-synaptic neurotransmitter of the sympathetic nervous system. Increased pre-synaptic Ach may augment post-synaptic release of norepinephrine, thereby increasing systemic blood pressure (BP). The primary objective of this investigation was to determine the hemodynamic effect of pyridostigmine bromide (PYRIDO: 60 mg), an Ach inhibitor (AchI), compared to no-drug (NO-D) during head-up tilt (HUT) in individuals with spinal cord injury (SCI). Secondarily, we aimed to determine the effects of PYRIDO compared to NO-D on symptoms of orthostatic intolerance (OI) and adverse event reporting (AE). Ten individuals with SCI (C4-C7) were studied on two occasions: visit (1) NO-D and visit (2) PYRIDO. On each visit subjects underwent a progressive HUT maneuver to 15A degrees, 25A degrees, 35A degrees for 5 min at each angle and 45 min at 45A degrees. Supine and orthostatic heart rate (HR), systolic and diastolic BP (SBP and DBP), as well as monitored and symptoms of OI and AE were monitored and recorded. Supine hemodynamics did not differ between the trials. The significant fall in SBP during the NO-D trial was diminished with PYRIDO, and five subjects had an increased DBP during HUT with PYRIDO compared to the NO-D trial. Individuals that responded to PYRIDO with an increase in orthostatic BP had significantly lower resting HR than non-responders (p < 0.01), which suggests increased levels of pre-synaptic Ach. Subjective symptoms of OI and AE reporting did not differ between the two trials. These preliminary data suggest that PYRIDO is safe and may be effective at ameliorating the orthostatic fall in BP in select individuals with SCI. C1 [Wecht, Jill M.; Cirnigliaro, Christopher M.; Azarelo, Frank; Bauman, William A.] James J Peters VAMC, Natl Ctr Excellence, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Wecht, Jill M.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Bauman, William A.] James J Peters VAMC, Med Serv, Bronx, NY 10468 USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Rutgers New Jersey Med Sch, Newark, NJ USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service [B9212C] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service (Grant # B9212C). NR 39 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0959-9851 EI 1619-1560 J9 CLIN AUTON RES JI Clin. Auton. Res. PD JUN PY 2015 VL 25 IS 3 BP 179 EP 187 DI 10.1007/s10286-015-0272-3 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CK1CF UT WOS:000355942300006 PM 25916633 ER PT J AU Pasparakis, E Koiliari, E Zouraraki, C Tsapakis, EM Roussos, P Giakoumaki, SG Bitsios, P AF Pasparakis, E. Koiliari, E. Zouraraki, C. Tsapakis, E. -M. Roussos, P. Giakoumaki, S. G. Bitsios, P. TI The effects of the CACNA1C rs1006737 A/G on affective startle modulation in healthy males SO EUROPEAN PSYCHIATRY LA English DT Article DE Psychosis; Bipolar affective disorder; Genetics; IAPS pictures; Emotional processing ID MAJOR DEPRESSIVE DISORDER; GENOME-WIDE ASSOCIATION; BORDERLINE PERSONALITY-DISORDER; BIPOLAR DISORDER; GENETIC-VARIATION; EMOTIONAL MEMORY; SCHIZOPHRENIA; REFLEX; ANXIETY; REACTIVITY AB Background: The CACNA1C rs1006737 risk A allele has been associated with affective psychoses and functional studies indicate that it is associated with increased hippocampal/amygdala activity during emotional face-processing. Here we studied the impact of the risk A allele on affective startle modulation. Methods: Hundred and ninety-four healthy males stratified for their CACNA1C rs1006737 genotype (GG:111, GA:67, AA:16) were presented with 18 pleasant, 18 unpleasant and 18 neutral pictures with acoustic probes (104 dB) occurring during 12 pictures in each affective category. Baseline startle was assessed during blank screens. State mood was self-rated on arrival, pre- and post-test and the emotional valence and arousal of affective pictures at post-test. Results: Relative to the other genotypes, risk A allele homozygotes presented with higher anxiety/negative affect at pre-test, reduced and exaggerated physiological responses to the pleasant and negative pictures respectively, negative affect with reduced arousal at post-test and rated the affective pictures as less arousing and inconsistently to their physiological responses (all P < 0.05). Sustained contextual negative mood predicted reduced baseline and affective startle reactivity in the AA group. Conclusions: Healthy homozygous males for the risk A allele appear to have marked contextual sensitivity, affective reactivity akin to anxiety and depression and inefficient emotional appraisal. Our findings provide phenotypic detail of the CACNA1C AA genotype in non-symptomatic individuals, which suggest primary effects in emotional circuitry, consistent with previously documented alterations in hippocampal/amygdala processing. (C) 2015 Elsevier Masson SAS. All rights reserved. C1 [Pasparakis, E.; Koiliari, E.; Tsapakis, E. -M.; Roussos, P.; Bitsios, P.] Univ Crete, Fac Med, Dept Psychiat & Behav Sci, Iraklion 71003, Crete, Greece. [Zouraraki, C.; Giakoumaki, S. G.] Univ Crete, Dept Psychol, Rethimnon, Crete, Greece. [Tsapakis, E. -M.] Aghios Charalambos Mental Hlth Clin, Iraklion, Crete, Greece. [Roussos, P.] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, Dept Psychiat,Friedman Brain Inst, New York, NY 10029 USA. [Roussos, P.] MIRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Bitsios, P (reprint author), Univ Crete, Fac Med, Dept Psychiat & Behav Sci, Iraklion 71003, Crete, Greece. EM pbitsios@med.uoc.gr RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU University of Crete Research Funds Account [E.L.K.E. 1348]; "Manasaki" scholarship FX This project was supported by the University of Crete Research Funds Account (E.L.K.E. 1348). E.K. was supported by a "Manasaki" scholarship. We thank the participants for their help with the study. NR 75 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0924-9338 EI 1778-3585 J9 EUR PSYCHIAT JI Eur. Psychiat. PD JUN PY 2015 VL 30 IS 4 BP 492 EP 498 DI 10.1016/j.eurpsy.2015.03.004 PG 7 WC Psychiatry SC Psychiatry GA CJ7LB UT WOS:000355675400009 PM 25841664 ER PT J AU Fargali, S Garcia, AL Sadahiro, M Jiang, C Janssen, WG Lin, WJ Cogliani, V Elste, A Mortillo, S Cero, C Veitenheimer, B Graiani, G Pasinetti, GM Mahata, SK Osborn, JW Huntley, GW Phillips, GR Benson, DL Bartolomucci, A Salton, SR AF Fargali, Samira Garcia, Angelo L. Sadahiro, Masato Jiang, Cheng Janssen, William G. Lin, Wei-Jye Cogliani, Valeria Elste, Alice Mortillo, Steven Cero, Cheryl Veitenheimer, Britta Graiani, Gallia Pasinetti, Giulio M. Mahata, Sushil K. Osborn, John W. Huntley, George W. Phillips, Greg R. Benson, Deanna L. Bartolomucci, Alessandro Salton, Stephen R. TI The granin VGF promotes genesis of secretory vesicles, and regulates circulating catecholamine levels and blood pressure (vol 28, pg 2120, 2014) SO FASEB JOURNAL LA English DT Correction C1 [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA. Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurol, New York, NY 10029 USA. FU NIGMS NIH HHS [T32 GM008471] NR 1 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD JUN PY 2015 VL 29 IS 6 BP 2679 EP 2679 DI 10.1096/fj.13-239509ERR PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA CJ0ZF UT WOS:000355209500042 PM 26032479 ER PT J AU Vu, JP Larauche, M Flores, M Luong, L Norris, J Oh, S Liang, LJ Waschek, J Pisegna, JR Germano, PM AF Vu, John P. Larauche, Muriel Flores, Martin Luong, Leon Norris, Joshua Oh, Suwan Liang, Li-Jung Waschek, James Pisegna, Joseph R. Germano, Patrizia M. TI Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP) SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Vasoactive intestinal peptide; Feeding; Body composition; Appetite; Metabolism; Hormones ID CYCLASE-ACTIVATING POLYPEPTIDE; RAT GASTRIC FUNDUS; ADENYLATE-CYCLASE; FOOD-INTAKE; GENE-EXPRESSION; DEFICIENT MICE; PEPTIDE VIP; NULL MICE; PITUITARY; LEPTIN AB Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide that belongs to the secretin-glucagon super-family of peptides and has 68 % homology with PACAP. VIP is abundantly expressed in the central and peripheral nervous system and in the gastrointestinal tract, where it exercises several physiological functions. Previously, it has been reported that VIP regulates feeding behavior centrally in different species of vertebrates such as goldfishes, chicken and rodents. Additional studies are necessary to analyze the role of endogenous VIP on the regulation of appetite/satiety, feeding behavior, metabolic hormones, body mass composition and energy balance. The aim of the study was to elucidate the physiological pathways by which VIP regulates appetite/satiety, feeding behavior, metabolic hormones, and body mass composition. VIP deficient (VIP -/-) and age-matched wild-type (WT) littermates were weekly monitored from 5 to 22 weeks of age using a whole body composition EchoMRI analyzer. Food intake and feeding behavior were analyzed using the BioDAQ automated monitoring system. Plasma levels of metabolic hormones including active-ghrelin, GLP-1, leptin, PYY, pancreatic polypeptide (PP), adiponectin, and insulin were measured in fasting as well as in postprandial conditions. The genetic lack of VIP led to a significant reduction of body weight and fat mass and to an increase of lean mass as the mice aged. Additionally, VIP-/- mice had a disrupted pattern of circadian feeding behavior resulting in an abolished regular nocturnal/diurnal feeding. These changes were associated with an altered secretion of adiponectin, GLP-1, leptin, PYY and insulin in VIP-/- mice. Our data demonstrates that endogenous VIP is involved in the control of appetite/satiety, feeding behavior, body mass composition and in the secretion of six different key regulatory metabolic hormones. VIP plays a key role in the regulation of body phenotype by significantly enhancing body weight and fat mass accumulation. Therefore, VIP signaling is critical for the modulation of appetite/satiety and body mass phenotype and is a potential target for future treatment of obesity. C1 [Vu, John P.; Larauche, Muriel; Luong, Leon; Norris, Joshua; Oh, Suwan; Pisegna, Joseph R.; Germano, Patrizia M.] Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, CURE, Los Angeles, CA 90024 USA. [Vu, John P.; Larauche, Muriel; Luong, Leon; Norris, Joshua; Oh, Suwan; Pisegna, Joseph R.; Germano, Patrizia M.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Flores, Martin] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Liang, Li-Jung] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Waschek, James] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90024 USA. RP Germano, PM (reprint author), Univ Calif Los Angeles, Dept Med, Digest Dis Res Ctr, CURE, Los Angeles, CA 90024 USA. EM pgermano@ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU Department of Veterans Affairs RRD Merit Review; NIH [K01 DK088937]; Animal Core Services performed through CURE: Digestive Disease Research Center - NIH [P30DK41301] FX This work received grant support from: Department of Veterans Affairs RR&D Merit Review (JRP); Department of Veterans Affairs RR&D Merit Review (PMG); NIH K01 DK088937 (ML); and Animal Core Services performed through CURE: Digestive Disease Research Center supported by NIH grant P30DK41301. NR 62 TC 3 Z9 4 U1 4 U2 22 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JUN PY 2015 VL 56 IS 2 BP 377 EP 387 DI 10.1007/s12031-015-0556-z PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CJ8LW UT WOS:000355753800014 PM 25904310 ER PT J AU Baker, JF Cannon, GW Ibrahim, S Haroldsen, C Caplan, L Mikuls, TR AF Baker, Joshua F. Cannon, Grant W. Ibrahim, Said Haroldsen, Candace Caplan, Liron Mikuls, Ted R. TI Predictors of Longterm Changes in Body Mass Index in Rheumatoid Arthritis SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE RHEUMATOID ARTHRITIS; BODY MASS INDEX; CACHEXIA; INFLAMMATION ID DISEASE-ACTIVITY; WEIGHT CHANGE; CIGARETTE-SMOKING; US VETERANS; NECROSIS-FACTOR; RISK-FACTORS; MORTALITY; CACHEXIA; ASSOCIATION; SEVERITY AB Objective. Low body mass index (BMI) is a risk factor for poor longterm outcomes in rheumatoid arthritis (RA). The purpose of this study was to identify factors associated with longterm changes in BMI. Methods. Subjects with RA from the Veterans Affairs (VA) Rheumatoid Arthritis (VARA) Registry (n = 1474) were studied. Information on inflammatory markers, presence of erosions, and smoking status were extracted from the VARA database. BMI was extracted from VA electronic medical records within 14 days of each visit date. VA pharmacy records were queried to identify prescriptions for specific RA therapies within 1 month of the visit date. We used robust generalized estimating equations marginal regression models to calculate independent associations between clinical variables and BMI over time. Similar models determined predictors of change in weight and risk of weight loss over the subsequent study observation period. Results. Increasing age, active smoking, and the presence of erosions at baseline were associated with lower BMI. Weight decreased over time among older adults. Factors associated with greater reductions in BMI over time and a greater risk of weight loss were higher inflammatory markers, smoking, older age, higher BMI, and less subsequent improvement in inflammation. Methotrexate use was associated with a lower risk of weight loss. The use of prednisone or anti-tumor necrosis factor therapies was not associated with change in BMI or the risk of weight loss independent of other factors. Conclusion. Greater age, greater inflammatory activity, and active smoking are associated with greater weight loss in RA over time. C1 [Baker, Joshua F.] Philadelphia Vet Affairs VA Med Ctr, Div Rheumatol, Camden, NJ USA. [Ibrahim, Said] Philadelphia Vet Affairs VA Med Ctr, Ctr Hlth Equ Res & Promot, Camden, NJ USA. [Baker, Joshua F.] Univ Penn, Div Rheumatol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Cannon, Grant W.; Haroldsen, Candace] Salt Lake City VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.; Haroldsen, Candace] Univ Utah, Salt Lake City, UT USA. [Caplan, Liron] Denver VA Med Ctr, Dept Med, Denver, CO USA. [Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Dept Med, Omaha, NE USA. RP Baker, JF (reprint author), Hosp Univ Penn, Div Rheumatol, Dept Med, 8 Penn Tower Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center; Veterans Affairs Health Services Research and Development Program of the Veterans Health Administration; VA Clinical Science Research and Development Career Development Award [IK2 CX000955]; VA Health Service Research and Development Career Development Award [07-221]; VA Merit Award FX The Veterans Affairs Rheumatoid Arthritis (VARA) registry is supported by the Nebraska Arthritis Outcomes Research Center at the University of Nebraska Medical Center and by the Veterans Affairs Health Services Research and Development Program of the Veterans Health Administration. Dr. Baker is funded by a VA Clinical Science Research and Development Career Development Award (IK2 CX000955). Dr. Caplan is supported by the VA Health Service Research and Development Career Development Award (07-221). Dr. Mikuls is funded by a VA Merit Award. NR 44 TC 3 Z9 3 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD JUN PY 2015 VL 42 IS 6 BP 920 EP 927 DI 10.3899/jrheum.141363 PG 8 WC Rheumatology SC Rheumatology GA CJ5QO UT WOS:000355543300004 PM 25834210 ER PT J AU Nowling, TK Mather, AR Thiyagarajan, T Hernandez-Corbacho, MJ Powers, TW Jones, EE Snider, AJ Oates, JC Drake, RR Siskind, LJ AF Nowling, Tamara K. Mather, Andrew R. Thiyagarajan, Thirumagal Hernandez-Corbacho, Maria Jose Powers, Thomas W. Jones, E. Ellen Snider, Ashley J. Oates, Jim C. Drake, Richard R. Siskind, Leah J. TI Renal Glycosphingolipid Metabolism Is Dysfunctional in Lupus Nephritis SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID TANDEM MASS-SPECTROMETRY; LIPID-METABOLISM; MRL/LPR MICE; BIOACTIVE SPHINGOLIPIDS; QUANTITATIVE-ANALYSIS; DISEASE-ACTIVITY; NERVOUS-SYSTEM; ERYTHEMATOSUS; GANGLIOSIDES; MANIFESTATIONS AB Nearly one half of patients with lupus develop glomerulonephritis (GN), which often leads to renal failure. Although nephritis is diagnosed by the presence of proteinuria, the pathology of nephritis can fall into one of five classes defined by different forms of tissue injury, and the mechanisms involved in pathogenesis are not completely understood. Glycosphingolipids are abundant in the kidney, have roles in many cellular functions, and were shown to be involved in other renal diseases. Here, we show dysfunctional glycosphingolipid metabolism in patients with lupus nephritis and MRL/Ipr lupus mice. Specifically, we found that glucosylceramide (GlcCer) and lactosylceramide (LacCer) levels are significantly higher in the kidneys of nephritic MRL/Ipr lupus mice than the kidneys of non-nephritic lupus mice or healthy controls. This elevation may be, in part, caused by altered transcriptional regulation and/or activity of LacCer synthase (GalT5) and neuraminidase 1, enzymes that mediate glycosphingolipid metabolism. We show increased neuraminidase 1 activity early during the progression of nephritis (before significant elevation of GlcCer and LacCer in the kidney). Elevated levels of urinary LacCer were detected before proteinuria in lupus mice. Notably, LacCer levels were higher in the urine and kidneys of patients with lupus and nephritis than patients with lupus without nephritis or healthy controls. Together, these results show early and significant dysfunction of the glycosphingolipid metabolic pathway in the kidneys of lupus mice and patients with lupus nephritis and suggest that molecules in this pathway may serve as early markers in lupus nephritis. C1 [Nowling, Tamara K.; Oates, Jim C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Nowling, Tamara K.; Thiyagarajan, Thirumagal; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. [Mather, Andrew R.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Powers, Thomas W.; Jones, E. Ellen; Drake, Richard R.] Med Univ S Carolina, Dept Cell & Mol Pharmacol, Charleston, SC 29425 USA. [Hernandez-Corbacho, Maria Jose; Snider, Ashley J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Snider, Ashley J.] Northport Vet Affairs Med Ctr, Res Serv, Northport, NY USA. [Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. [Siskind, Leah J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. RP Nowling, TK (reprint author), Med Univ S Carolina, Dept Med, 96 Jonathan Lucas St,CSB 912 MSC 637, Charleston, SC 29425 USA. EM Nowling@musc.edu; leah.siskind@louisville.edu FU National Institutes of Health National Institute of Arthritis & Musculoskeletal Skin Diseases [P60-AR062755]; South Carolina Clinical and Translational Research (SCTR) Institute; National Institutes of Health [UL1-RR029882, UL1-TR000062]; Veteran's Administration [BX000115, CX000218]; National Institutes of Health NIAMS [R01-AR45476-11]; Alliance for Lupus Research; National Institutes of Health National Cancer Institute [R01-CA135087]; Department of Defense [W81XWH-10-1-0136]; National Institutes of Health National Center for Research Resources [P20-RR17677]; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK093462]; Cancer Center Support Grant [P30CA138313] FX Support for these studies was provided by National Institutes of Health National Institute of Arthritis & Musculoskeletal & Skin Diseases Grant P60-AR062755 Multidisciplinary Clinical Research Center Pilot Project (to T.K.N.) and Patient Resource Core (to J.C.O.), South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through National Institutes of Health Grant Numbers UL1-RR029882 and UL1-TR000062, Veteran's Administration Merit Review Grants BX000115 (to T.K.N.) and CX000218 (to J.C.O.), National Institutes of Health NIAMS Grant R01-AR45476-11 (to J.C.O.), the Alliance for Lupus Research (to J.C.O.), National Institutes of Health National Cancer Institute Grant R01-CA135087 (to R.R.D.), Department of Defense Grant W81XWH-10-1-0136 (to R.R.D.), National Institutes of Health National Center for Research Resources Grant P20-RR17677 Center of Biomedical Research Excellence in Lipidomics and Pathobiology Pilot Project (to L.J.S.), National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK093462 (to L.J.S.), and the Lipidomics Shared Resource of the Hollings Cancer Center at the Medical University of South Carolina supported by Cancer Center Support Grant P30CA138313. NR 41 TC 4 Z9 4 U1 0 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JUN PY 2015 VL 26 IS 6 BP 1402 EP 1413 DI 10.1681/ASN.2014050508 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA CJ3LS UT WOS:000355386100018 PM 25270066 ER PT J AU Pascoe, S Locantore, N Dransfield, MT Barnes, NC Pavord, ID AF Pascoe, Steven Locantore, Nicholas Dransfield, Mark T. Barnes, Neil C. Pavord, Ian D. TI Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials SO LANCET RESPIRATORY MEDICINE LA English DT Article ID COMPUTED-TOMOGRAPHY ASSESSMENT; PLACEBO-CONTROLLED TRIAL; SHORT-TERM RESPONSE; SPUTUM-EOSINOPHILIA; COPD EXACERBATIONS; DOUBLE-BLIND; CORTICOSTEROID TREATMENT; BUDESONIDE/FORMOTEROL; PREDNISOLONE; INFLAMMATION AB Background The short-term benefits of inhaled corticosteroids for patients with chronic obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic airway inflammation. We investigated whether blood eosinophil count is a useful biomarker of the long-term effect of the inhaled corticosteroid fluticasone furoate on exacerbation frequency. Methods We did a post-hoc analysis of data from two replicate, randomised, double-blind trials of 12 months' duration (Sept 25, 2009 to Oct 21, 2011 and Oct 17, 2011) in which once a day vilanterol 25 mu g was compared with 25 mu g vilanterol plus 50 mu g, 100 mu g, or 200 mu g fluticasone furoate in patients with moderate-to-severe COPD and a history of one or more exacerbation in the previous year. We compared exacerbation rates according to two baseline eosinophil cell count strata (<2% and >= 2%), and according to four baseline percentage groupings. We also assessed lung function and incidence of pneumonia per strata in treatment groups. Findings We included 3177 patients in the analyses, with 2083 patients (66%) having an eosinophil count of 2% or higher at study entry. Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations by 29% compared with vilanterol alone (mean 0.91 vs 1.28 exacerbations per patient per year; p<0.0001) in patients with eosinophil counts of 2% or higher, and by 10% (0.79 vs 0.89; p=0.2827) in patients with eosinophil counts lower than 2%. Reductions in exacerbations with fluticasone furoate and vilanterol, compared with vilanterol alone, were 24% in patients with baseline eosinophil counts of >= 2-<4%, 32% for those with counts of 4-<6%, and 42% for those with eosinophil counts of >= 6%. In patients treated with vilanterol alone, exacerbation rates increased progressively with increasing eosinophil count percentage category. Improvement in trough forced expiratory volume in 1 s (FEV1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilanterol alone were not associated with eosinophil count. Interpretation Blood eosinophil count is a promising biomarker of response to inhaled corticosteroids in patients with COPD. Blood eosinophil count could potentially be used to stratify patients for different exacerbation rate reduction strategies. C1 [Pascoe, Steven; Locantore, Nicholas] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA. [Dransfield, Mark T.] Univ Alabama Birmingham, Lung Hlth Ctr, Birmingham, AL USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Barnes, Neil C.] GlaxoSmithKline, Uxbridge, Middx, England. [Barnes, Neil C.] Barts & London Queen Marys Sch Med & Dent, William Harvey Inst, London, England. [Pavord, Ian D.] Univ Oxford, Nuffield Dept Clin Med, Resp Med Unit, Oxford OX1 2JD, England. RP Pascoe, S (reprint author), GlaxoSmithKline, Res Triangle Pk, NC 27709 USA. EM steven.j.pascoe@gsk.com OI Pavord, Ian/0000-0002-4288-5973 FU GlaxoSmithKline [201595] FX GlaxoSmithKline (study ID 201595). NR 27 TC 118 Z9 123 U1 5 U2 27 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD JUN PY 2015 VL 3 IS 6 BP 435 EP 442 DI 10.1016/S2213-2600(15)00106-X PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CJ5UY UT WOS:000355558500020 PM 25878028 ER PT J AU Wang, DJ Ho, L Faith, J Ono, K Janle, EM Lachcik, PJ Cooper, BR Jannasch, AH D'Arcy, BR Williams, BA Ferruzzi, MG Levine, S Zhao, W Dubner, L Pasinetti, GM AF Wang, Dongjie Ho, Lap Faith, Jeremiah Ono, Kenjiro Janle, Elsa M. Lachcik, Pamela J. Cooper, Bruce R. Jannasch, Amber H. D'Arcy, Bruce R. Williams, Barbara A. Ferruzzi, Mario G. Levine, Samara Zhao, Wei Dubner, Lauren Pasinetti, Giulio M. TI Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease -amyloid oligomerization SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Article DE -Amyloid; Bioavailability; Grape seed polyphenol extract; Phenolic metabolites; Proanthocyanidins ID GRAPE SEED EXTRACT; BETA-PROTEIN; IN-VITRO; URINARY-EXCRETION; MOUSE MODEL; PROANTHOCYANIDIN METABOLITES; COLONIC METABOLISM; CHLOROGENIC ACID; BLOOD-PRESSURE; RING-FISSION AB ScopeGrape seed polyphenol extract (GSPE) is receiving increasing attention for its potential preventative and therapeutic roles in Alzheimer's disease (AD) and other age-related neurodegenerative disorders. The intestinal microbiota is known to actively convert many dietary polyphenols, including GSPE, to phenolic acids. There is limited information on the bioavailability and bioactivity of GSPE-derived phenolic acid in the brain. Methods and resultsWe orally administered GSPE to rats and investigated the bioavailability of 12 phenolic acids known to be generated by microbiota metabolism of anthocyanidins. GSPE treatment significantly increased the content of two of the phenolic acids in the brain: 3-hydroxybenzoic acid and 3-(3-hydroxyphenyl)propionic acid, resulting in the brain accumulations of the two phenolic acids at micromolar concentrations. We also provided evidence that 3-hydroxybenzoic acid and 3-(3 '-hydroxyphenyl)propionic acid potently interfere with the assembly of -amyloid peptides into neurotoxic -amyloid aggregates that play key roles in AD pathogenesis. ConclusionOur observation suggests important contribution of the intestinal microbiota to the protective activities of GSPE (as well as other polyphenol preparations) in AD. Outcomes from our studies support future preclinical and clinical investigations exploring the potential contributions of the intestinal microbiota in protecting against the onset/progression of AD and other neurodegenerative conditions. C1 [Wang, Dongjie; Williams, Barbara A.] Univ Queensland, ARC Ctr Excellence Plant Cell Walls, Ctr Nutr & Food Sci, Brisbane, Qld, Australia. [Ho, Lap; Levine, Samara; Zhao, Wei; Dubner, Lauren; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Faith, Jeremiah] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa, Japan. [Janle, Elsa M.; Lachcik, Pamela J.; Ferruzzi, Mario G.] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA. [Cooper, Bruce R.; Jannasch, Amber H.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [D'Arcy, Bruce R.] Univ Queensland, Sch Agr & Food Sci, Brisbane, Qld, Australia. [Ferruzzi, Mario G.] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Pasinetti, Giulio M.] James J Peter Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIH/NCCAM [P01AT004511-01]; Endeavour International Postgraduate Research Scholarship (IPRS) - Australia government; Graduate School International Travel Award (GSITA) from The University of Queensland; Career Scientist Award in the Research and Development unit FX The GSPE sample used in this study was generously provided by Polyphenolics (Madera, CA). Funding was provided by NIH/NCCAM grant P01AT004511-01 (to GMP) and by the Endeavour International Postgraduate Research Scholarship (IPRS), awarded by Australia government, and the Graduate School International Travel Award (GSITA) from The University of Queensland. This material is the result of work supported in part with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We also acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. GMP and LH disclose financial interest as inventors of a patent for use of GSPE for the treatment of neurodegenerative diseases (Patent number, US 8,747,924 B2). NR 74 TC 19 Z9 20 U1 2 U2 34 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD JUN PY 2015 VL 59 IS 6 BP 1025 EP 1040 DI 10.1002/mnfr.201400544 PG 16 WC Food Science & Technology SC Food Science & Technology GA CJ8JD UT WOS:000355745400002 PM 25689033 ER PT J AU Wang, D Ho, L Faith, J Ono, K Janle, EM Lachcik, PJ Cooper, BR Jannasch, AH D'Arcy, BR Williams, BA Ferruzzi, MG Levine, S Zhao, W Dubner, L Pasinetti, GM AF Wang, D. Ho, L. Faith, J. Ono, K. Janle, E. M. Lachcik, P. J. Cooper, B. R. Jannasch, A. H. D'Arcy, B. R. Williams, B. A. Ferruzzi, M. G. Levine, S. Zhao, W. Dubner, L. Pasinetti, G. M. TI Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease beta-amyloid oligomerization (vol 59, pg 1025, 2015) SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Correction C1 [Pasinetti, G. M.] James J Peters Vet Affairs Med Ctr, GRECC, Basic & Biomed Res & Training Program, Bronx, NY USA. NR 1 TC 0 Z9 0 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD JUN PY 2015 VL 59 IS 6 BP 1222 EP 1222 DI 10.1002/mnfr.201570064 PG 1 WC Food Science & Technology SC Food Science & Technology GA CJ8JD UT WOS:000355745400020 ER PT J AU Baca, CB Vickrey, BG Vassar, S Berg, AT AF Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie Berg, Anne T. TI Disease-targeted versus generic measurement of health-related quality of life in epilepsy SO QUALITY OF LIFE RESEARCH LA English DT Article DE Epilepsy; Quality of Life in Epilepsy Inventory (QOLIE-89); SF-36; Disease targeted; Generic; Sibling control ID ADULTS; POPULATION; CHILDHOOD; INSTRUMENTS; PREDICTORS; CHILDREN; SURGERY; PEOPLE; SF-36; TIME AB To assess (1) whether the generic Short Form (SF)-36, an integrated component of the epilepsy-targeted Quality of Life in Epilepsy Inventory-89 (QOLIE-89), is able to detect differences in the health-related quality of life (HRQOL) between young adults with epilepsy and healthy sibling controls and (2) whether the generic components are as sensitive to within-disease symptom severity as the epilepsy-targeted components of the QOLIE-89 in young adults with epilepsy. A cohort of young adults with epilepsy (N = 108, age 21.6 years SD = 3.8), followed since diagnosis in a prospective community-based study of childhood-onset epilepsy, completed the QOLIE-89, an epilepsy-targeted HRQOL instrument that includes within it a generic core measure (SF-36). Sibling controls (N = 82, age = 20.7 years, SD = 2.1) completed the generic core, SF-36. Age- and gender-adjusted QOLIE-89 epilepsy-targeted and cognitive-distress composite scores and the overall score were strongly associated with seizure-free duration: seizure-free a parts per thousand yen5 years (higher HRQOL), n = 57; seizure-free 1-5 years, n = 22; or seizure-free < 1 year, n = 29 (lower HRQOL) (p < 0.001). However, on QOLIE-89 physical health and mental health composite scores, there were no differences across these seizure-free duration groups. For cases compared with sibling controls, there were no differences on SF-36 physical and mental health composite scores or the global composite score, using either classical test or item-response theory scoring procedures. While the epilepsy-targeted components of the QOLIE-89 are sensitive to seizure-related factors in young adults with epilepsy, the SF-36 generic core measures are not, thereby limiting HRQOL comparisons between young adults with epilepsy and sibling controls. C1 [Baca, Christine B.; Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Vassar, Stefanie] Univ Calif Los Angeles, Dept Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Northwestern Mem Feinberg Sch Med, Epilepsy Ctr, Dept Pediat, Chicago, IL 60611 USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, Box 951769,C-239 RNRC, Los Angeles, CA 90024 USA. EM cbower@mednet.ucla.edu FU National Institutes of Health [NINDS R37-NS31146]; NINDS; US Veterans Administration Health Services Research and Development Service; American Heart Association; UniHealth Foundation; UCLA Clinical and Translational Institute Catalyst Award [NIH/NCATS/ULITR000124]; Pediatric Epilepsy Research Foundation; [NINDS-R37-NS31146]; [NINDS R37 NS31146] FX This study is supported by a Grant from the National Institutes of Health, NINDS R37-NS31146 (PI-Berg). Dr. Baca receives support from Grant NINDS-R37-NS31146. Dr. Vickrey receives support from Grant NINDS R37 NS31146. She serves on the scientific advisory boards for the Sports Concussion Institute and is a section editor for Stroke, receives research support from NINDS, the US Veterans Administration Health Services Research and Development Service, the American Heart Association; and UniHealth Foundation, and she is a consultant to EMD Serono Canada and Genentech. Dr. Vassar received support from Grant NINDS R37 NS31146. She receives support from UCLA Clinical and Translational Institute Catalyst Award (NIH/NCATS/ULITR000124) Dr. Berg receives support from Grant NINDS-R37-NS31146 and Grant funds from the Pediatric Epilepsy Research Foundation. She serves on the Editorial Boards of Epileptic Disorders, Epilepsy and Behavior and Neurology. NR 33 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD JUN PY 2015 VL 24 IS 6 BP 1379 EP 1387 DI 10.1007/s11136-014-0867-5 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CJ9KU UT WOS:000355822000008 PM 25413780 ER PT J AU Alimi, A Weeth-Feinstein, LA Stettner, A Caldera, F Weiss, JM AF Alimi, Adebisi Weeth-Feinstein, Lauren A. Stettner, Amy Caldera, Freddy Weiss, Jennifer M. TI Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: Implications for treatment and surveillance SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE gastroenterology; hamartoma syndrome; multiple; intestinal polyposis; pediatrics ID GENE; MUTATIONS; 10Q23; MICRODELETIONS; PATIENT; INFANCY; DISEASE; CANCER AB We describe a patient with a severe juvenile polyposis phenotype, due to a de novo deletion of chromosome 10q22.3-q24.1. He was initially diagnosed with Juvenile polyposis syndrome (JPS) at age four after presenting with hematochezia due to multiple colonic juvenile polyps. He then re-presented at 23 years with recurrent hematochezia from juvenile polyps in his ileoanal pouch. He is one of the earliest reported cases of JPS associated with a large deletion of chromosome 10. Since his initial diagnosis of JPS further studies have confirmed an association between JPS and mutations in BMPR1A in chromosome band 10q23.2, which is in close proximity to PTEN. Mutations in PTEN cause Cowden syndrome (CS) and other PTEN hamartoma tumor syndromes. Due to the chromosome 10 deletion involving contiguous portions of BMPR1A and PTEN in our patient, he may be at risk for CS associated cancers and features, in addition to the polyps associated with JPS. This case presents new challenges in developing appropriate surveillance algorithms to account for the risks associated with each syndrome and highlights the importance of longitudinal follow-up and transitional care between pediatric and adult gastroenterology for patients with hereditary polyposis syndromes. (c) 2015 Wiley Periodicals, Inc. C1 [Alimi, Adebisi; Weeth-Feinstein, Lauren A.; Caldera, Freddy; Weiss, Jennifer M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Stettner, Amy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Oncol Genet, Madison, WI USA. [Caldera, Freddy; Weiss, Jennifer M.] Univ Wisconsin, Sch Med & Publ Hlth, Div Gastroenterol & Hepatol, Madison, WI USA. [Weiss, Jennifer M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. RP Weiss, JM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Med, Div Gastroenterol & Hepatol, 1685 Highland Ave,Room 4230, Madison, WI 53705 USA. EM jmw@medicine.wisc.edu FU American Cancer Society [MRSG-13-144-01-CPHPS]; National Institutes of Health Center for Advancing Translational Sciences [UL1TR000427]; National Cancer Institute [P30CA014520-34]; UW Health Innovation Program FX Grant sponsor: American Cancer Society; Grant number: MRSG-13-144-01-CPHPS; Grant sponsor: National Institutes of Health Center for Advancing Translational Sciences; Grant number: UL1TR000427; Grant sponsor: National Cancer Institute; Grant number: P30CA014520-34; Grant sponsor: UW Health Innovation Program. NR 19 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD JUN PY 2015 VL 167 IS 6 BP 1305 EP 1308 DI 10.1002/ajmg.a.36876 PG 4 WC Genetics & Heredity SC Genetics & Heredity GA CJ1WV UT WOS:000355276700019 PM 25846706 ER PT J AU Sims, M Redmond, N Khodneva, Y Durant, RW Halanych, J Safford, MM AF Sims, Mario Redmond, Nicole Khodneva, Yulia Durant, Raegan W. Halanych, Jewell Safford, Monika M. TI Depressive symptoms are associated with incident coronary heart disease or revascularization among blacks but not among whites in the Reasons for Geographical and Racial Differences in Stroke study SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Coronary disease; Epidemiology; Depressive symptoms; Myocardial infarction ID BYPASS GRAFT-SURGERY; PSYCHOSOCIAL FACTORS; AFRICAN-AMERICANS; RISK-FACTOR; CARDIOVASCULAR MORTALITY; STATISTICS-COMMITTEE; CARIBBEAN BLACKS; YOUNG-ADULTS; OLDER-ADULTS; RACE AB Purpose: To examine the association of depressive symptoms with coronary heart disease (CHD) end points by race and income. Methods: Study participants were blacks and whites (n = 24,443) without CHD at baseline from the national Reasons for Geographical and Racial Differences in Stroke cohort. Outcomes included acute CHD and CHD or revascularization. We estimated race-stratified multivariate Cox proportional hazards models of incident CHD and incident CHD or revascularization with the 4-item Center for Epidemiological Studies Depression Scale, adjusting for risk factors. Results: Mean follow-up was 4.2 +/- 1.5 years; CHD incidence was 8.3 events per 1000 person-years (n = 366) among blacks and 8.8 events per 1000 person-years (n = 613) among whites. After adjustment for age, sex, marital status, region, and socioeconomic status, depressive symptoms were significantly associated with incident CHD among blacks (hazard ratio [HR], 139; 95% confidence interval [Cl], 1.00-1.91) but not among whites (HR, 1.10; 95% Cl, 0.74-1.64). In the fully adjusted model, compared with blacks who reported no depressive symptoms, those reporting depressive symptoms had greater risk for the composite end point of CHD or revascularization (HR, 1.36; 95% CI, 1.01-1.81). Depressive symptoms were not associated with incident CHD end points among whites. Conclusions: High depressive symptoms were associated with higher risk of CHD or revascularization for blacks but not whites. (C) 2015 Elsevier Inc. All rights reserved. C1 [Sims, Mario] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39213 USA. [Redmond, Nicole; Khodneva, Yulia; Durant, Raegan W.; Halanych, Jewell; Safford, Monika M.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. [Durant, Raegan W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Sims, M (reprint author), Univ Mississippi, Med Ctr, Jackson Heart Study, Dept Med, 350 W Woodrow Wilson Dr, Jackson, MS 39213 USA. EM msims2@umc.edu OI Redmond, Nicole/0000-0001-7298-5804 FU National Institute of Neurological Disorders and Stroke [U01NSO41588] FX The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at http://www.regardsstudy.org. REGARDS is supported by cooperative agreement U01NSO41588 from the National Institute of Neurological Disorders and Stroke (Dr. G. Howard, PI). NR 51 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JUN PY 2015 VL 25 IS 6 BP 426 EP 432 DI 10.1016/j.annepidem.2015.03.014 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI8KM UT WOS:000355021200007 PM 25891100 ER PT J AU Gardner, RC Burke, JF Nettiksimmons, J Goldman, S Tanner, CM Yaffe, K AF Gardner, Raquel C. Burke, James F. Nettiksimmons, Jasmine Goldman, Sam Tanner, Caroline M. Yaffe, Kristine TI Traumatic brain injury in later life increases risk for Parkinson disease SO ANNALS OF NEUROLOGY LA English DT Article ID HEAD-INJURY; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; IMPROVES ACCURACY; SEVERITY SCORE; DEMENTIA; PARAQUAT; COHORT AB ObjectiveTraumatic brain injury (TBI) is thought to be a risk factor for Parkinson disease (PD), but results are conflicting. Many studies do not account for confounding or reverse causation. We sought to address these concerns by quantifying risk of PD after TBI compared to non-TBI trauma (NTT; defined as fractures). MethodsUsing inpatient/emergency department (ED) International Classification of Disease, Ninth Revision code data for California hospitals from 2005-2006, we identified patients aged 55 years with TBI (n=52,393) or NTT (n=113,406) and without baseline PD or dementia who survived hospitalization. Using Kaplan-Meier estimates and Cox proportional hazards models (adjusted for age, sex, race/ethnicity, income, comorbidities, health care use, and trauma severity), we estimated risk of PD after TBI during follow-up ending in 2011. We also assessed interaction with mechanism of injury (fall vs nonfall) and effect of TBI severity (mild vs moderate/severe) and TBI frequency (1 TBI vs >1 TBI). ResultsTBI patients were significantly more likely to be diagnosed with PD compared to NTT patients (1.7% vs 1.1%, p<0.001, adjusted hazard ratio [HR]=1.44, 95% confidence interval [CI]=1.31-1.58). Risk of PD was similar for TBI sustained via falls versus nonfalls (interaction p=0.6). Assessment by TBI severity (mild TBI: HR=1.24, 95% CI=1.04-1.48; moderate/severe TBI: HR=1.50, 95% CI=1.35-1.66) and TBI frequency (1 TBI: HR=1.45, 95% CI=1.30-1.60; >1 TBI: HR=1.87, 95% CI=1.58-2.21) revealed a dose response. InterpretationAmong patients aged 55 years presenting to inpatient/ED settings with trauma, TBI is associated with a 44% increased risk of developing PD over 5 to 7 years that is unlikely to be due to confounding or reverse causation. Ann Neurol 2015;77:987-995 C1 [Gardner, Raquel C.; Goldman, Sam; Tanner, Caroline M.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Gardner, Raquel C.; Nettiksimmons, Jasmine; Goldman, Sam; Tanner, Caroline M.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Burke, James F.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Burke, James F.] Ann Arbor VA Healthcare Syst, Dept Vet Affairs, VA Ctr Clin Management & Res, Ann Arbor, MI USA. [Nettiksimmons, Jasmine; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Gardner, RC (reprint author), 4150 Clement St,Neurol 127, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center; UCSF Pepper Center Research Career Development Core; NIH [K24 AG031155, K08 NS082597]; Department of Defense [W81XWH-12-1-0581]; Department of Veterans Affairs; California Department of Public Health; Bright Focus Foundation; Alzheimer's Association; USCF FX This study was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment (R.C.G.); Medical Research Service of the San Francisco Veterans Affairs Medical Center (R.C.G.); Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (R.C.G.); the UCSF Pepper Center Research Career Development Core (R.C.G.); NIH (K24 AG031155, K.Y.; K08 NS082597, J.F.B.); Department of Defense (W81XWH-12-1-0581, K.Y.); Department of Veterans Affairs (K.Y.); California Department of Public Health (K.Y.); Bright Focus Foundation (K.Y.); and Alzheimer's Association (K.Y.). [Correction added on April 27, 2015, after first online publication: USCF support added for R.C.G.]. The authors thank the Healthcare Cost and Utilization Project for compiling and managing the data used in this study. NR 39 TC 33 Z9 33 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD JUN PY 2015 VL 77 IS 6 BP 987 EP 995 DI 10.1002/ana.24396 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CJ1GA UT WOS:000355230100008 PM 25726936 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Does Hospital Volume Predict Outcomes and Complications After Total Shoulder Arthroplasty in the US? SO ARTHRITIS CARE & RESEARCH LA English DT Article ID SURGEON PROCEDURE VOLUME; TOTAL KNEE ARTHROPLASTY; TOTAL HIP-REPLACEMENT; UNITED-STATES; ASSOCIATION; POPULATION; DATABASES AB ObjectiveTo assess the association of hospital procedure volume for total shoulder arthroplasty (TSA) with patient outcomes and complications. MethodsWe used the US Nationwide Inpatient Sample from 1998-2011 to study the association of hospital annual TSA procedure volume with patient characteristics and TSA outcomes, including discharge disposition (home versus inpatient facility), length of index hospitalization, postarthroplasty periprosthetic fracture, and revision. Annual hospital TSA volume was categorized as <5, 5-9, 10-14, 15-24, and 25 TSA procedures annually. ResultsPatients receiving TSA at higher volume hospitals were more likely to be female (P<0.0001) and white (P<0.0001). Compared to low volume hospitals (<5, 5-9, or 10-14 procedures annually), patients receiving TSA at higher volume hospitals (15-24 or 25 procedures annually) had significantly lower likelihood of being discharged to an inpatient medical facility: 16.5%, 13.4%, 13.0%, 12.7%, and 11.5%, respectively (P<0.0001); hospital stay above the overall median: 46.6%, 40.4%, 36.6%, 34.4%, and 29.2%, respectively (P<0.0001); postarthroplasty fracture: 1.2%, 0.8%, 0.9%, 0.6%, and 0.8%, respectively (P=0.0004); blood transfusion: 8%, 7.1%, 6.7%, 7.1%, and 5.5%, respectively (P=0.006); and TSA revision: 0.5%, 0.3%, 0.2%, 0.3%, 0.3%, respectively (P=0.045). ConclusionIn this study, we found that higher annual hospital TSA volume was associated with better TSA outcomes in the US. These findings document the impact of annual hospital TSA volume on TSA outcomes. Patients, surgeons, and policy-makers should be aware of these findings and take them into account in decision-making, policy decisions, and resource allocation. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19-HS-021110]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [P50-AR-060772, U34-AR-062891]; National Institute on Aging [U01-AG-018947]; National Cancer Institute [U10-CA-149950]; Patient Centered Outcomes Research Institute [CE-1304-6631]; Takeda; Savient FX Dr. Singh's work was supported by the Agency for Health Quality and Research Center for Education and Research on Therapeutics (grant U19-HS-021110), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants P50-AR-060772 and U34-AR-062891), the National Institute on Aging (grant U01-AG-018947), the National Cancer Institute (grant U10-CA-149950), the Patient Centered Outcomes Research Institute (research contract CE-1304-6631), and by the resources and facilities at the VA Medical Center at Birmingham, Alabama.; Dr. Singh has received research grants (more than $10,000 each) from Takeda and Savient, honoraria (less than $10,000 each) from Allergan, Savient, and Regeneron, and (more than $10,000) from Takeda. NR 14 TC 5 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUN PY 2015 VL 67 IS 6 BP 885 EP 890 DI 10.1002/acr.22507 PG 6 WC Rheumatology SC Rheumatology GA CJ2QQ UT WOS:000355330000019 PM 25370499 ER PT J AU Weiss, NH Tull, MT Davis, LT Searcy, J Williams, I Gratz, KL AF Weiss, Nicole H. Tull, Matthew T. Davis, Lindsey T. Searcy, Jasmin Williams, Iman Gratz, Kim L. TI A Preliminary Experimental Investigation of Emotion Dysregulation and Impulsivity in Risky Behaviours SO BEHAVIOUR CHANGE LA English DT Article DE emotion dysregulation; impulsivity; risky behaviours; African American; experimental design ID DELIBERATE SELF-HARM; BORDERLINE PERSONALITY-DISORDER; SUBSTANCE DEPENDENT INPATIENTS; POSTTRAUMATIC-STRESS-DISORDER; SEXUAL-BEHAVIOR; SENSATION SEEKING; POSITIVE URGENCY; NEGATIVE URGENCY; RASH ACTION; ABUSE AB This prospective experimental study sought to examine the unique effects of emotion dysregulation and impulsivity on risky behaviours over time. To this end, 20 African American women enrolled in a historically Black university in the southern United States were randomly assigned to receive one of two brief empirically supported skills training modules (i.e., emotion modulation [EM] or impulsivity reduction [IR]). Participants completed measures of emotion dysregulation, impulsivity, and past-week risky behaviours before (pre-) and one week after (post-) the experimental manipulation. Participants assigned to the EM condition reported significant improvements from pre- to post-manipulation in overall emotion dysregulation (as well as all specific dimensions of emotion dysregulation other than lack of emotional awareness), as well as two dimensions of impulsivity: negative and positive urgency. Participants assigned to the IR condition reported a significant decrease in one dimension of impulsivity (lack of premeditation) from pre- to post-manipulation. Findings also revealed a significant effect of time on risky behaviours, with participants reporting significantly fewer past-week risky behaviours at the post- (vs. pre-) manipulation assessment. Finally, changes in emotion dysregulation from pre- to post-manipulation accounted for the observed reduction in risky behaviours over time (above and beyond changes in impulsivity dimensions). Results highlight the relevance of emotion dysregulation to risky behaviours and suggest that treatments targeting emotion dysregulation may be useful in reducing risky behaviours. C1 [Weiss, Nicole H.] Yale Univ, Sch Med, New Haven, CT 06511 USA. [Tull, Matthew T.; Gratz, Kim L.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [Davis, Lindsey T.] Ralph H Johnson VA Med Ctr, Savannah Primary Care Clin, Savannah, GA USA. [Searcy, Jasmin; Williams, Iman] Jackson State Univ, Dept Psychol, Jackson, MS USA. RP Weiss, NH (reprint author), Yale Univ, Sch Med, Dept Psychiat, 389 Whitney Ave, New Haven, CT 06511 USA. EM nhweiss7@gmail.com FU National Institutes of Health [T32 DA019426] FX The research described here was supported, in part, by a grant from the National Institutes of Health (T32 DA019426). NR 52 TC 2 Z9 2 U1 2 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0813-4839 EI 2049-7768 J9 BEHAV CHANGE JI Behav. Change PD JUN PY 2015 VL 32 IS 2 BP 127 EP 142 DI 10.1017/bec.2015.5 PG 16 WC Psychology, Clinical SC Psychology GA CJ3XJ UT WOS:000355417500005 ER PT J AU Abreu, LN Lafer, B Burke, A Grunebaum, MF Sher, L Sullivan, GM Sublette, ME Pietrobon, R Vissoci, JR Mann, JJ Oquendo, MA AF Abreu, L. N. Lafer, B. Burke, A. Grunebaum, M. F. Sher, L. Sullivan, G. M. Sublette, M. E. Pietrobon, R. Vissoci, J. R. Mann, J. J. Oquendo, M. A. TI Impact of comorbid anxiety disorders in prospective suicide attempts SO BIPOLAR DISORDERS LA English DT Meeting Abstract C1 [Abreu, L. N.; Lafer, B.] Univ Sao Paulo, Inst Psychiat, Sao Paulo, Brazil. [Burke, A.; Grunebaum, M. F.; Sullivan, G. M.; Sublette, M. E.; Mann, J. J.; Oquendo, M. A.] New York State Psychiat Inst & Hosp, Mol Imaging & Neuropathol Div, New York, NY 10032 USA. [Sher, L.] Mt Sinai Sch Med, James J Peters Vet Adm Med Ctr, New York, NY USA. [Pietrobon, R.; Vissoci, J. R.] Duke Univ, Med Ctr, Durham, NC 27706 USA. RI Sublette, M/A-8391-2009 OI Sublette, M/0000-0001-7378-4262; Lafer, Beny/0000-0002-6132-9999 NR 0 TC 0 Z9 0 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUN PY 2015 VL 17 SU 1 SI SI BP 114 EP 114 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CJ2TS UT WOS:000355338100320 ER PT J AU Shamsi, MM Hassan, ZM Quinn, LS Gharakhanlou, R Baghersad, L Mahdavi, M AF Shamsi, Mahdieh Molanouri Hassan, Zuhair Mohammad Quinn, LeBris S. Gharakhanlou, Reza Baghersad, Leila Mahdavi, Mehdi TI Time course of IL-15 expression after acute resistance exercise in trained rats: effect of diabetes and skeletal muscle phenotype SO ENDOCRINE LA English DT Article DE Interleukin-15; Interleukin-6; Resistance training; Type-1 diabetes; Exercise; Myokines; Cytokines ID GENE-EXPRESSION; INTERLEUKIN-15; HYPERTROPHY; ACTIVATION; PROTEIN; MICE; PATHWAYS; CYTOKINE; ATROPHY; BIOLOGY AB Type 1 diabetes is associated with skeletal muscle atrophy. Skeletal muscle is an endocrine organ producing myokines such as interleukin-15 (IL-15) and interleukin-6 (IL-6) in response to contraction. These factors may mediate the effects of exercise on skeletal muscle metabolism and anabolic pathways. Lack of correlation between muscle IL-15 mRNA and protein levels after exercise training has been observed, while regulatory effects of IL-6 on IL-15 expression have also been suggested. This study determined post-exercise changes in muscle IL-15 and IL-6 mRNA expression and IL-15 protein levels in healthy and streptozotocin-induced diabetic rats in both the fast flexor hallucis longus (FHL) and slow soleus muscles. Resistance training preserved FHL muscle weight in diabetic rats and increased IL-15 protein levels in both the soleus and FHL muscles. However, the temporal pattern of this response was distinct in normal and diabetic rats. Moreover, discordance between post-exercise muscle IL-15 mRNA and protein expression was observed in our study, and diabetes suppressed post-exercise increases in FHL muscle IL-6 mRNA expression. Our study indicates that training, skeletal muscle phenotype, and metabolic status all influence the temporal pattern of post-exercise changes in IL-15 expression. Muscle IL-15 protein levels increase following training, suggesting this may be an adaptation contributing to increased capacity for secretion of this myokine that is not depressed by the diabetic state. C1 [Shamsi, Mahdieh Molanouri; Gharakhanlou, Reza; Baghersad, Leila] Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran, Iran. [Shamsi, Mahdieh Molanouri; Hassan, Zuhair Mohammad; Gharakhanlou, Reza; Baghersad, Leila] Jala Ale Ahmad Exp, Tehran, Iran. [Hassan, Zuhair Mohammad] Tarbiat Modares Univ, Sch Med Sci, Dept Immunol, Tehran, Iran. [Quinn, LeBris S.] Univ Washington, Div Gerontol & Geriatr Med, VA Puget Sound Hlth Care Syst, Dept Med,Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Mahdavi, Mehdi] Pasteur Inst Iran, Dept Immunol, Tehran, Iran. RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, Tehran, Iran. EM molanouri@modares.ac.ir; Hassan_zm@modares.ac.ir; quinnL@uw.edu; ghara_re@modares.ac.ir; l.baghersad@gmail.com; mahdavivac@gmail.com FU Research Center of Tarbiat Modares University (TMU), Tehran, Iran FX This work was supported by the Research Center of Tarbiat Modares University (TMU), Tehran, Iran. We wish to thank Professor Yaghob Fathoallahy for his help and sincere cooperation. NR 37 TC 5 Z9 5 U1 0 U2 5 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD JUN PY 2015 VL 49 IS 2 BP 396 EP 403 DI 10.1007/s12020-014-0501-x PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CJ1GD UT WOS:000355230500012 ER PT J AU Dawson, AZ Walker, RJ Campbell, JA Egede, LE AF Dawson, Aprill Z. Walker, Rebekah J. Campbell, Jennifer A. Egede, Leonard E. TI Effect of perceived racial discrimination on self-care behaviors, glycemic control, and quality of life in adults with type 2 diabetes SO ENDOCRINE LA English DT Article DE Perceived racial discrimination; Self-care; Glycemic control; Type 2 diabetes ID MEDICATION ADHERENCE; RATED HEALTH; DISPARITIES; COMMUNITY; VALIDITY; STRESS; WHITES AB Objective: This study used a large sample size of black and white patients with type 2 diabetes to investigate the influence of perceived racial discrimination on biologic measures (glycemic control, blood pressure, and LDL cholesterol), the mental component of quality of life (MCS), and health behaviors known to improve diabetes outcomes. Methods: 602 patients were recruited from two adult primary care clinics in the southeastern United States. Linear regression models were used to assess the associations between perceived racial discrimination, self-care, clinical outcomes, MCS, adjusting for relevant covariates. Race-stratified models were conducted to examine differential associations by race. Results: The mean age was 61 years, with 64.9 % non-Hispanic black, and 41.6 % earning less than $20,000 annually. Perceived discrimination was significantly negatively associated with MCS (beta = -0.56, 95 % CI -0.90, 0.23), general diet (beta = -0.37, CI -0.65, -0.08), and specific diet (beta = -0.25, CI -0.47, -0.03). In African Americans, perceived discrimination was significantly associated with higher systolic blood pressure (beta = 10.17, CI 1.13, -19.22). In Whites, perceived discrimination was significantly associated with lower MCS (beta = -0.51, CI -0.89, -0.14), general diet (beta = -0.40, CI -0.69, -0.99), specific diet (beta = -0.25, CI -0.47, -0.03), and blood glucose testing (beta = -0.43, CI -0.80, -0.06).Conclusions: While no association was found with biologic measures, perceived discrimination was associated with health behaviors and the MCS. In addition, results showed a difference in influence of perceived discrimination by race. C1 [Dawson, Aprill Z.; Walker, Rebekah J.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VAMC, Charleston VA HSR&D COIN, HEROIC, Charleston, VA USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK09369 9-01] FX This study was supported by Grant K24DK09369 9-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 29 TC 6 Z9 6 U1 3 U2 14 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1355-008X EI 1559-0100 J9 ENDOCRINE JI Endocrine PD JUN PY 2015 VL 49 IS 2 BP 422 EP 428 DI 10.1007/s12020-014-0482-9 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CJ1GD UT WOS:000355230500015 PM 25414069 ER PT J AU Bartels, CM Singh, JA Parperis, K Huber, K Rosenthal, AK AF Bartels, Christie M. Singh, Jasvinder A. Parperis, Konstantinos Huber, Karri Rosenthal, Ann K. TI Validation of Administrative Codes for Calcium Pyrophosphate Deposition A Veterans Administration Study SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE calcium pyrophosphate; chondrocalcinosis; ICD-9-CM code; veterans; CPPD disease ID SYNOVIAL-FLUID EXAMINATION; RHEUMATOID-ARTHRITIS; CRYSTALS; PREVALENCE; AFFAIRS; CHONDROCALCINOSIS; OSTEOARTHRITIS; DATABASES; DIAGNOSES; ACCURACY AB Background: Despite high prevalence, progress in calcium pyrophosphate deposition (CPPD) has been limited by poor awareness and absence of validated approaches to study it in large data sets. Objectives: We aimed to determine the accuracy of administrative codes for the diagnosis of CPPD as a foundational step for future studies. Methods: We identified all patients with an International Classification of Diseases, Ninth Revision, Clinical Modification code for chondrocalcinosis (712.1-712.39) or pseudogout/other disorders of mineral metabolism (275.49), and convenience sample selected a comparison group with gout (274.00-03 or 274.8-9), or rheumatoid arthritis (714.0) from 2009 to 2011 at a Veterans Affairs medical center. Each patient was categorized as having definite, probable, or possible CPPD or absence of CPPD based on the McCarty and Ryan criteria using chart abstracted data including crystal analysis, radiographs, and arthritis history. Results: Two hundred forty-nine patients met the clinical gold standard criteria for CPPD based on medical records, whereas 48 patients met definite criteria, 183 probable, and 18 met possible criteria. The accuracy of administrative claims with a code of 712 or 275.49 for definite or probable CPPD was as follows: 98% sensitivity (95% confidence interval, 96%-99%), 78% specificity (74%-83%), 91% positive predictive value, and 94% negative predictive value. Conclusions: At this center, single administrative code 275.49 or 712 accurately identifies patients with CPPD with a positive predictive value of 91%. These findings suggest that administrative codes can have strong clinical accuracy and merit further validation to allow adoption in future epidemiologic studies of CPPD. C1 [Bartels, Christie M.] Univ Wisconsin, Div Rheumatol, Dept Med, Madison, WI 53705 USA. [Bartels, Christie M.] William S Middleton VA Med Ctr, Madison, WI USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Birmingham, AL 35294 USA. [Parperis, Konstantinos; Huber, Karri; Rosenthal, Ann K.] Med Coll Wisconsin, Dept Med, Div Rheumatol, Milwaukee, WI 53226 USA. [Rosenthal, Ann K.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA. RP Bartels, CM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, UWMF Centennial Bldg,1685 Highland Ave,Room 4132, Madison, WI 53705 USA. EM cb4@medicine.wisc.edu FU National Institutes of Health National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [AR062381]; Agency for Health Quality and Research Center for Education and Research on Therapeutics, NIAMS [AR062381]; National Institute of Aging; National Cancer Institute; Takeda; Savient; Regeneron; Allergan; National VA Research Service [110BX000812-01] FX C.M.B. receives support from the National Institutes of Health National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) (K23 #AR062381). J.A.S. is supported by the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, AL. J.A.S. is also supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics, NIAMS (#AR062381), the National Institute of Aging, and the National Cancer Institute. J.A.S. has received research and travel grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, and Allergan, unrelated to this work. A.K.R. receives support from National VA Research Service (#110BX000812-01). The remaining authors declare no conflict of interest. NR 18 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JUN PY 2015 VL 21 IS 4 BP 189 EP 192 DI 10.1097/RHU.0000000000000251 PG 4 WC Rheumatology SC Rheumatology GA CJ1OR UT WOS:000355253800004 PM 26010181 ER PT J AU Singh, JA Bharat, A Edwards, NL AF Singh, Jasvinder A. Bharat, Aseem Edwards, N. Lawrence TI An Internet Survey of Common Treatments Used by Patients With Gout Including Cherry Extract and Juice and Other Dietary Supplements SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article ID PERSPECTIVE; POPULATION; ADHERENCE C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Bharat, Aseem] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Bharat, Aseem] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham; Agency for Health Quality and Research Center for Education and Research on Therapeutics [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases [P50 AR060772, U34 AR062891]; National Institute of Aging [U01 AG018947]; National Cancer Institute [U10 CA149950]; Patient Centered Outcomes Research Institute [CE-1304-6631]; Takeda; Savient; Regeneron; Allergan; Crealta; AstraZeneca; Cymabay Pharmaceuticals FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama. J.A.S. is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (U19 HS021110), National Institute of Arthritis, Musculoskeletal and Skin Diseases (P50 AR060772 and U34 AR062891), National Institute of Aging (U01 AG018947), and National Cancer Institute (U10 CA149950), and research contract (CE-1304-6631) from Patient Centered Outcomes Research Institute.; There are no financial conflicts related directly to this study. J.A.S. has received research and travel grants from Takeda and Savient; and consultant fees from Savient, Takeda, Regeneron, and Allergan. N.L.E. has received consultation fees from Takeda, Crealta, AstraZeneca, and Cymabay Pharmaceuticals. A.B. has no conflicts to declare. NR 11 TC 0 Z9 0 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-1608 EI 1536-7355 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JUN PY 2015 VL 21 IS 4 BP 225 EP 226 DI 10.1097/RHU.0000000000000246 PG 2 WC Rheumatology SC Rheumatology GA CJ1OR UT WOS:000355253800012 PM 26010189 ER PT J AU Chen, JA Splenser, A Guillory, B Luo, JH Mendiratta, M Belinova, B Halder, T Zhang, GH Li, YP Garcia, JM AF Chen, Ji-an Splenser, Andres Guillory, Bobby Luo, Jiaohua Mendiratta, Meenal Belinova, Blaga Halder, Tripti Zhang, Guohua Li, Yi-Ping Garcia, Jose M. TI Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE LA English DT Article DE Cachexia; Cancer; Muscle; Ghrelin; Growth hormone ID GROWTH-HORMONE SECRETAGOGUES; SKELETAL-MUSCLE; CANCER CACHEXIA; MYOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; WEIGHT-LOSS; MICE; CELLS; CATABOLISM AB Background Cachexia and muscle atrophy are common consequences of cancer and chemotherapy administration. The novel hormone ghrelin has been proposed as a treatment for this condition. Increases in food intake and direct effects on muscle proteolysis and protein synthesis are likely to mediate these effects, but the pathways leading to these events are not well understood. Methods We characterized molecular pathways involved in muscle atrophy induced by Lewis lung carcinoma (LLC) tumour implantation in c57/bl6 adult male mice and by administration of the chemotherapeutic agent cisplatin in mice and in C2C12 myotubes. The effects of exogenous ghrelin administration and its mechanisms of action were examined in these settings. Results Tumour implantation and cisplatin induced muscle atrophy by activating pro-inflammatory cytokines, p38-C/EBP-beta, and myostatin, and by down-regulating Akt, myoD, and myogenin, leading to activation of ubiquitin-proteasome-mediated proteolysis and muscle weakness. Tumour implantation also increased mortality. In vitro, cisplatin up-regulated myostatin and atrogin-1 by activating C/EBP-beta and FoxO1/3. Ghrelin prevented these changes in vivo and in vitro, significantly increasing muscle mass (P<0.05 for LLC and P<0.01 for cisplatin models) and grip strength (P = 0.038 for LLC and P = 0.001 for cisplatin models) and improving survival (P = 0.021 for LLC model). Conclusion Ghrelin prevents muscle atrophy by down-regulating inflammation, p38/C/EBP-beta/myostatin, and activating Akt, myogenin, and myoD. These changes appear, at least in part, to target muscle cells directly. Ghrelin administration in this setting is associated with improved muscle strength and survival. C1 [Chen, Ji-an] Third Mil Med Univ, Coll Prevent Med, Dept Hlth Educ, Chongqing, Peoples R China. [Chen, Ji-an; Splenser, Andres; Guillory, Bobby; Luo, Jiaohua; Mendiratta, Meenal; Belinova, Blaga; Halder, Tripti; Garcia, Jose M.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis,MCL,Div Endocri, Houston, TX 77030 USA. [Luo, Jiaohua] Third Mil Med Univ, Coll Prevent Med, Dept Environm Hyg, Chongqing, Peoples R China. [Zhang, Guohua; Li, Yi-Ping] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA. RP Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd,Bldg 109,Rm 210, Houston, TX 77030 USA. EM Jgarcia1@bcm.edu FU US Department of Veterans Affairs [I01-BX000507, I01 CX000174]; Caroline Wiess Law Fund for Molecular Medicine; National Institutes of Health [AG040583, AR063786]; National Institute of aging [T32AG000183]; National Natural Science Foundation of China [81072262, 81372944]; Vanderbilt MMPC [U24 DK59637]; Vanderbilt University Medical Center Hormone Assay and Analytical Services Core (National Institutes of Health) [DK059637, DK020593]; University of Virginia [DK076037]; Baylor Diabetes & Endocrinology Research Center [P30 DK079638] FX US Department of Veterans Affairs (Merit grants I01-BX000507 and I01 CX000174, Merit Review Entry Program and a South-central healthcare network career development award); Caroline Wiess Law Fund for Molecular Medicine; National Institutes of Health (AG040583 to J.M.G. and AR063786 to Y.P.L); National Institute of aging (T32AG000183) to B.G.; National Natural Science Foundation of China (81072262 and 81372944) to J.A.C; Vanderbilt MMPC (supported in part by U24 DK59637); Vanderbilt University Medical Center Hormone Assay and Analytical Services Core (supported by National Institutes of Health grants DK059637 and DK020593); University of Virginia (DK076037); and Baylor Diabetes & Endocrinology Research Center (P30 DK079638). NR 52 TC 19 Z9 20 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2190-5991 EI 2190-6009 J9 J CACHEXIA SARCOPENI JI J. Caxhexia Sarcopenia Muscle PD JUN PY 2015 VL 6 IS 2 BP 132 EP 143 DI 10.1002/jcsm.12023 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CJ2UP UT WOS:000355340500003 PM 26136189 ER PT J AU Kilbane, C Ramirez-Zamora, A Ryapolova-Webb, E Qasim, S Glass, GA Starr, PA Ostrem, JL AF Kilbane, Camilla Ramirez-Zamora, Adolfo Ryapolova-Webb, Elena Qasim, Selman Glass, Graham A. Starr, Philip A. Ostrem, Jill L. TI Pallidal stimulation for Holmes tremor: clinical outcomes and single-unit recordings in 4 cases SO JOURNAL OF NEUROSURGERY LA English DT Article DE Holmes tremor; deep brain stimulation; neurophysiology; oscillation; globus pallidus; Parkinson's disease; functional neurosurgery ID DEEP BRAIN-STIMULATION; NUCLEUS VENTRALIS INTERMEDIUS; MULTIPLE-SCLEROSIS; THALAMIC-STIMULATION; MIDBRAIN TREMOR; PARKINSONS-DISEASE; NEURONAL DISCHARGE; POSTTRAUMATIC TREMOR; STEREOTAXIC SURGERY; MOVEMENT-DISORDERS AB OBJECT Holmes tremor (HT) is characterized by irregular, low-frequency (< 4.5 Hz) tremor occurring at rest, with posture, and with certain actions, often affecting proximal muscles. Previous reports have tended to highlight the use of thalamic deep brain stimulation (DBs) in cases of medication-refractory HT. In this study, the authors report the clinical outcome and analysis of single-unit recordings in patients with medication-refractory HT treated with globus pallidus internus (GPi) DBS. METHODS The authors retrospectively reviewed the medical charts of 4 patients treated with pallidal DBS for medication-refractory HT at the University of California, San Francisco, and San Francisco Veterans Affairs Medical Center. Clinical outcomes were measured at baseline and after surgery using an abbreviated motor-severity Fahn-Tolosa-Marin (FTM) tremor rating scale. Intraoperative microelectrode recordings were performed with patients in the awake state. The neurophysiological characteristics identified in HT were then also compared with characteristics previously described in Parkinson's disease (PD) studied at the authors' institution. RESULTS The mean percentage improvement in tremor motor severity was 78.87% (range 59.9%-94.4%) as measured using the FTM tremor rating scale, with an average length of follow-up of 33.75 months (range 18-52 months). Twenty-eight GPi neurons were recorded intraoperatively in the resting state and 13 of these were also recorded during contralateral voluntary arm movement. The mean firing rate at rest in HT was 56.2 +/- 28.5 Hz, and 63.5 +/- 19.4 Hz with action, much lower than the GPi recordings in PD. GPi unit oscillations of 2-8 Hz were prominent in both patients with HT and those with PD, but in HT, unlike PD, these oscillations were not suppressed by voluntary movement. CONCLUSIONS The efficacy of GPi DBS exceeded that reported in prior studies of ventrolateral thalamus DBS and suggest GPi may be a better target for treating HT. These clinical and neurophysiological findings help illuminate evolving models of HT and highlight the importance of cerebellar basal ganglia interactions. C1 [Kilbane, Camilla] Stanford Univ, Dept Neurol, Med Ctr, Stanford, CA 94305 USA. [Ostrem, Jill L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94115 USA. [Ryapolova-Webb, Elena; Qasim, Selman; Starr, Philip A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA. [Glass, Graham A.; Starr, Philip A.; Ostrem, Jill L.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Ramirez-Zamora, Adolfo] Albany Med Coll, Albany, NY 12208 USA. RP Ostrem, JL (reprint author), Univ Calif San Francisco, Surg Movement Disorder Ctr, 1635 Divisadero St,Ste 520-530, San Francisco, CA 94115 USA. EM jill.ostrem@ucsf.edu OI Qasim, Salman/0000-0001-8739-5962; Ramirez-Zamora, Adolfo/0000-0001-9253-3899 NR 68 TC 3 Z9 3 U1 1 U2 3 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 EI 1933-0693 J9 J NEUROSURG JI J. Neurosurg. PD JUN PY 2015 VL 122 IS 6 BP 1306 EP 1314 DI 10.3171/2015.2.JNS141098 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA CI8OK UT WOS:000355031400007 PM 25794341 ER PT J AU Benzing, T Wilhoit, C Wright, S McCann, A Lessner, S Brothers, TE AF Benzing, Travis Wilhoit, Cameron Wright, Sharee McCann, Aaron Lessner, Susan Brothers, Thomas E. TI Standard duplex criteria overestimate the degree of stenosis after eversion carotid endarterectomy SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID ARTERY STENOSIS; CT ANGIOGRAPHY; FOLLOW-UP; SYMPTOMATIC PATIENTS; VELOCITY CRITERIA; PATCH CLOSURE; ULTRASOUND; TRIAL; BIFURCATION; SONOGRAPHY AB Objective: The eversion technique for carotid endarterectomy (eCEA) offers an alternative to longitudinal arteriotomy and patch closure (pCEA) for open carotid revascularization. In some reports, eCEA has been associated with a higher rate of >50% restenosis of the internal carotid when it is defined as peak systolic velocity (PSV) >125 cm/s by duplex imaging. Because the conformation of the carotid bifurcation may differ after eCEA compared with native carotid arteries, it was hypothesized that standard duplex criteria might not accurately reflect the presence of restenosis after eCEA. Methods: In a case-control study, the outcomes of all patients undergoing carotid endarterectomy by one surgeon during the last 10 years were analyzed retrospectively, with a primary end point of PSV >125 cm/s. Duplex flow velocities were compared with luminal diameter measurements for any carotid computed tomography arteriography or magnetic resonance angiography study obtained within 2 months of duplex imaging, with the degree of stenosis calculated by the methodology used in the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) as well as cross-sectional area (CSA) reduction. Simulations were generated and analyzed by computational model simulations of the eCEA and pCEA arteries. Results: Eversion and longitudinal arteriotomy with patch techniques were used in 118 and 177 carotid arteries, respectively. Duplex follow-up was available in 90 eCEA arteries at a median of 16 (range, 2-136) months and in 150 pCEA arteries at a median of 41 (range, 3-115) months postoperatively. PSV >125 cm/s was present at some time during follow-up in 31% of eCEA and pCEA carotid arteries, each, and in the most recent duplex examination in 7% after eCEA and 21% after pCEA (P = . 003), with no eCEA and two pCEA arteries occluding completely during follow-up (P = .29). In 19 carotid arteries with PSV >125 cm/s after angle correction (median, 160 cm/s; interquartile range, 146-432 cm/s) after eCEA that were subsequently examined by axial imaging, the mean percentage stenosis was 8% +/- 11% by NASCET, 11% +/- 5% by ECST, and 20% +/- 9% by CSA criteria. For eight pCEA arteries with PSV >125 cm/s (median velocity, 148 cm/s; interquartile range, 139-242 cm/s), the corresponding NASCET, ECST, and CSA stenoses were 8% +/- 35%, 26% +/- 32%, and 25% +/- 33%, respectively. NASCET internal carotid diameter reduction of at least 50% was noted by axial imaging after two of the eight pCEAs, and the PSV exceeded 200 cm/s in each case. Conclusions: The presence of hemodynamically significant carotid artery restenosis may be overestimated by standard duplex criteria after eCEA and perhaps after pCEA. Insufficient information currently exists to determine what PSV does correspond to hemodynamically significant restenosis. C1 [Brothers, Thomas E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Benzing, Travis; Wilhoit, Cameron; Wright, Sharee; Brothers, Thomas E.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [McCann, Aaron; Lessner, Susan] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC USA. RP Brothers, TE (reprint author), 25 Courtenay Dr,Ste 7018, Charleston, SC 29425 USA. EM brothete@musc.edu OI Lessner, Susan/0000-0002-8409-5216 FU Research Program for Medical Students at USC School of Medicine FX P.A.McC. was supported by the Research Program for Medical Students at USC School of Medicine. NR 39 TC 2 Z9 2 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2015 VL 61 IS 6 BP 1457 EP 1463 DI 10.1016/j.jvs.2015.01.039 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA CI8JL UT WOS:000355018500010 PM 25758452 ER PT J AU Burke, RE Juarez-Colunga, E Levy, C Prochazka, AV Coleman, EA Ginde, AA AF Burke, Robert E. Juarez-Colunga, Elizabeth Levy, Cari Prochazka, Allan V. Coleman, Eric A. Ginde, Adit A. TI Patient and Hospitalization Characteristics Associated With Increased Postacute Care Facility Discharges From US Hospitals SO MEDICAL CARE LA English DT Article DE post-acute care; nursing home; geriatrics ID POST-ACUTE CARE; COMMUNITY-ACQUIRED PNEUMONIA; SKILLED NURSING FACILITIES; PROSPECTIVE-PAYMENT SYSTEM; UNITED-STATES; CONTROLLED-TRIAL; SEVERE SEPSIS; CRITICAL PATHWAY; OLDER; IMPAIRMENT AB Background/Objectives: The number of patients discharged to postacute care (PAC) facilities after hospitalization increased by 50% nationally between 1996 and 2010. We sought to describe payors and patients most affected by this trend and to identify diagnoses for which PAC facility care may be substituting for continued hospital care. Design: Retrospective analysis of the National Hospital Discharge Survey from 1996 to 2010. Setting: Adult discharges from a national sample of non-Federal hospitals. Participants/Exposures: Adults admitted and discharged to a PAC facility between 1996 and 2010. Our analysis includes 2.99 million sampled discharges, representative of 386 million discharges nationally. Measurements: Patient demographic and hospitalization characteristics, including length of stay (LOS) and diagnoses treated. Results: More than half (50.7%) of all patients discharged to PAC facilities were 80 years old or older in 2010; 40% of hospitalizations in this age group ended with a PAC stay. Decreases in LOS and increases in PAC facility use were consistent across payors and patient demographics. PAC facilities may be substituting for continued inpatient care for patients with pneumonia, hip fracture, and sepsis as these diagnoses demonstrated the clearest trends of decreasing LOS and increasing discharges to PAC facilities. Conclusions: The rise in discharges to PAC facilities is occurring in all age groups and payors, though the predominant population is the very old Medicare patient, for whom successful rehabilitation may be most unsure. PAC facility care may be increasingly substituted for prolonged hospitalizations for patients with pneumonia, hip fracture, and sepsis. C1 [Burke, Robert E.; Prochazka, Allan V.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Denver, CO USA. [Juarez-Colunga, Elizabeth] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. EM robert.burke5@va.gov RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017 FU Colorado Clinical Translational Science Institute [NIH UL1 TR001082]; VA HSR&D Center for Innovation: Value-Centered and Value-Driven Care; NIH [K23AG040708] FX R.E.B., E.J.-C., A.V.P., and A.A.G. were supported by the Colorado Clinical Translational Science Institute (NIH UL1 TR001082) and R.E.B., C.L., and A.V.P. by the VA HSR&D Center for Innovation: Value-Centered and Value-Driven Care. A.A.G. was supported by NIH grant K23AG040708. These sponsors had no role in the design, conduct, analysis, interpretation, or presentation of the study. NR 34 TC 11 Z9 11 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUN PY 2015 VL 53 IS 6 BP 492 EP 500 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CI4NI UT WOS:000354726500005 PM 25906015 ER PT J AU Godwin, BD Simianu, VV Drake, FT Dighe, M Flum, D Bhargava, P AF Godwin, Benjamin David Simianu, Vlad Valentin Drake, Frederick Thurston Dighe, Manjiri Flum, David Bhargava, Puneet TI Is There a Need to Standardize Reporting Terminology in Appendicitis? SO ULTRASOUND QUARTERLY LA English DT Editorial Material ID LOWER QUADRANT PAIN; SUSPECTED APPENDICITIS; CLINICAL-OUTCOMES; RADIOLOGY; DIAGNOSIS; IMPROVE; SONOGRAPHY; CLARITY; IMPACT; SCORE AB While computed tomography (CT) remains the most accurate and widely used modality for appendicitis imaging, ultrasound has developed its own niche role, especially in the pediatric population and in premenopausal women. Ultrasound is commonly used as the initial imaging test when available, with indeterminate or clinically equivocal cases proceeding to CT. To avoid the radiation and time and cost of CT, ultrasound needs to be improved. While previous studies have focused on improving the diagnostic accuracy of ultrasound through better patient selection and technique, relatively little attention has been brought to the ultrasound report, which often serves as the sole mode of communication between the radiologist and the clinician. Standardization of reporting and terminology has been found to improve patient outcomes and management in breast imaging. A standardized report for appendicitis has the potential to decrease confusion and increase accuracy. A potential format could include a standardized list of the presence or absence of imaging findings associated with appendicitis, with a final summary or score indicating the likelihood of appendicitis being present. Aggregation of data over time through use of a common format could help guide radiologist recommendations based on which imaging findings are present. Overall, a standardized report could help increase the value of ultrasound, leading to improved radiologist-clinician communication, better patient outcomes, and decreased costs. C1 [Godwin, Benjamin David; Dighe, Manjiri] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Simianu, Vlad Valentin; Drake, Frederick Thurston; Flum, David] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. RP Godwin, BD (reprint author), 1959 NE Pacific St,RR 215,UW Mailbox 357115, Seattle, WA 98195 USA. EM benjag@uw.edu FU NIDDK NIH HHS [T32 DK070555] NR 22 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-8771 EI 1536-0253 J9 ULTRASOUND Q JI Ultrasound Q. PD JUN PY 2015 VL 31 IS 2 BP 92 EP 94 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CJ0CS UT WOS:000355140900003 PM 26002523 ER PT J AU Cheng, KA Kurtis, B Babayeva, S Zhuge, J Tantchou, I Cai, DM Lafaro, RJ Fallon, JT Zhong, MH AF Cheng, Katherine A. Kurtis, Boaz Babayeva, Sabina Zhuge, Jian Tantchou, Irlna Cai, Dongming Lafaro, Rocco J. Fallon, John T. Zhong, Minghao TI Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites SO ANNALS OF DIAGNOSTIC PATHOLOGY LA English DT Article DE TERT promoter mutations; Squamous cell carcinoma; Heterogeneity ID DISEASE RECURRENCE; MELANOMA; CANCER; COMMON AB Squamous cell carcinoma (SCC) can arise from different anatomical sites including the skin, head and neck, lung, esophagus, genital area, and so on. Despite the same histopathologic features and immunohistochemistry profile, the SCCs of different body sites can show tremendous differences in their presenting symptoms, risk factor associations, natural history, prognosis, and response to treatment. This may reflect the fact that SCCs are heterogenous and likely have unique molecular characteristics at different anatomical sites. Recurrent somatic mutations in the TERT promoter region were first reported in human melanomas. Subsequently, other tumors including cutaneous SCC were found to demonstrate high frequencies of the same mutations. However, the incidences of TERT promoter mutation in noncutaneous SCCs have not been systemically studied. We investigated the TERT promoter mutation status among SCCs from different sites. We collected 84 cases of SCC from the skin (27), head and neck (12), lung (25), and cervix (10), as well as 10 cases of urothelial carcinoma with squamous differentiation (UC-SqD). We found that the frequencies of TERT promoter mutation among SCC of different sits are quite heterogenous: similar to 70% in skin SCC and UC-SqD, 16.67% in head and neck SCC, and 0% in lung and cervix SCC. These results may support the hypothesis of different carcinogenesis mechanisms of SCC in different sites. It also indicates that TERT promoter mutation could be a biomarker for distinguishing skin SCC or UC-SqD vs pulmonary SCC. (C) 2015 Elsevier Inc. All rights reserved. C1 [Cheng, Katherine A.; Kurtis, Boaz; Babayeva, Sabina; Zhuge, Jian; Fallon, John T.; Zhong, Minghao] New York Med Coll, Westchester Med Ctr, Dept Pathol, Valhalla, NY 10595 USA. [Cheng, Katherine A.] New York Med Coll, Westchester Med Ctr, Dept Oncol, Valhalla, NY 10595 USA. [Tantchou, Irlna; Lafaro, Rocco J.] New York Med Coll, Westchester Med Ctr, Dept Surg, Valhalla, NY 10595 USA. [Cai, Dongming] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Cai, Dongming] James J Peters VA Med Ctr, New York, NY USA. RP Zhong, MH (reprint author), New York Med Coll, Westchester Med Ctr, Dept Pathol, 100 Woods Rd, Valhalla, NY 10595 USA. EM ZhongM@WCMC.com FU Pathology Department at Westchester Medical Center/New York Medical College; New York Medical College summer research program FX This study is supported by resident research fund from Pathology Department at Westchester Medical Center/New York Medical College. K.C. was supported by The New York Medical College summer research program. NR 10 TC 8 Z9 8 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1092-9134 EI 1532-8198 J9 ANN DIAGN PATHOL JI Ann. Diagn. Pathol. PD JUN PY 2015 VL 19 IS 3 BP 146 EP 148 DI 10.1016/j.anndiagpath.2015.03.005 PG 3 WC Pathology SC Pathology GA CI8OT UT WOS:000355032300010 PM 25862495 ER PT J AU Sher, L AF Sher, Leo TI Brief psychotic disorder and suicidal behavior SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter ID OBSESSIVE-COMPULSIVE DISORDER C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 3 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD JUN PY 2015 VL 49 IS 6 BP 578 EP 578 DI 10.1177/0004867415569804 PG 1 WC Psychiatry SC Psychiatry GA CI5CB UT WOS:000354769400014 PM 25648142 ER PT J AU McGregor, KM Sudhyadhom, A Nocera, J Seff, A Crosson, B Butler, AJ AF McGregor, Keith M. Sudhyadhom, Atchar Nocera, Joe Seff, Ari Crosson, Bruce Butler, Andrew J. TI Reliability of negative BOLD in ipsilateral sensorimotor areas during unimanual task activity SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE fMRI; Ipsilateral inhibition; Negative BOLD; Reliability; Sensorimotor activity ID UNILATERAL HAND MOVEMENTS; PRIMARY SOMATOSENSORY CORTEX; PRIMARY MOTOR CORTEX; INTERHEMISPHERIC INHIBITION; MIRROR MOVEMENTS; MULTIPLE-SCLEROSIS; NEURONAL INHIBITION; SIGNAL CHANGES; AGE; ACTIVATION AB Research using functional magnetic resonance imaging has for numerous years now reported the existence of a negative blood oxygenation level dependent (BOLD) response. Based on accumulating evidence, this negative BOLD signal appears to represent an active inhibition of cortical areas in which it is found during task activity. This particularly important with respect to motor function given that it is fairly well-established that, in younger adults, the ipsilateral sensorimotor cortex exhibits negative BOLD during unimanual movements in fMRI. This interhemispheric suppression of cortical activity may have useful implications for our understanding of both basic motor function and rehabilitation of injury or disease. However, to date, we are aware of no study that has tested the reliability of evoked negative BOLD in ipsilateral sensorimotor cortex in individuals across sessions. The current study employs a unimanual finger opposition task previously shown to evoke negative BOLD in ipsilateral sensorimotor cortex across three sessions. Reliability metrics across sessions indicates that both the magnitude and location of ipsilateral sensorimotor negative BOLD response is relatively stable over each of the three sessions. Moreover, the volume of negative BOLD in ipsilateral cortex was highly correlated with volume of positive BOLD activity in the contralateral primary motor cortex. These findings show that the negative BOLD signal can be reliably evoked in unimanual task paradigms, and that the signal dynamic could represent an active suppression of the ipsilateral sensorimotor cortex originating from the contralateral motor areas. C1 [McGregor, Keith M.; Nocera, Joe; Seff, Ari; Crosson, Bruce; Butler, Andrew J.] US Dept Vet Affairs, Ctr Visual & Neurocognit, Atlanta, GA USA. [McGregor, Keith M.; Nocera, Joe; Crosson, Bruce] Emory Univ, Dept Neurol, Decatur, GA 30033 USA. [Sudhyadhom, Atchar] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA. [Butler, Andrew J.] Georgia State Univ, Dept Phys Therapy, Atlanta, GA 30303 USA. RP McGregor, KM (reprint author), Emory Univ, Dept Neurol, 1518 Clifton Rd NE, Decatur, GA 30033 USA. EM keith.mcgregor@emory.edu OI McGregor, Keith/0000-0003-3654-351X FU Department of Veteran Affairs (VA) Rehabilitation R&D Center of Excellence [F2182C]; Career Development Award Level-2 award; Senior Research Career Scientist award [B6364L] FX The contents do not represent the views of the Department of Veterans Affairs or the United States Government. This work was supported by a Department of Veteran Affairs (VA) Rehabilitation R&D Center of Excellence #F2182C, Career Development Award Level-2 (KMM) and Senior Research Career Scientist (BC: #B6364L) awards. NR 61 TC 4 Z9 4 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD JUN PY 2015 VL 9 IS 2 BP 245 EP 254 DI 10.1007/s11682-014-9302-3 PG 10 WC Neuroimaging SC Neurosciences & Neurology GA CI7TB UT WOS:000354966600010 PM 24788334 ER PT J AU Rosell, DR Siever, LJ AF Rosell, Daniel R. Siever, Larry J. TI The neurobiology of aggression and violence SO CNS SPECTRUMS LA English DT Review DE Amgydala; cortisol; dopamine; intermittent explosive disorder (IED); monoamine oxidase A (MAOA); orbitofrontal cortex; serotonin; testosterone; tryptophan hydroxylase 2 (TPH2); vasopressin ID BORDERLINE PERSONALITY-DISORDER; SEROTONIN TRANSPORTER GENE; MONOAMINE-OXIDASE-A; 1B RECEPTOR GENE; IMPAIRED IMPULSE CONTROL; IPSAPIRONE CHALLENGE CORRELATE; ALCOHOL-HEIGHTENED AGGRESSION; POSITRON-EMISSION-TOMOGRAPHY; CALLOUS-UNEMOTIONAL TRAITS; ACUTE TRYPTOPHAN DEPLETION AB Aggression and violence represent a significant public health concern and a clinical challenge for the mental healthcare provider. A great deal has been revealed regarding the neurobiology of violence and aggression, and an integration of this body of knowledge will ultimately serve to advance clinical diagnostics and therapeutic interventions. We will review here the latest findings regarding the neurobiology of aggression and violence. First, we will introduce the construct of aggression, with a focus on issues related to its heterogeneity, as well as the importance of refining the aggression phenotype in order to reduce pathophysiologic variability. Next we will examine the neuroanatomy of aggression and violence, focusing on regional volumes, functional studies, and interregional connectivity. Significant emphasis will be on the amygdala, as well as amygdala-frontal circuitry. Then we will turn our attention to the neurochemistry and molecular genetics of aggression and violence, examining the extensive findings on the serotonergic system, as well as the growing literature on the dopaminergic and vasopressinergic systems. We will also address the contribution of steroid hormones, namely, cortisol and testosterone. Finally, we will summarize these findings with a focus on reconciling inconsistencies and potential clinical implications; and, then we will suggest areas of focus for future directions in the field. C1 [Rosell, Daniel R.; Siever, Larry J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Rosell, Daniel R.; Siever, Larry J.] Icahn Sch Med Mt Sinai, Special Evaluat Program Mood & Personal Disorders, New York, NY 10029 USA. [Siever, Larry J.] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. [Siever, Larry J.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN3, Bronx, NY USA. RP Siever, LJ (reprint author), James J Peters Dept Vet Affairs Med Ctr, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM larry.siever@va.gov FU National Institute of Mental Health [MH63875]; Department of Veterans Affairs Office of Academic Affiliations Psychiatric Research/Neurosciences Advanced Fellowship FX Writing of this manuscript was supported by Grant MH63875 from the National Institute of Mental Health to Larry J. Siever. Writing of this manuscript was also supported by The Department of Veterans Affairs Office of Academic Affiliations Psychiatric Research/Neurosciences Advanced Fellowship. NR 249 TC 23 Z9 23 U1 15 U2 104 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1092-8529 EI 2165-6509 J9 CNS SPECTRUMS JI CNS Spectr. PD JUN PY 2015 VL 20 IS 3 BP 254 EP 279 DI 10.1017/S109285291500019X PG 26 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CI7XP UT WOS:000354979800014 PM 25936249 ER PT J AU Kotloff, RM Blosser, S Fulda, GJ Malinoski, D Ahya, VN Angel, L Byrnes, MC DeVita, MA Grissom, TE Halpern, SD Nakagawa, TA Stock, PG Sudan, DL Wood, KE Anillo, SJ Bleck, TP Eidbo, EE Fowler, RA Glazier, AK Gries, C Hasz, R Herr, D Khan, A Landsberg, D Lebovitz, DJ Levine, DJ Mathur, M Naik, P Niemann, CU Nunley, DR O'Connor, KJ Pelletier, SJ Rahman, O Ranjan, D Salim, A Sawyer, RG Shafer, T Sonneti, D Spiro, P Valapour, M Vikraman-Sushama, D Whelan, TPM AF Kotloff, Robert M. Blosser, Sandralee Fulda, Gerard J. Malinoski, Darren Ahya, Vivek N. Angel, Luis Byrnes, Matthew C. DeVita, Michael A. Grissom, Thomas E. Halpern, Scott D. Nakagawa, Thomas A. Stock, Peter G. Sudan, Debra L. Wood, Kenneth E. Anillo, Sergio J. Bleck, Thomas P. Eidbo, Elling E. Fowler, Richard A. Glazier, Alexandra K. Gries, Cynthia Hasz, Richard Herr, Dan Khan, Akhtar Landsberg, David Lebovitz, Daniel J. Levine, Deborah Jo Mathur, Mudit Naik, Priyumvada Niemann, Claus U. Nunley, David R. O'Connor, Kevin J. Pelletier, Shawn J. Rahman, Omar Ranjan, Dinesh Salim, Ali Sawyer, Robert G. Shafer, Teresa Sonneti, David Spiro, Peter Valapour, Maryam Vikraman-Sushama, Deepak Whelan, Timothy P. M. CA Soc Critical Care Med Amer Coll Chest Phys Assoc Organ Procurement Org Donor TI Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement SO CRITICAL CARE MEDICINE LA English DT Article DE critical care; organ donor; organ transplantation ID BRAIN-DEAD DONORS; ORTHOTOPIC LIVER-TRANSPLANTATION; HEART-BEATING DONORS; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; ANTIBODY-POSITIVE DONORS; SINGLE-CENTER EXPERIENCE; DELAYED GRAFT FUNCTION; TASK-FORCE RECOMMENDATIONS; OF-WISCONSIN EXPERIENCE AB This document was developed through the collaborative efforts of the Society of Critical Care Medicine, the American College of Chest Physicians, and the Association of Organ Procurement Organizations. Under the auspices of these societies, a multidisciplinary, multi-institutional task force was convened, incorporating expertise in critical care medicine, organ donor management, and transplantation. Members of the task force were divided into 13 subcommittees, each focused on one of the following general or organ-specific areas: death determination using neurologic criteria, donation after circulatory death determination, authorization process, general contraindications to donation, hemodynamic management, endocrine dysfunction and hormone replacement therapy, pediatric donor management, cardiac donation, lung donation, liver donation, kidney donation, small bowel donation, and pancreas donation. Subcommittees were charged with generating a series of management-related questions related to their topic. For each question, subcommittees provided a summary of relevant literature and specific recommendations. The specific recommendations were approved by all members of the task force and then assembled into a complete document. Because the available literature was overwhelmingly comprised of observational studies and case series, representing low-quality evidence, a decision was made that the document would assume the form of a consensus statement rather than a formally graded guideline. The goal of this document is to provide critical care practitioners with essential information and practical recommendations related to management of the potential organ donor, based on the available literature and expert consensus. C1 [Kotloff, Robert M.; Valapour, Maryam] Cleveland Clin, Dept Pulm Med, Cleveland, OH 44106 USA. [Blosser, Sandralee] Penn State Hershey Med Ctr, Div Pulm Allergy & Crit Care Med, Hershey, PA USA. [Blosser, Sandralee] Pittsburgh Crit Care Assoc, Pittsburgh, PA USA. [Fulda, Gerard J.] Christiana Care Hlth Syst, Dept Surg, Newark, DE USA. [Malinoski, Darren] Portland VA Med Ctr, Dept Surg, Portland, OR USA. [Ahya, Vivek N.; Halpern, Scott D.] Hosp Univ Penn, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA. [Angel, Luis; Levine, Deborah Jo] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Dis & Crit Care Med, San Antonio, TX 78229 USA. [Byrnes, Matthew C.] Univ Minnesota, Med Ctr, Dept Surg, Minneapolis, MN 55455 USA. [DeVita, Michael A.] Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Gen Surg, New York, NY 10032 USA. [Grissom, Thomas E.] Univ Maryland, Med Ctr, Dept Anesthesiol, Baltimore, MD 21201 USA. [Nakagawa, Thomas A.] Wake Forest Baptist Hlth Med Ctr, Pediat Crit Care Sect, Winston Salem, NC USA. [Stock, Peter G.; Niemann, Claus U.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Sudan, Debra L.; Vikraman-Sushama, Deepak] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA. [Wood, Kenneth E.] Geisinger Med Ctr, Danville, PA 17822 USA. [Anillo, Sergio J.] SUNY Buffalo, Buffalo, NY 14260 USA. [Bleck, Thomas P.] Rush Med Coll, Dept Neurol, Chicago, IL 60612 USA. [Eidbo, Elling E.; Fowler, Richard A.] Assoc Organ Procurement Organizat, Vienna, VA USA. [Glazier, Alexandra K.] New England Organ Bank Inc, Waltham, MA USA. [Gries, Cynthia] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [Hasz, Richard] Gift Life, Philadelphia, PA USA. [Herr, Dan] Univ Maryland, Med Ctr, Dept Med, Baltimore, MD 21201 USA. [Khan, Akhtar] Allegheny Gen Hosp, Dept Surg, Pittsburgh, PA 15212 USA. [Landsberg, David] SUNY Upstate Med Ctr, Dept Emergency Med, Syracuse, NY USA. [Lebovitz, Daniel J.] Akron Childrens Hosp, Dept Pediat Crit Care Med, Akron, OH USA. [Mathur, Mudit] Loma Linda Univ, Childrens Hosp, Dept Crit Care Med, Loma Linda, CA 92350 USA. [Nunley, David R.] Univ Louisville Hosp, Div Pulm & Crit Care Med, Louisville, KY USA. [O'Connor, Kevin J.] LifeCtr Northwest, Bellevue, WA USA. [Pelletier, Shawn J.; Sawyer, Robert G.] Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA USA. [Rahman, Omar] Indiana Univ Hlth Syst, Pulm & Crit Care, Indianapolis, IN USA. [Ranjan, Dinesh] Oscar G Johnson Vet Adm Med Ctr, Dept Surg, Iron Mt, MI USA. [Salim, Ali] Brigham & Womens Hosp, Trauma Burns & Surg Crit Care Div, Boston, MA 02115 USA. [Shafer, Teresa] Texas Transplantat Soc, Austin, TX USA. [Sonneti, David] Univ Wisconsin, Div Pulm & Crit Care Med, Madison, WI USA. [Spiro, Peter] Harlem Hosp Med Ctr, Dept Pulm, New York, NY USA. [Whelan, Timothy P. M.] Med Univ S Carolina, Div Pulm Crit Care & Sleep Med, Charleston, SC 29425 USA. RP Kotloff, RM (reprint author), Cleveland Clin, Dept Pulm Med, Cleveland, OH 44106 USA. EM kotlofr@ccf.org FU Society of Critical Care Medicine; American College of Chest Physicians; Association of Organ Procurement Organizations; Health Resources and Services Administration (HRSA); Agency for Healthcare Research and Quality grants; AOPO; Washington Regional Transplant Community; PneumRx; National Heart, Lung and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health FX Supported, in part, by the Society of Critical Care Medicine, American College of Chest Physicians, and Association of Organ Procurement Organizations.; Dr. Malinoski consulted for the Organ Donation and Transplantation Alliance, lectured for multiple organ procurement organizations, and disclosed government work. His institution received grant support from Health Resources and Services Administration (HRSA). Dr. Ahya consulted for Catapult Consulting (the entity is contracted by Centers for Medicare and Medicaid Services to review lung transplant programs with lower than expected outcomes) and received royalties from UptoDate (Lung Transplant section in UptoDate). Dr. Byrnes is employed by the Saint Catherine Hospital. Dr. Nakagawa received royalties from UpToDate and consulted for the U.S. Department of Health and Human Services, HRSA, and the Organ Donation and Transplantation Alliance. Dr. Wood and his institution received grant support from Agency for Healthcare Research and Quality grants. Mr. Eidbo has disclosed that he is executive director of the Association of Organ Procurement Organizations (AOPO). Mr. Fowler received support for article writing/review from the AOPO (led AOPO's expert review of the article and associated revisions), consulted for the AOPO (independent consultant-relevant client during the time period) and the Washington Regional Transplant Community (independent consultant-relevant client during the time period), and has stock in Johnson & Johnson. Dr. Gries received support for travel from American Society of Transplantation (travel to Board of Directors meeting, travel to give talk). Her institution received grant support from PneumRx. Dr. Mathur is employed by the Faculty Physicians and Surgeons of Loma Linda University School of Medicine. His institution received grant support from the National Heart, Lung and Blood Institute (the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials). Dr. Niemann served as a board member for the International Liver Transplant Society, consulted for MedSleuth, is employed by University of California, San Francisco, has stock options with MedSleuth (nothing paid), and received support for article research from HRSA. He and his institution received grant support from HRSA. Dr. Salim's institution received grant support from National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Sonetti is employed by the University of Wisconsin Hospital and Clinic, University of Wisconsin Medical Foundation, and the William S. Middleton Memorial Veteran Hospital (Madison, WI). Dr. Valapour is employed by the University of Minnesota and the Cleveland Clinic and received support for article research from the National Institutes of Health (the topic was covered by this article but the funding was not for this particular project). She and her institution received Federal grant support (investigator for Scientific Registry of Transplant Recipients). Dr. Whelan consulted for LifePoint (Organ Procurement Organization of South Carolina). The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 311 TC 29 Z9 30 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD JUN PY 2015 VL 43 IS 6 BP 1291 EP 1325 DI 10.1097/CCM.0000000000000958 PG 35 WC Critical Care Medicine SC General & Internal Medicine GA CI4LL UT WOS:000354720300039 PM 25978154 ER PT J AU Spoont, MR Nelson, DB Murdoch, M Sayer, NA Nugent, S Rector, T Westermeyer, J AF Spoont, Michele R. Nelson, David B. Murdoch, Maureen Sayer, Nina A. Nugent, Sean Rector, Thomas Westermeyer, Joseph TI ARE THERE RACIAL/ETHNIC DISPARITIES IN VA PTSD TREATMENT RETENTION? SO DEPRESSION AND ANXIETY LA English DT Article DE PTSD; posttraumatic stress disorder; adherence; ethnicity; race; health services; treatment ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE PATIENTS; OF-VETERANS-AFFAIRS; MENTAL-HEALTH-SERVICES; UNITED-STATES; DEPRESSION TREATMENT; PROLONGED EXPOSURE; PSYCHOTROPIC MEDICATION; RACIAL-DIFFERENCES; CLINICAL-RESEARCH AB BackgroundChronic posttraumatic stress disorder (PTSD) can result in significant social and physical impairments. Despite the Department of Veterans Affairs' (VA) expansion of mental health services into primary care clinics to reach larger numbers of Veterans with PTSD, many do not receive sufficient treatment to clinically benefit. This study explored whether the odds of premature mental health treatment termination varies by patient race/ethnicity and, if so, whether such variation is associated with differential access to services or beliefs about mental health treatments. MethodsProspective national cohort study of VA patients who were recently diagnosed with PTSD (n = 6,788). Self-administered surveys and electronic VA databases were utilized to examine mental health treatment retention across racial/ethnic groups in the 6 months following the PTSD diagnosis controlling for treatment need, access factors, age, gender, treatment beliefs, and facility factors. ResultsAfrican American and Latino Veterans were less likely to receive a minimal trial of pharmacotherapy and African American Veterans were less likely to receive a minimal trial of any treatment in the 6 months after being diagnosed with PTSD. Controlling for beliefs about mental health treatments diminished the lower odds of pharmacotherapy retention among Latino but not African American Veterans. Access factors did not contribute to treatment retention disparities. ConclusionsEven in safety-net healthcare systems like VA, racial and ethnic disparities in mental health treatment occur. To improve treatment equity, clinicians may need to more directly address patients' treatment beliefs. More understanding is needed to address the treatment disparity for African American Veterans. C1 [Spoont, Michele R.] Univ Minnesota, Sch Med, US Dept Vet Affairs, Natl Ctr PTSD, Minneapolis, MN 55455 USA. [Spoont, Michele R.; Nelson, David B.; Murdoch, Maureen; Sayer, Nina A.; Nugent, Sean; Rector, Thomas; Westermeyer, Joseph] Univ Minnesota, Sch Med, Minneapolis VA Healthcare Syst, CCDOR, Minneapolis, MN 55455 USA. RP Spoont, MR (reprint author), Minneapolis VA Healthcare Syst, CCDOR, 152,Bldg 9,One Vet Dr, Minneapolis, MN 55417 USA. EM michele.spoont@va.gov RI Sayer, Nina/E-3249-2016 FU U.S. Department of Veterans Affairs (VA); Veterans Health Administration; Health Services Research and Development Service [IAC 06-266] FX Contract grant sponsor: U.S. Department of Veterans Affairs (VA); Veterans Health Administration; Health Services Research and Development Service; Contract grant number: IAC 06-266. NR 67 TC 9 Z9 9 U1 5 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUN PY 2015 VL 32 IS 6 BP 415 EP 425 DI 10.1002/da.22295 PG 11 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CI2IB UT WOS:000354568500005 PM 25421265 ER PT J AU Zhang, HJ Garcia, JM AF Zhang, Hongjie Garcia, Jose M. TI Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE anamorelin; cancer-anorexia-cachexia syndrome; ghrelin; NSCLC ID GROWTH-HORMONE SECRETAGOGUE; GHRELIN RECEPTOR AGONIST; PLACEBO-CONTROLLED TRIAL; CELL LUNG-CANCER; DOUBLE-BLIND; MESSENGER-RNA; HEALTHY-VOLUNTEERS; ARCUATE NUCLEUS; TUMOR-GROWTH; BODY-WEIGHT AB Introduction: Cancer anorexia-cachexia syndrome (CACS) is associated with increased morbidity and mortality. Anamorelin is a novel, orally active ghrelin receptor agonist in clinical development for the treatment of CACS in NSCLC. The aim of this review is to summarize preclinical and clinical studies evaluating anamorelin as a potential promising treatment for CACS in NSCLC. Areas covered: Pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability of anamorelin for the treatment of CACS in NSCLC were reviewed. Anamorelin administration may lead to increases in food intake, body weight and lean body mass, and a stimulatory effect on growth hormone secretion in NSCLC patients. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. Expert opinion: Targeting ghrelin receptors presents the advantage of potentially addressing multiple mechanisms of CACS simultaneously including appetite, muscle protein balance, adipose tissue metabolism, energy expenditure and inflammation. Clinical data suggest that anamorelin is well tolerated and it effectively increases appetite, body weight and lean mass in patients with advanced NSCLC. Long-term safety remains unknown at this time. The potential synergistic effects of anamorelin with nutritional support or exercise as well as its efficacy/safety in other tumor types are also unknown. C1 [Zhang, Hongjie; Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, CTRID, Houston, TX 77030 USA. RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, CTRID, 2002 Holcombe Blvd,Bldg 109,Room 210, Houston, TX 77030 USA. EM jgarcia1@bcm.edu FU Department of Veterans Affairs (MERIT) [BX000507, CX000174]; NIA [AG040583]; Aeterna Zentaris Inc.; Helsinn Therapeutics (US), Inc. FX The authors have received funding from Department of Veterans Affairs (MERIT grants: BX000507 and CX000174) and the NIA (AG040583), Aeterna Zentaris Inc., and Helsinn Therapeutics (US), Inc. J Garcia has received consulting or advisory role's fees from Aeterna Zentaris Inc. and Helsinn Therapeutics (US), Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 73 TC 10 Z9 11 U1 2 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD JUN PY 2015 VL 16 IS 8 BP 1245 EP 1253 DI 10.1517/14656566.2015.1041500 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CH7KI UT WOS:000354214700012 PM 25945893 ER PT J AU Smith, RK Fry, RD Mahmoud, NN Paulson, EC AF Smith, Radhika K. Fry, Robert D. Mahmoud, Najjia N. Paulson, E. Carter TI Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE LA English DT Article DE Complete clinical response; Non-operative management; Neoadjuvant chemoradiation; Rectal cancer ID ABDOMINOPERINEAL RESECTION; NONOPERATIVE MANAGEMENT; CHEMORADIATION THERAPY; MORBIDITY; CHEMORADIOTHERAPY; ADENOCARCINOMA AB While the standard of care for patients with rectal cancer who sustain a complete clinical response (cCR) to chemoradiotherapy (CRT) remains proctectomy with total mesorectal excision, data suggests that non-operative management may be a safe alternative. The purpose of this study is to compare outcomes between patients treated with CRT that attained a cCR and opted for a vigilant surveillance to those of the patients who had a complete pathologic response (cPR) following proctectomy. This is a retrospective review of patients treated for adenocarcinoma of the rectum who achieved either a cCR or a cPR following CRT. Patients with a cCR were enrolled in an active surveillance program which included regularly scheduled exams, proctoscopy, serum carcinoembryonic antigen (CEA), endorectal ultrasound, and cross-sectional imaging. Outcomes were compared to those patients who underwent proctectomy with a cPR. Our primary outcome measures were post-treatment complications, recurrence, and survival. We reviewed 18 patients who opted for surveillance after cCR and 30 patients who underwent proctectomy after a cPR. No non-operative patients had a documented treatment complication, while 17 patients with cPR suffered significant morbidity. There were two recurrences in the active surveillance group, one local and once distant, both treated by salvage resection with no associated mortality at 54 and 62 months. In the cPR group, one patient had a distant recurrence 24 months after surgery which was managed non-operatively. This patient died of unrelated causes 35 months after surgery. Active surveillance can be a safe option that avoids the morbidity associated with proctectomy and preserves oncologic outcomes. C1 [Smith, Radhika K.] Temple Univ Hlth Syst, Dept Gen Surg, Philadelphia, PA 19140 USA. [Fry, Robert D.] Hosp Univ Penn, Div Colon & Rectal Surg, Philadelphia, PA 19106 USA. [Mahmoud, Najjia N.; Paulson, E. Carter] Hosp Univ Penn, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. [Paulson, E. Carter] Hosp Univ Penn, Dept Surg, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Paulson, EC (reprint author), Hosp Univ Penn, Dept Surg, Philadelphia VA Med Ctr, 3900 Woodland Ave,5th Floor Surg Business Off, Philadelphia, PA 19104 USA. EM paulsone@uphs.upenn.edu NR 19 TC 11 Z9 11 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-1958 EI 1432-1262 J9 INT J COLORECTAL DIS JI Int. J. Colorectal Dis. PD JUN PY 2015 VL 30 IS 6 BP 769 EP 774 DI 10.1007/s00384-015-2165-2 PG 6 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA CI4HI UT WOS:000354708800005 PM 25787162 ER PT J AU Ballard, A Parker-Autry, C Lin, CP Markland, AD Ellington, DR Richter, HE AF Ballard, Alicia Parker-Autry, Candace Lin, Chee Paul Markland, Alayne D. Ellington, David R. Richter, Holly E. TI Postoperative bowel function, symptoms, and habits in women after vaginal reconstructive surgery SO INTERNATIONAL UROGYNECOLOGY JOURNAL LA English DT Article DE Bowel preparation; Postoperative bowel function; Vaginal reconstructive surgery ID RANDOMIZED-CONTROLLED-TRIAL; PELVIC FLOOR DISORDERS; URINARY-INCONTINENCE; PROLAPSE SURGERY; ORGAN PROLAPSE; UNITED-STATES; PREVALENCE; OUTCOMES AB The objective was to characterize postoperative bowel symptoms in women undergoing vaginal prolapse reconstructive surgery randomized to preoperative bowel preparation vs a regular diet. Subjects (N = 121) completed two bowel diaries: a 7-day bowel diary immediately before surgery and a 14-day diary postoperatively. Self-reported bowel diary data and symptoms included the time to first bowel movement (BM), daily number of BMs, Bristol Stool Form Scale score, pain, and urgency associated with BM, episodes of fecal incontinence, and use of laxatives. Antiemetic use was abstracted from medical records. Outcomes of groups were compared using Chi-squared/Fisher's exact test or Student's t test as appropriate. Mean time to first postoperative BM was similar in the bowel preparation (n = 60) and control groups (n = 61), 81.2 +/- 28.9 vs 78.6 +/- 28.2 h, p = 0.85. With the first BM, there were no significant differences between bowel preparation and control groups regarding pain (17.2 vs 27.9 %, p = 0.17), fecal urgency with defecation (56.9 vs 52.5 %, p = 0.63), fecal incontinence (14.0 vs 15.0 %, p = 0.88) and > 1 use of laxatives (93.3 vs 96.7 % p = 0.44) respectively. Antiemetic use was similar in both groups (48.3 vs 55.7 % respectively, p = 0.42). There were no differences in the return of bowel function and other bowel symptoms postoperatively between the randomized groups. Lack of bowel preparation does not have an impact on the risk of painful defecation postoperatively. This information may be used to inform patients regarding expectations for bowel function after vaginal reconstructive surgery. C1 [Ballard, Alicia; Parker-Autry, Candace; Ellington, David R.; Richter, Holly E.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35249 USA. [Lin, Chee Paul] Univ Alabama Birmingham, Ctr Clin & Translat Sci CCTS, Birmingham, AL 35249 USA. [Markland, Alayne D.] Univ Alabama Birmingham, Dept Med, Birmingham VA Med Ctr, Birmingham, AL 35249 USA. [Ballard, Alicia; Parker-Autry, Candace; Ellington, David R.; Richter, Holly E.] Univ Alabama Birmingham, Div Urogynecol & Pelv Reconstruct Surg, Birmingham, AL 35249 USA. RP Richter, HE (reprint author), Univ Alabama Birmingham, Div Urogynecol & Pelv Reconstruct Surg, 619 19th St South,176F Suite 10832, Birmingham, AL 35249 USA. EM hrichter@uabmc.edu OI Markland, Alayne/0000-0002-6567-6744 FU NIDDK NIH HHS [2K24-DK068389, K24 DK068389] NR 19 TC 1 Z9 1 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-3462 EI 1433-3023 J9 INT UROGYNECOL J JI Int. Urogynecol. J. PD JUN PY 2015 VL 26 IS 6 BP 817 EP 821 DI 10.1007/s00192-015-2634-8 PG 5 WC Obstetrics & Gynecology; Urology & Nephrology SC Obstetrics & Gynecology; Urology & Nephrology GA CI6RN UT WOS:000354888800006 PM 25672646 ER PT J AU Padrez, KA Asch, DA Merchant, RM AF Padrez, Kevin A. Asch, David A. Merchant, Raina M. TI The Patient Diarist in the Digital Age SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE patient diary; digital strategies; data mining; social media C1 [Padrez, Kevin A.; Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Ctr Hlth Care Innovat, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. EM Raina.merchant@uphs.upenn.edu FU NHLBI NIH HHS [K23 HL109083]; PHS HHS [K23 10714038] NR 5 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2015 VL 30 IS 6 BP 708 EP 709 DI 10.1007/s11606-014-3145-x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CI7RE UT WOS:000354961100005 PM 25515138 ER PT J AU Wallace, ML Magnan, EM Thorpe, CT Schumacher, JR Smith, MA Johnson, HM AF Wallace, Margaret L. Magnan, Elizabeth M. Thorpe, Carolyn T. Schumacher, Jessica R. Smith, Maureen A. Johnson, Heather M. TI Diagnosis and Treatment of Incident Hypertension Among Patients with Diabetes: a US Multi-Disciplinary Group Practice Observational Study SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE hypertension; diabetesmellitus; diagnosis; electronic health records ID BLOOD-PRESSURE CONTROL; PRIMARY-CARE USE; CLINICAL INERTIA; CARDIOVASCULAR-DISEASE; AMBULATORY POPULATION; ADMINISTRATIVE DATA; UNITED-STATES; YOUNG-ADULTS; RISK-FACTORS; PREVALENCE AB Early hypertension control reduces the risk of cardiovascular complications among patients with diabetes mellitus. There is a need to improve hypertension management among patients with diabetes mellitus. We aimed to evaluate rates and associations of hypertension diagnosis and treatment among patients with diabetes mellitus and incident hypertension. This was a 4-year retrospective analysis of electronic health records. Adults a parts per thousand yen18 years old (n = 771) with diabetes mellitus, who met criteria for incident hypertension and received primary care at a large, Midwestern academic group practice from 2008 to 2011 were included Cut-points of 130/80 and 140/90 mmHg were used to identify incident cases of hypertension. Kaplan-Meier analysis estimated the probability of receiving: 1) an initial hypertension diagnosis and 2) antihypertensive medication at specific time points. Cox proportional-hazard frailty models (HR; 95 % CI) were fit to identify associations of time to hypertension diagnosis and treatment. Among patients with diabetes mellitus who met clinical criteria for hypertension, 41 % received a diagnosis and 37 % received medication using the 130/80 mmHg cut-point. At the 140/90 mmHg cut-point, 52 % received a diagnosis and 49 % received medication. Atrial fibrillation (HR 2.18; 1.21-4.67) was associated with faster diagnosis rates; peripheral vascular disease (HR 0.18; 0.04-0.74) and fewer primary care visits (HR 0.93; 0.88-0.98) were associated with slower diagnosis rates. Atrial fibrillation (HR 3.07; 1.39-6.74) and ischemic heart disease/congestive heart failure (HR 2.16; 1.24-3.76) were associated with faster treatment rates; peripheral vascular disease (HR 0.16; 0.04-0.64) and fewer visits (HR 0.93; 0.88-0.98) predicted slower medication initiation. Diagnosis and treatment of incident hypertension were similar using cut-points of 130/80 and 140/90 mmHg. Among patients with diabetes mellitus, even using a cut-point of 140/90 mmHg, approximately 50 % remained undiagnosed and untreated for hypertension. Future interventions should target patients with multiple comorbidities to improve hypertension and diabetes clinical care. C1 [Wallace, Margaret L.; Magnan, Elizabeth M.; Smith, Maureen A.; Johnson, Heather M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Ctr Hlth Equity Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Schumacher, Jessica R.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI USA. [Schumacher, Jessica R.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA. [Johnson, Heather M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Cardiovasc Med, Madison, WI USA. RP Johnson, HM (reprint author), Div Cardiovasc Med, H4-512 CSC,MC 3248,600 Highland Ave, Madison, WI 53792 USA. EM hm2@medicine.wisc.edu OI Johnson, Heather/0000-0002-4916-3519 FU UW Health Innovation Program; Clinical and Translational Science Award (CTSA) program [UL1RR025011]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health [U54TR000021]; National Research Service Award from the Health Resources and Services Administration [T32HP10010]; National Heart, Lung, and Blood Institute of the National Institutes of Health [K23HL112907]; University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health FX Funders: Research reported in this manuscript was supported by the UW Health Innovation Program and the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) under award number UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health under award number U54TR000021. Margaret Wallace and Elizabeth Magnan are supported by a National Research Service Award (T32HP10010) from the Health Resources and Services Administration to the University of Wisconsin Department of Family Medicine. Heather Johnson is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL112907, and also by the University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 43 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2015 VL 30 IS 6 BP 768 EP 776 DI 10.1007/s11606-015-3202-0 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CI7RE UT WOS:000354961100015 PM 25650264 ER PT J AU Morgan, RO Bass, DM Judge, KS Liu, CF Wilson, N Snow, AL Pirraglia, P Garcia-Maldonado, M Raia, P Fouladi, NN Kunik, ME AF Morgan, Robert O. Bass, David M. Judge, Katherine S. Liu, C. F. Wilson, Nancy Snow, A. Lynn Pirraglia, Paul Garcia-Maldonado, Maurilio Raia, Paul Fouladi, N. N. Kunik, Mark E. TI A Break-Even Analysis for Dementia Care Collaboration: Partners in Dementia Care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE costs and cost analysis; dementia; veterans ID CASE-MANAGEMENT; INTERVENTION; COSTS; VETERANS; OUTCOMES; PROGRAM AB Dementia is a costly disease. People with dementia, their families, and their friends are affected on personal, emotional, and financial levels. Prior work has shown that the "Partners in Dementia Care" (PDC) intervention addresses unmet needs and improves psychosocial outcomes and satisfaction with care. We examined whether PDC reduced direct Veterans Health Administration (VHA) health care costs compared with usual care. This study was a cost analysis of the PDC intervention in a 30-month trial involving five VHA medical centers. Study subjects were veterans (N = 434) 50 years of age and older with dementia and their caregivers at two intervention (N = 269) and three comparison sites (N = 165). PDC is a telephone-based care coordination and support service for veterans with dementia and their caregivers, delivered through partnerships between VHA medical centers and local Alzheimer's Association chapters. We tested for differences in total VHA health care costs, including hospital, emergency department, nursing home, outpatient, and pharmacy costs, as well as program costs for intervention participants. Covariates included caregiver reports of veterans' cognitive impairment, behavior problems, and personal care dependencies. We used linear mixed model regression to model change in log total cost post-baseline over a 1-year follow-up period. Intervention participants showed higher VHA costs than usual-care participants both before and after the intervention but did not differ significantly regarding change in log costs from pre- to post-baseline periods. Pre-baseline log cost (p a parts per thousand currency signaEuro parts per thousand 0.001), baseline cognitive impairment (p a parts per thousand currency signaEuro parts per thousand 0.05), number of personal care dependencies (p a parts per thousand currency signaEuro parts per thousand 0.01), and VA service priority (p a parts per thousand currency signaEuro parts per thousand 0.01) all predicted change in log total cost. These analyses show that PDC meets veterans' needs without significantly increasing VHA health care costs. PDC addresses the priority area of care coordination in the National Plan to Address Alzheimer's Disease, offering a low-cost, structured, protocol-driven, evidence-based method for effectively delivering care coordination. C1 [Morgan, Robert O.; Fouladi, N. N.] Univ Texas Sch Publ Hlth, Houston, TX 77030 USA. [Bass, David M.] Benjamin Rose Inst Aging, Cleveland, OH USA. [Judge, Katherine S.] Cleveland State Univ, Cleveland, OH 44115 USA. [Liu, C. F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Liu, C. F.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Wilson, Nancy; Kunik, Mark E.] Houston VA HSR & D Ctr Innovat Qual Effectiveness, Houston, TX USA. [Wilson, Nancy; Garcia-Maldonado, Maurilio; Kunik, Mark E.] Baylor Coll Med, Houston, TX 77030 USA. [Snow, A. Lynn] Tuscaloosa Vet Affairs Med Ctr, Tuscaloosa, AL USA. [Snow, A. Lynn] Univ Alabama, Tuscaloosa, AL USA. [Pirraglia, Paul] Providence Vet Affairs Med Ctr, Providence, RI USA. [Pirraglia, Paul] Brown Univ, Sch Med, Providence, RI 02912 USA. [Garcia-Maldonado, Maurilio] Beaumont Vet Affairs Community Based Outpatient C, Beaumont, TX USA. [Raia, Paul] Massachusetts New Hampshire Chapter, Alzheimers Assoc, Watertown, MA USA. [Kunik, Mark E.] VA South Cent Mental Illness Educ Res & Clin Ctr, Houston, TX USA. RP Morgan, RO (reprint author), Univ Texas Sch Publ Hlth, Houston, TX 77030 USA. EM Robert.O.Morgan@uth.tmc.edu FU Department of Veterans Affairs, Health Services Research and Development [HR 04-238-3]; Alzheimer's Association [IIRG-08-89058]; Robert Wood Johnson Foundation [57816]; Houston VA HSR&D Center for Innovations in Quality, Effectiveness Safety [CIN 13-413] FX This work was supported by a grant from the Department of Veterans Affairs, Health Services Research and Development (HR 04-238-3), and grants from the Alzheimer's Association (IIRG-08-89058) and the Robert Wood Johnson Foundation (#57816). This work was supported in part by the Houston VA HSR&D Center for Innovations in Quality, Effectiveness & Safety [CIN 13-413]. The attitudes expressed herein are those of the authors and do not necessarily reflect those of the Department of Veterans Affairs/U.S. government or Baylor College of Medicine. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 0 Z9 0 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2015 VL 30 IS 6 BP 804 EP 809 DI 10.1007/s11606-015-3205-x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CI7RE UT WOS:000354961100020 PM 25666216 ER PT J AU Lewis, CL Adams, J Tai-Seale, M Huang, QW Knowles, SB Nielsen, ME Pignone, MP Walter, LC Frosch, DL AF Lewis, Carmen L. Adams, Jared Tai-Seale, Ming Huang, Qiwen Knowles, Sarah B. Nielsen, Matthew E. Pignone, Michael P. Walter, Louise C. Frosch, Dominick L. TI A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cancer prevention; prostate cancer; medical decision making; prostate-specific antigen; early detection of cancer ID PROSTATE-CANCER; PATIENT KNOWLEDGE; ANTIGEN TEST; AIDS; MEN; GUIDELINES; STATEMENT; INTERNET AB Decision support interventions (DESIs) provide a mechanism to translate comparative effectiveness research results into clinical care so that patients are able to make informed decisions. Patient decision support interventions for prostate-specific antigen (PSA) have been shown to promote informed decision making and reduce PSA testing in efficacy trials, but their impact in real world settings is not clear. We performed an effectiveness trial of PSA decision support interventions in primary care. A randomized controlled trial of three distribution strategies was compared to a control. Participants included 2,550 men eligible for PSA testing (76.6 % of the eligible population) and 2001 survey respondents (60.1 % survey response rate). The intervention groups were: 1) mailed the DESI in DVD format, 2) offered a shared medical appointment (SMA) to view the DESI with other men and discuss, and 3) both options. We measured PSA testing identified via electronic medical record at 12 months and DESI use by self-report 4 months after the intervention mailing. We found no differences in PSA testing across the three distribution strategies over a year-long follow-up period: 21 %, 24 %, 22 % in the DESI, SMA, and combined group respectively, compared to 21 % in the control group (p = 0.51). Self-reported DESI use was low across all strategies at 4 months: 16 % in the mailed DESI group, 6 % in the SMA group, and 15 % in the combined group (p = < 0.0001). Mailing PSA decision support interventions or inviting men to shared medical appointments unrelated to a primary care office visit do not appear to promote informed decision making, or change PSA testing behavior. C1 [Lewis, Carmen L.] Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med, Chapel Hill, NC 27514 USA. [Pignone, Michael P.] Univ N Carolina, Dept Med, Div Gen Internal Med & Clin Epidemiol, Chapel Hill, NC USA. [Adams, Jared; Tai-Seale, Ming; Huang, Qiwen; Knowles, Sarah B.; Frosch, Dominick L.] Palo Alto Med Fdn Res Inst, Palo Alto, CA USA. [Adams, Jared] UCSF Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA. [Nielsen, Matthew E.] Univ N Carolina, Dept Urol, Chapel Hill, NC USA. [Walter, Louise C.] UCSF Div Geriatr, San Francisco, CA USA. [Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Frosch, Dominick L.] Gordon & Betty Moore Fdn, Palo Alto, CA USA. [Frosch, Dominick L.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. [Pignone, Michael P.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. RP Lewis, CL (reprint author), Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med, Mail Stop B180,Acad Off 1,Room 8415, Chapel Hill, NC 27514 USA. EM Carmen.L.Lewis@ucdenver.edu FU U.S. Department of Health and Human Services (DHHS), Assistant Secretary for Planning and Evaluation [R18 AE000023]; National Institute on Aging [K24 AG041180]; National Cancer Institute [R01 CA1334425-01] FX The study was supported by a grant from the U.S. Department of Health and Human Services (DHHS), Assistant Secretary for Planning and Evaluation (R18 AE000023). Dr. Walter also received funding from the National Institute on Aging (K24 AG041180), and the National Cancer Institute (R01 CA1334425-01). Prior presentations: Presented in part at The International Shared Decision Making Conference, 18 June 2013, Lima, Peru. NR 24 TC 2 Z9 2 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2015 VL 30 IS 6 BP 810 EP 816 DI 10.1007/s11606-015-3214-9 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CI7RE UT WOS:000354961100021 PM 25666221 ER PT J AU Chiang, S Levin, HS Haneef, Z AF Chiang, Sharon Levin, Harvey S. Haneef, Zulfi TI Computer-automated focus lateralization of temporal lobe epilepsy using fMRI SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE functional magnetic resonance imaging; graph theory; temporal lobe epilepsy; lateralization; functional connectivity; automated pattern recognition ID FUNCTIONAL CONNECTIVITY MRI; HUMAN BRAIN; NETWORKS AB PurposeTo compare the performance of computer-automated diagnosis using functional magnetic resonance imaging (fMRI) interictal graph theory (CADFIG) to that achieved in standard clinical practice with MRI, for lateralizing the affected hemisphere in temporal lobe epilepsy (TLE). Materials and MethodsInterictal resting state fMRI and high-resolution MRI were performed on 14 left and 10 right TLE patients. Functional topology measures were calculated from fMRI using graph theory, and used to lateralize the epileptogenic hemisphere using quadratic discriminant analysis. Leave-one-out cross-validation prediction accuracy of CADFIG was compared to performance based on expert manual analysis (MA) of MRI, using video EEG as the "gold standard" for focus lateralization. ResultsCADFIG correctly lateralized 95.8% (23/24) of cases, compared to 66.7% (16/24) with expert MA of MRI. Combining MA with CADFIG allowed all cases (24/24) to be correctly lateralized. CADFIG correctly identified the affected hemisphere for all patients (8/8) where MRI failed to lateralize. ConclusionCADFIG based on fMRI lateralized the affected hemisphere in TLE with superior performance compared to expert MA of MRI. These results demonstrate that functional patterns in fMRI can be used with automated machine learning for diagnostic lateralization in TLE. Addition of fMRI-based tests to existing protocols for identifying the affected hemisphere in presurgical assessment can improve diagnostic accuracy and surgical outcome in TLE.J. Magn. Reson. Imaging 2015;41:1689-1694. (c) 2014 Wiley Periodicals, Inc. C1 [Chiang, Sharon] Rice Univ, Dept Stat, Houston, TX 77251 USA. [Levin, Harvey S.] Baylor Coll Med, Dept Phys Med, Houston, TX 77030 USA. [Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Haneef, Zulfi] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Haneef, Zulfi] VA Med Ctr, Neurol Care Line, Houston, TX USA. RP Haneef, Z (reprint author), Baylor Coll Med, Dept Neurol, Peter Kellaway Sect Neurophysiol, Neurol, One Baylor Plaza,MS NB302, Houston, TX 77030 USA. EM zulfi.haneef@bcm.edu FU Epilepsy Foundation of America (Research Grants Program); Baylor College of Medicine Computational and Integrative Biomedical Research Center (CIBR) Seed Grant Awards; ARCO Foundation Young Teacher-Investigator Award; Naman Family Fund for Basic Research from the Baylor College of Medicine; National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences [2T15LM007093-21]; National Institutes of Health [5T32CA096520-07]; Moody Foundation FX Contract grant sponsor: Epilepsy Foundation of America (Research Grants Program); Contract grant sponsor: Baylor College of Medicine Computational and Integrative Biomedical Research Center (CIBR) Seed Grant Awards; Contract grant sponsor: ARCO Foundation Young Teacher-Investigator Award and the Naman Family Fund for Basic Research from the Baylor College of Medicine; Contract grant sponsor: National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences; Contract grant number: 2T15LM007093-21; Contract grant sponsor: National Institutes of Health; Contract grant number: 5T32CA096520-07; Contract grant sponsor: Moody Foundation. NR 20 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 EI 1522-2586 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD JUN PY 2015 VL 41 IS 6 BP 1689 EP 1694 DI 10.1002/jmri.24696 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CI4QU UT WOS:000354738100024 PM 25044773 ER PT J AU Rothlind, JC York, MK Carlson, K Luo, P Marks, WJ Weaver, FM Stern, M Follett, K Reda, D AF Rothlind, Johannes C. York, Michele K. Carlson, Kim Luo, Ping Marks, William J., Jr. Weaver, Frances M. Stern, Matthew Follett, Kenneth Reda, Domenic CA CSP-468 Study Grp TI Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID QUALITY-OF-LIFE; CLINICAL-SIGNIFICANCE; COGNITIVE DECLINES; RELIABLE CHANGE; NUCLEUS; TRIAL; MULTICENTER AB Background Deep brain stimulation (DBS) improves motor symptoms in Parkinson's disease (PD), but questions remain regarding neuropsychological decrements sometimes associated with this treatment, including rates of statistically and clinically meaningful change, and whether there are differences in outcome related to surgical target. Methods Neuropsychological functioning was assessed in patients with Parkinson's disease (PD) at baseline and after 6 months in a prospective, randomised, controlled study comparing best medical therapy (BMT, n=116) and bilateral deep brain stimulation (DBS, n=164) at either the subthalamic nucleus (STN, n=84) or globus pallidus interna (GPi, n=80), using standardised neuropsychological tests. Measures of functional outcomes were also administered. Results Comparison of the two DBS targets revealed few significant group differences. STN DBS was associated with greater mean reductions on some measures of processing speed, only one of which was statistically significant in comparison with stimulation of GPi. GPi DBS was associated with lower mean performance on one measure of learning and memory that requires mental control and cognitive flexibility. Compared to the group receiving BMT, the combined DBS group had significantly greater mean reductions at 6-month follow-up in performance on multiple measures of processing speed and working memory. After calculating thresholds for statistically reliable change from data obtained from the BMT group, the combined DBS group also displayed higher rates of decline in neuropsychological test performance. Among study completers, 18 (11%) study participants receiving DBS displayed reliable decline by multiple indicators in two or more cognitive domains, a significantly higher rate than in the BMT group (3%). This multi-domain cognitive decline was associated with less beneficial change in subjective ratings of everyday functioning and quality of life (QOL). The multi-domain cognitive decline group continued to function at a lower level at 24-month follow-up. Conclusions In those with PD, the likelihood of significant decline in neuropsychological functioning increases with DBS, affecting a small minority of patients who also appear to respond less optimally to DBS by other indicators of QOL. C1 [Rothlind, Johannes C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Rothlind, Johannes C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [York, Michele K.] Michael E DeBakey VA Med Ctr, Dept Neurol, Houston, TX USA. [York, Michele K.] Baylor Coll Med, Houston, TX 77030 USA. [Carlson, Kim; Luo, Ping] Hines VA Hosp, Cooperat Studies Coordinating Ctr, Hines, IL USA. [Marks, William J., Jr.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Weaver, Frances M.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. [Stern, Matthew] Univ Penn Hlth Syst, Philadelphia, PA USA. [Follett, Kenneth] Iowa City VA Med Ctr, Iowa City, IA USA. [Follett, Kenneth] Univ Nebraska Med Ctr, Omaha, NE USA. RP Rothlind, JC (reprint author), San Francisco VA Med Ctr, MHS 116B,4150 Clement St, San Francisco, CA 94121 USA. EM johannes.rothlind@va.gov FU Cooperative Studies Program; Department of Veterans Affairs Office of Research and Development; National Institute of Neurological Disorders and Stroke; Medtronic, Inc [468] FX The research described in this article was financially supported by the Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development, National Institute of Neurological Disorders and Stroke, and Medtronic, Inc. VA Cooperative Study #468. NR 21 TC 21 Z9 21 U1 0 U2 26 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD JUN PY 2015 VL 86 IS 6 BP 622 EP 629 DI 10.1136/jnnp-2014-308119 PG 8 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA CI1DN UT WOS:000354482000007 PM 25185211 ER PT J AU Bjornsdottir, E Keenan, BT Eysteinsdottir, B Arnardottir, ES Janson, C Gislason, T Sigurdsson, JF Kuna, ST Pack, AI Benediktsdottir, B AF Bjornsdottir, Erla Keenan, Brendan T. Eysteinsdottir, Bjorg Arnardottir, Erna Sif Janson, Christer Gislason, Thorarinn Sigurdsson, Jon Fridrik Kuna, Samuel T. Pack, Allan I. Benediktsdottir, Bryndis TI Quality of life among untreated sleep apnea patients compared with the general population and changes after treatment with positive airway pressure SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE Personalized medicine; compliance; Icelandic sleep apnea cohort (ISAC); mental and physical health ID CPAP TREATMENT; HEALTH SURVEY; HEART HEALTH; SYMPTOMS; DEPRESSION; INSOMNIA; TRIAL; RELIABILITY; DISORDERS; IMPROVES AB Obstructive sleep apnea leads to recurrent arousals from sleep, oxygen desaturations, daytime sleepiness and fatigue. This can have an adverse impact on quality of life. The aims of this study were to compare: (i) quality of life between the general population and untreated patients with obstructive sleep apnea; and (ii) changes of quality of life among patients with obstructive sleep apnea after 2years of positive airway pressure treatment between adherent patients and non-users. Propensity score methodologies were used in order to minimize selection bias and strengthen causal inferences. The enrolled obstructive sleep apnea subjects (n=822) were newly diagnosed with moderate to severe obstructive sleep apnea who were starting positive airway pressure treatment, and the general population subjects (n=742) were randomly selected Icelanders. The Short Form 12 was used to measure quality of life. Untreated patients with obstructive sleep apnea had a worse quality of life when compared with the general population. This effect remained significant after using propensity scores to select samples, balanced with regard to age, body mass index, gender, smoking, diabetes, hypertension and cardiovascular disease. We did not find significant overall differences between full and non-users of positive airway pressure in improvement of quality of life from baseline to follow-up. However, there was a trend towards more improvement in physical quality of life for positive airway pressure-adherent patients, and the most obese subjects improved their physical quality of life more. The results suggest that co-morbidities of obstructive sleep apnea, such as obesity, insomnia and daytime sleepiness, have a great effect on life qualities and need to be taken into account and addressed with additional interventions. C1 [Bjornsdottir, Erla; Arnardottir, Erna Sif; Gislason, Thorarinn; Sigurdsson, Jon Fridrik; Benediktsdottir, Bryndis] Univ Iceland, Fac Med, Reykjavik, Iceland. [Bjornsdottir, Erla; Eysteinsdottir, Bjorg; Arnardottir, Erna Sif; Gislason, Thorarinn; Benediktsdottir, Bryndis] Landspitali, Dept Resp Med & Sleep, IS-105 Reykjavik, Iceland. [Keenan, Brendan T.; Kuna, Samuel T.; Pack, Allan I.] Univ Penn, Dept Med, Ctr Sleep & Circadian Neurobiol, Div Sleep Med,Perelman Sch Med, Philadelphia, PA 19104 USA. [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden. [Sigurdsson, Jon Fridrik] Landspitali, Mental Hlth Serv, IS-105 Reykjavik, Iceland. [Sigurdsson, Jon Fridrik] Reykjavik Univ, Reykjavik, Iceland. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Bjornsdottir, E (reprint author), Landspitali, Dept Resp Med & Sleep E7, IS-105 Reykjavik, Iceland. EM erlabjo@gmail.com RI Sigurdsson, Jon Fridrik/M-1844-2015 OI Sigurdsson, Jon Fridrik/0000-0001-6873-8157 FU NIH [HL72067, HL94307]; Eimskip Fund of the University of Iceland; Landspitali University Hospital Research Fund FX The authors are grateful to Sigrun Gudmundsdottir, Lovisa Gudmundsdottir, Magdalena Osk Sigurgunnarsdottir, Oddny Fjola Larusdottir, Kristjan Andri Kristjansson, Bjorn Magnusson, Bethany Staley, Greg Maislin, Nick Jackson, and the other staff at the Sleep Centers of Landspitali - The National University Hospital of Iceland and the University of Pennsylvania who helped assemble and analyse the data. This work was supported by the NIH grant HL72067 for 'A Family Linkage Study of Obstructive Sleep Apnea' and HL94307 for 'Endophenotypes of Sleep Apnea and Role of Obesity', the Eimskip Fund of the University of Iceland, and the Landspitali University Hospital Research Fund. NR 40 TC 7 Z9 7 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD JUN PY 2015 VL 24 IS 3 BP 328 EP 338 DI 10.1111/jsr.12262 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CI5OD UT WOS:000354805600012 PM 25431105 ER PT J AU Sacks, GD Lawson, EH Dawes, AJ Gibbons, MM Zingmond, DS Ko, CY AF Sacks, Greg D. Lawson, Elise H. Dawes, Aaron J. Gibbons, Melinda M. Zingmond, David S. Ko, Clifford Y. TI Which Patients Require More Care after Hospital Discharge? An Analysis of Post-Acute Care Use among Elderly Patients Undergoing Elective Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID FEE-FOR-SERVICE; POSTACUTE REHABILITATION; MEDICARE; DISPOSITION; ACCESS AB BACKGROUND: The use of post-acute care is common among the elderly and accounts for $62 billion in annual Medicare expenditures. However, little is known about post-acute care use after surgery. STUDY DESIGN: Data were merged between the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) and Medicare claims for 2005 to 2008. Post-acute care use, including skilled nursing facilities (SNF), inpatient rehabilitation facilities (IRF), and home health care (HHC) were analyzed for 3 operations: colectomy, pancreatectomy, and open abdominal aortic aneurysm repair. Controlling for both preoperative risk factors and the occurrence of postoperative complications, we used multinomial logistic regression to estimate the odds of use for each type of post-acute care after elective surgery compared with home discharge. RESULTS: Post-acute care was used frequently for patients undergoing colectomy (40.0%; total n = 10,932), pancreatectomy (46.0%; total n = 2,144), and open abdominal aortic aneurysm (AAA) repair (44.9%; total n = 1,736). Home health was the most frequently reported post-acute care service for each operation (range 23.2% to 31.5%) followed by SNF (range 12.0% to 15.0%), and then by IRF (range 2.5% to 5.4%). The majority of patients with at least 1 inpatient complication were discharged to post-acute care (range 58.6% for open AAA repair to 64.4% for colectomy). In multivariable analysis, specific preoperative risk factors, including advanced age, poor functional status, and inpatient complications were significantly associated with increased risk-adjusted odds of discharge to post-acute care for each operation studied. CONCLUSIONS: Among elderly patients, post-acute care use is frequent after surgery and is significantly associated with several preoperative risk factors and postoperative inpatient complications. Further work is needed to ensure that post-acute care services are used appropriately and cost-effectively. (C) 2015 by the American College of Surgeons C1 [Sacks, Greg D.; Lawson, Elise H.; Dawes, Aaron J.; Gibbons, Melinda M.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Zingmond, David S.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Dawes, Aaron J.; Gibbons, Melinda M.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 FU Robert Wood Johnson Foundation Clinical Scholars program at the University of California, Los Angeles (RWJ) [71897, 70989] FX Drs Sacks and Dawes were supported by the Robert Wood Johnson Foundation Clinical Scholars program at the University of California, Los Angeles (RWJ Grants #71897 and #70989). NR 23 TC 5 Z9 5 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JUN PY 2015 VL 220 IS 6 BP 1113 EP U198 DI 10.1016/j.jamcollsurg.2015.02.029 PG 11 WC Surgery SC Surgery GA CI5VC UT WOS:000354826900027 PM 25872686 ER PT J AU Seay, K Church, C Zheng, JH Deneroff, K Ochsenbauer, C Kappes, JC Liu, B Jeng, EK Wong, HC Goldstein, H AF Seay, Kieran Church, Candice Zheng, Jian Hua Deneroff, Kathryn Ochsenbauer, Christina Kappes, John C. Liu, Bai Jeng, Emily K. Wong, Hing C. Goldstein, Harris TI In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice SO JOURNAL OF VIROLOGY LA English DT Article ID NATURAL-KILLER-CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; CD8(+) T-CELLS; NEUTRALIZING ANTIBODIES; MOLECULAR CLONES; RECEPTOR-ALPHA; IL-15; EXPRESSION; COMPLEX AB Natural killer (NK) cells with anti-HIV-1 activity may inhibit HIV-1 replication and dissemination during acute HIV-1 infection. We hypothesized that the capacity of NK cells to suppress acute in vivo HIV-1 infection would be augmented by activating them via treatment with an interleukin-15 (IL-15) superagonist, IL-15 bound to soluble IL-15R alpha, an approach that potentiates human NK cell-mediated killing of tumor cells. In vitro stimulation of human NK cells with a recombinant IL-15 superagonist significantly induced their expression of the cytotoxic effector molecules granzyme B and perforin; their degranulation upon exposure to K562 cells, as indicated by cell surface expression of CD107a; and their capacity to lyse K562 cells and HIV-1-infected T cells. The impact of IL-15 superagonist-induced activation of human NK cells on acute in vivo HIV-1 infection was investigated by using hu-spl-PBMC-NSG mice, NOD-SCID-IL2 gamma(-/-) (NSG) mice intrasplenically injected with human peripheral blood mononuclear cells (PBMCs) which develop productive in vivo infection after intrasplenic inoculation with HIV-1. IL-15 superagonist treatment potently inhibited acute HIV-1 infection in hu-spl-PBMC-NSG mice even when delayed until 3 days after intrasplenic HIV-1 inoculation. Removal of NK cells from human PBMCs prior to intrasplenic injection into NSG mice completely abrogated IL-15 superagonist-mediated suppression of in vivo HIV-1 infection. Thus, the in vivo activation of NK cells, integral mediators of the innate immune response, by treatment with an IL-15 superagonist increases their anti-HIV activity and enables them to potently suppress acute in vivo HIV-1 infection. These results indicate that in vivo activation of NK cells may represent a new immunotherapeutic approach to suppress acute HIV-1 infection. C1 [Seay, Kieran; Church, Candice; Goldstein, Harris] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Zheng, Jian Hua; Deneroff, Kathryn; Goldstein, Harris] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA. [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. [Liu, Bai; Jeng, Emily K.; Wong, Hing C.] Altor BioSci Corp, Miramar, FL USA. RP Goldstein, H (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. EM harris.goldstein@einstein.yu.edu FU NIAID NIH HHS [P30 AI027767, P30 AI051519, P30-AI277670, P30-AI51519, T32 AI007501, T32-AI007501, U01 AI067854, U01-AI067854]; NIDA NIH HHS [DA033788, R01 DA033788] NR 59 TC 12 Z9 12 U1 2 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD JUN PY 2015 VL 89 IS 12 BP 6264 EP 6274 DI 10.1128/JVI.00563-15 PG 11 WC Virology SC Virology GA CI3OU UT WOS:000354657900011 PM 25833053 ER PT J AU Mandal, R Muthukrishnan, A Ferris, RL de Almeida, JR Duvvuri, U AF Mandal, Rajarsi Muthukrishnan, Ashok Ferris, Robert L. de Almeida, John R. Duvvuri, Umamaheswar TI Accuracy of early-phase versus dual-phase single-photon emission computed tomography/computed tomography in the localization of Parathyroid disease SO LARYNGOSCOPE LA English DT Article DE Parathyroid; parathyroid preoperative localization; parathyroid single-photon emission computed tomography; computed tomography; minimally invasive parathyroidectomy ID TC-99M SESTAMIBI SPECT; PRIMARY HYPERPARATHYROIDISM; PREOPERATIVE LOCALIZATION; COMBINED TRANSMISSION; OPERATIVE TIME; TECHNETIUM-99M-SESTAMIBI; SCINTIGRAPHY; ADENOMA; TECHNOLOGY; PLANAR AB Objectives/HypothesisPreoperative localization for parathyroid disease has improved in recent years with the advent of dual-phase Tc-99m-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) imaging. However, dual-phase imaging is associated with increased cost, time, and radiation dose. The aim of this study was to investigate the need for late-phase imaging when using SPECT/CT for the preoperative localization of parathyroid disease. Study DesignRetrospective chart analysis. MethodsA retrospective review of 75 patients who underwent preoperative imaging localization and subsequent surgical resection for parathyroid disease at a tertiary referral center was performed. Of these, 50 patients met study criteria including preoperative SPECT/CT imaging and specific reporting of early- and late-phase focal radiotracer uptake. Localization accuracy was verified with definitive surgical findings confirmed by histological analysis and evidence of biochemical cure. ResultsAccurate localization of adenoma(s) was seen in 78.0% of patients using dual-phase SPECT/CT. Early-phase imaging alone localized 76.0%, whereas late-phase imaging alone localized 74.0%. Sensitivity and specificity for dual-phase imaging was 84.8% and 89.6%, respectively. In comparison, early-phase localization alone was found to have a sensitivity/specificity of 84.4%/89.4%; sensitivity/specificity of late-phase scanning alone was found to be 80.4%/89.1%. Dual-phase SPECT/CT scanning did not provide a statistically significant improvement in adenoma localization when compared to early-phase scanning alone. ConclusionsAlthough further investigation is needed, the results of this study suggest that early-phase SPECT/CT scanning alone may obviate the need for dual-phase SPECT/CT scanning in the initial preoperative localization workup of parathyroid disease. Level of Evidence4. Laryngoscope, 125:1496-1501, 2015 C1 [Mandal, Rajarsi; Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Mandal, Rajarsi; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Div Otolaryngol, Dept Surg,Med Ctr, Pittsburgh, PA 15260 USA. [Muthukrishnan, Ashok] Univ Pittsburgh, Dept Radiol, Div Nucl Med, Med Ctr, Pittsburgh, PA 15260 USA. [de Almeida, John R.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada. RP Duvvuri, U (reprint author), Eye & Ear Inst Pittsburgh, Suite 300,203 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs, BSLRED FX This work was supported in part by the Department of Veterans Affairs, BSLRED. NR 31 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD JUN PY 2015 VL 125 IS 6 BP 1496 EP 1501 DI 10.1002/lary.25020 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA CI4RW UT WOS:000354741600049 PM 25645695 ER PT J AU Eisendrath, SJ Gillung, E Delucchi, K Mathalon, DH Yang, TT Satre, DD Rosser, R Sipe, WEB Wolkowitz, OM AF Eisendrath, Stuart J. Gillung, Erin Delucchi, Kevin Mathalon, Daniel H. Yang, Tony T. Satre, Derek D. Rosser, Rebecca Sipe, Walter E. B. Wolkowitz, Owen M. TI A Preliminary Study: Efficacy of Mindfulness-Based Cognitive Therapy versus Sertraline as First-line Treatments for Major Depressive Disorder SO MINDFULNESS LA English DT Article DE Major depressive disorder; Mindfulness; Meditation; Cognitive therapy; Antidepressants; Sertraline ID TREATMENT-RESISTANT DEPRESSION; RELAPSE PREVENTION; RECURRENT DEPRESSION; METAANALYSIS; TRIALS; RELAPSE/RECURRENCE; PHARMACOTHERAPY; BUPROPION; CLINICIAN; SYMPTOMS AB Major depressive disorder (MDD) is the leading cause of disability in the developed world, yet broadly effective treatments remain elusive. The primary aim of this pilot study was to investigate the efficacy of mindfulness-based cognitive therapy (MBCT) monotherapy, compared to sertraline monotherapy, for patients with acute MDD. This open-label, nonrandomized controlled trial examined a MBCT cohort (N = 23) recruited to match the gender, age, and depression severity of a depressed control group (N = 20) that completed 8 weeks of monotherapy with the antidepressant sertraline. The 17-item clinician-rated Hamilton Depression Severity Rating Scale (HAMD-17) was the primary outcome measure of depression to assess overall change after 8 weeks and rates of response and remission. The 16-item Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) was the secondary outcome measure to further assess depression severity. Both cohorts were demographically similar and showed significant improvement in depression ratings. No difference was found in the degree of change in HAMD-17 scores (t(34) = 1.42, p = 0.165) between groups. Secondary analysis showed statistically significant differences in mean scores of the QIDS-SR16 (t(32) = 4.39, p < 0.0001), with the MBCT group showing greater mean improvement. This study was limited by the small sample size and non-randomized, non-blinded design. Preliminary findings suggest that an 8-week course of MBCT monotherapy may be effective in treating MDD and is a viable alternative to antidepressant medication. Greater changes in the self-rated QIDS-SR16 for the MBCT cohort raise the possibility that patients derive additional subjective benefit from enhanced self-efficacy skills. C1 [Eisendrath, Stuart J.; Gillung, Erin; Delucchi, Kevin; Yang, Tony T.; Satre, Derek D.; Rosser, Rebecca; Sipe, Walter E. B.; Wolkowitz, Owen M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Satre, Derek D.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. RP Eisendrath, SJ (reprint author), Univ Calif San Francisco, Dept Psychiat, Box 0984-AIP, San Francisco, CA 94143 USA. EM StuartE@lppi.ucsf.edu FU NCCIH NIH HHS [R01 AT004572]; NIDDK NIH HHS [T32 DK007762]; NIMH NIH HHS [R01 MH085734] NR 43 TC 6 Z9 6 U1 11 U2 29 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD JUN PY 2015 VL 6 IS 3 BP 475 EP 482 DI 10.1007/s12671-014-0280-8 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CI0SP UT WOS:000354448500007 PM 26085853 ER PT J AU Morales, AM Kohno, M Robertson, CL Dean, AC Mandelkern, MA London, ED AF Morales, A. M. Kohno, M. Robertson, C. L. Dean, A. C. Mandelkern, M. A. London, E. D. TI Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users SO MOLECULAR PSYCHIATRY LA English DT Article ID IMAGE REGISTRATION ALGORITHM; REFERENCE TISSUE MODEL; INDUCED REINSTATEMENT; DEPENDENT SUBJECTS; SEEKING BEHAVIOR; COCAINE ABUSERS; MR-IMAGES; NEUROTOXICITY; ASSOCIATION; IMPULSIVITY AB Dysfunction of the mesocorticolimbic system has a critical role in clinical features of addiction. Despite evidence suggesting that midbrain dopamine receptors influence amphetamine-induced dopamine release and that dopamine is involved in methamphetamine-induced neurotoxicity, associations between dopamine receptors and gray-matter volume have been unexplored in methamphetamine users. Here we used magnetic resonance imaging and [F-18] fallypride positron emission tomography, respectively, to measure gray-matter volume (in 58 methamphetamine users) and dopamine D2/D3 receptor availability (binding potential relative to nondisplaceable uptake of the radiotracer, BPND) (in 31 methamphetamine users and 37 control participants). Relationships between these measures and self-reported drug craving were examined. Although no difference in midbrain D2/D3 BPND was detected between methamphetamine and control groups, midbrain D2/D3 BPND was positively correlated with gray-matter volume in the striatum, prefrontal cortex, insula, hippocampus and temporal cortex in methamphetamine users, but not in control participants (group-by-midbrain D2/D3 BPND interaction, P < 0.05 corrected for multiple comparisons). Craving for methamphetamine was negatively associated with gray-matter volume in the insula, prefrontal cortex, amygdala, temporal cortex, occipital cortex, cerebellum and thalamus (P < 0.05 corrected for multiple comparisons). A relationship between midbrain D2/D3 BPND and methamphetamine craving was not detected. Lower midbrain D2/D3 BPND may increase vulnerability to deficits in gray-matter volume in mesocorticolimbic circuitry in methamphetamine users, possibly reflecting greater dopamine-induced toxicity. Identifying factors that influence prefrontal and limbic volume, such as midbrain BPND, may be important for understanding the basis of drug craving, a key factor in the maintenance of substance-use disorders. C1 [Morales, A. M.; Kohno, M.; Robertson, C. L.; Dean, A. C.; London, E. D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Robertson, C. L.; London, E. D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [Dean, A. C.; London, E. D.] Univ Calif Los Angeles, Dept Brain Res Inst, Los Angeles, CA 90024 USA. [Mandelkern, M. A.] Univ Calif Irvine, Dept Phys, Irvine, CA USA. [Mandelkern, M. A.; London, E. D.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA. RP London, ED (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Morales, Angelica/P-4108-2015 FU NIH [P20 DA022539, R01 DA015179, R01 DA020726, M01RR00865]; [F31 DA033117]; [F31 DA033120]; [T32 DA024635] FX This research was supported by NIH Grants P20 DA022539, R01 DA015179, R01 DA020726 (EDL) and M01RR00865 (UCLA GCRC). Additional funding was provided by an endowment from the Thomas P and Katherine K Pike Chair in Addiction Studies and a gift from the Marjorie M Greene Trust. Drs Morales and Kohno were supported by F31 DA033117 and F31 DA033120, respectively, as well as T32 DA024635. None of the sponsors were involved with the design, collection, analysis or interpretation of data, writing the manuscript or the decision to submit the manuscript for publications. NR 69 TC 7 Z9 7 U1 1 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD JUN PY 2015 VL 20 IS 6 BP 764 EP 771 DI 10.1038/mp.2015.47 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA CI6SB UT WOS:000354890200015 PM 25896164 ER PT J AU Giardina, TD Callen, J Georgiou, A Westbrook, JI Greisinger, A Esquivel, A Forjuoh, SN Parrish, DE Singh, H AF Giardina, Traber Davis Callen, Joanne Georgiou, Andrew Westbrook, Johanna I. Greisinger, Anthony Esquivel, Adol Forjuoh, Samuel N. Parrish, Danielle E. Singh, Hardeep TI Releasing test results directly to patients: A multisite survey of physician perspectives SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Test result notification; Direct notification; Patient access to medical information ID SHARED DECISION-MAKING; RESPONSE RATES; PRIMARY-CARE; INFORMATION-TECHNOLOGY; MEDICAL-RECORDS; FOLLOW-UP; PRACTITIONERS; PARTICIPATION; COMMUNICATION; EXPECTATIONS AB Objective: To determine physician perspectives about direct notification of normal and abnormal test results. Methods: We conducted a cross-sectional survey at five clinical sites in the US and Australia. The US-based study was conducted via web-based survey of primary care physicians and specialists between July and October 2012. An identical paper-based survey was self-administered between June and September 2012 with specialists in Australia. Results: Of 1417 physicians invited, 315 (22.2%) completed the survey. Two-thirds (65.3%) believed that patients should be directly notified of normal results, but only 21.3% were comfortable with direct notification of clinically significant abnormal results. Physicians were more likely to endorse direct notification of abnormal results if they believed it would reduce the number of patients lost to follow-up (OR = 4.98, 95% CI = 2.21-1.21) or if they had personally missed an abnormal test result (OR = 2.95, 95% CI = 1.44-6.02). Conversely, physicians were less likely to endorse if they believed that direct notification interfered with the practice of medicine (OR = 0.39, 95%CI = 0.20-0.74). Conclusion: Physicians we surveyed generally favor direct notification of normal results but appear to have substantial concerns about direct notification of abnormal results. Practice implications: Widespread use of direct notification should be accompanied by strategies to help patients manage test result abnormalities they receive. Published by Elsevier Ireland Ltd. C1 [Giardina, Traber Davis; Singh, Hardeep] Baylor Coll Med, Dept Med, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Giardina, Traber Davis; Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Giardina, Traber Davis; Parrish, Danielle E.] Univ Houston, Grad Coll Social Work, Houston, TX USA. [Callen, Joanne; Georgiou, Andrew; Westbrook, Johanna I.] Macquarie Univ, Ctr Hlth Syst & Safety Res, Australian Inst Hlth Innovat, Sydney, NSW 2109, Australia. [Greisinger, Anthony] Kelsey Res Fdn, Houston, TX USA. [Esquivel, Adol] CHI St Lukes Hlth, Dept Clin Effectiveness & Performance Measurement, Houston, TX USA. [Forjuoh, Samuel N.] Texas A&M Hlth Sci Ctr, Coll Med, Baylor Scott & White Hlth, Dept Family & Community Med, Temple, TX USA. RP Giardina, TD (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM traberd@bcm.edu FU VA Office of Academic Affiliations, Advanced Fellowships in Health Services Research; VA Health Services Research and Development Service [CRE 12-033]; VA National Center for Patient Safety; Agency for Health Care Research and Quality [R01HS022087, R21HS023602]; Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413]; National Health and Medical Research Program [1054146]; Australian Research Council [DP 120100297] FX Dr. Giardina is a VA Health Services Research postdoctoral fellow supported by VA Office of Academic Affiliations, Advanced Fellowships in Health Services Research. Dr. Singh is supported by the VA Health Services Research and Development Service (CRE 12-033; Presidential Early Career Award for Scientists and Engineers USA 14-274), the VA National Center for Patient Safety and the Agency for Health Care Research and Quality (R01HS022087 and R21HS023602). This work is supported in part by the Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). This work was also supported by a National Health and Medical Research Program Grant (1054146) and an Australian Research Council Grant (DP 120100297). These sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 57 TC 5 Z9 5 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD JUN PY 2015 VL 98 IS 6 BP 788 EP 796 DI 10.1016/j.pec.2015.02.011 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA CI8LB UT WOS:000355022700016 PM 25749024 ER PT J AU Luciano, JA Waltz, P Kautza, B Gomez, H Zuckerbraun, BS AF Luciano, J. A. Waltz, P. Kautza, B. Gomez, H. Zuckerbraun, B. S. TI FREE HEME AS AN IMPORTANT CAUSE OF INJURY IN TRAUMATIC SHOCK SO SHOCK LA English DT Meeting Abstract CT 38th Annual Conference of the Shock-Society on Shock CY JUN 06-09, 2015 CL Denver, CO SP Shock Soc C1 [Luciano, J. A.; Waltz, P.; Kautza, B.; Gomez, H.; Zuckerbraun, B. S.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Luciano, J. A.; Waltz, P.; Kautza, B.; Zuckerbraun, B. S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1073-2322 EI 1540-0514 J9 SHOCK JI Shock PD JUN PY 2015 VL 43 IS 6 SU 1 MA P99 BP 73 EP 73 PG 1 WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology GA CI4QC UT WOS:000354736000136 ER PT J AU Stey, AM Russell, MM Sugar, CA Hall, BL Zingmond, DS Lawson, EH Ko, CY AF Stey, Anne M. Russell, Marcia M. Sugar, Catherine A. Hall, Bruce L. Zingmond, David S. Lawson, Elise H. Ko, Clifford Y. TI Extending the value of the National Surgical Quality Improvement Program claims dataset to study long-term outcomes: Rate of repeat ventral hernia repair SO SURGERY LA English DT Article; Proceedings Paper CT 99th Annual Clinical Congress of the American-College-of-Surgeons / 68th Annual Sessions of the Owen H Wangensteen Surgical Forum on Fundamental Surgical Problems CY OCT 06-10, 2013 CL Washington, DC SP Amer Coll Surg ID RANDOMIZED CONTROLLED-TRIAL; INCISIONAL HERNIA; MESH REPAIR; FOLLOW-UP; CLINICAL REGISTRY; UMBILICAL HERNIA; COMPLICATIONS; SUTURE; HERNIORRHAPHY; RECURRENCE AB Background. Existing large clinical registries capture short-term follow-up. Yet, there are many important long-term outcomes in surgery, such as recurrence of a ventral hernia after ventral hernia repair. The goal of the current study was to conduct an exploratory analysis to determine whether the rates, timing, and risk factors for ventral hernia re-repair in claims data linked to registry data were consistent with the known clinical literature. Study Design. The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) and Medicare inpatient claims linked data set from 2005 to 2008 was queried to identify ventral hernia re-repairs after index ventral hernia repairs. Survival analysis was used to examine the ventral hernia re-repair rate over time and to quantify the relationship with clinical variables. Results. Of 3,730 index ventral hernia repairs identified in ACS-NSQIP, 247 patients (6.6%) underwent re-repair of a ventral hernia during the study period (2005-2008) in the Medicare claims data. ACS-NSQIP clinical variables that were associated with the ventral hernia re-repair rate in Medicare claims data I year after index ventral hernia repair were being a smoker (hazard ratio [HR] = 1.70, P = .02), body mass index (HR = 1.16, P = .04), and postoperative superficial surgical-site infection (HR = 2.88, P < .001). Conclusion. Long-term rate and timing of ventral hernia re-repair obtained from claims data were an underestimate compared with clinical studies. Yet, several known clinical risk factors for recurrence in the clinical registry were associated with the re-repair rate in claims data at one year It may be possible to study certain long-term outcomes using selected reoperation rates using the technique of linked clinical registry-claims data, with an understanding that event rates are conservative estimates. C1 [Stey, Anne M.] Mt Sinai Med Ctr, Icahn Sch Med, New York, NY 10029 USA. [Stey, Anne M.; Russell, Marcia M.; Sugar, Catherine A.; Zingmond, David S.; Lawson, Elise H.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Russell, Marcia M.; Sugar, Catherine A.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, Olin Business Sch, St Louis, MO 63130 USA. [Hall, Bruce L.] BJC Healthcare St Louis, St Louis VA Med Ctr, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Amer Coll Surg, Chicago, IL USA. RP Stey, AM (reprint author), 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA. EM as013j@gmail.com OI Stey, Anne/0000-0002-8334-0304 NR 32 TC 6 Z9 6 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD JUN PY 2015 VL 157 IS 6 BP 1157 EP 1165 DI 10.1016/j.surg.2014.12.027 PG 9 WC Surgery SC Surgery GA CI6YR UT WOS:000354910600023 PM 25731782 ER PT J AU Sher, L Rice, T AF Sher, Leo Rice, Timothy CA World Federation Soc Biol Psychiat TI Prevention of homicidal behaviour in men with psychiatric disorders SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY LA English DT Article DE homicide; homicide-suicide; men's mental health; endophenotypes; help-seeking behaviour ID NATIONAL CLINICAL SURVEY; MALE DEPRESSIVE SYNDROME; DOMAIN CRITERIA RDOC; TIME-SERIES ANALYSIS; PERSONALITY-DISORDERS; BIOLOGICAL TREATMENT; WFSBP GUIDELINES; WORLD-FEDERATION; EMOTION REGULATION; SUICIDAL-BEHAVIOR AB Objectives. Homicide is overwhelmingly committed by men compared to women. Conservative estimates suggest that more than a third of these individuals have a treatable psychiatric disorder. These data present an opportunity to mental health clinicians to assist in the prevention of homicide by improving men's mental health. Methods. We review the current literature on men's mental health with a focus on assessing and reducing homicide risk in men with psychiatric conditions. Results. Bipolar disorder and schizophrenia appear to share a neural endophenotype that is a risk factor for homicide. Dual disorders, or the presence of a substance use disorder with other major mental illness, are a major risk factor for homicide in males. Dual diagnosis disorders, personality disorders and pathological traits and male depression share emotion dysregulation, irritability, and reactive aggression. Promoting physician education, addressing firearm safety, reducing the reluctance of men relative to women to engage in help-seeking behaviour, and using targeted risk interviews which integrate these data are all currently recommended. Conclusions. The main focus in prevention of homicidal behaviour in males with psychiatric disorders should be to identify high risk groups, to provide adequate treatment, and to facilitate compliance with long-term treatment while considering male specific problems and needs. C1 [Sher, Leo; Rice, Timothy] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY 10468 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. EM Leo.Sher@mssm.edu FU World Federation of Societies of Biological Psychiatry FX The authors acknowledge the World Federation of Societies of Biological Psychiatry for support of the novel Task Force on Men's Mental Health. NR 168 TC 3 Z9 3 U1 1 U2 13 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1562-2975 EI 1814-1412 J9 WORLD J BIOL PSYCHIA JI World J. Biol. Psychiatry PD JUN PY 2015 VL 16 IS 4 BP 212 EP 229 DI 10.3109/15622975.2015.1028998 PG 18 WC Psychiatry SC Psychiatry GA CI5PV UT WOS:000354811400002 PM 25913698 ER PT J AU Gray, KM McClure, EA Baker, NL Hartwell, KJ Carpenter, MJ Saladin, ME AF Gray, Kevin M. McClure, Erin A. Baker, Nathaniel L. Hartwell, Karen J. Carpenter, Matthew J. Saladin, Michael E. TI An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women SO ADDICTION LA English DT Article DE Gender; nicotine; nicotine patch; NRT; pharmacotherapy; randomized clinical trial; tobacco; varenicline; women ID SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; REPLACEMENT THERAPY; ABSTINENCE; DEPENDENCE; EFFICACY; SMOKERS; PLACEBO; TOBACCO; RATES AB AimsWithin a parent study examining ovarian hormone effects on smoking cessation in women, we conducted an exploratory short-term trial of varenicline versus transdermal nicotine patch. DesignDouble-blind double-dummy randomized trial. SettingSingle-site out-patient research clinic in the United States. ParticipantsFemale smokers, ages 18-45years and averaging 10 cigarettes per day for at least 6 months (n=140). InterventionsParticipants were randomized to receive a 4-week course of (a) varenicline tablets and placebo patches (n=67) or (b) placebo tablets and nicotine patches (n=73). Two brief cessation counseling sessions were provided for all participants. MeasurementsThe outcome of primary clinical interest was 2-week end-of-treatment abstinence. Secondary outcomes included 1- and 4-week end-of treatment abstinence and abstinence at a post-treatment follow-up visit occurring 4 weeks after treatment conclusion. Breath carbon monoxide (10parts per million) was used to confirm biochemically self-reported abstinence. FindingsTwo-week end-of-treatment abstinence was achieved by 37.3% (25 of 67) of varenicline participants and by 17.8% (13 of 73) of nicotine patch participants [odds ratio (OR)=2.7, 95% confidence interval (CI)=1.3-6.0, P=0.011]. One-week (44.8 versus 20.6%, OR=3.1, 95% CI=1.5-6.6, P=0.003) and 4-week (22.4 versus 9.6%, OR=2.7, 95% CI=1.0-7.2, P=0.043) end-of-treatment abstinence similarly favored varenicline, although post-treatment follow-up Russell Standard abstinence was not significantly different between groups (23.9 versus 13.7%, OR=2.0, 95% CI=0.8-4.7, P=0.126). ConclusionIn an exploratory 4-week head-to-head trial in female smokers, varenicline, compared with nicotine patch, more than doubled the odds of end-of-treatment abstinence, although this diminished somewhat at post-treatment follow-up. C1 [Gray, Kevin M.; McClure, Erin A.; Hartwell, Karen J.; Carpenter, Matthew J.; Saladin, Michael E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Baker, Nathaniel L.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Carpenter, Matthew J.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Hartwell, Karen J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Gray, KM (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 125 Doughty St,Suite 190,MSC861, Charleston, SC 29425 USA. EM graykm@musc.edu FU NIH [P50DA16511, K23DA020482, UL1RR029882, UL1TR000062]; Merck, Inc.; Supernus Pharmaceuticals; Pfizer, Inc. FX NIH grants P50DA16511 Component 4 (K.M.G. and M.E.S.), K23DA020482 (M.J.C.) and UL1RR029882 and UL1TR000062 (South Carolina Clinical and Translational Research Institute). Varenicline and matched placebo were supplied by Pfizer, Inc. NIH and Pfizer, Inc. had no further role in study design, in the collection, analysis and interpretation of data, in the writing of the report or in the decision to submit the paper for publication. K.M.G. has received research funding from Merck, Inc. and Supernus Pharmaceuticals and K.J.H. has received research funding from Pfizer, Inc. for other projects. The other authors report no potential conflicts of interest. NR 27 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JUN PY 2015 VL 110 IS 6 BP 1027 EP 1034 DI 10.1111/add.12895 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CH9PN UT WOS:000354368300023 PM 25727442 ER PT J AU Williams, JS Walker, RJ Lynch, CP Voronca, D Egede, LE AF Williams, Joni Strom Walker, Rebekah J. Lynch, Cheryl P. Voronca, Delia Egede, Leonard E. TI Meaning of Illness and Self-Care in Patients With Type 2 Diabetes SO DIABETES EDUCATOR LA English DT Article ID QUESTIONNAIRE; RELIABILITY; VALIDATION; KNOWLEDGE; EDUCATION; MELLITUS; VALIDITY; PROFILE; SCALE AB Purpose The purpose of this study was to assess the relationship between meaning of illness, diabetes knowledge, self-care understanding, and behaviors in a group of individuals with type 2 diabetes. Methods Patients diagnosed with type 2 diabetes completed questionnaires with measures for diabetes knowledge, self-care understanding, diet adherence, and control problems based on the validated Diabetes Care Profile, as well as a 5-factor Meaning of Illness Questionnaire (MIQ) measure. Linear regression investigated the associations between self-care outcomes and the 5 MIQ factors. Results After adjustment for possible confounders, both diabetes self-care understanding and diet adherence were negatively and significantly associated with little effect of illness. Control problems were negatively associated with degree of stress/change in commitments. Diabetes knowledge was not significantly associated with meaning of illness. Conclusion Aspects of the meaning attributed to illness were significantly associated with self-care in patients with type 2 diabetes. Therefore, cognitive appraisals may explain variances observed in self-care understanding and behaviors. Based on these results, it is important to understand the negative effect that diabetes could have when promoting self-care understanding and diet adherence. In addition, it shows that helping patients address the stress and changing commitments that result from diabetes may help decrease the amount of diabetes control problems, even if there is little effect on diabetes understanding. Taking these differences into account may help in creating more personalized and effective self-care education plans. C1 [Williams, Joni Strom; Walker, Rebekah J.; Lynch, Cheryl P.; Voronca, Delia; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Williams, Joni Strom; Lynch, Cheryl P.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Walker, Rebekah J.; Lynch, Cheryl P.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Hlth Equ & Rural Outreach Innovat Ctr, POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU Veterans Health Administration Health Services Research and Development (HSRD) program [TRP 04-038] FX This study was supported by grant #TRP 04-038 funded by the Veterans Health Administration Health Services Research and Development (HSR&D) program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The manuscript represents the views of the authors and not those of Veterans Affairs or HSR&D. NR 22 TC 1 Z9 1 U1 1 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD JUN PY 2015 VL 41 IS 3 BP 301 EP 308 DI 10.1177/0145721715572445 PG 8 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA CI1DJ UT WOS:000354481400005 ER PT J AU Ferguson, MO Long, JA Zhu, JS Small, DS Lawson, B Glick, HA Schapira, MM AF Ferguson, Monica O. Long, Judith A. Zhu, Jingsan Small, Dylan S. Lawson, Brittany Glick, Henry A. Schapira, Marilyn M. TI Low Health Literacy Predicts Misperceptions of Diabetes Control in Patients With Persistently Elevated A1C SO DIABETES EDUCATOR LA English DT Article ID GLYCEMIC CONTROL; GLUCOSE CONTROL; SELF-EFFICACY; BELIEF MODEL; CARE; KNOWLEDGE; ASSOCIATION; VALIDATION; MORTALITY; NUMERACY AB Purpose The purpose of this study is to identify factors associated with perceived control of diabetes in a group of poorly controlled patients. Identifying factors associated with perceived control in these patients is an important step in improving actual control as measured by A1C. As health literacy is essential for understanding complex medical information, we hypothesized that low health literacy would be associated with inaccurate perceptions of diabetes control. Methods A cross-sectional analysis was performed on 280 adults with type 2 diabetes whose last 2 A1C measurements were >8.0%. Participants were recruited primarily from 6 University of Pennsylvania primary care practices. Perceived control and factors potentially associated with this outcome, including health literacy, were assessed during an in-person interview. Health literacy was measured using the Rapid Estimate of Adult Literacy. Results Thirty-nine percent of patients responded that they were managing to control their diabetes well or very well. However, 57% of those at the seventh to eighth-grade health literacy level and 61% of those at the level of sixth grade and below reported that they were controlling their diabetes well or very well. Conclusions In this population of patients with poorly controlled diabetes, a majority of those with low health literacy believed that they were controlling their disease well or very well. Patients who believe that they are already controlling their diabetes well may be less likely to make changes to improve control. Health care providers and educators should consider health literacy when discussing control of diabetes and when setting management goals with patients. C1 [Ferguson, Monica O.; Long, Judith A.; Lawson, Brittany; Glick, Henry A.; Schapira, Marilyn M.] Univ Penn, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Long, Judith A.; Schapira, Marilyn M.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Long, Judith A.; Zhu, Jingsan; Small, Dylan S.; Schapira, Marilyn M.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. RP Ferguson, MO (reprint author), Univ Penn, Dept Med, 3701 Market St,Suite 640, Philadelphia, PA 19104 USA. EM monica.ferguson@uphs.upenn.edu FU National Institute of Diabetes and Digestive and Kidney Disease [5-R01-DK-087874-04] FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Disease (5-R01-DK-087874-04). The authors have no conflicts of interest to disclose. NR 35 TC 5 Z9 5 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD JUN PY 2015 VL 41 IS 3 BP 309 EP 319 DI 10.1177/0145721715572446 PG 11 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA CI1DJ UT WOS:000354481400006 PM 25699568 ER PT J AU Davies, TF Latif, R AF Davies, Terry F. Latif, Rauf TI Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies SO EXPERT OPINION ON THERAPEUTIC TARGETS LA English DT Review DE autoantibodies; glycoprotein-hormone receptor; Graves' disease; small molecule ligands; thyroid cancer; thyroid-stimulating hormone receptor ID HUMAN THYROTROPIN RECEPTOR; RECOMBINANT HUMAN THYROTROPIN; LEUCINE-RICH DOMAIN; HUMAN TSH RECEPTOR; GRAVES-DISEASE; AMINO-ACIDS; EXTRACELLULAR DOMAIN; HOMOLOGOUS DESENSITIZATION; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION AB Introduction: The thyroid-stimulating hormone receptor (TSHR) is the essential molecule for thyroid growth and thyroid hormone production. Since it is also a key autoantigen in Graves' disease and is involved in thyroid cancer pathophysiology, the targeting of the TSHR offers a logical model for disease control. Areas covered: We review the structure and function of the TSHR and the progress in both small molecule ligands and TSHR antibodies for their therapeutic potential. Expert opinion: Stabilization of a preferential conformation for the TSHR by allosteric ligands and TSHR antibodies with selective modulation of the signaling pathways is now possible. These tools may be the next generation of therapeutics for controlling the pathophysiological consequences mediated by the effects of the TSHR in the thyroid and other extrathyroidal tissues. C1 Icahn Sch Med Mt Sinai, New York, NY 10029 USA. James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. RP Davies, TF (reprint author), Icahn Sch Med Mt Sinai, Thyroid Res Unit, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM terry.davies@mssm.edu FU NIDDK NIH HHS [R01 DK069713] NR 95 TC 7 Z9 9 U1 2 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1472-8222 EI 1744-7631 J9 EXPERT OPIN THER TAR JI Expert Opin. Ther. Targets PD JUN PY 2015 VL 19 IS 6 BP 835 EP 847 DI 10.1517/14728222.2015.1018181 PG 13 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CI1YT UT WOS:000354541900010 PM 25768836 ER PT J AU Hezode, C Hirschfield, GM Ghesquiere, W Sievert, W Rodriguez-Torres, M Shafran, SD Thuluvath, PJ Tatum, HA Waked, I Esmat, G Lawitz, EJ Rustgi, VK Pol, S Weis, N Pockros, PJ Bourliere, M Serfaty, L Vierling, JM Fried, MW Weiland, O Brunetto, MR Everson, GT Zeuzem, S Kwo, PY Sulkowski, M Brau, N Hernandez, D McPhee, F Wind-Rotolo, M Liu, ZH Noviello, S Hughes, EA Yin, PD Schnittman, S AF Hezode, Christophe Hirschfield, Gideon M. Ghesquiere, Wayne Sievert, William Rodriguez-Torres, Maribel Shafran, Stephen D. Thuluvath, Paul J. Tatum, Harvey A. Waked, Imam Esmat, Gamal Lawitz, Eric J. Rustgi, Vinod K. Pol, Stanislas Weis, Nina Pockros, Paul J. Bourliere, Marc Serfaty, Lawrence Vierling, John M. Fried, Michael W. Weiland, Ola Brunetto, Maurizia R. Everson, Gregory T. Zeuzem, Stefan Kwo, Paul Y. Sulkowski, Mark Braeu, Norbert Hernandez, Dennis McPhee, Fiona Wind-Rotolo, Megan Liu, Zhaohui Noviello, Stephanie Hughes, Eric A. Yin, Philip D. Schnittman, Steven TI Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study SO GUT LA English DT Article ID NS5A INHIBITOR BMS-790052; PHASE-III TRIAL; VIRUS-INFECTION; SIMEPREVIR TMC435; PROTEIN; EPIDEMIOLOGY; LOCALIZATION; MANAGEMENT; SOFOSBUVIR; CIRRHOSIS AB Objective To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. Design In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20mg or 60mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA10% of people >65 years old; >30% of people >85 years old); anxiety (4%); and depression (lifetime incidence 2%-15%; one year prevalence 3%). Prospective research is needed to establish (1) the prevalence and severity of chronic symptoms that pre-date the diagnosis of a life-limiting illness in people referred to hospice/palliative care services, comparing this to whole-of-population estimates; and (2) whether this group is disproportionately represented in people with refractory symptoms. C1 [Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Discipline Serv, Bedford Pk, SA 5042, Australia. [Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Palliat Serv, Bedford Pk, SA 5042, Australia. [Currow, David C.; Collier, Aileen; Agar, Meera R.] Flinders Univ S Australia, Support Serv, Bedford Pk, SA 5042, Australia. [Currow, David C.] Repatriat Gen Hosp, Southern Adelaide Palliat Serv, Daw Pk, SA, Australia. [Clark, Katherine] Calvary Mater Hlth Care, Palliat Care Dept, Waratah, NSW, Australia. [Clark, Katherine] Univ Newcastle, Callaghan, NSW 2308, Australia. [Kamal, Arif] Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC USA. [Agar, Meera R.] Braeside Hosp, HammondCare, Braeside, NSW, Australia. [Lovell, Melanie R.; Phillips, Jane L.] Greenwich Hosp, HammondCare, Greenwich, NSW, Australia. [Lovell, Melanie R.; Phillips, Jane L.] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia. [Phillips, Jane L.] Univ Technol Sydney, Ultimo, Sydney, NSW 2007, Australia. [Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA. [Ritchie, Christine] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Currow, DC (reprint author), Flinders Univ S Australia, Palliat & Support Care Dept, Daw Pk, SA 5041, Australia. EM david.currow@health.sa.gov.au NR 33 TC 2 Z9 2 U1 1 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JUN 1 PY 2015 VL 18 IS 6 BP 480 EP 485 DI 10.1089/jpm.2014.0444 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CI2WJ UT WOS:000354608100003 PM 25859908 ER PT J AU Kvale, E Dionne-Odom, JN Redden, DT Bailey, FA Bakitas, M Goode, PS Williams, BR Haddock, KS Burgio, KL AF Kvale, Elizabeth Dionne-Odom, J. Nicholas Redden, David T. Bailey, F. Amos Bakitas, Marie Goode, Patricia S. Williams, Beverly R. Haddock, Kathlyn Sue Burgio, Kathryn L. TI Predictors of Physical Restraint Use in Hospitalized Veterans at End of Life: An Analysis of Data from the BEACON Trial SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID NURSING-HOME RESIDENTS; SMALL-SAMPLE ADJUSTMENTS; INTENSIVE-CARE-UNIT; OLDER PATIENTS; ESTIMATOR; SETTINGS; DELIRIUM; HEALTH; ADULTS AB Background: The use of physical restraints in dying patients may be a source of suffering and loss of dignity. Little is known about the prevalence or predictors for restraint use at end of life in the hospital setting. Objective: The objective was to determine the prevalence and predictors of physical restraint use at the time of death in hospitalized adults. Methods: Secondary analysis was performed on data from the "Best Practices for End-of-Life Care for Our Nation's Veterans" (BEACON) trial conducted between 2005 and 2011. Medical record data were abstracted from six Veterans Administration Medical Centers (VAMCs). Data on processes of care in the last seven days of life were abstracted from the medical records of 5476 who died in the six VAMCs. We prospectively identified potential risk factors for restraint use at the time of death from among the variables measured in the parent trial, including location of death, medications administered, nasogastric tube, intravenous (IV) fluids, family presence, and receipt of a palliative care consultation. Results: Physical restraint use at time of death was documented in 890 decedents (16.3%). Restraint use varied by location of death, with patients in intensive settings being at higher risk. Restraint use was significantly more likely in patients with a nasogastric tube and those receiving IV fluids, benzodiazepines, or antipsychotics. Conclusions: This is the first study to document that one in six hospitalized veterans were restrained at the time of death and to identify predictors of restraint use. Further research is needed to identify intervention opportunities. C1 [Kvale, Elizabeth; Redden, David T.; Bailey, F. Amos; Bakitas, Marie; Goode, Patricia S.; Williams, Beverly R.; Burgio, Kathryn L.] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Birmingham, AL USA. [Kvale, Elizabeth; Bailey, F. Amos; Goode, Patricia S.; Williams, Beverly R.; Burgio, Kathryn L.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL 35294 USA. [Dionne-Odom, J. Nicholas; Bakitas, Marie] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA. [Redden, David T.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Haddock, Kathlyn Sue] William Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA. RP Kvale, E (reprint author), Univ Alabama Birmingham, CH19 Suite 301, Birmingham, AL 35294 USA. EM EKvale@uabmc.edu OI Bakitas, Marie/0000-0002-2913-2053 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IIR 03-126]; VA Birmingham/Atlanta Geriatric Research, Education and Clinical Center; UAB Cancer Prevention and Control Training Program [5R25CA047888] FX This research was supported by a merit review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IIR 03-126 "Intervention to Improve Care at Life's End in VA Medical Centers;" PI: KL Burgio, Co-PI: FA Bailey) and the VA Birmingham/Atlanta Geriatric Research, Education and Clinical Center. Dr. Dionne-Odom is a postdoctoral fellow supported by the UAB Cancer Prevention and Control Training Program (5R25CA047888). NR 42 TC 3 Z9 3 U1 3 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JUN 1 PY 2015 VL 18 IS 6 BP 520 EP 526 DI 10.1089/jpm.2014.0354 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CI2WJ UT WOS:000354608100009 PM 25927909 ER PT J AU Smith, AK Jain, N Wallhagen, ML AF Smith, Alexander K. Jain, Nelia Wallhagen, Margaret L. TI Hearing Loss in Palliative Care SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material ID QUALITY-OF-LIFE; SERVICES TASK-FORCE; OLDER-ADULTS; LONGITUDINAL ANALYSIS; UNITED-STATES; AID USE; IMPAIRMENT; PREVALENCE; IMPACT; DEAF AB Background: Age-related hearing loss is remarkably common, affecting more than 60% of adults over the age of 75. Moreover, hearing loss has detrimental effects on quality of life and communication, outcomes that are central to palliative care. Despite its high prevalence, there is remarkably little written on the impact of hearing loss in the palliative care literature. Objective: The objective was to emphasize its importance and the need for further study. We use a case as a springboard for discussing what is known and unknown about the epidemiology, presentation, screening methodologies, and treatment strategies for age-related hearing loss in palliative care. Discussion: The case describes a 65-year-old man with acute myelogenous leukemia (AML) that has progressed despite treatment. No concerns are raised about communication challenges during conversations between the palliative care team and the patient in his quiet room. However, in the midst of a family meeting, shortly after discussing prognosis, the patient reports that he cannot hear what anyone is saying. Conclusion: We describe simple methods of screening patients for hearing loss, and suggest that practical approaches should be used universally in patient encounters. These include facing the patient, pitching one's voice low, using a pocket talker, and creating a hearing-friendly environment when planning a family or group meeting. C1 [Smith, Alexander K.; Jain, Nelia] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Wallhagen, Margaret L.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Smith, Alexander K.; Jain, Nelia] Vet Affairs Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA. RP Smith, AK (reprint author), San Francisco VA Med Ctr, UCSF Div Geriatr, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU NIA NIH HHS [1K23AG040772, K23 AG040772]; NIDCD NIH HHS [R33 DC011510, R33DC011510] NR 29 TC 3 Z9 3 U1 3 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD JUN 1 PY 2015 VL 18 IS 6 BP 559 EP 562 DI 10.1089/jpm.2014.0367 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CI2WJ UT WOS:000354608100018 PM 25867966 ER PT J AU Zheng, C Zhou, XH AF Zheng, Cheng Zhou, Xiao-Hua TI Causal mediation analysis in the multilevel intervention and multicomponent mediator case SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY LA English DT Article DE Causal inference; Generalized estimating equation; Mediation analysis ID SENSITIVITY-ANALYSIS; HETEROGENEITY; INVENTORY; MODELS AB Mediation analysis is an important tool in social and medical sciences as it helps to understand why an intervention works. The commonly used approach, given by Baron and Kenny, requires the strong assumption sequential ignorability' to yield causal interpretation. Ten Have and his colleagues proposed a rank preserving model to relax this assumption. However, the rank preserving model is restricted to the case with binary intervention and single mediator and needs another strong assumption rank preserving'. We propose a new model that can relax this assumption and can handle both multilevel intervention and multicomponent mediators. As an estimating-equation-based method, our model can handle both correlated data with the generalized estimating equation and missing data with inverse probability weighting. Finally, our method can also be used in many other research settings, using mathematical models similar to mediation analysis, such as treatment compliance and post-randomized treatment component analysis. For the causal mediation model proposed, we first show identifiability for the parameters in the model. We then propose a semiparametric method for estimating the model parameters and derive asymptotic results for the estimators proposed. Simulation shows good performance for the proposed estimators in finite sample sizes. Finally, we apply the method proposed to two real world clinical studies: the college student drinking study, and the Improving mood promoting access to collaborative treatment for late life depression' study. C1 [Zheng, Cheng; Zhou, Xiao-Hua] Univ Washington, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, H-655E,Hlth Sci Bldg,1705 North East Pacific St, Seattle, WA 98195 USA. EM azhou@uw.edu FU US Department of Veterans Affairs, Veterans Affairs Health Administration, Research Career Scientist award [RCS 05-196] FX We thank Jurgen Unutzer and the 'Improving model promoting access to collaborative treatment' team for providing us with the data set and we thank David Atkins and the Center for the Study of Health and Risk Behaviors team for providing us with the college student drinking data set. The views that are expressed in this paper are those of the authors and do not neccssarily represent the views of the Department of Veterans Affairs. Dr Zhou's work was supported in part by a US Department of Veterans Affairs, Veterans Affairs Health Administration, Research Career Scientist award (RCS 05-196). NR 26 TC 3 Z9 3 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-7412 EI 1467-9868 J9 J R STAT SOC B JI J. R. Stat. Soc. Ser. B-Stat. Methodol. PD JUN PY 2015 VL 77 IS 3 BP 581 EP 615 DI 10.1111/rssb.12082 PG 35 WC Statistics & Probability SC Mathematics GA CI0ES UT WOS:000354409800002 ER PT J AU Wininger, M Williams, DJ AF Wininger, Michael Williams, David J. TI More with less: A comparative kinematical analysis of Django Reinhardt's adaptations to hand injury SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Article DE Guitar; kinematics; Django; Django Reinhardt AB Background: At the age of 18 years, jazz guitarist Django Reinhardt (1910-1953) sustained significant burns to his left-hand ring and little fingers; yet, subsequently, he relearned to play and achieved international fame, despite his injuries. Case description and methods: Archive film footage and novel motion analysis software were used to compare movements of Django's fretting hand with that of six other guitarists of the same genre. Findings and outcomes: Django employed greater abduction of index and middle fingers (-9.11 6.52 degrees vs -5.78 2.41 degrees; p < 0.001) and more parallel alignment of fingers to the guitar neck (157.7 +/- 3.37 degrees vs 150.59 +/- 2.67 degrees; p < 0.001) compared to controls. Conclusion: In response to debilitating hand injury, Django developed quantifiable compensatory adaptation of function of his remaining functional fingers by developing an original playing technique. Clinical relevance Hand function following injury may be optimized by maximizing latent degrees of freedom in remaining digits, rather than through extensive surgical reconstruction or complex prostheses. Further study of adaptation strategies may inform prosthesis design. C1 [Wininger, Michael] Univ Hartford, Prosthet & Orthot Program, Hartford, CT 06117 USA. [Wininger, Michael] US Dept Vet Affairs, VA Cooperat Studies Program, Hartford, CT USA. [Williams, David J.] Morriston Hosp ABMU NHS Trust, Welsh Ctr Burns, Dept Anaesthet, Swansea, W Glam, Wales. RP Wininger, M (reprint author), Univ Hartford, 200 Bloomfield Ave, Hartford, CT 06117 USA. EM wininger@hartford.edu NR 18 TC 0 Z9 0 U1 6 U2 10 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0309-3646 EI 1746-1553 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PD JUN PY 2015 VL 39 IS 3 BP 238 EP 243 DI 10.1177/0309364614523173 PG 6 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA CI1AT UT WOS:000354473000009 PM 24570018 ER PT J AU Xiao, X Luo, HM Vanek, KN Larue, AC Schulte, BA Wang, GY AF Xiao, Xia Luo, Hongmei Vanek, Kenneth N. Larue, Amanda C. Schulte, Bradley A. Wang, Gavin Y. TI Catalase Inhibits Ionizing Radiation-Induced Apoptosis in Hematopoietic Stem and Progenitor Cells SO STEM CELLS AND DEVELOPMENT LA English DT Article ID STAT3; INJURY; IRRADIATION; ACTIVATION; REGENERATION; CHEMOTHERAPY; SENESCENCE; EXPRESSION; PEROXIDE AB Hematologic toxicity is a major cause of mortality in radiation emergency scenarios and a primary side effect concern in patients undergoing chemo-radiotherapy. Therefore, there is a critical need for the development of novel and more effective approaches to manage this side effect. Catalase is a potent antioxidant enzyme that coverts hydrogen peroxide into hydrogen and water. In this study, we evaluated the efficacy of catalase as a protectant against ionizing radiation (IR)-induced toxicity in hematopoietic stem and progenitor cells (HSPCs). The results revealed that catalase treatment markedly inhibits IR-induced apoptosis in murine hematopoietic stem cells and hematopoietic progenitor cells. Subsequent colony-forming cell and cobble-stone area-forming cell assays showed that catalase-treated HSPCs can not only survive irradiation-induced apoptosis but also have higher clonogenic capacity, compared with vehicle-treated cells. Moreover, transplantation of catalase-treated irradiated HSPCs results in high levels of multi-lineage and long-term engraftments, whereas vehicle-treated irradiated HSPCs exhibit very limited hematopoiesis reconstituting capacity. Mechanistically, catalase treatment attenuates IR-induced DNA double-strand breaks and inhibits reactive oxygen species. Unexpectedly, we found that the radioprotective effect of catalase is associated with activation of the signal transducer and activator of transcription 3 (STAT3) signaling pathway and pharmacological inhibition of STAT3 abolishes the protective activity of catalase, suggesting that catalase may protect HSPCs against IR-induced toxicity via promoting STAT3 activation. Collectively, these results demonstrate a previously unrecognized mechanism by which catalase inhibits IR-induced DNA damage and apoptosis in HSPCs. C1 [Xiao, Xia; Luo, Hongmei; Larue, Amanda C.; Schulte, Bradley A.; Wang, Gavin Y.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Xiao, Xia] Tianjin First Ctr Hosp, Dept Hematol, Tianjin, Peoples R China. [Luo, Hongmei] Univ South China, Dept Histol & Embryol, Hengyang City, Hunan, Peoples R China. [Vanek, Kenneth N.] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Larue, Amanda C.] Ralph H Johnson VAMC, Res Serv, Charleston, SC USA. [Larue, Amanda C.; Wang, Gavin Y.] Med Univ S Carolina, Canc Genes & Mol Regulat Program, Hollings Canc Ctr, Charleston, SC 29425 USA. RP Wang, GY (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 171 Ashley Ave,MSC908, Charleston, SC 29425 USA. EM wangy@musc.edu FU National Heart, Lung, and Blood Institute (NHLBI) [HL106451]; Hollings Cancer Center [P30 CA138313] FX The authors want to thank Mrs. Aimin Yang for excellent technical assistance. This study was supported, in part, by a grant from the National Heart, Lung, and Blood Institute (NHLBI) no. HL106451 (G.Y.W.) and a pilot grant from the Hollings Cancer Center (G.Y.W.) via P30 CA138313. NR 35 TC 6 Z9 6 U1 1 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1547-3287 EI 1557-8534 J9 STEM CELLS DEV JI Stem Cells Dev. PD JUN 1 PY 2015 VL 24 IS 11 BP 1342 EP 1351 DI 10.1089/scd.2014.0402 PG 10 WC Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation SC Cell Biology; Hematology; Research & Experimental Medicine; Transplantation GA CI2XX UT WOS:000354612600007 PM 25603016 ER PT J AU Flory, JD Yehuda, R AF Flory, Janine D. Yehuda, Rachel TI Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations SO DIALOGUES IN CLINICAL NEUROSCIENCE LA English DT Article DE PTSD; MDD; comorbidity; glucocorticoid receptor; FKBP5 ID COMBAT-RELATED PTSD; MENTAL-DISORDERS; DSM-IV; TRAUMA; VULNERABILITY; METAANALYSIS; REPLICATION; PERSONALITY; PREVALENCE; MECHANISMS AB Approximately half of people with post-traumatic stress disorder (PTSD) also suffer from Major Depressive Disorder ( MDD). The current paper examines evidence for two explanations of this comorbidity. First, that the comorbidity reflects overlapping symptoms in the two disorders. Second, that the co-occurrence of PTSD and MDD is not an artifact, but represents a trauma-related phenotype, possibly a subtype of PTSD. Support for the latter explanation is inferred from literature that examines risk and biological correlates of PTSD and MDD, including molecular processes. Treatment implications of the comorbidity are considered. (C) 2015, AICH - Servier Research Group C1 [Flory, Janine D.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Flory, Janine D.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Flory, JD (reprint author), James J Peters Bronx VAMC, Mt Sinai Sch Med, Psychiat, Room 3B-42,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM janine.flory@mssm.edu FU CSRD VA [I01 CX000952] NR 58 TC 13 Z9 13 U1 2 U2 3 PU INST CONFERENCE HIPPOCRATE PI SURESNESS-CEDEX PA 50 RUE CARNOT, SURESNESS-CEDEX, 92284, FRANCE SN 1294-8322 EI 1958-5969 J9 DIALOGUES CLIN NEURO JI Dialogues Clin. Neurosci. PD JUN PY 2015 VL 17 IS 2 BP 141 EP 150 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EF2XV UT WOS:000390189800004 PM 26246789 ER PT J AU Pompon, RH McNeil, MR Spencer, KA Kendall, DL AF Pompon, Rebecca Hunting McNeil, Malcolm R. Spencer, Kristie A. Kendall, Diane L. TI Intentional and Reactive Inhibition During Spoken-Word Stroop Task Performance in People With Aphasia SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article ID FRONTAL-LOBE LESIONS; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; SELECTIVE ATTENTION; SHORT-TERM; INTERFERENCE; LANGUAGE; COMPREHENSION; DISTRACTORS; MECHANISMS AB Purpose: The integrity of selective attention in people with aphasia (PWA) is currently unknown. Selective attention is essential for everyday communication, and inhibition is an important part of selective attention. This study explored components of inhibition-both intentional and reactive inhibition-during spoken-word production in PWA and in controls who were neurologically healthy (HC). Intentional inhibition is the ability to suppress a response to interference, and reactive inhibition is the delayed reactivation of a previously suppressed item. Method: Nineteen PWA and 20 age-and education-matched HC participated in a Stroop spoken-word production task. This task allowed the examination of intentional and reactive inhibition by evoking and comparing interference, facilitation, and negative priming effects in different contexts. Results: Although both groups demonstrated intentional inhibition, PWA demonstrated significantly more interference effects. PWA demonstrated no significant facilitation effects. HC demonstrated significant reverse facilitation effects. Neither group showed significant evidence of reactive inhibition, though both groups showed similar individual variability. Conclusions: These results underscore the challenge interference presents for PWA during spoken-word production, indicating diminished intentional inhibition. Although reactive inhibition was not different between PWA and HC, PWA showed difficulty integrating and adapting to contextual information during language tasks. C1 [Pompon, Rebecca Hunting; Spencer, Kristie A.; Kendall, Diane L.] Univ Washington, Seattle, WA 98195 USA. [McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [McNeil, Malcolm R.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Kendall, Diane L.] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Pompon, RH (reprint author), Univ Washington, Seattle, WA 98195 USA. EM rhpompon@uw.edu FU National Institute on Deafness and Other Communication Disorders Grant [F31DC012457] FX This research was supported by National Institute on Deafness and Other Communication Disorders Grant F31DC012457, awarded to Rebecca Hunting Pompon. The authors acknowledge Amanda Hendricks, Hallie Mass, Erin McDonald, Leslie Yoo, and all participants for their contributions to this study. NR 72 TC 0 Z9 0 U1 2 U2 2 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1092-4388 EI 1558-9102 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD JUN PY 2015 VL 58 IS 3 BP 767 EP 780 DI 10.1044/2015_JSLHR-L-14-0063 PG 14 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA DX6XE UT WOS:000384528400018 PM 25674773 ER PT J AU Fergadiotis, G Kellough, S Hula, WD AF Fergadiotis, Gerasimos Kellough, Stacey Hula, William D. TI Item Response Theory Modeling of the Philadelphia Naming Test SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article ID LEXICAL ACCESS; SPEECH PRODUCTION; WORD PRODUCTION; FIT STATISTICS; RASCH MODELS; RETRIEVAL; FREQUENCY; APHASIA; PERFORMANCE; BEHAVIOR AB Purpose: In this study, we investigated the fit of the Philadelphia Naming Test (PNT; Roach, Schwartz, Martin, Grewal, & Brecher, 1996) to an item-response-theory measurement model, estimated the precision of the resulting scores and item parameters, and provided a theoretical rationale for the interpretation of PNT overall scores by relating explanatory variables to item difficulty. This article describes the statistical model underlying the computer adaptive PNT presented in a companion article (Hula, Kellough, & Fergadiotis, 2015). Method: Using archival data, we evaluated the fit of the PNT to 1- and 2-parameter logistic models and examined the precision of the resulting parameter estimates. We regressed the item difficulty estimates on three predictor variables: word length, age of acquisition, and contextual diversity. Results: The 2-parameter logistic model demonstrated marginally better fit, but the fit of the 1-parameter logistic model was adequate. Precision was excellent for both person ability and item difficulty estimates. Word length, age of acquisition, and contextual diversity all independently contributed to variance in item difficulty. Conclusions: Item-response-theory methods can be productively used to analyze and quantify anomia severity in aphasia. Regression of item difficulty on lexical variables supported the validity of the PNT and interpretation of anomia severity scores in the context of current word-finding models. C1 [Fergadiotis, Gerasimos] Portland State Univ, Portland, OR 97207 USA. [Kellough, Stacey; Hula, William D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. RP Fergadiotis, G (reprint author), Portland State Univ, Portland, OR 97207 USA. EM gfergadiotis@pdx.edu FU VA Rehabilitation Research and Development Career Development Award [C7476W]; VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center FX This research was supported by VA Rehabilitation Research and Development Career Development Award C7476W (awarded to William Hula) and the VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center. The authors would like to acknowledge the helpful assistance of Daniel Mirman and Myrna Schwartz. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. NR 71 TC 2 Z9 2 U1 2 U2 3 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1092-4388 EI 1558-9102 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD JUN PY 2015 VL 58 IS 3 BP 865 EP 877 DI 10.1044/2015_JSLHR-L-14-0249 PG 13 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA DX6XE UT WOS:000384528400025 ER PT J AU Hula, WD Kellough, S Fergadiotis, G AF Hula, William D. Kellough, Stacey Fergadiotis, Gerasimos TI Development and Simulation Testing of a Computerized Adaptive Version of the Philadelphia Naming Test SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article ID LEXICAL ACCESS; COMMUNICATIVE PARTICIPATION; APHASIC PERFORMANCE; RASCH ANALYSIS; SHORT-FORM; ITEM; SYSTEM; COMPREHENSION; CALIBRATION; FREQUENCY AB Purpose: The purpose of this study was to develop a computerized adaptive test (CAT) version of the Philadelphia Naming Test (PNT; Roach, Schwartz, Martin, Grewal, & Brecher, 1996), to reduce test length while maximizing measurement precision. This article is a direct extension of a companion article (Fergadiotis, Kellough, & Hula, 2015), in which we fitted the PNT to a 1-parameter logistic item-response-theory model and examined the validity and precision of the resulting item parameter and ability score estimates. Method: Using archival data collected from participants with aphasia, we simulated two PNT-CAT versions and two previously published static PNT short forms, and compared the resulting ability score estimates to estimates obtained from the full 175-item PNT. We used a jackknife procedure to maintain independence of the samples used for item estimation and CAT simulation. Results: The PNT-CAT recovered full PNT scores with equal or better accuracy than the static short forms. Measurement precision was also greater for the PNT-CAT than the static short forms, though comparison of adaptive and static nonoverlapping alternate forms showed minimal differences between the two approaches. Conclusion: These results suggest that CAT assessment of naming in aphasia has the potential to reduce test burden while maximizing the accuracy and precision of score estimates. C1 [Hula, William D.; Kellough, Stacey] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Fergadiotis, Gerasimos] Portland State Univ, Portland, OR 97207 USA. RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. EM william.hula@va.gov FU VA Rehabilitation Research & Development Career Development Award [C7476W]; VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center FX This research was supported by VA Rehabilitation Research & Development Career Development Award C7476W, and the VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 56 TC 3 Z9 3 U1 2 U2 2 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1092-4388 EI 1558-9102 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD JUN PY 2015 VL 58 IS 3 BP 878 EP 890 DI 10.1044/2015_JSLHR-L-14-0297 PG 13 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA DX6XE UT WOS:000384528400026 ER PT J AU Hula, WD Doyle, PJ Stone, CA Hula, SNA Kellough, S Wambaugh, JL Ross, KB Schumacher, JG Jacque, AS AF Hula, William D. Doyle, Patrick J. Stone, Clement A. Hula, Shannon N. Austermann Kellough, Stacey Wambaugh, Julie L. Ross, Katherine B. Schumacher, James G. Jacque, Ann St. TI The Aphasia Communication Outcome Measure (ACOM): Dimensionality, Item Bank Calibration, and Initial Validation SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article ID QUALITY-OF-LIFE; RESPONSE THEORY; PSYCHOMETRIC EVALUATION; COGNITIVE IMPAIRMENT; BIFACTOR ANALYSIS; STROKE SURVIVORS; SCALE; MODELS; RELIABILITY; BURDEN AB Purpose: The purpose of this study is to investigate the structure and measurement properties of the Aphasia Communication Outcome Measure (ACOM), a patient-reported outcome measure of communicative functioning for persons with aphasia. Method: Three hundred twenty-nine participants with aphasia responded to 177 items asking about communicative functioning. The data were analyzed using a categorical item factor analysis approach. Validity of ACOM scores on the basis of their convergence with performance-based, clinician-reported, and surrogate-reported assessments of communication was also assessed. Results: Fifty-nine items that obtained adequate fit to a modified bifactor measurement model and functioned similarly across several demographic and clinical subgroupings were identified. The factor model estimates were transformed to item response theory graded response model parameters, and the resulting score estimates showed good precision and moderately strong convergence with other measures of communicative ability and functioning. A free software application for administration and scoring of the ACOM item bank is available from the first author. Conclusions: The ACOM provides reliable measurement of patient-reported communicative functioning in aphasia. The results supported the validity of ACOM scores insofar as (a) factor analyses provided support for a coherent measurement model, (b) items functioned similarly across demographic and clinical subgroups, and (c) scores showed good convergence with measures of related constructs. C1 [Hula, William D.; Doyle, Patrick J.; Hula, Shannon N. Austermann; Kellough, Stacey; Schumacher, James G.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Hula, William D.; Doyle, Patrick J.; Stone, Clement A.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Wambaugh, Julie L.] VA Salt Lake City Healthcare Syst, Salt Lake City, UT USA. [Wambaugh, Julie L.] Univ Utah, Salt Lake City, UT USA. [Ross, Katherine B.] Phoenix VA Healthcare Syst, Phoenix, AZ USA. [Jacque, Ann St.] Minneapolis VA Healthcare Syst, Minneapolis, MN USA. RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. EM william.hula@va.gov FU VA Rehabilitation Research & Development Merit Review Award [6098R]; VA Rehabilitation Research & Development Career Development Award [C7476W]; VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center FX This work was supported by VA Rehabilitation Research & Development Merit Review Award 6098R (principal investigator: Patrick Doyle), Career Development Award C7476W (principal investigator: William Hula), and the VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center. The authors would like to thank Beth Friedman, Janet Malotky, Martha Manthie, Christina Nessler, Rebecca Owens, Jessica Rapier, Mary Sullivan, Brooke Swoyer, Neil Szuminsky, and Sandra Wright for their assistance with data collection and management. We would also like to thank the aforementioned along with Michael Dickey, Malcolm McNeil, Christine Matthews, Ronda Winans-Mitrik, and Gerasimos Fergadiotis for helpful discussions during the development and execution of this project. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. NR 71 TC 1 Z9 1 U1 8 U2 8 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA SN 1092-4388 EI 1558-9102 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD JUN PY 2015 VL 58 IS 3 BP 906 EP 919 DI 10.1044/2015_JSLHR-L-14-0235 PG 14 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA DX6XE UT WOS:000384528400028 PM 25812178 ER PT J AU Schure, MB Goins, RT AF Schure, Marc B. Goins, R. Turner TI Association of Depressive Symptomatology with Receipt of Informal Caregiving Among Older American Indians: The Native Elder Care Study SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE American Indians; depressive symptomatology; informal caregiving ID MENTAL-HEALTH-SERVICES; SELF-REPORTED USE; QUALITY-OF-LIFE; LONG-TERM-CARE; ADMINISTRATIVE RECORDS; UNITED-STATES; DISABILITY; SYMPTOMS; ADULTS; PREVALENCE AB Objective: Our study objectives were to identify the primary sources of informal caregiving and to examine the association of depressive symptomatology with receipt of informal caregiving among a sample of community-dwelling older American Indians. Design: We conducted a cross-sectional study of older American Indians. Participants: Community-dwelling adults aged 55 years and older who are members of a federally recognized American Indian tribe in the Southeast United States. Measurements: We collected information on the participant's primary caregiver, number of informal care hours received in the past week, depressive symptomatology, demographic characteristics, physical health status, and assistance need. Results: Daughters, spouses, and sons were the most common informal primary caregivers with distinct differences by sex of those receiving care. Compared with participants with lower levels, those with a high level of depressive symptomatology received substantially greater hours of informal care (33.4 versus 11.5 hours per week). Conclusion: Older American Indians with higher levels of depressive symptomatology received more informal caregiving than those with lower depressive symptomatology. The burden of caregiving of older adults is primarily shouldered by spouses and children with those who care for older adults with depressive symptomatology likely experiencing an even greater burden of care. C1 [Schure, Marc B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA. [Goins, R. Turner] Western Carolina Univ, Dept Social Work, Coll Hlth & Human Sci, Cullowhee, NC 28723 USA. Mt Area Hlth Educ Ctr, Ctr Hlth Aging, Asheville, NC USA. RP Schure, MB (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA. EM Mark.Schure@va.gov FU National Institute of Aging, NIH [AG022336]; Oregon State University's College of Public Health and Human Sciences FX This study was funded in part from the National Institute of Aging, NIH (# AG022336) and from Oregon State University's College of Public Health and Human Sciences. We would like to thank Drs. Adam Branscum and Alan Acock for providing analytic recommendations. NR 58 TC 1 Z9 1 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2015 VL 23 IS 6 BP 579 EP 588 DI 10.1016/j.jagp.2014.03.013 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CH9EF UT WOS:000354338100005 PM 24801609 ER PT J AU Phillips, KL Copeland, LA Zeber, JE Stock, EM Tsan, JY MacCarthy, AA AF Phillips, Karon L. Copeland, Laurel A. Zeber, John E. Stock, Eileen M. Tsan, Jack Y. MacCarthy, Andrea A. TI Racial/Ethnic Disparities in Monitoring Metabolic Parameters for Patients with Schizophrenia Receiving Antipsychotic Medications SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE African Americans; healthcare quality assessment; Hispanic; metabolic syndrome; schizophrenia; veterans ID HEALTH-CARE; CARDIOVASCULAR-DISEASE; RACIAL DISPARITIES; AFRICAN-AMERICANS; EXCESS MORTALITY; VETERANS; PATTERNS; CATIE; TRIAL; INTERVENTION AB Objective: Patients with schizophrenia experience risks for metabolic dysregulation from medications and lifestyle behaviors. Although most patients with schizophrenia in the Veterans Health Administration (VA) receive antipsychotics, variation in monitoring metabolic dysregulation by race/ethnicity has not been assessed. This study analyzed differential monitoring of metabolic parameters by minority status. Methods: This retrospective study approximated the five components of metabolic syndrome (fasting glucose, high-density-lipoprotein cholesterol, triglycerides, blood pressure, and large waistline) using archival data, substituting body mass index for waistline. VA patients with schizophrenia age 50 or older were followed from October 1, 2001 through September 2009 (N = 30,258). Covariates included age, gender, race (white, black), Hispanic ethnicity, region, marital status, VA priority status, comorbidity, and antipsychotic type. Repeated-measures analysis assessed the association of race/ethnicity with metabolic monitoring. Results: Average patients age was 59 years (standard deviation: 9; range: 50-101), 97% were men, 70% white, 30% black, and 8% Hispanic. At baseline, 6% were monitored on all five metabolic components; this increased to 29% by 2005. In adjusted models, blacks were less likely to be monitored on all parameters, whereas Hispanics were less likely to have glucose and high-density-lipoprotein cholesterol monitored but more likely to have triglycerides tested. By 2009, lab assays were similar across race and ethnicity. Conclusion: Guideline-concordant monitoring metabolic parameters appear to be equitable but low and somewhat at odds with racial/ethnic risk among older patients with schizophrenia. Physicians should discuss lipids, weight, and glucose with patients at risk for developing heart disease, diabetes, and other sequelae of the metabolic syndrome. C1 [Phillips, Karon L.] IMPAQ Int, Columbia, MD USA. [Copeland, Laurel A.; Zeber, John E.; Stock, Eileen M.] Scott & White Healthcare, Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Tsan, Jack Y.] Cent Texas Vet Hlth Care Syst, Temple, TX USA. [MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Copeland, LA (reprint author), Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM LaurelACopeland@gmail.com OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs [IIR-05-326]; Center for Applied Health Research; Central Texas Veterans Health Care System; Scott & White Healthcare; Texas A&M Health Science Center FX Supported by the Department of Veterans Affairs (grant IIR-05-326; Copeland, PI) with additional support from the Center for Applied Health Research, Central Texas Veterans Health Care System, Scott & White Healthcare, and Texas A&M Health Science Center. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors have no disclosures to report. NR 43 TC 2 Z9 2 U1 4 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2015 VL 23 IS 6 BP 596 EP 606 DI 10.1016/j.jagp.2014.07.007 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA CH9EF UT WOS:000354338100007 PM 25154537 ER PT J AU Kim, IA Long, J AF Kim, Irene A. Long, Jennifer TI Laryngotracheal Stenosis as a Complication of Photodynamic Therapy SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE photodynamic; cancer; photosensitizer; laryngotracheal; stenosis; laryngeal ID HEAD; MANAGEMENT; CANCER AB Objective: Photodynamic therapy (PDT) has been proposed as an effective treatment for mucosal carcinomas such as early-stage laryngeal squamous cell carcinoma. Its advantage over other conventional modalities (surgery and chemoradiation) lies in its ability to treat disease while preserving the function and structure of the larynx. While not FDA-approved in the United States, it is used in some countries as a treatment for laryngeal cancer and is an area of active investigation. This report documents a severe complication of tracheostomy-dependent laryngotracheal stenosis resulting from PDT. Methods: Methods include a case report and review of the literature. Results: A 65-year-old male presented with severe stenosis of the supraglottic, glottic, and subglottic larynx following successful treatment of his laryngeal carcinoma with PDT. His presentation, staged airway reconstruction, and outcome are detailed. Conclusion: PDT is a minimally invasive technique which in early clinical trials has matched the effectiveness of conventional therapies for treating early head and neck squamous cell cancers. It uses a photosensitizing agent that is retained by tumor cells, allowing for the selective destruction of neoplastic cells. Permanent sequelae following treatment have rarely been reported; the most commonly described adverse effects include pain, hoarseness, and phototoxicity. However, our case report discusses the potential for significant laryngotracheal stenosis requiring airway reconstruction following PDT. C1 [Kim, Irene A.; Long, Jennifer] UCLA David Geffen Sch Med Head & Neck Surg, Los Angeles, CA 90095 USA. [Long, Jennifer] Greater Los Angeles VAMC, Los Angeles, CA USA. RP Kim, IA (reprint author), UCLA David Geffen Sch Med Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA. EM iakim@mednet.ucla.edu OI Long, Jennifer/0000-0002-4185-2328 NR 12 TC 0 Z9 0 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD JUN PY 2015 VL 124 IS 6 BP 495 EP 498 DI 10.1177/0003489415570930 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA CH6GR UT WOS:000354135100012 PM 25667216 ER PT J AU MacDonald, ML Ding, Y Newman, J Hemby, S Penzes, P Lewis, DA Yates, NA Sweet, RA AF MacDonald, Matthew L. Ding, Ying Newman, Jason Hemby, Scott Penzes, Peter Lewis, David A. Yates, Nathan A. Sweet, Robert A. TI Altered Glutamate Protein Co-Expression Network Topology Linked to Spine Loss in the Auditory Cortex of Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Auditory cortex; Glutamate; Postmortem; Proteomics; Schizophrenia; Spine ID MISMATCH NEGATIVITY GENERATION; ONSET DYSTONIA-PARKINSONISM; CORTICAL PYRAMIDAL NEURONS; AMPA RECEPTOR TRAFFICKING; PREFRONTAL CORTEX; DENDRITIC SPINES; COGNITIVE IMPAIRMENT; PSYCHIATRIC-DISORDERS; SYNAPTIC-TRANSMISSION; UBIQUITIN-PROTEASOME AB BACKGROUND: Impaired glutamatergic signaling is believed to underlie auditory cortex pyramidal neuron dendritic spine loss and auditory symptoms in schizophrenia. Many schizophrenia risk loci converge on the synaptic glutamate signaling network. We therefore hypothesized that alterations in glutamate signaling protein expression and co-expression network features are present in schizophrenia. METHODS: Gray matter homogenates were prepared from auditory cortex gray matter of 22 schizophrenia and 23 matched control subjects, a subset of whom had been previously assessed for dendritic spine density. One hundred fifty-five selected synaptic proteins were quantified by targeted mass spectrometry. Protein co-expression networks were constructed using weighted gene co-expression network analysis. RESULTS: Proteins with evidence for altered expression in schizophrenia were significantly enriched for glutamate signaling pathway proteins (GRIA4, GRIA3, ATP1A3, and GNAQ). Synaptic protein co-expression was significantly decreased in schizophrenia with the exception of a small group of postsynaptic density proteins, whose co-expression increased and inversely correlated with spine density in schizophrenia subjects. CONCLUSIONS: We observed alterations in the expression of glutamate signaling pathway proteins. Among these, the novel observation of reduced ATP1A3 expression is supported by strong genetic evidence indicating it may contribute to psychosis and cognitive impairment phenotypes. The observations of altered protein network topology further highlight the complexity of glutamate signaling network pathology in schizophrenia and provide a framework for evaluating future experiments to model the contribution of genetic risk to disease pathology. C1 [MacDonald, Matthew L.; Newman, Jason; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Yates, Nathan A.] Univ Pittsburgh, Biomed Mass Spectrometry Ctr, Pittsburgh, PA 15213 USA. [Hemby, Scott] Wake Forest Univ, Sch Med, Neurosci Program, Winston Salem, NC 27109 USA. [Hemby, Scott] Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27109 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Educ & Clin Ctr, Vet Integrated Serv Network Mental Illness Res 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Univ Pittsburgh, Biomed Sci Tower,3811 OHara St,BST W1645, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Penzes, Peter/L-3987-2016 OI Penzes, Peter/0000-0001-5449-1640; Ding, Ying/0000-0003-1352-1000; Lewis, David/0000-0002-3225-6778 FU National Institutes of Health [MH 071533, T32 MH 16804]; Biomedical Mass Spectrometry Center; University of Pittsburgh Cancer Institute Cancer Biomarker Facility [P30CA047904]; Bristol-Myers Squibb Foundation; Bristol-Myers Squibb; Curridium Ltd; Pfizer FX This work was funded by National Institutes of Health Grants MH 071533 and T32 MH 16804. The Biomedical Mass Spectrometry Center and University of Pittsburgh Cancer Institute Cancer Biomarker Facility are supported in part by award P30CA047904.; DAL currently receives investigator-initiated research support from the Bristol-Myers Squibb Foundation, Bristol-Myers Squibb, Curridium Ltd, and Pfizer and in 2007 to 2010 served as a consultant in the areas of target identification and validation and new compound development to AstraZeneca, BioLine RX, Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life Science. MLM, YD, JN, SH, PP, NY, and RAS report no biomedical financial interests or potential conflicts of interest. NR 94 TC 12 Z9 12 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JUN 1 PY 2015 VL 77 IS 11 BP 959 EP 968 DI 10.1016/j.biopsych.2014.09.006 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CH6ZM UT WOS:000354185300010 PM 25433904 ER PT J AU Suri, P Carlson, MJ Rainville, J AF Suri, Pradeep Carlson, M. Jake Rainville, James TI Nonoperative Treatment for Lumbosacral Radiculopathy: What Factors Predict Treatment Failure? SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID LUMBAR DISC HERNIATION; RESEARCH TRIAL SPORT; LOW-BACK-PAIN; PROGNOSTIC-FACTORS; DISABILITY COMPENSATION; CONSERVATIVE TREATMENT; NONSURGICAL TREATMENT; PHYSICAL-EXAMINATION; TREATMENT OUTCOMES; FOLLOW-UP AB Prior studies of nonoperative treatment for lumbosacral radiculopathy have identified potential predictors of treatment failure, defined by persistent pain, persistent disability, lack of recovery, or subsequent surgery. However, few predictors have been replicated, with the exception of higher leg pain intensity, as a predictor of subsequent surgery. We asked two research questions: (1) Does higher baseline leg pain intensity predict subsequent lumbar surgery? (2) Can other previously identified "candidate" predictors of nonoperative treatment failure be replicated? Between January 2008 and March 2009, 154 participants with acute lumbosacral radicular pain were enrolled in a prospective database; 128 participants (83%) received nonoperative treatment and 26 (17%) received surgery over 2-year followup. Ninety-four nonoperative participants (73%) responded to followup questionnaires. We examined associations between previously identified "candidate" predictors and treatment failure defined as (1) subsequent surgery; (2) persistent leg pain on a visual analog scale; (3) persistent disability on the Oswestry Disability Index; or (4) participant-reported lack of recovery over 2-year followup. Confounding variables including sociodemographics, clinical factors, and imaging characteristics were evaluated using an exploratory bivariate analysis followed by a multivariate analysis. With the numbers available, higher baseline leg pain intensity was not an independent predictor of subsequent surgery (adjusted odds ratio [aOR], 1.22 per point of baseline leg pain; 95% confidence interval [CI], 0.98-1.53; p = 0.08). Prior low back pain (aOR, 4.79; 95% CI, 1.01-22.7; p = 0.05) and a positive straight leg raise test (aOR, 4.38; 95% CI, 1.60-11.9; p = 0.004) predicted subsequent surgery. Workers compensation claims predicted persistent leg pain (aOR, 9.04; 95% CI, 1.01-81; p = 0.05) and disability (aOR, 5.99; 95% CI, 1.09-32.7; p = 0.04). Female sex predicted persistent disability (aOR, 3.16; 95% CI, 1.03-9.69; p = 0.05) and perceived lack of recovery (aOR, 2.44; 95% CI, 1.02-5.84; p = 0.05). Higher baseline leg pain intensity was not confirmed as a predictor of subsequent surgery. However, the directionality of the association seen was consistent with prior reports, suggesting Type II error as a possible explanation; larger studies are needed to further examine this relationship. Clinicians should be aware of potential factors that may predict nonoperative treatment failure, including prior low back pain or a positive straight leg raise test as predictors of subsequent surgery, workers compensation claims as predictors of persistent leg pain and disability, and female sex as a predictor of persistent disability and lack of recovery. Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence. C1 [Suri, Pradeep] VA Puget Sound Healthcare Syst, Seattle, WA 98108 USA. [Suri, Pradeep; Carlson, M. Jake] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Rainville, James] New England Baptist Hosp, Boston, MA USA. [Rainville, James] Harvard Univ, Sch Med, Boston, MA USA. RP Suri, P (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,RCS 117, Seattle, WA 98108 USA. EM pradeep.suriyaarachchi@va.gov FU Rehabilitation Medicine Scientist Training K12 Program (RMSTP); National Institutes of Health [K12 HD 01097] FX VA Puget Sound provided support for one of the author's (PS) participation in this research. A portion of this research was conducted while this author was funded by the Rehabilitation Medicine Scientist Training K12 Program (RMSTP) and the National Institutes of Health (K12 HD 01097). NR 35 TC 3 Z9 3 U1 3 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X EI 1528-1132 J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD JUN PY 2015 VL 473 IS 6 BP 1931 EP 1939 DI 10.1007/s11999-014-3677-8 PG 9 WC Orthopedics; Surgery SC Orthopedics; Surgery GA CH6FX UT WOS:000354133000013 PM 24832829 ER PT J AU Brown, DL Cowdery, JE Jones, TS Langford, A Gammage, C Jacobs, TL AF Brown, Devin L. Cowdery, Joan E. Jones, Toni Stokes Langford, Aisha Gammage, Catherine Jacobs, Teresa L. TI Adolescent knowledge and attitudes related to clinical trials SO CLINICAL TRIALS LA English DT Article DE Adolescent; knowledge; attitude; biomedical research; clinical trials ID CANCER; PARTICIPATION; RACE AB Background or aims Poor enrollment plagues most clinical trials. Furthermore, despite mandates to improve minority representation in clinical trial participation, little progress has been made. We investigated the knowledge and attitudes of adolescents related to clinical trials and made race/ethnicity comparisons in an attempt to identify a possible educational intervention target. Methods Students aged 13-18 years in southeast Michigan were offered participation through a class at one high school or two academic summer enrichment programs that drew from multiple high schools (73% response). Questionnaires previously validated in adults were administered. Non-Hispanic whites were compared with minorities using Wilcoxon rank-sum tests. Results Of the 82 respondents, the median age was 16 years (interquartile range: 15-17 years); 22 (28%) were white, 41 (51%) were African American, 11 (14%) were multiracial, 2 (2%) were American Indian or Alaska Native, 1 (1%) was Asian, 3 (4%) were Native Hawaiian or other Pacific Islander, and 2 respondents did not report a race (but did report Hispanic ethnicity). Nine (12%) were Hispanic. Only 27 (33%) had ever heard of a clinical trial. On a scale from 1 (most receptive) to 5 (least receptive) for learning more about a clinical trial for a relevant medical condition, the median score was 2 (interquartile range: 1-3) and for participating in a clinical trial for a relevant medical condition was 2 (interquartile range: 2-3). Overall knowledge was poor, with a median of 46% (interquartile range: 23%-62%) of knowledge answers correct. Knowledge was reduced (p=0.0006) and attitudes were more negative (p=0.05) in minorities than non-Hispanic whites, while minorities also endorsed more substantial barriers to trial participation (p=0.0002). Distrust was similar between minority students and non-Hispanic whites (p=0.15), and self-efficacy was greater in non-Hispanic whites (p=0.05). Conclusion Educational interventions directed toward adolescents that address knowledge, attitudes, and distrust in order to improve clinical trial awareness and receptivity overall are needed and may represent a tool to address disparities in minority enrollment in clinical trials. C1 [Brown, Devin L.; Jacobs, Teresa L.] Univ Michigan, Stroke Program, Cardiovasc Ctr, Ann Arbor, MI 48109 USA. [Cowdery, Joan E.] Eastern Michigan Univ, Sch Hlth Promot & Human Performance, Ypsilanti, MI 48197 USA. [Jones, Toni Stokes] Eastern Michigan Univ, Dept Teacher Educ, Ypsilanti, MI 48197 USA. [Langford, Aisha] US Dept Vet Affairs, Ctr Clin Management Res, Washington, DC USA. [Langford, Aisha] Univ Michigan, Ctr Bioeth & Social Sci Med, Ann Arbor, MI 48109 USA. [Gammage, Catherine] Melvindale High Sch, Dept Sci, Melvindale, MI USA. [Jacobs, Teresa L.] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA. RP Brown, DL (reprint author), Univ Michigan, Stroke Program, Cardiovasc Ctr, 1500 East Med Ctr Dr,SPC 5855, Ann Arbor, MI 48109 USA. EM devinb@umich.edu OI Langford, Aisha/0000-0003-1758-691X NR 12 TC 2 Z9 2 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD JUN PY 2015 VL 12 IS 3 BP 212 EP 214 DI 10.1177/1740774515571443 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA CH4EC UT WOS:000353984100004 PM 25673637 ER PT J AU Cho, E Mostaghel, EA Russell, KJ Liao, JJ Konodi, MA Kurland, BF Marck, BT Matsumoto, AM Dalkin, BL Montgomery, RB AF Cho, Eunpi Mostaghel, Elahe A. Russell, Kenneth J. Liao, Jay J. Konodi, Mark A. Kurland, Brenda F. Marck, Brett T. Matsumoto, Alvin M. Dalkin, Bruce L. Montgomery, R. Bruce TI External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID GROUP PROTOCOL 92-02; PHASE-III TRIAL; DEPRIVATION THERAPY; DNA-REPAIR; RADIOTHERAPY; SUPPRESSION; NEOADJUVANT; SURVIVAL; TOXICITY; ACETATE AB Purpose: Optimizing androgen suppression may provide better control of localized prostate cancer (PCa). Numerous trials have supported the benefit of combining androgen deprivation therapy with definitive radiation therapy in men with locally advanced or high-grade disease. Addition of abiraterone to luteinizing hormone-releasing hormone agonist (LHRHa) with radiation has not been reported. We examined the safety of this combination as well as its impact on androgen suppression. Methods and Materials: A prospective, phase 2 study was conducted in men with localized PCa treated with 6 months of neoadjuvant and concurrent abiraterone with LHRHa and radiation. Duration of adjuvant LHRHa was at the discretion of the treating clinician. Prostate biopsy assays were obtained prior to the start of therapy and prior to radiation. Sera and tissue androgen levels were measured by liquid chromatography-tandem mass spectrometry. Results: A total of 22 men with intermediate- (n=3) and high-risk PCa (n=19) received study therapy. Sixteen men completed the intended course of abiraterone, and 19 men completed planned radiation to 77.4 to 81 Gy. Radiation to pelvic nodes was administered in 20 men. The following grade 3 toxicities were reported: lymphopenia (14 patients), fatigue (1 patient), transaminitis (2 patients), hypertension (2 patients), and hypokalemia (1 patient). There were no grade 4 toxicities. All 21 men who complied with at least 3 months of abiraterone therapy had a preradiation prostate-specific antigen (PSA) concentration nadir of < 0.3 ng/mL. Median levels of tissue androgen downstream of CYP17A were significantly suppressed after treatment with abiraterone, and upstream steroids were increased. At median follow-up of 21 months (range: 3-37 months), only 1 patient (who had discontinued abiraterone at 3 months) had biochemical relapse. Conclusions: Addition of abiraterone to LHRHa with radiation is safe and achieves effective prostatic androgen suppression. Preliminary analysis of the clinical data is also promising, with excellent PSA nadir and no relapse to date in this high-risk population. (C) 2015 Elsevier Inc. All rights reserved. C1 [Cho, Eunpi; Russell, Kenneth J.; Liao, Jay J.; Konodi, Mark A.; Matsumoto, Alvin M.; Dalkin, Bruce L.; Montgomery, R. Bruce] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Cho, Eunpi; Mostaghel, Elahe A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Kurland, Brenda F.] Univ Pittsburgh, Pittsburgh, PA USA. [Marck, Brett T.; Matsumoto, Alvin M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Montgomery, RB (reprint author), Univ Washington, Dept Med, Div Oncol, 1959 NE Pacific St,Box 356158, Seattle, WA 98195 USA. EM rbmontgo@uw.edu OI Cho, Eunpi/0000-0002-7441-6311; Kurland, Brenda/0000-0002-5669-0595 FU Pacific Northwest Prostate Cancer SPORE [P50CA097186]; Prostate Cancer Foundation; Wayne D. Kuni and Joan E. Kuni Foundation; Johnson Johnson, Inc.; National Institutes of Health [UL1TR000423]; National Cancer Institute [T32 CA009515] FX This work was supported by the Pacific Northwest Prostate Cancer SPORE P50CA097186, the Prostate Cancer Foundation, the Wayne D. Kuni and Joan E. Kuni Foundation, Johnson & Johnson, Inc., National Institutes of Health UL1TR000423, and National Cancer Institute grant T32 CA009515. NR 30 TC 7 Z9 7 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD JUN 1 PY 2015 VL 92 IS 2 BP 236 EP 243 DI 10.1016/j.ijrobp.2015.01.020 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA CH4FO UT WOS:000353989000011 PM 25772183 ER PT J AU Yuen, EK Gros, DF Price, M Zeigler, S Tuerk, PW Foa, EB Acierno, R AF Yuen, Erica K. Gros, Daniel F. Price, Matthew Zeigler, Stephanie Tuerk, Peter W. Foa, Edna B. Acierno, Ron TI Randomized Controlled Trial of Home-Based Telehealth Versus In-Person Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary Results SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE telehealth; telemental health; psychotherapy; posttraumatic stress disorder; prolonged exposure; veterans ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; MENTAL-HEALTH PROBLEMS; IRAQ; AFGHANISTAN; SERVICE; VIDEOCONFERENCE; TELEPSYCHIATRY; NONINFERIORITY; PSYCHOTHERAPY AB ObjectivesTelehealth technology may reduce the effect of treatment barriers and improve participation in treatment for veterans with posttraumatic stress disorder (PTSD). The present study is an ongoing randomized controlled trial comparing the effectiveness of prolonged exposure (PE) delivered via in person or home-based video telehealth modalities. MethodA total of 52 veterans with combat-related PTSD were randomized to receive 8-12 weeks of PE through either home-based telehealth or standard in-person office-based care. ResultsParticipants evinced significant reductions in symptoms of PTSD, depression, and anxiety from pre- to posttreatment across both conditions. Analyses conducted within a noninferiority framework suggested nonsignificant treatment outcome differences in clinician-reported PTSD and self-reported anxiety between the conditions. Results were inconclusive for self-reported PTSD and depression symptoms. Patient satisfaction ratings did not significantly differ between the two groups. ConclusionsResults suggest that PE can be delivered via home-based telehealth with outcomes and satisfaction ratings comparable to in-person practices for certain symptoms, however additional research is needed. This modality has the potential to address stigma- and geographic-related barriers to treatment, such as travel time and cost. C1 [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA. [Gros, Daniel F.; Zeigler, Stephanie; Tuerk, Peter W.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Gros, Daniel F.; Zeigler, Stephanie; Tuerk, Peter W.; Acierno, Ron] Med Univ S Carolina, Columbia, SC USA. [Price, Matthew] Univ Vermont, Burlington, VT 05405 USA. [Foa, Edna B.] Univ Penn, Philadelphia, PA 19104 USA. RP Yuen, EK (reprint author), Univ Tampa, Dept Psychol, Box Q,401 W Kennedy Blvd, Tampa, FL 33606 USA. EM eyuen@ut.edu FU Veterans Affairs Health Services Research and Development [NCT01102764]; Veteran Affairs Clinical Sciences Research and Development [CX000845, NCT01031979] FX This work was supported by grants from Veterans Affairs Health Services Research and Development awarded to R. Acierno (NCT01102764) and from Veteran Affairs Clinical Sciences Research and Development awarded to D. Gros (CX000845) and Dr. Tuerk (NCT01031979). NR 42 TC 13 Z9 13 U1 3 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD JUN PY 2015 VL 71 IS 6 BP 500 EP 512 DI 10.1002/jclp.22168 PG 13 WC Psychology, Clinical SC Psychology GA CI0HG UT WOS:000354417100002 PM 25809565 ER PT J AU Yoon, JH Larson, P Grandelis, A La, C Cui, E Carter, CS Minzenberg, MJ AF Yoon, Jong H. Larson, Paul Grandelis, Anthony La, Christian Cui, Edward Carter, Cameron S. Minzenberg, Michael J. TI Delay Period Activity of the Substantia Nigra during Proactive Control of Response Selection as Determined by a Novel fMRI Localization Method SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID VENTRAL TEGMENTAL AREA; BASAL GANGLIA; SUBTHALAMIC NUCLEUS; PREFRONTAL CORTEX; PARKINSONS-DISEASE; DOPAMINERGIC MIDBRAIN; COGNITIVE CONTROL; FUNCTIONAL MRI; WORKING-MEMORY; DECISION-MAKING AB The ability to proactively control motor responses, particularly to overcome overlearned or automatic actions, is an essential prerequisite for adaptive, goal-oriented behavior. The substantia nigra (SN), an element of the BG, has figured prominently in current models of response selection. However, because of its small size and proximity to functionally distinct subcortical structures, it has been challenging to test the SN's involvement in response selection using conventional in vivo functional neuroimaging approaches. We developed a new fMRI localization method for directly distinguishing, on echoplanar images, the SN BOLD signal from that of neighboring structures, including the subthalamic nucleus (STN). Using this method, we tested the hypothesis that the SN supports the proactive control of response selection. We acquired high-resolution EPI volumes at 3 T from 16 healthy participants while they completed the Preparing to Overcome Prepotency task of proactive control. There was significantly elevated delay period signal selectively during high-compared with lowcontrol trials in the SN. The STN did not show delay period activity in either condition. SN delay period signal was significantly inversely associated with task performance RTs across participants. These results suggest that our method offers a novel means for measuring SN BOLD responses, provides unique evidence of SN involvement in cognitive control in humans, and suggests a novel mechanism for proactive response selection. C1 [Yoon, Jong H.] Stanford Univ, Stanford, CA 94305 USA. [Yoon, Jong H.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Larson, Paul; Minzenberg, Michael J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grandelis, Anthony; La, Christian; Carter, Cameron S.] Univ Calif Davis, Davis, CA 95616 USA. [Cui, Edward] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Minzenberg, Michael J.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Yoon, JH (reprint author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave,Bldg 4,2nd Floor, Palo Alto, CA 94304 USA. EM jhyoon1@stanford.edu FU NARSAD Foundation; NIH/NIMH FX This study has been funded by the NARSAD Foundation and NIH/NIMH. NR 72 TC 0 Z9 0 U1 2 U2 5 PU MIT PRESS PI CAMBRIDGE PA ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA SN 0898-929X EI 1530-8898 J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD JUN PY 2015 VL 27 IS 6 BP 1238 EP 1248 DI 10.1162/jocn_a_00775 PG 11 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA CH5YI UT WOS:000354111600014 PM 25514657 ER PT J AU Harel, NY Martinez, SA Knezevic, S Asselin, PK Spungen, AM AF Harel, Noam Y. Martinez, Stephanie A. Knezevic, Steven Asselin, Pierre K. Spungen, Ann M. TI Acute changes in soleus H-reflex facilitation and central motor conduction after targeted physical exercises SO JOURNAL OF ELECTROMYOGRAPHY AND KINESIOLOGY LA English DT Article DE H-reflex facilitation; Transcranial magnetic stimulation; Corticospinal; Reticulospinal; Balance exercise ID SPINAL-CORD-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; DESCENDING PATHWAYS; CLINICAL-TRIALS; MOTONEURONS; MODULATION; TRACT; RECOVERY; EXCITABILITY; CONNECTIONS AB We tested the acute effect of exercises targeted simultaneously at cortical and brainstem circuits on neural transmission through corticobulbar connections. Corticobulbar pathways represent a potential target for rehabilitation after spinal cord injury (SCI), which tends to spare brainstem circuits to a greater degree than cortical circuits. To explore this concept, able-bodied volunteers (n = 20) underwent one session each of three exercises targeted at different nervous system components: treadmill walking (spinal locomotor circuits), isolated balance exercise (brainstem and other pathways), and multimodal balance plus skilled hand exercise (hand motor cortex and corticospinal tract). We found that short-interval soleus H-reflex facilitation increased after one session of balance and multimodal exercise by 13.2 +/- 4.0% and 8.3 +/- 4.7%, and slightly decreased by 1.9 +/- 4.4% after treadmill exercise (p = 0.042 on ANOVA across exercise type). Increases in long-interval H-reflex facilitation were not significantly different between exercises. Both balance and multimodal exercise increased central motor conduction velocity by 4.3 +/- 2.6% and 4.5 +/- 2.8%, whereas velocity decreased by 4.3 +/- 2.7% after treadmill exercise (p = 0.045 on ANOVA across exercise type). In conclusion, electrophysiological transmission between the motor cortex and spinal motor neurons in able-bodied subjects increased more following one session of balance exercise than treadmill exercise. Published by Elsevier Ltd. C1 [Harel, Noam Y.; Martinez, Stephanie A.; Knezevic, Steven; Asselin, Pierre K.; Spungen, Ann M.] RR&D Natl Ctr Excellence Med Consequences Spinal, James J Peters VA Med Ctr, Bronx, NY USA. [Harel, Noam Y.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Harel, Noam Y.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. RP Harel, NY (reprint author), 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM noam.harel@mssm.edu FU VA Rehabilitation Research Development [B0881-W, B9212-C]; Department of Neurology at Icahn School of Medicine at Mount Sinai FX This work was funded by VA Rehabilitation Research & Development Grants B0881-W and B9212-C, as well as salary and equipment support from the Department of Neurology at Icahn School of Medicine at Mount Sinai. We thank Ajax Yang, MD, DPT, for insights into different exercises related to this work. We thank William A. Bauman, MD, for review and improvement of this manuscript. NR 36 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1050-6411 EI 1873-5711 J9 J ELECTROMYOGR KINES JI J. Electromyogr. Kinesiol. PD JUN PY 2015 VL 25 IS 3 BP 438 EP 443 DI 10.1016/j.jelekin.2015.02.009 PG 6 WC Neurosciences; Physiology; Rehabilitation; Sport Sciences SC Neurosciences & Neurology; Physiology; Rehabilitation; Sport Sciences GA CH4TQ UT WOS:000354026200003 PM 25771437 ER PT J AU Spraggins, JM Rizzo, DG Moore, JL Rose, KL Hammer, ND Skaar, EP Caprioli, RM AF Spraggins, Jeffrey M. Rizzo, David G. Moore, Jessica L. Rose, Kristie L. Hammer, Neal D. Skaar, Eric P. Caprioli, Richard M. TI MALDI FTICR IMS of Intact Proteins: Using Mass Accuracy to Link Protein Images with Proteomics Data SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY LA English DT Article DE FTICR MS; Imaging MS; MALDI; Proteomics; Mass accuracy; Top-down; Calprotectin; PTMs; Staphylococcus aureus; Nutritional immunity ID NEUTROPHIL EXTRACELLULAR TRAPS; STAPHYLOCOCCUS-AUREUS; ATMOSPHERIC-PRESSURE; TISSUE-SECTIONS; POSTTRANSLATIONAL MODIFICATIONS; ELECTROSPRAY-IONIZATION; TRYPTIC PEPTIDES; SPECTROMETRY; LASER; CALPROTECTIN AB MALDI imaging mass spectrometry is a highly sensitive and selective tool used to visualize biomolecules in tissue. However, identification of detected proteins remains a difficult task. Indirect identification strategies have been limited by insufficient mass accuracy to confidently link ion images to proteomics data. Here, we demonstrate the capabilities of MALDI FTICR MS for imaging intact proteins. MALDI FTICR IMS provides an unprecedented combination of mass resolving power (similar to 75,000 at m/z 5000) and accuracy (< 5ppm) for proteins up to similar to 12kDa, enabling identification based on correlation with LC-MS/MS proteomics data. Analysis of rat brain tissue was performed as a proof-of-concept highlighting the capabilities of this approach by imaging and identifying a number of proteins including N-terminally acetylated thymosin beta(4) (m/z 4,963.502, 0.6ppm) and ATP synthase subunit epsilon (m/z 5,636.074, -2.3ppm). MALDI FTICR IMS was also used to differentiate a series of oxidation products of S100A8 (m/z 10,164.03, -2.1ppm), a subunit of the heterodimer calprotectin, in kidney tissue from mice infected with Staphylococcus aureus. S100A8 - M37O/C42O(3) (m/z 10228.00, -2.6ppm) was found to co-localize with bacterial microcolonies at the center of infectious foci. The ability of MALDI FTICR IMS to distinguish S100A8 modifications is critical to understanding calprotectin's roll in nutritional immunity. C1 [Spraggins, Jeffrey M.; Rose, Kristie L.; Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37205 USA. [Spraggins, Jeffrey M.; Rizzo, David G.; Moore, Jessica L.; Rose, Kristie L.; Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA. [Rizzo, David G.; Moore, Jessica L.; Caprioli, Richard M.] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA. [Hammer, Neal D.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. [Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA. [Caprioli, Richard M.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA. RP Spraggins, JM (reprint author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37205 USA. EM jeff.spraggins@vanderbilt.edu FU NIH/NIGMS [5 P41 GM103391-04, 5R01GM058008]; National Institutes of Health [1S10OD012359-01]; National Institute of Allergy and Infectious Diseases [R01 AI101171-01A1, R21 AI107233]; Vanderbilt University; Vanderbilt Chemical Biology Interface training program [T32 GM 065086]; Mitchum Warren Graduate Research Fellowship FX The authors acknowledge support for this work by grants from the NIH/NIGMS (5 P41 GM103391-04 and 5R01GM058008) and the National Institutes of Health Shared Instrumentation Grant Program (1S10OD012359-01) awarded to R.M.C. and the National Institute of Allergy and Infectious Diseases (R01 AI101171-01A1 and R21 AI107233) awarded to E.P.S.D.G.R. is supported by the Aegis Sciences Fellowship in Chemistry, Vanderbilt University. J.L.M. is supported by Vanderbilt Chemical Biology Interface training program (T32 GM 065086) and the Mitchum Warren Graduate Research Fellowship. N.D.H. is a CF Foundation Ann Weinberg Memorial Research Fellow. The authors also thank Dr. Junhai Yang, Dr. Dhananjay Sakrikar, Salisha Hill M.S., and Amanda Hachey for their technical support. NR 63 TC 20 Z9 20 U1 7 U2 66 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1044-0305 EI 1879-1123 J9 J AM SOC MASS SPECTR JI J. Am. Soc. Mass Spectrom. PD JUN PY 2015 VL 26 IS 6 BP 974 EP 985 DI 10.1007/s13361-015-1147-5 PG 12 WC Biochemical Research Methods; Chemistry, Analytical; Chemistry, Physical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA CH5OE UT WOS:000354084400017 PM 25904064 ER PT J AU Zvolensky, MJ Farris, SG Kotov, R Schechter, CB Bromet, E Gonzalez, A Vujanovic, A Pietrzak, RH Crane, M Kaplan, J Moline, J Southwick, SM Feder, A Udasin, I Reissman, DB Luft, BJ AF Zvolensky, Michael J. Farris, Samantha G. Kotov, Roman Schechter, Clyde B. Bromet, Evelyn Gonzalez, Adam Vujanovic, Anka Pietrzak, Robert H. Crane, Michael Kaplan, Julia Moline, Jacqueline Southwick, Steven M. Feder, Adriana Udasin, Iris Reissman, Dori B. Luft, Benjamin J. TI World Trade Center disaster and sensitization to subsequent life stress: A longitudinal study of disaster responders SO PREVENTIVE MEDICINE LA English DT Article DE Stress exposure; Disaster; Trauma; Responder; Posttraumatic stress; Functioning ID CENTER HEALTH REGISTRY; PTSD CHECKLIST PCL; POSTTRAUMATIC-STRESS; RECOVERY WORKERS; RISK-FACTORS; PSYCHOMETRIC PROPERTIES; CENTER RESCUE; SYMPTOMS; DISORDER; EXPOSURE AB Purpose. : The current study examined the role of World Trade Center (WTC) disaster exposure (hours spent working on the site, dust cloud exposure, and losing friend/loved one) in exacerbating the effects of post-disaster life stress on posttraumatic stress disorder (PTSD) symptoms and overall functioning among WTC responders. Method. : Participants were 18,896 responders (8466 police officers and 10,430 non-traditional responders) participating in the WTC Health Program who completed an initial examination between July, 2002 and April, 2010 and were reassessed an average of two years later. Results.: Among police responders, there was a significant interaction, such that the effect of post-disaster life stress on later PTSD symptoms and overall functioning was stronger among police responders who had greater WTC disaster exposure (beta's=.029 and .054, respectively, for PTSD symptoms and overall functioning). This moderating effect was absent in non-traditional responders. Across both groups, post-disaster life stress also consistently was related to the dependent variables in a more robust manner than WTC exposure. Discussion.: The present findings suggest that WTC exposure may compound post-disaster life stress, thereby resulting in a more chronic course of PTSD symptoms and reduced functioning among police responders. (C) 2015 Elsevier Inc All rights reserved. C1 [Zvolensky, Michael J.; Farris, Samantha G.] Univ Houston, Dept Psychol, Houston, TX 77204 USA. [Zvolensky, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA. [Kotov, Roman; Bromet, Evelyn; Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. [Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA. [Vujanovic, Anka] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Pietrzak, Robert H.; Southwick, Steven M.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Crane, Michael; Kaplan, Julia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA. [Moline, Jacqueline] North Shore LIJ Hlth Syst, Dept Populat Hlth, Great Neck, NY USA. [Feder, Adriana] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Udasin, Iris] Rutgers Robert Wood Johnson Med Sch, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA. [Reissman, Dori B.] NIOSH, World Trade Ctr, Hlth Program, Washington, DC USA. [Reissman, Dori B.] US PHS, Washington, DC USA. [Luft, Benjamin J.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. RP Zvolensky, MJ (reprint author), Univ Houston, 126 Heyne Bldg,Suite 104, Houston, TX 77204 USA. EM mjzvolen@central.uh.edu NR 42 TC 5 Z9 5 U1 3 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD JUN PY 2015 VL 75 BP 70 EP 74 DI 10.1016/j.ypmed.2015.03.017 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CH6MC UT WOS:000354149700011 PM 25840022 ER PT J AU Macleod, LC Chery, LJ Hu, EYC Zeliadt, SB Holt, SK Lin, DW Porter, MP Gore, JL Wright, JL AF Macleod, L. C. Chery, L. J. Hu, E. Y. C. Zeliadt, S. B. Holt, S. K. Lin, D. W. Porter, M. P. Gore, J. L. Wright, J. L. TI Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article ID TREATMENT PANEL-III; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; MULTIETHNIC COHORT; ANDROGEN RECEPTOR; NATURAL-HISTORY; UNITED-STATES; RISK; ASSOCIATION; CHOLESTEROL AB BACKGROUND: Metabolic syndrome (MetS) has been hypothesized to be associated with cancer, including prostate cancer (PCa), but the relationship is not well characterized. We analyze the relationship between MetS features and localized PCa recurrence after treatment. METHODS: Men having primary treatment for localized PCa were included from a multi-site regional veteran network. Recurrence was defined as nadir PSA +2 ng ml(-1) (radiation) or PSA >= 0.2 ng ml(-1) (prostatectomy). MetS was based on consensus professional society guidelines from the American Heart Association and International Diabetes Federation (three of: hypertension > 130/85mmHg, fasting blood glucose >= 100 mg dl(-1), waist circumference > 102 cm, high-density lipoprotein < 40 mg dl(-1), triglycerides >= 150 mg dl(-1)). Closely related abnormality in low-density lipoprotein (LDL; > 130 mg dl(-1)) was also examined. Analysis of PCa recurrence risk included multivariable Cox proportional hazards regression with propensity adjustment. RESULTS: Of the 1706 eligible men, 279 experienced recurrence over a median follow-up period of 41 months (range 1-120 months). Adjustment variables associated with PCa recurrence included: index PSA, Gleason, and tumor stage. Independent variables of interest associated with PCa recurrence were hyperglycemia and elevated LDL. Elevated LDL was associated with PCa recurrence (multivariable hazard ratio (HR) 1.34, 95% confidence interval (CI) 1.03, 1.74; propensity adjusted HR 1.33, 95% CI 1.03, 1.72). There was also an association between impaired fasting glucose and PCa recurrence in (multivariable HR 1.54, 95% CI 1.10, 2.15; propensity adjusted HR 1.41, 95% CI 1.01, 1.95). MetS was not associated with PCa recurrence (multivariable: HR 0.96, 95% CI 0.61, 1.50; propensity adjusted HR 1.04, 95% CI 0.67, 1.62). CONCLUSIONS: PCa recurrence is not associated with MetS but is associated with elevated LDL and impaired fasting glucose. If confirmed, these data may help provide modifiable targets in preventing recurrence of PCa. C1 [Macleod, L. C.; Chery, L. J.; Holt, S. K.; Lin, D. W.; Porter, M. P.; Gore, J. L.; Wright, J. L.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Hu, E. Y. C.; Zeliadt, S. B.; Lin, D. W.; Porter, M. P.; Wright, J. L.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Lin, D. W.; Gore, J. L.; Wright, J. L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. RP Macleod, LC (reprint author), Univ Washington, Med Ctr, Dept Urol, 1959 NE Pacific St, Seattle, WA 98195 USA. EM liamcm@uw.edu OI macleod, liam/0000-0003-1163-6621 FU NIH from the National Cancer Institute [P50CA097186]; Fred Hutchinson Cancer Research Center; VA Puget Sound Health Care system FX This work was supported by an NIH Grant: P50CA097186 from the National Cancer Institute, with additional support and resources from the Fred Hutchinson Cancer Research Center and VA Puget Sound Health Care system. NR 51 TC 2 Z9 2 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD JUN PY 2015 VL 18 IS 2 BP 190 EP 195 DI 10.1038/pcan.2015.12 PG 6 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA CH9NU UT WOS:000354363300015 PM 25823651 ER PT J AU Kaplan, KA McGlinchey, EL Soehner, A Gershon, A Talbot, LS Eidelman, P Gruber, J Harvey, AG AF Kaplan, K. A. McGlinchey, E. L. Soehner, A. Gershon, A. Talbot, L. S. Eidelman, P. Gruber, J. Harvey, A. G. TI Hypersomnia subtypes, sleep and relapse in bipolar disorder SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Bipolar disorder; diagnosis; hypersomnia; relapse; sleep ID STRUCTURED CLINICAL INTERVIEW; TEST-RETEST RELIABILITY; OF-FIT INDEXES; MOOD DISORDERS; QUALITY INDEX; BRIGHT LIGHT; OLDER-ADULTS; DEPRESSIVE SYMPTOMATOLOGY; PSYCHOMETRIC EVALUATION; STATE MISPERCEPTION AB Background. Though poorly defined, hypersomnia is associated with negative health outcomes and new-onset and recurrence of psychiatric illness. Lack of definition impedes generalizability across studies. The present research clarifies hypersomnia diagnoses in bipolar disorder by exploring possible subgroups and their relationship to prospective sleep data and relapse into mood episodes. Method. A community sample of 159 adults (aged 18-70 years) with bipolar spectrum diagnoses, euthymic at study entry, was included. Self-report inventories and clinician-administered interviews determined features of hypersomnia. Participants completed sleep diaries and wore wrist actigraphs at home to obtain prospective sleep data. Approximately 7 months later, psychiatric status was reassessed. Factor analysis and latent profile analysis explored empirical groupings within hypersomnia diagnoses. Results. Factor analyses confirmed two separate subtypes of hypersomnia ('long sleep' and 'excessive sleepiness') that were uncorrelated. Latent profile analyses suggested a four-class solution, with 'long sleep' and 'excessive sleepiness' again representing two separate classes. Prospective sleep data suggested that the sleep of 'long sleepers' is characterized by a long time in bed, not long sleep duration. Longitudinal assessment suggested that 'excessive sleepiness' at baseline predicted mania/hypomania relapse. Conclusions. This study is the largest of hypersomnia to include objective sleep measurement, and refines our understanding of classification, characterization and associated morbidity. Hypersomnia appears to be comprised of two separate subgroups: long sleep and excessive sleepiness. Long sleep is characterized primarily by long bedrest duration. Excessive sleepiness is not associated with longer sleep or bedrest, but predicts relapse to mania/hypomania. Understanding these entities has important research and treatment implications. C1 [Kaplan, K. A.; Gershon, A.] Stanford Univ Sch Med, Dept Psychiat, Stanford, CA USA. [McGlinchey, E. L.] Columbia Univ Med Ctr, New York State Psychiat Inst, Div Child & Adolescent Psychiat, New York, NY USA. [Soehner, A.] Univ Pittsburgh Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Talbot, L. S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Eidelman, P.] Cognit Behav Therapy & Sci Ctr, Oakland, CA USA. [Gruber, J.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA. [Harvey, A. G.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA. RP Harvey, AG (reprint author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA. EM aharvey@berkeley.edu FU National Institute of Mental Health [R34 MH080958]; National Science Foundation Graduate Research Fellowship FX This project was supported by a National Institute of Mental Health grant (no. R34 MH080958) awarded to A.G.H. and a National Science Foundation Graduate Research Fellowship grant awarded to K.A.K. NR 104 TC 4 Z9 4 U1 0 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD JUN PY 2015 VL 45 IS 8 BP 1751 EP 1763 DI 10.1017/S0033291714002918 PG 13 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA CH4WW UT WOS:000354035000017 PM 25515854 ER PT J AU Smucny, J Olincy, A Eichman, LS Tregellas, JR AF Smucny, Jason Olincy, Ann Eichman, Lindsay S. Tregellas, Jason R. TI Neuronal effects of nicotine during auditory selective attention SO PSYCHOPHARMACOLOGY LA English DT Article DE Attention; Auditory; fMRI; Nicotine; Parietal cortex ID ANTERIOR CINGULATE CORTEX; SHORT-TERM-MEMORY; TRANSDERMAL NICOTINE; DEFICIT/HYPERACTIVITY DISORDER; ACETYLCHOLINE-RECEPTORS; VISUOSPATIAL ATTENTION; VISUAL-ATTENTION; PARIETAL CORTEX; BRAIN; DISTRACTION AB Although the attention-enhancing effects of nicotine have been behaviorally and neurophysiologically well-documented, its localized functional effects during selective attention are poorly understood. In this study, we examined the neuronal effects of nicotine during auditory selective attention in healthy human nonsmokers. We hypothesized to observe significant effects of nicotine in attention-associated brain areas, driven by nicotine-induced increases in activity as a function of increasing task demands. A single-blind, prospective, randomized crossover design was used to examine neuronal response associated with a go/no-go task after 7 mg nicotine or placebo patch administration in 20 individuals who underwent functional magnetic resonance imaging at 3T. The task design included two levels of difficulty (ordered vs. random stimuli) and two levels of auditory distraction (silence vs. noise). Significant treatment x difficulty x distraction interaction effects on neuronal response were observed in the hippocampus, ventral parietal cortex, and anterior cingulate. In contrast to our hypothesis, U and inverted U-shaped dependencies were observed between the effects of nicotine on response and task demands, depending on the brain area. These results suggest that nicotine may differentially affect neuronal response depending on task conditions. These results have important theoretical implications for understanding how cholinergic tone may influence the neurobiology of selective attention. C1 [Smucny, Jason; Olincy, Ann; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Smucny, Jason; Olincy, Ann; Eichman, Lindsay S.; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO USA. [Smucny, Jason; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA. RP Smucny, J (reprint author), Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA. EM jason.smucny@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Smucny, Jason/0000-0001-5656-7987 FU NIMH Conte Center [MH-086383]; VA Biomedical Laboratory and Clinical Science Research and Development Service; Brain and Behavior Foundation; Blowitz-Ridgeway Foundation FX The authors thank Debra Singel for assistance with data acquisition. This work was supported by NIMH Conte Center Grant MH-086383, the VA Biomedical Laboratory and Clinical Science Research and Development Service, the Brain and Behavior Foundation, and the Blowitz-Ridgeway Foundation. NR 51 TC 5 Z9 5 U1 1 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JUN PY 2015 VL 232 IS 11 BP 2017 EP 2028 DI 10.1007/s00213-014-3832-7 PG 12 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CH7VV UT WOS:000354245600015 PM 25491929 ER PT J AU Rossini, PM Burke, D Chen, R Cohen, LG Daskalakis, Z Di Iorio, R Di Lazzaro, V Ferreri, F Fitzgerald, PB George, MS Hallett, M Lefaucheur, JP Langguth, B Matsumoto, H Miniussi, C Nitsche, MA Pascual-Leone, A Paulus, W Rossi, S Rothwell, JC Siebner, HR Ugawa, Y Walsh, V Ziemann, U AF Rossini, P. M. Burke, D. Chen, R. Cohen, L. G. Daskalakis, Z. Di Iorio, R. Di Lazzaro, V. Ferreri, F. Fitzgerald, P. B. George, M. S. Hallett, M. Lefaucheur, J. P. Langguth, B. Matsumoto, H. Miniussi, C. Nitsche, M. A. Pascual-Leone, A. Paulus, W. Rossi, S. Rothwell, J. C. Siebner, H. R. Ugawa, Y. Walsh, V. Ziemann, U. TI Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an IFCN Committee SO CLINICAL NEUROPHYSIOLOGY LA English DT Review DE Non-invasive stimulation; Transcranial magnetic stimulation; Human cortex; Clinical neurophysiology; TMS measures; Excitability threshold ID HUMAN MOTOR CORTEX; THETA-BURST-STIMULATION; PAIRED ASSOCIATIVE STIMULATION; INTRACTABLE DEAFFERENTATION PAIN; DORSOLATERAL PREFRONTAL CORTEX; AMYOTROPHIC-LATERAL-SCLEROSIS; LATENCY AFFERENT INHIBITION; FORAMEN MAGNUM LEVEL; INTERVAL INTRACORTICAL INHIBITION; PROGRESSIVE MYOCLONUS EPILEPSY AB These guidelines provide an up-date of previous IFCN report on ``Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application'' (Rossini et al., 1994). A new Committee, composed of international experts, some of whom were in the panel of the 1994 ''Report'', was selected to produce a current state-of-the-art review of non-invasive stimulation both for clinical application and research in neuroscience. Since 1994, the international scientific community has seen a rapid increase in non-invasive brain stimulation in studying cognition, brain-behavior relationship and pathophysiology of various neurologic and psychiatric disorders. New paradigms of stimulation and new techniques have been developed. Furthermore, a large number of studies and clinical trials have demonstrated potential therapeutic applications of non-invasive brain stimulation, especially for TMS. Recent guidelines can be found in the literature covering specific aspects of non-invasive brain stimulation, such as safety (Rossi et al., 2009), methodology (Groppa et al., 2012) and therapeutic applications (Lefaucheur et al., 2014). This up-dated review covers theoretical, physiological and practical aspects of non-invasive stimulation of brain, spinal cord, nerve roots and peripheral nerves in the light of more updated knowledge, and include some recent extensions and developments. (C) 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. C1 [Rossini, P. M.; Di Iorio, R.] Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthoped, Policlin A Gemelli, Inst Neurol, I-00168 Rome, Italy. [Burke, D.] Univ Sydney, Royal Prince Alfred Hosp, Dept Neurol, Sydney, NSW 2006, Australia. [Chen, R.] Univ Toronto, Toronto Western Res Inst, Div Neurol, Toronto, ON, Canada. [Cohen, L. G.] NINDS, Human Cort Physiol & Neurorehabil Sect, NIH, Bethesda, MD 20892 USA. [Daskalakis, Z.] Univ Toronto, Temerty Ctr Therapeut Brain Intervent, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Di Lazzaro, V.; Ferreri, F.] Univ Campus Biomed, Dept Neurol, Rome, Italy. [Ferreri, F.] Univ Eastern Finland, Dept Clin Neurophysiol, Kuopio, Finland. [Fitzgerald, P. B.] Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia. [Fitzgerald, P. B.] The Alfred, Melbourne, Vic, Australia. [George, M. S.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Hallett, M.] NINDS, Human Motor Control Sect, Med Neurol Branch, NIH, Bethesda, MD 20892 USA. [Lefaucheur, J. P.] Henri Mondor Hosp, AP HP, Dept Physiol, F-94010 Creteil, France. [Lefaucheur, J. P.] Paris Est Creteil Univ, Fac Med, Nerve Excitabil & Therapeut Team, EA 4391, F-94010 Creteil, France. [Langguth, B.] Univ Regensburg, Dept Psychiat & Psychotherapy, D-93053 Regensburg, Germany. [Matsumoto, H.] Japanese Red Cross Med Ctr, Dept Neurol, Tokyo, Japan. [Miniussi, C.] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy. [Miniussi, C.] IRCCS, Ctr San Giovanni Dio Fatebenefratelli, Brescia, Italy. [Nitsche, M. A.] Univ Gottingen, Univ Med Ctr Groningen, Dept Clin Neurophysiol, D-37073 Gottingen, Germany. [Pascual-Leone, A.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA USA. [Paulus, W.] Univ Gottingen, Dept Clin Neurophysiol, D-37073 Gottingen, Germany. [Rossi, S.] Univ Siena, Brain Invest & Neuromodulat Lab, Unit Neurol & Clin Neurophysiol, Dept Neurosci, I-53100 Siena, Italy. [Rothwell, J. C.] UCL, Inst Neurol, London, England. [Siebner, H. R.] Univ Copenhagen, Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark. [Siebner, H. R.] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, Ctr Funct & Diagnost Imaging & Res, DK-2650 Hvidovre, Denmark. [Ugawa, Y.] Fukushima Med Univ, Dept Neurol, Sch Med, Fukushima, Japan. [Walsh, V.] UCL, Inst Cognit Neurosci, London, England. [Ziemann, U.] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany. [Ziemann, U.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany. RP Di Iorio, R (reprint author), Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthoped, Policlin A Gemelli, Inst Neurol, Lgo A Gemelli 8, I-00168 Rome, Italy. EM r.diiorio@live.it RI Siebner, Hartwig/G-4052-2016; Miniussi, Carlo/E-7602-2010; Chen, Robert/B-3899-2009; Paulus, Walter/A-3544-2009 OI Miniussi, Carlo/0000-0002-5436-4745; Chen, Robert/0000-0002-8371-8629; Paulus, Walter/0000-0001-5549-8377; Ferreri, Florinda/0000-0002-7938-905X; Di Lazzaro, Vincenzo/0000-0002-9113-5925; rossi, simone/0000-0001-6697-9459; Rothwell, John/0000-0003-1367-6467 NR 493 TC 143 Z9 144 U1 29 U2 104 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1388-2457 EI 1872-8952 J9 CLIN NEUROPHYSIOL JI Clin. Neurophysiol. PD JUN PY 2015 VL 126 IS 6 BP 1071 EP 1107 DI 10.1016/j.clinph.2015.02.001 PG 37 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CH1ME UT WOS:000353785000006 PM 25797650 ER PT J AU Bryant, AE Bayer, CR Aldape, MJ Stevens, DL AF Bryant, Amy E. Bayer, Clifford R. Aldape, Michael J. Stevens, Dennis L. TI The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE group A streptococcus; myonecrosis; necrotizing fasciitis; NSAIDs; trauma ID SKELETAL-MUSCLE REGENERATION; NECROTIZING FASCIITIS; FIBRO/ADIPOGENIC PROGENITORS; BACTERIAL-INFECTIONS; VIMENTIN EXPRESSION; GENE-EXPRESSION; SATELLITE CELLS; RISK; VARICELLA; CHILDREN AB Purpose of review This review summarizes clinical and basic science evidence linking trauma and nonsteroidal anti-inflammatory drug (NSAID) use to initiation and progression of severe group A streptococcal (GAS) soft tissue infection. Recent findings New evidence includes recent clinical series and controlled studies that lend support to an NSAID/GAS association, basic science studies that demonstrate unique roles for nonpenetrating injury and NSAID administration in initiation of cryptogenic GAS infection and experimental studies showing that nonselective NSAIDs accelerate disease progression and limit antibiotic efficacy in established GAS soft tissue infections. Potential mechanisms for these processes are discussed. Summary NSAIDs are important anti-inflammatory and analgesic drugs; however, new experimental data suggest that nonselective NSAIDs do more than simply mask the signs and symptoms of developing GAS infection. A more thorough understanding of the triadic interplay of injury-triggered immune signaling, GAS soft tissue infection and NSAIDs is of significant clinical importance and could shift the current paradigm of pain management to avert the consequences of such devastating infections. C1 [Bryant, Amy E.; Bayer, Clifford R.; Aldape, Michael J.; Stevens, Dennis L.] US Dept Vet Affairs, Off Res & Dev, Boise, ID USA. [Bryant, Amy E.; Stevens, Dennis L.] Univ Washington, Sch Med, Seattle, WA USA. RP Bryant, AE (reprint author), Res & Dev Serv, US Dept Vet Affairs, Med Ctr, Infect Dis Sect, Bldg 117,500 West Ft St, Boise, ID 83702 USA. EM amy.bryant@va.gov FU United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Program [I01BX007080]; National Institute of General Medical Sciences of the National Institutes of Health [P20GM103408] FX This work was supported in part by a Merit Review Award (#I01BX007080, A.E.B.) from the United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Program and by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant #P20GM103408. NR 51 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD JUN PY 2015 VL 28 IS 3 BP 231 EP 239 DI 10.1097/QCO.0000000000000160 PG 9 WC Infectious Diseases SC Infectious Diseases GA CH0DI UT WOS:000353688800006 PM 25918957 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Ignorance isn't bliss: why patients become angry SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE anger; cognitive deficits; decision analysis; medical practice; outcome research; threshold analysis ID ANGER AB Patients with cognitive limitations may struggle understanding complex arguments and feel overwhelmed by the need to choose among medical options that they poorly understand. Such struggle may result in frustration and anger directed at the physician. The aim of the present study is to explain the characteristics underlying such situations. A decision tree is modeled to capture the choice that every patient has to make after receiving medical advice. Patient choices are phrased in terms of a threshold probability for accepting or rejecting advice by physicians. To a patient with poor understanding of medical exigencies all differences between present or absent disease state, prognosis, and risks of intervention may seem largely arbitrary and meaningless. With little or no guidance to make an informed decision, taking any medical action is deemed wasted and harmful, whereas inaction leaves the underlying medical problem unsolved. Both choices appear equally ineffective with respect to the patient's symptoms and therefore unappealing. As shown by applying threshold analysis to a patient in a state of ignorance, no threshold probability for following medical advice exists. Patients with cognitive limitations will become frustrated and angry by a seemingly dismal situation without good alternatives to choose from. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 12 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JUN PY 2015 VL 27 IS 6 BP 619 EP 622 DI 10.1097/MEG.0000000000000323 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CH0DE UT WOS:000353688400001 PM 25769095 ER PT J AU Pasinetti, GM Wang, J Ho, L Zhao, W Dubner, L AF Pasinetti, Giulio Maria Wang, Jun Ho, Lap Zhao, Wei Dubner, Lauren TI Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Review DE Resveratrol; Alzheimer's disease; Polyphenol; SIRT1 ID MILD COGNITIVE IMPAIRMENT; ACTIVATED PROTEIN-KINASE; HUNTINGTONS-DISEASE; MOUSE MODEL; NEURODEGENERATIVE DISORDERS; AMYLOID NEUROPATHOLOGY; CALORIE RESTRICTION; SIRT1 ACTIVATION; OLDER-ADULTS; LIFE-SPAN AB Alzheimer's disease (AD) is a devastating disorder that strikes 1 in 10 Americans over the age of 65, and almost half of all Americans over 85 years old. The odds of an individual developing AD double every five years after the age of 65. While it has become increasingly common to meet heart attack or cancer survivors, there are no AD survivors. There is mounting evidence that dietary polyphenols, including resveratrol, may beneficially influence AD. Based on this consideration, several studies reported in the last few years were designed to validate sensitive and reliable translational tools to mechanistically characterize brain bioavailable polyphenols as disease-modifying agents to help prevent the onset of AD dementia and other neurodegenerative disorders. Several research groups worldwide with expertise in AD, plant biology, nutritional sciences, and botanical sciences have reported very high quality studies that ultimately provided the necessary information showing that polyphenols and their metabolites, which Come from several dietary sources, including grapes, cocoa etc., are capable of preventing AD. The ultimate goal of these studies was to provide novel strategies to prevent the disease even before the onset of clinical symptoms. The studies discussed in this review article provide support that the information gathered in the last few years of research will have a major impact on AD prevention by providing vital knowledge on the protective roles of polyphenols, including resveratrol. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (C) 2014 Elsevier B.V. All rights reserved. C1 [Pasinetti, Giulio Maria; Wang, Jun; Ho, Lap; Zhao, Wei; Dubner, Lauren] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Psychiat, New York, NY 10029 USA. [Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY 10029 USA. [Pasinetti, Giulio Maria; Wang, Jun; Ho, Lap; Zhao, Wei] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIH-NCCAM, program of the Icahn School of Mount Sinai Center of Excellence for Research in Complementary and Alternative Medicine for Alzheimer's Disease [P01AT004511-01] FX Funding was provided by the NIH-NCCAM grant P01AT004511-01 as part of a program of the Icahn School of Mount Sinai Center of Excellence for Research in Complementary and Alternative Medicine for Alzheimer's Disease (to Pasinetti). NR 83 TC 26 Z9 29 U1 8 U2 64 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 EI 0006-3002 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD JUN PY 2015 VL 1852 IS 6 SI SI BP 1202 EP 1208 DI 10.1016/j.bbadis.2014.10.006 PG 7 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA CG2FX UT WOS:000353091400011 PM 25315300 ER PT J AU Brownlow, JA Harb, GC Ross, RJ AF Brownlow, Janeese A. Harb, Gerlinde C. Ross, Richard J. TI Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Psychotherapy; Pharmacotherapy; Sleep disturbance; Insomnia; Nightmares; Post-traumatic stress disorder ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; COMBAT VETERANS; PSYCHIATRIC-DISORDERS; CHRONIC NIGHTMARES; IMAGERY REHEARSAL; DOUBLE-BLIND; ADJUNCTIVE RISPERIDONE; PROLONGED EXPOSURE; TRAUMA NIGHTMARES AB Sleep disturbances are among the most commonly endorsed symptoms of post-traumatic stress disorder (PTSD). Treatment modalities that are effective for the waking symptoms of PTSD may have limited efficacy for post-traumatic sleep problems. The aim of this review is to summarize the evidence for empirically supported and/or utilized psychotherapeutic and pharmacological treatments for post-traumatic nightmares and insomnia. While there are few controlled studies of the applicability of general sleep-focused interventions to the management of the sleep disturbances in PTSD, evidence is growing to support several psychotherapeutic and pharmacological treatments. Future investigations should include trials that combine treatments focused on sleep with treatments effective in managing the waking symptoms of PTSD. C1 [Brownlow, Janeese A.; Ross, Richard J.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Brownlow, Janeese A.; Harb, Gerlinde C.; Ross, Richard J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Brownlow, Janeese A.] Univ Penn, Behav Sleep Med Program, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. RP Brownlow, JA (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. EM brownlow@mail.med.upenn.edu FU National Research Service Award (NRSA) Fellowship from the National Heart, Lung, and Blood Institute [HL07713] FX This material is the result of work supported by a National Research Service Award (NRSA) Fellowship to a T32 to Dr. Allan Pack from the National Heart, Lung, and Blood Institute (grant number HL07713). The opinions expressed in this article do not represent those of the Department of Veterans Affairs or the U.S. Government. NR 120 TC 8 Z9 9 U1 6 U2 30 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD JUN PY 2015 VL 17 IS 6 AR 41 DI 10.1007/s11920-015-0587-8 PG 10 WC Psychiatry SC Psychiatry GA CG2YD UT WOS:000353141000004 PM 25894359 ER PT J AU Mize, TW Sundararaj, KP Leite, RS Huang, Y AF Mize, T. W. Sundararaj, K. P. Leite, R. S. Huang, Y. TI Increased and correlated expression of connective tissue growth factor and transforming growth factor beta 1 in surgically removed periodontal tissues with chronic periodontitis SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE connective tissue growth factor; gene expression; growth factors; periodontitis; transforming growth factor beta 1 ID INDUCED GINGIVAL OVERGROWTH; CREVICULAR FLUID; TGF-BETA; FIBROBLASTS; DISEASE; CELLS; CYCLOSPORINE; INFLAMMATION; MACROPHAGE; CYTOKINES AB Background and ObjectiveBoth gingival tissue destruction and regeneration are associated with chronic periodontitis, although the former overwhelms the latter. Studies have shown that transforming growth factor beta 1 (TGF-1), a growth factor largely involved in tissue regeneration and remodeling, is upregulated in chronic periodontitis. However, the gingival expression of connective tissue growth factor (CTGF or CCN2), a TGF-1-upregulated gene, in patients with periodontitis remains undetermined. Although both CTGF/CCN2 and TGF-b1 increase the production of extracellular matrix, they have many different biological functions. Therefore, it is important to delineate the impact of periodontitis on gingival CTGF/CCN2 expression. Material and MethodsPeriodontal tissue specimens were collected from seven individuals without periodontitis (group 1) and from 14 with periodontitis (group 2). The expression of CTGF and TGF1mRNAs were quantified using real-time PCR. ResultsAnalysis using the nonparametric Mann-Whitney U-test showed that the levels of expression of both CTGF/CCN2 and TGF1 mRNAs were significantly increased in individuals with periodontitis compared with individuals without periodontitis. Furthermore, analysis using a nonparametric correlation (Spearman r) test showed a positive correlation between TGF1 and CTGF/CCN2mRNAs. ConclusionThe gingival expression levels of CTGF/CCN2 and TGF1mRNAs in individuals with periodontitis are upregulated and correlated. C1 [Mize, T. W.; Leite, R. S.] Med Univ S Carolina, Div Periodont, James B Edwards Coll Dent Med, Charleston, SC 29425 USA. [Sundararaj, K. P.; Huang, Y.] Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Coll Med, Charleston, SC 29425 USA. [Leite, R. S.] James B Edwards Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC USA. [Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Huang, Y (reprint author), Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, 114 Doughty St, Charleston, SC 29425 USA. EM huangyan@musc.edu FU NIH [DE016353]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX This work was supported by NIH grant DE016353 and Merit Review Grant from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (to Y.H.). NR 27 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3484 EI 1600-0765 J9 J PERIODONTAL RES JI J. Periodont. Res. PD JUN PY 2015 VL 50 IS 3 BP 315 EP 319 DI 10.1111/jre.12208 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA CG7VE UT WOS:000353513000003 PM 25040058 ER PT J AU Lytle, MC De Luca, SM Blosnich, JR Brownson, C AF Lytle, Megan C. De Luca, Susan M. Blosnich, John R. Brownson, Chris TI Associations of racial/ethnic identities and religious affiliation with suicidal ideation among lesbian, gay, bisexual, and questioning individuals SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; LGBT; Race/ethnicity; Religious affiliation ID UNITED-STATES 1991-1992; COLLEGE-STUDENTS; MENTAL-HEALTH; YOUNG-ADULTS; INTERSECTING IDENTITIES; SEXUAL ORIENTATION; AFRICAN-AMERICAN; USE DISORDERS; RISK-FACTORS; SELF-HARM AB Background: Our aim was to examine the associations of racial/ethnic identity and religious affiliation with suicidal ideation among lesbian, gay, bisexual, and questioning (LGBQ) and heterosexual college students. An additional aim was to determine the prevalence of passive suicidal ideation (i.e., death ideation) and active suicidal ideation among culturally diverse LGBQ individuals. Methods: Data from the National Research Consortium probability-based sample of college students from 70 postsecondary institutions (n=24,626) were used to examine active and passive suicidal ideation in the past 12-months and lifetime active suicidal ideation among students by sexual orientation, racial/ethnic identity, and religious affiliation. Results: Across most racial/ethnic groups and religious affiliations. LGBQ students were more likely to report active suicidal ideation than non-LGBQ individuals. Among LGBQ students, Latino individuals had lower odds of reporting both past 12-month passive and active suicidal ideation than their non-Hispanic white LGBQ counterparts. Compared to Christian LGBQ students, Agnostic/Atheist LGBQ individuals had greater odds of reporting past 12-month passive suicidal ideation, and Jewish LGBQ students were less likely to endorse past 12-month passive and active suicidal ideation. Limitations: Cross-sectional design and self-reported data. Conclusions: Results corroborate previous research showing elevated prevalence of suicidal ideation among LGBQ individuals in comparison to their heterosexual counterparts. These findings are among the first to document prevalence differences within the LGBQ population based on intersectional identities (race/ethnicity and religious affiliation). Providers should recognize that LGBQ individuals might need support in negotiating the complex relationship between multiple identities, especially due to their elevated prevalence of suicidal ideation. (C) 2015 Elsevier B.V. All rights reserved. C1 [Lytle, Megan C.] Univ Rochester, Dept Psychiat, Med Ctr, Rochester, NY 14642 USA. [De Luca, Susan M.] Univ Texas Austin, Sch Social Work, Austin, TX 78712 USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Brownson, Chris] Univ Texas Austin, Counseling & Mental Hlth Ctr, Austin, TX 78712 USA. RP Lytle, MC (reprint author), Univ Rochester, Dept Psychiat, Med Ctr, 300 Crittcndcn Blvd, Rochester, NY 14642 USA. EM megan_lytle@unnc.rochester.edu FU National Institute of Mental Health [5T32MH020061]; University of Rochester CTSA from the National Center for Advancing Translational Sciences of the National Institutes of Health [KL2TR000095] FX The project described in this publication was supported partially by postdoctoral fellowships to Megan C. Lytle and John Blosnich in an Institutional National Research Service Award from the National Institute of Mental Health (5T32MH020061). Dr. Lytle has also received support front the University of Rochester CTSA Award number KL2TR000095 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The opinions expressed in this work are those of the authors and do not necessarily represent those of the finders, institutions, the Department of Veterans Affairs, or the U.S. Government. NR 50 TC 1 Z9 1 U1 2 U2 29 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUN 1 PY 2015 VL 178 BP 39 EP 45 DI 10.1016/j.jad.2014.07.039 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CF7DO UT WOS:000352716600007 PM 25795534 ER PT J AU Hepworth, MR Fung, TC Masur, SH Kelsen, JR McConnell, FM Dubrot, J Withers, DR Hugues, S Farrar, MA Reith, W Eberl, G Baldassano, RN Laufer, TM Elson, CO Sonnenberg, GF AF Hepworth, Matthew R. Fung, Thomas C. Masur, Samuel H. Kelsen, Judith R. McConnell, Fiona M. Dubrot, Juan Withers, David R. Hugues, Stephanie Farrar, Michael A. Reith, Walter Eberl, Gerard Baldassano, Robert N. Laufer, Terri M. Elson, Charles O. Sonnenberg, Gregory F. TI Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells SO SCIENCE LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASS-II TRANSACTIVATOR; NEGATIVE SELECTION; DENDRITIC CELLS; IMMUNE-SYSTEM; PROMOTER-IV; HOMEOSTASIS; MICROBIOTA; RESPONSES; EXPRESSION AB Inflammatory CD4(+) T cell responses to self or commensal bacteria underlie the pathogenesis of autoimmunity and inflammatory bowel disease (IBD), respectively. Although selection of self-specific T cells in the thymus limits responses to mammalian tissue antigens, the mechanisms that control selection of commensal bacteria-specific T cells remain poorly understood. Here, we demonstrate that group 3 innate lymphoid cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is regulated similarly to thymic epithelial cells and that MHCII+ ILC3s directly induce cell death of activated commensal bacteria-specific T cells. Further, MHCII on colonic ILC3s was reduced in pediatric IBD patients. Collectively, these results define a selection pathway for commensal bacteria-specific CD4(+) T cells in the intestine and suggest that this process is dysregulated in human IBD. C1 [Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA. [Hepworth, Matthew R.; Fung, Thomas C.; Sonnenberg, Gregory F.] Cornell Univ, Dept Microbiol & Immunol, Weill Cornell Med Coll, New York, NY 10021 USA. [Fung, Thomas C.; Laufer, Terri M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Masur, Samuel H.; Kelsen, Judith R.; Baldassano, Robert N.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA. [McConnell, Fiona M.; Withers, David R.] Univ Birmingham, MRC, Coll Med & Dent Sci, Ctr Immune Regulat, Birmingham, W Midlands, England. [Hugues, Stephanie; Reith, Walter] Univ Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva, Switzerland. [Farrar, Michael A.] Univ Minnesota, Ctr Immunol, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Eberl, Gerard] Inst Pasteur, Microenvironm & Immun Unit, Paris, France. [Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Elson, Charles O.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Elson, Charles O.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. RP Sonnenberg, GF (reprint author), Cornell Univ, Jill Roberts Inst Res Inflammatory Bowel Dis, Joan & Sanford I Weill Dept Med, Div Gastroenterol, New York, NY 10021 USA. EM gfsonnenberg@med.cornell.edu RI Withers, David/C-7055-2015 OI Withers, David/0000-0003-3757-7594 FU National Institutes of Health [DP5OD012116, DK071176]; National Institute of Allergy and Infectious Diseases Mucosal Immunology Studies Team (MIST) Scholar Award in Mucosal Immunity; Institute for Translational Medicine and Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics (from the U.S. National Center for Research Resources) [UL1-RR024134]; Crohn's and Colitis Foundation of America (CCFA) [297365]; Cancer Research Institute Student Training and Research in Tumor immunology (STaRT) grant; Wellcome Trust Research Career Development Fellowship FX The authors thank members of the Sonnenberg laboratory for discussions and critical reading of the manuscript. We thank C. Hunter and S. Wagage (University of Pennsylvania) for the Ahr-deficient mice; I. Brodsky (University of Pennsylvania) for the Caspase 1/11-deficient mice; and M. Jenkins, J. Walter, and T. Dileepan (University of Minnesota) for tetramer reagents and protocols. Data presented in this manuscript are tabulated in the main paper and in the supplementary materials. Microarray data are accessible at Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) via accession number GSE67076. CBir1 Tg mice are available from University of Alabama, Rorc(gamma t)-GfpTG and RorcCre mice are available from Institut Pasteur, STAT5-CA mice are available from University of Minnesota, IAbbSTOPfl/fl mice and CD11c Tg mice are available from University of Pennsylvania, and Il23a deficient mice are available from Janssen Research and Development LLC, all under Material Transfer Agreement. Research in the Sonnenberg laboratory is supported by the National Institutes of Health (DP5OD012116), the National Institute of Allergy and Infectious Diseases Mucosal Immunology Studies Team (MIST) Scholar Award in Mucosal Immunity, and the Institute for Translational Medicine and Therapeutics Transdisciplinary Program in Translational Medicine and Therapeutics (UL1-RR024134 from the U.S. National Center for Research Resources). M.R.H. is supported by a research fellowship from the Crohn's and Colitis Foundation of America (CCFA, no. 297365). T.C.F. is supported by a Cancer Research Institute Student Training and Research in Tumor immunology (STaRT) grant. D.R.W. is supported by a Wellcome Trust Research Career Development Fellowship. C.O.E. is supported by the National Institutes of Health (DK071176). NR 41 TC 60 Z9 64 U1 10 U2 34 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD MAY 29 PY 2015 VL 348 IS 6238 BP 1031 EP 1035 DI 10.1126/science.aaa4812 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ1WU UT WOS:000355276600048 PM 25908663 ER PT J AU Halpern, SD French, B Small, DS Saulsgiver, K Harhay, MO Audrain-McGovern, J Loewenstein, G Brennan, TA Asch, DA Volpp, KG AF Halpern, Scott D. French, Benjamin Small, Dylan S. Saulsgiver, Kathryn Harhay, Michael O. Audrain-McGovern, Janet Loewenstein, George Brennan, Troyen A. Asch, David A. Volpp, Kevin G. TI Randomized Trial of Four Financial-Incentive Programs for Smoking Cessation SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INSTRUMENTAL VARIABLES; ADAPTIVE DESIGNS; COLLECTIVE DYNAMICS; CLINICAL-TRIALS; WEIGHT-LOSS; BEHAVIOR; THERAPY; HEALTH; PAY; DEPENDENCE AB BACKGROUND Financial incentives promote many health behaviors, but effective ways to deliver health incentives remain uncertain. METHODS We randomly assigned CVS Caremark employees and their relatives and friends to one of four incentive programs or to usual care for smoking cessation. Two of the incentive programs targeted individuals, and two targeted groups of six participants. One of the individual-oriented programs and one of the group-oriented programs entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care included informational resources and free smoking-cessation aids. RESULTS Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted the assignment, as compared with 13.7% of those assigned to deposit-based programs (P<0.001). In intention-to-treat analyses, rates of sustained abstinence from smoking through 6 months were higher with each of the four incentive programs (range, 9.4 to 16.0%) than with usual care (6.0%) (P<0.05 for all comparisons); the superiority of reward-based programs was sustained through 12 months. Group-oriented and individual-oriented programs were associated with similar 6-month abstinence rates (13.7% and 12.1%, respectively; P = 0.29). Reward-based programs were associated with higher abstinence rates than deposit-based programs (15.7% vs. 10.2%, P<0.001). However, in instrumental-variable analyses that accounted for differential acceptance, the rate of abstinence at 6 months was 13.2 percentage points (95% confidence interval, 3.1 to 22.8) higher in the deposit-based programs than in the reward-based programs among the estimated 13.7% of the participants who would accept participation in either type of program. CONCLUSIONS Reward-based programs were much more commonly accepted than deposit-based programs, leading to higher rates of sustained abstinence from smoking. Group-oriented incentive programs were no more effective than individual-oriented programs. (Funded by the National Institutes of Health and CVS Caremark; ClinicalTrials.gov number, NCT01526265.) C1 [Halpern, Scott D.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Saulsgiver, Kathryn; Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Halpern, Scott D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Audrain-McGovern, Janet] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Halpern, Scott D.; French, Benjamin; Small, Dylan S.; Saulsgiver, Kathryn; Audrain-McGovern, Janet; Loewenstein, George; Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Equ Res & Promot, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn Hlth Syst, Ctr Hlth Care Innovat, Philadelphia, PA USA. [Loewenstein, George] Carnegie Mellon Univ, Ctr Behav Decis Res, Pittsburgh, PA 15213 USA. [Brennan, Troyen A.] CVS Caremark, Woonsocket, RI USA. RP Halpern, SD (reprint author), Univ Penn, Perelman Sch Med, 719 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu FU NCI NIH HHS [R01 CA159932]; NIA NIH HHS [RC2 AG036592] NR 45 TC 55 Z9 56 U1 5 U2 26 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 28 PY 2015 VL 372 IS 22 BP 2108 EP 2117 DI 10.1056/NEJMoa1414293 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0EI UT WOS:000355146800006 PM 25970009 ER PT J AU Khalil, HA Lei, NY Nie, WX Lewis, MS Stelzner, MG Martin, MG Dunn, JCY Yoo, J AF Khalil, Hassan A. Lei, Nan Ye Nie, Wenxian Lewis, Michael S. Stelzner, Matthias G. Martin, Martin G. Dunn, James C. Y. Yoo, James TI Primary Myofibroblasts Maintain Short-Term Viability following Submucosal Injection in Syngeneic, Immune-Competent Mice Utilizing Murine Colonoscopy SO PLOS ONE LA English DT Article ID HUMAN COLONIC MYOFIBROBLASTS; TNF-ALPHA; EXPRESSION; MODELS; COX-2; EGFR AB The myofibroblast is an important stromal cell of the gastrointestinal tract. Current in vitro and in vivo models either do not accurately recreate stromal-epithelial interactions or are not specific to myofibroblasts. We sought to create an animal model that would allow the study of myofibroblast-epithelial interactions. We isolated and cultured colonic myofibroblasts from FVB mice. Cells were alpha-SMA and vimentin positive but desmin negative on immunoblot analysis. We injected the myofibroblasts into the colonic submucosa of syngeneic adult mice (n = 8) via a miniendoscopic system. We then isolated green fluorescent protein (GFP) positive colonic myofibroblasts from C57BL/6-Tg(CAG-EGFP) 1Osb/Jmice and injected them into the colonic lamina propria of C57BL/6J mice at 1x10(5) (n = 14), 1x10(6) (n = 9), or 5x10(6) cells/mL (n = 4). A subset of mice were injected with serum-free media and ink without cells (n = 3). Mice underwent repeat endoscopy and euthanasia one or 7 days after injection. Colons were isolated and either fixed in 10% formalin or the inked sites were individually excised and lysed for DNA. We assessed the injection sites via histology and immunohistochemical stains for alpha-SMA and GFP. We used qPCR to quantify GFP DNA transcripts at the lamina propria injection sites. Submucosal injection ofmyofibroblasts resulted in the formation of a subepithelial wheal on endoscopy, which persisted to day 7. Myofibroblasts injected either into the submucosa or lamina propria maintained viability on post-injection day 7 as evidenced by positive alpha-SMA staining. qPCR of lamina propria injections showed a dose-dependent increase in GFP DNA transcripts on post-injection day 1, whereas the number of transcripts on day 7 was equivalent for the concentrations injected. We demonstrate short-term survival of primary cultured colonic myofibroblasts in syngeneic mice. This may prove to be a valuable model for studying the role ofmyofibroblasts in states of health and disease. C1 [Khalil, Hassan A.; Lei, Nan Ye; Nie, Wenxian; Stelzner, Matthias G.; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lewis, Michael S.] VA Greater Los Angeles Hlth Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Stelzner, Matthias G.] VA Greater Los Angeles Hlth Syst, Dept Surg, Los Angeles, CA USA. [Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90024 USA. [Yoo, James] Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA. RP Yoo, J (reprint author), Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA. EM JYoo@tuftsmedicalcenter.org OI Khalil, Hassan/0000-0002-3835-1290 FU National Institutes of Health K08 award [DK085136-03]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases [DK085535] FX This project was funded by a National Institutes of Health K08 award #DK085136-03 (JY), and was performed as a project of the Intestinal Stem Cell Consortium (https://iscc.coh.org), a collaborative research project funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases #DK085535 (MGM, JCYD, MS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 15 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 27 PY 2015 VL 10 IS 5 AR e0127258 DI 10.1371/journal.pone.0127258 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ0RO UT WOS:000355185600077 PM 26016485 ER PT J AU Case, MA Volpp, KG Patel, MS AF Case, Meredith A. Volpp, Kevin G. Patel, Mitesh S. TI Electronic Devices and Applications to Track Physical Activity Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Case, Meredith A.] Univ Penn, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Case, MA (reprint author), Univ Penn, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 3 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 26 PY 2015 VL 313 IS 20 BP 2080 EP 2080 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0DC UT WOS:000355142400029 PM 26010644 ER PT J AU Filley, CM Brown, MS Onderko, K Ray, M Bennett, RE Berry-Kravis, E Grigsby, J AF Filley, Christopher M. Brown, Mark S. Onderko, Karen Ray, Megan Bennett, Rachael E. Berry-Kravis, Elizabeth Grigsby, Jim TI White matter disease and cognitive impairment in FMR1 premutation carriers SO NEUROLOGY LA English DT Article ID TREMOR/ATAXIA SYNDROME FXTAS; VOXEL-BASED ANALYSIS; PHENOTYPE; DEMENTIA; DYSFUNCTION; INSIGHTS; MALES AB Objective:This cross-sectional, observational study examined the role of white matter involvement in the cognitive impairment of individuals with the fragile X mental retardation 1 (FMR1) premutation.Methods:Eight asymptomatic premutation carriers, 5 participants with fragile X tremor/ataxia syndrome (FXTAS), and 7 noncarrier controls were studied. The mean age of the asymptomatic premutation carriers, participants with FXTAS, and noncarrier controls was 60, 71, and 67 years, respectively. Magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) were used to examine the middle cerebellar peduncles (MCP) and the genu and splenium of the corpus callosum in relation to executive function and processing speed. MRS measures were N-acetyl aspartate/creatine (NAA/Cr) and choline/creatine, and fractional anisotropy (FA) was used for DTI. Executive function was assessed with the Behavioral Dyscontrol Scale and the Controlled Oral Word Association Test (COWAT), and processing speed with the Symbol Digit Modalities Test.Results:Among all 13 FMR1 premutation carriers, significant correlations were found between N-acetyl aspartate/creatine and choline/creatine in the MCP and COWAT scores, and between FA in the genu and performance on the Behavioral Dyscontrol Scale, COWAT, and Symbol Digit Modalities Test; a correlation was also found between FA in the splenium and COWAT performance. In all regions studied, participants with FXTAS had the lowest mean FA.Conclusion:Microstructural white matter disease as determined by MRS and DTI correlated with executive dysfunction and slowed processing speed in these FMR1 premutation carriers. Neuroimaging abnormalities in the genu and MCP suggest that disruption of white matter within frontocerebellar networks has an important role in the cognitive impairment associated with the FMR1 premutation. C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA. [Filley, Christopher M.] Univ Colorado, Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Brown, Mark S.] Univ Colorado, Sch Med, Dept Radiol, Boulder, CO 80309 USA. [Bennett, Rachael E.; Grigsby, Jim] Univ Colorado, Sch Med, Dept Med, Boulder, CO 80309 USA. [Onderko, Karen; Ray, Megan; Grigsby, Jim] Univ Colorado Denver, Dept Psychol, Denver, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Pediat, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. RP Filley, CM (reprint author), Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA. EM christopher.filley@ucdenver.edu FU Strategic Initiative Review Committee of the University of Colorado School of Medicine FX Funded by the Strategic Initiative Review Committee of the University of Colorado School of Medicine. NR 34 TC 9 Z9 9 U1 4 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 26 PY 2015 VL 84 IS 21 BP 2146 EP 2152 DI 10.1212/WNL.0000000000001612 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CJ2LT UT WOS:000355317000014 PM 25925982 ER PT J AU de Figueiredo, ASP Salmon, AB Bruno, F Jimenez, F Martinez, HG Halade, GV Ahuja, SS Clark, RA DeFronzo, RA Abboud, HE El Jamali, A AF de Figueiredo, Alvaro Souto Padron Salmon, Adam B. Bruno, Francesca Jimenez, Fabio Martinez, Herman G. Halade, Ganesh V. Ahuja, Seema S. Clark, Robert A. DeFronzo, Ralph A. Abboud, Hanna E. El Jamali, Amina TI Nox2 Mediates Skeletal Muscle Insulin Resistance Induced by a High Fat Diet SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NADPH OXIDASE ACTIVITY; ELECTRON-TRANSPORT; DIABETES-MELLITUS; OXIDATIVE STRESS; PLASMA-MEMBRANE; NAD(P)H OXIDASE; L6 MYOTUBES; GLUCOSE; GLUT4; DYSFUNCTION AB Inflammation and oxidative stress through the production of reactive oxygen species (ROS) are consistently associated with metabolic syndrome/type 2 diabetes. Although the role of Nox2, a major ROS-generating enzyme, is well described in host defense and inflammation, little is known about its potential role in insulin resistance in skeletal muscle. Insulin resistance induced by a high fat diet was mitigated in Nox2-null mice compared with wild-type mice after 3 or 9 months on the diet. High fat feeding increased Nox2 expression, superoxide production, and impaired insulin signaling in skeletal muscle tissue of wild-type mice but not in Nox2-null mice. Exposure of C2C12 cultured myotubes to either high glucose concentration, palmitate, or H2O2 decreases insulin-induced Akt phosphorylation and glucose uptake. Pretreatment with catalase abrogated these effects, indicating a key role for H2O2 in mediating insulin resistance. Down-regulation of Nox2 in C2C12 cells by shRNA prevented insulin resistance induced by high glucose or palmitate but not H2O2. These data indicate that increased production of ROS in insulin resistance induced by high glucose in skeletal muscle cells is a consequence of Nox2 activation. This is the first report to show that Nox2 is a key mediator of insulin resistance in skeletal muscle. C1 [de Figueiredo, Alvaro Souto Padron; Bruno, Francesca; Jimenez, Fabio; Martinez, Herman G.; Halade, Ganesh V.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.; El Jamali, Amina] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Salmon, Adam B.] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Salmon, Adam B.; Ahuja, Seema S.; Clark, Robert A.; DeFronzo, Ralph A.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX 78229 USA. RP El Jamali, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM AkoulouzeBik@uthscsa.edu RI Regan, Clinton/E-6250-2012 FU National Institutes of Health [P30 CA054174, P30 AG013319, P01 AG019316] FX The confocal microscopy studies were performed in the Institutional Optical Imaging Facility of the University of Texas Health Science Center at San Antonio, which is supported by National Institutes of Health Grants P30 CA054174 (Cancer Therapy and Research Center), P30 AG013319 (Nathan Shock Center), and P01 AG019316 (Aging, Oxidative Stress, and Cell Death). We thank Drs. Alain Virion for helpful discussions, Dr. John Cornell for insightful advice on statistical analysis, Dr. James Lechleiter for expert guidance on the confocal microscope image acquisition and analysis, and Yimin Wu, Maria Gamez, and Jacob Crandall for expert technical assistance. NR 48 TC 10 Z9 10 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 22 PY 2015 VL 290 IS 21 BP 13427 EP 13439 DI 10.1074/jbc.M114.626077 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CI7WL UT WOS:000354975700038 ER PT J AU Burton, MJ Curtis, JR Yang, S Chen, L Singh, JA Mikuls, TR Winthrop, KL Baddley, JW AF Burton, Mary Jane Curtis, Jeffrey R. Yang, Shuo Chen, Lang Singh, Jasvinder A. Mikuls, Ted R. Winthrop, Kevin L. Baddley, John W. TI Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID LONG-TERM SAFETY; IMMUNOSUPPRESSIVE THERAPY; POSITIVE PATIENTS; OCCULT CARRIERS; REACTIVATION; RECOMMENDATIONS; HEPATOTOXICITY; MANAGEMENT; ANTIGEN; RISK AB Introduction: We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort. Methods: We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data from the US Veterans Health Administration. Eligible episodes had evidence of HBV infection (HBV surface antigen, HBV core antibody, HBV e-antibody and/or HBV DNA) and had a baseline alanine aminotransferase (ALT) < 1.5 times the upper limit of laboratory normal within 90 days prior to initiation of a new biologic or nonbiologic DMARD. The main outcome of interest was hepatotoxicity, defined as ALT elevation > 100 IU/mL. Results were reported as the cumulative incidence of treatment episodes achieving hepatotoxicity at 3, 6 and 12 months post biologic exposure. Results: Five hundred sixty-six unique RA patients with HBV contributed 959 treatment episodes. Mean age was 62.1 +/- 10.3 years; 91.8% were male. Hepatotoxicity was uncommon, with 26 events identified among 959 episodes (2.7%) within 12 months. Hepatotoxicity was comparable between biologic and nonbiologic DMARDs (2.6% vs. 2.8%, P = 0.87). The median time between HBV screening and starting a new RA drug was 504 days (IQR 144, 1,163). Follow-up HBV testing occurred among 14 hepatotoxicity episodes (53.8%) at a median of 202 days (IQR 82, 716) from the date of ALT elevation. A total of 146 (15.2%) treatment episodes received at least one test for HBV DNA at any point in the observation period. Conclusions: Among US veterans with RA and HBV the risk of hepatotoxicity is low (2.7%), and comparable between biologic and nonbiologic DMARDS (2.8% vs. 2.6%, P = 0.87). HBV testing associated with DMARD initiation or hepatotoxicity was infrequent. C1 [Burton, Mary Jane] GV Sonny Montgomery VA Med Ctr, Jackson, MS 39216 USA. [Burton, Mary Jane] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Birmingham VAMC, Birmingham, AL 35233 USA. [Curtis, Jeffrey R.; Yang, Shuo; Chen, Lang; Singh, Jasvinder A.; Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL 35233 USA. [Mikuls, Ted R.] UNMC, Omaha VAMC, Omaha, NE 68105 USA. [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Burton, MJ (reprint author), GV Sonny Montgomery VA Med Ctr, 1500 E Woodrow Wilson Ave, Jackson, MS 39216 USA. EM Mary.burton2@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Bristol Myers Squibb; Veterans Affairs Clinical Science Research and Development (VA CSRD) [1IK2CX00536]; Agency for Healthcare Research and Quality (AHRQ) [R01 HS018517]; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient-Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; VA CSR&D Merit Review Awards FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development as well as an investigator-initiated grant from Bristol Myers Squibb. Dr. Burton's work was supported by Veterans Affairs Clinical Science Research and Development (VA CSR&D) (Grant 1IK2CX00536, PI-Burton). Dr. Curtis was supported by the Agency for Healthcare Research and Quality (AHRQ) (R01 HS018517). Dr. Singh is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Mikuls is supported by VA CSR&D Merit Review Awards. Funding organizations did not contribute to study design, data collection, data analysis and interpretation, or manuscript preparation and submission. NR 35 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD MAY 22 PY 2015 VL 17 AR 136 DI 10.1186/s13075-015-0628-z PG 9 WC Rheumatology SC Rheumatology GA CI7UU UT WOS:000354971100001 PM 26001631 ER PT J AU Grytdal, SP Rimland, D Shirley, SH Rodriguez-Barradas, MC Goetz, MB Brown, ST Lucero-Obusan, C Holodniy, M Graber, C Parashar, U Vinje, J Lopman, B AF Grytdal, Scott P. Rimland, David Shirley, S. Hannah Rodriguez-Barradas, Maria C. Goetz, Matthew Bidwell Brown, Sheldon T. Lucero-Obusan, Cynthia Holodniy, Mark Graber, Christopher Parashar, Umesh Vinje, Jan Lopman, Ben TI Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012 SO PLOS ONE LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; SURVEILLANCE; COMMUNITY; ENGLAND; DEATHS AB An estimated 179 million acute gastroenteritis (AGE) illnesses occur annually in the United States. The role of noroviruses in hospital-related AGE has not been well-documented in the U. S. We estimated the population incidence of community-acquired outpatient and inpatient norovirus AGE encounters, as well as hospital-acquired inpatient norovirus AGE among inpatients at four Veterans Affairs (VA) Medical Centers (VAMCs). Fifty (4%) of 1,160 stool specimens collected <= 7 days from symptom onset tested positive for norovirus. During a one year period, the estimated incidence of outpatient, community-and hospital-acquired inpatient norovirus AGE was 188 cases, 11 cases, and 54 cases/100,000 patients, respectively. This study demonstrates the incidence of outpatient and community- and hospital-acquired inpatient norovirus AGE among the VA population seeking care at these four VAMCs. C1 [Grytdal, Scott P.; Shirley, S. Hannah; Parashar, Umesh; Vinje, Jan; Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Washington, DC USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Palo Alto, CA USA. [Holodniy, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Grytdal, SP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM spgrytdal@cdc.gov OI Goetz, Matthew/0000-0003-4542-992X FU Centers for Disease Control and Prevention FX Funding provided by Centers for Disease Control and Prevention. The funders participated in the study design, data analysis, decision to publish, and preparation of the manuscript. NR 17 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 21 PY 2015 VL 10 IS 5 AR e0126733 DI 10.1371/journal.pone.0126733 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK7VW UT WOS:000356444000030 PM 25996826 ER PT J AU Sawyer, RG Claridge, JA Nathens, AB Rotstein, OD Duane, TM Evans, HL Cook, CH O'Neill, PJ Mazuski, JE Askari, R Wilson, MA Napolitano, LM Namias, N Miller, PR Dellinger, EP Watson, CM Coimbra, R Dent, DL Lowry, SF Cocanour, CS West, MA Banton, KL Cheadle, WG Lipsett, PA Guidry, CA Popovsky, K AF Sawyer, R. G. Claridge, J. A. Nathens, A. B. Rotstein, O. D. Duane, T. M. Evans, H. L. Cook, C. H. O'Neill, P. J. Mazuski, J. E. Askari, R. Wilson, M. A. Napolitano, L. M. Namias, N. Miller, P. R. Dellinger, E. P. Watson, C. M. Coimbra, R. Dent, D. L. Lowry, S. F. Cocanour, C. S. West, M. A. Banton, K. L. Cheadle, W. G. Lipsett, P. A. Guidry, C. A. Popovsky, K. TI Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID ANTIBIOTIC-THERAPY; CHILDREN GUIDELINES; DISEASES SOCIETY; RANDOMIZED-TRIAL; MANAGEMENT; MORTALITY; SEPSIS; ADULTS; DIAGNOSIS; BACTERIAL AB BACKGROUND The successful treatment of intraabdominal infection requires a combination of anatomical source control and antibiotics. The appropriate duration of antimicrobial therapy remains unclear. METHODS We randomly assigned 518 patients with complicated intraabdominal infection and adequate source control to receive antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, with a maximum of 10 days of therapy (control group), or to receive a fixed course of antibiotics (experimental group) for 4 +/- 1 calendar days. The primary outcome was a composite of surgical-site infection, recurrent intraabdominal infection, or death within 30 days after the index source-control procedure, according to treatment group. Secondary outcomes included the duration of therapy and rates of subsequent infections. RESULTS Surgical-site infection, recurrent intraabdominal infection, or death occurred in 56 of 257 patients in the experimental group (21.8%), as compared with 58 of 260 patients in the control group (22.3%) (absolute difference, -0.5 percentage point; 95% confidence interval [CI], -7.0 to 8.0; P = 0.92). The median duration of antibiotic therapy was 4.0 days (interquartile range, 4.0 to 5.0) in the experimental group, as compared with 8.0 days (interquartile range, 5.0 to 10.0) in the control group (absolute difference, -4.0 days; 95% CI, -4.7 to -3.3; P<0.001). No significant between-group differences were found in the individual rates of the components of the primary outcome or in other secondary outcomes. CONCLUSIONS In patients with intraabdominal infections who had undergone an adequate source-control procedure, the outcomes after fixed-duration antibiotic therapy (approximately 4 days) were similar to those after a longer course of antibiotics (approximately 8 days) that extended until after the resolution of physiological abnormalities. C1 [Sawyer, R. G.; Guidry, C. A.; Popovsky, K.] Univ Virginia Hlth Syst, Dept Surg, Charlottesville, VA 22908 USA. [Duane, T. M.] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA. [Claridge, J. A.] Case Western Reserve Univ, Dept Surg, Cleveland, OH 44106 USA. [Nathens, A. B.; Rotstein, O. D.] Univ Toronto, Dept Surg, Toronto, ON, Canada. [Evans, H. L.; Dellinger, E. P.] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Cook, C. H.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA. [Askari, R.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [O'Neill, P. J.] Maricopa Integrated Hlth Syst, Dept Surg, Phoenix, AZ USA. [Mazuski, J. E.] Washington Univ, Dept Surg, St Louis, MO USA. [Wilson, M. A.] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA. [Napolitano, L. M.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Namias, N.] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA. [Miller, P. R.] Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA. [Watson, C. M.] Univ S Carolina, Dept Surg, Columbia, SC 29208 USA. [Coimbra, R.] Univ Calif San Diego, San Diego, CA 92103 USA. [Cocanour, C. S.] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA. [West, M. A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Dent, D. L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Lowry, S. F.] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA. [Banton, K. L.] Univ Minnesota, Sch Med, Dept Surg, Minneapolis, MN 55455 USA. [Cheadle, W. G.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40292 USA. [Lipsett, P. A.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. RP Sawyer, RG (reprint author), Univ Virginia Hlth Syst, Dept Surg, Box 800709, Charlottesville, VA 22908 USA. EM rws2k@virginia.edu FU National Institutes of Health [R01GM081510, T32 AI078875]; 3M; Pfizer; Bayer; Merck; AstraZeneca; Baxter; Ortho-McNeil; Targanta Therapeutics; Schering-Plough; Astellas; CareFusion; Durata Therapeutics; Rib-X Pharmaceuticals; Affinium Pharmaceuticals; Tetraphase Pharmaceuticals; R-Pharm; Applied Medical FX Supported by grants (R01GM081510 and T32 AI078875) from the National Institutes of Health.; Dr. Sawyer reports receiving consulting fees from 3M and Pfizer; Dr. Duane, lecture fees from Pfizer; Dr. O'Neill, fees for serving on a surgical review panel for Cubist; Dr. Mazuski, fees for serving on advisory boards from AstraZeneca, Cubist, Merck, and Pfizer, consulting fees from Bayer, lecture fees from Merck, and grant support from AstraZeneca, Bayer, Merck, and Pfizer; and Dr. Dellinger, fees for serving on advisory boards from Merck, Baxter, Ortho-McNeil, Targanta Therapeutics, Schering-Plough, Astellas, CareFusion, Durata Therapeutics, Pfizer, Rib-X Pharmaceuticals, Affinium Pharmaceuticals, Tetraphase Pharmaceuticals, and R-Pharm, and lecture fees from Applied Medical. No other potential conflict of interest relevant to this article was reported. NR 18 TC 82 Z9 87 U1 0 U2 12 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 1996 EP 2005 DI 10.1056/NEJMoa1411162 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300006 PM 25992746 ER PT J AU Olfson, M Druss, BG Marcus, SC AF Olfson, Mark Druss, Benjamin G. Marcus, Steven C. TI Trends in Mental Health Care among Children and Adolescents SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID PSYCHOSOCIAL TREATMENTS; IMPAIRMENT; DEPRESSION; MEDICATION; DISORDER; AMERICANS AB BACKGROUND Increasing mental health treatment of young people and broadening conceptualizations of psychopathology have triggered concerns about a disproportionate increase in the treatment of youths with low levels of mental health impairment. METHODS We analyzed the 1996-1998, 2003-2005, and 2010-2012 Medical Expenditure Panel Surveys, which were nationally representative surveys of U.S. households, for trends in outpatient use of mental health services by persons 6 to 17 years of age; 53,622 persons were included in the analysis. Mental health impairment was measured with the use of the Columbia Impairment Scale (range, 0 to 52, with higher scores indicating more severe impairment); we classified youths with scores of 16 or higher as having more severe impairment and those with scores of less than 16 as having less severe impairment. RESULTS The percentage of youths receiving any outpatient mental health service increased from 9.2% in 1996-1998 to 13.3% in 2010-2012 (odds ratio, 1.52; 95% confidence interval, 1.35 to 1.72). The proportionate increase in the use of mental health services among youths with more severe impairment (from 26.2% to 43.9%) was larger than that among youths with less severe or no impairment (from 6.7% to 9.6%). However, the absolute increase in annual service use was larger among youths with less severe or no impairment (from 2.74 million to 4.19 million) than among those with more severe impairment (from 1.56 million to 2.28 million). Significant overall increases occurred in the use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including stimulants and related medications (from 4.0% to 6.6%), antidepressants (from 1.5% to 2.6%), and antipsychotic drugs (from 0.2% to 1.2%). CONCLUSIONS Outpatient mental health treatment and psychotropic-medication use in children and adolescents increased in the United States between 1996-1998 and 2010-2012. Although youths with less severe or no impairment accounted for most of the absolute increase in service use, youths with more severe impairment had the greatest relative increase in use, yet fewer than half accessed services in 2010-2012. C1 [Olfson, Mark] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY 10032 USA. [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Druss, Benjamin G.] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Practice & Policy, Philadelphia, PA 19104 USA. RP Olfson, M (reprint author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, Coll Phys & Surg, 1051 Riverside Dr, New York, NY 10032 USA. EM mo49@cumc.columbia.edu FU Agency for Healthcare Research and Quality [U19 HS021112]; New York State Psychiatric Institute FX Supported by a grant (U19 HS021112) from the Agency for Healthcare Research and Quality and by the New York State Psychiatric Institute. NR 39 TC 29 Z9 30 U1 6 U2 16 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 21 PY 2015 VL 372 IS 21 BP 2029 EP 2038 DI 10.1056/NEJMsa1413512 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CI5PD UT WOS:000354809300009 PM 25992747 ER PT J AU Arney, J Chen, GQJ Helm, A Braun, U Richardson, PA Chen, P Hayes, TG AF Arney, Jennifer Chen, Guoqing J. Helm, Ashley Braun, Ursula Richardson, Peter A. Chen, Ping Hayes, Teresa Gray TI Oncologists perceptions and behaviors regarding genomic-based targeted therapy: Findings of a pilot study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Univ Houston Clear Lake City, Dept Sociol, Houston, TX 77058 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Univ Kansas, Sch Med, Kansas City, KS USA. Kansas City VA Med Ctr, Dept Vet Affairs, Vet Hlth Adm, Off Res & Dev, Kansas City, KS USA. Effectiveness & Safety Michael E DeBakey VAMC, Dept Vet Affairs, Vet Hlth Adm, Off Res & Development, Houston, TX USA. Effectiveness & Safety Michael E DeBakey VAMC, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Univ Massachusetts, Boston, MA 02125 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17560 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903530 ER PT J AU Kvale, EA Rocque, GB Bevis, KS Acemgil, A Taylor, RA Demark-Wahnefried, W Kenzik, K Li, YF Meneses, K Martin, M Fouad, M Partridge, EE Pisu, M AF Kvale, Elizabeth Ann Rocque, Gabrielle Betty Bevis, Kerri S. Acemgil, Aras Taylor, Richard A. Demark-Wahnefried, Wendy Kenzik, Kelly Li, Yufeng Meneses, Karen Martin, Michelle Fouad, Mona Partridge, Edward E. Pisu, Maria TI Distress in older adult cancer patients approaching end of life SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9548 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902043 ER PT J AU Malhotra, S Huang, K Simeunovic, K Vinnakota, R Gavrancic, T Villanueva, N Dietz, D Fenn, K Beck, K Coker, C Park, YHA Acharyya, S AF Malhotra, Sheetal Huang, Kan Simeunovic, Kosana Vinnakota, Ravi Gavrancic, Tatjana Villanueva, Nicholas Dietz, Donny Fenn, Kathleen Beck, Kristen Coker, Courtney Park, Yeun-Hee Anna Acharyya, Swarnali TI Survival in veterans with lung cancer: Cancer cachexia and the importance of weight. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 North Cent Bronx Hosp, Bronx, NY USA. New York Presbyterian Columbia Med Ctr, Ft Lee, NJ USA. JJ Peters VA Med Ctr, Bronx, NY USA. James J Peters VA Med Ctr, New York, NY USA. Columbia Univ, Dept Med, Med Ctr, New York, NY USA. Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. Columbia Univ, Inst Canc Genet, New York, NY USA. Onc & Hem White Plains, Mt Vernon, NY USA. Columbia Univ, Canc Genet 4Inst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e20608 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036904225 ER PT J AU Malhotra, S Wu, DPH Park, YHA AF Malhotra, Sheetal Wu, David Ping-Hsin Park, Yeun-Hee Anna TI National data on sorafenib therapy adherence for veterans with hepatocellular carcinoma SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 North Cent Bronx Hosp, Bronx, NY USA. Yale Univ Internal Med, New Haven, CT USA. James J Peters VA Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 9593 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036902088 ER PT J AU Medaglia, JD VanKirk, KK Oswald, CB Church, LWP AF Medaglia, John D. VanKirk, Kathryn K. Oswald, Cameron B. Church, L. W. Preston TI Interdisciplinary Differential Diagnosis and Care of a Patient with Atypical Delusional Parasitosis due to early HIV-related Dementia SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Neuropsychological assessment; Treatment planning.; HIV ID NEUROCOGNITIVE DISORDERS; INFESTATION; DISEASE; ERA AB Objective: To provide a differential diagnosis and recommendations for care for an individual with suspected delusional parasitosis secondary to human immunodeficiency virus (HIV). Method: A 62-year-old male with sexually acquired, chronic, and well-managed HIV infection was referred for neuropsychological evaluation and treatment recommendations following extensive self-manipulation of a sternoclavicular cystic mass and superficial skin lesions over most of his body. The patient reported that he had pulled long calcified tendrils out of the mass over a period of several weeks and that "encapsulated fat" was flowing beneath his skin. Results: Numerous lab panels were negative for any acute medical pathology. Clinical neuroimaging was unremarkable. Neuropsychological evaluation revealed a profile consistent with mild neurocognitive disorder due to HIV. Medical and behavioral recommendations were made for the management of delusional thought processes consistent with atypical delusional parasitosis and other symptoms. The patient was responsive to carefully crafted provider feedback and his delusional and somatic symptoms decreased significantly with risperidone. Conclusions: This case illustrates the utility of neuropsychological assessment and provider feedback in the diagnosis and care of HIV-related neurocognitive disorder, the context of a delusional disorder. C1 [Medaglia, John D.] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Medaglia, John D.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [VanKirk, Kathryn K.; Oswald, Cameron B.; Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Dept Neuropsychol, Charleston, SC USA. [VanKirk, Kathryn K.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Church, L. W. Preston] Med Univ S Carolina, Div Infect Dis, Charleston, SC 29425 USA. RP Medaglia, JD (reprint author), Univ Penn, Moss Rehabil Res Inst, Translat Neurosci, 316 Hayden Hall, Philadelphia, PA 19104 USA. EM medaglia@seas.upenn.edu NR 24 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD MAY 19 PY 2015 VL 29 IS 4 BP 559 EP 569 DI 10.1080/13854046.2015.1042921 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA CM8FZ UT WOS:000357935100011 PM 25978635 ER PT J AU Kerlikowske, K Zhu, WW Tosteson, ANA Sprague, BL Tice, JA Lehman, CD Miglioretti, DL AF Kerlikowske, Karla Zhu, Weiwei Tosteson, Anna N. A. Sprague, Brian L. Tice, Jeffrey A. Lehman, Constance D. Miglioretti, Diana L. CA Breast Canc Surveillance TI Identifying Women With Dense Breasts at High Risk for Interval Cancer A Cohort Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID POSTMENOPAUSAL HORMONE-THERAPY; CARCINOMA IN-SITU; SCREENING MAMMOGRAPHY; DIGITAL MAMMOGRAPHY; TUMOR CHARACTERISTICS; UNITED-STATES; TOMOSYNTHESIS; PERFORMANCE; ULTRASOUND; OUTCOMES AB Background: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider. Objective: To better direct discussions of supplemental imaging by determining which combinations of breast cancer risk and Breast Imaging Reporting and Data System (BI-RADS) breast density categories are associated with high interval cancer rates. Design: Prospective cohort. Setting: Breast Cancer Surveillance Consortium (BCSC) breast imaging facilities. Patients: 365 426 women aged 40 to 74 years who had 831 455 digital screening mammography examinations. Measurements: BI-RADS breast density, BCSC 5-year breast cancer risk, and interval cancer rate (invasive cancer <= 12 months after a normal mammography result) per 1000 mammography examinations. High interval cancer rate was defined as more than 1 case per 1000 examinations. Results: High interval cancer rates were observed for women with 5-year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts). The interval rate of advanced-stage disease was highest (> 0.4 case per 1000 examinations) among women with 5-year risk of 2.50% or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts). Five-year risk was low to average (0% to 1.66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.63 and 0.72 to 0.89 case per 1000 examinations, respectively. Limitation: The benefit of supplemental imaging was not assessed. Conclusion: Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patientprovider discussions about alternative screening strategies. C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Grp Hlth Cooperat Puget Sound, Seattle, WA USA. Univ Washington, Sch Med, Seattle, WA 98109 USA. Geisel Sch Med Dartmouth, Lebanon, NH 03756 USA. Univ Vermont, Burlington, VT USA. Univ Calif Davis, Davis, CA 95616 USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. FU National Cancer Institute [P01 CA154292, HHSN261201100031C, U54 CA163303] FX This work was supported by the National Cancer Institute-funded BCSC (P01 CA154292, HHSN261201100031C, and U54 CA163303). The collection of cancer data used in this study was supported in part by several state public health departments and cancer registries throughout the United States. A full description of these sources is available at http://breastscreening.cancer.gov/work/acknowledgement.html. NR 40 TC 34 Z9 34 U1 0 U2 18 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 19 PY 2015 VL 162 IS 10 BP 673 EP + DI 10.7326/M14-1465 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA CI8IF UT WOS:000355015200016 PM 25984843 ER PT J AU Honda, JR Hess, T Malcolm, KC Ovrutsky, AR Bai, XY Irani, VR Dobos, KM Chan, ED Flores, SC AF Honda, Jennifer R. Hess, Tamara Malcolm, Kenneth C. Ovrutsky, Alida R. Bai, Xiyuan Irani, Vida R. Dobos, Karen M. Chan, Edward D. Flores, Sonia C. TI Pathogenic Nontuberculous Mycobacteria Resist and Inactivate Cathelicidin: Implication of a Novel Role for Polar Mycobacterial Lipids SO PLOS ONE LA English DT Article ID AVIUM COMPLEX; CELL-WALL; LUNG-DISEASE; ANTIMICROBIAL PEPTIDES; COLONY MORPHOLOGY; EPITHELIAL-CELLS; TUBERCULOSIS; EXPRESSION; SURFACE; GLYCOPEPTIDOLIPIDS AB Nontuberculous mycobacteria (NTM) are a large group of environmental organisms with worldwide distribution, but only a relatively few are known to be pathogenic. Chronic, debilitating lung disease is the most common manifestation of NTM infection, which is often refractory to treatment. The incidence and prevalence of NTM lung disease are increasing in the United States and in many parts of the world. Hence, a more complete understanding of NTM pathogenesis will provide the foundation to develop innovative approaches to treat this recalcitrant disease. Herein, we demonstrate that several species of NTM show broad resistance to the antimicrobial peptide, cathelicidin (LL-37). Resistance to LL-37 was not significantly different between M. avium that contain serovar-specific glycopeptidolipid (GPL, M. avium(ssGPL)) and M. avium that do not (M. avium(Delta ssGPL)). Similarly, M. abscessus containing non-specific GPL (M. abscessus(nsGPL(+))) or lacking nsGPL (M. abscessus(nsGPL(-))) remained equally resistant to LL-37. These findings would support the notion that GPL are not the components responsible for NTM resistance to LL-37. Unexpectedly, the growth of M. abscessus(nsGPL(-)) increased with LL-37 or scrambled LL-37 peptide in a dose-dependent fashion. We also discovered that LL-37 exposed to NTM had reduced antimicrobial activity, and initial work indicates that this is likely due to inactivation of LL-37 by lipid component(s) of the NTM cell envelope. We conclude that pathogenic NTM resist and inactivate LL-37. The mechanism by which NTM circumvent the antimicrobial activity of LL-37 remains to be determined. C1 [Honda, Jennifer R.; Malcolm, Kenneth C.; Chan, Edward D.; Flores, Sonia C.] Univ Colorado, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA. [Honda, Jennifer R.; Malcolm, Kenneth C.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Natl Jewish Hlth, Denver, CO USA. [Hess, Tamara] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Irani, Vida R.] Indiana Univ Penn, Dept Biol, Indiana, PA USA. [Honda, Jennifer R.; Ovrutsky, Alida R.; Bai, Xiyuan; Chan, Edward D.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu RI Dobos, Karen/D-1170-2017 OI Dobos, Karen/0000-0001-7115-8524 FU National Institutes of Health (NIH) [3R01HL059785-09S1]; University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Division; NIH NRSA Infectious Disease Training Award [T32-AI007447-19]; Tim Gill Endowment for AIDS Research, NIH NRSA Pulmonary and Critical Care Medicine Training Award [T32 HL 7085-83]; Potts Memorial Foundation FX Study support was provided in part by Institutional Funds and the National Institutes of Health (NIH) Supplement 3R01HL059785-09S1 for SCF, University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Division. JRH is supported by a NIH NRSA Infectious Disease Training Award (T32-AI007447-19), the Tim Gill Endowment for AIDS Research, NIH NRSA Pulmonary and Critical Care Medicine Training Award (T32 HL 7085-83), and the Potts Memorial Foundation. NR 54 TC 1 Z9 1 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 18 PY 2015 VL 10 IS 5 AR e0126994 DI 10.1371/journal.pone.0126994 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7BG UT WOS:000354917300075 PM 25993058 ER PT J AU Pandol, SJ Edderkaoui, M AF Pandol, Stephen J. Edderkaoui, Mouad TI What are the macrophages and stellate cells doing in pancreatic adenocarcinoma? SO FRONTIERS IN PHYSIOLOGY LA English DT Review DE stellate cells; macrophages; pancreatic cancer; periostin; TGF-beta ID EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; DUCTAL ADENOCARCINOMA; GROWTH-FACTOR; INTRAEPITHELIAL NEOPLASIA; INDUCE FIBROSIS; TRANSGENIC MICE; NAB-PACLITAXEL; ACINAR-CELLS; TUMOR-GROWTH AB Pancreatic ductal adenocarcinoma is a devastating disease characterized by a dense desmoplastic stroma. Chemo- and radio-therapeutic strategies based on targeting cancer cells have failed in improving the outcome of this cancer suggesting important roles for stroma in therapy resistance. Cells in the tumor stroma have been shown to regulate proliferation, resistance to apoptosis and treatments, epithelial to mesenchymal transition (EMT) and stemness of cancer cells. Stellate cells in their activated state have been thought over the past decade to only have tumor promoting roles. However, recent findings suggest that stellate cells may have protective roles as well. The present review highlights the latest findings on the role of two major components of tumor stroma, pancreatic stellate cells and macrophages, in promoting or inhibiting pancreatic cancer, focused on their effects on EMT and cancer stemness. C1 [Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Pandol, Stephen J.; Edderkaoui, Mouad] Univ Calif Los Angeles, Los Angeles, CA USA. RP Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Med, Vet Affairs Los Angeles, 8700 Beverly Blvd,Davis Bldg,Suite 3100, Los Angeles, CA 90048 USA. EM mouad.edderkaoui@cshs.org FU Department of Veterans Affairs [K01AA019996, P01CA163200] FX Supported by K01AA019996, P01CA163200 and Department of Veterans Affairs. NR 52 TC 2 Z9 2 U1 2 U2 9 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PD MAY 15 PY 2015 VL 6 AR 125 DI 10.3389/fphys.2015.00125 PG 6 WC Physiology SC Physiology GA CM3NN UT WOS:000357589200001 PM 26029109 ER PT J AU Khan, M Shunmugavel, A Dhammu, TS Matsuda, F Singh, AK Singh, I AF Khan, Mushfiquddin Shunmugavel, Anandakumar Dhammu, Tajinder S. Matsuda, Fumiyo Singh, Avtar K. Singh, Inderjit TI Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in rats SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Lumbar spinal canal stenosis; Cauda equina compression; Cytosolic phospholipase A2; Neuroinflammation; Arachidonyl trifluoromethyl ketone; Pain; Motor function ID SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; LOW-BACK-PAIN; PHOSPHOLIPASE A(2); NEUROPATHIC PAIN; LYSOPHOSPHATIDIC ACID; THERAPEUTIC TARGETS; SECONDARY INJURY; POTENT INHIBITOR; NERVE LIGATION AB Background: Phospholipase A2 (PLA2)-derived proinflammatory lipid mediators such as prostaglandin E2 (PGE2), leukotrienes B4 (LTB4), lysophosphatidylcholine (LPC), and free fatty acids (FFA) are implicated in spinal cord injury (SCI) pathologies. Reducing the levels of these injurious bioactive lipid mediators is reported to ameliorate SCI. However, the specific role of the group IVA isoform of PLA2 cytosolic PLA2 (cPLA2) in lumbar spinal canal stenosis (LSS) due to cauda equina compression (CEC) injury is not clear. In this study, we investigated the role of cPLA2 in a rat model of CEC using a non-toxic cPLA2-preferential inhibitor, arachidonyl trifluoromethyl ketone (ATK). Methods: LSS was induced in adult female rats by CEC procedure using silicone blocks within the epidural spaces of L4 to L6 vertebrae. cPLA2 inhibitor ATK (7.5 mg/kg) was administered by oral gavage at 2 h following the CEC. cPLA2-derived injurious lipid mediators and the expression/activity of cPLA2, 5-lipoxygenase (5-LOX), and cyclooxygenase-2 (COX-2) were assessed. ATK-treated (CEC + ATK) were compared with vehicle-treated (CEC + VEH) animals in terms of myelin levels, pain threshold, and motor function. Results: ATK treatment of CEC animals reduced the phosphorylation of cPLA2 (pcPLA2) determined by Western blot, improved locomotor function evaluated by rotarod task, and reduced pain threshold evaluated by mechanical hyperalgesia method. Levels of FFA and LPC, along with PGE2 and LTB4, were reduced in CEC + ATK compared with CEC + VEH group. However, ATK treatment reduced neither the activity/expression of 5-LOX nor the expression of COX-2 in CEC + VEH animals. Increased cPLA2 activity in the spinal cord from CEC + VEH animals correlated well with decreased spinal cord as well as cauda equina fiber myelin levels, which were restored after ATK treatment. Conclusion: The data indicate that cPLA2 activity plays a significant role in tissue injury and pain after LSS. Reducing the levels of proinflammatory and tissue damaging eicosanoids and the deleterious lipid mediator LPC shows therapeutic potential. ATK inhibits cPLA2 activity, thereby decreasing the levels of injurious lipid mediators, reducing pain, improving functional deficits, and conferring protection against LSS injury. Thus, it shows potential for preclinical evaluation in LSS. C1 [Khan, Mushfiquddin; Shunmugavel, Anandakumar; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan. [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. EM khanm@musc.edu; singhi@musc.edu FU Extramural Research Facilities Program of the National Center for Research Resources [CO6 RR018823, CO6 RR0015455]; NIH [07506]; [NS-72511]; [NS-22576]; [NS-37766]; [DC00422] FX This work was supported by grants NS-72511, NS-22576, and NS-37766 and DC00422; 07506 from the NIH, CO6 RR018823 and CO6 RR0015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We are grateful to Dr. Thomas G. Smith from the MUSC Writing Center for his valuable editing and correction of the manuscript. We would like to thank Ms. Danielle Lowe for assistance with statistical analysis and manuscript review. We would also like to thank Ms. Joyce Bryan for procurement of animals and chemicals and Ms. Terry Hope for secretarial assistance. NR 70 TC 1 Z9 1 U1 2 U2 76 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD MAY 15 PY 2015 VL 12 AR 94 DI 10.1186/s12974-015-0311-y PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CK4SQ UT WOS:000356213900001 PM 25971887 ER PT J AU Meya, DB Okurut, S Zziwa, G Rolfes, MA Kelsey, M Cose, S Joloba, M Naluyima, P Palmer, BE Kambugu, A Mayanja-Kizza, H Bohjanen, PR Eller, MA Wahl, SM Boulware, DR Manabe, YC Janoff, EN AF Meya, David B. Okurut, Samuel Zziwa, Godfrey Rolfes, Melissa A. Kelsey, Melander Cose, Steve Joloba, Moses Naluyima, Prossy Palmer, Brent E. Kambugu, Andrew Mayanja-Kizza, Harriet Bohjanen, Paul R. Eller, Michael A. Wahl, Sharon M. Boulware, David R. Manabe, Yuka C. Janoff, Edward N. TI Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE cryptococcal meningitis; cryptococcus; HIV; cerebrospinal fluid; immune responses; cell activation ID CENTRAL-NERVOUS-SYSTEM; CD4(+) T-CELLS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; CLINICAL-FEATURES; INFECTED PATIENTS; HIV-INFECTION; NEOFORMANS; TUBERCULOSIS; MECHANISMS AB Methods.aEuro integral We characterized the lineage and activation status of mononuclear cells in blood and CSF of HIV-infected patients with noncryptococcal meningitis (NCM) (n = 10), those with CM at day 0 (n = 40) or day 14 (n = 21) of antifungal therapy, and those with CM-IRIS (n = 10). Results.aEuro integral At diagnosis, highly activated CD8(+) T cells predominated in CSF in both CM and NCM. CM-IRIS was associated with an increasing frequency of CSF CD4(+) T cells (increased from 2.2% to 23%; P = .06), a shift in monocyte phenotype from classic to an intermediate/proinflammatory, and increased programmed death ligand 1 expression on natural killer cells (increased from 11.9% to 61.6%, P = .03). CSF cellular responses were distinct from responses in peripheral blood. Conclusions.aEuro integral After CM, T cells in CSF tend to evolve with the development of IRIS, with increasing proportions of activated CD4(+) T cells, migration of intermediate monocytes to the CSF, and declining fungal burden. These changes provide insight into IRIS pathogenesis and could be exploited to more effectively treat CM and prevent CM-IRIS. C1 [Meya, David B.; Kambugu, Andrew; Manabe, Yuka C.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda. [Meya, David B.; Cose, Steve; Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Sch Med, Kampala, Uganda. [Joloba, Moses] Makerere Univ, Dept Microbiol, Sch Biomed Sci, Kampala, Uganda. [Okurut, Samuel; Zziwa, Godfrey] Makerere Univ Reed Project, Kampala, Uganda. [Cose, Steve] Uganda Virus Res Inst, Med Res Council, Uganda Res Unit AIDS, Entebbe, Uganda. [Meya, David B.; Rolfes, Melissa A.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Minneapolis, MN 55455 USA. [Kelsey, Melander; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Program Colorado, Aurora, CO USA. [Kelsey, Melander; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Baltimore, MD USA. [Manabe, Yuka C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA. [Eller, Michael A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA. [Eller, Michael A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA. [Wahl, Sharon M.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD USA. [Cose, Steve] London Sch Hyg & Trop Med, London, England. RP Meya, DB (reprint author), Makerere Univ, Coll Hlth Sci, Infect Dis Inst, POB 22418, Kampala, Uganda. EM david.meya@gmail.com OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Boulware, David/0000-0002-4715-0060; Cose, Stephen/0000-0002-5156-037X FU National Institutes of Health [R01AI078934, U01AI089244, NS065713, R01AI108479, K24AI096925, T32AI055433, R21NS065713]; Wellcome Trust (Training Health Researchers into Vocational Excellence [THRiVE]) in East Africa [087540]; GlaxoSmithKline Collaborative Investigator Research Award; Veterans Affairs Research Service FX This work was supported by the National Institutes of Health (grants R01AI078934, U01AI089244, NS065713, R01AI108479, K24AI096925, T32AI055433, and R21NS065713); the Wellcome Trust (Training Health Researchers into Vocational Excellence [THRiVE]) in East Africa (grant 087540), the GlaxoSmithKline Collaborative Investigator Research Award, and the Veterans Affairs Research Service. NR 45 TC 9 Z9 9 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2015 VL 211 IS 10 BP 1597 EP 1606 DI 10.1093/infdis/jiu664 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4MG UT WOS:000354723000010 PM 25492918 ER PT J AU Tanner, NT Silvestri, GA AF Tanner, Nichole T. Silvestri, Gerard A. TI Screening for Lung Cancer Using Low-Dose Computed Tomography Are We Headed for DANTE's Paradise or Inferno? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID TRIAL C1 [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ S Carolina, Charleston, SC 29425 USA. [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equity & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Tanner, NT (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA. NR 17 TC 2 Z9 2 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD MAY 15 PY 2015 VL 191 IS 10 BP 1100 EP 1101 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI8KO UT WOS:000355021400005 PM 25978569 ER PT J AU Cheng, A Owens, D AF Cheng, Andrew Owens, David TI Marfan syndrome, inherited aortopathies and exercise: What is the right answer? SO HEART LA English DT Review ID ARTERIAL BLOOD-PRESSURE; SUDDEN CARDIAC DEATH; AORTIC DISSECTION; CARDIOVASCULAR-DISEASE; HEMODYNAMIC-RESPONSE; SPORTS PARTICIPATION; RESISTANCE EXERCISE; PHYSICAL-ACTIVITY; ASSOCIATION; RECOMMENDATIONS AB Exercise recommendations for those who have Marfan syndrome or other genetic predisposition for thoracic aortic disease remain controversial and at times ambiguous. There are no outcomes studies to help guide recommendations. In this review, we examine the guidelines regarding exercise and inherited aortic conditions, the theoretical reasoning and circumstantial evidence that support the guidelines, as well as the knowledge gaps that continue to exist. C1 [Cheng, Andrew] VA Puget Sound, Dept Cardiol, Seattle, WA 98108 USA. [Cheng, Andrew; Owens, David] Univ Washington, Dept Cardiol, Seattle, WA 98195 USA. RP Cheng, A (reprint author), VA Puget Sound, Dept Cardiol, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ACheng@cardiology.washington.edu OI Owens, David/0000-0002-7293-9688 NR 39 TC 1 Z9 1 U1 0 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD MAY 15 PY 2015 VL 101 IS 10 BP 752 EP 757 DI 10.1136/heartjnl-2014-306440 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CH8GR UT WOS:000354274900006 PM 25911666 ER PT J AU Wong, CC Ramanathan, DS Gulati, T Won, SJ Ganguly, K AF Wong, Chelsea C. Ramanathan, Dhakshin S. Gulati, Tanuj Won, Seok Joon Ganguly, Karunesh TI An automated behavioral box to assess forelimb function in rats SO JOURNAL OF NEUROSCIENCE METHODS LA English DT Article DE Motor learning; Reach; Electrophysiology ID FOREBRAIN CHOLINERGIC SYSTEM; SPINAL-CORD-INJURY; MOTOR CORTEX; CORTICAL PLASTICITY; TASK; STROKE; IMPAIRMENT; RECOVERY AB Background: Rodent forelimb reaching behaviors are commonly assessed using a single-pellet reach-to-grasp task. While the task is widely recognized as a very sensitive measure of distal limb function, it is also known to be very labor-intensive, both for initial training and the daily assessment of function. New method: Using components developed by open-source electronics platforms, we have designed and tested a low-cost automated behavioral box to measure forelimb function in rats. Our apparatus, made primarily of acrylic, was equipped with-multiple sensors to control the duration and difficulty of the task, detect reach outcomes, and dispense pellets. Our control software, developed in MATLAB, was also used to control a camera in order to capture and process video during reaches. Importantly, such processing could monitor task performance in near real-time. Results: We further demonstrate that the automated apparatus can be used to expedite skill acquisition, thereby increasing throughput as well as facilitating studies of early versus late motor learning. The setup is also readily compatible with chronic electrophysiological monitoring. Comparison with existing methods: Compared to a previous version of this task, our setup provides a more efficient method to train and test rodents for studies of motor learning and recovery of function after stroke. The unbiased delivery of behavioral cues and outcomes also facilitates electrophysiological studies. Conclusions: In summary, our automated behavioral box will allow high-throughput and efficient monitoring of rat forelimb function in both healthy and injured animals. Published by Elsevier B.V. C1 [Wong, Chelsea C.; Ramanathan, Dhakshin S.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94158 USA. [Wong, Chelsea C.; Gulati, Tanuj; Won, Seok Joon; Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Ramanathan, Dhakshin S.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94158 USA. [Ramanathan, Dhakshin S.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Ganguly, K (reprint author), San Francisco VA Med Ctr, Neurol & Rehabil Serv, 1700 Owens St,Rm 479, San Francisco, CA 94158 USA. EM karunesh.ganguly@ucsf.edu FU U.S. Department of Veterans Affairs [CDA-2B6674W]; Burroughs Wellcome Fund [1009855]; American Heart Association/Stroke Association [0875016N]; UCSF Department of Neurology FX This work was supported by the U.S. Department of Veterans Affairs (CDA-2B6674W), the Burroughs Wellcome Fund (1009855), the American Heart Association/Stroke Association (0875016N) and departmental funds from the UCSF Department of Neurology. We would also like to thank Roy Tangsombatvisit for assistance with the design and the manufacturing of the reach boxes. NR 33 TC 6 Z9 6 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0270 EI 1872-678X J9 J NEUROSCI METH JI J. Neurosci. Methods PD MAY 15 PY 2015 VL 246 BP 30 EP 37 DI 10.1016/j.jneumeth.2015.03.008 PG 8 WC Biochemical Research Methods; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CI1KC UT WOS:000354502100004 PM 25769277 ER PT J AU Evans, CT Safdar, N AF Evans, Charlesnika T. Safdar, Nasia TI Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Clostridium difficile; epidemiology; costs ID CARE-ASSOCIATED INFECTIONS; UNITED-STATES; DIARRHEA; RISK; METAANALYSIS; ANTIBIOTICS; RATES; HOSPITALS; COLITIS; MULTICENTER AB Clostridium difficile is the most frequently identified cause of nosocomial diarrhea and has been associated with epidemics of diarrhea in hospitals and long-term care facilities. The continued increase in C. difficile infection (CDI) suggests that it has surpassed other pathogens in causing healthcare-associated infections. The Centers for Disease Control and Prevention recently identified CDI as an "urgent threat" in its recent report on antibiotic resistance threats in the United States, highlighting the need for urgent and aggressive action to prevent this infection. The impact of antibiotics as a risk factor for new-onset CDI is well established; however, recognizing classes of antibiotics with the highest risks and reducing unnecessary antibiotic use are important strategies for prevention of CDI and subsequent recurrence. In addition, the recognition of the community as an important setting for onset of CDI presents a challenge and is an area for future research. C1 [Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Dept Vet Affairs VA, Ctr Innovat Complex Chron Healthcare, Hines, IL 60141 USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Evans, CT (reprint author), Edward Hines Jr VA Hosp, 5000 S Fifth Ave,151H,Bldg 1,Rm D302, Hines, IL 60141 USA. EM charlesnika.evans@va.gov FU Presidential Early Career Award for Scientists and Engineers [USA 12-564]; VA Health Services Research and Development Service [IIR 10-148] FX This work was supported by the Presidential Early Career Award for Scientists and Engineers (grant number USA 12-564 to C. T. E.) and the VA Health Services Research and Development Service (grant number IIR 10-148 to C. T. E.). NR 43 TC 33 Z9 33 U1 1 U2 24 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2015 VL 60 SU 2 BP S66 EP S71 DI 10.1093/cid/civ140 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0OB UT WOS:000353719500002 PM 25922403 ER PT J AU Repunte-Canonigo, V Herman, MA Kawamura, T Kranzler, HR Sherva, R Gelernter, J Farrer, LA Roberto, M Sanna, PP AF Repunte-Canonigo, Vez Herman, Melissa A. Kawamura, Tomoya Kranzler, Henry R. Sherva, Richard Gelernter, Joel Farrer, Lindsay A. Roberto, Marisa Sanna, Pietro Paolo TI Nf1 Regulates Alcohol Dependence-Associated Excessive Drinking and Gamma-Aminobutyric Acid Release in the Central Amygdala in Mice and Is Associated with Alcohol Dependence in Humans SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Alcohol dependence; Amygdala; Electrophysiology; GABA; Genetic association; Presynaptic mechanisms ID CHRONIC ETHANOL EXPOSURE; LEARNING-DEFICITS; C57BL/6J MICE; GABA RELEASE; INTERMITTENT; WITHDRAWAL; MODEL; INTOXICATION; INHIBITION; MEMORY AB BACKGROUND: The neurofibromatosis type 1 (Nf1) gene encodes a GTPase activating protein that negatively regulates small GTPases of the Ras family. METHODS: We assessed alcohol-related behaviors including alcohol sensitivity, dependent and nondependent drinking, and basal and alcohol-induced gamma-aminobutyric acid (GABA) release in the central nucleus of the amygdala (CeA) in Nf1 heterozygous null mice (Nf1(+/-)). We also investigated the associations of NF1 polymorphisms with alcohol dependence risk and severity in humans. RESULTS: Nf1(+/-) mice do not differ from wild-type mice in nondependent drinking, such as 24-hour, 2-bottle choice drinking in the dark binge drinking or limited access 2-bottle choice. However, Nf1(+/-) mice failed to escalate alcohol drinking following chronic intermittent ethanol vapor exposure (CIE) to induce dependence. Alcohol acutely increases GABA release in the CeA and alcohol dependence is characterized by increased baseline GABA release in CeA. Interestingly, GABA release in Nf1(+/-) mice is greater at baseline than wild-type mice, is not elevated by induction of dependence by CIE, and failed to show alcohol-induced facilitation both before and after CIE. Additionally, we observed that multiple variants in the human NF1 gene are associated with a quantitative measure of alcohol dependence in both African Americans and European Americans. CONCLUSIONS: In this translational investigation, we found that Nf1 activity regulates excessive drinking and basal and ethanol-stimulated GABA release in the mouse central amygdala. We also found that genetic variation in NF1 may confer an inherent susceptibility to the transition from nondependent to dependent drinking in humans. C1 [Repunte-Canonigo, Vez; Kawamura, Tomoya; Sanna, Pietro Paolo] Scripps Res Inst, Mol & Cellular Neurosci Dept, La Jolla, CA 92037 USA. [Herman, Melissa A.; Roberto, Marisa] Scripps Res Inst, Comm Neurobiol Addict Disorders, La Jolla, CA 92037 USA. [Kranzler, Henry R.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network Mental Illness Res Ed, Philadelphia, PA USA. [Kranzler, Henry R.] Philadelphia Vet Affairs Med Ctr, Ctr Clin, Philadelphia, PA USA. [Sherva, Richard; Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02215 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Psychiat, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Genet, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Vet Affairs Connecticut Healthcare Ctr, Dept Neurobiol, West Haven, CT 06516 USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. RP Sanna, PP (reprint author), Scripps Res Inst, Mol & Cellular Med, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA. EM psanna@scripps.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health [F32 AA020430, AA015566, AA017371, AA020960, AA013191, AA013498, AA021491, AA021667, AA11330, AA17535, DA12690, DA12849, DA18432, DA028909, N01-HG-65403, HHSN268200782096C]; Pearson Center for Alcoholism and Addiction Research; National Institutes of Health Genes, Environment and Health Initiative [U01 HG004422, U01HG004438]; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; Lilly; Lundbeck; AbbVie; Ethypharm; Pfizer FX This work was supported by National Institutes of Health Grants F32 AA020430, AA015566, AA017371, AA020960, AA013191, AA013498, AA021491, AA021667, AA11330, AA17535, DA12690, DA12849, DA18432, and DA028909 and the Pearson Center for Alcoholism and Addiction Research. Genotyping services for a part of our genome-wide association study were provided by the Center for Inherited Disease Research and Yale University (Center for Genome Analysis). Center for Inherited Disease Research is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). The publicly available datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0 00092.v1.p1 through dbGaP accession number phs000092.v1.p. Funding support for the Study of Addiction: Genetics and Environment was provided through the National Institutes of Health Genes, Environment and Health Initiative (U01 HG004422). Study of Addiction: Genetics and Environment is one of the genome-wide association studies funded as part of the Gene Environment Association Studies under Genes, Environment and Health Initiative. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies Coordinating Center (U01 HG004446).; Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (P01 CA089392), and the Family Study of Cocaine Dependence (R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the National Institutes of Health Genes, Environment and Health Initiative (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the National Institutes of Health contract "High throughput genotyping for studying the genetic contributions to human disease" (HHSN268200782096C).; HRK has been a consultant or advisory board member with Alkermes, Lilly, Lundbeck, Otsuka, Pfizer, and Roche. He has also received honoraria from the Alcohol Clinical Trials Initiative of the American Society of Clinical Psychopharmacology, which is supported by Lilly, Lundbeck, AbbVie, Ethypharm, and Pfizer. All other authors report no biomedical financial interests or potential conflicts of interest. NR 33 TC 5 Z9 5 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAY 15 PY 2015 VL 77 IS 10 BP 870 EP 879 DI 10.1016/j.biopsych.2014.07.031 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CG8LP UT WOS:000353559600006 PM 25483400 ER PT J AU Liu, HB Cadaneanu, RM Lai, K Zhang, BH Huo, LH An, DS Li, XM Lewis, MS Garraway, IP AF Liu, Haibo Cadaneanu, Radu M. Lai, Kevin Zhang, Baohui Huo, Lihong An, Dong Sun Li, Xinmin Lewis, Michael S. Garraway, Isla P. TI Differential Gene Expression Profiling of Functionally and Developmentally Distinct Human Prostate Epithelial Populations SO PROSTATE LA English DT Article DE human prostate epithelial microarray; fetal prostate; prostate stem cell; basal cell; prostate tissue regeneration; prostate tubule initiation ID STEM-CELLS; LUMINAL CELLS; BASAL-CELLS; MURINE; CANCER; IDENTIFICATION; SUBPOPULATION; DISEASE; MARKER; TISSUE AB BACKGROUNDHuman fetal prostate buds appear in the 10th gestational week as solid cords, which branch and form lumens in response to androgen 1. Previous in vivo analysis of prostate epithelia isolated from benign prostatectomy specimens indicated that Epcam(+)CD44(-)CD49f(Hi) basal cells possess efficient tubule initiation capability relative to other subpopulations 2. Stromal interactions and branching morphogenesis displayed by adult tubule-initiating cells (TIC) are reminiscent of fetal prostate development. In the current study, we evaluated in vivo tubule initiation by human fetal prostate cells and determined expression profiles of fetal and adult epithelial subpopulations in an effort to identify pathways used by TIC. METHODSImmunostaining and FACS analysis based on Epcam, CD44, and CD49f expression demonstrated the majority (99.9%) of fetal prostate epithelial cells (FC) were Epcam(+)CD44(-) with variable levels of CD49f expression. Fetal populations isolated via cell sorting were implanted into immunocompromised mice. Total RNA isolation from Epcam(+)CD44(-)CD49f(Hi) FC, adult Epcam(+)CD44(-)CD49f(Hi) TIC, Epcam(+)CD44(+)CD49f(Hi) basal cells (BC), and Epcam(+)CD44(-)CD49f(Lo) luminal cells (LC) was performed, followed by microarray analysis of 19 samples using the Affymetrix Gene Chip Human U133 Plus 2.0 Array. Data was analyzed using Partek Genomics Suite Version 6.4. Genes selected showed >2-fold difference in expression and P<5.00E-2. Results were validated with RT-PCR. RESULTSGrafts retrieved from Epcam(+)CD44(-) fetal cell implants displayed tubule formation with differentiation into basal and luminal compartments, while only stromal outgrowths were recovered from Epcam- fetal cell implants. Hierarchical clustering revealed four distinct groups determined by antigenic profile (TIC, BC, LC) and developmental stage (FC). TIC and BC displayed basal gene expression profiles, while LC expressed secretory genes. FC had a unique profile with the most similarities to adult TIC. Functional, network, and canonical pathway identification using Ingenuity Pathway Analysis Version 7.6 compiled genes with the highest differential expression (TIC relative to BC or LC). Many of these genes were found to be significantly associated with prostate tumorigenesis. CONCLUSIONSOur results demonstrate clustering gene expression profiles of FC and adult TIC. Pathways associated with TIC are known to be deregulated in cancer, suggesting a cell-of-origin role for TIC versus re-emergence of pathways common to these cells in tumorigenesis. Prostate 75: 764-776, 2015. (c) The Authors. The Prostate, published by Wiley Periodicals, Inc. C1 [Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; Garraway, Isla P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Liu, Haibo; Cadaneanu, Radu M.; Lai, Kevin; Zhang, Baohui; Huo, Lihong; An, Dong Sun; Li, Xinmin; Garraway, Isla P.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [An, Dong Sun] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [An, Dong Sun; Garraway, Isla P.] Univ Calif Los Angeles, Broad Stem Cell Ctr, Los Angeles, CA USA. [Li, Xinmin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Lewis, Michael S.; Garraway, Isla P.] West Los Angeles VA Hosp, Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Garraway, IP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. EM igarraway@mednet.ucla.edu FU National Institutes of Health [CA-16042, AI-28697 U54 CA 143931]; Department of Defense [PC073073]; Prostate Cancer Foundation Challenge and Young Investigator Awards; Jean Perkins Foundation; Margaret E. Early Medical Research Trust FX Grant sponsor: National Institutes of Health awards; Grant numbers: CA-16042; AI-28697 U54 CA 143931; Grant sponsor: Department of Defense; Grant number: PC073073; Grant sponsor: Prostate Cancer Foundation Challenge and Young Investigator Awards; Grant sponsor: Jean Perkins Foundation; Grant sponsor: Margaret E. Early Medical Research Trust. NR 25 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD MAY 15 PY 2015 VL 75 IS 7 BP 764 EP 776 DI 10.1002/pros.22959 PG 13 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA CF7DL UT WOS:000352716300009 PM 25663004 ER PT J AU Joy, M AF Joy, Mark TI Acid-Base Problems in Diabetic Ketoacidosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID LACTIC-ACIDOSIS; BICARBONATE C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Joy, M (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM mark.joy@va.gov NR 4 TC 0 Z9 0 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 14 PY 2015 VL 372 IS 20 BP 1968 EP 1968 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CI1HB UT WOS:000354493300022 PM 25970064 ER PT J AU Bourguignon, LYW Bikle, D AF Bourguignon, Lilly Y. W. Bikle, Daniel TI Selective hyaluronan-CD44 signaling promotes miRNA-21 expression and interacts with vitamin D function during cutaneous squamous cell carcinomas progression following UV irradiation SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE hyaluronan; CD44; RhoGTPase; vitamin D; UVR; miR21; vitamin D; skin cancer ID TUMOR-SUPPRESSOR PDCD4; PROTEIN-KINASE-C; NF-KAPPA-B; BREAST-CANCER CELLS; RHO-KINASE; CD44 INTERACTION; SKIN-CANCER; KERATINOCYTE DIFFERENTIATION; TRANSCRIPTION FACTORS; INHIBITS TRANSLATION AB Hyaluronan (HA), the major extracellular matrix component, is often anchored to CD44, a family of structurally/functionally important cell surface receptors. Recent results indicate that UV irradiation (UVR)-induced cutaneous squamous cell carcinomas (SCC) overexpress a variety of CD44 variant isoforms (CD44v), with different CD44v isoforms appear to confer malignant SCC properties. UVR also stimulates HA degradation in epidermal keratinocytes. Both large HA polymers and their UVR-induced catabolic products (small HA) selectively activate CD44-mediated cellular signaling in normal keratinocytes and SCC cells, with all of the downstream processes being mediated by RhoGTPases (e.g., Rac1 and Rho). Importantly, we found that the hormonally active form of vitamin D 1,25(OH)(2) D-3 not only prevents the UVR-induced small HA activation of abnormal keratinocyte behavior and SCC progression, but also enhances large HA stimulation of normal keratinocyte activities and epidermal function(s). The aim of this hypothesis and theory article is to question whether matrix HA and its UVR-induced catabolic products (e.g., large and small HA) can selectively activate CD44-mediated cellular signaling such as GTPase (Rac and RhA) activation. We suggested that large HA CD44 interaction promotes Rac-signaling and normal keratinocyte differentiation (lipid synthesis), DNA repair, and keratinocyte survival function. Conversely, small HA CD44 interaction stimulates RhoA activation, NFKB/Stat-3 signaling, and miR-21 production, resulting in inflammation and proliferation as well as SCC progression. We also question whether vitamin D treatment displays any effect on small HA CD44v-mediated RhoA signaling, inflammation, and SCC progression, as well as large HA CD44-mediated differentiation, DNA repair, keratinocyte survival, and normal keratinocyte function. In addition, we discussed that the topical application of signaling perturbation agents (e.g., Y27623, a ROK inhibitor) may be used to treat certain skin diseases displaying upregulation of keratinocyte proliferation such as psoriasis and actinic keratoses in order to correct the imbalance between Rac and RhoA signaling during various UV irradiation-induced skin diseases in patients. Finally, we proposed that matrix HA/CD44-signaling strategies and matrix HA (HA(S) vs. HA(L) or HA(S) -> HA(L))-based therapeutic approaches (together with vitamin D) may be used for the treatment of patients suffering a number of UV irradiation-induced skin diseases (e.g., inflammation, skin cancer, and chronic non-healing wounds). C1 [Bourguignon, Lilly Y. W.; Bikle, Daniel] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, Dept Med, Endocrine Unit 111N2, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU Veterans Affairs (VA) Merit Review Awards [RR & D-1101 RX000601, BLR & D-5101 BX000628]; United States Public Health grants [R01 CA66163]; DOD grant FX We gratefully acknowledge the assistance of Dr. Gerard J. Bourguignon in the preparation and review of this manuscript. This work was supported by Veterans Affairs (VA) Merit Review Awards (RR & D-1101 RX000601 and BLR & D-5101 BX000628), United States Public Health grants (R01 CA66163), and DOD grant. LB is a VA Senior Research Career Scientist. NR 80 TC 2 Z9 3 U1 3 U2 7 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD MAY 13 PY 2015 VL 6 AR 224 DI 10.3389/fimmu.2015.00224 PG 13 WC Immunology SC Immunology GA CJ2NQ UT WOS:000355322100001 PM 26029210 ER PT J AU Broyles, LM Wieland, ME Confer, AL DiNardo, MM Kraemer, KL Hanusa, BH Youk, AO Gordon, AJ Sevick, MA AF Broyles, Lauren M. Wieland, Melissa E. Confer, Andrea L. DiNardo, Monica M. Kraemer, Kevin L. Hanusa, Barbara H. Youk, Ada O. Gordon, Adam J. Sevick, Mary Ann TI Alcohol brief intervention for hospitalized veterans with hazardous drinking: protocol for a 3-arm randomized controlled efficacy trial SO ADDICTION SCIENCE & CLINICAL PRACTICE LA English DT Article DE Inpatients; Risk reduction behavior; Drinking behavior; Alcohol drinking; Binge drinking; Brief intervention; Clinical trial; Assessment reactivity; Measurement effects AB Background: Various hospital accreditation and quality assurance entities in the United States have approved and endorsed performance measures promoting alcohol brief intervention (BI) for hospitalized individuals who screen positive for unhealthy alcohol use, the spectrum of use ranging from hazardous use to alcohol use disorders. These performance measures have been controversial due to the limited and equivocal evidence for the efficacy of BI among hospitalized individuals. The few BI trials conducted with hospital inpatients vary widely in methodological quality. While the majority of these studies indicate limited to no effects of BI in this population, none have been designed to account for the most pervasive methodological issue in BI studies presumed to drive study findings towards the null: assessment reactivity (AR). Methods/Design: This is a three-arm, single-site, randomized controlled trial of BI for hospitalized patients at a large academic medical center affiliated with the U.S. Department of Veterans Affairs who use alcohol at hazardous levels but do not have an alcohol use disorder. Participants are randomized to one of three study conditions. Study Arm 1 receives a three-part alcohol BI. Study Arm 2 receives attention control. To account for potential AR, Study Arm 3 receives AC with limited assessment. Primary outcomes will include the number of standard drinks/week and binge drinking episodes reported in the 30-day period prior to a final measurement visit obtained 6 months after hospital discharge. Additional outcomes will include readiness to change drinking behavior and number of adverse consequences of alcohol use. To assess differences in primary outcomes across the three arms, we will use mixed-effects regression models that account for a patient's repeated measures over the timepoints and clustering within medical units. Intervention implementation will be assessed by: a) review of intervention audio recordings to characterize barriers to intervention fidelity; and b) feasibility of participant recruitment, enrollment, and follow-up. Discussion: The results of this methodologically rigorous trial will provide greater justification for or against the use of BI performance measures in the inpatient setting and inform organizational responses to BI-related hospital accreditation and performance measures. C1 [Broyles, Lauren M.; Wieland, Melissa E.; Confer, Andrea L.; DiNardo, Monica M.; Youk, Ada O.; Gordon, Adam J.] Ctr Hlth Equity Res & Promot, Vet Affairs VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Broyles, Lauren M.; Kraemer, Kevin L.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. [Broyles, Lauren M.; Hanusa, Barbara H.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Educ & Clin Ctr, Vet Integrated Serv Network VISN4 4, Mental Illnes Res, Univ Dr C 151C, Pittsburgh, PA 15240 USA. [Youk, Ada O.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA. [Sevick, Mary Ann] New York Univ, Sch Med, Ctr Healthful Behav Change, Dept Populat Hlth, 227 East 30th St, New York, NY 10016 USA. RP Broyles, LM (reprint author), Ctr Hlth Equity Res & Promot, Vet Affairs VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM lauren.broyles@va.gov FU Nursing Research Initiative of the Health Services Research and Development (HSR D) [1 IO1 HX000802-01]; Career Development Award [CDA 10-014]; HSR D FX We acknowledge the staff nurses from the 4 West,5 West,and 6 West patient care units,and the leadership at VAPHS for their support of the study.Funding for this study was provided by the Nursing Research Initiative of the Health Services Research and Development (HSR & D) Service of the VA (1 IO1 HX000802-01,PI: Lauren M. Broyles).Dr.Broyles is currently supported by a Career Development Award (CDA 10-014) from the HSR & D Service of the VA.The material is the result of work supported with resources and the use of facilities at VAPHS.The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the United States Government. NR 46 TC 0 Z9 0 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1940-0640 J9 ADDICT SCI CLIN PRAC JI Addict. Sci. Clin. Pract. PD MAY 13 PY 2015 VL 10 AR 13 DI 10.1186/s13722-015-0033-6 PG 11 WC Substance Abuse SC Substance Abuse GA V49KB UT WOS:000210084800001 PM 25968121 ER PT J AU Sico, JJ Chang, CCH So-Armah, K Justice, AC Hylek, E Skanderson, M McGinnis, K Kuller, LH Kraemer, KL Rimland, D Goetz, MB Butt, AA Rodriguez-Barradas, MC Gibert, C Leaf, D Brown, ST Samet, J Kazis, L Bryant, K Freiberg, MS AF Sico, Jason J. Chang, Chung-Chou H. So-Armah, Kaku Justice, Amy C. Hylek, Elaine Skanderson, Melissa McGinnis, Kathleen Kuller, Lewis H. Kraemer, Kevin L. Rimland, David Goetz, Matthew Bidwell Butt, Adeel A. Rodriguez-Barradas, Maria C. Gibert, Cynthia Leaf, David Brown, Sheldon T. Samet, Jeffrey Kazis, Lewis Bryant, Kendall Freiberg, Matthew S. CA Vet Aging Cohort Study TI HIV status and the risk of ischemic stroke among men SO NEUROLOGY LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; CEREBROVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; ADMINISTRATIVE DATA; INFECTED PATIENTS; HEPATITIS-C; CARE; VETERANS; AIDS; PREVENTION AB Objective:Given conflicting data regarding the association of HIV infection and ischemic stroke risk, we sought to determine whether HIV infection conferred an increased ischemic stroke risk among male veterans.Methods:The Veterans Aging Cohort Study-Virtual Cohort consists of HIV-infected and uninfected veterans in care matched (1:2) for age, sex, race/ethnicity, and clinical site. We analyzed data on 76,835 male participants in the Veterans Aging Cohort Study-Virtual Cohort who were free of baseline cardiovascular disease. We assessed demographics, ischemic stroke risk factors, comorbid diseases, substance use, HIV biomarkers, and incidence of ischemic stroke from October 1, 2003, to December 31, 2009.Results:During a median follow-up period of 5.9 (interquartile range 3.5-6.6) years, there were 910 stroke events (37.4% HIV-infected). Ischemic stroke rates per 1,000 person-years were higher for HIV-infected (2.79, 95% confidence interval 2.51-3.10) than for uninfected veterans (2.24 [2.06-2.43]) (incidence rate ratio 1.25 [1.09-1.43]; p < 0.01). After adjusting for demographics, ischemic stroke risk factors, comorbid diseases, and substance use, the risk of ischemic stroke was higher among male veterans with HIV infection compared with uninfected veterans (hazard ratio 1.17 [1.01-1.36]; p = 0.04).Conclusions:HIV infection is associated with an increased ischemic stroke risk among HIV-infected compared with demographically and behaviorally similar uninfected male veterans. C1 [Sico, Jason J.; Justice, Amy C.; Skanderson, Melissa; McGinnis, Kathleen] West Haven Vet Adm Med Ctr, VA Connecticut Hlth Care Syst, West Haven, CT 06516 USA. [Sico, Jason J.; So-Armah, Kaku; Justice, Amy C.] Yale Univ, Sch Med, New Haven, CT USA. [Chang, Chung-Chou H.; Kraemer, Kevin L.; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chang, Chung-Chou H.; Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Hylek, Elaine] Boston Med Ctr, Boston, MA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Rimland, David] Atlanta Vet Adm Med Ctr, Atlanta, GA USA. [Goetz, Matthew Bidwell; Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Goetz, Matthew Bidwell; Leaf, David] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Butt, Adeel A.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Gibert, Cynthia] Washington DC Vet Adm Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA. [Brown, Sheldon T.] James J Peters VA, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA. [Samet, Jeffrey] Boston Univ, Sch Med, Boston, MA 02215 USA. [Kazis, Lewis] Boston Univ, Ctr Assessment Pharmaceut Practices, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA 02215 USA. [Kazis, Lewis] Vet Adm Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Bryant, Kendall] NIAAA, Bethesda, MD USA. [Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Freiberg, Matthew S.] Nashville Vet Affairs Med Ctr, Nashville, TN USA. RP Sico, JJ (reprint author), West Haven Vet Adm Med Ctr, VA Connecticut Hlth Care Syst, West Haven, CT 06516 USA. EM jason.sico@va.gov OI Butt, Adeel/0000-0002-1118-1826; Goetz, Matthew/0000-0003-4542-992X; Justice, Amy/0000-0003-0139-5502 FU NIH, National Institute on Alcohol Abuse and Alcoholism [5U10AA013566-10]; NIH, National Heart Lung and Blood Institute [R01 HL095136-05]; Department of Veteran Affairs Health Services Research and Development [11-262] FX Research funding was made possible by the NIH, National Institute on Alcohol Abuse and Alcoholism (grant 5U10AA013566-10); NIH, National Heart Lung and Blood Institute (grant R01 HL095136-05); and Department of Veteran Affairs Health Services Research and Development (grant 11-262). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veteran Affairs. No conflicts of interest are reported. NR 34 TC 26 Z9 26 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 12 PY 2015 VL 84 IS 19 BP 1933 EP 1940 DI 10.1212/WNL.0000000000001560 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CI2BY UT WOS:000354550900009 PM 25862803 ER PT J AU Singh, JA Akhras, KS Shiozawa, A AF Singh, Jasvinder A. Akhras, Kasem S. Shiozawa, Aki TI Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large US managed care cohort SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Gout; Comparative effectiveness; Serum urate; Febuxostat; Allopurinol ID QUALITY-OF-LIFE; SERUM URATE; HEALTH; COMORBIDITIES; HYPERURICEMIA; RISK; POPULATION; PREVALENCE; ARTHRITIS; DISEASE AB Introduction: To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA) levels in a real-world U.S. managed care setting. Methods: This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large U.S. commercial and Medicare Advantage health plan. Study patients had at least one medical claim with a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement post-index prescription. Reduction in sUA was examined using propensity score-matched cohorts, matched on patient demographics (gender, age), baseline sUA, comorbidities, geographic region and insurance type. Results: The study sample included 2,015 patients taking febuxostat and 14,025 taking allopurinol. At baseline, febuxostat users had a higher Quan-Charlson comorbidity score (0.78 vs. 0.53; P < 0.001), but similar age and gender distribution. Mean (standard deviation (SD)) sUA level following propensity score matching among treatment-naive febuxostat vs. allopurinol users (n = 873 each) were: pre-index sUA, 8.86 (SD, 1.79) vs. 8.72 (SD, 1.63; P = 0.20); and post-index sUA, 6.53 (SD, 2.01) vs. 6.71 (SD, 1.70; P = 0.04), respectively. A higher proportion of febuxostat users attained sUA goals of < 6.0 mg/dl (56.9% vs. 44.8%; P < 0.001) and < 5.0 mg/dl (35.5% vs. 19.2%; P < 0.001), respectively. Time to achieve sUA goals of < 6.0 mg/dl (346 vs. 397 days; P < 0.001) and < 5.0 mg/dl was shorter in febuxostat vs. allopurinol users (431 vs. 478 days; P < 0.001), respectively. Similar observations were made for overall propensity score-matched cohorts that included both treatment-naive and current users (n = 1,932 each). Conclusions: Febuxostat was more effective than allopurinol at the currently used doses (40 mg/day for febuxostat in 83% users and 300 mg/day or lower for allopurinol in 97% users) in lowering sUA in gout patients as demonstrated by post-index mean sUA level, the likelihood of and the time to achieving sUA goals. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35233 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN 55905 USA. [Akhras, Kasem S.; Shiozawa, Aki] Takeda Pharmaceut Int Inc, Deerfield, IL 60015 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, 700 South 19th St, Birmingham, AL 35233 USA. EM jassingh@uab.edu RI Shiozawa, Aki/O-2443-2014 OI Shiozawa, Aki/0000-0001-9757-6337 FU Takeda Pharmaceuticals International Inc.; Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient-Centered Outcomes Research Institute (PCORI) [CE-1304-6631]; VA Medical Center at Birmingham, Alabama, USA FX This study was funded by Takeda Pharmaceuticals International Inc. JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA) U01 AG018947, and National Cancer Institute (NCI) U10 CA149950, and research contract CE-1304-6631 from Patient-Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. The views expressed in this manuscript are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 37 TC 10 Z9 10 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD MAY 12 PY 2015 VL 17 AR 120 DI 10.1186/s13075-015-0624-3 PG 12 WC Rheumatology SC Rheumatology GA CH6QV UT WOS:000354162000001 PM 25963969 ER PT J AU Damschroder, LJ Moin, T Datta, SK Reardon, CM Steinle, N Weinreb, J Billington, CJ Maciejewski, ML Yancy, WS Hughes, M Makki, F Richardson, CR AF Damschroder, Laura J. Moin, Tannaz Datta, Santanu K. Reardon, Caitlin M. Steinle, Nanette Weinreb, Jane Billington, Charles J. Maciejewski, Matt L. Yancy, William S., Jr. Hughes, Maria Makki, Fatima Richardson, Caroline R. TI Implementation and evaluation of the VA DPP clinical demonstration: protocol for a multi-site non-randomized hybrid effectiveness-implementation type III trial SO IMPLEMENTATION SCIENCE LA English DT Article DE Diabetes prevention; Implementation; Veterans; Pragmatic study design ID DIABETES PREVENTION PROGRAM; IMPAIRED GLUCOSE-TOLERANCE; CONSENSUAL QUALITATIVE RESEARCH; LIFE-STYLE INTERVENTION; BUDGET IMPACT ANALYSIS; FOLLOW-UP; WEIGHT-LOSS; VETERANS; OBESITY; COMMUNITY AB Background: The Diabetes Prevention Program (DPP) study showed that lifestyle intervention resulted in a 58% reduction in incidence of type 2 diabetes among individuals with prediabetes. Additional large randomized controlled trials have confirmed these results, and long-term follow-up has shown sustained benefit 10-20 years after the interventions ended. Diabetes is a common and costly disease, especially among Veterans, and despite strong evidence supporting the feasibility of type 2 diabetes prevention, the DPP has not been widely implemented. The first aim of this study will evaluate implementation of the Veterans Affairs (VA) DPP in three VA medical centers. The second aim will assess weight and hemoglobin A1c (A1c) outcomes, and the third aim will determine the cost-effectiveness and budget impact of implementation of the VA DPP from a health system perspective. Methods/Design: This partnered multi-site non-randomized systematic assignment study will use a highly pragmatic hybrid effectiveness-implementation type III mixed methods study design. The implementation and administration of the VA DPP will be funded by clinical operations while the evaluation of the VA DPP will be funded by research grants. Seven hundred twenty eligible Veterans will be systematically assigned to the VA DPP clinical demonstration or the usual care VA MOVE!(R) weight management program. A multi-phase formative evaluation of the VA DPP implementation will be conducted. A theoretical program change model will be used to guide the implementation process and assess applicability and feasibility of the DPP for VA. The Consolidated Framework for Implementation Research (CFIR) will be used to guide qualitative data collection, analysis, and interpretation of barriers and facilitators to implementation. The RE-AIM framework will be used to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance of the VA DPP. Twelve-month weight and A1c change will be evaluated for the VA DPP compared to the VA MOVE! program. Mediation analyses will be conducted to identify whether program design differences impact outcomes. Discussion: Findings from this pragmatic evaluation will be highly applicable to practitioners who are tasked with implementing the DPP in clinical settings. In addition, findings will determine the effectiveness and cost-effectiveness of the VA DPP in the Veteran population. C1 [Damschroder, Laura J.; Reardon, Caitlin M.; Hughes, Maria; Makki, Fatima; Richardson, Caroline R.] Ann Arbor VA Ctr Clin Management Res, Ann Arbor, MI 48113 USA. [Damschroder, Laura J.; Richardson, Caroline R.] VA Diabet QUERI, Ann Arbor, MI USA. [Moin, Tannaz; Weinreb, Jane] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Moin, Tannaz; Weinreb, Jane] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moin, Tannaz] Greater Los Angeles VA Hlth Serv Res & Dev HSR &, Ctr Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Datta, Santanu K.; Maciejewski, Matt L.; Yancy, William S., Jr.] Durham VA Med Ctr, Durham, NC USA. [Datta, Santanu K.; Maciejewski, Matt L.; Yancy, William S., Jr.] Duke Univ, Sch Med, Durham, NC USA. [Steinle, Nanette] Baltimore VA Med Ctr, Baltimore, MD USA. [Steinle, Nanette] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Billington, Charles J.] Minneapolis VA Healthcare Syst, Minneapolis, MN USA. [Billington, Charles J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. RP Damschroder, LJ (reprint author), Ann Arbor VA Ctr Clin Management Res, POB 130170, Ann Arbor, MI 48113 USA. EM laura.damschroder@va.gov OI Damschroder, Laura/0000-0002-3657-8459 FU Veteran Affairs (VA) Quality Enhancement Research Initiative (QUERI) program [RRP 12-440, SDP 12-549, XVA 41-048]; VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program [TPM65-010]; VA Greater Los Angeles FX This work was funded by the Veteran Affairs (VA) Quality Enhancement Research Initiative (QUERI) program through two research grants (RRP 12-440 and SDP 12-549) and clinical quality improvement funding (XVA 41-048). Dr. Moin received support from the VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program (TPM65-010), VA Greater Los Angeles, from 2011-2014. We want to thank our partners at NCP, led by Dr. Linda Kinsinger, without whom this complex multi-component study could not have happened. NR 46 TC 4 Z9 4 U1 2 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 12 PY 2015 VL 10 AR UNSP 68 DI 10.1186/s13012-015-0250-0 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CH7RF UT WOS:000354233600001 PM 25962598 ER PT J AU Patel, MS Asch, DA Volpp, KG AF Patel, Mitesh S. Asch, David A. Volpp, Kevin G. TI Use of Wearable Monitoring Devices to Change Health Behavior Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID INCENTIVES; TRIAL C1 [Patel, Mitesh S.; Asch, David A.; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Patel, MS (reprint author), Univ Penn, 423 Guardian Dr, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 4 TC 1 Z9 1 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 12 PY 2015 VL 313 IS 18 BP 1865 EP 1866 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CH9XW UT WOS:000354391000038 PM 25965243 ER PT J AU Sutherasan, Y Penuelas, O Muriel, A Vargas, M Frutos-Vivar, F Brunetti, I Raymondos, K D'Antini, D Nielsen, N Ferguson, ND Bottiger, BW Thille, AW Davies, AR Hurtado, J Rios, F Apezteguia, C Violi, DA Cakar, N Gonzalez, M Du, B Kuiper, MA Soares, MA Koh, Y Moreno, RP Amin, P Tomicic, V Soto, L Bulow, HH Anzueto, A Esteban, A Pelosi, P AF Sutherasan, Yuda Penuelas, Oscar Muriel, Alfonso Vargas, Maria Frutos-Vivar, Fernando Brunetti, Iole Raymondos, Konstantinos D'Antini, Davide Nielsen, Niklas Ferguson, Niall D. Boettiger, Bernd W. Thille, Arnaud W. Davies, Andrew R. Hurtado, Javier Rios, Fernando Apezteguia, Carlos Violi, Damian A. Cakar, Nahit Gonzalez, Marco Du, Bin Kuiper, Michael A. Soares, Marco Antonio Koh, Younsuck Moreno, Rui P. Amin, Pravin Tomicic, Vinko Soto, Luis Buelow, Hans-Henrik Anzueto, Antonio Esteban, Andres Pelosi, Paolo CA VENTILA Grp TI Management and outcome of mechanically ventilated patients after cardiac arrest SO CRITICAL CARE LA English DT Article ID INTENSIVE-CARE-UNIT; AMERICAN-HEART-ASSOCIATION; TIDAL-VOLUME VENTILATION; EXPERIMENTAL LUNG INJURY; ARTERIAL CARBON-DIOXIDE; IN-HOSPITAL MORTALITY; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; ABDOMINAL-SURGERY; PRESSURE AB Introduction: The aim of this study was to describe and compare the changes in ventilator management and complications over time, as well as variables associated with 28-day hospital mortality in patients receiving mechanical ventilation (MV) after cardiac arrest. Methods: We performed a secondary analysis of three prospective, observational multicenter studies conducted in 1998, 2004 and 2010 in 927 ICUs from 40 countries. We screened 18,302 patients receiving MV for more than 12 hours during a one-month-period. We included 812 patients receiving MV after cardiac arrest. We collected data on demographics, daily ventilator settings, complications during ventilation and outcomes. Multivariate logistic regression analysis was performed to calculate odds ratios, determining which variables within 24 hours of hospital admission were associated with 28-day hospital mortality and occurrence of acute respiratory distress syndrome (ARDS) and pneumonia acquired during ICU stay at 48 hours after admission. Results: Among 812 patients, 100 were included from 1998, 239 from 2004 and 473 from 2010. Ventilatory management changed over time, with decreased tidal volumes (VT) (1998: mean 8.9 (standard deviation (SD) 2) ml/kg actual body weight (ABW), 2010: 6.7 (SD 2) ml/kg ABW; 2004: 9 (SD 2.3) ml/kg predicted body weight (PBW), 2010: 7.95 (SD 1.7) ml/kg PBW) and increased positive end-expiratory pressure (PEEP) (1998: mean 3.5 (SD 3), 2010: 6.5 (SD 3); P < 0.001). Patients included from 2010 had more sepsis, cardiovascular dysfunction and neurological failure, but 28-day hospital mortality was similar over time (52% in 1998, 57% in 2004 and 52% in 2010). Variables independently associated with 28-day hospital mortality were: older age, PaO2 < 60 mmHg, cardiovascular dysfunction and less use of sedative agents. Higher VT, and plateau pressure with lower PEEP were associated with occurrence of ARDS and pneumonia acquired during ICU stay. Conclusions: Protective mechanical ventilation with lower VT and higher PEEP is more commonly used after cardiac arrest. The incidence of pulmonary complications decreased, while other non-respiratory organ failures increased with time. The application of protective mechanical ventilation and the prevention of single and multiple organ failure may be considered to improve outcome in patients after cardiac arrest. C1 [Sutherasan, Yuda] Mahidol Univ, Ramathibodi Hosp, Dept Med, Bangkok 10400, Thailand. [Sutherasan, Yuda; Brunetti, Iole; Pelosi, Paolo] IRCCS AOU San Martino, IST, Dept Surg Sci & Integrated Diagnost, I-16131 Genoa, Italy. [Penuelas, Oscar] Hosp Univ Infanta Cristina, Madrid 28981, Spain. [Penuelas, Oscar] CIBER Enfermedades Resp, Madrid 28981, Spain. [Muriel, Alfonso] Hosp Ramon y Cajal Ctra, CIBERESP, IRYCIS, Ramon Cajal Inst & Res Hlth,Biostat Unit, Madrid 28034, Spain. [Vargas, Maria] Univ Naples Federico II, Dept Neurosci Odonthostomatol & Reprod Sci, I-80100 Naples, Italy. [Frutos-Vivar, Fernando; Esteban, Andres] Hosp Univ Getafe, Madrid 28905, Spain. [Frutos-Vivar, Fernando; Esteban, Andres] CIBER Enfermedades Resp, Madrid 28905, Spain. [Raymondos, Konstantinos] Med Sch Hanover, Anaesthesiol & Intens Care Med, D-30625 Hannover, Germany. [D'Antini, Davide] Univ Foggia, Dipartimento Anestesia Rianimaz & Terapia Intens, I-71100 Foggia, Italy. [Nielsen, Niklas] Helsingborg Hosp, Dept Anesthesia & Intens Care, Intens Care Unit, S-25187 Helsingborg, Sweden. [Ferguson, Niall D.] Univ Toronto, Univ Hlth Network, Dept Med, Interdept Div Crit Care Med, Toronto, ON M5G 2N2, Canada. [Ferguson, Niall D.] Mt Sinai Hosp, Toronto, ON M5G 2N2, Canada. [Boettiger, Bernd W.] Univ Hosp Cologne, Dept Anaesthesiol & Intens Care Med, D-50937 Cologne, Germany. [Thille, Arnaud W.] Univ Poitiers, Ctr Hosp, INSERM, CIC 1402,Reanimat Med, F-86000 Poitiers, France. [Davies, Andrew R.] Monash Univ, ANZIC RC, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Hurtado, Javier] Univ Republica, Hosp Clin, Dept Pathophysiol, Montevideo 11600, Uruguay. [Rios, Fernando; Apezteguia, Carlos] Hosp Nacl Prof Alejandro Posadas El Palomar, Dept Intens Care, RA-1684 Buenos Aires, DF, Argentina. [Violi, Damian A.] Hosp Prof Dr Luis Guemes, Med Staff Crit Care, Buenos Aires, DF, Argentina. [Cakar, Nahit] Istanbul Univ, Istanbul Fac Med, Anesthesiol & Intens Care, TR-34093 Istanbul, Turkey. [Gonzalez, Marco] Clin Medellin, Medellin, Colombia. [Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia. [Du, Bin] Beijing Union Med Coll Hosp, Med ICU, Beijing 100730, Peoples R China. [Kuiper, Michael A.] Med Ctr Leeuwarden, Dept Intens Care, NL-8934 AD Leeuwarden, Netherlands. [Soares, Marco Antonio] Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil. [Koh, Younsuck] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, Seoul 138736, South Korea. [Moreno, Rui P.] Sao Jose Ctr Hosp Lisboa Cent, Unidade Cuidados Intensivos Neurocrit Hosp, P-1150199 Lisbon, Portugal. [Amin, Pravin] Bombay Hosp Inst Med Sci, Mumbai 400020, Maharashtra, India. [Tomicic, Vinko] Clin Lilas Santiago, Santiago, Chile. [Soto, Luis] Inst Nacl Torax Santiago, Santiago, Chile. [Buelow, Hans-Henrik] Reg Zealand Univ Copenhagen, Holbaek Hosp, Anaesthesiol & Intens Care, DK-4300 Holbaek, Denmark. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Pelosi, P (reprint author), IRCCS AOU San Martino, IST, Dept Surg Sci & Integrated Diagnost, Largo Rosanna Benzi 8, I-16131 Genoa, Italy. EM ppelosi@hotmail.com RI ; koca, ugur/F-1265-2016; Vargas, Maria/H-6876-2014 OI Ferguson, Niall/0000-0002-6213-5264; koca, ugur/0000-0002-2949-4265; Muriel, Alfonso /0000-0002-4805-4011; Vargas, Maria/0000-0001-7652-970X; D'Antini, Davide/0000-0002-2346-9720; Frutos-Vivar, Fernando/0000-0002-4648-9636 FU Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES); Instituto de Salud Carlos III, Madrid, Spain; Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada) FX We are grateful to all investigators of the VENTILA study group for collecting data for this article (see Additional file 1). The VENTILA study was supported by Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Dr Ferguson is supported by a Canadian Institutes of Health Research New Investigator Award (Ottawa, Canada). The funding organizations had no role in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript. NR 48 TC 12 Z9 13 U1 3 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1466-609X EI 1364-8535 J9 CRIT CARE JI Crit. Care PD MAY 8 PY 2015 VL 19 AR 215 DI 10.1186/s13054-015-0922-9 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA CK4ZE UT WOS:000356231100001 PM 25953483 ER PT J AU Liu, Y Lear, T Iannone, O Shiva, S Corey, C Rajbhandari, S Jerome, J Chen, BB Mallampalli, RK AF Liu, Yuan Lear, Travis Iannone, Olivia Shiva, Sruti Corey, Catherine Rajbhandari, Shristi Jerome, Jacob Chen, Bill B. Mallampalli, Rama K. TI The Proapoptotic F-box Protein Fbxl7 Regulates Mitochondrial Function by Mediating the Ubiquitylation and Proteasomal Degradation of Survivin SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Cell Biology; E3 Ubiquitin Ligase; Lung Injury; Mitochondria; Protein Degradation; Oxygen ID SCF UBIQUITIN LIGASE; RECOGNIZES SUGAR CHAINS; X-LINKED INHIBITOR; IAP PROTEINS; CANCER; APOPTOSIS; COMPLEX; FAMILY; PHOSPHORYLATION; LOCALIZATION AB Background: The SCF ubiquitin E3 ligase component Fbxl7 possesses proapoptotic activity. Results: Fbxl7 targets the antiapoptotic protein survivin for polyubiquitylation and proteasomal degradation. Conclusion: Survivin protects mitochondria from damage induced by Fbxl7. Significance: Understanding how F-box proteins regulate survivin might impact therapies to preserve cellular bioenergetics. Fbxl7, a component of the Skp1Cul1F-box protein type ubiquitin E3 ligase, regulates mitotic cell cycle progression. Here we demonstrate that overexpression of Fbxl7 in lung epithelia decreases the protein abundance of survivin, a member of the inhibitor of apoptosis family. Fbxl7 mediates polyubiquitylation and proteasomal degradation of survivin by interacting with Glu-126 within its carboxyl-terminal helix. Furthermore, both Lys-90 and Lys-91 within survivin serve as ubiquitin acceptor sites. Ectopically expressed Fbxl7 impairs mitochondrial function, whereas depletion of Fbxl7 protects mitochondria from actions of carbonyl cyanide m-chlorophenylhydrazone, an inhibitor of oxidative phosphorylation. Compared with wild-type survivin, cellular expression of a survivin mutant protein deficient in its ability to interact with Fbxl7 (E126A) and a ubiquitylation-resistant double point mutant (KK90RR/KK91RR) rescued mitochondria to a larger extent from damage induced by overexpression of Fbxl7. Therefore, these data suggest that the Skp1Cul1F-box protein complex subunit Fbxl7 modulates mitochondrial function by controlling the cellular abundance of survivin. The results raise opportunities for F-box protein targeting to preserve mitochondrial function. C1 [Liu, Yuan; Lear, Travis; Iannone, Olivia; Rajbhandari, Shristi; Jerome, Jacob; Chen, Bill B.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Shiva, Sruti; Corey, Catherine] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Chen, BB (reprint author), Univ Pittsburgh, Dept Med, Pulm Allergy & Crit Care Med, Biomed Sci Tower 1,W1254, Pittsburgh, PA 15213 USA. EM chenb@upmc.edu; mallampallirk@upmc.edu RI Regan, Clinton/E-6250-2012 OI Lear, Travis/0000-0001-9156-0844 FU National Institutes of Health [HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, P01 HL114453, HL116472]; Department of Veterans Affairs; Flight Attendants Medical Research Institute FX This work was supported, in whole or in part, by National Institutes of Health R01 Grants HL096376, HL097376, HL098174, HL081784, 1UH2HL123502, and P01 HL114453 (to R. K. M.) and HL116472 (to B. B. C.). This work was also supported by a merit review award from the Department of Veterans Affairs and the Flight Attendants Medical Research Institute. NR 41 TC 6 Z9 6 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 8 PY 2015 VL 290 IS 19 BP 11843 EP 11852 DI 10.1074/jbc.M114.629931 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CH9XA UT WOS:000354388600004 PM 25778398 ER PT J AU Kim, SH Wu, SY Baek, JI Choi, SY Su, Y Flynn, CR Gamse, JT Ess, KC Hardiman, G Lipschutz, JH Abumrad, NN Rockey, DC AF Kim, Seok-Hyung Wu, Shu-Yu Baek, Jeong-In Choi, Soo Young Su, Yanhui Flynn, Charles R. Gamse, Joshua T. Ess, Kevin C. Hardiman, Gary Lipschutz, Joshua H. Abumrad, Naji N. Rockey, Don C. TI A Post-Developmental Genetic Screen for Zebrafish Models of Inherited Liver Disease SO PLOS ONE LA English DT Article ID CHEDIAK-HIGASHI-SYNDROME; ANIMAL-MODELS; HEPATIC STEATOSIS; LEADS; IDENTIFICATION; INHIBITION; STRESS AB Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease such as simple steatosis, nonalcoholic steatohepatitis (NASH), cirrhosis and fibrosis. However, the molecular pathogenesis and genetic variations causing NAFLD are poorly understood. The high prevalence and incidence of NAFLD suggests that genetic variations on a large number of genes might be involved in NAFLD. To identify genetic variants causing inherited liver disease, we used zebrafish as a model system for a large-scale mutant screen, and adopted a whole genome sequencing approach for rapid identification of mutated genes found in our screen. Here, we report on a forward genetic screen of ENU mutagenized zebrafish. From 250 F2 lines of ENU mutagenized zebrafish during post-developmental stages (5 to 8 days post fertilization), we identified 19 unique mutant zebrafish lines displaying visual evidence of hepatomegaly and/or steatosis with no developmental defects. Histological analysis of mutants revealed several specific phenotypes, including common steatosis, micro/macrovesicular steatosis, hepatomegaly, ballooning, and acute hepatocellular necrosis. This work has identified multiple post-developmental mutants and establishes zebrafish as a novel animal model for post-developmental inherited liver disease. C1 [Kim, Seok-Hyung; Baek, Jeong-In; Choi, Soo Young; Su, Yanhui; Hardiman, Gary; Lipschutz, Joshua H.; Rockey, Don C.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Wu, Shu-Yu; Gamse, Joshua T.] Vanderbilt Univ, Dept Biol, Nashville, TN 37232 USA. [Flynn, Charles R.; Abumrad, Naji N.] Vanderbilt Univ, Dept Surg, Nashville, TN 37232 USA. [Ess, Kevin C.] Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC 29401 USA. RP Kim, SH (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM kims@musc.edu RI Flynn, Charles/M-3895-2015 OI Flynn, Charles/0000-0002-3749-0598 FU Norman S. Coplon Extramural Research Grant; Metabolic Technologies, Inc.; [W81XWH-10-1-0854]; [DK069909]; [DK070980]; [DK057830]; [DK098819]; [DK091748]; [DK096527]; [P30 DK020593]; [P30 DK058404] FX This study was supported by the following grants: W81XWH-10-1-0854 (to KCE) (http://www.defense.gov/); Merit Award (to JHL) (http://www.va.gov/); Norman S. Coplon Extramural Research Grant (to JHL) (http://www.satellitehealth.com/); DK069909 and DK070980 (to JHL), DK057830 and DK098819 (to DCR), DK091748 and DK096527 (to NNA), P30 DK020593 and P30 DK058404 (to CRF) (http://www.nih.gov/); Metabolic Technologies, Inc. (to NNA) (http://www.mettechinc.com/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 23 TC 1 Z9 1 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 7 PY 2015 VL 10 IS 5 AR e0125980 DI 10.1371/journal.pone.0125980 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH7KF UT WOS:000354214400058 PM 25950913 ER PT J AU Hoo, GWS Klaustermeyer, WB AF Hoo, Guy W. Soo Klaustermeyer, William B. TI Icatibant in ACE-Inhibitor-Induced Angioedema SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID UNITED-STATES C1 [Hoo, Guy W. Soo; Klaustermeyer, William B.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. RP Hoo, GWS (reprint author), VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA. EM guy.soohoo@va.gov NR 3 TC 0 Z9 0 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 7 PY 2015 VL 372 IS 19 BP 1866 EP 1866 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA CH4BB UT WOS:000353974700021 ER PT J AU Cunningham, KF Beeson, GC Beeson, CC Baicu, CF Zile, MR McDermott, PJ AF Cunningham, Kathryn F. Beeson, Gyda C. Beeson, Craig C. Baicu, Catalin F. Zile, Michael R. McDermott, Paul J. TI Estrogen-Related Receptor a (ERRa) is required for adaptive increases in PGC-1 isoform expression during electrically stimulated contraction of adult cardiomyocytes in sustained hypoxic conditions SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Contraction; Cardiomyocyte; Hypoxia; Estrogen-Related Receptor; Peroxisome Proliferator-Activated Receptor; gamma Coactivator-1 ID PROLIFERATOR-ACTIVATED RECEPTOR; HEART-FAILURE; ENERGY-METABOLISM; INVERSE AGONIST; TRANSCRIPTIONAL CONTROL; FELINE CARDIOCYTES; BROWN-ADIPOCYTES; ALPHA EXPRESSION; SKELETAL-MUSCLE; GENE-EXPRESSION AB Background and objectives: In adultmyocardium, Estrogen-Related Receptora(ERR alpha) programs energetic capacity of cardiomyocytes by regulating expression of target genes required for mitochondrial biogenesis, fatty acid metabolism and oxidative phosphorylation. Transcriptional activation by ERRa is dependent on the alpha or beta isoform of Peroxisome Proliferator-Activated Receptor gamma Coactivator-1 (PGC-1). This study utilized a model of continuously contracting adult cardiomyocytes to determine the effects of sustained oxygen reduction (hypoxia) on ERRa target gene expression. Methods and results: Adult feline cardiomyocytes in primary culture were electrically stimulated to contract at 1 Hz in either normoxia (21% O-2) or hypoxia (0.5% O-2). Compared to normoxia, hypoxia increased PGC-1 alpha mRNA and PGC-1 beta mRNA levels by 16-fold and 14-fold after 24 h. ERRa mRNA levels were increased 3-fold by hypoxia over the same time period. Treatment of cardiomyocytes with XCT-790, an ERRa inverse agonist, caused knockdown of ERR alpha protein expression. The increases in PGC-1 mRNA levels in response to hypoxia were blocked by XCT-790 treatment, which indicates that expression of PGC-1 isoforms is dependent on ERRa activity. The products of two ERRa target genes required for energy metabolism, Cox6c mRNA and Fabp3 mRNA, increased by 4.5-fold and 3.5 fold after 24 h of hypoxia as compared to normoxic controls. These increases were blocked by XCT-790 treatment of hypoxic cardiomyocytes with a concomitant decrease in ERRa expression. Conclusions: ERRa activity is required to increase expression of PGC-1 isoforms and downstream target genes as part of the adaptive response of contracting adult cardiomyocytes to sustained hypoxia. Published by Elsevier Ireland Ltd. C1 [Cunningham, Kathryn F.; Baicu, Catalin F.; Zile, Michael R.; McDermott, Paul J.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29425 USA. [Beeson, Gyda C.; Beeson, Craig C.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Zile, Michael R.; McDermott, Paul J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 114 Doughty St,Room 303,MSC 773, Charleston, SC 29425 USA. EM mcdermp@musc.edu FU Merit Review Award of the Department of Veterans Affairs; NIH Predoctoral Fellowship Training Grant to Improve Cardiovascular Therapies; American Heart Association Predoctoral Fellowship [12PRE1205007] FX We wish to thank Daisy Dominick, Dr. Harinath Kasiganesan and Shaun R. Wahl for their excellent technical assistance. This research was supported by a Merit Review Award of the Department of Veterans Affairs (to P.J.M.); NIH Predoctoral Fellowship Training Grant to Improve Cardiovascular Therapies (to K.F.C.); and American Heart Association Predoctoral Fellowship (K.F.C., 12PRE1205007). NR 50 TC 2 Z9 4 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD MAY 6 PY 2015 VL 187 BP 393 EP 400 DI 10.1016/j.ijcard.2015.03.353 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CI6WT UT WOS:000354905600111 PM 25841134 ER PT J AU Gerding, DN Meyer, T Lee, C Cohen, SH Murthy, UK Poirier, A Van Schooneveld, TC Pardi, DS Ramos, A Barron, MA Chen, HZ Villano, S AF Gerding, Dale N. Meyer, Thomas Lee, Christine Cohen, Stuart H. Murthy, Uma K. Poirier, Andre Van Schooneveld, Trevor C. Pardi, Darrell S. Ramos, Antonio Barron, Michelle A. Chen, Hongzi Villano, Stephen TI Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C difficile Infection A Randomized Clinical Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID DIARRHEA; DISEASE; METRONIDAZOLE; COLONIZATION; VANCOMYCIN; HAMSTERS AB IMPORTANCE Clostridium difficile is the most common cause of health care-associated infection in US hospitals. Recurrence occurs in 25% to 30% of patients. OBJECTIVE To determine the safety, fecal colonization, recurrence rate, and optimal dosing schedule of nontoxigenic C difficile strain M3 (VP20621; NTCD-M3) for prevention of recurrent C difficile infection (CDI). DESIGN, SETTING, AND PARTICIPANTS Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from June 2011 to June 2013 among 173 patients aged 18 years or older who were diagnosed as having CDI (first episode or first recurrence) and had successfully completed treatment with metronidazole, oral vancomycin, or both at 44 study centers in the United States, Canada, and Europe. INTERVENTIONS Patients were randomly assigned to receive 1 of 4 treatments: oral liquid formulation of NTCD-M3, 104 spores/d for 7 days (n = 43), 107 spores/d for 7 days (n = 44), or 107 spores/d for 14 days (n = 42), or placebo for 14 days (n = 44). MAIN OUTCOMES AND MEASURES The primary outcomewas safety and tolerability of NTCD-M3 within 7 days of treatment. Exploratory secondary outcomes included fecal colonization with NTCD-M3 from end of study drug through week 6 and CDI recurrence from day 1 through week 6. RESULTS Among 168 patients who started treatment, 157 completed treatment. One or more treatment-emergent adverse events were reported in 78% of patients receiving NTCD-M3 and 86% of patients receiving placebo. Diarrhea and abdominal pain were reported in 46% and 17% of patients receiving NTCD-M3 and 60% and 33% of placebo patients, respectively. Serious treatment-emergent adverse events were reported in 7% of patients receiving placebo and 3% of all patients who received NTCD-M3. Headache was reported in 10% of patients receiving NTCD-M3 and 2% of placebo patients. Fecal colonization occurred in 69% of NTCD-M3 patients: 71% with 10(7) spores/d and 63% with 10(4) spores/d. Recurrence of CDI occurred in 13 (30%) of 43 placebo patients and 14 (11%) of 125 NTCD-M3 patients (odds ratio [OR], 0.28; 95% CI, 0.11-0.69; P = .006); the lowest recurrence was in 2 (5%) of 43 patients receiving 10(7) spores/d for 7 days (OR, 0.1; 95% CI, 0.0-0.6; P = .01 vs placebo]). Recurrence occurred in 2 (2%) of 86 patients who were colonized vs 12 (31%) of 39 patients who received NTCD-M3 and were not colonized (OR, 0.01; 95% CI, 0.00-0.05; P < .001). CONCLUSIONS AND RELEVANCE Among patients with CDI who clinically recovered following treatment with metronidazole or vancomycin, oral administration of spores of NTCD-M3 was well tolerated and appeared to be safe. Nontoxigenic C difficile strain M3 colonized the gastrointestinal tract and significantly reduced CDI recurrence. Copyright 2015 American Medical Association. All rights reserved. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Meyer, Thomas] Indiana Univ, Hlth Arnett Hosp, Lafayette, IN USA. [Lee, Christine] McMaster Univ, St Josephs Healthcare Hamilton, Hamilton, ON, Canada. [Cohen, Stuart H.] Univ Calif Davis, Med Ctr, Div Infect Dis, Sacramento, CA 95817 USA. [Murthy, Uma K.] VA Med Ctr, Syracuse, NY USA. [Murthy, Uma K.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Poirier, Andre] Ctr Sante & Serv Sociaux Trois Rivieres, Trois Rivieres, PQ, Canada. [Van Schooneveld, Trevor C.] Univ Nebraska Med Ctr, Div Infect Dis, Omaha, NE USA. [Pardi, Darrell S.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Ramos, Antonio] Hosp Univ Puerta Hierro, Madrid, Spain. [Barron, Michelle A.] Univ Colorado Denver, Internal Med & Infect Dis, Aurora, CO USA. [Chen, Hongzi; Villano, Stephen] Shire, Wayne, PA USA. RP Gerding, DN (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev, Fifth Ave & Roosevelt Rd,Bldg 1,Room B347, Hines, IL 60141 USA. EM dale.gerding2@va.gov RI Ramos, Antonio/G-5535-2016 OI Ramos, Antonio/0000-0002-4840-9425 FU ViroPharma Incorporated, which is now part of the Shire group of companies FX This study was sponsored by ViroPharma Incorporated, which is now part of the Shire group of companies. NR 20 TC 61 Z9 61 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 5 PY 2015 VL 313 IS 17 BP 1719 EP 1727 DI 10.1001/jama.2015.3725 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA CH3HQ UT WOS:000353921000017 PM 25942722 ER PT J AU Poordad, F Sievert, W Mollison, L Bennett, M Tse, E Brau, N Levin, J Sepe, T Lee, SS Angus, P Conway, B Pol, S Boyer, N Bronowicki, JP Jacobson, I Muir, AJ Reddy, KR Tam, E Ortiz-Lasanta, G de Ledinghen, V Sulkowski, M Boparai, N McPhee, F Hughes, E Swenson, ES Yin, PD AF Poordad, Fred Sievert, William Mollison, Lindsay Bennett, Michael Tse, Edmund Braeu, Norbert Levin, James Sepe, Thomas Lee, Samuel S. Angus, Peter Conway, Brian Pol, Stanislas Boyer, Nathalie Bronowicki, Jean-Pierre Jacobson, Ira Muir, Andrew J. Reddy, K. Rajender Tam, Edward Ortiz-Lasanta, Grisell de Ledinghen, Victor Sulkowski, Mark Boparai, Navdeep McPhee, Fiona Hughes, Eric Swenson, E. Scott Yin, Philip D. CA UNITY-1 Study Grp TI Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID HEPATITIS-C VIRUS; TREATMENT-NAIVE PATIENTS; PLUS ASUNAPREVIR; RIBAVIRIN; ABT-450/R-OMBITASVIR; SOFOSBUVIR; LEDIPASVIR; DASABUVIR; BMS-791325 AB IMPORTANCE The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), and beclabuvir (a nonnucleoside NS5B inhibitor). DESIGN, SETTING, AND PARTICIPANTS Thiswas an open-label, single-group, uncontrolled international study (UNITY-1) conducted at 66 sites in the United States, Canada, France, and Australia between December 2013 and August 2014. Patients without cirrhosis who were either treatment-naive (n = 312) or treatment-experienced (n = 103) and had chronic HCV genotype 1 infection were included. INTERVENTIONS Patients received a twice-daily fixed-dose combination of daclatasvir, 30mg; asunaprevir, 200mg; and beclabuvir, 75 mg. MAIN OUTCOMES AND MEASURES The primary study outcome was SVR12 (HCV-RNA <25 IU/mL at posttreatment week 12) in patients naive to treatment. A key secondary outcome was SVR12 in the treatment-experienced cohort. RESULTS Baseline characteristics were comparable between the treatment-naive and treatment-experienced cohorts. Patients were 58% male, 26% had IL28B (rs12979860) CC genotype, 73% were infected with genotype 1a, and 27% were infected with genotype 1b. Overall, SVR12 was observed in 379 of 415 patients (91.3%; 95% CI, 88.6%-94.0%): 287 of 312 treatment-naive patients (92.0%; 95% CI, 89.0%-95.0%) and 92 of 103 treatment-experienced patients (89.3%; 95% CI, 83.4%-95.3%). Virologic failure occurred in 34 patients (8%) overall. One patient died at posttreatment week 3; this was not considered related to study medication. There were 7 serious adverse events, all considered unrelated to study treatment, and 3 adverse events (<1%) leading to treatment discontinuation, including 2 grade 4 alanine aminotransferase elevations. The most common adverse events (in >= 10% of patients) were headache, fatigue, diarrhea, and nausea. CONCLUSIONS AND RELEVANCE In this open-label, nonrandomized, uncontrolled study, a high rate of SVR12 was achieved in treatment-naive and treatment-experienced noncirrhotic patients with chronic HCV genotype 1 infection who received 12 weeks of treatment with the oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir. Copyright 2015 American Medical Association. All rights reserved. C1 [Poordad, Fred] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78215 USA. [Sievert, William] Monash Hlth, Melbourne, Vic, Australia. [Sievert, William] Monash Univ, Melbourne, Vic 3004, Australia. [Mollison, Lindsay] Univ Western Australia, Sch Med & Pharmacol, Fremantle Hepatitis Serv, Fremantle, WA, Australia. [Bennett, Michael] Med Associates Res Grp, San Diego, CA USA. [Tse, Edmund] Royal Adelaide Hosp, Adelaide, SA 5000, Australia. [Braeu, Norbert] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, Norbert] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Levin, James] Dean Fdn, Madison, WI USA. [Sepe, Thomas] Univ Gastroenterol, Providence, RI USA. [Lee, Samuel S.] Univ Calgary, Calgary, AB, Canada. [Angus, Peter] Austin Hosp, Heidelberg, Vic, Australia. [Conway, Brian] Vancouver Infect Dis Ctr, Vancouver, BC, Canada. [Pol, Stanislas] Univ Paris 05, Hop Cochin, AP HP, Unite Hepatol,INSERM,UMS 20,Inst Pasteur, Paris, France. [Boyer, Nathalie] Hop Beaujon, Serv Hepatol, Clichy, France. [Bronowicki, Jean-Pierre] Univ Lorraine, Ctr Hosp Univ Nancy, INSERM, U954, Vandoeuvre Les Nancy, France. [Jacobson, Ira] Weill Cornell Med Coll, New York, NY USA. [Muir, Andrew J.] Duke Univ, Med Ctr, Durham, NC USA. [Reddy, K. Rajender] Univ Penn, Philadelphia, PA 19104 USA. [Tam, Edward] LAIR Ctr, Vancouver, BC, Canada. [Ortiz-Lasanta, Grisell] Fdn Invest, San Juan, PR USA. [de Ledinghen, Victor] Hop Du Haut Leveque, Pessac, France. [Sulkowski, Mark] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Boparai, Navdeep; Hughes, Eric] Bristol Myers Squibb Co, Princeton, NJ USA. [McPhee, Fiona; Swenson, E. Scott; Yin, Philip D.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA. RP Poordad, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, 607 Camden St,Ste 101, San Antonio, TX 78215 USA. EM poordad@uthscsa.edu OI TAM, EDWARD/0000-0002-8306-3968 FU Bristol-Myers Squibb FX This study was funded by Bristol-Myers Squibb. Editorial support was provided by Andrew Street, PhD, of Articulate Science and was funded by Bristol-Myers Squibb. NR 20 TC 42 Z9 44 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 5 PY 2015 VL 313 IS 17 BP 1728 EP 1735 DI 10.1001/jama.2015.3860 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CH3HQ UT WOS:000353921000018 PM 25942723 ER PT J AU Truchan, NA Brar, HK Gallagher, SJ Neuman, JC Kimple, ME AF Truchan, Nathan A. Brar, Harpreet K. Gallagher, Shannon J. Neuman, Joshua C. Kimple, Michelle E. TI A single-islet microplate assay to measure mouse and human islet insulin secretion SO ISLETS LA English DT Article DE assay development; islet culture; insulin secretion; microplate assay; beta-cell function ID PANCREATIC-ISLETS; TISSUE-CULTURE; CELL-SURVIVAL; RECEPTOR; GLUCOSE; MICE AB One complication to comparing -cell function among islet preparations, whether from genetically identical or diverse animals or human organ donors, is the number of islets required per assay. Islet numbers can be limiting, meaning that fewer conditions can be tested; other islet measurements must be excluded; or islets must be pooled from multiple animals/donors for each experiment. Furthermore, pooling islets negates the possibility of performing single-islet comparisons. Our aim was to validate a 96-well plate-based single islet insulin secretion assay that would be as robust as previously published methods to quantify glucose-stimulated insulin secretion from mouse and human islets. First, we tested our new assay using mouse islets, showing robust stimulation of insulin secretion 24 or 48h after islet isolation. Next, we utilized the assay to quantify mouse islet function on an individual islet basis, measurements that would not be possible with the standard pooled islet assay methods. Next, we validated our new assay using human islets obtained from the Integrated Islet Distribution Program (IIDP). Human islets are known to have widely varying insulin secretion capacity, and using our new assay we reveal biologically relevant factors that are significantly correlated with human islet function, whether displayed as maximal insulin secretion response or fold-stimulation of insulin secretion. Overall, our results suggest this new microplate assay will be a useful tool for many laboratories, expert or not in islet techniques, to be able to precisely quantify islet insulin secretion from their models of interest. C1 [Truchan, Nathan A.; Brar, Harpreet K.; Gallagher, Shannon J.; Kimple, Michelle E.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. [Neuman, Joshua C.; Kimple, Michelle E.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI USA. [Truchan, Nathan A.; Brar, Harpreet K.; Gallagher, Shannon J.; Neuman, Joshua C.; Kimple, Michelle E.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Kimple, ME (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. EM mkimple@medicine.wisc.edu FU University of Wisconsin Institute for Clinical and Translational Research (UW-ICTR) pilot grant [ICTR-UWHC-20120919]; Pharmaceutical Researchers and Manufacturers of America (PhRMA) Foundation; American Diabetes Association [1-14-BS-115]; NIH [R01 DK102598]; University of Wisconsin Institute of Aging [5T32 AG000213]; Hilldale Under-graduate/Faculty Research Award from the University of Wisconsin-Madison FX This work was funded primarily by University of Wisconsin Institute for Clinical and Translational Research (UW-ICTR) pilot grant ICTR-UWHC-20120919 (to M.E.K.) and a starter grant from the Pharmaceutical Researchers and Manufacturers of America (PhRMA) Foundation (to M.E.K.). Additional support was provided by American Diabetes Association grant 1-14-BS-115 (to M.E.K.) and NIH grant R01 DK102598 (to M.E.K.). Joshua Neuman is supported by a training fellowship from the University of Wisconsin Institute of Aging (5T32 AG000213). Harpreet K. Brar was funded in part through a Hilldale Under-graduate/Faculty Research Award from the University of Wisconsin-Madison. This material is the result of work supported in part with the resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 16 TC 2 Z9 2 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1938-2014 EI 1938-2022 J9 ISLETS JI Islets PD MAY 4 PY 2015 VL 7 IS 3 DI 10.1080/19382014.2015.1076607 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CZ8LO UT WOS:000367351400001 ER PT J AU Hughes, JM Martin, JL AF Hughes, Jaime M. Martin, Jennifer L. TI Sleep Characteristics of Veterans Affairs Adult Day Health Care Participants SO BEHAVIORAL SLEEP MEDICINE LA English DT Article ID INSOMNIA; DISORDERS; INDEX AB Addressing sleep disturbance can help to slow functional decline, delay nursing home admission, and improve overall health among older adults; however, sleep is not widely studied in high-risk older adults such as Adult Day Health Care (ADHC) participants. Sixty-eight ADHC participants were interviewed for sleep disturbance using a 28-item screening questionnaire. More than two thirds (n = 48, 70.6%) reported one or more characteristics of poor sleep, and 38% of participants met basic criteria for insomnia. Individuals with insomnia attended ADHC less frequently, reported worse sleep quality and shorter sleep duration, and were more likely to endorse trouble falling asleep, staying asleep, and waking up too early (ps < 0.001). Research is needed to better understand perceptions, predictors, and outcomes of sleep disturbance within ADHC participants. C1 [Hughes, Jaime M.] Univ N Carolina, Sch Social Work, Chapel Hill, NC USA. [Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Martin, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, 16111 Plummer St,11E, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU National Institute on Aging [K23 AG028452, L30 AG032916]; VA Rehabilitation Research and Development [1RX000135-01]; VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center FX This work was supported by the National Institute on Aging [K23 AG028452 and L30 AG032916 to Martin]; VA Rehabilitation Research and Development [1RX000135-01 to Martin]; and VA Greater Los Angeles Healthcare System Geriatric Research, Education, and Clinical Center. NR 22 TC 2 Z9 2 U1 1 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1540-2002 EI 1540-2010 J9 BEHAV SLEEP MED JI Behav. Sleep Med. PD MAY 4 PY 2015 VL 13 IS 3 BP 197 EP 207 DI 10.1080/15402002.2013.855212 PG 11 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CH0QR UT WOS:000353727800003 PM 24654988 ER PT J AU Viehman, J Clarke, L Shields, R Clancy, C Nguyen, M AF Viehman, J. Clarke, L. Shields, R. Clancy, C. Nguyen, M. TI Deep Surgical Site Infections (dSSI) After Liver Transplantation (LTx): Emergence of Multiple-Drug Resistant (MDR) Pathogens SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY 02-06, 2015 CL Philadelphia, PA C1 [Viehman, J.; Clarke, L.; Nguyen, M.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Shields, R.; Clancy, C.; Nguyen, M.] Univ Pittsburgh, Pittsburgh, PA USA. [Clancy, C.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2015 VL 15 SU 3 SI SI MA 330 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA DD7SK UT WOS:000370124200173 ER PT J AU Pyne, JM Fortney, JC Mouden, S Lu, LY Hudson, TJ Mittal, D AF Pyne, Jeffrey M. Fortney, John C. Mouden, Sip Lu, Liya Hudson, Teresa J. Mittal, Dinesh TI Cost-Effectiveness of On-Site Versus Off-Site Collaborative Care for Depression in Rural FQHCs SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE DEPRESSION; QUALITY IMPROVEMENT; MAJOR DEPRESSION; DECISION-SUPPORT; HEALTH CENTERS; MENTAL-HEALTH; MANAGEMENT; INTERVENTION; TELEPHONE AB Objective: Collaborative care for depression in primary care settings is effective and cost-effective. However, there is minimal evidence to support the choice of on-site versus off-site models. This study examined the cost-effectiveness of on-site practice-based collaborative care (PBCC) versus off-site telemedicine-based collaborative care (TBCC) for depression in federally qualified health centers (FQHCs). Methods: In a multisite, randomized, pragmatic comparative cost-effectiveness trial, 19,285 patients were screened for depression, 2,863 (14.8%) screened positive, and 364 were enrolled. Telephone interview data were collected at baseline and at six, 12, and 18 months. Base case analysis used Arkansas FQHC health care costs, and secondary analysis used national cost estimates. Effectiveness measures were depression-free days and quality-adjusted life years (QALYs) derived from depression-free days, the 12-Item Short-Form Survey, and the Quality of Well-Being (QWB) Scale. Nonparametric bootstrap with replacement methods were used to generate an empirical joint distribution of incremental costs and QALYs and acceptability curves. Results: The TBCC intervention resulted in more depression-free days and QALYs but at a greater cost than the PBCC intervention. The disease-specific (depression-free day) and generic (QALY) incremental cost-effectiveness ratios (ICERs) were below their respective ICER thresholds for implementation, suggesting that the TBCC intervention was more cost effective than the PBCC intervention. Conclusions: These results support the cost-effectiveness of TBCC in medically underserved primary care settings. Information about whether to insource (make) or outsource (buy) depression care management is important, given the current interest in patient-centered medical homes, value-based purchasing, and bundled payments for depression care. C1 [Pyne, Jeffrey M.; Lu, Liya; Hudson, Teresa J.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. [Pyne, Jeffrey M.; Hudson, Teresa J.] Cent Arkansas Vet Healthcare Syst, Dept Psychiat, North Little Rock, AR USA. [Fortney, John C.; Mittal, Dinesh] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Fortney, John C.; Mittal, Dinesh] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, Seattle, WA USA. [Mouden, Sip] Community Hlth Ctr Arkansas Inc, North Little Rock, AR USA. RP Pyne, JM (reprint author), Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. EM jmpyne@uams.edu FU National Institute of Mental Health [R01 MH076908, MH076908-04S1]; National Institutes of Health [UL1TR000039, KL2TR000063]; National Institute of General Medical Science [P30 GM110702] FX This research was supported by grants from the National Institute of Mental Health (R01 MH076908 and MH076908-04S1), National Institutes of Health (UL1TR000039 and KL2TR000063), and National Institute of General Medical Science (P30 GM110702). This study is registered at www.clinicaltrials.gov (NCT00439452). NR 37 TC 3 Z9 3 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAY PY 2015 VL 66 IS 5 BP 491 EP 499 DI 10.1176/appi.ps.201400186 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5RH UT WOS:000370688500011 PM 25686811 ER PT J AU Koo, KH Madden, E Maguen, S AF Koo, Kelly H. Madden, Erin Maguen, Shira TI Race-Ethnicity and Gender Differences in VA Health Care Service Utilization Among US Veterans of Recent Conflicts SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN VETERANS; UNITED-STATES; AMERICANS; IRAQ; PREVALENCE; DIAGNOSES; QUALITY; CLINICS; MEMBERS AB Objective: The purpose of this study was to compare health care utilization patterns by race-ethnicity and gender among veterans returning from Iraq and Afghanistan. Methods: A retrospective analysis was conducted with records from U.S. service members and veterans returning from Iraq and Afghanistan who enrolled in health care through the Veterans Health Administration, who received a psychiatric diagnosis, and who had used primary or mental health outpatient care between October 7, 2001, and December 31, 2012 (N=309,050). Racial-ethnic minority groups were first collapsed together and compared with whites and then separated by racial-ethnic group. Gender was also tested as a moderator of utilization. Results: Although rates of mental health outpatient care, primary care, and emergency service utilization were relatively similar for racial-ethnic minority groups and whites, minority groups were admitted to psychiatric inpatient care at lower rates than whites. When veterans were separately categorized by specific racial-ethnic groups, some differences in utilization rates emerged; most notably, only black and Hispanic men were admitted less frequently to psychiatric inpatient care, and male and female Asian/Pacific Islander veterans used emergency services less, than their white counterparts. Gender moderated the association between race-ethnicity and mental health outpatient use, such that American Indian and Hispanic women used mental health outpatient services less than white women, but American Indian and Hispanic men showed the opposite pattern. Furthermore, black men were more likely than white men to use mental health outpatient services, but there was no difference between these women. Conclusions: Although service utilization rates between minority groups and whites were similar when minority groups were combined, examination of utilization by racial-ethnic groups and by men and women separately yielded more robust findings. C1 [Koo, Kelly H.; Madden, Erin; Maguen, Shira] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Koo, Kelly H.; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Koo, KH (reprint author), San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. EM kelly.koo@va.gov FU Department of Defense [W81XWH-11-2-0189]; VA Advanced Fellowship in Women's Health FX This research was supported by Department of Defense Award Grant W81XWH-11-2-0189 and the VA Advanced Fellowship in Women's Health. NR 32 TC 4 Z9 4 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAY PY 2015 VL 66 IS 5 BP 507 EP 513 DI 10.1176/appi.ps.201300498 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5RH UT WOS:000370688500013 PM 25588415 ER PT J AU Manini, AF Yiannoulos, G Bergamaschi, MM Hernandez, S Olmedo, R Barnes, AJ Winkel, G Sinha, R Jutras-Aswad, D Huestis, MA Hurd, YL AF Manini, Alex F. Yiannoulos, Georgia Bergamaschi, Mateus M. Hernandez, Stephanie Olmedo, Ruben Barnes, Allan J. Winkel, Gary Sinha, Rajita Jutras-Aswad, Didier Huestis, Marilyn A. Hurd, Yasmin L. TI Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE cannabidiol; cannabis; opioid dependence; pharmacokinetics ID CANNABINOID RECEPTOR; OPIOID RECEPTORS; NEURAL BASIS; NUCLEUS; PLASMA; CB1; DELTA-9-TETRAHYDROCANNABINOL; SCHIZOPHRENIA; INHIBITION; HYDROLYSIS AB Objectives: Cannabidiol (CBD) is hypothesized as a potential treatment for opioid addiction, with safety studies an important first step for medication development. We determined CBD safety and pharmacokinetics when administered concomitantly with a high-potency opioid in healthy subjects. Methods: This double-blind, placebo-controlled cross-over study of CBD, coadministered with intravenous fentanyl, was conducted at the Clinical Research Center in Mount Sinai Hospital, a tertiary care medical center in New York City. Participants were healthy volunteers aged 21 to 65 years with prior opioid exposure, regardless of the route. Blood samples were obtained before and after 400 or 800 mg of CBD pretreatment, followed by a single 0.5 (session 1) or 1.0 mu g/kg (session 2) of intravenous fentanyl dose. The primary outcome was the Systematic Assessment for Treatment Emergent Events (SAFTEE) to assess safety and adverse effects. CBD peak plasma concentrations, time to reach peak plasma concentrations (t(max)), and area under the curve (AUC) were measured. Results: SAFTEE data were similar between groups without respiratory depression or cardiovascular complications during any test session. After low-dose CBD, t(max) occurred at 3 and 1.5 hours in sessions 1 and 2, respectively. After high-dose CBD, tmax occurred at 3 and 4 hours in sessions 1 and 2, respectively. There were no significant differences in plasma CBD or cortisol (AUC P = NS) between sessions. Conclusions: Cannabidiol does not exacerbate adverse effects associated with intravenous fentanyl administration. Coadministration of CBD and opioids was safe and well tolerated. These data provide the foundation for future studies examining CBD as a potential treatment for opioid abuse. C1 [Manini, Alex F.; Hernandez, Stephanie; Olmedo, Ruben] Icahn Sch Med Mt Sinai, Div Med Toxicol, Dept Emergency Med, New York, NY 10029 USA. [Yiannoulos, Georgia; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Psychiat, Bronx, NY USA. [Yiannoulos, Georgia; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Neurosci, Bronx, NY USA. [Yiannoulos, Georgia; Hurd, Yasmin L.] James J Peters VA Med Ctr, Bronx, NY USA. [Bergamaschi, Mateus M.] Univ Sao Paulo, Dept Clin Toxicol & Food Sci Anal, Sch Pharmaceut Sci Ribeirao Preto, BR-05508 Sao Paulo, Brazil. [Barnes, Allan J.; Huestis, Marilyn A.] NIDA, Chem & Drug Metab, Intramural Res Program, NIH, Baltimore, MD USA. [Winkel, Gary] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA. [Sinha, Rajita] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Jutras-Aswad, Didier] Univ Montreal, Ctr Hosp Univ Montreal, Res Ctr, Montreal, PQ, Canada. [Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada. RP Hurd, YL (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. EM yasmin.hurd@mssm.edu FU National Institutes of Health [DA027781]; CTSA [UL1RR029887] FX Supported by a research grant from the National Institutes of Health grant DA027781 (YLH) and CTSA (UL1RR029887). NR 39 TC 2 Z9 2 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2015 VL 9 IS 3 BP 204 EP 210 DI 10.1097/ADM.0000000000000118 PG 7 WC Substance Abuse SC Substance Abuse GA DD1VH UT WOS:000369710200006 PM 25748562 ER PT J AU Sato, N Lam, CS Teerlink, JR Greenberg, BH Tsutsui, H Oh, BH Zhang, J Hua, TA Wang, XL Ge, J AF Sato, N. Lam, C. S. Teerlink, J. R. Greenberg, B. H. Tsutsui, H. Oh, B. H. Zhang, J. Hua, T. A. Wang, X. L. Ge, J. CA Novartis Pharmaceuticals TI Evaluating the efficacy, safety and tolerability of serelaxin when added to standard therapy in asian patients with acute heart failure: The RELAX-AHF-ASIA trial SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Meeting Abstract C1 [Sato, N.] Musashi Kosugi Hosp, Nippon Med Sch, Cardiol & Intens Care Unit, Kanagawa, Japan. [Lam, C. S.] Natl Heart Ctr Singapore, Duke NUS, Singapore, Singapore. [Teerlink, J. R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Greenberg, B. H.] Univ Calif San Diego, Cardiol, San Diego, CA 92103 USA. [Tsutsui, H.] Hokkaido Univ, Grad Sch Med, Cardiovasc Med, Sapporo, Hokkaido, Japan. [Oh, B. H.] Seoul Natl Univ, Coll Med, Internal Med, Seoul, South Korea. [Zhang, J.] Chinese Acad Med Sci, Fuwai Hosp, Beijing 100730, Peoples R China. [Zhang, J.] Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing 100021, Peoples R China. [Hua, T. A.; Wang, X. L.] Nova Pharmaceut Corp, E Hanover, NJ USA. [Ge, J.] Fudan Univ, Zhongshan Hosp, Cardiol, Shanghai 200433, Peoples R China. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAY PY 2015 VL 17 SU 1 SI SI MA P210 BP 41 EP 41 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY1XB UT WOS:000366200401099 ER PT J AU Corvera-Tindel, T Doering, LVD AF Corvera-Tindel, Teresita Doering, L. V. D. TI Comparative validity of depression assessment scales for screening depression in heart failure SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Meeting Abstract C1 [Corvera-Tindel, Teresita] VA Greater Los Angeles Hlth Care Syst, Nursing Educ & Res, Los Angeles, CA USA. [Doering, L. V. D.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD MAY PY 2015 VL 17 SU 1 SI SI MA 624 BP 139 EP 140 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CY1XB UT WOS:000366200402012 ER PT J AU Suneja, G Boyer, M Yehia, BR Shiels, MS Engels, EA Bekelman, JE Long, JA AF Suneja, Gita Boyer, Matthew Yehia, Baligh R. Shiels, Meredith S. Engels, Eric A. Bekelman, Justin E. Long, Judith A. TI Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; LUNG-CANCER; IMMUNODEFICIENCY; INDIVIDUALS; POPULATION; CARE; CHEMOTHERAPY; ASSOCIATION; GUIDELINES AB Purpose: HIV-infected individuals with non-AIDS-defining cancers are less likely to receive cancer treatment compared with uninfected individuals. We sought to identify provider-level factors influencing the delivery of oncology care to HIV-infected patients. Methods: A survey was mailed to 500 randomly selected US medical and radiation oncologists. The primary outcome was delivery of standard treatment, assessed by responses to three specialty-specific management questions. We used the chi(2) test to evaluate associations between delivery of standard treatment, provider demographics, and perceptions of HIV-infected individuals. Multivariable logistic regression identified associations using factor analysis to combine several correlated survey questions. Results: Our response rate was 60%; 69% of respondents felt that available cancer management guidelines were insufficient for the care of HIV-infected patients with cancer; 45% never or rarely discussed their cancer management plan with an HIV specialist; 20% and 15% of providers were not comfortable discussing cancer treatment adverse effects and prognosis with their HIV-infected patients with cancer, respectively; 79% indicated that they would provide standard cancer treatment to HIV-infected patients. In multivariable analysis, physicians comfortable discussing adverse effects and prognosis were more likely to provide standard cancer treatment (adjusted odds ratio, 1.52; 95% CI, 1.12 to 2.07). Physicians with concerns about toxicity and efficacy of treatment were significantly less likely to provide standard cancer treatment (adjusted odds ratio, 0.67; 95% CI, 0.53 to 0.85). Conclusion: Provider-level factors are associated with delivery of nonstandard cancer treatment to HIV-infected patients. Policy change, provider education, and multidisciplinary collaboration are needed to improve access to cancer treatment. C1 Univ Utah, Salt Lake City, UT USA. Marshall Univ, Huntington, WV USA. Univ Penn, Philadelphia, PA 19104 USA. Vet Affairs Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. NCI, Bethesda, MD 20892 USA. RP Suneja, G (reprint author), Huntsman Canc Hosp, 1950 Cir Hope,Room 1570, Salt Lake City, UT 84112 USA. EM gita.suneja@icloud.com NR 27 TC 3 Z9 3 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD MAY PY 2015 VL 11 IS 3 BP E380 EP E387 DI 10.1200/JOP.2014.002709 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CY1PL UT WOS:000366179600014 PM 25873060 ER PT J AU Davison, BA Metra, M Cotter, G Massie, BM Cleland, JGF Dittrich, HC Edwards, C Filippatos, G Givertz, MM Greenberg, B Ponikowski, P Voors, AA O'Connor, CM Teerlink, JR AF Davison, Beth A. Metra, Marco Cotter, Gad Massie, Barry M. Cleland, John G. F. Dittrich, Howard C. Edwards, Christopher Filippatos, Gerasimos Givertz, Michael M. Greenberg, Barry Ponikowski, Piotr Voors, Adriaan A. O'Connor, Christopher M. Teerlink, John R. CA PROTECT & RELAX-AHF Executive Comm TI Worsening Heart Failure Following Admission for Acute Heart Failure A Pooled Analysis of the PROTECT and RELAX-AHF Studies SO JACC-HEART FAILURE LA English DT Article DE acute heart failure; heart failure readmission; mortality; prognosis; renal function; worsening heart failure ID RECEPTOR ANTAGONIST ROLOFYLLINE; 60-DAY OUTCOMES; ASSOCIATION; DYSPNEA; TEZOSENTAN; SERELAXIN; SYMPTOMS; VERITAS; TRIALS; DESIGN AB OBJECTIVES These studies conducted analyses to examine patient characteristics and outcomes associated with worsening heart failure (WHF). BACKGROUND WHF during an admission for acute heart failure (AHF) represents treatment failure and is a potential therapeutic target for clinical trials of AHF. METHODS Individual patient data from the PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) and RELAX-AHF (Relaxin in Acute Heart Failure) phase II and III studies were pooled for analysis. RESULTS Of 3,691 patients, death or WHF through day 5 occurred in 12.4%, ranging from 9.5% to 14.5% among studies. A multivariable model provided modest discrimination between patients who did or did not develop WHF (C-index = 0.68). After multivariable adjustment, WHF was associated with a mean increase in length of stay of 5.2 days (95% confidence interval [CI]: 4.6 to 5.8 days) and increased risks of 60-day HF or renal failure readmission or cardiovascular death (hazard ratio [HR]: 1.64, 95% CI: 1.34 to 2.01) and 180-day mortality (HR: 1.93, 95% CI: 1.55 to 2.41) (all p < 0.001). The risk of mortality was higher in patients whose WHF required intravenous inotropes or mechanical therapy (HR: 3.03, 95% CI: 2.11 to 4.36) compared with patients whose WHF was treated with intravenous loop diuretic alone (HR: 1.80, 95% CI: 1.36 to 2.36) (both p < 0.001). WHF was associated with larger increases in markers of renal and hepatic dysfunction during the first days of admission, but remained significantly associated with adverse outcomes after adjustment for these changes. CONCLUSIONS WHF during the first 5 days of admission for AHF occurred in approximately 10% to 15% of patients and was associated with longer length of stay and higher risk for readmission and death. (C) 2015 by the American College of Cardiology Foundation. C1 [Davison, Beth A.; Cotter, Gad; Edwards, Christopher] Momentum Res Inc, Durham, NC 27707 USA. [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Cardiol, Brescia, Italy. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, Div Cardiol, San Francisco, CA USA. [Cleland, John G. F.] Univ Hull, Dept Cardiol, Kingston Upon Hull, Yorks, England. [Cleland, John G. F.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield Hosp Natl Hlth Serv Tr, Natl Heart & Lung Inst, London, England. [Dittrich, Howard C.] NovaCardia, San Diego, CA USA. [Filippatos, Gerasimos] Athens Univ Hosp, Dept Cardiol, Athens, Greece. [Givertz, Michael M.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Greenberg, Barry] Univ Calif San Diego, Div Cardiol, San Diego, CA 92103 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Dept Cardiol, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. RP Edwards, C (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM bethdavison@momentum-research.com RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 FU Corthera, a Novartis affiliate company; Novartis; Corthera; Novacardia; Trevena; Merck; Amgen; ChanRx Corp.; Cardio3 Biosciences; Sorbent Therapeutics; Singulex; Bayer; Servier; Merck/Novacardia; Corthera/Novartis; MSD; Cardiorentis; Johnson Johnson; Coridea; Bayer Health Care; Cardio3Biosciences; Celladon; GlaxoSmithKline; Nephera Ltd.; Servuier; Vifor; Resmed; Stealth Peptides; Otsuka; Amgen/Cytokinetics FX The RELAX-AHF studies were sponsored by Corthera, a Novartis affiliate company. No external support was provided for these analyses. Drs. Davison, Cotter, and Edwards are employees of Momentum Research Inc., which has received research grants from Novartis, Corthera, Novacardia, Trevena, Merck, Amgen, ChanRx Corp., Cardio3 Biosciences, Sorbent Therapeutics, and Singulex. Dr. Metra has received consulting fees from Bayer, Novartis, Servier, and Trevena. Dr. Massie has received consulting fees and research funding from Merck/Novacardia and Corthera/Novartis. Dr. Cleland has received honoraria and research funding from MSD, Novartis, and Amgen. Dr. Dittrich is a former employee of NovaCardia and Sorbent; and is a consultant to Corthera. Dr. Filippatos is a member of the steering committees of trials sponsored by Novartis, Cardiorentis, and Bayer. Dr. Givertz is an employee of Brigham and Women's Hospital. Dr. Greenberg has received consulting fees from Novartis. Dr. Ponikowski has received consulting and lecture fees from Novartis, Johnson & Johnson, Bayer, Coridea, and Cardiorentis. Dr. Voors serves on the steering committee of RELAX-AHF, and has received speaker, consultancy, or research fees from Amgen, Bayer Health Care, Cardio3Biosciences, Celladon, GlaxoSmithKline, Merck, Nephera Ltd., Novartis, Servuier, Singulex, Trevena, and Vifor. Dr. O'Connor has received consulting fees from Cardiorentis, Resmed, and Stealth Peptides; and research funding from Otsuka and Resmed. Dr. Teerlink has received consulting fees and research funding from Merck/NovaCardia, Corthera, Novartis, and Amgen/Cytokinetics. Anthony DeMaria, MD, served as Guest Editor for this paper. NR 22 TC 18 Z9 18 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD MAY PY 2015 VL 3 IS 5 BP 395 EP 403 DI 10.1016/j.jchf.2015.01.007 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CX4EK UT WOS:000365651400009 PM 25951761 ER PT J AU Murphy, C Huang, S Peletier, C Harrington, A Clarridge, JE AF Murphy, Colin Huang, Sze Peletier, Chelsea Harrington, Amanda Clarridge, Jill E., III TI Ribotypes of Clostridium difficile Isolates Correlate With Whole Genome Mapping and Reveal Long-Term Presence of Both Toxigenic and Nontoxigenic Strains SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract CT 50th Annual Meeting of Academy-of-Clinical-Laboratory-Physicians-and-Scientists (ACLPS) CY MAY 28-30, 2015 CL Minneapolis, MN SP Acad Clin Lab Phys & Scientists C1 Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD MAY PY 2015 VL 143 SU 1 MA 68 BP A40 EP A40 PG 1 WC Pathology SC Pathology GA CV9DD UT WOS:000364586600041 ER PT J AU Lessard, CJ Sajuthi, S Zhao, J Kim, K Harley, JB Vyse, TJ Sivils, KL Langefeld, CD Bae, S Tsao, BP AF Lessard, C. J. Sajuthi, S. Zhao, J. Kim, K. Harley, J. B. Vyse, T. J. Sivils, K. L. Langefeld, C. D. Bae, S. Tsao, B. P. TI Identification of a systemic lupus erythematosus risk locus spanning the genes ATG16L2, FCHSD2, and p2RY2 in Koreans SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Article; Proceedings Paper CT 11th International Congress on Systemic Lupus Erythematosus CY SEP 02-06, 2015 CL Vienna, AUSTRIA C1 [Lessard, C. J.; Sivils, K. L.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Sajuthi, S.; Langefeld, C. D.] Wake Forest Univ Hlth Sci, Ctr Publ Hlth Genom, Winston Salem, NC USA. [Sajuthi, S.; Langefeld, C. D.] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC USA. [Zhao, J.; Tsao, B. P.] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90024 USA. [Kim, K.; Bae, S.] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea. [Harley, J. B.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, J. B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Vyse, T. J.] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England. [Vyse, T. J.] Kings Coll London, Div Immunol Infect & Inflammatory Dis, London WC2R 2LS, England. [Vyse, T. J.] System Lupus Erythematosus Genet SLEGEN Consort, London, England. [Bae, S.] Korean Rheumat Dis Grp, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X EI 1593-098X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD MAY-JUN PY 2015 VL 33 IS 3 SU 90 MA P8.01 BP S74 EP S74 PG 1 WC Rheumatology SC Rheumatology GA CQ2HY UT WOS:000360421900265 ER PT J AU Tiao, J Feng, R Carr, K Werth, VP AF Tiao, J. Feng, R. Carr, K. Werth, V. P. TI Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Determine Diagnosis of Systemic Lupus Erythematosus in Subacute Cutaneous Lupus Erythematosus SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Article; Proceedings Paper CT 11th International Congress on Systemic Lupus Erythematosus CY SEP 02-06, 2015 CL Vienna, AUSTRIA C1 [Tiao, J.; Carr, K.; Werth, V. P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Tiao, J.; Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Feng, R.] Hosp Univ Penn, Biostat & Epidemiol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X EI 1593-098X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD MAY-JUN PY 2015 VL 33 IS 3 SU 90 MA P5.88 BP S62 EP S62 PG 1 WC Rheumatology SC Rheumatology GA CQ2HY UT WOS:000360421900224 ER PT J AU Krumholz, A Wiebe, S Gronseth, GS Gloss, DS Sanchez, AM Kabir, AA Liferidge, AT Martello, JP Kanner, AM Shinnar, S Hopp, JL French, JA AF Krumholz, A. Wiebe, S. Gronseth, G. S. Gloss, D. S. Sanchez, A. M. Kabir, A. A. Liferidge, A. T. Martello, J. P. Kanner, A. M. Shinnar, S. Hopp, J. L. French, J. A. TI Evidence-Based Guideline: Management of an Unprovoked First Seizure in Adults Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society SO EPILEPSY CURRENTS LA English DT Article ID TONIC-CLONIC SEIZURE; QUALITY STANDARDS SUBCOMMITTEE; RANDOMIZED CLINICAL-TRIAL; NEW-ONSET EPILEPSY; ANTIEPILEPTIC DRUGS; PRACTICE PARAMETER; SINGLE SEIZURES; FOLLOW-UP; RECURRENCE; RISK AB OBJECTIVE: To provide evidence-based recommendations for treatment of adults with an unprovoked first seizure. METHODS: We defined relevant questions and systematically reviewed published studies according to the American Academy of Neurology's classification of evidence criteria; we based recommendations on evidence level. RESULTS AND RECOMMENDATIONS: Adults with an unprovoked first seizure should be informed that their seizure recurrence risk is greatest early within the first 2 years (21%-45%) (Level A), and clinical variables associated with increased risk may include a prior brain insult (Level A), an EEG with epileptiform abnormalities (Level A), a significant brain-imaging abnormality (Level B), and a nocturnal seizure (Level B). Immediate antiepileptic drug (AED) therapy, as compared with delay of treatment pending a second seizure, is likely to reduce recurrence risk within the first 2 years (Level B) but may not improve quality of life (Level C). Over a longer term (> 3 years), immediate AED treatment is unlikely to improve prognosis as measured by sustained seizure remission (Level B). Patients should be advised that risk for AED adverse events (AEs) may range from 7%-31% (Level B) and that these AEs are likely predominantly mild and reversible. Clinicians' recommendations whether to initiate immediate AED treatment after a first seizure should be based on individualized assessments that weigh the risk of recurrence against the AEs of AED therapy, consider educated patient preferences, and advise that immediate treatment will not improve the long-term prognosis for seizure remission but will reduce seizure risk over the subsequent 2 years. C1 [Krumholz, A.; Sanchez, A. M.; Kabir, A. A.; Martello, J. P.; Hopp, J. L.] Univ Maryland, Sch Med, Dept Neurol, Maryland Epilepsy Ctr, Baltimore, MD 21201 USA. [Krumholz, A.] US Dept Vet Affairs, Maryland Healthcare Syst, Epilepsy Ctr Excellence, Baltimore, MD USA. [Wiebe, S.] Univ Calgary, Dept Clin Neurosci, Fac Med, Calgary, AB T2N 1N4, Canada. [Gronseth, G. S.] Univ Kansas, Dept Neurol, Sch Med, Kansas City, KS USA. [Gloss, D. S.] Geisinger Hlth Syst, Dept Neurol, Danville, PA USA. [Liferidge, A. T.] George Washington Univ, Sch Med, Dept Emergency Med, Washington, DC USA. [Kanner, A. M.] Univ Miami, Dept Neurol, Int Ctr Epilepsy, Miller Sch Med, Coral Gables, FL 33124 USA. [Shinnar, S.] Yeshiva Univ, Dept Neurol, Albert Einstein Coll Med, Bronx, NY USA. [Shinnar, S.] Yeshiva Univ, Dept Pediat, Albert Einstein Coll Med, Bronx, NY USA. [Shinnar, S.] Yeshiva Univ, Dept Epidemiol & Populat Hlth, Albert Einstein Coll Med, Bronx, NY USA. [French, J. A.] NYU, Comprehens Epilepsy Ctr, New York, NY USA. RP Krumholz, A (reprint author), Univ Maryland, Sch Med, Dept Neurol, Maryland Epilepsy Ctr, Baltimore, MD 21201 USA. RI French, Jacqueline/G-6795-2013 OI French, Jacqueline/0000-0003-2242-8027 FU American Academy of Neurology FX This guideline was developed with financial support from the American Academy of Neurology. NR 36 TC 1 Z9 1 U1 1 U2 7 PU AMER EPILEPSY SOCIETY PI WEST HARTFORD PA 342 NORTH MAIN STREET, WEST HARTFORD, CT 06117-2507 USA SN 1535-7597 EI 1535-7511 J9 EPILEPSY CURR JI Epilepsy Curr. PD MAY-JUN PY 2015 VL 15 IS 3 BP 144 EP 152 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CQ6IL UT WOS:000360707900014 PM 26316856 ER PT J AU Littman, AJ Jacobson, IG Boyko, EJ Smith, TC AF Littman, Alyson J. Jacobson, Isabel G. Boyko, Edward J. Smith, Tyler C. TI Changes in Meeting Physical Activity Guidelines After Discharge From the Military SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE exercise; military personnel; Veterans ID MILLENNIUM COHORT; RELIABILITY; VETERANS; VALIDITY; SERVICE; HEALTH; VACCINATION; BEHAVIORS; PERSONNEL; TRENDS AB Background: Understanding physical activity (PA) after discharge from the military can inform theory on the role of habit and reinforcement in behavior maintenance and has implications for this population's future health. Methods: Using data from 28,866 Millennium Cohort Study participants (n = 3782 of whom were discharged during the years between assessments), we 1) investigated changes in meeting federal PA guidelines for moderate-to-vigorous activity (MVPA) following military discharge and 2) determined predictors of meeting these guidelines after discharge. Results: MVPA declined more in those who were discharged than in those who were not (-17.8 percentage points vs. 2.7 percentage points), with greater declines in former active-duty personnel, those who had deployed with combat exposures, had 14 to 25 years of service, and had been discharged more recently (>2 years prior). In those who were discharged, being normal or overweight (vs. obese), and a nonsmoker or former smoker (vs. current smoker) were positively associated with meeting MVPA Guidelines at follow-up, while meeting MVPA Guidelines at baseline and depression were inversely associated. Conclusions: Reductions in MVPA were substantial and unexpected. Increased understanding of transitional periods that may benefit from interventions to mitigate declines in PA will help prevent excess weight gain and physical inactivity-associated health consequences. C1 [Littman, Alyson J.; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Jacobson, Isabel G.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA USA. [Smith, Tyler C.] Natl Univ, Dept Community Hlth, Sch Hlth & Human Serv, San Diego, CA USA. RP Littman, AJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. EM Alyson.littman@va.gov OI Boyko, Edward/0000-0002-3695-192X FU Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD; VA Rehabilitation Research and Development Career Development Award [6982] FX We are indebted to the Millennium Cohort Study participants, without whom these analyses would not be possible, the other the Millennium Cohort Study Team members, includes Melissa Bagnell, MPH; James Davies; Raechel Del Rosario, MPH; Gia Gumbs, MPH; Nisara Granado, MPH, PhD; Jaime Horton, MPH; Andrea Ippolito; Lauren Kipp, MPH; Kelly Jones, MPH; Cynthia LeardMann, MPH; William Lee; Michelle Linfesty; Gordon Lynch; Hope McMaster, PhD; Sheila Medina-Torne, MPH; Teresa Powell, MS; Toni Rush, MPH; Emma Schaller; Amber Seelig, MPH; Beverly Sheppard; Donald Slymen, PhD; Katherine Snell; Steven Speigle; Karl Sausedo, MA; Jennifer Walstrom; John Wesner; Martin White, MPH; James Whitmer; and Charlene Wong, MPH; from the Deployment Health Research Department, Naval Health Research Center, San Diego, CA. We thank Scott L. Seggerman and Greg D. Boyd from the Management Information Division, Defense Manpower Data Center, Monterey, CA. In addition, we thank Michelle LeWark from the Naval Health Research Center. We also thank all the professionals from the US Army Medical Research and Materiel Command, especially those from the Military Operational Medicine Research Program, Fort Detrick, MD, We appreciate the support of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. This material is the result of work partly supported with resources and the use of facilities from the Cooperative Studies Program, Department of Veterans Affairs, and the Puget Sound VA Medical Center. Dr. Littman was supported by a VA Rehabilitation Research and Development Career Development Award (#6982). This work represents report 12-XX, supported by the Department of Defense, under work unit no. 60002. The views expressed in this article are those of the authors and do not reflect the official policy or position or constitute endorsement of the Department of the Navy, Department of the Army, Department of the Air Force, Department of Defense, Department of Veterans Affairs, the US Government, or the American College of Sports Medicine. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC.2000.0007). NR 23 TC 4 Z9 4 U1 0 U2 0 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAY PY 2015 VL 12 IS 5 BP 666 EP 674 DI 10.1123/jpah.2013-0260 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO5DD UT WOS:000359178900011 PM 26237780 ER PT J AU Bernskoetter, N Rold, T Szczodroski, A Hoffman, T AF Bernskoetter, Nicole Rold, Tammy Szczodroski, Ashley Hoffman, Timothy TI Enhancement of tumor directed radiopharmaceutical delivery: Assessing NEP inhibition effects in prostate and breast cancer models. SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging CY JUN 06-10, 2015 CL Baltimore, MD SP Soc Nucl Med & Mol Imaging C1 [Bernskoetter, Nicole; Szczodroski, Ashley; Hoffman, Timothy] US Dept Vet Affairs, Columbia, MO USA. [Rold, Tammy] Univ Missouri, Med, Columbia, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY 1 PY 2015 VL 56 IS 3 SU 3 MA 1201 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN9AU UT WOS:000358738802171 ER PT J AU Catafau, A Bullich, S Seibyl, J Barthel, H Ghetti, B Leverenz, J Ironside, J Walter, SS Hoffmann, A Sabri, O AF Catafau, Ana Bullich, Santiago Seibyl, John Barthel, Henryk Ghetti, Bernardino Leverenz, James Ironside, James Walter, Schulz-Schaefer Hoffmann, Anja Sabri, Osama TI Cerebellar senile plaques: How frequent are they, and do they influence 18F-Florbetaben SUVR? SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging CY JUN 06-10, 2015 CL Baltimore, MD SP Soc Nucl Med & Mol Imaging C1 [Catafau, Ana; Bullich, Santiago] Piramal Imaging GmbH, Berlin, Germany. [Seibyl, John] Mol Neuroimaging, New Haven, CT USA. [Barthel, Henryk; Sabri, Osama] Univ Leipzig, D-04109 Leipzig, Germany. [Ghetti, Bernardino] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Leverenz, James] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Leverenz, James] Univ Washington, Seattle, WA 98195 USA. [Ironside, James] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Walter, Schulz-Schaefer] Univ Gottingen, D-37073 Gottingen, Germany. [Hoffmann, Anja] Bayer Pharma AG, Berlin, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY 1 PY 2015 VL 56 IS 3 SU 3 MA 194 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN9AU UT WOS:000358738800195 ER PT J AU Cross, D Hysa, L Pagulayan, K Mayer, C Cook, D Petrie, E Raskind, M Minoshima, S Peskind, E AF Cross, Donna Hysa, Lisa Pagulayan, Kathleen Mayer, Cynthia Cook, David Petrie, Eric Raskind, Murray Minoshima, Satoshi Peskind, Elaine TI Longitudinal assessment of repetitive blast mild traumatic brain injury in veterans using FDG-PET imaging SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging CY JUN 06-10, 2015 CL Baltimore, MD SP Soc Nucl Med & Mol Imaging C1 [Cross, Donna; Hysa, Lisa] U Wash, Seattle, WA USA. [Pagulayan, Kathleen; Mayer, Cynthia; Cook, David; Petrie, Eric; Raskind, Murray; Peskind, Elaine] VA Puget Sound, Seattle, WA USA. [Minoshima, Satoshi] U Utah, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY 1 PY 2015 VL 56 IS 3 SU 3 MA 1609 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN9AU UT WOS:000358738803229 ER PT J AU Salavati, A Khiewvan, B Houshmand, S Cheng, G Akers, S Werner, T AF Salavati, Ali Khiewvan, Benjapa Houshmand, Sina Cheng, Gang Akers, Scott Werner, Thomas TI The impact of partial volume effect correction on the diagnostic performance of quantitative FDG-PET/CT parameters: A lesion based analysis of suspected lung malignancy. SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging CY JUN 06-10, 2015 CL Baltimore, MD SP Soc Nucl Med & Mol Imaging C1 [Salavati, Ali; Khiewvan, Benjapa; Houshmand, Sina; Werner, Thomas] Univ Penn, Philadelphia, PA 19104 USA. [Cheng, Gang; Akers, Scott] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY 1 PY 2015 VL 56 IS 3 SU 3 MA 1387 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN9AU UT WOS:000358738803007 ER PT J AU Serapio, P Hope, M Yee, J Aparici, CM Hope, T AF Serapio, Paulo Hope, Michael Yee, Judy Aparici, Carina Mari Hope, Thomas TI 18F-Sodium Fluoride Uptake in the Abdominal Aorta SO JOURNAL OF NUCLEAR MEDICINE LA English DT Meeting Abstract CT Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging CY JUN 06-10, 2015 CL Baltimore, MD SP Soc Nucl Med & Mol Imaging C1 [Serapio, Paulo] New York Med Coll, Valhalla, NY 10595 USA. [Serapio, Paulo; Hope, Michael; Yee, Judy; Hope, Thomas] Univ Calif San Francisco, Radiol, San Francisco, CA 94143 USA. [Aparici, Carina Mari] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD MAY 1 PY 2015 VL 56 IS 3 SU 3 MA 350 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CN9AU UT WOS:000358738801001 ER PT J AU Black, H Gonzalez, R Priolo, C Schapira, MM Sonnad, SS Hanson, CW Langlotz, CP Howell, JT Apter, AJ AF Black, Heather Gonzalez, Rodalyn Priolo, Chantel Schapira, Marilyn M. Sonnad, Seema S. Hanson, C. William, III Langlotz, Curtis P. Howell, John T. Apter, Andrea J. TI True "Meaningful Use": Technology Meets Both Patient and Provider Needs SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ELECTRONIC MEDICAL-RECORDS; HEALTH-CARE; ATTITUDES; ADOPTION; OUTCOMES; IMPLEMENTATION; PHYSICIANS; PORTALS; ACCESS; ASTHMA AB Objectives: Voluntary patient uptake and use of electronic health record (EHR) features have been low. It is unknown whether EHRs fully meet needs of providers or patients with chronic diseases. Study Design: To explore in-depth user experiences, we conducted 6 focus groups: 3 of patients followed by 3 of providers discussing 2 key EHR components: the after-visit summary (AVS) and the patient portal (PP). Focus groups were audio-recorded, transcribed, and analyzed by 3 independent coders. Methods: Participants with moderate-to-severe asthma and prevalent comorbidities were recruited from 4 primary care and 2 asthma clinics serving low-income urban neighborhoods. Participants discussed their expectations and experience using the AVS and PP, and responded to prototype formats of these features. Additionally, one-on-one interviews were conducted with 10 patients without PP experience to assess their ability to use the system. Results: The 21 patient and 13 provider perspectives differed regarding AVS features and use. Patients wanted a unified view of their medical issues and health management tools, while providers wanted to focus on recommendations from 1 visit at a time. Both groups advocated improving the AVS format and content. Lack of awareness and knowledge about the PP was patients' largest barrier, and was traced back to providers' lack of PP training. Conclusions: Our results underscore the importance of user-centered design when constructing the content and features of the EHR. As technology evolves, an ongoing understanding of patient and provider experiences will be critical to improve uptake, increase use, and ensure engagement, optimizing the potential of EHRs. C1 [Black, Heather; Gonzalez, Rodalyn; Priolo, Chantel; Apter, Andrea J.] Div Pulm Allergy & Crit Care Med, Sect Allergy & Immunol, Philadelphia, PA USA. [Black, Heather; Gonzalez, Rodalyn; Priolo, Chantel; Schapira, Marilyn M.; Apter, Andrea J.] Dept Med, Philadelphia, PA USA. [Langlotz, Curtis P.] Dept Radiol, Philadelphia, PA USA. [Black, Heather; Gonzalez, Rodalyn; Priolo, Chantel; Schapira, Marilyn M.; Hanson, C. William, III; Langlotz, Curtis P.; Howell, John T.; Apter, Andrea J.] Univ Penn, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Dept Vet Affairs Med Ctr, Ctr Hlth Equ Res Program, Philadelphia, PA 19104 USA. [Sonnad, Seema S.] Christiana Care Hlth Syst, Value Inst, Wilmington, DE USA. RP Apter, AJ (reprint author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM apter@mail.med.upenn.edu FU University of Pennsylvania Research Foundation; University of Pennsylvania Health System FX This study was funded by the University of Pennsylvania Research Foundation and Bach Fund Grant of the University of Pennsylvania Health System. These foundations had no role in study design; in data collection; analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 25 TC 2 Z9 2 U1 4 U2 15 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAY PY 2015 VL 21 IS 5 BP E329 EP E337 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CN8BI UT WOS:000358661300006 PM 26167781 ER PT J AU Nikolajski, C Miller, E McCauley, HL Akers, A Schwarz, EB Freedman, L Steinberg, J Ibrahim, S Borrero, S AF Nikolajski, Cara Miller, Elizabeth McCauley, Heather L. Akers, Aletha Schwarz, Eleanor Bimla Freedman, Lori Steinberg, Julia Ibrahim, Said Borrero, Sonya TI Race and Reproductive Coercion: A Qualitative Assessment SO WOMENS HEALTH ISSUES LA English DT Article ID INTIMATE PARTNER VIOLENCE; UNINTENDED PREGNANCY; CONTRACEPTIVE USE; FEMALE ADOLESCENTS; UNITED-STATES; EXPERIENCES; WOMEN; DISCONTINUATION; DISPARITIES; ATTITUDES AB Background: Unintended pregnancy is common and disproportionately occurs among low-income and African-American (AA) women. Male partners may influence women's risk of unintended pregnancy through reproductive coercion, although studies have not assessed whether racial differences in reproductive coercion impact AA women's disparate risk for unintended pregnancy. We sought to describe women's experiences with pregnancy-promoting behaviors by male partners and explore differences in such experiences by race. Methods: Semistructured interviews were conducted with low-income, AA and White women aged 18 to 45 years recruited from reproductive health clinics in Western Pennsylvania to explore contextual factors that shape women's contraceptive behaviors. Narratives were analyzed using content analysis and the constant comparison method. Findings: Among the 66 participants (36 AA and 30 White), 25 (38%) described experiences with male partner reproductive coercion. Narratives provided accounts of contraceptive sabotage, verbal pressure to promote pregnancy and specific pregnancy outcomes, and potential motives behind these behaviors. AA women in the sample reported experiences of reproductive coercion more often than White women (53% and 20%, respectively). AA women were also more likely than White women to attribute a current or prior pregnancy to reproductive coercion. AA women identified relationship transiency and impending incarceration as potential motivations for men to secure a connection with a female partner via pregnancy. Conclusions: Our findings suggest that reproductive coercion may be a factor contributing to disparities in unintended pregnancy. More research, including population-level studies, is needed to determine the impact of reproductive coercion on unintended pregnancy and to understand the social and structural factors associated with pregnancy-promoting behaviors. Published by Elsevier Inc. C1 [Nikolajski, Cara; Schwarz, Eleanor Bimla; Borrero, Sonya] Univ Pittsburgh, Ctr Res Hlth Care, Dept Med, Pittsburgh, PA 15213 USA. [Miller, Elizabeth; McCauley, Heather L.] Childrens Hosp Pittsburgh, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. [Miller, Elizabeth] Univ Pittsburgh, Sch Med, Pediat, Pittsburgh, PA 15213 USA. [Akers, Aletha; Schwarz, Eleanor Bimla] Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Freedman, Lori] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Oakland, CA USA. [Steinberg, Julia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Ibrahim, Said] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Ibrahim, Said] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [McCauley, Heather L.] Univ Pittsburgh, Pediat, Pittsburgh, PA 15213 USA. [Akers, Aletha] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Schwarz, Eleanor Bimla] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu OI Freedman, Lori/0000-0002-7919-9520 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH) [1 R21 HD068736-01]; NICHD [K01 D075834] FX This study was made possible by Dr. Borrero's grant (1 R21 HD068736-01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). Dr. Steinberg's effort on this project was funded by her K01 grant from NICHD (K01 D075834). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of NICHD or NIH. NR 42 TC 4 Z9 4 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAY-JUN PY 2015 VL 25 IS 3 BP 216 EP 223 DI 10.1016/j.whi.2014.12.004 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA CN7HG UT WOS:000358604400005 PM 25748823 ER PT J AU Tripathy, D Cobb, JE Gall, W Adam, KP George, T Schwenke, DC Banerji, M Bray, GA Buchanan, TA Clement, SC Henry, RR Kitabchi, AE Mudaliar, S Ratner, RE Stentz, FB Reaven, PD Musi, N Ferrannini, E DeFronzo, RA AF Tripathy, Devjit Cobb, Jeff E. Gall, Walter Adam, Klaus-Peter George, Tabitha Schwenke, Dawn C. Banerji, MaryAnn Bray, George A. Buchanan, Thomas A. Clement, Stephen C. Henry, Robert R. Kitabchi, Abbas E. Mudaliar, Sunder Ratner, Robert E. Stentz, Frankie B. Reaven, Peter D. Musi, Nicolas Ferrannini, Ele DeFronzo, Ralph A. TI A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID TYPE-2 DIABETES-MELLITUS; IMPAIRED FASTING GLUCOSE; HEPATIC FAT-CONTENT; BETA-CELL FUNCTION; LIFE-STYLE; PIOGLITAZONE; PREVENTION; METABOLISM; ROSIGLITAZONE; METABONOMICS AB Objective: The objective was to test the clinical utility of Quantose M-Q to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic subjects. Quantose M-Q is derived from fasting measurements of insulin, alpha-hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate, three nonglucose metabolites shown to correlate with insulin-stimulated glucose disposal. Research Design and Methods: Participants were 428 of the total of 602 ACT NOW impaired glucose tolerance (IGT) subjects randomized to pioglitazone (45 mg/d) or placebo and followed for 2.4 years. At baseline and study end, fasting plasma metabolites required for determination of Quantose, glycated hemoglobin, and oral glucose tolerance test with frequent plasma insulin and glucose measurements to calculate the Matsuda index of insulin sensitivity were obtained. Results: Pioglitazone treatment lowered IGT conversion to diabetes (hazard ratio = 0.25; 95% confidence interval = 0.13-0.50; P < .0001). Although glycated hemoglobin did not track with insulin sensitivity, Quantose M-Q increased in pioglitazone-treated subjects (by 1.45 [3.45] mg.min(-1).kg(wbm)(-1)) (median [interquartile range]) (P < .001 vs placebo), as did the Matsuda index (by 3.05 [4.77] units; P < .0001). Quantose M-Q correlated with the Matsuda index at baseline and change in the Matsuda index from baseline (rho, 0.85 and 0.79, respectively; P < .0001) and was progressively higher across closeout glucose tolerance status (diabetes, IGT, normal glucose tolerance). In logistic models including only anthropometric and fasting measurements, Quantose M-Q outperformed both Matsuda and fasting insulin in predicting incident diabetes. Conclusions: In IGT subjects, Quantose M-Q parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy. Due to its strong correlation with improved insulin sensitivity and its ease of use, Quantose M-Q may serve as a useful clinical test to identify and monitor therapy in insulin-resistant patients. C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, Texas Diabet Inst, San Antonio, TX 78229 USA. [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78228 USA. [Cobb, Jeff E.; Gall, Walter; Adam, Klaus-Peter; George, Tabitha] Metabolon Inc, Durham, NC 27713 USA. [Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ 85012 USA. [Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Care Innovat, Phoenix, AZ 85004 USA. [Banerji, MaryAnn] SUNY Hlth Sci Ctr Brooklyn, Brooklyn, NY 11203 USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA 92161 USA. [Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92161 USA. [Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA. [Clement, Stephen C.] Inova Fairfax Hosp, Falls Church, VA 22042 USA. [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD 20782 USA. [Ferrannini, Ele] CNR, Inst Clin Physiol, Dept Clin & Expt Med, I-56126 Pisa, Italy. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Diabet, 7703 Floyd Curl Dr,MSC 7886, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu FU National Institutes of Health Grant (CTSA) [UL1TR000130]; HDL Diagnostics Inc.; Phoenix Data Coordinating Center from a Takeda grant; Sanofi Aventis; Merck; Roche; Boehringer-Ingelheim; Takeda; Novartis; BMS; Allergan; AstraZeneca; Eli Lilly; Sanofi-Aventis; Medtronics; Astra-Zeneca; Janssen; Novo Nordisk; Lilly Co; Amylin; Bristol Myers Squibb FX This work was supported by National Institutes of Health Grant (CTSA) UL1TR000130. This trial is registered at Clinical Trials.gov, no. NCT00220961.; D.T. reports receiving consultant fees from HDL Diagnostics Inc. J.E.C., W.G., K.-P. A., and T.G. report working at Metabolon, Inc. D.C.S. reports receiving funding of the Phoenix Data Coordinating Center from a Takeda grant. MA.B. reports receiving consulting fees from Sanofi Aventis, Merck, Roche, and Boehringer-Ingelheim; grants from Takeda and Merck; and fees for participation in review activities from Novartis and BMS. T.A.B. reports receiving grant support from Allergan and Takeda, being on advisory panel and speakers bureau for Takeda, and receiving stock options from Tethys Bioscience. S.C.C. reports that he is a full-time employee of Merck and Co. R.R.H. reports receiving grant support from AstraZeneca, BMS, Eli Lilly, Sanofi-Aventis, and Medtronics; is a consultant to Boehringer-Ingelheim, Gilead, Intarcia, Isis, Eli Lilly, Novo Nordisk, Roche, and Medtronics; and is on the advisory board to Amgen, AstraZeneca, BMS, Gilead, Intarcia, Johnson & Johnson/Janssen, Eli Lilly, Merck, Novo Nordisk, Roche, Sanofi-Aventis, Daiichi Sankyo, and Elcelyx. S.M. reports being a speaker to Takeda ans Astra-Zeneca; a consultant to AstraZeneca and has received research support from Astra-Zeneca and Janssen. R.E.R. reports receiving research support from Takeda. P.D.R. reports receiving research grants from BMS and Novo Nordisk, speaker support through Amylin, and is a consultant of BMS. E.F. reports receiving grants from Boehringer-Ingelheim and Lilly & Co and serves on the advisory board of Boehringer-Ingelheim, GSK, Lilly & Co, Sanofi, Astra Zeneca, and Johnson & Johnson/Janssen. R.A.D. reports receiving grants from Amylin, Bristol Myers Squibb, Boehringer-Ingelheim, and Takeda; serves on the advisory board for Amylin, Takeda, Bristol Myers Squibb, Astra Zeneca, Novo Nordisk, Janssen, Lexicon, and Boehringer-Ingelheim; and is on the Speakers Bureau for Novo Nordisk, Bristol Myers Squibb, Astra Zeneca, and Janssen. A.E.K., F.B.S., N.M., and G.A.B. report no conflict of interest. NR 36 TC 3 Z9 3 U1 1 U2 6 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2015 VL 100 IS 5 BP 1855 EP 1862 DI 10.1210/jc.2014-3824 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CM4QG UT WOS:000357669000037 PM 25603459 ER PT J AU Moriarty, H Winter, L Robinson, K True, G Piersol, C Vause-Earland, T Iacovone, DB Holbert, L Newhart, B Fishman, D Short, TH AF Moriarty, Helene Winter, Laraine Robinson, Keith True, Gala Piersol, Catherine Vause-Earland, Tracey Iacovone, Dolores Blazer Holbert, Laura Newhart, Brian Fishman, Deborah Short, Thomas H. TI Exploration of Individual and Family Factors Related to Community Reintegration in Veterans With Traumatic Brain Injury SO JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION LA English DT Article DE traumatic brain injury; veterans; community reintegration; depression; posttraumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; MAJOR DEPRESSION; NEUROPSYCHIATRIC SEQUELAE; TEMPORAL RELATIONSHIP; LIFE SATISFACTION; COMBAT VETERANS; INTEGRATION; MILITARY; REHABILITATION AB BACKGROUND: Community reintegration (CR) poses a major problem for military veterans who have experienced a traumatic brain injury (TBI). Factors contributing to CR after TBI are poorly understood. OBJECTIVE: To address the gap in knowledge, an ecological framework was used to explore individual and family factors related to CR. DESIGN: Baseline data from an intervention study with 83 veterans with primarily mild to moderate TBI were analyzed. Instruments measured CR, depressive symptoms, physical health, quality of the relationship with the family member, and sociodemographics. Posttraumatic stress disorder and TBI characteristics were determined through record review. RESULTS: Five variables that exhibited significant bivariate relationships with CR (veteran rating of quality of relationship, physical functioning, bodily pain, posttraumatic stress disorder diagnosis, and depressive symptoms) were entered into hierarchical regression analysis. In the final analysis, the five variables together accounted for 35% of the variance, but only depression was a significant predictor of CR, with more depressed veterans exhibiting lower CR. CONCLUSIONS: Efforts to support CR of Veterans with TBI should carefully assess and target depression, a modifiable factor. C1 [Moriarty, Helene] Philadelphia Vet Affairs VA Med Ctr, Nursing Serv, Philadelphia, PA USA. [Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Winter, Laraine; Fishman, Deborah] Philadelphia VA Med Ctr, Nursing Serv, Philadelphia, PA USA. [Winter, Laraine; Holbert, Laura] Philadelphia VA Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA. [Robinson, Keith; Iacovone, Dolores Blazer; Newhart, Brian] Philadelphia VA Med Ctr, Polytrauma Serv, Philadelphia, PA USA. [Robinson, Keith; True, Gala] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [True, Gala] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Piersol, Catherine; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA 19107 USA. [Short, Thomas H.] John Carroll Univ, Dept Math & Comp Sci, University Hts, OH USA. RP Moriarty, H (reprint author), Villanova Univ, Coll Nursing, Driscoll Hall,800 Lancaster Ave, Villanova, PA 19085 USA. EM helene.moriarty@villanova.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [R21 HD068857-01] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The project described was supported by Award No. R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. This material is the result of work also supported with resources and the use of facilities at the Philadelphia VA Medical Center. NR 93 TC 3 Z9 3 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1078-3903 EI 1532-5725 J9 J AM PSYCHIAT NURSES JI J. Am. Psych. Nurses Assoc. PD MAY-JUN PY 2015 VL 21 IS 3 BP 195 EP 211 DI 10.1177/1078390315591879 PG 17 WC Nursing; Psychiatry SC Nursing; Psychiatry GA CM5SN UT WOS:000357749000005 PM 26156059 ER PT J AU Homma, S Thompson, JLP Qian, M Ye, SQ Di Tullio, MR Lip, GYH Mann, DL Sacco, RL Levin, B Pullicino, PM Freudenberger, RS Teerlink, JR Graham, S Mohr, JP Labovitz, AJ Buchsbaum, R Estol, CJ Lok, DJ Ponikowski, P Anker, SD AF Homma, Shunichi Thompson, John L. P. Qian, Min Ye, Siqin Di Tullio, Marco R. Lip, Gregory Y. H. Mann, Douglas L. Sacco, Ralph L. Levin, Bruce Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Graham, Susan Mohr, J. P. Labovitz, Arthur J. Buchsbaum, Richard Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. TI Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction Trial Substudy SO CIRCULATION-HEART FAILURE LA English DT Article DE anticoagulant; heart failure; hemorrhage; stroke ID NORMALIZED RATIO CONTROL; ATRIAL-FIBRILLATION INSIGHTS; NET CLINICAL BENEFIT; RE-LY TRIAL; ORAL ANTICOAGULANT; STROKE PREVENTION; MODELING ANALYSIS; DABIGATRAN; APIXABAN; EFFICACY AB Background The aim of this study is to examine the relationship between time in the therapeutic range (TTR) and clinical outcomes in heart failure patients in sinus rhythm treated with warfarin. Methods and Results We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined). Multivariable Cox models were used to examine how the event risk changed with TTR and to compare the high TTR, low TTR, and aspirin-treated patients, with TTR being treated as a time-dependent covariate. A total of 2217 patients were included in the analyses; among whom 1067 were randomized to warfarin and 1150 were randomized to aspirin. The median (interquartile range) follow-up duration was 3.6 (2.0-5.0) years. Mean (SD) age was 6111.3 years, with 80% being men. The mean (+/- SD) TTR was 57% (+/- 28.5%). Increasing TTR was significantly associated with reduction in primary outcome (adjusted P<0.001), death alone (adjusted P=0.001), and improved net clinical benefit (adjusted P<0.001). A similar trend was observed for the other 2 outcomes, but significance was not reached (adjusted P=0.082 for ischemic stroke and adjusted P=0.109 for major hemorrhage). Conclusions In patients with heart failure in sinus rhythm, increasing TTR is associated with better outcome and improved net clinical benefit. Patients in whom good quality anticoagulation can be achieved may benefit from the use of anticoagulants. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938. C1 [Homma, Shunichi; Ye, Siqin; Di Tullio, Marco R.] Columbia Univ, Med Ctr, Dept Med, Div Cardiol, New York, NY 10032 USA. [Mohr, J. P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA. [Thompson, John L. P.; Qian, Min; Levin, Bruce; Buchsbaum, Richard] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. [Mann, Douglas L.] Washington Univ, Dept Med, St Louis, MO USA. [Sacco, Ralph L.] Univ Miami, Sch Med, Dept Neurol, Coral Gables, FL 33124 USA. [Pullicino, Patrick M.] Univ Kent, Kent Inst Med & Hlth Sci, Canterbury, Kent, England. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Dept Med, Div Cardiol, Allentown, PA USA. [Teerlink, John R.] San Francisco VA Med Ctr, Dept Med, Cardiol Sect, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA. [Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. [Lok, Dirk J.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands. [Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] Univ Med Gottingen, Dept Cardiol, Div Innovat Clin Trials, Gottingen, Germany. RP Homma, S (reprint author), Columbia Univ, Med Ctr, PH 3-342,622 W 168th St, New York, NY 10032 USA. EM sh23@columbia.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Beran, David/0000-0001-7229-3920; Kohsaka, Shun/0000-0003-3779-2972 FU [U01-NS-043975]; [U01-NS-039143] FX The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial was supported by grant numbers U01-NS-043975 to S. Homma and U01-NS-039143 to J.L.P. Thompson from the National Institute of Neurological Diseases and Stroke. Warfarin and warfarin placebo were provided by Taro Pharmaceuticals, United States and aspirin and aspirin placebo by Bayer HealthCare. NR 23 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAY PY 2015 VL 8 IS 3 BP 504 EP 509 DI 10.1161/CIRCHEARTFAILURE.114.001725 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CL6LX UT WOS:000357079700014 PM 25850425 ER PT J AU Wells, JM Gagger, A Blalock, JE AF Wells, J. Michael Gagger, Amit Blalock, J. Edwin TI MMP generated matrikines SO MATRIX BIOLOGY LA English DT Article DE Matrix metalloproteinase; Elastin; Proline-glycine-proline; COPD ID ELASTIN-BINDING-PROTEIN; PROLINE-GLYCINE-PROLINE; EXTRACELLULAR-MATRIX DEGRADATION; OBSTRUCTIVE PULMONARY-DISEASE; ARGININE-THREONINE-ARGININE; LEUKOTRIENE A(4) HYDROLASE; INJURED RABBIT CORNEA; PRO-GLY-PRO; NEUTROPHIL CHEMOATTRACTANT; CHEMOTACTIC PEPTIDE AB Matrikines originate from the fragmentation of extracellular matrix proteins and regulate cellular activities by interacting with specific receptors. Matrikines are implicated in inflammation, immune responses, organ development, wound repair, angiogenesis, atherosclerosis, tumor progression and metastasis due to their ability to alter cellular migration, chemotaxis, and mitogenesis. Matrix metalloproteinases (MMPs) degrade extracellular matrix components under normal circumstances and in disease processes. Of the 20 MMPs identified, MMP-1, MMP-2, MMP-8, MMP-9, and MMP-12 have been implicated in regulating the matrikines Val-Gly-Val-Ala-Pro-Gly (elastin peptide) and proline glycine proline (PGP). Elastin peptide fragments are generated by elastolytic enzymes and have implications in atherosclerosis, neovascularization, chronic obstructive pulmonary disease, skin disease, as well as tumor invasion and spread. PGP is produced through a multistep pathway that liberates the tripeptide fragment from extracellular collagen. PGP is best described for its role in neutrophil chemotaxis and is implicated in the pathogenesis of corneal ulcers and in chronic lung conditions. In chronic cigarette smoke related lung disease, the PGP pathway can become a self-propagating cycle of inflammation through cigarette-smoke mediated inhibition of leukotriene A4 hydrolase, the enzyme responsible for degrading PGP and halting acute inflammation. This review highlights the roles of MMPs in generating these important matrikines. (C) 2015 Published by Elsevier B.V. C1 [Wells, J. Michael; Gagger, Amit; Blalock, J. Edwin] Univ Alabama Birmingham (UAB, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Wells, J. Michael; Gagger, Amit; Blalock, J. Edwin] UAB Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Gagger, Amit] Birmingham VA Med Ctr, Dept Med, Birmingham, AL USA. RP Wells, JM (reprint author), 1900 Univ Blvd,MCLM 894, Birmingham, AL 35294 USA. EM jmwells@uab.edu OI Blalock, J. Edwin/0000-0001-5303-8123 FU NHLBI; NIH; Family Smoking Prevention and Tobacco Control Act FX Research reported in this publication was supported by the NHLBI, NIH, and the Family Smoking Prevention and Tobacco Control Act. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration. NR 73 TC 25 Z9 26 U1 3 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2015 VL 44-46 SI SI BP 122 EP 129 DI 10.1016/j.matbio.2015.01.016 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CL8MT UT WOS:000357229500014 PM 25636538 ER PT J AU Clark, AM Wheeler, SE Taylor, DP Young, CL Pillai, VC Stolz, DB Venkataramanan, R Lauffenburger, DA Griffith, LG Wells, A AF Clark, Amanda M. Wheeler, Sarah E. Taylor, Donald P. Young, Carissa L. Pillai, Venkateswaran C. Stolz, Donna B. Venkataramanan, Raman Lauffenburger, Douglas A. Griffith, Linda G. Wells, Alan TI Modeling breast cancer dormancy and re-emergence SO CANCER RESEARCH LA English DT Meeting Abstract CT 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium CY DEC 09-13, 2014 CL San Antonio, TX SP Canc Therapy Res Ctr, Amer Assoc Canc Res C1 [Clark, Amanda M.; Wheeler, Sarah E.; Taylor, Donald P.; Young, Carissa L.; Pillai, Venkateswaran C.; Stolz, Donna B.; Venkataramanan, Raman; Lauffenburger, Douglas A.; Griffith, Linda G.; Wells, Alan] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Stolz, Donna B.; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA. [Wells, Alan] VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA USA. [Stolz, Donna B.] Univ Pittsburgh, Ctr Canc, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD MAY 1 PY 2015 VL 75 SU 9 MA P1-07-01 DI 10.1158/1538-7445.SABCS14-P1-07-01 PG 2 WC Oncology SC Oncology GA CL1UK UT WOS:000356730200220 ER PT J AU Roshanravan, B Patel, KV Robinson-Cohen, C de Boer, IH O'Hare, AM Ferrucci, L Himmelfarb, J Kestenbaum, B AF Roshanravan, Baback Patel, Kushang V. Robinson-Cohen, Cassianne de Boer, Ian H. O'Hare, Ann M. Ferrucci, Luigi Himmelfarb, Jonathan Kestenbaum, Bryan TI Creatinine Clearance, Walking Speed, and Muscle Atrophy: A Cohort Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Physical performance; skeletal muscle composition; muscle strength; mobility impairment; muscle atrophy; longitudinal trajectory; creatinine clearance (Clcr); renal function; chronic kidney disease (CKD) ID CHRONIC KIDNEY-DISEASE; OLDER-ADULTS; BODY-COMPOSITION; CYSTATIN-C; GAIT-SPEED; PHYSICAL PERFORMANCE; GLUCOSE-INTOLERANCE; MOBILITY DISABILITY; PROTEIN-DEGRADATION; METABOLIC-ACIDOSIS AB Background: Chronic kidney disease is associated with malnutrition and inflammation. These processes may lead to loss of skeletal muscle and reduced physical performance. Associations of kidney function with muscle composition and longitudinal measures of physical performance are unknown. Study Design: Prospective cohort study. Setting & Participants: We evaluated 826 community-dwelling older adults enrolled in the Invecchiare in Chianti (InCHIANTI) Study who were free of baseline stroke or activities of daily living disability. Predictor: Baseline creatinine clearance (Clcr) based on 24-hour urine collection. Outcomes: Cross-sectional and longitudinal trajectories of physical performance measured by 7-m usual gait speed, 400-m fast gait speed, and knee extension strength using isometric dynamometry. Calf muscle composition assessed by quantitative computed tomography. Results: Mean age of participants was 74 +/- 7 (SD) years, with 183 having Clcr < 60 mL/min/1.73 m(2). After adjustment, each 10-mL/min/1.73 m(2) decrement in Clcr was associated with 0.01 (95% CI, 0.004-0.017) m/s slower 7-m usual walking speed and 0.008 (95% CI, 0.002-0.014) m/s slower 400-m walking speed. Each 10-mL/min/1.73 m(2) decrement in Clcr was associated with 28 (95% CI, 0.8-55) mm(2) lower muscle area and 0.15 (95% CI, 0.04-0.26) mg/cm(3) lower muscle density. After adjustment, lower Clcr was associated with slower mean 7-m (P = 0.005) and 400-m (P = 0.02) walk and knee extension strength (P = 0.001) during the course of follow-up. During a mean follow-up of 7.1 +/- 2.5 years, each 10-mL/min/1.73 m(2) lower baseline Clcr was associated with 0.024 (95% CI, 0.01-0.037) kg/y greater decline in knee strength. Limitations: Single baseline measurement of Clcr and 3-year interval between follow-up visits may lead to nondifferential misclassification and attenuation of estimates. Conclusions: Among older adults, lower Clcr is associated with muscle atrophy, reduced walking speed, and more rapid declines in lower-extremity strength over time. (C) 2015 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Roshanravan, Baback; Robinson-Cohen, Cassianne; de Boer, Ian H.; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Div Nephrol, Kidney Res Inst, Dept Med, Seattle, WA 98104 USA. [Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA. [O'Hare, Ann M.] Univ Washington, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98104 USA. [Ferrucci, Luigi] NIA, Intramural Res Program, NIH, Baltimore, MD 21224 USA. RP Roshanravan, B (reprint author), Univ Washington, Div Nephrol, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM broshanr@u.washington.edu OI Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU Italian Ministry of Health [ICS110.1/RF97.71]; National Institute on Aging (NIA), National Institutes of Health (NIH); NIA [N.1-AG-1-1, N.1-AG-1-2111, N01-AG-5-0002, 1 Z01 AG001050-01]; NIH [1K23DK099442-01] FX The InCHIANTI Study baseline (1998-2000) was supported as a "targeted project" by the Italian Ministry of Health (ICS110.1/RF97.71) and in part by the Intramural Research Program of the National Institute on Aging (NIA), National Institutes of Health (NIH); the InCHIANTI follow-ups were supported by the NIA (N.1-AG-1-1, N.1-AG-1-2111, N01-AG-5-0002, and 1 Z01 AG001050-01). This work was also supported by NIH 1K23DK099442-01 (Dr Rashanravan). NR 37 TC 7 Z9 7 U1 4 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2015 VL 65 IS 5 BP 737 EP 747 DI 10.1053/j.ajkd.2014.10.016 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA CL1SA UT WOS:000356723300016 PM 25542415 ER PT J AU Dalrymple, LS Mu, Y Romano, PS Nguyen, DV Chertow, GM Delgado, C Grimes, B Kaysen, GA Johansen, KL AF Dalrymple, Lorien S. Mu, Yi Romano, Patrick S. Nguyen, Danh V. Chertow, Glenn M. Delgado, Cynthia Grimes, Barbara Kaysen, George A. Johansen, Kirsten L. TI Outcomes of Infection-Related Hospitalization in Medicare Beneficiaries Receiving In-Center Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Infection; infection-related hospitalization; hospital readmission; transitions of care; survival; mortality; hemodialysis; end-stage renal disease (ESRD); Medicare beneficiaries; discharge diagnosis; dialysis access; sepsis ID UNITED-STATES; RATES; FACILITIES; QUALITY AB Background: Infection is a common cause of hospitalization in adults receiving hemodialysis. Limited data are available about downstream events resulting from or following these hospitalizations. Study Design: Retrospective cohort study using the US Renal Data System. Setting & Participants: Medicare beneficiaries initiating in-center hemodialysis therapy in 2005 to 2008. Factors: Demographics, dual Medicare/Medicaid eligibility, body mass index, comorbid conditions, initial vascular access type, nephrology care prior to dialysis therapy initiation, residence in a care facility, tobacco use, biochemical measures, and type of infection. Outcomes: 30-day hospital readmission or death following first infection-related hospitalization. Results: 60,270 Medicare beneficiaries had at least one hospitalization for infection. Of those who survived the initial hospitalization, 15,113(27%) were readmitted and survived the 30 days following hospital discharge, 1,624(3%) were readmitted to the hospital and then died within 30 days of discharge, and 2,425 (4%) died without hospital readmission. Complications related to dialysis access, sepsis, and heart failure accounted for 12%, 9%, and 7% of hospital readmissions, respectively. Factors associated with higher odds of 30-day readmission or death without readmission included non-Hispanic ethnicity, lower serum albumin level, inability to ambulate or transfer, limited nephrology care prior to dialysis therapy, and specific types of infection. In comparison, older age, select comorbid conditions, and institutionalization had stronger associations with death without readmission than with readmission. Limitations: Findings limited to Medicare beneficiaries receiving in-center hemodialysis. Conclusions: Hospitalizations for infection among patients receiving in-center hemodialysis are associated with exceptionally high rates of 30-day hospital readmission and death without readmission. (C) 2015 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Dalrymple, Lorien S.; Romano, Patrick S.; Kaysen, George A.] Univ Calif Davis, Dept Med, Davis, CA 95616 USA. [Mu, Yi] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Nguyen, Danh V.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA. [Chertow, Glenn M.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA. [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Grimes, Barbara; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Dalrymple, LS (reprint author), Div Nephrol, 4150 5 St,Ste 3500, Sacramento, CA 95817 USA. EM lorien.dalrymple@ucdmc.ucdavis.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK093584, K24 DK085153, K24 DK085446, R01 DK092232]; National Center for Advancing Translational Sciences [UL1 TR000002, UL1 TR000153]; Department of Veterans Affairs [1K2CX000527]; Dialysis Clinic Inc.; Department of Veterans Affairs, Clinical Science Research and Development Program [1IK2CX000527-01A2] FX This publication was made possible by grants K23 DK093584 (Dr Dalrymple), K24 DK085153 (Dr Johansen), K24 DK085446 (Dr Chertow). and R01 DK092232 (Dr Nguyen) from the National Institute of Diabetes and Digestive and Kidney Diseases; grants UL1 TR000002 (Drs Dalrymple and Nguyen) and UL1 TR000153 (Dr Nguyen) from the National Center for Advancing Translational Sciences; 1K2CX000527 from the Department of Veterans Affairs (Dr Delgado); and a research grant from Dialysis Clinic Inc. Dr Delgado's work is supported by the Department of Veterans Affairs, Clinical Science Research and Development Program under Career Development Award 1IK2CX000527-01A2. Her contribution is the result of work supported with the resources and the use of facilities at the San Francisco VA Medical Center. The funding sources were not involved in the design or conduct of the study; the collection and management of the data; data analysis and interpretation; and preparation, review, or approval of the manuscript. The data reported here have been supplied by the USRDS. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government. NR 18 TC 4 Z9 5 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2015 VL 65 IS 5 BP 754 EP 762 DI 10.1053/j.ajkd.2014.11.030 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CL1SA UT WOS:000356723300018 PM 25641061 ER PT J AU Choi, SY Baek, JI Zuo, XF Kim, SH Dunaief, JL Lipschutz, JH AF Choi, Soo Young Baek, Jeong-In Zuo, Xiaofeng Kim, Seok-Hyung Dunaief, Joshua L. Lipschutz, Joshua H. TI Cdc42 and sec10 Are Required for Normal Retinal Development in Zebrafish SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE zebrafish; connecting cilium; cdc42; sec10; retinal degeneration; protein trafficking ID OUTER SEGMENT DEVELOPMENT; BARDET-BIEDL-SYNDROME; PRIMARY CILIOGENESIS; RHODOPSIN TRANSPORT; KUPFFERS VESICLE; USHER-SYNDROME; SENSORY CILIA; PHOTORECEPTORS; COMPLEX; DEGENERATION AB PURPOSE. To characterize the function and mechanisms of cdc42 and sec10 in eye development in zebrafish. METHODS. Knockdown of zebrafish cdc42 and sec10 was carried out using antisense morpholino injection. The phenotype of morphants was characterized by histology, immunohistology, and transmission electron microscopy (TEM). To investigate a synergistic genetic interaction between cdc42 and sec10, we titrated suboptimal doses of cdc42 and sec10 morpholinos, and coinjected both morpholinos. To study trafficking, a melanosome transport assay was performed using epinephrine. RESULTS. Cdc42 and sec10 knockdown in zebrafish resulted in both abnormal eye development and increased retinal cell death. Cdc42 morphants had a relatively normal retinal structure, aside from the absence of most connecting cilia and outer segments, whereas in sec10 morphants, much of the outer nuclear layer, which is composed of the photoreceptor nuclei, was missing and RPE cell thickness was markedly irregular. Knockdown of cdc42 and sec10 also resulted in an intracellular transport defect affecting retrograde melanosome transport. Furthermore, there was a synergistic genetic interaction between zebrafish cdc42 and sec10, suggesting that cdc42 and sec10 act in the same pathway in retinal development. CONCLUSIONS. We propose a model whereby sec10 and cdc42 play a central role in development of the outer segment of the retinal photoreceptor cell by trafficking proteins necessary for ciliogenesis. C1 [Choi, Soo Young; Baek, Jeong-In; Zuo, Xiaofeng; Kim, Seok-Hyung; Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. RP Lipschutz, JH (reprint author), Med Univ S Carolina, 96 Jonathan Lucas St,CSB 829, Charleston, SC 29425 USA. EM Lipschut@musc.edu FU Department of Veterans Affairs [I01, 2I01 BX000820]; National Institutes of Health [DK069909, DK070980]; Research to Prevent Blindness, Inc.; F.M. Kirby Foundation; Paul and Evanina Bell MacKall Foundation Trust FX Supported in part by Department of Veterans Affairs Merit Award I01 and 2I01 BX000820 (JHL), National Institutes of Health Grants DK069909 and DK070980 (JHL), Research to Prevent Blindness, Inc., the F.M. Kirby Foundation, and the Paul and Evanina Bell MacKall Foundation Trust (JLD). NR 54 TC 1 Z9 1 U1 2 U2 3 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAY PY 2015 VL 56 IS 5 BP 3361 EP 3370 DI 10.1167/iovs.14-15692 PG 10 WC Ophthalmology SC Ophthalmology GA CK7UJ UT WOS:000356439200074 PM 26024121 ER PT J AU Stiers, W Barisa, M Stucky, K Pawlowski, C Van Tubbergen, M Turner, AP Hibbard, M Caplan, B AF Stiers, William Barisa, Mark Stucky, Kirk Pawlowski, Carey Van Tubbergen, Marie Turner, Aaron P. Hibbard, Mary Caplan, Bruce TI Guidelines for Competency Development and Measurement in Rehabilitation Psychology Postdoctoral Training SO REHABILITATION PSYCHOLOGY LA English DT Article DE rehabilitation psychology; psychology; training ID PROFESSIONAL-PSYCHOLOGY; NATIONAL-COUNCIL; EDUCATION; MODEL; BENCHMARKS; CULTURE; SCHOOLS AB Objective: This study describes the results of a multidisciplinary conference (the Baltimore Conference) that met to develop consensus guidelines for competency specification and measurement in postdoctoral training in rehabilitation psychology. Methods: Forty-six conference participants were chosen to include representatives of rehabilitation psychology training and practice communities, representatives of psychology accreditation and certification bodies, persons involved in medical education practice and research, and consumers of training programs (students). Results: Consensus education and training guidelines were developed that specify the key competencies in rehabilitation psychology postdoctoral training, and structured observation checklists were developed for their measurement. Discussion: This study continues the development of more than 50 years of thinking about education and training in rehabilitation psychology and builds on the existing work to further advance the development of guidelines in this area. The conference developed aspirational guidelines for competency specification and measurement in rehabilitation psychology postdoctoral training (i.e., for studying the outcomes of these training programs). Structured observation of trainee competencies allows examination of actual training outcomes in relation to intended outcomes and provides a methodology for studying how program outcomes are related to program structures and processes so that program improvement can occur. Best practices in applying program evaluation research methods to the study of professional training programs are discussed. C1 [Stiers, William] Johns Hopkins Univ, Dept Phys Med & Rehabil, Sch Med, Baltimore, MD 21239 USA. [Barisa, Mark] Baylor Inst Rehabil, Neuropsychol & Rehabil Psychol Serv, Dallas, TX USA. [Stucky, Kirk] Hurley Med Ctr, Dept Psychol, Flint, MI USA. [Stucky, Kirk] Michigan State Univ, Coll Human Med, Dept Med, E Lansing, MI 48824 USA. [Pawlowski, Carey] VA Palo Alto Hlth Care Syst, Polytrauma Transit Rehabil Program, Palo Alto, CA USA. [Van Tubbergen, Marie] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA. [Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA USA. [Turner, Aaron P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hibbard, Mary] New York Langone Med Ctr, Dept Rehabil Med, New York, NY USA. RP Stiers, W (reprint author), Johns Hopkins Univ, Dept Phys Med & Rehabil, Sch Med, Suite 406-POB, Baltimore, MD 21239 USA. EM wstiers1@jhmi.edu OI Turner, Aaron/0000-0001-6897-8003; Stiers, William/0000-0002-1826-8350 FU Paralyzed Veterans of America (PVA Education Foundation Grant) [654] FX Conference funding for the activities reported here was provided by a grant from the Paralyzed Veterans of America (PVA Education Foundation Grant 654). NR 34 TC 5 Z9 5 U1 1 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD MAY PY 2015 VL 60 IS 2 BP 111 EP 122 DI 10.1037/a0038353 PG 12 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA CL5CG UT WOS:000356976800001 PM 25496436 ER PT J AU Roubinov, DS Turner, AP Williams, RM AF Roubinov, Danielle S. Turner, Aaron P. Williams, Rhonda M. TI Coping Among Individuals With Multiple Sclerosis: Evaluating a Goodness-of-Fit Model SO REHABILITATION PSYCHOLOGY LA English DT Article DE multiple sclerosis; goodness-of-fit; coping; depression; anxiety ID COGNITIVE DYSFUNCTION; PERCEIVED STRESS; COMMUNITY SAMPLE; PRIMARY-CARE; ADJUSTMENT; DEPRESSION; HYPOTHESIS; LIFE; CONTROLLABILITY; ACCEPTANCE AB Objective: Multiple sclerosis (MS) is a chronic illness involving both controllable and uncontrollable stressors. The goodness-of-fit hypothesis posits that managing stressors effectively requires the use of different coping approaches in the face of controllable and uncontrollable stressors. To test the applicability of the goodness-of-fit model in a sample of adults with MS, we evaluated the ratio of 2 types of coping (an active problem-solving approach and an emotion-based meaning-focused approach) as a moderator of the relations between stress uncontrollability and mental health outcomes. Methods: Participants were veterans with MS (N = 90) receiving medical services through the Veterans Health Administration who completed telephone-based interviews. Regression analyses tested the interaction of stress uncontrollability and the problem-and meaning-focused coping ratio on anxious and depressive symptoms. Significant interactions were probed at 1 SD above the mean of coping (use of predominantly problem-focused coping) and 1 SD below the mean of coping (use of predominantly meaning-focused coping). Results: Findings largely supported the goodness-of-fit hypothesis. Anxiety and depressive symptoms were elevated when participants used more problem-focused strategies relative to meaning-focused strategies in the face of perceived uncontrollable stress. Conversely, symptoms of anxiety and depression were lower when uncontrollable stress was met with predominantly meaning-focused coping; however, the relations did not reach statistical significance. Conclusions: The impact of uncontrollable stressors on mental health outcomes for individuals with MS may vary depending on the degree to which problem-focused versus meaning-focused coping strategies are employed, lending support to the goodness-of-fit model. C1 [Roubinov, Danielle S.; Turner, Aaron P.; Williams, Rhonda M.] Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Turner, Aaron P.; Williams, Rhonda M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Roubinov, DS (reprint author), Vet Affairs Puget Sound Healthcare Syst, Rehabil Care Serv, 1660 S Columbian Way,S-117-RCS, Seattle, WA 98108 USA. EM danielle.roubinov@va.gov NR 41 TC 2 Z9 2 U1 2 U2 8 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD MAY PY 2015 VL 60 IS 2 BP 162 EP 168 DI 10.1037/rep0000032 PG 7 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA CL5CG UT WOS:000356976800008 PM 25822181 ER PT J AU Mamoun, M Bergen, AW Shieh, J Wiggins, A Brody, AL AF Mamoun, Michael Bergen, Andrew W. Shieh, Jennifer Wiggins, Anna Brody, Arthur L. TI Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date SO CNS DRUGS LA English DT Article ID NICOTINE METABOLITE RATIO; RANDOMIZED CONTROLLED-TRIAL; GENOME-WIDE ASSOCIATION; TREATMENT-SEEKING SMOKERS; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; TRANSDERMAL NICOTINE; GENETIC-VARIATION; CYP2A6 GENOTYPE; REPLACEMENT THERAPY AB For the past 30 years, research examining predictors of successful smoking cessation treatment response has focused primarily on clinical variables, such as levels of tobacco dependence, craving, and self-efficacy. However, recent research has begun to determine biomarkers (such as genotype, nicotine and metabolite levels, and brain imaging findings) that may have utility in predicting smoking cessation. For genotype, genes associated with nicotinic acetylcholine receptors (nAChRs) and related proteins have been found to predict response to first-line medications (e.g. nicotine replacement therapy [NRT], bupropion, or varenicline) or quitting over time without a controlled treatment trial. For nicotine and metabolite levels, function of the cytochrome P450 2A6 liver enzyme, which can be assessed with the nicotine metabolite ratio or via genotype, has been found to predict response, with slow nicotine metabolizers having less severe nicotine dependence and a greater likelihood of quitting with NRT than normal metabolizers. For brain imaging, decreased activation of brain regions associated with emotion regulation and increased connectivity in emotion regulation networks, increased responsiveness to pleasant cues, and altered activation with the Stroop effect have been found in smokers who quit with the first-line medications listed above or counseling. In addition, our group recently demonstrated that lower pre-treatment brain nAChR density is associated with a greater chance of quitting smoking with NRT or placebo. Several of these studies found that specific biomarkers may provide additional information for predicting response beyond subjective symptom or rating scale measures, thereby giving an initial indication that biomarkers may, in the future, be useful for guiding smoking cessation treatment intensity, duration, and type. C1 [Mamoun, Michael; Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Res & Psychiat, Los Angeles, CA 90073 USA. [Bergen, Andrew W.] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA. [Shieh, Jennifer] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Wiggins, Anna] Univ So Calif, Dept Psychiat, Los Angeles, CA USA. [Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. RP Brody, AL (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Res & Psychiat, Los Angeles, CA 90073 USA. EM abrody@ucla.edu OI Bergen, Andrew/0000-0002-1237-7644 FU National Institute on Drug Abuse [R01 DA20872, R21 DA33813]; Department of Veterans Affairs, Office of Research and Development [I01 CX000412]; Tobacco-Related Disease Research Program [23XT-0002] FX This work was supported by grants from the National Institute on Drug Abuse (R01 DA20872), the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412), and the Tobacco-Related Disease Research Program (#23XT-0002) to Arthur L. Brody, and a grant from the National Institute on Drug Abuse (R21 DA33813) to Andrew W. Bergen. Michael Mamoun, Andrew W. Bergen, Arthur L. Brody, Jennifer Shieh and Anna Wiggins report no conflicts of interest. NR 148 TC 4 Z9 4 U1 4 U2 14 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1172-7047 EI 1179-1934 J9 CNS DRUGS JI CNS Drugs PD MAY PY 2015 VL 29 IS 5 BP 359 EP 369 DI 10.1007/s40263-015-0243-1 PG 11 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CK5GG UT WOS:000356250500002 PM 25895022 ER PT J AU Shah, SP Glenn, GL Hummel, EM Hamilton, JM Martine, RR Duda, JE Wilkinson, JR AF Shah, Shital P. Glenn, Gretchen L. Hummel, Eileen M. Hamilton, Jane M. Martine, Rebecca R. Duda, John E. Wilkinson, Jayne R. TI Caregiver tele-support group for Parkinson's disease: A pilot study SO GERIATRIC NURSING LA English DT Article DE Parkinson's disease; Telehealth; Caregiver; Support group; Telemedicine ID FAMILY CAREGIVERS; TELEPHONE SUPPORT; OLDER-ADULTS; BURDEN; DEPRESSION; DEMENTIA; CANCER; LIFE AB Background: Parkinson's disease (PD) is a disabling neurodegenerative disease that typically affects the geriatric population and requires a caregiver. Although caregiver burden reduces quality of life of the caregiver, support groups for caregivers have not been studied. Offering a tele-support group to PD caregivers would be an innovative approach to extending a novel resource. Methods: A single-center pilot study was conducted, enrolling caregivers in an 8-week tele-support group program. Mood state and caregiver burden were assessed at baseline and conclusion of the program using self-report questionnaires. Qualitative feedback was obtained at the conclusion of the program. Results: Seven female spouse caregivers enrolled: 86% completed the program. Although no statistically significant changes in questionnaire scores were found, the mean Geriatric Depression Scale decreased from 4.2 to 3 and qualitative feedback was universally positive. Conclusions: The use of tele-support groups for PD caregivers is a feasible and innovative resource to address caregiver burden. Published by Elsevier Inc. C1 [Shah, Shital P.; Glenn, Gretchen L.; Hummel, Eileen M.; Martine, Rebecca R.; Duda, John E.; Wilkinson, Jayne R.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA. [Shah, Shital P.; Duda, John E.; Wilkinson, Jayne R.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19107 USA. [Hamilton, Jane M.] Partners Path LLC, Gwynedd Valley, PA 19437 USA. RP Wilkinson, JR (reprint author), Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, 3900 Woodland Ave,Mail Stop 127, Philadelphia, PA 19104 USA. EM jayne.wilkinson@va.gov NR 30 TC 2 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4572 EI 1528-3984 J9 GERIATR NURS JI Geriatr. Nurs. PD MAY-JUN PY 2015 VL 36 IS 3 BP 207 EP 211 DI 10.1016/j.gerinurse.2015.02.002 PG 5 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA CK7HG UT WOS:000356402800007 PM 25744558 ER PT J AU Ballard, ME Mandelkern, MA Monterosso, JR Hsu, E Robertson, CL Ishibashi, K Dean, AC London, ED AF Ballard, Michael E. Mandelkern, Mark A. Monterosso, John R. Hsu, Eustace Robertson, Chelsea L. Ishibashi, Kenji Dean, Andy C. London, Edythe D. TI Low Dopamine D-2/D-3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Article DE addiction; delay discounting; dopamine; impulsivity; positron emission tomography ID POSITRON-EMISSION-TOMOGRAPHY; REFERENCE TISSUE MODEL; D-3 RECEPTOR; NICOTINE DEPENDENCE; DISTRIBUTION VOLUME; IMPULSIVE BEHAVIOR; CIGARETTE-SMOKING; CHRONIC COCAINE; FUTURE REWARDS; BRAIN IMAGES AB Background: Individuals with substance use disorders typically exhibit a predilection toward instant gratification with apparent disregard for the future consequences of their actions. Indirect evidence suggests that low dopamine D-2-type receptor availability in the striatum contributes to the propensity of these individuals to sacrifice long-term goals for short-term gain; however, this possibility has not been tested directly. We investigated whether striatal D-2/D-3 receptor availability is negatively correlated with the preference for smaller, more immediate rewards over larger, delayed alternatives among research participants who met DSM-IV criteria for methamphetamine (MA) dependence. Methods: Fifty-four adults (n = 27 each: MA-dependent, non-user controls) completed the Kirby Monetary Choice Questionnaire, and underwent positron emission tomography scanning with [F-18] fallypride. Results: MA users displayed steeper temporal discounting (p = 0.030) and lower striatal D-2/D-3 receptor availability (p < 0.0005) than controls. Discount rate was negatively correlated with striatal D-2/D-3 receptor availability, with the relationship reaching statistical significance in the combined sample (r = -0.291, p = 0.016) and among MA users alone (r = -0.342, p = 0.041), but not among controls alone (r = -0.179, p = 0.185); the slopes did not differ significantly between MA users and controls (p = 0.5). Conclusions: These results provide the first direct evidence of a link between deficient D-2/D-3 receptor availability and steep temporal discounting. This finding fits with reports that low striatal D-2/D-3 receptor availability is associated with a higher risk of relapse among stimulant users, and may help to explain why some individuals choose to continue using drugs despite knowledge of their eventual negative consequences. Future research directions and therapeutic implications are discussed. C1 [Ballard, Michael E.; Ishibashi, Kenji; Dean, Andy C.; London, Edythe D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Robertson, Chelsea L.; London, Edythe D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA. [London, Edythe D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Ballard, Michael E.; Mandelkern, Mark A.; Robertson, Chelsea L.; Ishibashi, Kenji; London, Edythe D.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [Monterosso, John R.; Hsu, Eustace] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. RP London, ED (reprint author), UCLA, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C8-831, Los Angeles, CA 90024 USA. EM elondon@mednet.ucla.edu RI Ballard, Michael/F-9146-2013 OI Ballard, Michael/0000-0002-2651-6588 FU NIH [R01 DA020726, P20 DA022539, M0I RR00865]; [T32 DA024635] FX This research was supported by NIH grants R01 DA020726, P20 DA022539, M0I RR00865, and endowments from the Thomas P and Katherine K Pike Chair in Addiction Studies (Dr London), and the Marjorie M Greene Trust. Dr Ballard was supported by T32 DA024635. NR 77 TC 10 Z9 10 U1 2 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD MAY PY 2015 VL 18 IS 7 DI 10.1093/ijnp/pyu119 PG 10 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA CL1KV UT WOS:000356702800004 ER PT J AU Grigoryan, KV Best, A Dellavalle, RP AF Grigoryan, Konstantin V. Best, Arthur Dellavalle, Robert P. TI University Tort Liability for Allowing College Debit Card Purchasing of Indoor UV Tanning Services SO JAMA DERMATOLOGY LA English DT Editorial Material C1 [Grigoryan, Konstantin V.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Best, Arthur] Univ Denver, Sturm Coll Law, Denver, CO USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Dermatol Serv, Denver, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Med Ctr, Dermatol Serv, 1055 Clermont St,Mail Code 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 6 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAY PY 2015 VL 151 IS 5 BP 479 EP 480 DI 10.1001/jamadermatol.2014.5350 PG 2 WC Dermatology SC Dermatology GA CK4FH UT WOS:000356176700002 PM 25650948 ER PT J AU Kutner, JS Blatchford, PJ Taylor, DH Ritchie, CS Bull, JH Fairclough, DL Hanson, LC LeBlanc, TW Samsa, GP Wolf, S Aziz, NM Currow, DC Ferrell, B Wagner-Johnston, N Zafar, SY Cleary, JF Dev, S Goode, PS Kamal, AH Kassner, C Kvale, EA McCallum, JG Ogunseitan, AB Pantilat, SZ Portenoy, RK Prince-Paul, M Sloan, JA Swetz, KM Von Gunten, CF Abernethy, AP AF Kutner, Jean S. Blatchford, Patrick J. Taylor, Donald H., Jr. Ritchie, Christine S. Bull, Janet H. Fairclough, Diane L. Hanson, Laura C. LeBlanc, Thomas W. Samsa, Greg P. Wolf, Steven Aziz, Noreen M. Currow, David C. Ferrell, Betty Wagner-Johnston, Nina Zafar, S. Yousuf Cleary, James F. Dev, Sandesh Goode, Patricia S. Kamal, Arif H. Kassner, Cordt Kvale, Elizabeth A. McCallum, Janelle G. Ogunseitan, Adeboye B. Pantilat, Steven Z. Portenoy, Russell K. Prince-Paul, Maryjo Sloan, Jeff A. Swetz, Keith M. Von Gunten, Charles F. Abernethy, Amy P. TI Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness A Randomized Clinical Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID SHARED DECISION-MAKING; PALLIATIVE CARE; SURPRISE QUESTION; OLDER PATIENTS; HEART-FAILURE; RISK; MEDICATIONS; DISEASE; METAANALYSIS; MEDICINE AB IMPORTANCE For patients with limited prognosis, some medication risks may outweigh the benefits, particularly when benefits take years to accrue; statins are one example. Data are lacking regarding the risks and benefits of discontinuing statin therapy for patients with limited life expectancy. OBJECTIVE To evaluate the safety, clinical, and cost impact of discontinuing statin medications for patients in the palliative care setting. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, parallel-group, unblinded, pragmatic clinical trial. Eligibility included adults with an estimated life expectancy of between 1 month and 1 year, statin therapy for 3 months or more for primary or secondary prevention of cardiovascular disease, recent deterioration in functional status, and no recent active cardiovascular disease. Participants were randomized to either discontinue or continue statin therapy and were monitored monthly for up to 1 year. The study was conducted from June 3, 2011, to May 2, 2013. All analyses were performed using an intent-to-treat approach. INTERVENTIONS Statin therapy was withdrawn from eligible patients who were randomized to the discontinuation group. Patients in the continuation group continued to receive statins. MAIN OUTCOMES AND MEASURES Outcomes included death within 60 days (primary outcome), survival, cardiovascular events, performance status, quality of life (QOL), symptoms, number of nonstatin medications, and cost savings. RESULTS A total of 381 patients were enrolled; 189 of these were randomized to discontinue statins, and 192 were randomized to continue therapy. Mean (SD) age was 74.1 (11.6) years, 22.0% of the participants were cognitively impaired, and 48.8% had cancer. The proportion of participants in the discontinuation vs continuation groups who died within 60 days was not significantly different (23.8% vs 20.3%; 90% CI, -3.5% to 10.5%; P =.36) and did not meet the noninferiority end point. Total QOL was better for the group discontinuing statin therapy (mean McGill QOL score, 7.11 vs 6.85; P =.04). Few participants experienced cardiovascular events (13 in the discontinuation group vs 11 in the continuation group). Mean cost savings were $3.37 per day and $716 per patient. CONCLUSIONS AND RELEVANCE This pragmatic trial suggests that stopping statin medication therapy is safe and may be associated with benefits including improved QOL, use of fewer nonstatin medications, and a corresponding reduction in medication costs. Thoughtful patient-provider discussions regarding the uncertain benefit and potential decrement in QOL associated with statin continuation in this setting are warranted. C1 [Kutner, Jean S.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Blatchford, Patrick J.; Fairclough, Diane L.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Denver, CO USA. [Taylor, Donald H., Jr.] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27710 USA. [Ritchie, Christine S.] San Francisco VA Med Ctr, Ctr Res Aging, Jewish Home San Francisco, San Francisco, CA USA. [Ritchie, Christine S.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Bull, Janet H.] Four Seasons Compass Life, Flat Rock, NC USA. [Hanson, Laura C.] Univ N Carolina, Div Geriatr Med, Chapel Hill, NC USA. [LeBlanc, Thomas W.; Zafar, S. Yousuf; Kamal, Arif H.; Abernethy, Amy P.] Duke Univ, Sch Med, Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC 27710 USA. [Samsa, Greg P.; Wolf, Steven] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA. [Aziz, Noreen M.] NINR, NIH, Bethesda, MD 20892 USA. [Currow, David C.] Flinders Univ S Australia, Discipline, Palliat Serv, Adelaide, SA 5001, Australia. [Currow, David C.] Flinders Univ S Australia, Discipline, Support Serv, Adelaide, SA 5001, Australia. [Ferrell, Betty] City Hope Natl Med Ctr, City Hope Med Ctr, Dept Nursing Res, Duarte, CA USA. [Wagner-Johnston, Nina] Washington Univ, Dept Med, St Louis, MO USA. [Cleary, James F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Hematol Oncol, Madison, WI 53706 USA. [Dev, Sandesh] Phoenix Vet Affairs Hlth Care Syst, Dept Med, Phoenix, AZ USA. [Goode, Patricia S.; Kvale, Elizabeth A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Goode, Patricia S.; Kvale, Elizabeth A.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Kassner, Cordt] Hosp Analyt, Denver, CO USA. [McCallum, Janelle G.] Denver Hosp, Denver, CO USA. [Ogunseitan, Adeboye B.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Pantilat, Steven Z.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Portenoy, Russell K.] Metropolitan Jewish Hlth Syst, Hosp & Palliat Care, New York, NY USA. [Prince-Paul, Maryjo] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA. [Sloan, Jeff A.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Swetz, Keith M.] Mayo Clin, Dept Med, Rochester, MN USA. [Von Gunten, Charles F.] OhioHealth, Dept Hosp & Palliat Med, Columbus, OH USA. RP Abernethy, AP (reprint author), Duke Univ, Sch Med, Duke Clin Res Inst, Ctr Learning Hlth Care, Durham, NC 27710 USA. EM amy.abernethy@duke.edu OI LeBlanc, Thomas/0000-0002-0546-7895; Currow, David/0000-0003-1988-1250 FU National Institute of Nursing Research [UC4-NR012584, U24-NR014637] FX This study received funding from the National Institute of Nursing Research (grants UC4-NR012584 and U24-NR014637). Furthermore, this work included the support of resources and facilities within the Veterans Affairs Health Care System (eg, Phoenix, Arizona, and Birmingham, Alabama). NR 45 TC 68 Z9 70 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2015 VL 175 IS 5 BP 691 EP 700 DI 10.1001/jamainternmed.2015.0289 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CK4FQ UT WOS:000356178400004 PM 25798575 ER PT J AU Bekelman, DB Plomondon, ME Carey, EP Sullivan, MD Nelson, KM Hattler, B McBryde, CF Lehmann, KG Gianola, K Heidenreich, PA Rumsfeld, JS AF Bekelman, David B. Plomondon, Mary E. Carey, Evan P. Sullivan, Mark D. Nelson, Karin M. Hattler, Brack McBryde, Connor F. Lehmann, Kenneth G. Gianola, Katherine Heidenreich, Paul A. Rumsfeld, John S. TI Primary Results of the Patient-Centered Disease Management (PCDM) for Heart Failure Study A Randomized Clinical Trial SO JAMA INTERNAL MEDICINE LA English DT Article ID COLLABORATIVE CARE INTERVENTION; HOME-BASED INTERVENTION; HEALTH-STATUS; DEPRESSIVE SYMPTOMS; RESOURCE UTILIZATION; OUTCOMES; RISK; HOSPITALIZATION; METAANALYSIS; READMISSION AB IMPORTANCE Heart failure (HF) has a major effect on patients' health status, including their symptom burden, functional status, and health-related quality of life. OBJECTIVE To determine the effectiveness of a collaborative care patient-centered disease management (PCDM) intervention to improve the health status of patients with HF. DESIGN, SETTING, AND PARTICIPANTS The Patient-Centered Disease Management (PCDM) trial was a multisite randomized clinical trial comparing a collaborative care PCDM intervention with usual care in patients with HF. A population-based sample of 392 patients with an HF diagnosis from 4 Veterans Affairs centers who had a Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score of less than 60 (heavy symptom burden and impaired functional status and quality of life) were enrolled between May 2009 and June 2011. INTERVENTIONS The PCDM intervention included collaborative care by a multidisciplinary care team consisting of a nurse coordinator, cardiologist, psychiatrist, and primary care physician; home telemonitoring and patient self-management support; and screening and treatment for comorbid depression. MAIN OUTCOMES AND MEASURES The primary outcome was change in the KCCQ overall summary score at 1 year (a 5-point change is clinically significant). Mortality, hospitalization, and depressive symptoms (Patient Health Questionnaire 9) were secondary outcomes. RESULTS There were no significant differences in baseline characteristics between patients randomized to the PCDM intervention (n = 187) vs usual care (n = 197); baseline mean KCCQ overall summary scores were 37.9 vs 36.9 (P =.48). There was significant improvement in the KCCQ overall summary scores in both groups after 1 year (mean change, 13.5 points in each group), with no significant difference between groups (P =.97). The intervention was not associated with greater improvement in the KCCQ overall summary scores when the effect over time was estimated using 3-month, 6-month, and 12-month data (P =.74). Among secondary outcomes, there were significantly fewer deaths at 1 year in the intervention arm (8 of 187 [4.3%]) than in the usual care arm (19 of 197 [9.6%]) (P =.04). Among those who screened positive for depression, there was a greater improvement in the Patient Health Questionnaire 9 scores after 1 year in the intervention arm than in the usual care arm (2.1 points lower, P =.01). There was no significant difference in 1-year hospitalization rates between the intervention arm and the usual care arm (29.4% vs 29.9%, P =.87). CONCLUSIONS AND RELEVANCE This multisite randomized trial of a multifaceted HF PCDM intervention did not demonstrate improved patient health status compared with usual care. C1 [Bekelman, David B.; Plomondon, Mary E.; Carey, Evan P.; Hattler, Brack; McBryde, Connor F.; Rumsfeld, John S.] Vet Affairs Eastern Colorado Hlth Care Syst, Res Geriatr Ambulatory Care & Cardiol, Denver, CO 80220 USA. [Bekelman, David B.; Hattler, Brack; McBryde, Connor F.; Rumsfeld, John S.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. [Bekelman, David B.; Plomondon, Mary E.; Carey, Evan P.; Nelson, Karin M.; Rumsfeld, John S.] Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Denver, CO USA. [Sullivan, Mark D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Nelson, Karin M.; Lehmann, Kenneth G.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Lehmann, Kenneth G.] Univ Washington, Dept Med, Seattle, WA USA. [Gianola, Katherine] Richmond Vet Affairs Med Ctr, Richmond, VA USA. [Heidenreich, Paul A.] Vet Affairs Palo Alto Hlth Care Syst, Cardiol, Palo Alto, CA USA. RP Bekelman, DB (reprint author), Vet Affairs Eastern Colorado Hlth Care Syst, Res 151, 1055 Clermont St, Denver, CO 80220 USA. EM david.bekelman@va.gov FU Department of Veterans Affairs Health Services Research and Development [IIR 06-068, 08-022] FX The Patient-Centered Heart Failure Trial was funded by grant IIR 06-068 from the Department of Veterans Affairs Health Services Research and Development. Dr Bekelman was supported by Career Development Award 08-022 from the Department of Veterans Affairs Health Services Research and Development during this study. NR 44 TC 20 Z9 20 U1 4 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2015 VL 175 IS 5 BP 725 EP 732 DI 10.1001/jamainternmed.2015.0315 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CK4FQ UT WOS:000356178400010 PM 25822284 ER PT J AU Tsai, J Harpaz-Rotem, I Armour, C Southwick, SM Krystal, JH Pietrzak, RH AF Tsai, Jack Harpaz-Rotem, Ilan Armour, Cherie Southwick, Steven M. Krystal, John H. Pietrzak, Robert H. TI Dimensional Structure of DSM-5 Posttraumatic Stress Disorder Symptoms: Results From the National Health and Resilience in Veterans Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID COMORBIDITY SURVEY REPLICATION; ADMINISTERED PTSD SCALE; QUALITY-OF-LIFE; 5-FACTOR MODEL; PHENOTYPIC HETEROGENEITY; DYSPHORIC AROUSAL; FIT INDEXES; US VETERANS; SYMPTOMATOLOGY; AFGHANISTAN AB Objective: To evaluate the prevalence of DSM-5 posttraumatic stress disorder (PTSD) and factor structure of PTSD symptomatology in a nationally representative sample of US veterans and examine how PTSD symptom clusters are related to depression, anxiety, suicidal ideation, hostility, physical and mental health-related functioning, and quality of life. Method: Data were analyzed from the National Health and Resilience in Veterans Study, a nationally representative survey of 1,484 US veterans conducted from September through October 2013. Confirmatory factor analyses were conducted to evaluate the factor structure of PTSD symptoms, and structural equation models were constructed to examine the association between PTSD symptom clusters and external correlates. Results: 12.0% of veterans screened positive for lifetime PTSD and 5.2% for past-month PTSD. A 5-factor dysphoric arousal model and a newly proposed 6-factor model both fit the data significantly better than the 4-factor model of DSM-5. The 6-factor model fit the data best in the full sample, as well as in subsamples of female veterans and veterans with lifetime PTSD. The emotional numbing symptom cluster was more strongly related to depression (P < .001) and worse mental health-related functioning (P < .001) than other symptom clusters, while the externalizing behavior symptom cluster was more strongly related to hostility (P < .001). Conclusions: A total of 5.2% of US veterans screened positive for past-month DSM-5 PTSD. A 6-factor model of DSM-5 PTSD symptoms, which builds on extant models and includes a sixth externalizing behavior factor, provides the best dimensional representation of DSM-5 PTSD symptom clusters and demonstrates validity in assessing health outcomes of interest in this population. (C) Copyright 2014 Physicians Postgraduate Press, Inc. C1 [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Harpaz-Rotem, Ilan; Southwick, Steven M.; Krystal, John H.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Harpaz-Rotem, Ilan; Southwick, Steven M.; Krystal, John H.; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. [Armour, Cherie] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland. RP Tsai, J (reprint author), 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu OI Armour, Cherie/0000-0001-7649-3874 FU Department of Veterans Affairs, via its funding of the VA National Center for PTSD; (Department of Defense) of the Coalition to Alleviate PTSD (CAP); National Institute on Alcohol Abuse and Alcoholism [3P50AA012870]; National Institute of Mental Health (FAST-PS); National Center for Advancing Translational Science [UH2TR000960-01, UL1 RR024139]; State of Connecticut Department of Mental Health and Addiction Services FX We gratefully acknowledge the Department of Veterans Affairs, via its funding of the VA National Center for PTSD and its joint funding (with the Department of Defense) of the Coalition to Alleviate PTSD (CAP), the National Institute on Alcohol Abuse and Alcoholism (3P50AA012870), National Institute of Mental Health (FAST-PS), the National Center for Advancing Translational Science (UH2TR000960-01; Clinical and Translational Science Award Grant No. UL1 RR024139), and support of the State of Connecticut Department of Mental Health and Addiction Services for its support of the Abraham Ribicoff Research Facilities of the Connecticut Mental Health Center. NR 51 TC 24 Z9 25 U1 6 U2 18 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAY PY 2015 VL 76 IS 5 BP 546 EP 553 DI 10.4088/JCP.14m09091 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA CK0ZT UT WOS:000355935300016 PM 25562376 ER PT J AU Zetterberg, H Gandy, S AF Zetterberg, Henrik Gandy, Sam TI Repetitive concussions - How dangerous are they? SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Editorial Material DE Concussion; Chronic traumatic encephalopathy; Amyloid; Tau; Risk factors ID CHRONIC TRAUMATIC ENCEPHALOPATHY; FOOTBALL-LEAGUE PLAYER; SEVERE BRAIN-INJURY C1 [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, S-43180 Molndal, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, London WC1N 3BG, England. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Zetterberg, H (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden. EM henrik.zetterberg@gu.se FU NIA NIH HHS [P50 AG005138]; RRD VA [I01 RX000684] NR 12 TC 0 Z9 0 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 EI 1095-9327 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD MAY PY 2015 VL 66 SI SI BP 73 EP 74 DI 10.1016/j.mcn.2015.02.004 PN B PG 2 WC Neurosciences SC Neurosciences & Neurology GA CK7FT UT WOS:000356398900001 PM 25655012 ER PT J AU Gardner, RC Yaffe, K AF Gardner, Raquel C. Yaffe, Kristine TI Epidemiology of mild traumatic brain injury and neurodegenerative disease SO MOLECULAR AND CELLULAR NEUROSCIENCE LA English DT Article DE Chronic traumatic encephalopathy; Traumatic brain injury; Mild traumatic brain injury; Concussion; Neurodegenerative disease; Epidemiology ID ENVIRONMENTAL RISK-FACTORS; FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; CLINICAL-OUTCOMES; PUNCH DRUNK; HIGH-SCHOOL; ENCEPHALOPATHY AB Every year an estimated 42 million people worldwide suffer a mild traumatic brain injury (MTBI) or concussion. More severe traumatic brain injury (TBI) is a well-established risk factor for a variety of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Recently, large epidemiological studies have additionally identified MTBI as a risk factor for dementia. The role of MTBI in risk of PD or ALS is less well established. Repetitive MTBI and repetitive sub-concussive head trauma have been linked to increased risk for a variety of neurodegenerative diseases including chronic traumatic encephalopathy (CTE). CTE is a unique neurodegenerative tauopathy first described in boxers but more recently described in a variety of contact sport athletes, military veterans, and civilians exposed to repetitive MTBI. Studies of repetitive MTBI and CTE have been limited by referral bias, lack of consensus clinical criteria for CTE, challenges of quantifying MTBI exposure, and potential for confounding. The prevalence of CTE is unknown and the amount of MTBI or subconcussive trauma exposure necessary to produce CTE is unclear. This review will summarize the current literature regarding the epidemiology of MTBI, post-TBI dementia and Parkinson's disease, and CTE while highlighting methodological challenges and critical future directions of research in this field. This article is part of a Special Issue entitled SI:Traumatic Brain Injury. Published by Elsevier Inc. C1 [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. RP Gardner, RC (reprint author), 4150 Clement St, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); National Institutes of Health (NIH) [K24 AG031155]; Department of Defense [W81XWH-12-1-0581]; Department of Veterans Affairs; California Department of Public Health; Bright Focus Foundation; Alzheimer's Association FX RCG is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). KY has received research support from the National Institutes of Health (NIH) via K24 AG031155, the Department of Defense via W81XWH-12-1-0581, the Department of Veterans Affairs, the California Department of Public Health, the Bright Focus Foundation, and the Alzheimer's Association. NR 73 TC 35 Z9 35 U1 10 U2 57 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1044-7431 EI 1095-9327 J9 MOL CELL NEUROSCI JI Mol. Cell. Neurosci. PD MAY PY 2015 VL 66 SI SI BP 75 EP 80 DI 10.1016/j.mcn.2015.03.001 PN B PG 6 WC Neurosciences SC Neurosciences & Neurology GA CK7FT UT WOS:000356398900002 PM 25748121 ER PT J AU Saigusa, T Bell, PD AF Saigusa, Takamitsu Bell, P. Darwin TI Molecular Pathways and Therapies in Autosomal-Dominant Polycystic Kidney Disease SO PHYSIOLOGY LA English DT Article ID PLANAR CELL POLARITY; RENIN-ANGIOTENSIN SYSTEM; CYST EPITHELIAL-CELLS; COLLECTING DUCT CELLS; RENAL-DISEASE; LIVER-DISEASE; BETA-CATENIN; CONDITIONAL INACTIVATION; SIGNALING PATHWAY; CFTR INHIBITORS AB Autosomal-dominant polycystic kidney disease (ADPKD) is the most prevalent inherited renal disease, characterized by multiple cysts that can eventually lead to kidney failure. Studies investigating the role of primary cilia and polycystins have significantly advanced our understanding of the pathogenesis of PKD. This review will present clinical and basic aspects of ADPKD, review current concepts of PKD pathogenesis, evaluate potential therapeutic targets, and highlight challenges for future clinical studies. C1 [Saigusa, Takamitsu] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. Ralph Johnson VA Med Ctr, Charleston, SC USA. RP Saigusa, T (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM bellpd@musc.edu FU Veterans Affairs Merit Grant, National Institute of Diabetes and Digestive and Kidney Diseases Grant [P30 DK-074038]; Dialysis Clinic FX This study was supported by Veterans Affairs Merit Grant, National Institute of Diabetes and Digestive and Kidney Diseases Grant P30 DK-074038, and funds from Dialysis Clinic (to P.D.B.). NR 158 TC 9 Z9 9 U1 4 U2 15 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1548-9213 EI 1548-9221 J9 PHYSIOLOGY JI Physiology PD MAY 1 PY 2015 VL 30 IS 3 BP 195 EP 207 DI 10.1152/physiol.00032.2014 PG 13 WC Physiology SC Physiology GA CL1BK UT WOS:000356677200007 PM 25933820 ER PT J AU Karabanov, A Ziemann, U Hamada, M George, MS Quartarone, A Classen, J Massimini, M Rothwell, J Siebner, HR AF Karabanov, Anke Ziemann, Ulf Hamada, Masashi George, Mark S. Quartarone, Angelo Classen, Joseph Massimini, Marcello Rothwell, John Siebner, Hartwig Roman TI Consensus Paper: Probing Homeostatic Plasticity of Human Cortex With Non-invasive Transcranial Brain Stimulation SO BRAIN STIMULATION LA English DT Review DE Homeostatic plasticity; Non-invasive transcranial brain stimulation; Metaplasticity; Long-term potentiation; Long-term inhibition; Synaptic homeostasis hypothesis ID HUMAN MOTOR CORTEX; LONG-TERM POTENTIATION; THETA-BURST STIMULATION; PAIRED ASSOCIATIVE STIMULATION; BIDIRECTIONAL SYNAPTIC PLASTICITY; PARKINSONS-DISEASE PATIENTS; DEPRESSION-LIKE PLASTICITY; LOW-FREQUENCY STIMULATION; MAGNETIC STIMULATION; CORTICAL PLASTICITY AB Homeostatic plasticity is thought to stabilize neural activity around a set point within a physiologically reasonable dynamic range. Over the last ten years, a wide range of non-invasive transcranial brain stimulation (NTBS) techniques have been used to probe homeostatic control of cortical plasticity in the intact human brain. Here, we review different NTBS approaches to study homeostatic plasticity on a systems level and relate the findings to both, physiological evidence from in vitro studies and to a theoretical framework of homeostatic function. We highlight differences between homeostatic and other non-homeostatic forms of plasticity and we examine the contribution of sleep in restoring synaptic homeostasis. Finally, we discuss the growing number of studies showing that abnormal homeostatic plasticity may be associated to a range of neuropsychiatric diseases. (C) 2015 The Authors. Published by Elsevier Inc. C1 [Karabanov, Anke; Siebner, Hartwig Roman] Copenhagen Univ Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark. [Ziemann, Ulf] Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany. [Ziemann, Ulf] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany. [Hamada, Masashi] Natl Hosp Neurol & Neurosurg, London, England. [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Quartarone, Angelo] Univ Messina, Dept Neurosci, I-98100 Messina, Italy. [Classen, Joseph] Univ Hosp Leipzig, Dept Neurol, Leipzig, Germany. [Massimini, Marcello] Univ Milan, Dept Clin Sci, I-20122 Milan, Italy. [Rothwell, John] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorde, London, England. [Siebner, Hartwig Roman] Copenhagen Univ Hosp Bispebjerg, Dept Neurol, Copenhagen, Denmark. RP Karabanov, A (reprint author), Copenhagen Univ Hosp, Danish Res Ctr Magnet Resonance, Kettegaard 30, DK-2650 Hvidovre, Denmark. EM ankenk@drcmr.dk OI QUARTARONE, Angelo/0000-0003-1485-6590; Karabanov, Anke Ninija/0000-0003-1874-393X; Rothwell, John/0000-0003-1367-6467 FU Swedish Research Council FX AK was supported by the Swedish Research Council. NR 149 TC 18 Z9 18 U1 6 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2015 VL 8 IS 3 BP 442 EP 454 DI 10.1016/j.brs.2015.01.404 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CJ8RX UT WOS:000355772300002 PM 26050599 ER PT J AU Sahlem, GL Badran, BW Halford, JJ Williams, NR Korte, JE Leslie, K Strachan, M Breedlove, JL Runion, J Bachman, DL Uhde, TW Borckardt, JJ George, MS AF Sahlem, Gregory L. Badran, Bashar W. Halford, Jonathan J. Williams, Nolan R. Korte, Jeffrey E. Leslie, Kimberly Strachan, Martha Breedlove, Jesse L. Runion, Jennifer Bachman, David L. Uhde, Thomas W. Borckardt, Jeffery J. George, Mark S. TI Oscillating Square Wave Transcranial Direct Current Stimulation (tDCS) Delivered During Slow Wave Sleep Does Not Improve Declarative Memory More Than Sham: A Randomized Sham Controlled Crossover Study SO BRAIN STIMULATION LA English DT Article DE Transcranial direct current stimulation; Sleep; Slow wave sleep; Memory consolidation; Cognitive enhancement ID CONSOLIDATION AB Background: A 2006 trial in healthy medical students found that anodal slow oscillating tDCS delivered bi-frontally during slow wave sleep had an enhancing effect in declarative, but not procedural memory. Although there have been supporting animal studies, and similar findings in pathological groups, this study has not been replicated, or refuted, in the intervening years. We therefore tested these earlier results for replication using similar methods with the exception of current waveform (square in our study, nearly sinusoidal in the original). Objective/hypothesis: Our objective was to test the findings of a 2006 trial suggesting bi-frontal anodal tDCS during slow wave sleep enhances declarative memory. Methods: Twelve students (mean age 25, 9 women) free of medical problems underwent two testing conditions (active, sham) in a randomized counterbalanced fashion. Active stimulation consisted of oscillating square wave tDCS delivered during early Non-Rapid Eye Movement (NREM) sleep. The sham condition consisted of setting-up the tDCS device and electrodes, but not turning it on during sleep. tDCS was delivered bi-frontally with anodes placed at F3/F4, and cathodes placed at mastoids. Current density was 0.517 mA/cm(2), and oscillated between zero and maximal current at a frequency of 0.75 Hz. Stimulation occurred during five-five minute blocks with 1-min inter-block intervals (25 min total stimulation). The primary outcomes were both declarative memory consolidation measured by a paired word association test (PWA), and non-declarative memory, measured by a non-dominant finger-tapping test (FTT). We also recorded and analyzed sleep EEG. Results: There was no difference in the number of paired word associations remembered before compared to after sleep [(active = 3.1 +/- 3.0 SD more associations) (sham = 3.8 +/- 3.1 SD more associations)]. Finger tapping improved, (non-significantly) following active stimulation [(3.6 +/- 2.7 SD correctly typed sequences) compared to sham stimulation (2.3 +/- 2.2 SD correctly typed sequences)]. Conclusion: In this study, we failed to find improvements in declarative or performance memory and could not replicate an earlier study using nearly identical settings. Specifically we failed to find a beneficial effect on either overnight declarative or non-declarative memory consolidation via squarewave oscillating tDCS intervention applied bi-frontally during early NREM sleep. It is unclear if the morphology of the tDCS pulse is critical in any memory related improvements. (C) 2015 Elsevier Inc. All rights reserved. C1 [Sahlem, Gregory L.; Badran, Bashar W.; Williams, Nolan R.; Leslie, Kimberly; Strachan, Martha; Runion, Jennifer; Uhde, Thomas W.; Borckardt, Jeffery J.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Halford, Jonathan J.; Williams, Nolan R.; Bachman, David L.; George, Mark S.] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. [Korte, Jeffrey E.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Badran, Bashar W.; Breedlove, Jesse L.; George, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Sahlem, GL (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St,502N, Charleston, SC 29425 USA. EM sahlem@musc.edu OI Williams, Nolan/0000-0003-4368-3203 FU MUSC Drug and Alcohol Research Training Program [NIDA R25 DA020537-06] FX We would like to thank the MUSC Sleep and Anxiety Treatment and Research Program for all of their help in the development, and implementation of this project. We would also like to thank the MUSC Drug and Alcohol Research Training Program with special thanks to Nicky Thornley and Drs. Sudie Back, Sarah Book, and Kathleen Brady along with the grant that supports it (NIDA R25 DA020537-06 (PI's Back and Brady)). NR 12 TC 9 Z9 9 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD MAY-JUN PY 2015 VL 8 IS 3 BP 528 EP 534 DI 10.1016/j.brs.2015.01.414 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CJ8RX UT WOS:000355772300013 PM 25795621 ER PT J AU Rohde, NN Baca, CB Van Cott, AC Parko, KL Amuan, ME Pugh, MJ AF Rohde, Natalie N. Baca, Christine B. Van Cott, Anne C. Parko, Karen L. Amuan, Megan E. Pugh, Mary Jo TI Antiepileptic drug prescribing patterns in Iraq and Afghanistan war veterans with epilepsy SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy/seizures; Antiepileptic drugs; Cohort studies; Afghanistan war veterans; Iraq war veterans; Medical care ID NEW-ONSET EPILEPSY; QUALITY STANDARDS SUBCOMMITTEE; OLDER VETERANS; GERIATRIC EPILEPSY; AMERICAN ACADEMY; RISK-FACTORS; HEALTH-CARE; TRENDS; LEVETIRACETAM; EFFICACY AB Objective: We examined patterns of antiepileptic drug (AED) use in a cohort of Iraq/Afghanistan war veterans (IAVs) who were previously identified as having epilepsy. We hypothesized that clinicians would be more likely to prescribe newer AEDs and would select specific AEDs to treat seizures based on patient characteristics including gender and comorbidities. Methods: From the cohort of IAVs previously identified with epilepsy between fiscal years 2009 and 2010, we selected those who received AEDs from the Veterans Health Administration in FY2010. Regimens were classified as monotherapy or polytherapy, and specific AED use was examine overall and by gender. Multivariable logistic regression examined associations of age; gender; race/ethnicity; medical, psychiatric, and neurological comorbidities; and receipt of neurology specialty care associated with the six most commonly used AEDs. Results: Among 256,284 IAVs, 2123 met inclusion criteria (mean age: 33 years; 89% men). Seventy-two percent (n = 1526) received monotherapy, most commonly valproate (N = 425) and levetiracetam(n = 347). Sixty-one percent of those on monotherapy received a newer AED (levetiracetam, topiramate, lamotrigine, zonisamide, oxcarbazepine). Although fewer women than men received valproate, nearly 90% (N = 45) were of reproductive age (<= 45 years). Antiepileptic drug prescribing patterns were associated with posttraumatic stress disorder, bipolar disorder, cerebrovascular disease, dementia/cognitive impairment, headache, and receipt of neurological specialty care (all p < 0.01). Significance: In this cohort of veterans with epilepsy, most received AED monotherapy and newer AEDs. Prescribing patterns were different for men and women. The patterns observed between AEDs and neurological/psychiatric comorbidities suggest that clinicians are practicing rational prescribing. (C) 2015 Published by Elsevier Inc. C1 [Rohde, Natalie N.; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, VA Epilepsy Ctr Excellence, San Antonio, TX 78229 USA. [Rohde, Natalie N.; Pugh, Mary Jo] UTHSCSA, Dept Epidemiol & Biostat, San Antonio, TX USA. [Baca, Christine B.] VAGLAHS, VA Epilepsy Ctr Excellence, Los Angeles, CA USA. [Baca, Christine B.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Van Cott, Anne C.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15240 USA. [Parko, Karen L.] San Francisco VA Hlth Care Syst, VA Epilepsy Ctr Excellence, San Francisco, CA 94121 USA. [Parko, Karen L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Amuan, Megan E.] ENRM VAMC, CHOIR, Bedford, MA USA. [Pugh, Mary Jo] Texas A&M Hlth Sci Ctr, Dept Med, Bryan, TX USA. [Amuan, Megan E.] Bedford VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Natalie.Rohde@VA.gov; CBower@mednet.ucla.edu; Anne.VanCott@va.gov; karen.parko@ucsf.edu; megan.amuan@va.gov; MaryJo.Pugh2@VA.gov OI Pugh, Mary Jo/0000-0003-4196-7763 NR 38 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD MAY PY 2015 VL 46 BP 133 EP 139 DI 10.1016/j.yebeh.2015.03.027 PG 7 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA CJ7MD UT WOS:000355678600023 PM 25911209 ER PT J AU Struzyna, LA Harris, JP Katiyar, KS Chen, HI Cullen, DK AF Struzyna, Laura A. Harris, James P. Katiyar, Kritika S. Chen, H. Isaac Cullen, D. Kacy TI Restoring nervous system structure and function using tissue engineered living scaffolds SO NEURAL REGENERATION RESEARCH LA English DT Article DE living scaffolds; neural tissue engineering; cell transplant; biomaterials; regeneration; neurotrauma; neurodegeneration; axon pathfinding; cell migration ID LONG-TERM SURVIVAL; SPINAL-CORD INJURY; NEURAL STEM-CELLS; IN-VITRO; NEUROTROPHIC FACTORS; CHONDROITINASE ABC; AXON REGENERATION; GROWTH CONES; NEURONS; RECOVERY AB Neural tissue engineering is premised on the integration of engineered living tissue with the host nervous system to directly restore lost function or to augment regenerative capacity following nervous system injury or neurodegenerative disease. Disconnection of axon pathways - the long-distance fibers connecting specialized regions of the central nervous system or relaying peripheral signals - is a common feature of many neurological disorders and injury. However, functional axonal regeneration rarely occurs due to extreme distances to targets, absence of directed guidance, and the presence of inhibitory factors in the central nervous system, resulting in devastating effects on cognitive and sensorimotor function. To address this need, we are pursuing multiple strategies using tissue engineered "living scaffolds", which are preformed three-dimensional constructs consisting of living neural cells in a defined, often anisotropic architecture. Living scaffolds are designed to restore function by serving as a living labeled pathway for targeted axonal regeneration - mimicking key developmental mechanisms- or by restoring lost neural circuitry via direct replacement of neurons and axonal tracts. We are currently utilizing preformed living scaffolds consisting of neuronal clusters spanned by long axonal tracts as regenerative bridges to facilitate long-distance axonal regeneration and for targeted neurosurgical reconstruction of local circuits in the brain. Although there are formidable challenges in preclinical and clinical advancement, these living tissue engineered constructs represent a promising strategy to facilitate nervous system repair and functional recovery. C1 [Struzyna, Laura A.; Harris, James P.; Katiyar, Kritika S.; Chen, H. Isaac; Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA. [Struzyna, Laura A.; Harris, James P.; Chen, H. Isaac; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Ctr Neurotrauma Neurodegenerat & Restorat, Philadelphia, PA USA. [Katiyar, Kritika S.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), Univ Penn, Dept Neurosurg, Perelman Sch Med, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA. EM dkacy@mail.med.upenn.edu FU U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-13207004]; Axonia Medical, Inc.; Department of Veterans Affairs (RRD Merit Review) [B1097-I]; National Institutes of Health [NINDS T32-NS043126]; Penn Medicine Neuroscience Center; National Science Foundation [DGE-1321851] FX This work was made possible due to financial support provided by the U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-13207004); Axonia Medical, Inc.; Department of Veterans Affairs (RR&D Merit Review #B1097-I); National Institutes of Health (NINDS T32-NS043126); Penn Medicine Neuroscience Center; and the National Science Foundation (Graduate Research Fellowship DGE-1321851). NR 61 TC 3 Z9 4 U1 3 U2 16 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD MAY PY 2015 VL 10 IS 5 BP 679 EP 685 DI 10.4103/1673-5374.156943 PG 7 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA CK1JU UT WOS:000355964400002 PM 26109930 ER PT J AU Puhalla, S Elmquist, W Freyer, D Kleinberg, L Adkins, C Lockman, P McGregor, J Muldoon, L Nesbit, G Peereboom, D Smith, Q Walker, S Neuwelt, E AF Puhalla, Shannon Elmquist, William Freyer, David Kleinberg, Lawrence Adkins, Chris Lockman, Paul McGregor, John Muldoon, Leslie Nesbit, Gary Peereboom, David Smith, Quentin Walker, Sara Neuwelt, Edward TI Unsanctifying the sanctuary: challenges and opportunities with brain metastases SO NEURO-ONCOLOGY LA English DT Article DE brain metastases; CNS sanctuary; imaging; prevention; therapy ID CELL LUNG-CANCER; CENTRAL-NERVOUS-SYSTEM; HER2-POSITIVE BREAST-CANCER; PHASE-II TRIAL; INTERSTITIAL THERMAL THERAPY; LAPATINIB PLUS CAPECITABINE; TUMOR BARRIER PERMEABILITY; TYROSINE KINASE INHIBITORS; BLOOD-VOLUME MAPS; RADIATION-THERAPY AB While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate preclinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present. C1 [Puhalla, Shannon] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA. [Elmquist, William] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA. [Freyer, David] Childrens Hosp Los Angeles, Dept Hematol Oncol, Los Angeles, CA 90027 USA. [Kleinberg, Lawrence] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Adkins, Chris] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX USA. [Lockman, Paul] W Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV 26506 USA. [Lockman, Paul] Mary Babb Randolph Canc Ctr, Morgantown, WV USA. [McGregor, John] Ohio State Univ, Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA. [Muldoon, Leslie; Neuwelt, Edward] Oregon Hlth & Sci Univ, Blood Brain Barrier Program, Portland, OR 97239 USA. [Nesbit, Gary] Oregon Hlth & Sci Univ, Dotter Radiol Neuroradiol, Portland, OR 97239 USA. [Peereboom, David] Cleveland Clin Fdn, Brain Tumor & Neurooncol Ctr, Cleveland, OH 44195 USA. [Smith, Quentin] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Amarillo, TX USA. [Walker, Sara] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Neuwelt, Edward] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, E (reprint author), Oregon Hlth & Sci Univ, Blood Brain Barrier Program, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU National Institutes of Health NIH/NIGMS [U54GM104942, R13 NS076353]; Walter S. and Lucienne Driskill Foundation; R13 grant FX Grants from the National Institutes of Health NIH/NIGMS U54GM104942, and R13 NS076353 (E.N.) and the Walter S. and Lucienne Driskill Foundation (E.N.). This report was based on presentations at the 19th Annual Meeting of the Blood-Brain Barrier Consortium (March 21-23, 2013, Stevenson, Washington), which was partially funded by the R13 grant. NR 100 TC 9 Z9 9 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2015 VL 17 IS 5 BP 639 EP 651 DI 10.1093/neuonc/nov023 PG 13 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CK5KO UT WOS:000356263100004 PM 25846288 ER PT J AU Rogal, SS Bielefeldt, K Wasan, AD Szigethy, E Lotrich, F DiMartini, AF AF Rogal, Shari S. Bielefeldt, Klaus Wasan, Ajay D. Szigethy, Eva Lotrich, Francis DiMartini, Andrea F. TI Fibromyalgia Symptoms and Cirrhosis SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Widespread pain; Opioids; Steatohepatitis; Hepatitis C virus ID ALCOHOLIC LIVER-DISEASE; SLEEP QUALITY INDEX; DEPRESSION SCALE; HOSPITAL ANXIETY; PAIN; CYTOKINES; CORTISOL; QUESTIONNAIRE; TESTOSTERONE; PATHOGENESIS AB Background An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors. Aim We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease. Methods Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays. Results Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation. Conclusions Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis. C1 [Rogal, Shari S.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. [Rogal, Shari S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Bielefeldt, Klaus] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Wasan, Ajay D.] Univ Pittsburgh, Dept Anesthesia, Pittsburgh, PA USA. [Szigethy, Eva; Lotrich, Francis; DiMartini, Andrea F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RP Rogal, SS (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM rogalss@upmc.edu; bielefeldtk@upmc.edu; wasanad@upmc.edu; szigetheye@upmc.edu; lotrichfe@upmc.edu; dimartiniaf@upmc.edu FU Starzl Transplantation Institute Young Investigator Award, NIH [T32-DK063922] FX We would like to thank Amy Schmotzer and Sharon Boggiano for their help with this project. This project was supported by the Starzl Transplantation Institute Young Investigator Award, NIH grant T32-DK063922. NR 48 TC 1 Z9 2 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAY PY 2015 VL 60 IS 5 BP 1482 EP 1489 DI 10.1007/s10620-014-3453-3 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CJ5YN UT WOS:000355570200048 PM 25433921 ER PT J AU Patel, MS Volpp, KG AF Patel, Mitesh S. Volpp, Kevin G. TI Nudging Students Toward Healthier Food Choices-Applying Insights From Behavioral Economics SO JAMA PEDIATRICS LA English DT Editorial Material ID CONSUMPTION; SCHOOL; ARCHITECTURE; INTERVENTION; ADOLESCENTS; CHILDREN; IMPACT; CHEF C1 [Patel, Mitesh S.; Volpp, Kevin G.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Patel, Mitesh S.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst, Philadelphia, PA 19104 USA. [Patel, Mitesh S.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Patel, Mitesh S.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. RP Patel, MS (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, 423 Guardian Dr,13th Floor Blockley Hall, Philadelphia, PA 19104 USA. EM mpatel@upenn.edu NR 25 TC 0 Z9 0 U1 12 U2 43 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD MAY PY 2015 VL 169 IS 5 BP 425 EP 426 DI 10.1001/jamapediatrics.2015.0217 PG 2 WC Pediatrics SC Pediatrics GA CJ8EX UT WOS:000355734000008 PM 25798795 ER PT J AU Moin, T Ertl, K Schneider, J Vasti, E Makki, F Richardson, C Havens, K Damschroder, L AF Moin, Tannaz Ertl, Kristyn Schneider, Jessica Vasti, Elena Makki, Fatima Richardson, Caroline Havens, Kathryn Damschroder, Laura TI Women Veterans' Experience With a Web-Based Diabetes Prevention Program: A Qualitative Study to Inform Future Practice SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE prediabetic state; disease management; risk reduction behavior; program evaluation; patient satisfaction; attitude to computers; computers; Internet ID LIFE-STYLE INTERVENTIONS; IMPAIRED GLUCOSE-TOLERANCE; FOLLOW-UP; CLINICAL-PRACTICE; RISK-FACTORS; WEIGHT-LOSS; REDUCTION; OUTCOMES; METAANALYSIS; ADHERENCE AB Background: Diabetes prevention is a national goal and particularly important in the Veterans Health Administration (VHA) where 1 in 4 veterans has diabetes. There is growing evidence to support the use of Web-based diabetes prevention program (DPP) interventions, shown to be as effective and often more feasible than in-person interventions. Objective: Our primary objective was to qualitatively explore women veterans' early experiences with a Web-based DPP intervention. Our secondary objective was to estimate weight loss, participation, and engagement to provide context for our qualitative findings. Methods: We conducted and analyzed semistructured interviews and collected data on weight change, participation, and engagement. A total of 17 women veterans with prediabetes from a Midwest VA Women's Health Clinic were eligible to participate; 15 completed interviews. Results: Participants perceived the DPP program as an appealing way of initiating lifestyle changes and made them feel accountable in achieving their daily goals. The online program was convenient because it could be accessed at any time, and many found that it integrated well into daily life. However, some did not like the logging aspect and some found it to be too impersonal. Participants logged in a mean 76 times, posted a mean 46 group messages, and sent a mean 20.5 private messages to the health coach over 16 weeks. Participants lost 5.24% of baseline weight, and 82% (14/17) of participants completed at least 9 of 16 core modules. Conclusions: Women veterans' early experiences with a Web-based DPP intervention were generally positive. Accountability and convenience were key enabling factors for participation and engagement. A Web-based DPP intervention appears to be a promising means of translating the DPP for women veterans with prediabetes. C1 [Moin, Tannaz] VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles, VA Hlth Serv Res & Dev HSR&D, Ctr Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. [Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ertl, Kristyn] Clement J Zablocki VA Med Ctr, Dept Res, Milwaukee, WI USA. [Ertl, Kristyn] Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, Milwaukee, WI 53226 USA. [Schneider, Jessica; Havens, Kathryn] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Schneider, Jessica; Havens, Kathryn] Clement J Zablocki VA Med Ctr, Womens Hlth Clin, Milwaukee, WI USA. [Vasti, Elena] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Makki, Fatima; Damschroder, Laura] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA. [Richardson, Caroline] Univ Michigan, VA Ann Arbor Ctr Clin Management Res, Dept Family Med, Ann Arbor, MI 48109 USA. RP Moin, T (reprint author), VA Greater Los Angeles Healthcare Syst, VA Greater Los Angeles, VA Hlth Serv Res & Dev HSR&D, Ctr Healthcare Innovat Implementat & Policy, Los Angeles, CA 90073 USA. EM TMoin@mednet.ucla.edu OI Damschroder, Laura/0000-0002-3657-8459 FU VA Health Services Research Development [SDR 13-320]; VA Diabetes QUERI; VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program [TPM65-010]; VA Greater Los Angeles FX This project would not have been possible without project support from the VA Health Services Research & Development (SDR 13-320) and VA Diabetes QUERI. TM was supported by the VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program (TPM65-010), VA Greater Los Angeles from 2011-2014. NR 43 TC 4 Z9 4 U1 1 U2 4 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD MAY PY 2015 VL 17 IS 5 AR e127 DI 10.2196/jmir.4332 PG 12 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA CJ5MH UT WOS:000355531200002 PM 26006697 ER PT J AU Lambert, J Rodriguez, A Pearcy-Baluyot, M Shahi, SK AF Lambert, Jessica Rodriguez, Alexis Pearcy-Baluyot, Mischelle Shahi, Sanjeet K. TI Chronic Iritis Associated With Cutaneous Leukocytoclastic Vasculitis SO MILITARY MEDICINE LA English DT Article ID SMALL-VESSEL VASCULITIS; MANAGEMENT AB Cutaneous leukocytoclastic vasculitis (LCV) is a systemic condition that can be associated with iritis. LCV is characterized as a small-vessel vasculitis of the cutaneous area. The disease demonstrates purple lesions on the skin due to the destruction of small cutaneous blood vessels. These lesions are palpable and most often coalesce forming larger patches on the surface of the skin. During early stages of LCV, the disease can be undetected due to the infrequency and small size of the skin lesions. As such, the patient might go undiagnosed for years while having symptoms of LCV or iritis of unknown etiology. This article discusses the correlation seen with LCV and iritis. We report a case on a patient that presented to our clinic with a history of bilateral chronic iritis. After extensive laboratory testing, we concluded that the chronicity of her iritis was due to her LCV. The correlation between LCV and iritis was not evident for several years in our patient. We also discuss the correlation with systemic Sjogren's syndrome and LVC and how these two separate diseases are linked in many patients. We will illustrate the importance of serological testing, imaging, and skin lesion biopsy for the diagnosis of LCV. C1 [Lambert, Jessica; Rodriguez, Alexis; Pearcy-Baluyot, Mischelle] US Dept Vet Affairs, Malcom Randall VAMC, VA Optometry Clin, Gainesville, FL 32607 USA. [Shahi, Sanjeet K.] US Dept Vet Affairs, Ocala Community Based Outpatient Clin, Ocala, FL 34471 USA. RP Lambert, J (reprint author), US Dept Vet Affairs, Malcom Randall VAMC, VA Optometry Clin, 5533 SW 64th St, Gainesville, FL 32607 USA. NR 21 TC 0 Z9 0 U1 0 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAY PY 2015 VL 180 IS 5 BP E622 EP E625 DI 10.7205/MILMED-D-14-00287 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CJ5WF UT WOS:000355562600007 PM 25939124 ER PT J AU Chao, LDL Zhang, Y Buckley, S AF Chao, Linda L. Zhang, Yu Buckley, Shannon TI Effects of low-level sarin and cyclosarin exposure on white matter integrity in Gulf War Veterans SO NEUROTOXICOLOGY LA English DT Article DE Diffusion tensor imaging; White matter; Sarin; Cyclosarin; Gulf War veterans ID DIFFUSION-TENSOR MRI; TRAUMATIC BRAIN-INJURY; US ARMY VETERANS; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; RADIAL DIFFUSIVITY; AXONAL INJURY; DEGENERATION; SCLEROSIS; RECOVERY AB Background: We previously found evidence of reduced gray and white matter volume in Gulf War (GW) veterans with predicted low-level exposure to sarin (GB) and cyclosarin (GF). Because loss of white matter tissue integrity has been linked to both gray and white matter atrophy, the current study sought to test the hypothesis that GW veterans with predicted GB/CF exposure have evidence of disrupted white matter microstructural integrity. Methods: Measures of fractional anisotropy and directional (i.e., axial and radial) diffusivity were assessed from the 4 T diffusion tensor images (DTI) of 59 GW veterans with predicted GB/CF exposure and 59 "matched" unexposed GW veterans (mean age: 48 +/- 7 years). The DTI data were analyzed using regions of interest (ROI) analyses that accounted for age, sex, total brain gray and white matter volume, trauma exposure, posttraumatic stress disorder, current major depression, and chronic multisymptom illness status. Results: There were no significant group differences in fractional anisotropy or radial diffusivity. However, there was increased axial diffusivity in GW veterans with predicted GB/GF exposure compared to matched, unexposed veterans throughout the brain, including the temporal stem, corona radiata, superior and inferior (hippocampal) cingulum, inferior and superior fronto-occipital fasciculus, internal and external capsule, and superficial cortical white matter blades. Post hoc analysis revealed significant correlations between higher fractional anisotropy and lower radial diffusivity with better neurobehavioral performance in unexposed GW veterans. In contrast, only increased axial diffusivity in posterior limb of the internal capsule was associated with better psychomotor function in GW veterans with predicted GB/CF exposure. Conclusions: The finding that increased axial diffusivity in a region of the brain that contains descending corticospinal fibers was associated with better psychomotor function and the lack of significant neurobehavioral deficits in veterans with predicted GB/CF exposure hint at the possibility that the widespread increases in axial diffusivity that we observed in GW veterans with predicted GB/GF exposure relative to unexposed controls may reflect white matter reorganization after brain injury (i.e., exposure to GB/GF). Published by Elsevier Inc. C1 [Chao, Linda L.; Zhang, Yu; Buckley, Shannon] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Chao, Linda L.; Zhang, Yu] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Chao, LDL (reprint author), 4150 Clement St,114M, San Francisco, CA 94121 USA. EM linda.chao@ucsf.edu FU Department of Defense [DAMD17-01-1-0764]; US Army Medical Research and Materiel Command; Department of Veterans Affairs VA GWI [B3776]; VA grant [I01BX007080] FX The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the Army, Department of Defense, or Department of Veterans Affairs. This study also supported by Department of Defense grant DAMD17-01-1-0764 entitled 'Magnetic Resonance and Spectroscopy of the Human Brain in Gulf War Illness,' awarded to the Northern California Institute for Research and Education from the Department of Defense Gulf War Illnesses Research Program, US Army Medical Research and Materiel Command and a Department of Veterans Affairs grant VA GWI No. B3776 entitled 'Effects of Gulf War Illness on Brain Structure Function and Metabolism: MRI/MRS at 4 T', and VA grant No. I01BX007080 entitled 'Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure.' This material is the result of work supported with resources and the use of facilities at the San Francisco Veterans Affairs Medical Center. The authors would like to thank Dr. Michael Weiner for his support and the Gulf War veterans who participated in these studies. NR 57 TC 3 Z9 3 U1 4 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD MAY PY 2015 VL 48 BP 239 EP 248 DI 10.1016/j.neuro.2015.04.005 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA CJ6YR UT WOS:000355641600026 PM 25929683 ER PT J AU Singh, V Trescot, A Nishio, I AF Singh, Virtaj Trescot, Andrea Nishio, Isuta TI Injections for Chronic Pain SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Chronic pain; Regenerative injections; Trigger point injections; Botulinum toxins ID LOW-BACK-PAIN; MYOFASCIAL TRIGGER POINT; FIBRO-OSSEOUS PROLIFERATION; DEXTROSE PROLOTHERAPY; LATERAL EPICONDYLOSIS; ACUPUNCTURE ANALGESIA; PIRIFORMIS SYNDROME; SCLEROSING AGENT; META-ANALYSIS; THERAPY AB Although interventional procedures should be used cautiously in the setting of chronic pain, there is a role for a variety of injections to facilitate a patient's overall rehabilitation program. There are many resources available, including a prior issue of Physical Medicine and Rehabilitation Clinics of North America, which discuss the more conventional spinal injections. The focus of this article is on lesser-known injection options for treating chronic pain. The authors separately discuss trigger point injections, regenerative injections (prolotherapy), and injections using botulin toxins. C1 [Singh, Virtaj] Univ Washington, Seattle Spine & Sports Med, Dept Rehabil Med, Seattle, WA 98102 USA. [Trescot, Andrea] Pain & Headache Ctr, Wasilla, AK 99654 USA. [Nishio, Isuta] Univ Washington, VA Puget Sound Hlth Care Syst, Dept Anesthesiol & Pain Med, Seattle, WA 98108 USA. RP Singh, V (reprint author), Univ Washington, Seattle Spine & Sports Med, Dept Rehabil Med, 3213 Eastlake Ave East,Suite A, Seattle, WA 98102 USA. EM vsingh@seattlespine.com NR 54 TC 2 Z9 2 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD MAY PY 2015 VL 26 IS 2 BP 249 EP + DI 10.1016/j.pmr.2015.01.004 PG 14 WC Rehabilitation SC Rehabilitation GA CJ3AV UT WOS:000355356700008 PM 25952063 ER PT J AU Hage, FG Iskandrian, AE AF Hage, Fadi G. Iskandrian, Ami E. TI Multimodality Imaging for CAD Detection Before Renal Transplantation SO JACC-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE coronary angiography; coronary computed tomography angiography; renal transplantation; sensitivity and specificity; single-photon emission computed tomography ID PROGNOSTIC VALUE; KIDNEY-TRANSPLANTATION; LIVER-TRANSPLANTATION; HEART-DISEASE; PREDICTORS; CANDIDATES; SURVIVAL C1 [Hage, Fadi G.; Iskandrian, Ami E.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Sect Cardiol, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Lyons Harrison Res Bldg 314,1900 Univ Blvd, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 14 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X EI 1876-7591 J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD MAY PY 2015 VL 8 IS 5 BP 563 EP 565 DI 10.1016/j.jcmg.2015.01.017 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA CI9CR UT WOS:000355068500010 PM 25937194 ER PT J AU Tulsky, DS Kisala, PA Victorson, D Tate, DG Heinemann, AW Charlifue, S Kirshblum, SC Fyffe, D Gershon, R Spungen, AM Bombardier, CH Dyson-Hudson, TA Amtmann, D Kalpakjian, CZ Choi, SW Jette, AM Forchheimer, M Cella, D AF Tulsky, David S. Kisala, Pamela A. Victorson, David Tate, Denise G. Heinemann, Allen W. Charlifue, Susan Kirshblum, Steve C. Fyffe, Denise Gershon, Richard Spungen, Ann M. Bombardier, Charles H. Dyson-Hudson, Trevor A. Amtmann, Dagmar Kalpakjian, Claire Z. Choi, Seung W. Jette, Alan M. Forchheimer, Martin Cella, David TI Overview of the Spinal Cord Injury - Quality of Life (SCI-QOL) measurement system SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Computer Adaptive Testing; Health-Related Quality of Life; Item Response Theory; Patient Reported Outcomes; Spinal Cord Injury ID PATIENT-REPORTED OUTCOMES; ITEM RESPONSE THEORY; COMPUTERIZED ADAPTIVE ASSESSMENT; LONGITUDINAL ANALYSIS; CLINICAL-TRIALS; FUNCTIONAL INDEX; RISK-FACTORS; HEALTH; DEPRESSION; PROMIS AB Context/Objective: The Spinal Cord Injury - Quality of Life (SCI-QOL) measurement system was developed to address the shortage of relevant and psychometrically sound patient reported outcome (PRO) measures available for clinical care and research in spinal cord injury (SCI) rehabilitation. Using a computer adaptive testing (CAT) approach, the SCI-QOL builds on the Patient Reported Outcomes Measurement Information System (PROMIS) and the Quality of Life in Neurological Disorders (Neuro-QOL) initiative. This initial manuscript introduces the background and development of the SCI-QOL measurement system. Greater detail is presented in the additional manuscripts of this special issue. Design: Classical and contemporary test development methodologies were employed. Qualitative input was obtained from individuals with SCI and clinicians through interviews, focus groups, and cognitive debriefing. Item pools were field tested in a multi-site sample (n = 877) and calibrated using item response theory methods. Initial reliability and validity testing was performed in a new sample of individuals with traumatic SCI (n = 245). Setting: Five Model SCI System centers and one Department of Veterans Affairs Medical Center across the United States. Participants: Adults with traumatic SCI. Interventions: n/a Outcome Measures: n/a Results: The SCI-QOL consists of 19 item banks, including the SCI-Functional Index banks, and 3 fixed-length scales measuring physical, emotional, and social aspects of health-related QOL (HRQOL). Conclusion: The SCI-QOL measurement system consists of psychometrically sound measures for individuals with SCI. The manuscripts in this special issue provide evidence of the reliability and initial validity of this measurement system. The SCI-QOL also links to other measures designed for a general medical population. C1 [Tulsky, David S.; Kisala, Pamela A.] Univ Delaware, Coll Hlth Sci, Dept Phys Therapy, Newark, DE 19713 USA. [Tulsky, David S.; Fyffe, Denise; Dyson-Hudson, Trevor A.] Kessler Fdn, W Orange, NJ USA. [Victorson, David; Heinemann, Allen W.; Gershon, Richard; Cella, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Tate, Denise G.; Kalpakjian, Claire Z.; Forchheimer, Martin] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA. [Charlifue, Susan] Craig Hosp, Englewood, CO USA. [Kirshblum, Steve C.] Kessler Inst Rehabil, W Orange, NJ USA. [Fyffe, Denise] Rutgers State Univ, New Jersey Med Sch, Newark, NJ 07102 USA. [Spungen, Ann M.] James J Peters VA Med Ctr, Bronx, NY USA. [Bombardier, Charles H.; Amtmann, Dagmar] Univ Washington, Seattle, WA 98195 USA. [Choi, Seung W.] CTB McGraw Hill LLC, Monterey, CA USA. [Jette, Alan M.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Tulsky, DS (reprint author), Univ Delaware, Ctr Assessment Res & Translat, STAR Campus,540 S Coll Ave, Newark, DE 19713 USA. EM dtulsky@udel.edu OI Heinemann, Allen/0000-0003-2782-7326 FU National Institute of Child Health and Human Development/National Center on Medical Rehabilitation Research; National Institute of Neurological Disorders and Stroke (NINDS) [5R01HD0054659]; National Institute on Disability and Rehabilitation Research [H133N060022, H133N060024, H133N060014, H133N060005, H133N060027, H133N060032]; Department of Veterans Affairs, Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury [B8212-C] FX This work was co-funded by the National Institute of Child Health and Human Development/National Center on Medical Rehabilitation Research and the National Institute of Neurological Disorders and Stroke (NINDS) (Grant #5R01HD0054659). Additionally, funding for the development of the SCIFI physical functioning item banks was provided by the National Institute on Disability and Rehabilitation Research (Grant #s H133N060022, H133N060024, H133N060014, H133N060005, H133N060027, and H133N060032), and funding to expand the calibration sample into the VA was provided by the Department of Veterans Affairs, Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (Grant #B8212-C). NR 99 TC 16 Z9 16 U1 5 U2 21 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD MAY PY 2015 VL 38 IS 3 BP 257 EP 269 DI 10.1179/2045772315Y.0000000023 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA CJ0TV UT WOS:000355192100002 PM 26010962 ER PT J AU Tulsky, DS Kisala, PA Tate, DG Spungen, AM Kirshblum, SC AF Tulsky, David S. Kisala, Pamela A. Tate, Denise G. Spungen, Ann M. Kirshblum, Steven C. TI Development and psychometric characteristics of the SCI-QOL Bladder Management Difficulties and Bowel Management Difficulties item banks and short forms and the SCI-QOL Bladder Complications scale SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Urinary bladder; Neurogenic; Neurogenic bowel; Patient reported outcomes assessment; Quality of life; Psychometrics ID SPINAL-CORD-INJURY; QUALITY-OF-LIFE; NEUROGENIC BOWEL; INTERMITTENT CATHETERIZATION; NEUROPATHIC BLADDER; FOLLOW-UP; DYSFUNCTION; VALIDATION; QUESTIONNAIRE; MULTICENTER AB Objective: To describe the development and psychometric properties of the Spinal Cord Injury - Quality of Life (SCI-QOL) Bladder Management Difficulties and Bowel Management Difficulties item banks and Bladder Complications scale. Design: Using a mixed-methods design, a pool of items assessing bladder and bowel-related concerns were developed using focus groups with individuals with spinal cord injury (SCI) and SCI clinicians, cognitive interviews, and item response theory (IRT) analytic approaches, including tests of model fit and differential item functioning. Setting: Thirty-eight bladder items and 52 bowel items were tested at the University of Michigan, Kessler Foundation Research Center, the Rehabilitation Institute of Chicago, the University of Washington, Craig Hospital, and the James J. Peters VA Medical Center, Bronx, NY. Participants: Seven hundred fifty-seven adults with traumatic SCI. Results: The final item banks demonstrated unidimensionality (Bladder Management Difficulties CFI = 0.965; RMSEA = 0.093; Bowel Management Difficulties CFI = 0.955; RMSEA = 0.078) and acceptable fit to a graded response IRT model. The final calibrated Bladder Management Difficulties bank includes 15 items, and the final Bowel Management Difficulties item bank consists of 26 items. Additionally, 5 items related to urinary tract infections (UTI) did not fit with the larger Bladder Management Difficulties item bank but performed relatively well independently (CFI = 0.992, RMSEA = 0.050) and were thus retained as a separate scale. Conclusion: The SCI-QOL Bladder Management Difficulties and Bowel Management Difficulties item banks are psychometrically robust and are available as computer adaptive tests or short forms. The SCI-QOL Bladder Complications scale is a brief, fixed-length outcomes instrument for individuals with a UTI. C1 [Tulsky, David S.; Kisala, Pamela A.] Univ Delaware, Dept Phys Therapy, Newark, DE 19713 USA. [Tulsky, David S.] Kessler Fdn, Res Ctr, W Orange, NJ USA. [Tate, Denise G.] Univ Michigan, Sch Med, Dept Phys Med & Rehabil, Ann Arbor, MI USA. [Spungen, Ann M.] VA RR&D Ctr Excellence Med Consequences Spinal Co, James J Peters VA Med Ctr, Bronx, NY USA. [Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. RP Tulsky, DS (reprint author), Univ Delaware, Ctr Assessment Res & Translat, STAR Campus,540 S Coll Ave, Newark, DE 19713 USA. EM dtulsky@udel.edu FU National Institutes of Health [5R01HD054659] FX This study was supported by National Institutes of Health grant number 5R01HD054659 (Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Center on Medical Rehabilitation Research and the National Institute on Neurological Disorders and Stroke). NR 62 TC 3 Z9 3 U1 1 U2 5 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD MAY PY 2015 VL 38 IS 3 BP 288 EP 302 DI 10.1179/2045772315Y.0000000030 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA CJ0TV UT WOS:000355192100004 PM 26010964 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Blood pressure targets in patients with diabetes - a new perspective SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Editorial Material ID AMERICAN SOCIETY; EUROPEAN-SOCIETY; TASK-FORCE; HYPERTENSION; MANAGEMENT; CARDIOLOGY; ASSOCIATION; PREVENTION; GUIDELINES; STATEMENT C1 [Rosendorff, Clive] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, Marie Josee & Henry R Kravis Ctr Cardiovasc Hlth, Mt Sinai Heart, New York, NY 10029 USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 10 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD MAY PY 2015 VL 9 IS 5 BP 334 EP 336 DI 10.1016/j.jash.2015.03.003 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CI9DJ UT WOS:000355070300003 PM 25979409 ER PT J AU Mulshine, JL Avila, R Yankelevitz, D Baer, TM Estepar, RS Ambrose, LF Aldige, CR AF Mulshine, James L. Avila, Rick Yankelevitz, David Baer, Thomas M. Estepar, Raul San Jose Ambrose, Laurie Fenton Aldige, Carolyn R. TI Lung Cancer Workshop XI Tobacco-Induced Disease: Advances in Policy, Early Detection and Management SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Lung cancer; Screening; Low Dose CT; Quantitative imaging; Volumetric CT ID IMAGING BIOMARKER; DRUG DEVELOPMENT; VOLUMETRIC CT; LOBECTOMY; PROGRESS; SMOKERS AB The Prevent Cancer Foundation Lung Cancer Workshop XI: Tobacco-Induced Disease: Advances in Policy, Early Detection and Management was held in New York, NY on May 16 and 17, 2014. The two goals of the Workshop were to define strategies to drive innovation in precompetitive quantitative research on the use of imaging to assess new therapies for management of early lung cancer and to discuss a process to implement a national program to provide high quality computed tomography imaging for lung cancer and other tobacco-induced disease. With the central importance of computed tomography imaging for both early detection and volumetric lung cancer assessment, strategic issues around the development of imaging and ensuring its quality are critical to ensure continued progress against this most lethal cancer. C1 [Mulshine, James L.] Rush Univ, Chicago, IL 60612 USA. [Avila, Rick] US Dept Vet Affairs, Washington, DC USA. [Yankelevitz, David] Mt Sinai Sch Med, Dept Radiol, New York, NY USA. [Baer, Thomas M.] Stanford Univ, Photon Res Ctr, Palo Alto, CA 94304 USA. [Estepar, Raul San Jose] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Ambrose, Laurie Fenton] Lung Canc Alliance, Washington, DC USA. [Aldige, Carolyn R.] Prevent Canc Fdn, Alexandria, VA USA. RP Mulshine, JL (reprint author), Rush Univ, 1735 West Harrison St,Suite 206, Chicago, IL 60612 USA. EM jmulshin@rush.edu FU Prevent Cancer Foundation FX Riccardo S Avila has moved to become CEO, Accumetra since the time of the Workshop. The other authors declare no conflict of interest. This Workshop was supported through unrestricted grants to the Prevent Cancer Foundation. NR 24 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD MAY PY 2015 VL 10 IS 5 BP 762 EP 767 DI 10.1097/JTO.0000000000000489 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA CI8AP UT WOS:000354990100016 PM 25898957 ER PT J AU Pan, W Zhu, S Dai, D Liu, Z Li, D Li, B Gagliani, N Zheng, YJ Tang, YJ Weirauch, MT Chen, XT Zhu, W Wang, Y Chen, B Qian, YC Chen, YX Fang, JY Herbst, R Richman, L Jallal, B Harley, JB Flavell, RA Yao, YH Shen, N AF Pan, Wen Zhu, Shu Dai, Dai Liu, Zheng Li, Dan Li, Bin Gagliani, Nicola Zheng, Yunjiang Tang, Yuanjia Weirauch, Matthew T. Chen, Xiaoting Zhu, Wei Wang, Yue Chen, Bo Qian, Youcun Chen, Yingxuan Fang, Jingyuan Herbst, Ronald Richman, Laura Jallal, Bahija Harley, John B. Flavell, Richard A. Yao, Yihong Shen, Nan TI MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis SO NATURE COMMUNICATIONS LA English DT Article ID REGULATORY T-CELLS; DEVELOPING MICRORNA THERAPEUTICS; SYSTEM AUTOIMMUNE-DISEASE; ROR-GAMMA-T; MULTIPLE-SCLEROSIS; LINEAGE COMMITMENT; TGF-BETA; ENHANCER LANDSCAPE; FOXP3; TRANSCRIPTION AB Although different autoimmune diseases show discrete clinical features, there are common molecular pathways intimately involved. Here we show that miR-125a is downregulated in peripheral CD4(+) T cells of human autoimmune diseases including systemic lupus erythematosus and Crohn's disease, and relevant autoimmune mouse models. miR-125a stabilizes both the commitment and immunoregulatory capacity of Treg cells. In miR-125a-deficient mice, the balance appears to shift from immune suppression to inflammation, and results in more severe pathogenesis of colitis and experimental autoimmune encephalomyelitis (EAE). The genome-wide target analysis reveals that miR-125a suppresses several effector T-cell factors including Stat3, Ifng and Il13. Using a chemically synthesized miR-125a analogue, we show potential to re-programme the immune homeostasis in EAE models. These findings point to miR-125a as a critical factor that controls autoimmune diseases by stabilizing Treg-mediated immune homeostasis. C1 [Pan, Wen; Dai, Dai; Tang, Yuanjia; Qian, Youcun; Shen, Nan] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200032, Peoples R China. [Pan, Wen; Dai, Dai; Tang, Yuanjia; Shen, Nan] Chinese Acad Sci, Inst Hlth Sci, Joint Mol Rheumatol Lab, Shanghai 200025, Peoples R China. [Pan, Wen; Dai, Dai; Tang, Yuanjia; Shen, Nan] Chinese Acad Sci, Shanghai Renji Hosp, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China. [Pan, Wen; Dai, Dai; Tang, Yuanjia; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China. [Pan, Wen] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA. [Zhu, Shu; Gagliani, Nicola; Zheng, Yunjiang; Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA. [Liu, Zheng; Zhu, Wei; Wang, Yue; Chen, Bo; Herbst, Ronald; Richman, Laura; Jallal, Bahija; Yao, Yihong] MedImmune LLC, Gaithersburg, MD 20878 USA. [Li, Dan; Li, Bin] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai 200025, Peoples R China. [Weirauch, Matthew T.; Harley, John B.; Shen, Nan] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH 45229 USA. [Chen, Xiaoting] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Chen, Yingxuan; Fang, Jingyuan] Univ Cincinnati, Sch Elect & Comp Syst, Cincinnati, OH 45221 USA. [Chen, Xiaoting] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Digest Dis,Div Gastroenterol & Hepa, Shanghai 200001, Peoples R China. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH 45220 USA. [Shen, Nan] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Syst Biomed, Shanghai 200240, Peoples R China. RP Shen, N (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200032, Peoples R China. EM YaoY@medimmune.com; nanshensibs@gmail.com RI Pan, Wen/I-9965-2016 FU 973 programme [2014CB541902, 2014CB541901]; National Natural Science Foundation of China [81230072, 81421001, 81025016, 31370880]; Key Research Program of the Chinese Academy of Sciences [KSZD-EW-Z-003-3]; State Key Laboratory of Oncogenes and Related Genes [91-14-05]; Chinese Ministry of Health [201202008]; Program of the Shanghai Commission of Science and Technology [12431900703, 12JC1406000, 12ZR1435900]; Leukemia and Lymphoma Society; Howard Hughes Medical Institute-The Helen Hay Whitney Foundation; Shenzhen Foundation of Science and Technology [GJHZ2014041417082192] FX We thank Robert Georgantas and Philip Brohawn for their helpful discussions, technical expertise and/or review of this manuscript. This work is supported by grants from 973 programme (2014CB541902 and 2014CB541901), National Natural Science Foundation of China (81230072, 81421001, 81025016 and 31370880), the Key Research Program of the Chinese Academy of Sciences (KSZD-EW-Z-003-3), the grants from the State Key Laboratory of Oncogenes and Related Genes (No. 91-14-05) as well as Chinese Ministry of Health (201202008) and the Program of the Shanghai Commission of Science and Technology (12431900703, 12JC1406000 and 12ZR1435900). W.P. is supported by a fellowship from Leukemia and Lymphoma Society. S.Z. is supported by a fellowship from Howard Hughes Medical Institute-The Helen Hay Whitney Foundation and Shenzhen Foundation of Science and Technology (grant number GJHZ2014041417082192). NR 49 TC 9 Z9 10 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD MAY PY 2015 VL 6 AR 7096 DI 10.1038/ncomms8096 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ5ML UT WOS:000355531600004 PM 25963922 ER PT J AU McDonald, LT Russell, DL Kelly, RR Xiong, Y Motamarry, A Patel, RK Jones, JA Watson, PM Turner, DP Watson, DK Soloff, AC Findlay, VJ LaRue, AC AF McDonald, Lindsay T. Russell, Dayvia L. Kelly, Ryan R. Xiong, Ying Motamarry, Anjan Patel, Risha K. Jones, Jeffrey A. Watson, Patricia M. Turner, David P. Watson, Dennis K. Soloff, Adam C. Findlay, Victoria J. LaRue, Amanda C. TI Hematopoietic Stem Cell-Derived Cancer-Associated Fibroblasts Are Novel Contributors to the Pro-Tumorigenic Microenvironment SO NEOPLASIA LA English DT Article ID CARCINOMA-ASSOCIATED FIBROBLASTS; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; GENE-EXPRESSION SIGNATURE; PROMOTE TUMOR-GROWTH; MESENCHYMAL TRANSITION; STROMAL FIBROBLASTS; MICROVESSEL DENSITY; ANGIOGENIC SWITCH; POOR-PROGNOSIS AB Targeting the tumor microenvironment is critical toward improving the effectiveness of cancer therapeutics. Cancer-associated fibroblasts (CAFs) are one of the most abundant cell types of the tumor microenvironment, playing an important role in tumor progression. Multiple origins for CAFs have been proposed including resident fibroblasts, adipocytes, and bonemarrow. Our laboratory previously identified a novel hematopoietic stem cell (HSC) origin for CAFs; however, the functional roles of HSC-derived CAFs (HSC-CAFs) in tumor progression have not yet been examined. To test the hypothesis that HSC-CAFs promote tumor progression through contribution to extracellular matrix (ECM) and paracrine production of pro-angiogenic factors, we developed a method to isolate HSC-CAFs. HSC-CAFs were profiled on the basis of their expression of hematopoietic and fibroblastic markers in two murine tumor models. Profiling revealed production of factors associated with ECM deposition and remodeling. Functional in vivo studies showed that co-injection of HSC-CAFs with tumor cells resulted in increased tumor growth rate and significantly larger tumors than tumor cells alone. Immunohistochemical studies revealed increased blood vessel density with co-injection, demonstrating a role for HSC-CAFs in tumor vascularization. Mechanistic in vitro studies indicated that HSC-CAFs play a role in producing vascular endothelial growth factor A and transforming growth factor-beta 1 in endothelial tube formation and patterning. In vitro and in vivo findings suggest that HSC-CAFs are a critical component of the tumor microenvironment and suggest that targeting the novel HSC-CAF may be a promising therapeutic strategy. C1 [McDonald, Lindsay T.; Russell, Dayvia L.; Kelly, Ryan R.; Xiong, Ying; LaRue, Amanda C.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA. [McDonald, Lindsay T.; Russell, Dayvia L.; Kelly, Ryan R.; Xiong, Ying; Turner, David P.; Watson, Dennis K.; Findlay, Victoria J.; LaRue, Amanda C.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [McDonald, Lindsay T.; Russell, Dayvia L.; Kelly, Ryan R.; Xiong, Ying; Watson, Patricia M.; Turner, David P.; Watson, Dennis K.; Soloff, Adam C.; Findlay, Victoria J.; LaRue, Amanda C.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Motamarry, Anjan] Med Univ S Carolina, Coll Grad Studies, Charleston, SC 29425 USA. [Patel, Risha K.; Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Res, Charleston, SC 29425 USA. [Watson, Patricia M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Soloff, Adam C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP LaRue, AC (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St,Res 151, Charleston, SC 29425 USA. EM laruerc@musc.edu OI Soloff, Adam/0000-0002-1467-8168 FU NIH (National Institutes of Health)/NCI (National Cancer Institute) [R01 CA148772]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs; Hollings Cancer Center [P30 CA138313] FX This work is supported in part by the NIH (National Institutes of Health)/NCI (National Cancer Institute) (R01 CA148772, A.C.L.), the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (Merit Awards, A.C.L.), and the Hollings Cancer Center (Translational Research Pilot Project, P30 CA138313, A.C.L.). NR 73 TC 4 Z9 4 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1476-5586 J9 NEOPLASIA JI Neoplasia PD MAY PY 2015 VL 17 IS 5 BP 434 EP 448 DI 10.1016/j.neo.2015.04.004 PG 15 WC Oncology SC Oncology GA CJ1BN UT WOS:000355216700004 PM 26025666 ER PT J AU Rhee, CM Brent, GA Kovesdy, CP Soldin, OP Nguyen, D Budoff, MJ Brunelli, SM Kalantar-Zadeh, K AF Rhee, Connie M. Brent, Gregory A. Kovesdy, Csaba P. Soldin, Offie P. Danh Nguyen Budoff, Matthew J. Brunelli, Steven M. Kalantar-Zadeh, Kamyar TI Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Review DE cardiovascular risk; hyperthyrotropinemia; hypothyroidism; renal failure; thyroid functional disease ID STAGE RENAL-DISEASE; AMBULATORY PERITONEAL-DIALYSIS; HORMONE REPLACEMENT THERAPY; TANDEM MASS-SPECTROMETRY; MEAN PLATELET VOLUME; ALL-CAUSE MORTALITY; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; HUMAN RECOMBINANT ERYTHROPOIETIN; INCIDENT HEMODIALYSIS-PATIENTS AB Thyroid functional disease, and in particular hypothyroidism, is highly prevalent among chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients. In the general population, hypothyroidism is associated with impaired cardiac contractility, endothelial dysfunction, atherosclerosis and possibly higher cardiovascular mortality. It has been hypothesized that hypothyroidism is an under-recognized, modifiable risk factor for the enormous burden of cardiovascular disease and death in CKD and ESRD, but this has been difficult to test due to the challenge of accurate thyroid functional assessment in uremia. Low thyroid hormone levels (i.e. triiodothyronine) have been associated with adverse cardiovascular sequelae in CKD and ESRD patients, but these metrics are confounded by malnutrition, inflammation and comorbid states, and hence may signify nonthyroidal illness (i.e. thyroid functional test derangements associated with underlying ill health in the absence of thyroid pathology). Thyrotropin is considered a sensitive and specific thyroid function measure that may more accurately classify hypothyroidism, but few studies have examined the clinical significance of thyrotropin-defined hypothyroidism in CKD and ESRD. Of even greater uncertainty are the risks and benefits of thyroid hormone replacement, which bear a narrow therapeutic-to-toxic window and are frequently prescribed to CKD and ESRD patients. In this review, we discuss mechanisms by which hypothyroidism adversely affects cardiovascular health; examine the prognostic implications of hypothyroidism, thyroid hormone alterations and exogenous thyroid hormone replacement in CKD and ESRD; and identify areas of uncertainty related to the interplay between hypothyroidism, cardiovascular disease and kidney disease requiring further investigation. C1 [Rhee, Connie M.; Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Div Nephrol & Hypertens, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Orange, CA 92668 USA. [Brent, Gregory A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Brent, Gregory A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Kovesdy, Csaba P.] Memphis Vet Affairs Med Ctr, Div Nephrol, Memphis, TN USA. [Kovesdy, Csaba P.] Univ Tennessee, Hlth Sci Ctr, Div Nephrol, Memphis, TN USA. [Soldin, Offie P.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Danh Nguyen] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA. [Budoff, Matthew J.] Harbor UCLA Med Ctr, Div Cardiol, LA Biomed Res Inst, Los Angeles, CA USA. [Brunelli, Steven M.] Brigham & Womens Hosp, Div Nephrol, Boston, MA 02115 USA. [Brunelli, Steven M.] DaVita Clin Res, Minneapolis, MN USA. [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA. RP Rhee, CM (reprint author), Univ Calif Irvine, Div Nephrol & Hypertens, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Orange, CA 92668 USA. EM crhee1@uci.edu OI Kalantar-Zadeh, Kamyar/0000-0002-8666-0725 FU National Institutes of Health [F32 DK093201, R01 DK078106, K24 DK091419]; National Center for Advancing Translational Sciences grant [UL1 TR000153] FX CMR was supported by a National Institutes of Health grant (F32 DK093201). DVN is supported by a National Center for Advancing Translational Sciences grant (UL1 TR000153). KKZ is supported by research grants from the National Institutes of Health (R01 DK078106, K24 DK091419) and a philanthropist grant from Mr. Harold Simmons. NR 187 TC 14 Z9 15 U1 3 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD MAY PY 2015 VL 30 IS 5 BP 724 EP 737 DI 10.1093/ndt/gfu024 PG 14 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA CJ2LE UT WOS:000355315300007 PM 24574542 ER PT J AU Nuhi, V Parnell, A MacKenzie, E Macumber, M Castle, S AF Nuhi, Veldana Parnell, Anne MacKenzie, Elizabeth Macumber, Michelle Castle, Sharon TI Impact of a pharmacy technician admission medication history pilot program in a Veterans Affairs medical center. SO PHARMACOTHERAPY LA English DT Meeting Abstract C1 [Nuhi, Veldana; Parnell, Anne; MacKenzie, Elizabeth; Macumber, Michelle; Castle, Sharon] Ralph H Johnson Vet Affairs Med Ctr, Dept Pharm, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD MAY PY 2015 VL 35 IS 5 MA 50 BP E80 EP E80 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CJ1IC UT WOS:000355236300050 ER PT J AU Whitaker, RM Korrapati, MC Stallons, LJ Jesinkey, SR Arthur, JM Beeson, CC Zhong, Z Schnellmann, RG AF Whitaker, Ryan M. Korrapati, Midhun C. Stallons, Lindsey J. Jesinkey, Sean R. Arthur, John M. Beeson, Craig C. Zhong, Zhi Schnellmann, Rick G. TI Urinary ATP Synthase Subunit beta Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury SO TOXICOLOGICAL SCIENCES LA English DT Article DE acute kidney injury; ischemia-reperfusion; mitochondria; biomarker; ATP synthase beta ID ISCHEMIA-REPERFUSION INJURY; PATHOPHYSIOLOGY; BIOGENESIS; AKI; HOMEOSTASIS; RECOVERY; DISEASES; CELLS AB Although the importance of mitochondrial dysfunction in acute kidney injury (AKI) has been documented, noninvasive early biomarkers of mitochondrial damage are needed. We examined urinary ATP synthase subunit beta (ATPS beta) as a biomarker of renal mitochondrial dysfunction during AKI. Mice underwent sham surgery or varying degrees (5, 10, or 15 min ischemia) of ischemia/reperfusion (I/R)-induced AKI. Serum creatinine, BUN, and neutrophil gelatinase-associated lipocalin were elevated only in the 15 min I/R group at 24 h. Immunoblot analysis of urinary ATPS beta revealed two bands (full length similar to 52 kDa and cleaved similar to 25 kDa), both confirmed as ATPS beta by LC-MS/MS, that increased at 24 h in 10- and 15-min I/R groups. These changes were associated with mitochondrial dysfunction evidenced by reduced renal cortical expression of mitochondrial proteins, ATPS beta and COX1, proximal tubular oxygen consumption, and ATP. Furthermore, in the 15-min I/R group, urinary ATPS beta was elevated until 72 h before returning to baseline 144 h after reperfusion with recovery of renal function. Evaluation of urinary ATPS beta in a nonalcoholic steatohepatitis model of liver injury only revealed cleaved ATPS beta, suggesting specificity of full-length ATPS beta for renal injury. Immunoblot analyses of patient urine samples collected 36 h after cardiac surgery revealed increased urinary ATPS beta levels in patients with postcardiac surgery-induced AKI. LC-MS/MS urinalysis in human subjects with AKI confirmed increased ATPS beta. These translational studies provide evidence that ATPS beta may be a novel and sensitive urinary biomarker of renal mitochondrial dysfunction and could serve as valuable tool for the testing of potential therapies for AKI and chemical-induced nephrotoxicity. C1 [Whitaker, Ryan M.; Korrapati, Midhun C.; Stallons, Lindsey J.; Jesinkey, Sean R.; Beeson, Craig C.; Zhong, Zhi; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Arthur, John M.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Arthur, John M.; Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institute of Environmental Health and Sciences [SBIR/STTR ES023767-01]; South Carolina Clinical and Translational Research (SCTR) Institute; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX National Institute of Environmental Health and Sciences (SBIR/STTR ES023767-01 to R.G.S.); the South Carolina Clinical and Translational Research (SCTR) Institute, which has an academic home at the Medical University of South Carolina CTSA; the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. NR 26 TC 2 Z9 2 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 EI 1096-0929 J9 TOXICOL SCI JI Toxicol. Sci. PD MAY PY 2015 VL 145 IS 1 BP 108 EP 117 DI 10.1093/toxsci/kfv038 PG 10 WC Toxicology SC Toxicology GA CJ1YL UT WOS:000355280900012 PM 25666834 ER PT J AU Cheng, Y Nebeker, JR Knippenberg, KA Nelson, RE Goetz, MB LaFleur, J AF Cheng, Y. Nebeker, J. R. Knippenberg, K. A. Nelson, R. E. Goetz, M. B. LaFleur, J. TI PREDICTING HUMAN IMMUNODEFICIENCY VIRUS VETERANS' ADHERENCE TO ANTIRETROVIRAL AGENTS VIA OPTIMAL DATA ANALYSIS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Cheng, Y.; Nebeker, J. R.; Knippenberg, K. A.; Nelson, R. E.; LaFleur, J.] Univ Utah, Salt Lake City, UT USA. [Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PIN78 BP A241 EP A241 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498504090 ER PT J AU Mhatre, SK Sansgiry, S Serna, O Sansgiry, SS AF Mhatre, S. K. Sansgiry, S. Serna, O. Sansgiry, S. S. TI VALIDATION OF PRESCRIPTION MEDICATION ADHERENCE PREDICTION TOOL (RXAPT) TO PREDICT NON-ADHERENCE AMONG DIABETES PATIENTS ENROLLED IN MEDICARE SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Mhatre, S. K.; Sansgiry, S. S.] Univ Houston, Houston, TX USA. [Sansgiry, S.] VA Med Ctr, Houston, TX USA. [Serna, O.] Cigna HealthSpring, Houston, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PDB69 BP A64 EP + PG 4 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498501054 ER PT J AU Suda, KJ Hunkler, RJ Matusiak, L Vermeulen, L Schumock, G AF Suda, K. J. Hunkler, R. J. Matusiak, L. Vermeulen, L. Schumock, G. TI SPENDING ON HEPATITIS C ANTIVIRALS IN THE UNITED STATES, 2008-2014 SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Suda, K. J.] US Dept Vet Affairs, Hines, IL USA. [Suda, K. J.] Univ Illinois, Hines, IL USA. [Hunkler, R. J.; Matusiak, L.] IMS Hlth, Plymouth Meeting, PA USA. [Vermeulen, L.] UW Hosp & Clin, Madison, WI USA. [Schumock, G.] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PGI36 BP A228 EP A228 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498504018 ER PT J AU Maier-Hein, KH Westin, CF Shenton, ME Weiner, MW Raj, A Thomann, P Kikinis, R Stieltjes, B Pasternak, O AF Maier-Hein, Klaus H. Westin, Carl-Fredrik Shenton, Martha E. Weiner, Michael W. Raj, Ashish Thomann, Philipp Kikinis, Ron Stieltjes, Bram Pasternak, Ofer TI Widespread white matter degeneration preceding the onset of dementia SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Mild cognitive impairment; Diffusion tensor imaging; Partial volume elimination; Free-water imaging ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; DIFFUSION MRI; BRAIN; PROGRESSION; PREDICT; CONVERSION; DIAGNOSIS; REVEALS AB Background: Brain atrophy in subjects with mild cognitive impairment (MCI) introduces partial volume effects, limiting the sensitivity of diffusion tensor imaging to white matter microstructural degeneration. Appropriate correction isolates microstructural effects in MCI that might be precursors of Alzheimer's disease (AD). Methods: Forty-eight participants (18 MCI, 15 AD, and 15 healthy controls) had magnetic resonance imaging scans and clinical evaluations at baseline and follow-up after 36 months. Ten MCI subjects were diagnosed with AD at follow-up and eight remained MCI. Free-water (FW) corrected measures on the white matter skeleton were compared between groups. Results: FW corrected radial diffusivity, but not uncorrected radial diffusivity, was increased across the brain of the converted group compared with the nonconverted group (P < .05). The extent of increases was similar to that found comparing AD with controls. Conclusion: Partial volume elimination reveals microstructural alterations preceding dementia. These alterations may prove to be an effective and feasible early biomarker of AD. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Maier-Hein, Klaus H.; Westin, Carl-Fredrik; Shenton, Martha E.; Kikinis, Ron; Pasternak, Ofer] Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA. [Maier-Hein, Klaus H.] German Canc Res Ctr, Jr Grp Med Image Comp, Heidelberg, Germany. [Maier-Hein, Klaus H.; Stieltjes, Bram] German Canc Res Ctr, Jr Grp Quantitat Image Based Dis Characterizat, Heidelberg, Germany. [Shenton, Martha E.; Pasternak, Ofer] Harvard Univ, Sch Med, Dept Psychiat, Brigham & Womens Hosp, Boston, MA 02115 USA. [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Brockton Div, Brockton, MA USA. [Weiner, Michael W.] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94143 USA. [Raj, Ashish] Weill Cornell Med Coll, IDEAL, New York, NY USA. [Thomann, Philipp] Heidelberg Univ, Dept Gen Psychiat, Sect Geriatr Psychiat, Heidelberg, Germany. RP Maier-Hein, KH (reprint author), Harvard Univ, Sch Med, Dept Radiol, Brigham & Womens Hosp, Boston, MA 02115 USA. EM k.maier-hein@dkfz.de RI Maier-Hein, Klaus/M-6250-2016 OI Maier-Hein, Klaus/0000-0002-6626-2463 FU National Institutes of Health [R01MH074794, P41RR013218, P41EB015902]; German Research Foundation (DFG) [ME 833/15-1]; NARSAD Young Investigator grant from the Brain and Behavior Research Foundation FX This work was supported in part by National Institutes of Health grants (R01MH074794, P41RR013218, and P41EB015902); by the German Research Foundation (DFG) grant (ME 833/15-1) (to K.H.M.H. and B.S.); and by a NARSAD Young Investigator grant from the Brain and Behavior Research Foundation (to O.P.). NR 37 TC 9 Z9 9 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAY PY 2015 VL 11 IS 5 BP 485 EP 493 DI 10.1016/j.jalz.2014.04.518 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA CI8KN UT WOS:000355021300003 PM 25035154 ER PT J AU Willette, AA Johnson, SC Birdsill, AC Sager, MA Christian, B Baker, LD Craft, S Oh, J Statz, E Hermann, BP Jonaitis, EM Koscik, RL La Rue, A Asthana, S Bendlin, BB AF Willette, Auriel A. Johnson, Sterling C. Birdsill, Alex C. Sager, Mark A. Christian, Bradley Baker, Laura D. Craft, Suzanne Oh, Jennifer Statz, Eric Hermann, Bruce P. Jonaitis, Erin M. Koscik, Rebecca L. La Rue, Asenath Asthana, Sanjay Bendlin, Barbara B. TI Insulin resistance predicts brain amyloid deposition in late middle-aged adults SO ALZHEIMERS & DEMENTIA LA English DT Article DE Insulin resistance; Amyloid; PiB; Alzheimer's disease; Cognitively normal; Prefrontal ID PITTSBURGH COMPOUND-B; GRAY-MATTER VOLUME; ALZHEIMERS-DISEASE; DEGRADING ENZYME; IN-VIVO; RISK; PET; METABOLISM; COGNITION; DEMENTIA AB Background: Insulin resistance (IR) increases Alzheimer's disease (AD) risk. IR is related to greater amyloid burden post-mortem and increased deposition within areas affected by early AD. No studies have examined if IR is associated with an in vivo index of amyloid in the human brain in late middle-aged participants at risk for AD. Methods: Asymptomatic, late middle-aged adults (N = 186) from the Wisconsin Registry for Alzheimer's Prevention underwent [C-11]Pittsburgh compound B (PiB) positron emission tomography. The cross-sectional design tested the interaction between insulin resistance and glycemic status on PiB distribution volume ratio in three regions of interest (frontal, parietal, and temporal). Results: In participants with normoglycemia but not hyperglycemia, higher insulin resistance corresponded to higher PiB uptake in frontal and temporal areas, reflecting increased amyloirl deposition. Conclusions: This is the first human study to demonstrate that insulin resistance may contribute to amyloid deposition in brain regions affected by AD. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Willette, Auriel A.; Johnson, Sterling C.; Birdsill, Alex C.; Oh, Jennifer; Statz, Eric; Asthana, Sanjay; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. [Willette, Auriel A.; Johnson, Sterling C.; Birdsill, Alex C.; Sager, Mark A.; Oh, Jennifer; Statz, Eric; Hermann, Bruce P.; Asthana, Sanjay; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Willette, Auriel A.] NIA, Lab Neurosci, Baltimore, MD 21224 USA. [Johnson, Sterling C.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI USA. [Johnson, Sterling C.; Sager, Mark A.; Hermann, Bruce P.; Jonaitis, Erin M.; Koscik, Rebecca L.; La Rue, Asenath] Wisconsin Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Christian, Bradley] Wisconsin Sch Med & Publ Hlth, Dept Med Phys, Madison, WI USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA. RP Bendlin, BB (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA. EM bbb@medicine.wisc.edu OI Bendlin, Barbara/0000-0002-0580-9875 FU National Institute on Aging [R01 AG027161]; ADRC [P50 AG033514, R01 AG021155]; University of Wisconsin Institute for Clinical and Translational Research; National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award [1UL1RR025011]; National Center for Research Resources, United States National Institutes of Health FX The authors gratefully acknowledge Nancy Davenport-Sis, Amy Hawley, Sandra Harding, Caitlin Cleary, Chuck Illingworth, and the support of researchers and staff at the Waisman Center, University of Wisconsin Madison, for their assistance in recruitment, data collection, and data analysis. Above all, we wish to thank our dedicated volunteers for their participation in this research. This project was supported by the National Institute on Aging (R01 AG027161 [M.A.S.], ADRC P50 AG033514 [S.A.], R01 AG021155 [S.C.J.], the University of Wisconsin Institute for Clinical and Translational Research, funded through a National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award, 1UL1RR025011, a program of the National Center for Research Resources, United States National Institutes of Health), and by the facilities and resources at the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI. Barbara Bendlin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 40 TC 31 Z9 31 U1 3 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD MAY PY 2015 VL 11 IS 5 BP 504 EP 510 DI 10.1016/j.jalz.2014.03.011 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA CI8KN UT WOS:000355021300005 PM 25043908 ER PT J AU Anderson, BJ Hill, EG Sweeney, RE Wahlquist, AE Marshall, DT O'Carroll, KFS Cole, DJ Camp, ER AF Anderson, Brandon J. Hill, Elizabeth G. Sweeney, Robert E. Wahlquist, Amy E. Marshall, David T. O'Carroll, Kevin F. Staveley Cole, David J. Camp, Ernest Ramsay TI The Impact of Surgical Diversion Before Neoadjuvant Therapy for Rectal Cancer SO AMERICAN SURGEON LA English DT Article ID TOTAL MESORECTAL EXCISION; LOW ANTERIOR RESECTION; PREOPERATIVE CHEMORADIATION; ANASTOMOTIC LEAKAGE; DEFUNCTIONING STOMA; SURVIVAL; SURGERY; RECURRENCE; DISTAL AB Up-front fecal diversion can palliate emergent symptoms related to locally advanced rectal cancer (LARC) allowing patients to receive neoadjuvant chemoradiation therapy (nCRT). We analyzed outcomes of pretreatment-diverted LARC patients relative to nondiverted patients to define the impact of this management strategy. We retrospectively collected data on 103 LARC patients treated with nCRTand surgery. Medical records were reviewed for patient characteristics, staging, treatment plan, and outcomes. Thirteen LARC patients underwent pretreatment diversion for urgent symptoms and 90 LARC patients proceeded directly to nCRT. In all, 50 per cent of diverted patients presented with T4 tumor compared with 14 per cent in the nondiverted patients (P = 0.003). Diverted patients experienced a delay in time-to-treatment initiation of 12 days, although this difference was not statistically significant. Similar rates of chemoradiation and surgical toxicities were observed. Even though diverted patients demonstrated less pathologic response to nCRT compared with nondiverted patients (P = 0.04), there was no significant difference in overall survival. In conclusion, our study demonstrates the effectiveness of up-front fecal diversion at managing emergent obstructive symptoms related to advanced rectal cancer without additional complications, allowing patients to proceed with nCRT followed by radical surgery. C1 [Anderson, Brandon J.; O'Carroll, Kevin F. Staveley; Cole, David J.; Camp, Ernest Ramsay] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA. [Hill, Elizabeth G.; Wahlquist, Amy E.; O'Carroll, Kevin F. Staveley] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Hill, Elizabeth G.; Wahlquist, Amy E.; O'Carroll, Kevin F. Staveley; Cole, David J.; Camp, Ernest Ramsay] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Marshall, David T.] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Camp, Ernest Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Sweeney, Robert E.] Icahn Sch Med Mt Sinai, Dept Surg, New York, NY 10029 USA. RP Camp, ER (reprint author), Med Univ S Carolina, Dept Surg, Surg Oncol, 25 Courtenay Dr,Room 7018,MSC 295, Charleston, SC 29425 USA. EM campe@musc.edu FU Biostatistics Shared Resource as part of the Hollings Cancer Center at the Medical University of South Carolina - Cancer Center Support Grant [P30 CA138313] FX The research presented in this manuscript was supported in part by the Biostatistics Shared Resource as part of the Hollings Cancer Center at the Medical University of South Carolina, which is funded by a Cancer Center Support Grant P30 CA138313. NR 23 TC 0 Z9 0 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD MAY PY 2015 VL 81 IS 5 BP 444 EP 449 PG 6 WC Surgery SC Surgery GA CI6TS UT WOS:000354895700022 PM 25975325 ER PT J AU O'Conor, R Wolf, MS Smith, SG Martynenko, M Vicencio, DP Sano, M Wisnivesky, JP Federman, AD AF O'Conor, Rachel Wolf, Michael S. Smith, Samuel G. Martynenko, Melissa Vicencio, Daniel P. Sano, Mary Wisnivesky, Juan P. Federman, Alex D. TI Health Literacy, Cognitive Function, Proper Use, and Adherence to Inhaled Asthma Controller Medications Among Older Adults With Asthma SO CHEST LA English DT Article ID METERED-DOSE INHALERS; SELF-MANAGEMENT; MEMORY; ASSOCIATION; EDUCATION; STEROIDS; OUTCOMES; THERAPY; RISK; CARE AB BACKGROUND: We sought to investigate the degree to which cognitive skills explain associations between health literacy and asthma-related medication use among older adults with asthma. METHODS: Patients aged >= 60 years receiving care at eight outpatient clinics (primary care, geriatrics, pulmonology, allergy, and immunology) in New York, New York, and Chicago, Illinois, were recruited to participate in structured, in-person interviews as part of the Asthma Beliefs and Literacy in the Elderly (ABLE) study (n = 425). Behaviors related to medication use were investigated, including adherence to prescribed regimens, metered-dose inhaler (MDI) technique, and dry powder inhaler (DPI) technique. Health literacy was measured using the Short Test of Functional Health Literacy in Adults. Cognitive function was assessed in terms of fluid (working memory, processing speed, executive function) and crystallized (verbal) ability. RESULTS: The mean age of participants was 68 years; 40% were Hispanic and 30% non-Hispanic black. More than one-third (38%) were adherent to their controller medication, 53% demonstrated proper DPI technique, and 38% demonstrated correct MDI technique. In multivariable analyses, limited literacy was associated with poorer adherence to controller medication (OR, 2.3; 95% CI, 1.29-4.08) and incorrect DPI (OR, 3.51; 95% CI, 1.81-6.83) and MDI (OR, 1.64; 95% CI, 1.01-2.65) techniques. Fluid and crystallized abilities were independently associated with medication behaviors. However, when fluid abilities were added to the model, literacy associations were reduced. CONCLUSIONS: Among older patients with asthma, interventions to promote proper medication use should simplify tasks and patient roles to overcome cognitive load and suboptimal performance in self-care. C1 [O'Conor, Rachel; Wolf, Michael S.; Smith, Samuel G.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA. [Martynenko, Melissa; Wisnivesky, Juan P.; Federman, Alex D.] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA. [Sano, Mary] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Wisnivesky, Juan P.] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA. [Vicencio, Daniel P.] Mercy Hosp & Med Ctr, Dept Med, Chicago, IL USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. RP O'Conor, R (reprint author), Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med & Geriatr, 750 N Lakeshore Dr,10th Floor, Chicago, IL 60611 USA. EM r-oconor@northwestern.edu FU National Heart, Lung, and Blood Institute [5R01HL096612-04] FX Funding was provided by the National Heart, Lung, and Blood Institute [5R01HL096612-04]. NR 49 TC 13 Z9 13 U1 6 U2 14 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2015 VL 147 IS 5 BP 1307 EP 1315 DI 10.1378/chest.14-0914 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI2VW UT WOS:000354606600035 PM 25275432 ER PT J AU Golden-Mason, L Hurtado, CEW Cheng, LL Rosen, HR AF Golden-Mason, Lucy Hurtado, Christine E. Waasdorp Cheng, Linling Rosen, Hugo R. TI Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3 SO CLINICAL IMMUNOLOGY LA English DT Article DE Human; HCV; Natural cytotoxicity receptors; Cytotoxicity; IFN-gamma ID VIRUS-INFECTION; TIM-3 EXPRESSION; NK CELLS; RECEPTOR EXPRESSION; IN-VITRO; CYTOTOXICITY; IMMUNITY; INNATE; RESPONSES; BLOCKADE AB T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) is an inhibitory receptor implicated in T cell exhaustion characteristic of chronic viral infection. Limited data exist on NK cell Tim-3 expression and functional consequences. In chronic hepatitis C virus (HCV)-infected subjects, we found increased Tim-3 on NKs, which was associated with an activated phenotype. The high level of Tim-3 was not reversed by successful IFN-alpha-based antiviral therapy. Tim-3(high) NK cells up-regulated TRAIL in response to IFN-alpha to a greater extent and demonstrated greater lymphokine-activated killing activity, viral control, and degranulation but similar cytokine production than their Tim-3(low) counterparts. Our results suggest that Tim-3 on NKs is associated with activation of this innate lymphocyte population that is polarized towards cytotoxicity in chronic HCV. These findings reveal roles for Tim-3 in the regulation of NKs that might represent targets for treatment of chronic viral infections. (C) 2015 Published by Elsevier Inc. C1 [Golden-Mason, Lucy; Cheng, Linling; Rosen, Hugo R.] Univ Colorado Denver, Dept Med, Hepatitis C Ctr, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA. [Hurtado, Christine E. Waasdorp] Childrens Hosp Colorado, Digest Hlth Inst, Pediat Gastroenterol, Aurora, CO USA. [Rosen, Hugo R.] Denver VA Med Ctr, Denver, CO USA. RP Rosen, HR (reprint author), Div GI Hepatol B 158, Acad Off Bldg 1,12631 E 17th Ave,Rm 7614,POB 6511, Aurora, CO 80045 USA. EM Hugo.Rosen@UCDENVER.edu FU VA Merit Review grant; [U19 AI 1066328]; [K24AI083742] FX This study was supported by U19 AI 1066328, K24AI083742, and VA Merit Review grant (HRR). NR 46 TC 8 Z9 8 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD MAY PY 2015 VL 158 IS 1 BP 114 EP 125 DI 10.1016/j.clim.2015.03.008 PG 12 WC Immunology SC Immunology GA CI2QR UT WOS:000354592600014 PM 25797693 ER PT J AU Callegari, LS Zhao, XH Nelson, KM Borrero, S AF Callegari, Lisa S. Zhao, Xinhua Nelson, Karin M. Borrero, Sonya TI Contraceptive adherence among women Veterans with mental illness and substance use disorder SO CONTRACEPTION LA English DT Article DE Medication adherence; Contraception; Veterans health; Mental illness; Alcohol-related disorders; Substance-related disorders ID POSTTRAUMATIC-STRESS-DISORDER; UNINTENDED PREGNANCY; ADMINISTRATIVE DATA; UNITED-STATES; BIRTH-WEIGHT; HEALTH; AFGHANISTAN; DEPRESSION; ALCOHOL; IRAQ AB Objective: Emerging data suggest that mental illness and substance use disorder (SUD) are important risk factors for inconsistent contraceptive use. We investigated whether mental illness without or with SUD is associated with contraceptive adherence and continuation of hormonal methods among women Veterans. Study design: We conducted a retrospective analysis of national Veteran's Administration data among women aged 18-45 with a hormonal contraceptive prescription (pill/patch/ring/injectable) during the first week of fiscal year 2013. We tested associations between mental illness diagnoses (depression, posttraumatic stress disorder, anxiety, bipolar disorder, schizophrenia, adjustment disorder) without or with SUD diagnoses (drug/alcohol abuse) and 12-month contraceptive adherence (number and length of gaps 7 days between refills and months of contraceptive coverage) using multivariable regression models. Results: Among 9780 Veterans, 43.6% had mental illness alone, 9.4% comorbid mental illness and SUD, and 47.0% neither diagnosis. In adjusted analyses, compared to women with neither diagnosis, women with mental illness alone had a similar rate of gaps but increased odds of having gaps longer than 30 days [odds ratio (OR): 1.35, 95% confidence interval (Cl): 1.10-1.52] and fewer months of contraceptive coverage (beta_coefficient: -0.39, 95% CI: -0.56 to -0.23). Women with mental illness and SUD experienced more gaps (incidence rate ratio: 1.12, 95% CI: 1.03-1.21), increased odds of gaps longer than 30 days (OR: 1.46, 95% CI: 1.10-1.79), fewer months of contraceptive coverage ((beta_coefficient: -0.90, 95% CI: -1.20 to -0.62) and reduced odds of continuous 12-month coverage (adjusted OR: 0.76, 95% CI: 0.63-0.93). Conclusions: Mental illness, particularly with comorbid SUD, is associated with reduced contraceptive adherence and continuation among women Veterans. Women with these risk factors could potentially benefit from use of long-acting reversible methods. Implications: Women Veterans have a high burden of mental illness and SUD, which we found are associated with inconsistent contraceptive use. Efforts to improve adherence to hormonal contraceptives and to increase availability of long-acting reversible methods in this vulnerable population are warranted. Published by Elsevier Inc. C1 [Callegari, Lisa S.; Nelson, Karin M.] Dept Vet Affairs VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Callegari, Lisa S.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Zhao, Xinhua; Borrero, Sonya] VA Pittsburgh Hlth Care Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Nelson, Karin M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Borrero, Sonya] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15217 USA. RP Callegari, LS (reprint author), VA Puget Sound Hlth Care Syst, Seattle HSR&D Ctr, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM lisa.callegari@va.gov FU Department of Veterans Affairs, Veteran Health Administration, Health Services Research and Development Merit Review Award [II 12-124]; VA Health Services Research and Development Postdoctoral Fellowship [TPM 61-041] FX This study was supported by a Department of Veterans Affairs, Veteran Health Administration, Health Services Research and Development Merit Review Award (II 12-124, PI: S.B.). L.S.C. was supported by a VA Health Services Research and Development Postdoctoral Fellowship (TPM 61-041). NR 38 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD MAY PY 2015 VL 91 IS 5 BP 386 EP 392 DI 10.1016/j.contraception.2015.01.013 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CH4OI UT WOS:000354012400006 PM 25636807 ER PT J AU Levesque, AY de la Torre, JI AF Levesque, Andre Yuan de la Torre, Jorge I. TI Midface Anatomy, Aging, and Aesthetic Analysis SO FACIAL PLASTIC SURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Midface anatomy; Facial aging; Aesthetic analysis; Malar fat pad; Sub-orbicularis oculi fat ID APONEUROTIC SYSTEM SMAS; FACE LIFT FLAP; SURGICAL ANATOMY; CLINICAL-IMPLICATIONS; PHOTOGRAPHIC STANDARDS; LYMPHATIC DRAINAGE; PREMASSETER SPACE; FAT COMPARTMENTS; PLASTIC-SURGERY; REJUVENATION AB This article reviews the key anatomic structures in the region of the midface, including important surface and bony landmarks, innervation, blood supply, muscle layers, and fat compartments. It also discusses changes in these structures related to the aging process and aesthetic analysis of the midface to aid with operative planning. C1 [Levesque, Andre Yuan] Univ Alabama Birmingham, Div Plast Surg, Birmingham, AL 35210 USA. [de la Torre, Jorge I.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Div Plast Surg, Birmingham, AL 35210 USA. RP de la Torre, JI (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Div Plast Surg, 1102 Fac Off Tower,510 20th St South, Birmingham, AL 35210 USA. EM jdlt@uab.edu NR 42 TC 2 Z9 2 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-7406 J9 FACIAL PLAST SURG CL JI Facial Plast. Surg. Clin. N. Am. PD MAY PY 2015 VL 23 IS 2 BP 129 EP + DI 10.1016/j.fsc.2015.01.002 PG 9 WC Surgery SC Surgery GA CI8XK UT WOS:000355054800003 PM 25921564 ER PT J AU Liu, H Chen, J Li, WJ Rose, ME Shinde, SN Balasubramani, M Uechi, GT Mutus, B Graham, SH Hickey, RW AF Liu, Hao Chen, Jie Li, Wenjin Rose, Marie E. Shinde, Sunita N. Balasubramani, Manimalha Uechi, Guy T. Mutus, Buelent Graham, Steven H. Hickey, Robert W. TI Protein disulfide isomerase as a novel target for cyclopentenone prostaglandins: implications for hypoxic ischemic injury SO FEBS JOURNAL LA English DT Article DE brain; cyclooxygenase; cyclopentenone; ischemia; protein disulfide isomerase ID 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYSTEINE MODIFICATION; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; PDI FAMILY; IN-VIVO; AGGREGATION; CYCLOOXYGENASE-2; NEURODEGENERATION; INHIBITION AB Cyclooxygenase-2 (COX-2) is an important contributor to ischemic brain injury. Identification of the downstream mediators of COX-2 toxicity may allow the development of targeted therapies. Of particular interest is the cyclopentenone family of prostaglandin metabolites. Cyclopentenone prostaglandins (CyPGs) are highly reactive molecules that form covalent bonds with cellular thiols. Protein disulfide isomerase (PDI) is an important molecule for the restoration of denatured proteins following ischemia. Because PDI has several thiols, including thiols within the active thioredoxin-like domain, we hypothesized that PDI is a target of CyPGs and that CyPG binding of PDI is detrimental. CyPG-PDI binding was detected in vitro via immunoprecipitation and MS. CyPG-PDI binding decreased PDI enzymatic activity in recombinant PDI treated with CyPG, and PDI immunoprecipitated from neuronal culture treated with CyPG or anoxia. Toxic effects of binding were demonstrated in experiments showing that: (a) pharmacologic inhibition of PDI increased cell death in anoxic neurons, (b) PDI overexpression protected neurons exposed to anoxia and SH-SY5Y cells exposed to CyPG, and (c) PDI overexpression in SH-SY5Y cells attenuated ubiquitination of proteins and decreased activation of pro-apoptotic caspases. In conclusion, CyPG production and subsequent binding of PDI is a novel and potentially important mechanism of ischemic brain injury. We show that CyPGs bind to PDI, cyclopentenones inhibit PDI activity, and CyPG-PDI binding is associated with increased neuronal susceptibility to anoxia. Additional studies are necessary to determine the relative role of CyPG-dependent inhibition of PDI activity in ischemia and other neurodegenerative disorders. C1 [Liu, Hao; Li, Wenjin; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Liu, Hao; Chen, Jie; Li, Wenjin; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15224 USA. [Chen, Jie; Shinde, Sunita N.; Hickey, Robert W.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15224 USA. [Balasubramani, Manimalha; Uechi, Guy T.] Univ Pittsburgh, Biomed Mass Spectrometry Ctr, Pittsburgh, PA 15224 USA. [Mutus, Buelent] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada. RP Hickey, RW (reprint author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Adm Off Bldg,Suite 2400,4401 Penn Ave, Pittsburgh, PA 15224 USA. EM robert.hickey@chp.edu FU National Institutes of Health, National Institute of Child Health and Human Development; National Institute of Neurological Disorders and Stroke [R21HD058846, R01NS37549]; VA Merit Review program; Cancer Center Support Grant, National Cancer Institute [P30CA047904] FX This work was supported by National Institutes of Health, National Institute of Child Health and Human Development and National Institute of Neurological Disorders and Stroke: R21HD058846 (RWH), R01NS37549 (SHG) and the VA Merit Review program (SHG). The work done by the Biomedical Mass Spectrometry Center was supported in part by the Cancer Center Support Grant P30CA047904, National Cancer Institute. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 54 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1742-464X EI 1742-4658 J9 FEBS J JI FEBS J. PD MAY PY 2015 VL 282 IS 10 BP 2045 EP 2059 DI 10.1111/febs.13259 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA CI5PG UT WOS:000354809700015 PM 25754985 ER PT J AU Toledo, JB Bjerke, M Da, XA Landau, SM Foster, NL Jagust, W Jack, C Weiner, M Davatzikos, C Shaw, LM Trojanowski, JQ AF Toledo, Jon B. Bjerke, Maria Da, Xiao Landau, Susan M. Foster, Norman L. Jagust, William Jack, Clifford, Jr. Weiner, Michael Davatzikos, Christos Shaw, Leslie M. Trojanowski, John Q. TI Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 beta-Amyloid Measures Across the Spectrum of Alzheimer Disease SO JAMA NEUROLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; MILD COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; CSF BIOMARKERS; NEUROPATHOLOGIC ASSESSMENT; CLINICAL CHARACTERIZATION; APOLIPOPROTEIN-E; BRAIN; PATHOLOGY; TAU AB IMPORTANCE Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of Alzheimer disease (AD) pathology in living patients and for the tracking of longitudinal changes, but the relation between biomarkers needs further study. OBJECTIVE To determine the association between CSF and PET amyloid biomarkers (cross-sectional and longitudinal measures) and compare the cutoffs for these measures. DESIGN, SETTING, AND PARTICIPANTS Longitudinal clinical cohort study from 2005 to 2014 including 820 participants with at least 1 florbetapir F-18 (hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF beta-amyloid 1-42 (A beta 1-42) sample obtained within 30 days of each other (501 participants had a second PET scan after 2 years, including 150 participants with CSF A beta 1-42 measurements). Data were obtained from the Alzheimer's Disease Neuroimaging Initiative database. MAIN OUTCOMES AND MEASURES Four different PET scans processing pipelines from 2 different laboratories were compared. The PET cutoff values were established using a mixture-modeling approach, and different mathematical models were applied to define the association between CSF and PET amyloid measures. RESULTS The values of the CSF A beta 1-42 samples and florbetapir-PET scans showed a nonlinear association (R-2 = 0.48-0.66), with the strongest association for values in the middle range. The presence of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CSF A beta 1-42 plateau explained the differences in correlation with cognition (R-2 = 0.36 and R-2 = 0.25, respectively). The APOE genotype significantly modified the association between both biomarkers. The PET cutoff values derived from an unsupervised classifier converged with previous PET cutoff values and the established CSF A beta 1-42 cutoff levels. There was no association between longitudinal A beta 1-42 levels and standardized uptake value ratios during follow-up. CONCLUSIONS AND RELEVANCE The association between both biomarkers is limited to a middle range of values, is modified by the APOE genotype, and is absent for longitudinal changes; 4 different approaches in 2 different platforms converge on similar pathological A beta cutoff levels; and different pipelines to process PET scans showed correlated but not identical results. Our findings suggest that both biomarkers measure different aspects of AD A beta pathology. C1 [Toledo, Jon B.; Bjerke, Maria; Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Inst Aging,Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Da, Xiao; Davatzikos, Christos] Univ Penn, Ctr Biomed Image Comp & Analyt, Philadelphia, PA 19104 USA. [Landau, Susan M.; Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Foster, Norman L.] Univ Utah, Ctr Alzheimers Care Imaging & Res, Dept Neurol, Salt Lake City, UT USA. [Jack, Clifford, Jr.] Mayo Clin, Coll Med, Rochester, MN USA. [Weiner, Michael] Univ Calif San Francisco, San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Radiol, San Francisco, CA 94143 USA. RP Trojanowski, JQ (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, 3600 Spruce St,3 Maloney Bldg, Philadelphia, PA 19104 USA. EM trojanow@mail.med.upenn.edu RI Da, Xiao/F-8738-2015; Jack, Clifford/F-2508-2010; Kowall, Neil/G-6364-2012 OI Da, Xiao/0000-0001-9898-8130; Jack, Clifford/0000-0001-7916-622X; Kowall, Neil/0000-0002-6624-0213; Toledo, Jon/0000-0003-4366-9268 FU Swedish Brain Foundation; Sweden-America Foundation; ADNI [U01 AG024904]; US Department of Defense ADNI [W81XWH-12-2-0012]; National Institutes of Health [R01-AG011378, U01-HL096917, U01-AG024904, R01 AG041851, R01 AG37551, R01AG043392, U01-AG06786]; Mayo Foundation; [P01 AG032953]; [P01 AG017586]; [P30 AG010124]; [P50 NS053488] FX Dr Toledo is supported by grants P01 AG032953, P01 AG017586, P30 AG010124, and P50 NS053488. Dr Bjerke is supported by the Swedish Brain Foundation and the Sweden-America Foundation. Data collection and sharing for this project was funded by the ADNI (National Institutes of Health grant U01 AG024904) and US Department of Defense ADNI (Department of Defense award W81XWH-12-2-0012). Dr Jack receives research funding from the National Institutes of Health (grants R01-AG011378, U01-HL096917, U01-AG024904, R01 AG041851, R01 AG37551, R01AG043392, and U01-AG06786) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. NR 49 TC 23 Z9 24 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD MAY PY 2015 VL 72 IS 5 BP 571 EP 581 DI 10.1001/jamaneurol.2014.4829 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA CH9MY UT WOS:000354361000015 PM 25822737 ER PT J AU Oslin, DW Leong, SH Lynch, KG Berrettini, W O'Brien, CP Gordon, AJ Rukstalis, M AF Oslin, David W. Leong, Shirley H. Lynch, Kevin G. Berrettini, Wade O'Brien, Charles P. Gordon, Adam J. Rukstalis, Margaret TI Naltrexone vs Placebo for the Treatment of Alcohol Dependence A Randomized Clinical Trial SO JAMA PSYCHIATRY LA English DT Article ID OPIOID RECEPTOR GENE; FUNCTIONAL POLYMORPHISM; OPRM1; RELIABILITY; WARFARIN; PHARMACOTHERAPY; INTERVENTION; METAANALYSIS; SENSITIVITY; SETTINGS AB IMPORTANCE Alcohol use disorder is one of the leading causes of disability worldwide. While effective pharmacological treatments exist, they are efficacious only in certain individuals, contributing to their limited use. Secondary analysis of clinical trial data suggests that a functional polymorphism (rs1799971, Asn40Asp) of the mu-opioid receptor gene (OPRM1) is associated with the risk of relapse to heavy drinking following treatment with the opioid antagonist naltrexone. OBJECTIVE To prospectively examine whether rs1799971 is predictive of naltrexone treatment response. DESIGN, SETTING, AND PARTICIPANTS We conducted a 12-week, double-blind, randomized clinical trial of naltrexone vs placebo in individuals with alcohol dependence (intent-to-treat analysis). Participants were randomly assigned to study treatment based on the presence of 1 or 2 copies of the Asp40 allele compared with those homozygous for the Asn40 allele (2 x 2 cell design). Recruitment occurred between January 2009 and September 2013. All participants were seen in an outpatient clinical setting. A convenience sample of participants (n = 221) was recruited from 5 sites. All participants met DSM-IV criteria for alcohol dependence, with no concurrent psychotic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on illicit substances. I INTERVENTIONS The study drug was naltrexone (50 mg) given once daily or corresponding placebo. MAIN OUTCOMES AND MEASURES The primary study outcome measure was relapse to heavy drinking measured using the timeline follow-back method. RESULTS There was no evidence of a genotype x treatment interaction on the primary outcome of heavy drinking (P = .32). In the Asn40 group, the observed effect of naltrexone was similar to that in previous trials (odds ratio, 0.69; 95% CI, 0.41-1.18; P = .17), with a very small naltrexone effect in the Asp40 group (odds ratio, 1.10; 95% CI, 0.52-2.31; P = .80), contrary to the pattern expected a priori. A significant reduction in heavy drinking occurred across all groups (P = .001). Other drinking outcomes, and all secondary outcomes, demonstrated similar time effects, with no genotype x treatment interaction. CONCLUSIONS AND RELEVANCE The results of this study do not support the hypothesis that the Asp40 allele moderates the response to naltrexone treatment. It is premature to use the Asn40Asp polymorphism as a biomarker to predict the response to naltrexone treatment of alcohol dependence. C1 [Oslin, David W.; Lynch, Kevin G.; Berrettini, Wade; O'Brien, Charles P.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Oslin, David W.; Leong, Shirley H.] Philadelphia Vet Affairs Med Ctr, Ctr Excellence Subst Abuse Treatment & Evaluat, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gordon, Adam J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rukstalis, Margaret] Wake Forest Univ, Dept Psychiat, Winston Salem, NC 27109 USA. RP Oslin, DW (reprint author), Univ Penn, Perelman Sch Med, Dept Psychiat, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM oslin@upenn.edu FU National Institute on Alcohol Abuse and Alcoholism [AA017164]; Veterans Integrated Service Network 4 Mental Illness Research, Education, and Clinical Center FX This study was supported in part by grant AA017164 from the National Institute on Alcohol Abuse and Alcoholism and by the Veterans Integrated Service Network 4 Mental Illness Research, Education, and Clinical Center. NR 41 TC 16 Z9 18 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD MAY PY 2015 VL 72 IS 5 BP 430 EP 437 DI 10.1001/jamapsychiatry.2014.3053 PG 8 WC Psychiatry SC Psychiatry GA CH6YC UT WOS:000354181400005 PM 25760804 ER PT J AU Bebko, SP Green, DM Awad, SS AF Bebko, Serge P. Green, David M. Awad, Samir S. TI Effect of a Preoperative Decontamination Protocol on Surgical Site Infections in Patients Undergoing Elective Orthopedic Surgery With Hardware Implantation SO JAMA SURGERY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; INTRANASAL MUPIROCIN; EPIDEMIOLOGY; PREVENTION; ERADICATION; CARRIERS AB IMPORTANCE Surgical site infections (SSIs), commonly caused by methicillin-resistant Staphylococcus aureus (MRSA), are associated with significant morbidity and mortality, specifically when hardware is implanted in the patient. Previously, we have demonstrated that a preoperative decontamination protocol using chlorhexidine gluconate washcloths and intranasal antiseptic ointment is effective in eradicating MRSA in the nose and on the skin of patients. OBJECTIVE To examine the effect of a decontamination protocol on SSIs in patients undergoing elective orthopedic surgery with hardware implantation. DESIGN, SETTING, AND PARTICIPANTS A prospective database of patients undergoing elective orthopedic surgery with hardware implantation at the Michael E. DeBakey Veterans Affairs Medical Center in Houston, Texas, was analyzed from October 1, 2012, to December 31, 2013. Cohort groups before and after the intervention were compared. INTERVENTIONS Starting in May 2013, during their preoperative visit, all of the patients watched an educational video about MRSA decontamination and were given chlorhexidine washcloths and oral rinse and nasal povidone-iodine solution to be used the night before and the morning of scheduled surgery. MAIN OUTCOMES AND MEASURES Thirty-day SSI rates were collected according to the definitions of the Centers for Disease Control and Prevention National Nosocomial Infections Surveillance. Data on demographics, comorbidities such as chronic obstructive pulmonary disease and coronary artery disease, tobacco use, alcohol use, and body mass index were also collected. Univariate analysis was performed between the 2 groups of patients. Multivariate analysis was used to identify independent predictors of SSI. RESULTS A total of 709 patients were analyzed (344 controls and 365 patients who were decolonized). Both groups were well matched with no significant differences in age, body mass index, sex, or comorbidities. All of the patients (100%) completed the MRSA decontamination protocol. The SSI rate in the intervention group was significantly lower (1.1%; 4 of 365 patients developed an SSI) than the SSI rate in the control group (3.8%; 13 of 344 patients developed an SSI) (P =.02). Multivariate logistic regression identified MRSA decontamination as an independent predictor of not developing an SSI (adjusted odds ratio, 0.24 [95% CI, 0.08-0.77]; P =.02). CONCLUSIONS AND RELEVANCE Our study demonstrates that preoperative MRSA decontamination with chlorhexidine washcloths and oral rinse and intranasal povidone-iodine decreased the SSI rate by more than 50% among patients undergoing elective orthopedic surgery with hardware implantation. Universal decontamination using this low-cost protocol may be considered as an additional prevention strategy for SSIs in patients undergoing orthopedic surgery with hardware implantation and warrants further study. C1 [Bebko, Serge P.; Awad, Samir S.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Bebko, Serge P.; Green, David M.; Awad, Samir S.] Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX USA. RP Awad, SS (reprint author), Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Room 5A-350, Houston, TX 77030 USA. EM sawad@bcm.edu NR 22 TC 5 Z9 5 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAY PY 2015 VL 150 IS 5 BP 390 EP 395 DI 10.1001/jamasurg.2014.3480 PG 6 WC Surgery SC Surgery GA CI7RY UT WOS:000354963300004 PM 25738898 ER PT J AU Anderson, CE Nicksa, GA Stewart, L AF Anderson, Cristan E. Nicksa, Grace A. Stewart, Lygia TI Distractions During Resident Handoffs Incidence, Sources, and Influence on Handoff Quality and Effectiveness SO JAMA SURGERY LA English DT Article ID SIGN-OUT; TASK INTERRUPTION; PATIENT HANDOFFS; I-PASS; MULTITASKING; CARE; COMMUNICATION; INFORMATION; MEMORY; IMPACT AB IMPORTANCE Handoffs have significantly increased in number following Accreditation Council for Graduate Medical Education (ACGME) work-hour restrictions. Studies have shown correlations between the number of handoffs and errors/patient harm. Distractions are common during handoffs and may interfere with handoff quality and effectiveness. OBJECTIVE To examine the frequency of distractions and their impact on handoff quality. DESIGN, SETTING, AND PARTICIPANTS In this prospective observational study, a total of 214 surgical resident handoffs (residents = 184; Bay area residents [moonlighters] = 30) were observed over 18 months (July 11, 2012-December 19, 2014) by 2 independent observers in 3 teaching hospitals (university, county, and veterans). MAIN OUTCOMES AND MEASURES Handoff quality (both giver and receiver) was assessed using a standardized scoring system. The number and types of distractions were recorded. RESULTS Pages were the most common distraction (37.5%), followed by telephone calls (32.8%), residents/medical students (9.3%), talking (5.2%), and noise (4.1%). Distractions from attending physicians, electronics, nursing, consults, and room changes were less common (collectively 11%, each < 3%). Distractions were present in 102 resident handoffs (48%) (16% with 1 distraction; 15% with 2; 6% with 3, and 11% with >= 4). Distractions occurred in 54% of junior resident handoffs (mean, 1.4/handoff), 30% of moonlighter handoffs (mean, 0.5/handoff), and 38% of senior resident handoffs (mean, 0.89/handoff) (P =.01, junior vs moonlighter/senior). Distractions were more common during evening than morning handoffs (52% vs 36%; P =.045) and during team vs individual handoffs (58% vs 44%; P <.10). Handoffs without distractions were shorter in length (13.2 minutes without distractions vs 21.5 minutes with distractions; P <.001) and minutes per patient (1.78 without vs 2.15 with distractions; P =.04). Handoff quality was not diminished by distractions, as measured by handoff giver score (15.41 without vs 15.47 with distractions; P =.90) and receiver score (7.42 without vs 7.25 with distractions; P =.45). CONCLUSIONS AND RELEVANCE To our knowledge, this is the largest study of distractions during surgical resident handoffs. Distractions were very common during handoffs; they were more common in the evening when junior residents more commonly performed the handoff and they increased the handoff length. However, distractions did not negatively affect the quality of resident handoffs. This may demonstrate the resilience of surgical residents to distractions. C1 San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. RP Stewart, L (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Surg 112, 4150 Clement St, San Francisco, CA 94121 USA. EM lygia.stewart@va.gov NR 34 TC 5 Z9 5 U1 3 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAY PY 2015 VL 150 IS 5 BP 396 EP 401 DI 10.1001/jamasurg.2014.2459 PG 6 WC Surgery SC Surgery GA CI7RY UT WOS:000354963300005 PM 25738805 ER PT J AU Mohanty, S Liu, YM Paruch, JL Kmiecik, TE Cohen, ME Ko, CY Bilimoria, KY AF Mohanty, Sanjay Liu, Yaoming Paruch, Jennifer L. Kmiecik, Thomas E. Cohen, Mark E. Ko, Clifford Y. Bilimoria, Karl Y. TI Risk of Discharge to Postacute Care A Patient-Centered Outcome for the American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator SO JAMA SURGERY LA English DT Article ID ELDER LIFE PROGRAM; KNEE ARTHROPLASTY; FUNCTIONAL DECLINE; NSQIP; HOME; HIP; SAFETY AB IMPORTANCE Individualized risk prediction tools have an important role as decision aids for use by patients and surgeons before surgery. Patient-centered outcomes should be incorporated into such tools to widen their appeal and improve their usability. OBJECTIVE To develop a patient-centered outcome for the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Surgical Risk Calculator, a web-based, individualized risk prediction tool. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study using data from the ACS NSQIP, a national clinical data registry. A total of 973 211 patients from July 2010 to June 2012, encompassing 392 hospitals, were used in this analysis. MAIN OUTCOMES AND MEASURES Risk of discharge to a postacute care setting. RESULTS The overall rate of discharge to postacute care was 8.8%. Significant predictors of discharge to postacute care included being 85 years or older (odds ratio [OR] = 9.17; 95% CI, 8.84-9.50), the presence of septic shock (OR = 2.43; 95% CI, 2.20-2.69) or ventilator dependence (OR = 2.81; 95% CI, 2.56-3.09) preoperatively, American Society of Anesthesiologists class of 4 or 5 (OR = 3.59; 95% CI, 3.46-3.71), and totally dependent functional status (OR = 2.27; 95% CI, 2.11-2.44). The final model predicted risk of discharge to postacute care with excellent accuracy (C statistic = 0.924) and calibration (Brier score = 0.05). CONCLUSIONS AND RELEVANCE Individualized risk of discharge to postacute care can be predicted with excellent accuracy. This outcome will be incorporated into the ACS NSQIP Surgical Risk Calculator. C1 [Mohanty, Sanjay] Henry Ford Hosp, Dept Surg, Detroit, MI 48202 USA. [Mohanty, Sanjay; Liu, Yaoming; Paruch, Jennifer L.; Cohen, Mark E.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Kmiecik, Thomas E.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Surg Outcomes & Qual Improvement Ctr, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Mohanty, S (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA. EM smohanty@facs.org FU American College of Surgeons; American Geriatric Society; Hartford Foundation FX Dr Mohanty is supported by the Clinical Scholar in Residence Program from the American College of Surgeons and by the American Geriatric Society and the Hartford Foundation. NR 15 TC 6 Z9 6 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAY PY 2015 VL 150 IS 5 BP 480 EP 484 DI 10.1001/jamasurg.2014.3176 PG 5 WC Surgery SC Surgery GA CI7RY UT WOS:000354963300020 PM 25806660 ER PT J AU Lee, HJ Preda, A Ford, JM Mathalon, DH Keator, DB van Erp, TGM Turner, JA Potkin, SG AF Lee, Hyo Jong Preda, Adrian Ford, Judith M. Mathalon, Daniel H. Keator, David B. van Erp, Theo G. M. Turner, Jessica A. Potkin, Steven G. TI Functional Magnetic Resonance Imaging of Motor Cortex Activation in Schizophrenia SO JOURNAL OF KOREAN MEDICAL SCIENCE LA English DT Article DE Motor Cortex; Schizophrenia; Motor Dysfunction; Functional MRI; Laterality Quotient; Power Analysis ID SENSORIMOTOR CORTEX; CORTICAL RESPONSE; BRAIN; DYSFUNCTION; LATERALIZATION; STIMULATION; PERFORMANCE; ROBUST AB Previous fMRI studies of sensorimotor activation in schizophrenia have found in some cases hypoactivity, no difference, or hyperactivity when comparing patients with controls; similar disagreement exists in studies of motor laterality. In this multi-site fMRI study of a sensorimotor task in individuals with chronic schizophrenia and matched healthy controls, subjects responded with a right-handed finger press to an irregularly flashing visual checker board. The analysis includes eighty-five subjects with schizophrenia diagnosed according to the DSM-IV criteria and eighty-six healthy volunteer subjects. Voxel-wise statistical parametric maps were generated for each subject and analyzed for group differences; the percent Blood Oxygenation Level Dependent (BOLD) signal changes were also calculated over predefined anatomical regions of the primary sensory, motor, and visual cortex. Both healthy controls and subjects with schizophrenia showed strongly lateralized activation in the precentral gyrus, inferior frontal gyrus, and inferior parietal lobule, and strong activations in the visual cortex. There were no significant differences between subjects with schizophrenia and controls in this multi-site fMRI study. Furthermore, there was no significant difference in laterality found between healthy controls and schizophrenic subjects. This study can serve as a baseline measurement of schizophrenic dysfunction in other cognitive processes. C1 [Lee, Hyo Jong] Chonbuk Natl Univ, Div Comp Sci & Engn, CAIIT, Jeonju 561756, South Korea. [Preda, Adrian; Keator, David B.; van Erp, Theo G. M.; Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Turner, Jessica A.] Georgia State Univ, Dept Psychol & Neurosci, Atlanta, GA 30303 USA. RP Lee, HJ (reprint author), Chonbuk Natl Univ, Div Comp Sci & Engn, 567 Baekje Daero, Jeonju 561756, South Korea. EM hlee@chonbuk.ac.kr OI Keator, David/0000-0001-5281-5576; Preda, Adrian /0000-0003-3373-2438 FU National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2012R1A2A2A03]; [U24-RR021992] FX This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2012R1A2A2A03). Data used for this study were supported by grants to the Function BIRN (U24-RR021992). NR 33 TC 0 Z9 0 U1 1 U2 6 PU KOREAN ACAD MEDICAL SCIENCES PI SEOUL PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA SN 1011-8934 EI 1598-6357 J9 J KOREAN MED SCI JI J. Korean Med. Sci. PD MAY PY 2015 VL 30 IS 5 BP 625 EP 631 DI 10.3346/jkms.2015.30.5.625 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CI7YB UT WOS:000354981600017 PM 25931795 ER PT J AU Lendon, JP Ahluwalia, SC Walling, AM Lorenz, KA Oluwatola, OA Price, RA Quigley, D Teno, JM AF Lendon, Jessica Penn Ahluwalia, Sangeeta C. Walling, Anne M. Lorenz, Karl A. Oluwatola, Oluwatobi A. Price, Rebecca Anhang Quigley, Denise Teno, Joan M. TI Measuring Experience With End-of-Life Care: A Systematic Literature Review SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Review DE End-of-life care; assessment; family caregivers ID INFORMAL CAREGIVERS SATISFACTION; BEREAVED FAMILY-MEMBERS; DYING CANCER-PATIENTS; PALLIATIVE CARE; PERCEPTIONS AB Context. Increasing interest in end-of-life care has resulted in many tools to measure the quality of care. An important outcome measure of end-of-life care is the family members' or caregivers' experiences of care. Objectives. To evaluate the instruments currently in use to inform next steps for research and policy in this area. Methods. We conducted a systematic review of PubMed, PsycINFO, and PsycTESTS (R) for all English-language articles published after 1990 using instruments to measure adult patient, family, or informal caregiver experiences with end-of-life care. Survey items were abstracted and categorized into content areas identified through an iterative method using three independent reviewers. We also abstracted information from the most frequently used surveys about the identification of proxy respondents for after-death surveys, the timing and method of survey administration, and the health care setting being assessed. Results. We identified 88 articles containing 51 unique surveys with available content. We characterized 14 content areas variably present across the 51 surveys. Information and care planning, provider care, symptom management, and overall experience were the most frequent areas addressed. There was also considerable variation across the surveys in the identification of proxy respondents, the timing of survey administration, and in the health care settings and services being evaluated. Conclusion. This review identified several comprehensive surveys aimed at measuring the experiences of end-of-life care, covering a variety of content areas and practical issues for survey administration. Future work should focus on standardizing surveys and administration methods so that experiences of care can be reliably measured and compared across care settings. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. C1 [Lendon, Jessica Penn; Walling, Anne M.; Lorenz, Karl A.] VA Greater Los Angeles, Los Angeles, CA 90073 USA. [Walling, Anne M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ahluwalia, Sangeeta C.; Walling, Anne M.; Oluwatola, Oluwatobi A.; Quigley, Denise] RAND Corp, Santa Monica, CA USA. [Price, Rebecca Anhang] RAND Corp, Arlington, VA USA. [Teno, Joan M.] Brown Univ, Providence, RI 02912 USA. RP Lendon, JP (reprint author), VA Greater Los Angeles, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jessicapenn@gmail.com FU Centers for Medicare and Medicaid Services, Department of Health and Human Services [HHSM-500-2012-00126G]; Veterans Affairs (VA) Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program; National Institutes of Health (NIH)/National Center for Advancing Translational Science UCLA CTSI grant [UL1TR000124]; NIH loan repayment program; National Palliative Care Research Center FX The literature review on which this publication is based was performed under Contract HHSM-500-2012-00126G, entitled, "Hospice Experience of Care Survey," funded by the Centers for Medicare and Medicaid Services, Department of Health and Human Services. The content of this publication neither necessarily reflect the views or policies of the Department of Health and Human Services nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The authors assume full responsibility for the accuracy and completeness of the ideas presented. Dr. Lendon was supported by the Veterans Affairs (VA) Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program. Dr. Walling was supported by National Institutes of Health (NIH)/National Center for Advancing Translational Science UCLA CTSI grant no. UL1TR000124 and the NIH loan repayment program. Dr. Ahluwalia was supported by a Career Development Award from the National Palliative Care Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 20 TC 4 Z9 4 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD MAY PY 2015 VL 49 IS 5 BP 904 EP + DI 10.1016/j.jpainsymman.2014.10.018 PG 15 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA CI5VI UT WOS:000354827500018 PM 25543110 ER PT J AU White, HR Jiao, Y Ray, AE Huh, D Atkins, DC Larimer, ME Fromme, K Corbin, WR Baer, JS LaBrie, JW Mun, EY AF White, Helene R. Jiao, Yang Ray, Anne E. Huh, David Atkins, David C. Larimer, Mary E. Fromme, Kim Corbin, William R. Baer, John S. LaBrie, Joseph W. Mun, Eun-Young TI Are There Secondary Effects on Marijuana Use From Brief Alcohol Interventions for College Students? SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; REDUCING DRUG CONSUMPTION; SUBSTANCE USE; EMERGENCY-DEPARTMENT; PRIMARY-CARE; CANNABIS DEPENDENCE; HEAVY-DRINKING; YOUNG-PEOPLE; FEEDBACK; RISK AB Objective: This study examined whether brief motivational interventions (BMIs) designed for reducing heavy drinking among college students have secondary effects on reducing marijuana use. Method: The data came from Project INTEGRATE, which combined data from 24 independent trials of HMIs and other individual-focused interventions designed to reduce heavy drinking and related problems among college students. We analyzed data from 10 samples across nine studies that used random assignment of participants into either a BMI or a control group and assessed marijuana use outcomes (N = 6,768; 41.5% men; 73.2% White; 57.7% first-year students; 19.2% current marijuana users at baseline). We derived three marijuana use groups within studies by cross-tabulating baseline and follow-up data: Nonusers, Reducers, and Stayers/Increasers. Results: Peto's one-step odds ratio analyses for meta-analysis revealed no significant intervention effects on marijuana use at either short-term (1-3 month) or long-term (6-12 month) follow-up. Subsequent exploratory analyses showed that those who reduced drinking were more likely to be a marijuana Reducer or Nonuser, compared with a Stayer/Increaser, at both follow-ups. Conclusions: The BMIs to reduce heavy drinking evaluated in this study did not reduce marijuana use. However, our exploratory results suggest that if we can develop interventions for college students that effectively reduce drinking, we may also reduce their marijuana use. Furthermore, as recreational use of marijuana becomes legal or decriminalized and marijuana becomes more readily available, it may be necessary to develop interventions specifically targeting marijuana use among college students. C1 [White, Helene R.; Jiao, Yang; Ray, Anne E.; Mun, Eun-Young] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Huh, David; Atkins, David C.; Larimer, Mary E.] Univ Washington, Dept Psychiat & Behav Sci, Ctr Study Hlth & Risk Behav, Seattle, WA 98195 USA. [Fromme, Kim] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA. [Corbin, William R.] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA. [Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Baer, John S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [LaBrie, Joseph W.] Loyola Marymount Univ, Dept Psychol, Los Angeles, CA 90045 USA. RP White, HR (reprint author), Rutgers State Univ, Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA. EM hewhite@rci.rutgers.edu OI Atkins, David/0000-0002-5781-9880 FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01 AA019511]; National Institute on Drug Abuse (NIDA) [R01 DA034608] FX Project INTEGRATE was supported by National Institute on Alcohol Abuse and Alcoholism (NIAAA) Grant R01 AA019511. In addition, the writing of the article was supported, in part, by National Institute on Drug Abuse (NIDA) Grant R01 DA034608. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAAA, NIDA, or National Institutes of Health. NR 60 TC 1 Z9 1 U1 4 U2 6 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2015 VL 76 IS 3 BP 367 EP 377 PG 11 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA CI4WR UT WOS:000354755100004 PM 25978822 ER PT J AU Perron, BE Bohnert, K Perone, AK Bonn-Miller, MO Ilgen, M AF Perron, Brian E. Bohnert, Kipling Perone, Angela K. Bonn-Miller, Marcel O. Ilgen, Mark TI Use Of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use SO JOURNAL OF STUDIES ON ALCOHOL AND DRUGS LA English DT Article ID COLLEGE-STUDENTS; CONTROLLED-TRIAL; MARIJUANA USE; FEASIBILITY; RELIABILITY; COMBINATION; POPULATION; ADULTS; AUDIT AB Objective: Management of chronic pain is one of the most common reasons given by individuals seeking medical cannabis. However, very little information exists about the concurrent use of cannabis and prescription pain medication (PPM). This study fills this gap in knowledge by systematically comparing medical cannabis users who use or do not use PPM, with an emphasis on understanding whether concurrent use of cannabis and PPM is associated with more serious forms of alcohol and other drug involvement. Method: Data from this study were collected from a medical cannabis clinic in southwestern Michigan (N = 273). Systematic comparisons were made on measures of sociodemographics, reasons for substance use, pain, functioning, and perceptions of PPM and medical cannabis efficacy. Results: PPM users tended to be older and reported higher levels of pain and lower levels of functioning. The overall sample exhibited higher lifetime and past-3-month rates of alcohol and other noncannabis drug use than did the general population. Approximately 40% of subjects reported combining cannabis with alcohol, but no significant difference was observed between PPM users and nonusers. PPM users and nonusers did not exhibit any difference in either lifetime or past-3-month use of other drugs, including cocaine, sedatives, street opioids, and amphetamines. PPM users rated the efficacy of cannabis higher than PPM for pain management and indicated a strong desire to reduce PPM usage. Conclusions: Use of PPM among medical cannabis users was not identified as a correlate for more serious forms of alcohol and other drug involvement. However, longitudinal study designs are needed to better understand the trajectories of alcohol and other drug involvement over time among medical cannabis users. C1 [Perron, Brian E.; Perone, Angela K.] Univ Michigan, Sch Social Work, Ann Arbor, MI 48109 USA. [Bohnert, Kipling; Ilgen, Mark] Dept Vet Affairs Healthcare Syst, Vet Affairs VA Serious Mental Illness Treatment R, Ann Arbor, MI USA. [Bohnert, Kipling; Ilgen, Mark] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Perron, BE (reprint author), Univ Michigan, Sch Social Work, 1080 S Univ Ave, Ann Arbor, MI 48109 USA. EM beperron@umich.edu FU National Institute on Drug Abuse [R01 DA033397] FX This work was supported by the National Institute on Drug Abuse grant R01 DA033397 to Mark Ilgen. NR 34 TC 1 Z9 1 U1 2 U2 5 PU ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV PI PISCATAWAY PA C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA SN 1937-1888 EI 1938-4114 J9 J STUD ALCOHOL DRUGS JI J. Stud. Alcohol Drugs PD MAY PY 2015 VL 76 IS 3 BP 406 EP 413 PG 8 WC Substance Abuse; Psychology SC Substance Abuse; Psychology GA CI4WR UT WOS:000354755100008 PM 25978826 ER PT J AU Leff, B Weston, CM Garrigues, S Patel, K Ritchie, C AF Leff, Bruce Weston, Christine M. Garrigues, Sarah Patel, Kanan Ritchie, Christine CA Natl Home-Based Primary Care TI Home-Based Primary Care Practices in the United States: Current State and Quality Improvement Approaches SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE house calls; home-based primary care; home-based palliative care; quality of care ID STANDARDS; VETERANS; HEALTH AB ObjectivesTo describe the characteristics of home-based primary care practices: staffing, administrative, population served, care practices, and quality of care challenges. DesignSurvey of home-based primary care practices. SettingHome-based primary care practices in the United States. ParticipantsMembers of the American Academy of Home Care Medicine and nonmember providers identified by surveyed members. MeasurementsA 58-item questionnaire that assessed practice characteristics, care provided by the practice, and how the quality of care that the practice provided was assessed. ResultsSurvey response rate was 47.9%, representing 272 medical house calls practices. Mean average daily census was 457 patients (median 100 patients, range 1-30,972 patients). Eighty-eight percent of practices offered around-the-clock coverage for urgent concerns, 60% held regularly scheduled team meetings, 89% used an electronic medical record, and one-third used a defined quality improvement process. The following factors were associated with practices that used a defined quality improvement process: practice holds regularly scheduled team meetings to discuss specific patients (odds ratio (OR)=2.07, 95% confidence interval (CI)=1.02-4.21), practice conducts surveys of patients (OR=8.53, 95% CI=4.07-17.88), and practice is involved in National Committee for Quality Assurance patient-centered medical home (OR=3.27, 95% CI=1.18-9.07). Ninety percent of practices would or might participate in quality improvement activities that would provide them timely feedback on patient and setting-appropriate quality indicators. ConclusionsThere is a substantial heterogeneity of home-based primary care practice types. Most practices perform activities that lend themselves to robust quality improvement efforts, and nearly all indicated interest in a national registry to inform quality improvement. C1 [Leff, Bruce] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA. [Leff, Bruce; Weston, Christine M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21224 USA. [Leff, Bruce] Johns Hopkins Univ, Sch Nursing, Dept Community & Publ Hlth, Baltimore, MD 21224 USA. [Garrigues, Sarah; Patel, Kanan; Ritchie, Christine] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Garrigues, Sarah; Patel, Kanan; Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA. [Garrigues, Sarah; Patel, Kanan; Ritchie, Christine] Jewish Home San Francisco, San Francisco, CA USA. RP Leff, B (reprint author), Johns Hopkins Univ, Sch Med, Div Geriatr Med, 5505 Hopkins Bayview Circle, Baltimore, MD 21224 USA. EM bleff@jhmi.edu FU Commonwealth Fund, Retirement Research Foundation; Retirement Research Foundation; Commonwealth Fund, a national private foundation based in New York City FX The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper. Dr. Leff is a member of the Board of Directors of the American Academy of Home Care Medicine. Bruce Leff, Christine M. Weston, Sarah Garrigues, and Kanan Patel were funded by the Commonwealth Fund, Retirement Research Foundation.; This work was supported by the Retirement Research Foundation and the Commonwealth Fund, a national private foundation based in New York City that supports independent research on healthcare and makes grants to improve healthcare practice and policy. The views presented here are those of the authors and not necessarily those of the Commonwealth Fund, its directors, officers, or staff. We acknowledge the contributions made by members of the National Home-Based Primary Care and Palliative Care Network to the development of the survey instrument: Gresham Bayne, MD, Nant Health; Lynn Beatty, MD, Visiting Physicians Association; Peter A. Boling, MD, Virginia Commonwealth University; Tom Cornwell, MD, Home Centered Care Institute; Eric De Jonge, MD, Medstar Washington Hospital Center Medical House Call Program; Tom Edes, MD, FACP, U.S. Department of Veterans Affairs; Lynn Friss Feinberg, AARP Public Policy Institute; Alanna Goldstein, MPH, American Geriatrics Society; Jen Hayashi, MD, Johns Hopkins Elder House Call Program; Benneth Husted, DO, Housecall Providers; Julia Jung, CPA, House Call Doctors; Tricia Neuman, ScD, Kaiser Family Foundation; Patricia Tomsko Nay, MD, CMD, American Academy of Hospice and Palliative Medicine; Tom Reed, Senior Advocate Resources; Constance Row, American Academy of Home Care Medicine; Christine Broderick, National Partnership For Women & Families; Theresa Soriano, MD, MPH, Mount Sinai Visiting Doctors Program; Robert Sowislo, Visiting Physicians Association. NR 13 TC 4 Z9 4 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2015 VL 63 IS 5 BP 963 EP 969 DI 10.1111/jgs.13382 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CI4NH UT WOS:000354726400016 PM 25940131 ER PT J AU Bowling, CB Batten, A O'Hare, AM AF Bowling, C. Barrett Batten, Adam O'Hare, Ann M. TI Distribution of Survival Times in a Real-World Cohort of Older Adults with Chronic Kidney Disease: The Median May Not Be the Message SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID STAGE RENAL-DISEASE; DECISION-MAKING C1 [Bowling, C. Barrett] Atlanta Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA. [Bowling, C. Barrett] Emory Univ, Dept Med, Atlanta, GA 30322 USA. [Batten, Adam; O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA USA. RP Bowling, CB (reprint author), Atlanta Vet Affairs Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Decatur, GA 30033 USA. FU Beeson Career Development Award from the National Institute on Aging; National Institute on Aging [R03AG042336-01]; T. Franklin Williams Scholarship Award - Atlantic Philanthropies, Inc.; John A. Hartford Foundation; Association of Specialty Professors; American Society of Nephrology; American Geriatrics Society; Department of Veterans Affairs [1IK2CX000856-01A1] FX Original data extraction for this project was supported by a Beeson Career Development Award to Dr. O'Hare from the National Institute on Aging. Additional support was provided through the National Institute on Aging (R03AG042336-01), the T. Franklin Williams Scholarship Award (funding provided by Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the Association of Specialty Professors, the American Society of Nephrology, and the American Geriatrics Society), and the Department of Veterans Affairs (1IK2CX000856-01A1). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. NR 7 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2015 VL 63 IS 5 BP 1033 EP 1035 DI 10.1111/jgs.13425 PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CI4NH UT WOS:000354726400029 PM 25989569 ER PT J AU Pahwa, R Tanner, CM Hauser, RA Sethi, K Isaacson, S Truong, D Struck, L Ruby, AE McClure, NL Went, GT Stempien, MJ AF Pahwa, Rajesh Tanner, Caroline M. Hauser, Robert A. Sethi, Kapil Isaacson, Stuart Truong, Daniel Struck, Lynn Ruby, April E. McClure, Natalie L. Went, Gregory T. Stempien, Mary Jean TI Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study) SO MOVEMENT DISORDERS LA English DT Article DE clinical trial; randomized controlled trial; Parkinson's disease; levodopa-induced dyskinesia; amantadine ID MOTOR FLUCTUATIONS; SCALE; PSYCHOSIS AB ADS-5102 is a long-acting, extended-release capsule formulation of amantadine HCl administered once daily at bedtime. This study investigated the safety, efficacy, and tolerability of ADS-5102 in Parkinson's disease (PD) patients with levodopa-induced dyskinesia. This was a randomized, double-blind, placebo-controlled, parallel-group study of 83 PD patients with troublesome dyskinesia assigned to placebo or one of three doses of ADS-5102 (260 mg, 340 mg, 420 mg) administered daily at bedtime for 8 weeks. The primary efficacy analysis compared change from baseline to week 8 in Unified Dyskinesia Rating Scale (UDysRS) total score for 340 mg ADS-5102 versus placebo. Secondary outcome measures included change in UDysRS for 260 mg, 420 mg, Fatigue Severity Scale (FSS), Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), patient diary, Clinician's Global Impression of Change, and Parkinson's Disease Questionnaire (PDQ-39). ADS-5102 340 mg significantly reduced dyskinesia versus placebo (27% reduction in UDysRS, P=0.005). In addition, ADS-5102 significantly increased ON time without troublesome dyskinesia, as assessed by PD patient diaries, at 260 mg (P=0.004), 340 mg (P=0.008) and 420 mg (P=0.018). Adverse events (AEs) were reported for 82%, 80%, 95%, and 90% of patients in the placebo, 260-mg, 340-mg, and 420-mg groups, respectively. Constipation, hallucinations, dizziness, and dry mouth were the most frequent AEs. Study withdrawal rates were 9%, 15%, 14%, and 40% for the placebo, 260-mg, 340-mg, and 420-mg groups, respectively. All study withdrawals in the active treatment groups were attributable to AEs. ADS-5102 was generally well tolerated and resulted in significant and dose-dependent improvements in dyskinesia in PD patients. (c) 2015 Adamas Pharmaceuticals, Inc. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. C1 [Pahwa, Rajesh] Univ Kansas, Med Ctr, Kansas City, KS 66160 USA. [Tanner, Caroline M.] Parkinsons Inst, Sunnyvale, CA USA. [Tanner, Caroline M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Tanner, Caroline M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hauser, Robert A.] Univ S Florida, Tampa, FL USA. [Sethi, Kapil] Georgia Regents Univ, Augusta, GA USA. [Isaacson, Stuart] Parkinsons Dis & Movement Disorders Ctr, Boca Raton, FL USA. [Truong, Daniel] Parkinsons & Movement Disorder Inst, Fountain Valley, CA USA. [Struck, Lynn] Iowa Hlth Phys, Des Moines, IA USA. [Ruby, April E.; McClure, Natalie L.; Went, Gregory T.; Stempien, Mary Jean] Adamas Pharmaceut Inc, Emeryville, CA USA. RP Pahwa, R (reprint author), Univ Kansas, Med Ctr, Dept Neurol, 3599 Rainbow Blvd,Mailstop 2012, Kansas City, KS 66160 USA. EM rpahwa@kumc.edu FU Adamas Pharmaceuticals, Inc. FX This study was supported by Adamas Pharmaceuticals, Inc. NR 18 TC 18 Z9 19 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2015 VL 30 IS 6 BP 788 EP 795 DI 10.1002/mds.26159 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CI4OT UT WOS:000354731500009 PM 25650051 ER PT J AU Swanson, CR Li, K Unger, TL Gallagher, MD Van Deerlin, VM Agarwal, P Leverenz, J Roberts, J Samii, A Gross, RG Hurtig, H Rick, J Weintraub, D Trojanowski, JQ Zabetian, C Chen-Plotkin, AS AF Swanson, Christine R. Li, Katherine Unger, Travis L. Gallagher, Michael D. Van Deerlin, Vivianna M. Agarwal, Pinky Leverenz, James Roberts, John Samii, Ali Gross, Rachel Goldmann Hurtig, Howard Rick, Jacqueline Weintraub, Daniel Trojanowski, John Q. Zabetian, Cyrus Chen-Plotkin, Alice S. TI Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype SO MOVEMENT DISORDERS LA English DT Article DE Apolipoprotein A1; Parkinson's disease; biomarker; genotype; ApoA1 ID CEREBRAL AMYLOID ANGIOPATHY; PROMOTER REGION; I GENE; CEREBROSPINAL-FLUID; HDL-CHOLESTEROL; ALPHA-SYNUCLEIN; LIPID LEVELS; POLYMORPHISM; BIOMARKERS; POPULATION AB The discovery of novel plasma-based biomarkers could lead to new approaches in the treatment of Parkinson's disease (PD). Here, we explore the role of plasma apolipoprotein A1 (ApoA1) as a risk marker for PD and evaluate the influence of APOA1 promoter variation on plasma ApoA1 levels. Plasma ApoA1 and the single-nucleotide polymorphism, rs670, were assayed in a discovery cohort (cohort 1) of 301 PD patients, 80 normal controls (NCs), and 165 subjects with other neurodegenerative diseases, as well as a cohort (cohort 2) of 158 PD patients from a second clinical site. Additionally, rs670 was genotyped in a third cohort of 1,494 PD and 925 NC subjects from both clinical sites. Compared to both normal and disease controls, PD patients have lower plasma ApoA1 (P<0.001 for both comparisons). Moreover, in PD patients, plasma ApoA1 levels are correlated with genotype at the APOA1 promoter polymorphism, rs670. Specifically, lower plasma ApoA1 levels were found in rs670 major allele (G) homozygotes in both cohort 1 (P=0.009) and in a replication cohort (cohort 2; n=158 PD patients; P=0.024). Finally, evaluating rs670 genotype frequencies in 1,930 PD cases versus 997 NCs, the rs670 GG genotype shows a trend toward association (odds ratio: 1.1; P=0.10) with PD. Our results are compatible with a model whereby circulating ApoA1 levels may be useful in risk-stratifying subjects for the development of PD, with higher ApoA1 levels suggesting relative protection. Future studies evaluating modulation of ApoA1 as a novel therapeutic strategy in PD are warranted. (c) 2014 International Parkinson and Movement Disorder Society C1 [Swanson, Christine R.; Li, Katherine; Unger, Travis L.; Gallagher, Michael D.; Gross, Rachel Goldmann; Hurtig, Howard; Rick, Jacqueline; Chen-Plotkin, Alice S.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gallagher, Michael D.] Univ Penn, Cellular & Mol Biol Grad Grp, Perelman Sch Med, Philadelphia, PA 19104 USA. [Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Agarwal, Pinky] Evergreen Hosp, Med Ctr, Booth Gardner Parkinsons Care Ctr, Washington, DC USA. [Leverenz, James] Cleveland Clin, Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. [Roberts, John] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Samii, Ali; Zabetian, Cyrus] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Samii, Ali; Zabetian, Cyrus] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Chen-Plotkin, AS (reprint author), Univ Penn, Dept Neurol, Perelman Sch Med, 3 West Gates,3400 Spruce St, Philadelphia, PA 19104 USA. EM chenplot@mail.med.upenn.edu RI Gallagher, Michael/G-7113-2015 OI Gallagher, Michael/0000-0002-2109-1293; Zabetian, Cyrus/0000-0002-7739-4306 FU National Institute of Neurological Disorders and Stroke [P50 NS053488, P50NS062684]; National Institutes of Health (NIH) [UO1 NS082134, R01 NS065070]; Burroughs Wellcome Fund Career Award for Medical Scientists; Doris Duke Clinician Scientist Development Award; Benaroya Fund; Department of Veterans Affairs [1101BX000531] FX The clinical data in this project were collected though the support of the University of Pennsylvania and University of Washington Morris K. Udall Parkinson's Disease Research Center of Excellence grants from the National Institute of Neurological Disorders and Stroke (P50 NS053488 and P50NS062684). A.S.C.-P. is supported by the National Institutes of Health (NIH; UO1 NS082134), the Burroughs Wellcome Fund Career Award for Medical Scientists, a Doris Duke Clinician Scientist Development Award, and the Benaroya Fund. C.Z. is supported by the NIH (R01 NS065070) and the Department of Veterans Affairs (Merit Award 1101BX000531). NR 43 TC 5 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD MAY PY 2015 VL 30 IS 6 BP 805 EP 812 DI 10.1002/mds.26022 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA CI4OT UT WOS:000354731500011 PM 25227208 ER PT J AU Dobscha, SK Morasco, BJ Kovas, AE Peters, DM Hart, K McFarland, BH AF Dobscha, Steven K. Morasco, Benjamin J. Kovas, Anne E. Peters, Dawn M. Hart, Kyle McFarland, Bentson H. TI Short-Term Variability in Outpatient Pain Intensity Scores in a National Sample of Older Veterans with Chronic Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Veterans; Numeric Rating Scale; Aged ID CHRONIC NONCANCER PAIN; PRESCRIPTION OPIOID USE; NUMERIC RATING-SCALE; HEALTH-CARE-SYSTEM; PERSISTENT PAIN; RACIAL-DIFFERENCES; MENTAL-HEALTH; BACK-PAIN; DEPRESSION; PATTERNS AB ObjectiveThe Department of Veterans Affairs (VA) uses the 11-point pain numeric rating scale (NRS) to gather pain intensity information from veterans at outpatient appointments. Yet, little is known about how NRS scores may vary over time within individuals; NRS variability may have important ramifications for treatment planning. Our main objective was to describe variability in NRS scores within a 1-month timeframe, as obtained during routine outpatient care in older patients with chronic pain treated in VA hospitals. A secondary objective was to explore for patient characteristics associated with within-month NRS score variability. DesignRetrospective cohort study. SubjectsNational sample of veterans 65 years or older seen in VA in 2010 who had multiple elevated NRS scores indicating chronic pain. MethodsVA datasets were used to identify the sample and demographic and clinical variables including NRS scores. For the main analysis, we identified subjects with two or more NRS scores obtained in each of two or more months in a 12-month period; we examined ranges in NRS scores across the first two qualifying months. ResultsAmong 4,336 individuals in the main analysis cohort, the mean and median of the average NRS score range across the 2 months were 2.7 and 2.5, respectively. In multivariable models, main significant predictors of within-month NRS score variability were baseline pain intensity, overall medical comorbidity, and being divorced/separated. ConclusionsThe majority of patients in the sample had clinically meaningful variation in pain scores within a given month. This finding highlights the need for clinicians and their patients to consider multiple NRS scores when making chronic pain treatment decisions. C1 [Dobscha, Steven K.; Morasco, Benjamin J.; Kovas, Anne E.; Hart, Kyle] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR 97207 USA. [Dobscha, Steven K.; Morasco, Benjamin J.; McFarland, Bentson H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Peters, Dawn M.; McFarland, Bentson H.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Dobscha, SK (reprint author), Portland VA Med Ctr, POB 1034 R&D 66, Portland, OR 97207 USA. EM steven.dobscha@va.gov FU National Institutes of Health, National Institute on Aging [R03-AG042756]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [CIN 13-404] FX This material is based upon work supported by the National Institutes of Health, National Institute on Aging, R03-AG042756 (PI: Dobscha) and the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, CIN 13-404 (PI: Dobscha). Dr. Dobscha is the Director of the Center to Improve Veteran Involvement in Care (CIVIC) at the Portland VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, National Institutes of Health, or United States government. NR 52 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAY PY 2015 VL 16 IS 5 BP 855 EP 865 DI 10.1111/pme.12643 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CI4SC UT WOS:000354742300004 PM 25545398 ER PT J AU Weiner, DK AF Weiner, Debra K. TI Introduction to Special Series: Deconstructing Chronic Low Back Pain in the Older Adult: Shifting the Paradigm from the Spine to the Person SO PAIN MEDICINE LA English DT Editorial Material DE Back Pain; Chronic Low Back Pain; Chronic Pain; Elderly; Geriatric; Homeostenosis; Low Back Pain; Lumbar; Magnetic Resonance Imaging; Older Adults; Pain Management; Treatment Outcome ID HEALTH-CARE; MANAGEMENT; PREVALENCE; PROGRAMS; US C1 [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Weiner, Debra K.] Univ Pittsburgh, Div Geriatr Med, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov NR 19 TC 11 Z9 11 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAY PY 2015 VL 16 IS 5 BP 881 EP 885 DI 10.1111/pme.12759 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CI4SC UT WOS:000354742300008 PM 25846799 ER PT J AU Weiner, DK Fang, MK Gentili, A Kochersberger, G Marcum, ZA Rossi, MI Semla, TP Shega, J AF Weiner, Debra K. Fang, Meika Gentili, Angela Kochersberger, Gary Marcum, Zachary A. Rossi, Michelle I. Semla, Todd P. Shega, Joseph TI Deconstructing Chronic Low Back Pain in the Older AdultStep by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part I: Hip Osteoarthritis SO PAIN MEDICINE LA English DT Review DE Aged; Assessment; Hip Osteoarthritis; Chronic Pain; Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain ID RANDOMIZED CLINICAL-TRIAL; SPINE SYNDROME; KNEE OSTEOARTHRITIS; EXERCISE THERAPY; SELF-MANAGEMENT; MANUAL THERAPY; PREVALENCE; ARTHRITIS; OUTCOMES; CRITERIA AB ObjectiveTo present the first in a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults. The series presents CLBP as a syndrome, a final common pathway for the expression of multiple contributors rather than a disease localized exclusively to the lumbosacral spine. Each article addresses one of twelve important contributors to pain and disability in older adults with CLBP. This article focuses on hip osteoarthritis (OA). MethodsThe evaluation and treatment algorithm, a table articulating the rationale for the individual algorithm components, and stepped-care drug recommendations were developed using a modified Delphi approach. The Principal Investigator, a five-member content expert panel and a nine-member primary care panel were involved in the iterative development of these materials. The algorithm was developed keeping in mind medications and other resources available within Veterans Health Administration (VHA) facilities. As panelists were not exclusive to the VHA, the materials can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributor's clinical practice. ResultsWe present an algorithm and supportive materials to help guide the care of older adults with hip OA, an important contributor to CLBP. The case illustrates an example of complex hip-spine syndrome, in which hip OA was an important contributor to disability in an older adult with CLBP. ConclusionsHip OA is common and should be evaluated routinely in the older adult with CLBP so that appropriately targeted treatment can be designed. C1 [Weiner, Debra K.; Rossi, Michelle I.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Weiner, Debra K.; Marcum, Zachary A.; Rossi, Michelle I.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Fang, Meika] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Fang, Meika] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY USA. [Kochersberger, Gary] VA Med Ctr, Canandaigua, NY USA. [Semla, Todd P.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Shega, Joseph] VITAS Hlth Care, Miami, FL USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Drive,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. The author thanks Dave Newman, Dr. Rollin Gallagher, and Dr. Eric Rodriguez for their thoughtful review of the manuscript. NR 48 TC 6 Z9 6 U1 4 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAY PY 2015 VL 16 IS 5 BP 886 EP 897 DI 10.1111/pme.12757 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA CI4SC UT WOS:000354742300009 PM 25846648 ER PT J AU Cornejo-Olivas, MR Torres, L Mata, IF Mazzetti, P Rivas, D Cosentino, C Inca-Martinez, M Cuba, JM Zabetian, CP Leverenz, JB AF Cornejo-Olivas, Mario R. Torres, Luis Mata, Ignacio F. Mazzetti, Pilar Rivas, Diana Cosentino, Carlos Inca-Martinez, Miguel Cuba, Juan M. Zabetian, Cyrus P. Leverenz, James B. TI A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Familial parkinsonism; Parkin; Mutations; Pathology ID RECESSIVE JUVENILE PARKINSONISM; EARLY-ONSET PARKINSONISM; LEWY BODIES; DISEASE; GENE; IDENTIFICATION; DELETION; PATIENT AB Background: Mutations in PARK2 result in autosomal recessive young onset Parkinson's disease (YOPD). Although there have been a number of reports on the clinical characteristics of PARK2-related PD, there is limited information available on the associated neuropathologic changes. Design: We describe the clinical and pathological characteristics of a Peruvian family with YOPD. The proband and one unaffected sibling were screened for PARK2 dosage and point mutations. One affected sibling had detailed neuropathologic examination. Setting: Instituto Nacional de Ciencias Neurologicas (INCN) in Lima, Peru. Results: The proband and two of her four siblings developed YOPD and both parents were unaffected. The clinical course has been characterized by akinetic-rigid parkinsonism predominantly affecting the lower limbs and dyskinesias. Analysis of PARK2 showed that the proband is compound heterozygous for a novel acceptor splice site mutation in intron 5 (IVS5-1G>A) and an exon 7 deletion. Neuropathologic assessment of an affected sibling revealed severe neuronal loss in the substantia nigra (SN) and loss of tyrosine hydroxylase immunopositive fibers in the striatum. No Lewy body pathology was observed using standard histology or immunohistochemistry for alpha-synuclein. Conclusions: Consistent with most neuropathologic reports of patients with PARK2 mutations, we did not observe Lewy body inclusions, despite marked SN degeneration and severe dopaminergic denervation of the striatum. These data describe a novel splice site mutation and further extend the clinicopathological characterization of PARK2-associated PD. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Cornejo-Olivas, Mario R.] Northern Pacific Global Hlth Res Fellows Training, Bethesda, MD USA. [Cornejo-Olivas, Mario R.; Mazzetti, Pilar; Inca-Martinez, Miguel] Neurogenet Res Ctr, Inst Nacl Ciencias Neurol, Lima, Peru. [Torres, Luis; Cosentino, Carlos; Cuba, Juan M.] Inst Natl Ciencias Neurol, Movement Disorders Unit, Lima, Peru. [Rivas, Diana] Inst Natl Ciencias Neurol, Dept Neuropathol, Lima, Peru. [Mata, Ignacio F.; Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. [Mata, Ignacio F.; Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Leverenz, James B.] Cleveland Clin, Neurol Inst, Lou Ruvo Ctr Brain Hlth, Cleveland, OH 44106 USA. RP Leverenz, JB (reprint author), 9500 Euclid Ave U10, Cleveland, OH 44195 USA. EM leverej@ccf.org OI Zabetian, Cyrus/0000-0002-7739-4306; Cornejo-Olivas, Mario /0000-0001-6313-5680 FU Department of Veterans Affairs; National Institutes of Health [R01 NS065070, P50 NS062684, P50 NS040256]; Parkinson's Disease Foundation; Jane and Lee Seidman Fund; NIH [R24 TW007988]; Northern Pacific Global Health Research Fellows Training Consortium [R25 TW009345] FX This work was supported by the Department of Veterans Affairs, National Institutes of Health (R01 NS065070, P50 NS062684, P50 NS040256), the Parkinson's Disease Foundation, and the Jane and Lee Seidman Fund. Dr Cornejo-Olivas is the recipient of an NIH Fogarty International Clinical Research Fellowship at Vanderbilt University (R24 TW007988) and Northern Pacific Global Health Research Fellows Training Consortium (R25 TW009345). NR 30 TC 2 Z9 3 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAY PY 2015 VL 21 IS 5 BP 444 EP 448 DI 10.1016/j.parkreldis.2015.01.005 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA CI8PL UT WOS:000355034100004 PM 25817512 ER PT J AU Katz, M Won, SJ Park, Y Orr, A Jones, DP Swanson, RA Glass, GA AF Katz, Maya Won, Seok Joon Park, Youngja Orr, Adrienne Jones, Dean P. Swanson, Raymond A. Glass, Graham A. TI Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease SO PARKINSONISM & RELATED DISORDERS LA English DT Article DE Glutathione; Cysteine; Neuroprotection; Therapeutics; Parkinson's disease ID ACETYL-CYSTEINE; GLUTATHIONE; MOUSE; MICE AB Introduction: Depletion of neuronal glutathione may contribute to the pathogenesis of Parkinson's disease (PD). N-acetylcysteine (NAC) can restore neuronal glutathione levels, but it has not been established whether NAC can cross the blood brain barrier in humans. Methods: Twelve patients with PD were given oral NAC twice daily for 2 days. Three doses were compared: 7 mg/kg, 35 mg/kg, and 70 mg/kg. NAC, cysteine, and glutathione were measured in the cerebrospinal fluid (CSF) at baseline and 90 min after the last dose. Cognitive and motor functions were assessed pre- and post-NAC administration using the Montreal Cognitive Assessment (MoCA) and the Unified Parkinson's Disease Rating Scale part III motor subscore (UPDRS-III). Results: Oral NAC produced a dose-dependent increase in CSF NAC concentrations (p < 0.001), with the highest dose producing a CSF concentration of 9.26 +/- 1.62 mu M. There were no significant adverse events. NAC had no acute effect on motor or cognitive function. Conclusion: Orally administered NAC produces biologically relevant CSF NAC concentrations at doses that are well tolerated. The findings support the feasibility of NAC as a potential disease-modifying therapy for PD. Published by Elsevier Ltd. C1 [Katz, Maya; Won, Seok Joon; Orr, Adrienne; Swanson, Raymond A.; Glass, Graham A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Katz, Maya; Won, Seok Joon; Orr, Adrienne; Swanson, Raymond A.; Glass, Graham A.] Univ Calif San Francisco, San Francisco Med Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Park, Youngja; Jones, Dean P.] Emory Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA. RP Katz, M (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Neurol Serv, 4150 Clement St,1B-31 127P, San Francisco, CA 94121 USA. EM maya.katz@ucsfmedctr.org FU San Luis Obispo County Community Foundation; Singing Field Foundation; Department of Veterans Affairs FX We would like to acknowledge the hard work of, Elaine Lanier NP and Mary McCormack, who made this study possible. This study was supported by the San Luis Obispo County Community Foundation, the Singing Field Foundation, and the Department of Veterans Affairs. NR 23 TC 6 Z9 6 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD MAY PY 2015 VL 21 IS 5 BP 500 EP 503 DI 10.1016/j.parkreldis.2015.02.020 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA CI8PL UT WOS:000355034100014 PM 25765302 ER PT J AU Talbot, LS Rao, MN Cohen, BE Richards, A Inslicht, SS O'Donovan, A Maguen, S Metzler, TJ Neylan, TC AF Talbot, Lisa S. Rao, Madhu N. Cohen, Beth E. Richards, Anne Inslicht, Sabra S. O'Donovan, Aoife Maguen, Shira Metzler, Thomas J. Neylan, Thomas C. TI Metabolic Risk Factors and Posttraumatic Stress Disorder: The Role of Sleep in Young, Healthy Adults SO PSYCHOSOMATIC MEDICINE LA English DT Article DE posttraumatic stress disorder; cholesterol; triglycerides; lipoproteins; visceral adiposity; sleep duration ID SERUM-LIPID CONCENTRATIONS; ADMINISTERED PTSD SCALE; VIETNAM VETERANS; VISCERAL OBESITY; POLICE OFFICERS; INSOMNIA; SYMPTOMS; ASSOCIATION; DURATION; METAANALYSIS AB Objective: Posttraumatic stress disorder (PTSD) is associated with indicators of poor physical health and sleep disturbance. This study investigated the relationship between PTSD and metabolic risk factors and examined the role of sleep duration in medically healthy and medication-free adults. Methods: Participants with PTSD (n = 44, mean age = 30.6 years) and control participants free of lifetime psychiatric history (n = 50, mean age = 30.3 years) recorded sleep using sleep diary for 10 nights and actigraphy for 7 nights. We assessed metabolic risk factors including fasting triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein cholesterol, as well as abdominal fat using dual-energy x-ray absorptiometry. Results: PTSD was associated with shorter sleep duration (based on self-report, not actigraphy) and higher metabolic risks (controlling for body fat percentage), including increased triglycerides (p = .03), total cholesterol (p < .001), LDL cholesterol (p = .006), very low density lipoprotein cholesterol (p = .002), and cholesterol/high-density lipoprotein ratio (p = .024). In addition, sleep duration was associated with metabolic risks in PTSD (significant correlations ranged from r = -0.20 to r = -0.40) but did not fully account for the association between PTSD and metabolic measures. Conclusions: Metabolic risk factors are associated with PTSD even in early adulthood, which highlights the need for early intervention. Future longitudinal research should assess whether sleep disturbance in PTSD is a mechanism that contributes to heightened metabolic risk to elucidate the pathway from PTSD to higher rates of medical disorders such as obesity, diabetes, and heart disease. C1 [Talbot, Lisa S.; Rao, Madhu N.; Cohen, Beth E.; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Maguen, Shira; Metzler, Thomas J.; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Rao, Madhu N.; Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Talbot, Lisa S.; Richards, Anne; Inslicht, Sabra S.; O'Donovan, Aoife; Maguen, Shira; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Talbot, LS (reprint author), San Francisco VA Med Ctr, 116-H,4150 Clement St, San Francisco, CA 94121 USA. EM lisa.talbot@gmail.com FU National Institute for Mental Health [5R01MH073978-04, 5R34MH077667-03]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 RR024131]; Department of Defense; Department of Veterans Affairs FX This research was supported by grants from the National Institute for Mental Health (TCN: 5R01MH073978-04, 5R34MH077667-03) and the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration. This project was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant No. UL1 RR024131. Dr. Cohen reported that her spouse is employed by Gilead Sciences, Inc. Dr. Neylan reported receiving study medication from Actelion for a study funded by the Department of Defense and receiving study medication from GlaxoSmithKline for a study funded by the Department of Veterans Affairs. For the remaining authors, no conflicts of interest were declared. NR 53 TC 6 Z9 6 U1 3 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD MAY PY 2015 VL 77 IS 4 BP 383 EP 391 DI 10.1097/PSY.0000000000000176 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA CI2CR UT WOS:000354553000004 PM 25886830 ER PT J AU Chartier, M Blais, RK Steinberg, T Catella, S Dehon, E Ross, D Zeiss, RA AF Chartier, Maggie Blais, Rebecca K. Steinberg, Tara Catella, Stephanie Dehon, Erin Ross, David Zeiss, Robert A. TI A Psychology Postdoctoral Fellowship Program in Integrated HIV and Hepatitis C Clinical Care: Rationale, Progress, and Future Directions SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY LA English DT Article DE postdoctoral fellowship; training; HIV; hepatitis C; integrated care ID SUBSTANCE USE DISORDERS; OF-VETERANS-AFFAIRS; VIRUS-INFECTION; PSYCHIATRIC-DISORDERS; DISEASE PROGRESSION; ANTIVIRAL TREATMENT; MENTAL-ILLNESS; STIGMA; PREVALENCE; THERAPY AB Individuals with HIV/AIDS and hepatitis C virus (HCV) often present with complex mental health (MH) and substance use disorder (SUD) treatment needs. Evidence shows that providing MH and SUD services in integrated care settings results in improved medical treatment outcomes and disease management for these populations. Given the importance of addressing the MH and SUD needs of veterans seeking care at Veterans Health Administration (VHA) facilities for HIV and HCV, the Office of Public Health is collaborating with VHA's Office of Academic Affiliations to support a clinical psychology postdoctoral training program with this emphasis. Through a discussion of fellowship competencies, structure, and implementation, this article highlights the unique contribution that a psychology postdoctoral training program with a focus on these populations provides. C1 [Chartier, Maggie; Ross, David] Off Publ Hlth, Clin Publ Hlth, Washington, DC USA. [Blais, Rebecca K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Steinberg, Tara] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Catella, Stephanie] San Francisco VA Med Ctr, San Francisco, CA USA. [Dehon, Erin] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA. [Zeiss, Robert A.] VA Cent Off, Off Acad Affiliat, Hlth Educ, Washington, DC USA. RP Chartier, M (reprint author), San Francisco VA Med Ctr 116B, 4150 Clement St, San Francisco, CA 94121 USA. EM maggie.chartier@va.gov FU VHA Office of Public Health; Office of Academic Affiliations FX THIS FELLOWSHIP WAS FUNDED by the VHA Office of Public Health in collaboration with the Office of Academic Affiliations. NR 46 TC 0 Z9 0 U1 1 U2 4 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1931-3918 EI 1931-3926 J9 TRAIN EDUC PROF PSYC JI Train. Educ. Prof. Psychol. PD MAY PY 2015 VL 9 IS 2 BP 77 EP 84 DI 10.1037/tep0000038 PG 8 WC Psychology, Educational SC Psychology GA CI2VZ UT WOS:000354607000001 ER PT J AU Karimkhani, C Boyers, LN Naghavi, M Coffeng, LE Lott, JP Wulf, S Hay, R Williams, HC Weinstock, MA Norton, SA Armstrong, AW Dunnick, CA Norris, DA Dellavalle, RP AF Karimkhani, C. Boyers, L. N. Naghavi, M. Coffeng, L. E. Lott, J. P. Wulf, S. Hay, R. Williams, H. C. Weinstock, M. A. Norton, S. A. Armstrong, A. W. Dunnick, C. A. Norris, D. A. Dellavalle, R. P. TI The global burden of disease associated with alopecia areata SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Letter ID HIDRADENITIS SUPPURATIVA; PREVALENCE; PSORIASIS; SEVERITY; ACNE C1 [Karimkhani, C.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA. [Boyers, L. N.] Georgetown Univ, Sch Med, Washington, DC USA. [Naghavi, M.; Coffeng, L. E.; Wulf, S.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Lott, J. P.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA. [Lott, J. P.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Hay, R.] Kings Coll Hosp NHS Trust, Dept Dermatol, London, England. [Williams, H. C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England. [Weinstock, M. A.] VA Med Ctr Providence, Dermatoepidemiol Unit, Providence, RI USA. [Weinstock, M. A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA. [Weinstock, M. A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, M. A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Norton, S. A.] Childrens Natl Med Ctr, Div Dermatol, Washington, DC 20010 USA. [Armstrong, A. W.; Dunnick, C. A.; Norris, D. A.; Dellavalle, R. P.] Univ Colorado, Sch Publ Hlth, Dept Dermatol, Aurora, CO 80045 USA. [Dellavalle, R. P.] Univ Colorado, Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Armstrong, A. W.; Dunnick, C. A.; Norris, D. A.; Dellavalle, R. P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA. RP Dellavalle, RP (reprint author), Univ Colorado, Sch Publ Hlth, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. EM robert.dellavalle@ucdenver.edu NR 10 TC 1 Z9 2 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD MAY PY 2015 VL 172 IS 5 BP 1424 EP 1426 DI 10.1111/bjd.13559 PG 3 WC Dermatology SC Dermatology GA CH9XU UT WOS:000354390800097 PM 25422028 ER PT J AU Calvi, AR Gliesing, J Eapen, B AF Calvi, Ashley R. Gliesing, Julie Eapen, Blessen TI Syndrome of the Trephined: Improvement in Neurolinguistic Deficits and Global Aphasia After Cranioplasty SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Calvi, Ashley R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA. [Gliesing, Julie; Eapen, Blessen] South Texas Vet Hlth Care Syst, Audie L Murphy VA Med Ctr, Polytrauma Rehabil Ctr, San Antonio, TX USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 MA 0119 BP E111 EP E111 PG 1 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100117 ER PT J AU Jaramillo, C Swan, A Eapen, B Pugh, MJ AF Jaramillo, Carlos Swan, Alicia Eapen, Blessen Pugh, Mary Jo TI Vestibular Dysfunction and Traumatic Brain Injury in Veterans of the Wars in Iraq and Afghanistan SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Jaramillo, Carlos; Swan, Alicia; Eapen, Blessen; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 MA 0116 BP E109 EP E110 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100114 ER PT J AU Swan, A Jaramillo, C Eapen, B Pugh, MJ AF Swan, Alicia Jaramillo, Carlos Eapen, Blessen Pugh, Mary Jo TI Tinnitus: Prevalence and Co-morbidities in a Cohort of Iraq and Afghanistan Veterans SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Swan, Alicia; Jaramillo, Carlos; Eapen, Blessen; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD MAY-JUN PY 2015 VL 30 IS 3 MA 0113 BP E109 EP E109 PG 1 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA CH8PJ UT WOS:000354298100112 ER PT J AU Yehuda, R Lehrner, A Rosenbaum, TY AF Yehuda, Rachel Lehrner, Amy Rosenbaum, Talli Y. TI PTSD and Sexual Dysfunction in Men and Women SO JOURNAL OF SEXUAL MEDICINE LA English DT Review DE Sexual Dysfunction; Posttraumatic Stress Disorder; Neurobiology; Neuroendocrinology ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; CONDITIONED FEAR; TRAUMATIC EVENT; EX-PRISONERS; WAR VETERANS; RESPONSES; AROUSAL; PREDICTORS; SYMPTOMS AB IntroductionDifficulties in sexual desire and function often occur in persons with posttraumatic stress disorder (PTSD), but many questions remain regarding the mechanisms underlying the occurrence of sexual problems in PTSD. AimThe aim of this review was to present a model of sexual dysfunction in PTSD underpinned by an inability to regulate and redirect the physiological arousal needed for healthy sexual function away from aversive hyperarousal and intrusive memories. MethodA literature review pertaining to PTSD and sexual function was conducted. Evidence for the comorbidity of sexual dysfunction and PTSD is presented, and biological and psychological mechanisms that may underlie this co-occurrence are proposed. Main Outcome MeasuresThis manuscript presents evidence of sexual dysfunction in conjunction with PTSD, and of the neurobiology and neuroendocrinology of PTSD and sexual function. ResultsSexual dysfunction following trauma exposure may be mediated by PTSD-related biological, cognitive, and affective processes. ConclusionsThe treatment of PTSD must include attention to sexual dysfunction and vice versa. Yehuda R, Lehrner A, and Rosenbaum TY. PTSD and sexual dysfunction in men and women. J Sex Med 2015;12:1107-1119. C1 [Yehuda, Rachel; Lehrner, Amy] James J Peters Vet Affairs Med Ctr, Mental Hlth Care Ctr, Bronx, NY 10468 USA. [Yehuda, Rachel; Lehrner, Amy] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Rosenbaum, Talli Y.] Inner Stabil Ltd, Dept Sex Therapy, Bet Shemesh, Israel. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Mental Hlth Primary Care Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov NR 75 TC 5 Z9 5 U1 3 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD MAY PY 2015 VL 12 IS 5 BP 1107 EP 1119 DI 10.1111/jsm.12856 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA CI1UW UT WOS:000354531400003 PM 25847589 ER PT J AU Morris, BJ Krieger, JN AF Morris, Brian J. Krieger, John N. TI The Literature Supports Policies Promoting Neonatal Male Circumcision in North America SO JOURNAL OF SEXUAL MEDICINE LA English DT Letter C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Sydney, NSW 2006, Australia. [Krieger, John N.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Urol, Seattle, WA USA. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Sydney, NSW 2006, Australia. NR 5 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD MAY PY 2015 VL 12 IS 5 BP 1305 EP 1305 DI 10.1111/jsm.12855 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CI1UW UT WOS:000354531400029 PM 25757531 ER PT J AU Maximin, S Moshiri, M Bhargava, P AF Maximin, Suresh Moshiri, Mariam Bhargava, Puneet TI Understanding the Cost of Conflict and an Approach to Conflict-Management Design SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Maximin, Suresh; Moshiri, Mariam; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98108 USA. [Maximin, Suresh; Bhargava, Puneet] Vet Affairs Puget Sound Hlth Care Syst, Diagnost Imaging Serv, Seattle Div, Seattle, WA 98108 USA. RP Bhargava, P (reprint author), Univ Washington, Sch Med, Dept Radiol, S-1 14 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 13 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD MAY PY 2015 VL 12 IS 5 BP 507 EP 509 DI 10.1016/j.jacr.2014.07.006 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CI0IS UT WOS:000354420900018 PM 25156203 ER PT J AU Morey, JM Haney, NM Schoppe, K Hawkins, CM AF Morey, Jose M. Haney, Nora M. Schoppe, Kurt Hawkins, C. Matthew TI Adding Value as Young Radiologists: Challenges and Opportunities, Part 1 SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID ACCOUNTABLE CARE ORGANIZATIONS; HEALTH-CARE; STRATEGIES; IMPACT; COMMUNICATION; REFORM C1 [Morey, Jose M.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Morey, Jose M.] US Dept Vet Affairs, Hampton, VA USA. [Haney, Nora M.] Tulane Univ, Sch Med, New Orleans, LA 70130 USA. [Schoppe, Kurt] Radiol Associates North Texas, Arlington, TX USA. [Hawkins, C. Matthew] Emory Univ, Sch Med, Atlanta, GA 30322 USA. RP Haney, NM (reprint author), Tulane Univ, Sch Med, 929 Washington Ave, New Orleans, LA 70130 USA. EM nhaney@tulane.edu NR 37 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD MAY PY 2015 VL 12 IS 5 BP 533 EP 536 DI 10.1016/j.jacr.2015.02.003 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CI0IS UT WOS:000354420900027 PM 25940366 ER PT J AU Weinstein, S Mabray, MC Aslam, R Hope, T Yee, J Owens, C AF Weinstein, Stefanie Mabray, Marc C. Aslam, Riz Hope, Tom Yee, Judy Owens, Christopher TI Intraoperative Sonography During Carotid Endarterectomy Normal Appearance and Spectrum of Complications SO JOURNAL OF ULTRASOUND IN MEDICINE LA English DT Article DE carotid; endarterectomy; intraoperative; thromboembolic; vascular; vascular ultrasound ID DUPLEX ULTRASONOGRAPHY; BLOOD-FLOW; ULTRASOUND; STENOSIS; ANGIOGRAPHY; OUTCOMES; DEFECTS; DOPPLER; IMPACT; FATE AB Carotid endarterectomy is a commonly performed procedure for prevention of stroke related to carotid stenosis. Intraoperative sonography is used to identify potentially correctable technical defects during carotid endarterectomy. The main risk of endarterectomy is perioperative stroke, and great effort has been put into trying to reduce this risk through various surgical techniques and evaluation of the surgical bed. Postoperative carotid thrombosis, or thombo-embolization from the arterectomy site, remains a common cause of perioperative stroke and is often related to technical defects in the arterial reconstruction procedure. Re-exploration and repair of any imperfections have the potential to improve outcomes. Intraoperative imaging can identify potentially occult lesions, provide the option for correction, and thus reduce chance of stroke. Familiarity with the spectrum of intraoperative sonographic findings helps correctly identify residual intimal dissection flaps, plaque, thrombi, and stenosis, which may require immediate surgical revision. Our objective is to illustrate the spectrum of intraoperative findings and their importance. C1 [Weinstein, Stefanie; Mabray, Marc C.; Aslam, Riz; Hope, Tom; Yee, Judy; Owens, Christopher] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Weinstein, S (reprint author), San Francisco VA Med Ctr, Serv Radiol, 4150 Clement St, San Francisco, CA 94121 USA. EM stefanie.weinstein@ucsf.edu NR 33 TC 0 Z9 0 U1 0 U2 0 PU AMER INST ULTRASOUND MEDICINE PI LAUREL PA SUBSCRIPTION DEPT, 14750 SWEITZER LANE, STE 100, LAUREL, MD 20707-5906 USA SN 0278-4297 EI 1550-9613 J9 J ULTRAS MED JI J. Ultrasound Med. PD MAY PY 2015 VL 34 IS 5 BP 885 EP 894 DI 10.7863/ultra.34.5.885 PG 10 WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging GA CH4ON UT WOS:000354012900019 PM 25911722 ER PT J AU Mehta, P Carter, T Vinoya, C Kangovi, S Srinivas, SK AF Mehta, Pooja Carter, Tamala Vinoya, Cjloe Kangovi, Shreya Srinivas, Sindhu Kikkeri TI Understanding High Utilization of Emergency Obstetric Care in Pregnant Women of Low Socioeconomic Status SO OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 61st Annual Clinical Meeting of the American-College-of-Obstetricians-and-Gynecologists - Women's Health Care Physicians CY MAY 07, 2013 CL New Orleans, LA SP Amer Coll Obstetricians & Gynecologists C1 [Mehta, Pooja] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAY PY 2015 VL 125 SU 1 MA 170 BP 58S EP 58S PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CH6EI UT WOS:000354128700191 ER PT J AU Taylor, JJ Williams, NR George, MS AF Taylor, Joseph J. Williams, Nolan R. George, Mark S. TI Beyond Neural Cubism: Promoting a Multidimensional View of Brain Disorders by Enhancing the Integration of Neurology and Psychiatry in Education SO ACADEMIC MEDICINE LA English DT Article ID TRANSCRANIAL MAGNETIC STIMULATION; OBSESSIVE-COMPULSIVE DISORDER; GRAY-MATTER DENSITY; CONTROLLED-TRIAL; STROKE PATIENTS; DOUBLE-BLIND; NEUROPSYCHIATRY; DEPRESSION; LAMOTRIGINE; 21ST-CENTURY AB Cubism was an influential early-20th-century art movement characterized by angular, disjointed imagery. The two-dimensional appearance of Cubist figures and objects is created through juxtaposition of angles. The authors posit that the constrained perspectives found in Cubism may also be found in the clinical classification of brain disorders. Neurological disorders are often separated from psychiatric disorders as if they stemmed from different organ systems. Maintaining two isolated clinical disciplines fractionalizes the brain in the same way that Pablo Picasso fractionalized figures and objects in his Cubist art. This Neural Cubism perpetuates a clinical divide that does not reflect the scope and depth of neuroscience. All brain disorders are complex and multidimensional, with aberrant circuitry and resultant psychopharmacology manifesting as altered behavior, affect, mood, or cognition. Trainees should receive a multidimensional education based on modern neuroscience, not a partial education based on clinical precedent. The authors briefly outline the rationale for increasing the integration of neurology and psychiatry and discuss a nested model with which clinical neuroscientists (neurologists and psychiatrists) can approach and treat brain disorders. C1 [Taylor, Joseph J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Williams, Nolan R.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [George, Mark S.] Med Univ S Carolina, Charleston, SC 29403 USA. [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29403 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Taylor, JJ (reprint author), Brain Stimulat Lab, Inst Psychiat, 67 President St,Room 504 North, Charleston, SC 29414 USA. EM taylorjj@musc.edu OI Williams, Nolan/0000-0003-4368-3203 FU National Institute on Drug Abuse [F30 DA033748]; National Institute of Mental Health [R25 DA020537] FX Mr. Taylor is funded by the National Institute on Drug Abuse (F30 DA033748), and Dr. Williams is funded by the National Institute of Mental Health (R25 DA020537). NR 58 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD MAY PY 2015 VL 90 IS 5 BP 581 EP 586 DI 10.1097/ACM.0000000000000530 PG 6 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CH2UH UT WOS:000353879700016 PM 25340364 ER PT J AU Bowen, JL Hirsh, D Aagaard, E Kaminetzky, CP Smith, M Hardman, J Chheda, SG AF Bowen, Judith L. Hirsh, David Aagaard, Eva Kaminetzky, Catherine P. Smith, Marie Hardman, Joseph Chheda, Shobhina G. TI Advancing Educational Continuity in Primary Care Residencies: An Opportunity for Patient-Centered Medical Homes SO ACADEMIC MEDICINE LA English DT Article ID CAMBRIDGE INTEGRATED CLERKSHIP; ENTRUSTABLE PROFESSIONAL ACTIVITIES; INTERNAL-MEDICINE; INTERPERSONAL CONTINUITY; CLINICAL EDUCATION; PERSONAL PHYSICIAN; TASK-FORCE; OUTCOMES; REDESIGN; PROGRAM AB Continuity of care is a core value of patients and primary care physicians, yet in graduate medical education (GME), creating effective clinical teaching environments that emphasize continuity poses challenges. In this Perspective, the authors review three dimensions of continuity for patient care-informational, longitudinal, and interpersonal-and propose analogous dimensions describing continuity for learning that address both residents learning from patient care and supervisors and interprofessional team members supporting residents' competency development. The authors review primary care GME reform efforts through the lens of continuity, including the growing body of evidence that highlights the importance of longitudinal continuity between learners and supervisors for making competency judgments. The authors consider the challenges that primary care residency programs face in the wake of practice transformation to patient-centered medical home models and make recommendations to maximize the opportunity that these practice models provide. First, educators, researchers, and policy makers must be more precise with terms describing various dimensions of continuity. Second, research should prioritize developing assessments that enable the study of the impact of interpersonal continuity on clinical outcomes for patients and learning outcomes for residents. Third, residency programs should establish program structures that provide informational and longitudinal continuity to enable the development of interpersonal continuity for care and learning. Fourth, these educational models and continuity assessments should extend to the level of the interprofessional team. Fifth, policy leaders should develop a meaningful recognition process that rewards academic practices for training the primary care workforce. C1 [Bowen, Judith L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bowen, Judith L.] Vet Hlth Adm, Off Acad Affiliat, Washington, DC USA. [Hirsh, David] Harvard Univ, Sch Med, Med, Boston, MA USA. [Hirsh, David] Cambridge Hlth Alliance, Dept Med, Cambridge, MA USA. [Aagaard, Eva] Univ Colorado, Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Staff Educ, Seattle, WA USA. [Kaminetzky, Catherine P.] Univ Washington, Sch Med, Seattle, WA USA. [Smith, Marie] Univ Connecticut, Community Pharm Practice, Storrs, CT USA. [Smith, Marie] Univ Connecticut, Practice & Publ Policy Partnerships, Storrs, CT USA. [Hardman, Joseph] Oregon Hlth & Sci Univ, Internal Med Resident Practice, Portland, OR 97201 USA. [Chheda, Shobhina G.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Gen Internal Med,Med Pediat, Madison, WI USA. RP Chheda, SG (reprint author), 750 Highland Ave,42870 HSLC, Madison, WI 53705 USA. EM sgc@medicine.wisc.edu FU Josiah Macy Jr. Foundation; United Health Foundation FX The authors wish to thank the Josiah Macy Jr. Foundation for financial support of the 2011 Society of General Internal Medicine Education Summit where the formative work for this paper took place. They also thank the United Health Foundation for financial support and the American College of Physicians, Primary Care Progress, and the Veterans Health Administration Office of Academic Affiliations for in-kind support of the Education Summit. Leaders from the American Board of Internal Medicine, American College of Physicians, Association of Program Directors in Internal Medicine, Association of Subspecialty Professors, Clerkship Directors in Internal Medicine, and the Society of General Internal Medicine served as advisors in designing the Education Summit. Although the majority of summit participants were university-, Veterans Affairs-, and community-based physician educators in internal medicine and family medicine, participants from nursing and pharmacy provided crucial contributions. NR 71 TC 1 Z9 1 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD MAY PY 2015 VL 90 IS 5 BP 587 EP 593 DI 10.1097/ACM.0000000000000589 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CH2UH UT WOS:000353879700017 PM 25470307 ER PT J AU Mansh, M White, W Gee-Tong, L Lunn, MR Obedin-Maliver, J Stewart, L Goldsmith, E Brenman, S Tran, E Wells, M Fetterman, D Garcia, G AF Mansh, Matthew White, William Gee-Tong, Lea Lunn, Mitchell R. Obedin-Maliver, Juno Stewart, Leslie Goldsmith, Elizabeth Brenman, Stephanie Tran, Eric Wells, Maggie Fetterman, David Garcia, Gabriel TI Sexual and Gender Minority Identity Disclosure During Undergraduate Medical Education: "In the Closet" in Medical School SO ACADEMIC MEDICINE LA English DT Article ID STUDENT MISTREATMENT; UNITED-STATES; GAY MEN; POPULATIONS; ORIENTATION; HEALTH; TIME AB Purpose To assess identity disclosure among sexual and gender minority (SGM) students pursuing undergraduate medical training in the United States and Canada. Method From 2009 to 2010, a survey was made available to all medical students enrolled in the 176 MD-and DO-granting medical schools in the United States and Canada. Respondents were asked about their sexual and gender identity, whether they were "out" (i.e., had publicly disclosed their identity), and, if they were not, their reasons for concealing their identity. The authors used a mixed-methods approach and analyzed quantitative and qualitative survey data. Results Of 5,812 completed responses (of 101,473 eligible respondents; response rate 5.7%), 920 (15.8%) students from 152 (of 176; 86.4%) institutions identified as SGMs. Of the 912 sexual minorities, 269 (29.5%) concealed their sexual identity in medical school. Factors associated with sexual identity concealment included sexual minority identity other than lesbian or gay, male gender, East Asian race, and medical school enrollment in the South or Central regions of North America. The most common reasons for concealing one's sexual identity were "nobody's business" (165/269; 61.3%), fear of discrimination in medical school (117/269; 43.5%), and social or cultural norms (110/269; 40.9%). Of the 35 gender minorities, 21 (60.0%) concealed their gender identity, citing fear of discrimination in medical school (9/21; 42.9%) and lack of support (9/21; 42.9%). Conclusions SGM students continue to conceal their identity during undergraduate medical training. Medical institutions should adopt targeted policies and programs to better support these individuals. C1 [Mansh, Matthew; White, William; Gee-Tong, Lea; Lunn, Mitchell R.; Obedin-Maliver, Juno; Stewart, Leslie; Goldsmith, Elizabeth; Brenman, Stephanie; Tran, Eric; Wells, Maggie; Fetterman, David; Garcia, Gabriel] Stanford Univ, Sch Med, Lesbian Gay Bisexual & Transgender Med Educ Res G, Stanford, CA 94305 USA. [Mansh, Matthew; White, William; Wells, Maggie] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Lunn, Mitchell R.] Univ Calif San Francisco, Sch Med, Dept Med, Div Nephrol, San Francisco, CA USA. [Obedin-Maliver, Juno] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [Obedin-Maliver, Juno] Univ Calif San Francisco, Sch Med, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Stewart, Leslie] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Goldsmith, Elizabeth] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Goldsmith, Elizabeth] Univ Minnesota, Sch Med, Sch Publ Hlth, Minneapolis, MN 55455 USA. [Brenman, Stephanie] Univ Calif Los Angeles, Sch Med, Dept Emergency Med, Los Angeles, CA USA. [Tran, Eric] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Fetterman, David] Arkansas Evaluat Ctr, Pine Bluff, AR USA. [Fetterman, David] Charleston Univ, Sch Business & Leadership, Charleston, WV USA. [Fetterman, David] Univ Arkansas, Dept Educ, Pine Bluff, AR USA. [Fetterman, David] San Jose State Univ, Dept Anthropol, San Jose, CA 95192 USA. [Fetterman, David] Fetterman & Associates, San Jose, CA USA. [Garcia, Gabriel] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. RP Mansh, M (reprint author), Stanford Univ, Sch Med, 291 Campus Dr, Stanford, CA 94305 USA. EM mmansh@stanford.edu FU Stanford University School of Medicine; Office of the Dean, Stanford University School of Medicine; Office of Diversity and Leadership, Stanford University School of Medicine; Haas Center for Public Service at Stanford University; Stanford University Lesbian, Gay, Bisexual, and Transgender (LGBT) Community Resources Center; Stanford University School of Medicine Medical Scholars Fellowship Program FX This work was supported by Stanford University School of Medicine; Office of the Dean, Stanford University School of Medicine; Office of Diversity and Leadership, Stanford University School of Medicine; Haas Center for Public Service at Stanford University; and the Stanford University Lesbian, Gay, Bisexual, and Transgender (LGBT) Community Resources Center. W. White, J. Obedin-Maliver, and S. Brenman report receipt of support from the Stanford University School of Medicine Medical Scholars Fellowship Program. NR 36 TC 9 Z9 9 U1 5 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD MAY PY 2015 VL 90 IS 5 BP 634 EP 644 DI 10.1097/ACM.0000000000000657 PG 11 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA CH2UH UT WOS:000353879700027 PM 25692563 ER PT J AU Wang, W Young, BA Fulop, T de Boer, IH Boulware, LE Katz, R Correa, A Griswold, ME AF Wang, Wei Young, Bessie A. Fueloep, Tibor de Boer, Ian H. Boulware, L. Ebony Katz, Ronit Correa, Adolfo Griswold, Michael E. TI Effects of Serum Creatinine Calibration on Estimated Renal Function in African Americans: The Jackson Heart Study SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Calibration; Chronic kidney disease; CKD-EPI equation; Deming regression; Serum creatinine ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; CKD-EPI EQUATION; CYSTATIN C; RISK; GFR AB Background: The calibration to isotope dilution mass spectrometry-traceable creatinine is essential for valid use of the new Chronic Kidney Disease Epidemiology Collaboration equation to estimate the glomerular filtration rate. Methods: For 5,210 participants in the Jackson Heart Study (JHS), serum creatinine was measured with a multipoint enzymatic spectrophotometric assay at the baseline visit (2000-2004) and remeasured using the Roche enzymatic method, traceable to isotope dilution mass spectrometry in a subset of 206 subjects. The 200 eligible samples (6 were excluded, 1 for failure of the remeasurement and 5 for outliers) were divided into 3 disjoint sets-training, validation and test-to select a calibration model, estimate true errors and assess performance of the final calibration equation. The calibration equation was applied to serum creatinine measurements of 5,210 participants to estimate glomerular filtration rate and the prevalence of chronic kidney disease (CKD). Results: The selected Deming regression model provided a slope of 0.968 (95% confidence interval [CI], 0.904-1.053) and intercept of 20.0248 (95% CI, -0.0862 to 0.0366) with R-2 value of 0.9527. Calibrated serum creatinine showed high agreement with actual measurements when applying to the unused test set (concordance correlation coefficient 0.934, 95% CI, 0.894-0.960). The baseline prevalence of CKD in the JHS (2000-2004) was 6.30% using calibrated values compared with 8.29% using noncalibrated serum creatinine with the Chronic Kidney Disease Epidemiology Collaboration equation (P<0.001). Conclusions: A Deming regression model was chosen to optimally calibrate baseline serum creatinine measurements in the JHS, and the calibrated values provide a lower CKD prevalence estimate. C1 [Wang, Wei; Griswold, Michael E.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA. [Young, Bessie A.; de Boer, Ian H.; Katz, Ronit] Vet Affairs Puget Sound Hlth Care Syst, Ctr Innovat & Hosp & Specialty Care, Seattle, WA USA. [Young, Bessie A.; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Young, Bessie A.; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Fueloep, Tibor; Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Boulware, L. Ebony] Duke Univ, Dept Med, Durham, NC USA. RP Wang, W (reprint author), Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, 2500 North State St, Jackson, MS 39216 USA. EM wwang@umc.edu FU National Heart, Lung, and Blood Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities; National Institute of Diabetes, Digestive, and Kidney Disease [1R01DK102134-01]; Veterans Affairs Puget Sound Health Care System; Abbvie FX The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. Additional support was provided by Dr. Young's National Institute of Diabetes, Digestive, and Kidney Disease grant 1R01DK102134-01. B.A.Y. is also supported in part by funding from the Veterans Affairs Puget Sound Health Care System. I.H.d.B. received research funding from Abbvie. NR 20 TC 4 Z9 4 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAY PY 2015 VL 349 IS 5 BP 379 EP 384 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA CH2IE UT WOS:000353848100001 PM 25806862 ER PT J AU Carpenter, R Estrada, CA Medrano, M Smith, A Massie, FS AF Carpenter, Riley Estrada, Carlos A. Medrano, Martha Smith, Ann Massie, F. Stanford, Jr. TI A Web-Based Cultural Competency Training for Medical Students: A Randomized Trial SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Cultural competence; Medical education; Educational intervention ID ACHIEVABLE BENCHMARKS; HEALTH; EDUCATION; CURRICULUM; KNOWLEDGE; TOOL AB The objectives of this research were to compare a Web-based curriculum with a traditional lecture format on medical students' cultural competency attitudes using a standardized instrument and to examine the internal consistency of the standardized instrument. Methods: In 2010, we randomized all 180 1st-year medical students into a Web-based (intervention group) or a lecture-based (control group) cultural competency training. The main outcome was the overall score on the Health Belief Attitudes Survey (1 5 lowest, 6 5 highest). We examined internal consistency with factor analysis. Results: No differences were observed in the overall median scores between the intervention (median 5.2; 25th percentile [Q1] 4.9, 75th percentile [Q3] 5.5) and the control groups (median 5.3, Q1 4.9, Q3 5.6) (P = 0.77). The internal consistency of the 2 main subcomponents was good (Cronbach's alpha = 0.83) to acceptable (Cronbach's alpha = 0.69). Conclusions: A Web-based and a lecture-based cultural competency training strategies were associated with equally high positive attitudes among 1st-year medical students. These findings warrant further evaluation of Web-based cultural competency educational interventions. C1 [Carpenter, Riley] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Qual Scholars Program, Birmingham, AL USA. [Estrada, Carlos A.; Massie, F. Stanford, Jr.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Medrano, Martha] Univ Texas Hlth Sci Ctr San Antonio, Continuing Med Educ & Family Practice & Psychiat, San Antonio, TX 78229 USA. [Medrano, Martha] Med Hispan Ctr Excellence, San Antonio, TX USA. [Smith, Ann] Univ Alabama Birmingham, UAB Minor Hlth & Hlth Dispar Res Ctr, Div Prevent Med, Birmingham, AL 35294 USA. RP Estrada, CA (reprint author), Univ Alabama Birmingham, 720 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu FU National Heart, Lung, and Blood Institute [K07 HL081373-01]; Department of Veterans Affairs Office of Academic Affiliations (OAA) FX Supported by the National Heart, Lung, and Blood Institute (K07 HL081373-01 to C.A.E.).; The Department of Veterans Affairs Quality Scholars Fellowship (VAQS) is funded by the Department of Veterans Affairs Office of Academic Affiliations (OAA). The opinions expressed in this article are those of the authors alone and do not reflect the views of the Department of Veterans Affairs. NR 21 TC 2 Z9 2 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD MAY PY 2015 VL 349 IS 5 BP 442 EP 446 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CH2IE UT WOS:000353848100011 PM 25325193 ER PT J AU Martin-Harris, B McFarland, D Hill, EG Strange, CB Focht, KL Wan, Z Blair, J McGrattan, K AF Martin-Harris, Bonnie McFarland, David Hill, Elizabeth G. Strange, Charlton B. Focht, Kendrea L. Wan, Zhuang Blair, Julie McGrattan, Katlyn TI Respiratory-Swallow Training in Patients With Head and Neck Cancer SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Deglutition disorders; Feedback, sensory; Head and neck neoplasms; Rehabilitation; Respiratory aspiration ID SWALLOW/RESPIRATORY PHASE-RELATIONSHIPS; OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; OROPHARYNGEAL CANCER; DYSPHAGIC PATIENTS; NORMAL ADULTS; BOLUS VOLUME; PHARYNGEAL PHASES; APNEA DURATION; ORAL-CANCER AB Objective: To test a novel intervention to train swallowing to occur in the midexpiratory to low expiratory phase of quiet breathing to improve swallowing safety and efficiency. Design: Safety and efficacy nonrandomized controlled trial with 1-month follow-up. Setting: Ambulatory clinics. Participants: Patients (N=30) with head and neck cancer (HNC) and chronic dysphagia completed the intervention. Fifteen of these patients participated in a 1-month follow-up visit. Interventions: Training protocol based on hierarchy of motor skill acquisition to encourage autonomous and optimal respiratory-swallowing coordination. Visual feedback of respiratory phase and volume for swallowing initiation was provided by nasal airflow and rib cage/abdomen signals. Main Outcome Measures: Respiratory-swallow phase pattern, Modified Barium Swallow Impairment Profile (MBSIrnP) scores, Penetration-Aspiration Scale (PAS) scores, and MD Anderson Dysphagia Inventory scores. Results: Using visual feedback, patients were trained to initiate swallows during the midexpiratory phase of quiet breathing and continue to expire after swallowing. This optimal phase patterning increased significantly after treatment (P<.0001). Changes in respiratory-swallowing coordination were associated with improvements in 3 MBSIrnP component scores: laryngeal vestibular closure (P=.0004), tongue base retraction (P<.0001), and pharyngeal residue (P=.01). Significant improvements were also seen in PAS scores (P<.0001). Relative to pretreatment values, patients participating in 1-month follow-up had increased optimal phase patterning (P<.0001), improved laryngeal vestibular closure (P=.01), tongue base retraction (P=.003), and pharyngeal residue (P=.006) MBSImP scores and improved PAS scores (P<.0001). Conclusions: Improvements in respiratory-swallowing coordination can be trained using a systematic protocol and respiratory phase-lung volume-related biofeedback in patients with HNC and chronic dysphagia, with favorable effects on airway protection and bolus clearance. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Martin-Harris, Bonnie; Focht, Kendrea L.; McGrattan, Katlyn] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Coll Med, Charleston, SC 29425 USA. [Martin-Harris, Bonnie; Focht, Kendrea L.; Blair, Julie; McGrattan, Katlyn] Med Univ S Carolina, Evelyn Trammell Inst Voice & Swallowing, Charleston, SC 29425 USA. [Martin-Harris, Bonnie; Focht, Kendrea L.; Blair, Julie] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [McFarland, David] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada. [McFarland, David] McGill Univ, Fac Med, Montreal, PQ, Canada. [Hill, Elizabeth G.; Wan, Zhuang] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Strange, Charlton B.] Med Univ S Carolina, Coll Med, Div Pulm & Crit Med, Charleston, SC 29425 USA. RP Martin-Harris, B (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM harrisbm@musc.edu FU Department of Veterans Affairs [C7135R]; National Institutes of Health [R21DC010480] FX Supported by the Department of Veterans Affairs (grant no. C7135R); and the National Institutes of Health (grant no. R21DC010480). NR 74 TC 6 Z9 6 U1 2 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2015 VL 96 IS 5 BP 885 EP 893 DI 10.1016/j.apmr.2014.11.022 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CH6JL UT WOS:000354142800016 PM 25498307 ER PT J AU Hughes, AJ Beier, M Hartoonian, N Turner, AP Amtmann, D Ehde, DM AF Hughes, Abbey J. Beier, Meghan Hartoonian, Narineh Turner, Aaron P. Amtmann, Dagmar Ehde, Dawn M. TI Self-Efficacy as a Longitudinal Predictor of Perceived Cognitive Impairment in Individuals With Multiple Sclerosis SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Cognition; Executive function; Longitudinal studies; Multiple sclerosis; Rehabilitation; Self efficacy; Self report ID QUALITY-OF-LIFE; DISABILITY STATUS SCALE; TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; HEALTH-STATUS; DEPRESSION; ADJUSTMENT; MANAGEMENT; DISORDERS; ADHERENCE AB Objectives: To determine whether self-efficacy longitudinally predicts 2 types of perceived cognitive impairment (PCI) in multiple sclerosis (MS): general cognitive functioning and executive functioning; and secondarily to assess whether self-efficacy mediates the relationships between depression, fatigue, and PCI. Design: Longitudinal analysis of self-report survey data collected over 3 years. Hierarchical regression analyses examined the relationship between self-efficacy and PCI, adjusting for depression and fatigue. Additional analyses tested self-efficacy as a mediator between depression, fatigue, and PCI. Setting: Community. Participants: Community-dwelling individuals with MS (N=233; age range, 22-83y) were recruited from a larger longitudinal survey study of individuals with MS (N=562). Interventions: Not applicable. Main Outcome Measures: Primary outcome measures were the Applied Cognition General Concerns and the Applied Cognition Executive Function domains of the Quality of Life in Neurological Disorders (NeuroQoL) measures. Results: Self-efficacy was significantly correlated with PCI at baseline (r=.40.53) and 3 years later (r=.36.44). In multivariate regression analyses, self-efficacy was a significant longitudinal predictor of PCI, both for general cognitive functioning (13=20, P<.01) and executive functioning (13=.16, P<.05). Self-efficacy partially mediated the relationships between depression, fatigue, and PCI. Conclusions: Self-efficacy may influence how individuals with MS perceive their cognitive functioning over time. Interventions that target self-efficacy, particularly early in the disease course, may lead to improvements in PCI, as well as improvements in fatigue and depression. (C) 2015 by the American Congress of Rehabilitation Medicine C1 [Hughes, Abbey J.; Beier, Meghan; Turner, Aaron P.; Amtmann, Dagmar; Ehde, Dawn M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA. [Hughes, Abbey J.; Hartoonian, Narineh; Turner, Aaron P.] Vet Affairs Puget Sound Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. RP Hughes, AJ (reprint author), Univ Washington, Dept Rehabil Med, 325 Ninth Ave,Box 359612, Seattle, WA 98104 USA. EM ajhughes@uw.edu RI Hughes, Abbey/K-8861-2015 OI Hughes, Abbey/0000-0002-7612-6887 FU Department of Education, National Institute on Disability and Rehabilitation Research [H133B031129, H133B080025]; National Institutes of Health (NIH) through the NIH Roadmap for Medical Research [5U01AR052171-03]; National Multiple Sclerosis Society [MB 0026] FX Supported by the Department of Education, National Institute on Disability and Rehabilitation Research (grant nos. H133B031129, H133B080025); the National Institutes of Health (NIH) through the NIH Roadmap for Medical Research (grant no. 5U01AR052171-03); and the National Multiple Sclerosis Society (grant no. MB 0026). The contents of this article do not necessarily represent the policy of the Department of Education and should not assume endorsement by the Federal Government. NR 51 TC 3 Z9 3 U1 4 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAY PY 2015 VL 96 IS 5 BP 913 EP 919 DI 10.1016/j.apmr.2015.01.008 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CH6JL UT WOS:000354142800019 PM 25597915 ER PT J AU Lord, SP Sheng, E Imel, ZE Baer, J Atkins, DC AF Lord, Sarah Peregrine Sheng, Elisa Imel, Zac E. Baer, John Atkins, David C. TI More Than Reflections: Empathy in Motivational Interviewing Includes Language Style Synchrony Between Therapist and Client SO BEHAVIOR THERAPY LA English DT Article DE empathy; motivational interviewing; synchrony; linguistic inquiry word count; motivational interviewing treatment integrity ID SOCIAL-INTERACTION; PSYCHOTHERAPY; METAANALYSIS; COUNSELORS; BEHAVIORS AB Empathy is a basic psychological process that involves the development of synchrony in dyads. It is also a foundational ingredient in specific, evidence-based behavioral treatments like motivational interviewing (MI). Ratings of therapist empathy typically rely on a gestalt, "felt sense" of therapist understanding and the presence of specific verbal behaviors like reflective listening. These ratings do not provide a direct test of psychological processes like behavioral synchrony that are theorized to be an important component of empathy in psychotherapy. To explore a new objective indicator of empathy, we hypothesized that synchrony in language style (i.e., matching how statements are phrased) between client and therapists would predict gestalt ratings of empathy over and above the contribution of reflections. We analyzed 122 MI transcripts with high and low empathy ratings based on the Motivational Interviewing Treatment Integrity global rating scale. Linguistic inquiry and word count was used to estimate language style synchrony (LSS) of adjacent client and therapist talk turns. High-empathy sessions showed greater LSS across 11 language style categories compared with low-empathy sessions (p<.01), and overall, average LSS was notably higher in high-empathy versus low-empathy sessions (d = 0.62). Regression analyses showed that LSS was predictive of empathy ratings over and above reflection counts; a 1 SD increase in LSS is associated with a 2.4 times increase in the odds of a high-empathy rating, controlling for therapist reflections (odds ratio = 2.4; 95% CI: 1.36; 4.24, p<.01). These findings suggest empathy ratings are related to synchrony in language style, over and above synchrony of content as measured by therapist reflections. Novel indicators of therapist empathy may have implications for the study of MI process as well as the training of therapists. C1 [Lord, Sarah Peregrine; Sheng, Elisa; Baer, John; Atkins, David C.] Univ Washington, Seattle, WA 98195 USA. [Imel, Zac E.] Univ Utah, Salt Lake City, UT 84112 USA. [Baer, John] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA. RP Lord, SP (reprint author), Univ Washington, Ctr Study Hlth & Risk Behav, Dept Psychiat & Behav Sci, 1100 Northeast 45th St,Suite 300,Box 354944, Seattle, WA 98195 USA. EM grinlord@uw.edu OI Atkins, David/0000-0002-5781-9880 FU University of Utah; National Institute of Drug Abuse (NIDA) of the National Institutes of Health [R34/DA034860]; National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01/AA018673]; NIDA [R01/DA016360] FX Funding for the preparation of this manuscript was provided by a University of Utah Seed Grant and was also supported by the National Institute of Drug Abuse (NIDA) of the National Institutes of Health under award number R34/DA034860 and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under award number R01/AA018673. The original trial was supported by a grant from NIDA (R01/DA016360). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 47 TC 4 Z9 4 U1 6 U2 16 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAY PY 2015 VL 46 IS 3 BP 296 EP 303 PG 8 WC Psychology, Clinical SC Psychology GA CH6LP UT WOS:000354148400002 PM 25892166 ER PT J AU Wang, TY McElroy, A Halaney, D Vela, D Fung, E Hossain, S Phipps, J Wang, BQ Yin, BW Feldman, MD Milner, TE AF Wang, Tianyi McElroy, Austin Halaney, David Vela, Deborah Fung, Edmund Hossain, Shafat Phipps, Jennifer Wang, Bingqing Yin, Biwei Feldman, Marc D. Milner, Thomas E. TI Dual-modality fiber-based OCT-TPL imaging system for simultaneous microstructural and molecular analysis of atherosclerotic plaques SO BIOMEDICAL OPTICS EXPRESS LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; COMBINED 2-PHOTON MICROSCOPY; CORONARY-ARTERY-DISEASE; IN-VIVO; FLUORESCENCE MICROSCOPY; MULTIPHOTON MICROSCOPY; GOLD NANORODS; INFLAMMATION; MACROPHAGES; CATHETER AB New optical imaging techniques that provide contrast to study both the anatomy and composition of atherosclerotic plaques can be utilized to better understand the formation, progression and clinical complications of human coronary artery disease. We present a dual-modality fiber-based optical imaging system for simultaneous microstructural and molecular analysis of atherosclerotic plaques that combines optical coherence tomography (OCT) and two-photon luminescence (TPL) imaging. Experimental results from ex vivo human coronary arteries show that OCT and TPL optical contrast in recorded OCT-TPL images is complimentary and in agreement with histological analysis. Molecular composition (e. g., lipid and oxidized-LDL) detected by TPL imaging can be overlaid onto plaque microstructure depicted by OCT, providing new opportunities for atherosclerotic plaque identification and characterization. (C) 2015 Optical Society of America C1 [Wang, Tianyi; McElroy, Austin; Fung, Edmund; Hossain, Shafat; Wang, Bingqing; Yin, Biwei; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Halaney, David; Phipps, Jennifer; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Halaney, David; Feldman, Marc D.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Vela, Deborah] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX 77030 USA. RP Wang, TY (reprint author), Univ Texas Austin, Dept Biomed Engn, 1 Univ Stn C0800, Austin, TX 78712 USA. EM Tianyi.Wang@utexas.edu OI Halaney, David/0000-0003-4437-0516 FU ASLMS Research Grant; Veterans Health Administration Merit Grant [I01 BX000397]; American Heart Association [13POST17080074]; Clayton Foundation for Biomedical Research; University of Texas at Austin FX The authors would like to acknowledge the technical support from Chris Hoy, PhD and Jingjing Sun, ME. This work is supported by ASLMS Research Grant to Wang, Veterans Health Administration Merit Grant (I01 BX000397) to Feldman, American Heart Association Grant (13POST17080074) to Phipps, Research Grant from Clayton Foundation for Biomedical Research to Milner and Feldman, and Biomedical Engineering Advancement Fund from the University of Texas at Austin to Milner. NR 63 TC 4 Z9 4 U1 0 U2 8 PU OPTICAL SOC AMER PI WASHINGTON PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA SN 2156-7085 J9 BIOMED OPT EXPRESS JI Biomed. Opt. Express PD MAY 1 PY 2015 VL 6 IS 5 BP 1665 EP 1678 DI 10.1364/BOE.6.001665 PG 14 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA CH3JN UT WOS:000353927100009 PM 26137371 ER PT J AU Wu, WL Adams, CE Stevens, KE Chow, KH Freedman, R Patterson, PH AF Wu, Wei-Li Adams, Catherine E. Stevens, Karen E. Chow, Ke-Huan Freedman, Robert Patterson, Paul H. TI The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Maternal immune activation (MIA); Maternal infection; Poly(I:C); Nicotinic acetylcholine receptor alpha 7 subunit (alpha 7AChR, CHRNA7, Chrna7); Choline supplementation; Interleukin-6 (IL-6); Schizophrenia; Autism ID FETAL-BRAIN-DEVELOPMENT; CHOLINE SUPPLEMENTATION; GENE-EXPRESSION; ADULT PSYCHOPATHOLOGY; C57BL/6 SUBSTRAINS; SENSORY INHIBITION; ANIMAL-MODELS; MOUSE; SCHIZOPHRENIA; AUTISM AB Mutation of human chromosome 15q13.3 increases the risk for autism and schizophrenia. One of the noteworthy genes in 15q13.3 is CHRNA7, which encodes the nicotinic acetylcholine receptor alpha 7 subunit (alpha 7nAChR) associated with schizophrenia in clinical studies,and rodent models. This study investigates the role of alpha 7nAChR in maternal immune activation (MIA) mice model, a murine model of environmental risk factor for autism and schizophrenia. We provided choline, a selective alpha 7nAChR agonist among its several developmental roles, in the diet of C57BL/6N wild-type dams throughout the gestation and lactation period and induced MIA at mid-gestation. The adult offspring behavior and gene expression profile in the maternal-placental-fetal axis at mid-gestation were investigated. We found that choline supplementation prevented several MIA-induced behavioral abnormalities in the wild-type offspring. Pro-inflammatory cytokine interleukin-6 (Il6) and Chrna7 gene expression in the wild-type fetal brain were elevated by poly(I:C) injection and were suppressed by gestational choline supplementation. We further investigated the gene expression level of Il6 in Chrna7 mutant mice. We found that the basal level of Il6 was higher in Chrna7 mutant fetal brain, which suggests that alpha 7nAChR may serve an anti-inflammatory role in the fetal brain during development. Lastly, we induced MIA in Chrna7(+/-) offspring. The Chrna7(+/-) offspring were more vulnerable to MIA, with increased behavioral abnormalities. Our study shows that alpha 7nAChR modulates inflammatory response affecting the fetal brain and demonstrates its effects on offspring behavior development after MIA. (C) 2015 Elsevier Inc. All rights reserved. C1 [Wu, Wei-Li; Chow, Ke-Huan; Patterson, Paul H.] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA. [Adams, Catherine E.] Denver VA Med Ctr, Denver, CO 80220 USA. [Adams, Catherine E.; Stevens, Karen E.; Freedman, Robert] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Wu, WL (reprint author), MC 156-29,1200 E Calif Blvd, Pasadena, CA 91125 USA. EM wlwu@caltech.edu OI Wu, Wei-Li/0000-0003-2610-1881 FU NIH Conte Center Award, United States [NIH 5P50MH086383-04]; Autism Speaks, United States [7670]; National Science Council, Taiwan [NSC 101-2917-I-564-039] FX We acknowledge Laura Rodriguez for administrative assistance; Jan Ko, Elaine Y. Hsiao and Natalia Malkova for technical assistance; Lorena C. Sandoval, Kwan F. Lee and Jaime Rodriguez for caring for the animals. This work was supported by NIH Conte Center Award, United States (to P.H.P.; NIH 5P50MH086383-04), Autism Speaks, United States (to P.H.P; #7670), and postdoctoral fellowship from National Science Council, Taiwan (to W.-L.W.; NSC 101-2917-I-564-039). NR 63 TC 12 Z9 12 U1 5 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAY PY 2015 VL 46 BP 192 EP 202 DI 10.1016/j.bbi.2015.02.005 PG 11 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA CH0ZO UT WOS:000353751100023 PM 25683697 ER PT J AU Tanoue, S Chang, LY Li, YH Kaplan, DE AF Tanoue, Shiroh Chang, Li-Yuan Li, Yonghai Kaplan, David E. TI Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects SO CELLULAR IMMUNOLOGY LA English DT Article DE Dendritic cell; Cirrhosis; Hepatitis C; Monocyte; M1 macrophage; M2 macrophage; Human; Glypican-3 ID HEPATITIS-C VIRUS; HEPATOCELLULAR-CARCINOMA PATIENTS; CONSTITUTIVELY ACTIVE TLR4; CELLULAR IMMUNE-RESPONSES; MESSENGER-RNA; IN-VITRO; ALLOSTIMULATORY CAPACITY; ADOPTIVE IMMUNOTHERAPY; PERIPHERAL-BLOOD; PHASE-I/II AB Few studies have investigated the impact of liver cirrhosis on dendritic cell function. The purpose of this study was to compare the activation and antigen-presentation capacity of monocyte-derived dendritic cells (MoDC) from cirrhotic patients (CIR) relative to healthy donors (HD). MoDC from CIR and HD were matured, phenotyped, irradiated and pulsed with 15mer peptides for two hepatocellular carcinoma-related antigens, alphafetoprotein and glypican-3, then co-cultured with autologous T-cells. Expanded T-cells were evaluated by interferon-gamma ELISPOT and intracellular staining. 15 CIR and 7 HD were studied. While CD14+ monocytes from CIR displayed enhanced M2 polarization, under MoDC-polarizing conditions, we identified no significant difference between HD and CIR in maturation-induced upregulation of co-stimulation markers. Furthermore, no significant differences were observed between CIR and HD in subsequent expansion of tumor antigen-specific IFN gamma+ T-cells. Conclusion: MoDCs isolated from cirrhotic individuals retain similar capacity for in vitro activation, maturation and antigen-presentation as those from healthy donors. Published by Elsevier Inc. C1 Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Res Bldg 21,A402A,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM dakaplan@mail.med.upenn.edu FU NIH [R01 CA166111]; Pennsylvania Commonwealth Universal Research Endowment FX This work was supported by the NIH R01 CA166111 (DEK) and the Pennsylvania Commonwealth Universal Research Endowment. The content of this article does not reflect the views of the VA or of the US Government. NR 52 TC 1 Z9 3 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0008-8749 EI 1090-2163 J9 CELL IMMUNOL JI Cell. Immunol. PD MAY PY 2015 VL 295 IS 1 BP 36 EP 45 DI 10.1016/j.cellimm.2015.02.008 PG 10 WC Cell Biology; Immunology SC Cell Biology; Immunology GA CH5KN UT WOS:000354074600004 PM 25734547 ER PT J AU Xiang, J Wojtczak, HA Wachter, AM Lee, ML Burns, L Chen, D Stephen, J AF Xiang, Joyce Wojtczak, Henry Albert Wachter, Allan Mark Lee, Martin Laurence Burns, Lisa Chen, Diana Stephen, Joseph TI Understanding asthma medical nonadherence in an adult and pediatric population SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Letter ID MANAGEMENT; ADHERENCE C1 [Xiang, Joyce; Stephen, Joseph] VA Greater Los Angeles Med Ctr, Div Allergy Immunol, Los Angeles, CA 90073 USA. [Wojtczak, Henry Albert; Burns, Lisa; Chen, Diana] Naval Med Ctr San Diego, Dept Pediat, Div Pulm Med, San Diego, CA USA. [Wachter, Allan Mark] Fdn Asthma Res & Intervent, Phoenix, AZ USA. [Lee, Martin Laurence] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Stephen, Joseph] Phoenix VA Hlth Care Syst, Sect Allergy Immunol, Phoenix, AZ USA. RP Xiang, J (reprint author), VA Greater Los Angeles Med Ctr, 11301 Wilshire Blvd 111R, Los Angeles, CA 90073 USA. EM joycexianglee@gmail.com NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD MAY-JUN PY 2015 VL 3 IS 3 BP 436 EP 437 DI 10.1016/j.jaip.2014.11.022 PG 2 WC Allergy; Immunology SC Allergy; Immunology GA CH7JS UT WOS:000354212900021 ER PT J AU Roux, BM Cheng, MH Brey, EM AF Roux, Brianna M. Cheng, Ming-Huei Brey, Eric M. TI Engineering clinically relevant volumes of vascularized bone SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE LA English DT Article DE vascularization; bone tissue engineering; clinical applications ID MESENCHYMAL STEM-CELLS; ENDOTHELIAL GROWTH-FACTOR; MARROW STROMAL CELLS; BIOACTIVE GLASS SCAFFOLDS; PLATELET-RICH PLASMA; BIODEGRADABLE POLYMER SCAFFOLDS; TRICALCIUM PHOSPHATE SCAFFOLD; POROUS SPACE MAINTAINERS; SIZED CALVARIAL DEFECTS; IN-VIVO AB Vascularization remains one of the most important challenges that must be overcome for tissue engineering to be consistently implemented for reconstruction of large volume bone defects. An extensive vascular network is needed for transport of nutrients, waste and progenitor cells required for remodelling and repair. A variety of tissue engineering strategies have been investigated in an attempt to vascularize tissues, including those applying cells, soluble factor delivery strategies, novel design and optimization of bio-active materials, vascular assembly pre-implantation and surgical techniques. However, many of these strategies face substantial barriers that must be overcome prior to their ultimate translation into clinical application. In this review recent progress in engineering vascularized bone will be presented with an emphasis on clinical feasibility. C1 [Roux, Brianna M.; Brey, Eric M.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Roux, Brianna M.; Brey, Eric M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res Serv, Hines, IL 60141 USA. [Cheng, Ming-Huei] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Taoyuan, Taiwan. [Cheng, Ming-Huei] Chang Gung Mem Hosp, Ctr Tissue Engn, Taoyuan, Taiwan. RP Brey, EM (reprint author), IIT, Dept Biomed Engn, 3255 South Dearborn St, Chicago, IL 60616 USA. EM brey@iit.edu FU Department of Veterans Affairs; Chang Gung Memorial Hospital [CMRPG3C1061]; National Institute of Health [R01AR061460]; National Science Foundation [CBET-1263994, IIS-1125412] FX The authors on this work are supported, in part, by funding from the Department of Veterans Affairs, Chang Gung Memorial Hospital (CMRPG3C1061), National Institute of Health (grant no: R01AR061460), and the National Science Foundation (CBET-1263994, IIS-1125412). NR 124 TC 11 Z9 11 U1 3 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1582-4934 J9 J CELL MOL MED JI J. Cell. Mol. Med. PD MAY PY 2015 VL 19 IS 5 BP 903 EP 914 DI 10.1111/jcmm.12569 PG 12 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CH4GE UT WOS:000353991100001 PM 25877690 ER PT J AU Phelan, CH Schumacher, S Roiland, R Royer, H Roberts, T AF Phelan, Cynthia H. Schumacher, Sandra Roiland, Rachel Royer, Heather Roberts, Tonya TI Building Capacity for the Conduct of Nursing Research at a Veterans Administration Hospital SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article ID INFRASTRUCTURE; SUPPORT AB Evidence is the bedrock of nursing practice, and nursing research is the key source for this evidence. In this article, we draw distinctions between the use and the conduct of nursing research and provide a perspective for how the conduct of nursing research in a Veterans Administration hospital can build an organization's capacity for nursing research. C1 [Phelan, Cynthia H.; Schumacher, Sandra; Roiland, Rachel; Royer, Heather; Roberts, Tonya] William S Middleton Mem Vet Adm Med Ctr, GRECC Serv, Madison, WI 53705 USA. [Phelan, Cynthia H.; Schumacher, Sandra; Roiland, Rachel; Royer, Heather; Roberts, Tonya] Univ Wisconsin Madison, Sch Nursing, Madison, WI USA. RP Phelan, CH (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC Serv, 2500 Overlook Ter, Madison, WI 53705 USA. EM Cynthia.Phelan@va.gov FU US Department of Veterans Affairs, Clinical Sciences Research & Development Program [IK2 CX000535] FX This material is the result of work supported with resources and use of facilities at the William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin. Dr Phelan's research is supported by Career Development Award IK2 CX000535 from the US Department of Veterans Affairs, Clinical Sciences Research & Development Program. The contents of this article do not represent the views of the Department of Veterans Affairs of the US Government. NR 23 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD MAY PY 2015 VL 45 IS 5 BP 270 EP 275 DI 10.1097/NNA.0000000000000197 PG 6 WC Nursing SC Nursing GA CH9AF UT WOS:000354327700008 PM 25906135 ER PT J AU Kirrane, EF Bowman, C Davis, JA Hoppin, JA Blair, A Chen, HL Patel, MM Sandler, DP Tanner, CM Vinikoor-Imler, L Ward, MH Luben, TJ Kamel, F AF Kirrane, Ellen F. Bowman, Christal Davis, J. Allen Hoppin, Jane A. Blair, Aaron Chen, Honglei Patel, Molini M. Sandler, Dale P. Tanner, Caroline M. Vinikoor-Imler, Lisa Ward, Mary H. Luben, Thomas J. Kamel, Freya TI Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID FINE PARTICULATE MATTER; LONG-TERM EXPOSURE; AIR-POLLUTION; COGNITIVE FUNCTION; CARDIOVASCULAR MORTALITY; OXIDATIVE STRESS; OLDER-ADULTS; US ADULTS; BRAIN; COHORT AB Objective: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa. Methods: We used logistic regression to determine the associations of these pollutants with self-reported, doctor-diagnosed Parkinson's disease. Daily predicted pollutant concentrations were used to derive surrogates of long-term exposure and link them to study participants' geocoded addresses. Results: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa. Conclusions: The plausibility of an effect of ambient concentrations of these pollutants on Parkinson's disease risk is supported by experimental data demonstrating damage to dopaminergic neurons at relevant concentrations. Additional studies are needed to address uncertainties related to confounding and to examine temporal aspects of the associations we observed. C1 [Kirrane, Ellen F.; Bowman, Christal; Davis, J. Allen; Patel, Molini M.; Vinikoor-Imler, Lisa; Luben, Thomas J.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27709 USA. [Hoppin, Jane A.; Chen, Honglei; Sandler, Dale P.; Kamel, Freya] NIEHS, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Blair, Aaron; Ward, Mary H.] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Rockville, MD USA. [Tanner, Caroline M.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Kirrane, EF (reprint author), US EPA, Natl Ctr Environm Assessment, Off Res & Dev, 109 TW Alexander Dr, Res Triangle Pk, NC 27709 USA. EM kirrane.ellen@epa.gov OI Kamel, Freya/0000-0001-5052-6615; Chen, Honglei/0000-0003-3446-7779; Sandler, Dale/0000-0002-6776-0018 FU intramural research program of the National Institutes of Health; National Institute of Environmental Health Sciences [Z01-ES049030]; National Cancer Institute [Z01-CP010119] FX This work was supported in part by the intramural research program of the National Institutes of Health, the National Institute of Environmental Health Sciences (Z01-ES049030), and National Cancer Institute (Z01-CP010119). Data were obtained from Agricultural Health Study data release versions P1REL0906.00 (for phase 1), P2REL0907.00 (phase 2), and P3RREL0901 (phase 3). The views expressed in this article are those of the authors and do not necessarily represent the views or policies of the US Environmental Protection Agency. Dr Caroline Tanner has served as a consultant to Pfizer Pharmaceuticals, a manufacturer of treatments for Parkinson's disease. No other potential conflicts of interest were declared. NR 46 TC 6 Z9 6 U1 4 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAY PY 2015 VL 57 IS 5 BP 509 EP 517 DI 10.1097/JOM.0000000000000451 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH7NY UT WOS:000354225000006 PM 25951420 ER PT J AU Petrik, ML Billera, M Kaplan, Y Matarazzo, B Wortzel, H AF Petrik, Megan L. Billera, Melodi Kaplan, Yuliya Matarazzo, Bridget Wortzel, Hal TI Balancing Patient Care and Confidentiality Considerations in Obtaining Collateral Information SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE ethics; confidentiality; autonomy; collateral information; multi-informant data AB Collateral information facilitates comprehensive mental health care and is consistent with recovery-oriented models of care. But providers are often faced with complex decisions about obtaining collateral information, particularly when patients do not consent to communication with third parties for information gathering. Such situations require a thoughtful balance of best clinical practices, legal and ethical responsibilities, and patient safety concerns. This column offers an overview of the clinical utility of collateral information as well as the ethical and legal regulations concerning confidentiality that guide the process of obtaining collateral information. The risk-benefit analysis process related to obtaining collateral information without patient permission is illustrated. Recommendations about clinical consultation and documentation that facilitate optimal and ethical patient care are offered. C1 [Petrik, Megan L.; Kaplan, Yuliya] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, Denver, CO USA. [Petrik, Megan L.] Univ Colorado, Dept Psychiat, Aurora, CO USA. [Billera, Melodi] Rocky Mt MIRECC, Denver, CO USA. [Billera, Melodi] Univ Denver, Grad Sch Social Work, Denver, CO USA. [Matarazzo, Bridget] Rocky Mt MIRECC, Rocky Mt MIRECC Suicide Consultat Serv, Denver, CO USA. [Matarazzo, Bridget] Univ Colorado, Psychiat, Aurora, CO USA. [Wortzel, Hal] Univ Colorado, Neurocognit Dis, Aurora, CO USA. [Wortzel, Hal] Univ Colorado, Neuropsychiat, Aurora, CO USA. [Wortzel, Hal] Univ Colorado, Psychiat Neurol & Phys Med & Rehabil, Aurora, CO USA. [Wortzel, Hal] Univ Colorado, Forens Psychiat Fellowship, Aurora, CO USA. [Wortzel, Hal] Denver VA, Rocky Mt MIRECC, Neuropsychiat Serv, Denver, CO USA. RP Wortzel, H (reprint author), Univ Colorado Denver VA, 1055 Clermont St, Denver, CO 80217 USA. EM hal.wortzel@ucdenver.edu FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs FX Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. NR 15 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD MAY PY 2015 VL 21 IS 3 BP 220 EP 224 DI 10.1097/PRA.0000000000000072 PG 5 WC Psychiatry SC Psychiatry GA CH8PA UT WOS:000354297100007 PM 25955265 ER PT J AU Maung, AA Johnson, DC Luckianow, GM Kaplan, LJ AF Maung, Adrian Anthony Johnson, Dirk C. Luckianow, Gina M. Kaplan, Lewis J. TI Ventilator gas delivery wave form substantially impacts plateau pressure and peak-to-plateau pressure gradient determination SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article; Proceedings Paper CT 73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery CY SEP 09-13, 2014 CL Philadelphia, PA SP Amer Assoc Surg Trauma DE Mechanical ventilation; gas delivery wave forms; airway pressure; peak pressure; plateau pressure ID RESPIRATORY-DISTRESS-SYNDROME; CRITICAL-CARE MEDICINE; ACUTE LUNG INJURY; AIRWAY PRESSURE; RELEASE VENTILATION; VOLUME; TITRATION; STRAIN AB BACKGROUND: To determine whether plateau pressure (Pplat) measurement is lowered and peak airway pressure (Pawpeak)-to-Plat gradient is increased by measurement on a decelerating compared with square gas delivery wave form. METHODS: Prospective before and after study of mechanically ventilated injured and critically ill patients in an adult surgical intensive care unit. Pplat, Pawpeak, and Pawpeak-to-Pplat gradient were measured on decelerating and square gas delivery wave forms. RESULTS: Pplat and other routine ventilator parameters were measured in 82 (47 trauma, 35 emergency general surgery) consecutive convenience sampled adult intensive care unit patients on decelerating and then square gas delivery wave forms. Peak gas flow was fixed at 40 L/min; all other parameters (rate, tidal volume, positive end-expiratory pressure) were held constant. All patients were managed on assist control volume cycled ventilation using fentanyl and midazolam or propofol; no neuromuscular blockade was used. Patients with Pawpeak more than 35 cm H2O were excluded. Comparing decelerating with square gas delivery, mean Pawpeak was lower (25.1 perpendicular to 2.3 cm H2O vs. 33.1 perpendicular to 2.1 cm H2O; p < 0.0001) and mean Pplat was lower (21.3 perpendicular to 1.9 cm H2O vs. 24.8 + 2.5 cm H2O; p < 0.0001), resulting in a decreased Pawpeak-to-Pplat gradient (3.8 + 2.1 vs. 8.3 + 2.3; p < 0.0001). CONCLUSION: Changing from a decelerating to a square gas delivery wave form significantly increases Pplat and Pawpeak, thereby increasing the Pawpeak-to-Pplat gradient. This increase may prompt unwarranted therapy aimed at reducing the gradient to its normal value of 4 cm H2O pressure or less. Conversely, patients with a high Pawpeak on a square wave form may benefit from transitioning to a decelerating wave form before changing ventilation parameters. (J Trauma Acute Care Surg. 2015; 78: 976-979. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.) C1 [Maung, Adrian Anthony; Johnson, Dirk C.; Luckianow, Gina M.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06510 USA. [Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Div Trauma Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA. [Kaplan, Lewis J.] Philadelphia Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA USA. RP Kaplan, LJ (reprint author), PVAMC Sect, Surg Crit Care, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Lewis.Kaplan@va.gov NR 21 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD MAY PY 2015 VL 78 IS 5 BP 976 EP 979 DI 10.1097/TA.0000000000000615 PG 4 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA CH3KR UT WOS:000353930100012 PM 25909418 ER PT J AU Carnes, M Vogelman, B AF Carnes, Molly Vogelman, Bennett TI Women's Health Fellowships: Examining the Potential Benefits and Harms of Accreditation SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID GENERAL-INTERNAL-MEDICINE; GENDER-DIFFERENCES; PHYSICIAN-RESEARCHERS; GERIATRIC-MEDICINE; NATIONAL-SURVEY; PROGRAMS; EDUCATION; GAP; SPECIALTIES; SEGREGATION AB This commentary responds to the assertions by Foreman et al. that credentialing of women's health (WH) fellows by the American Board of Medical Subspecialties and accreditation of current and future WH fellowships by the Accreditation Council for Graduate Medical Education would improve the health and healthcare of women by increasing the number of primary care providers competent to meet a growing clinical need. They speculate that such accreditation would raise the status of WH fellowships, increase the number of applicants, and result in more academic leaders in WH. They assert that curricular deficiencies in WH exist in physician training and that WH fellowships are the preferred means of training physicians to care for midlife women. We review the evidence to support or refute these claims and conclude that accrediting WH fellowships would not have the forecasted outcomes and would jeopardize the success of current WH fellowships. C1 [Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA. [Carnes, Molly; Vogelman, Bennett] Univ Wisconsin, Dept Med, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA. [Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA. [Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA. EM mlcarnes@wisc.edu NR 53 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAY 1 PY 2015 VL 24 IS 5 BP 341 EP 348 DI 10.1089/jwh.2015.5289 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA CI0ZF UT WOS:000354468500004 PM 25919589 ER PT J AU Caverly, TJ Prochazka, AV Combs, BP Lucas, BP Mueller, SR Kutner, JS Binswanger, I Fagerlin, A McCormick, J Pfister, S Matlock, DD AF Caverly, Tanner J. Prochazka, Allan V. Combs, Brandon P. Lucas, Brian P. Mueller, Shane R. Kutner, Jean S. Binswanger, Ingrid Fagerlin, Angela McCormick, Jacqueline Pfister, Shirley Matlock, Daniel D. TI Doctors and Numbers: An Assessment of the Critical Risk Interpretation Test SO MEDICAL DECISION MAKING LA English DT Article DE medical decision making; risk perception; risk communication; numeracy ID MEDICAL DECISION-MAKING; NUMERACY SCALE; COMMUNICATION; COMPREHENSION; INFORMATION; STATISTICS; BENEFIT; SKILLS; CARE AB Background. Risk interpretation affects decision making. Yet, there is no valid assessment of how clinicians interpret the risk data that they commonly encounter. Objective. To establish the reliability and validity of a 20-item test of clinicians' risk interpretation. Methods. The Critical Risk Interpretation Test (CRIT) measures clinicians' abilities to 1) modify the interpretation based on meaningful differences in the outcome (e.g., disease specific v. all-cause mortality) and time period (e.g., lifetime v. 10-year mortality), 2) maintain a stable interpretation for different risk framings (e.g., relative v. absolute risk), and 3) correctly interpret how diagnostic testing modifies risk. There were 658 clinicians and medical trainees who participated: 116 nurse practitioners (NPs) at a national conference, 273 medical students at 1 institution, 148 residents in internal medicine at 2 institutions, and 121 internists at 1 institution. Participants completed a self-administered paper test during educational conferences. Seventeen evidence-based medicine experts took the test online and formally assessed content validity. Eighteen second-year medical students were recruited to take the test and a retest 3 weeks later to explore test-retest correlation. Results. Expert review supported test clarity and content validity. Factor analysis supported that the CRIT identifies at least 3 separable areas of clinician knowledge. Test-retest correlation was fair (intraclass correlation coefficient = 0.65; standard error = 0.15). Scores on our test correlated with other tests of related abilities. Mean test scores varied among groups, with differences in prior evidence-based medicine training and experience (93 for NPs, 101 for medical students, 101 for residents, 103 for academic internists, and 110 for physician experts; P < 0.001). Conclusions. Our results provide supporting evidence for the reliability and validity of the CRIT as an index of critical risk interpretation abilities, which is acceptable and feasible to administer in an educational setting. C1 [Caverly, Tanner J.; Fagerlin, Angela] Univ Michigan Med Sch, Ann Arbor Vet Affairs Hlth Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA. [Prochazka, Allan V.; Combs, Brandon P.; Mueller, Shane R.; Kutner, Jean S.; Binswanger, Ingrid; Matlock, Daniel D.] Univ Colorado Sch Med, Internal Med, Aurora, CO USA. [Prochazka, Allan V.; McCormick, Jacqueline; Pfister, Shirley] Denver Vet Affairs Med Ctr, Ambulatory Care, Denver, CO USA. [Lucas, Brian P.] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA. RP Caverly, TJ (reprint author), Univ Michigan Sch Med, 2800 Plymouth Rd,Bldg 16,Room 326W, Ann Arbor, MI 48109 USA. EM tcaverly@med.umich.edu OI Binswanger, Ingrid/0000-0001-8862-8078 FU Society of General Internal Medicine [T32HP1006]; Society of General Internal Medicine FX Received 5 March 2014 from the Veterans Affairs Center for Clinical Management Research, Ann Arbor Veterans Affairs Health System, University of Michigan Medical School, Ann Arbor, MI (TJC, AF); Internal Medicine, University of Colorado School of Medicine, Aurora, CO (AVP, BPC, SRM, JSK, IB, DDM); Ambulatory Care, Denver Veterans Affairs Medical Center, Denver, CO (AVP, JM, SP); and Department of Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL (BPL). Dr. Caverly was supported by an institutional T32HP1006 grant and the 2012 Founder's Award from the Society of General Internal Medicine. Financial support for this study was provided entirely or in part by a grant (Founder's Award) from the Society of General Internal Medicine. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. This research was previously presented in oral and abstract form at the 2013 annual meeting for the Society of General Internal Medicine, May 2013. There are no conflicts of interest. Revision accepted for publication 26 September 2014. NR 38 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD MAY PY 2015 VL 35 IS 4 BP 512 EP 524 DI 10.1177/0272989X14558423 PG 13 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA CH6FJ UT WOS:000354131500011 PM 25378297 ER PT J AU Brown, K Poppe, A Kaminetzky, C Wipf, J Woods, NF AF Brown, Kameka Poppe, Anne Kaminetzky, Catherine Wipf, Joyce Woods, Nancy Fugate TI Recommendations for Nurse Practitioner Residency Programs SO NURSE EDUCATOR LA English DT Article DE graduate nursing education; nurse practitioner program; nursing practitioner residency; residencies AB The purpose of this study was to identify and prioritize critical aspects needed in the design and execution of new nurse practitioner (NP) residency programs. Subjects answered a series of questions on formulating residency programs and on key outcomes and cost measures related to their sustainability. These results serve as potential guideposts for future work in NP residency standardization and sustainability development. C1 [Brown, Kameka; Poppe, Anne; Wipf, Joyce] Ctr Excellence Primary Care Educ, Seattle, WA USA. [Kaminetzky, Catherine] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Brown, Kameka; Poppe, Anne; Woods, Nancy Fugate] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Kaminetzky, Catherine; Wipf, Joyce] Univ Washington, Sch Med, Seattle, WA USA. RP Brown, K (reprint author), 1660 S Columbian Way,S 123 COE, Seattle, WA 98108 USA. EM kameka.brown2@va.gov FU Veteran Affairs Office of Academic Affiliations FX This study was funded by a grant from Veteran Affairs Office of Academic Affiliations. NR 16 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-3624 EI 1538-9855 J9 NURS EDUC JI Nurs. Educ. PD MAY-JUN PY 2015 VL 40 IS 3 BP 148 EP 151 DI 10.1097/NNE.0000000000000117 PG 4 WC Nursing SC Nursing GA CH5ZU UT WOS:000354115700013 PM 25501654 ER PT J AU Palma, E Deatrick, JA Hobbie, WL Ogle, SK Kobayashi, K Maldonado, L AF Palma, Erica Deatrick, Janet A. Hobbie, Wendy L. Ogle, Sue K. Kobayashi, Kyoko Maldonado, Linda TI Maternal Caregiving Demands for Adolescent and Young Adult Survivors of Pediatric Brain Tumors SO ONCOLOGY NURSING FORUM LA English DT Article DE caregiver tasks; pediatric brain tumors; caregiving demands; caregiving burden; parents; qualitative research ID QUALITY-OF-LIFE; HEALTH-RELATED QUALITY; CHILDHOOD-CANCER; CEREBRAL-PALSY; FAMILY CAREGIVERS; CHILDREN; PARENTS; BURDEN; IMPACT; MOTHERS AB Purpose/Objectives: To examine the daily maternal caregiving demands for adolescent and young adult survivors of pediatric brain tumors who live with their families. Design: A secondary analysis was conducted on interview data gathered during a large mixed-methods study that focused on perceived maternal caregiver competency and survivor health-related quality of life. Setting: Home interviews. Sample: A purposive sample of 46 maternal caregivers was selected from participants in the larger study. Methods: Semistructured interviews were conducted with mothers. A directed content analysis was informed by Sullivan-Bolyai's framework describing the components of primary caregiving. Main Research Variables: Caregiving demands. Findings: Data regarding four main categories of maternal daily caregiving demands were identified from 25 of the 46 interviews: managing the illness; identifying, accessing, and coordinating resources; assisting with everyday responsibilities; and fostering psychosocial health. Conclusions: Potential day-to-day management tasks or demands of mothers of adolescent and young adult survivors of pediatric brain tumors were identified. Implications for Nursing: The major demands of caregiving are similar to those for children with other chronic conditions, with the addition of assisting with everyday responsibilities and fostering psychosocial health. C1 [Palma, Erica; Hobbie, Wendy L.; Maldonado, Linda] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Palma, Erica] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Hobbie, Wendy L.] Childrens Hosp Philadelphia, Canc Survivorship Program, Philadelphia, PA USA. [Ogle, Sue K.] Childrens Hosp Philadelphia, Med & Med Subspecialty Nursing, Philadelphia, PA USA. [Ogle, Sue K.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Kobayashi, Kyoko] St Lukes Int Univ, Sch Nursing, Dept Child & Family Nursing, Tokyo, Japan. [Maldonado, Linda] Univ Penn, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Maldonado, Linda] Univ Penn, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Palma, E (reprint author), Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. EM deatrick@nursing.upenn.edu FU National Institutes of Nursing Research [R01 NR009651, 3-T32-NR007100]; National Institutes of Health; ONS Foundation through American Brain Tumor Association FX Erica Palma, BSN, RN, OCN (R), is a graduate student in the School of Nursing at the University of Pennsylvania in Philadelphia and a clinical nurse at Memorial Sloan-Kettering Cancer Center in New York, NY; Janet A. Deatrick, PhD, RN, FAAN, is a professor, a Shearer Endowed Term Chair in Healthy Community Practices, and a director of the Center for Health Equity Research, all in the School of Nursing at the University of Pennsylvania; Wendy L. Hobbie, MSN, CRNP, FAAN, is the associate director for the Cancer Survivorship Program at the Children's Hospital of Philadelphia and the director of the Pediatric Oncology Nurse Practitioner Concentration in the School of Nursing at the University of Pennsylvania; Sue K. Ogle, MSN, CRNP, is an advanced practice nurse manager for Medical and Medical Subspecialty Nursing and a cancer survivorship nurse practitioner at the Children's Hospital of Philadelphia; Kyoko Kobayashi, PhD, RN, PHN, is an associate professor in the Department of Child and Family Nursing at St. Luke's International University School of Nursing in Tokyo, Japan; and Linda Maldonado, PhD, RN, is a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow in the School of Nursing and the Centers for Global Women's Health and Health Equity Research, both at the University of Pennsylvania. This study was supported, in part, by grants (R01 NR009651 and 3-T32-NR007100) from the National Institutes of Nursing Research and National Institutes of Health, and funding from the ONS Foundation through a grant from the American Brain Tumor Association. Deatrick can be reached at deatrick@nursing.upenn.edu, with copy to editor at ONFEditor@ons.org. (Submitted August 2014. Accepted for publication November 13, 2014.) NR 42 TC 2 Z9 2 U1 2 U2 12 PU ONCOLOGY NURSING SOC PI PITTSBURGH PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA SN 0190-535X EI 1538-0688 J9 ONCOL NURS FORUM JI Oncol. Nurs. Forum PD MAY PY 2015 VL 42 IS 3 BP 222 EP 229 DI 10.1188/15.ONF.222-229 PG 8 WC Oncology; Nursing SC Oncology; Nursing GA CH7QZ UT WOS:000354233000005 PM 25901374 ER PT J AU Peng, KA Kuan, EC Unger, L Lorentz, WC Wang, MB Long, JL AF Peng, Kevin A. Kuan, Edward C. Unger, Lindsey Lorentz, William C. Wang, Marilene B. Long, Jennifer L. TI A Swallow Preservation Protocol Improves Function for Veterans Receiving Chemoradiation for Head and Neck Cancer SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE dysphagia; head and neck cancer; chemoradiation; swallow preservation ID QUALITY-OF-LIFE; LOCALLY ADVANCED HEAD; LONG-TERM DYSPHAGIA; OROPHARYNGEAL DYSPHAGIA; DEFINITIVE RADIOTHERAPY; ASPIRATION; CHEMORADIOTHERAPY; REHABILITATION; THERAPY; IMPACT AB Objective Determine the efficacy of a swallow preservation protocol (SPP) on maintaining swallow function in patients undergoing chemoradiation (CRT) or radiation therapy alone (RT) for head and neck squamous cell carcinoma (HNSCC). Study design Retrospective case series. Setting Veterans Affairs medical center. Subjects and Methods Patients treated with CRT or RT for HNSCC between February 2006 and November 2013 were studied. Those enrolled in the SPP participated in swallowing, jaw, and tongue exercises during cancer therapy. The comparator group received no swallowing intervention during CRT. A previously described functional outcome swallowing scale (FOSS; 0 = no symptoms and 5 = nonoral feeding for all nutrition) was used to quantify dysphagia prior to and at the completion of cancer therapy, and an analysis was performed to compare swallowing function. Results Forty-one (all male; mean age, 66 years) and 66 patients (all male; mean age, 61 years) were included in the SPP and comparator groups, respectively. In the SPP group, mean pre- and posttreatment FOSS scores were 2.2 and 2.2, respectively, while the corresponding scores in the comparator group were 1.8 and 2.7, respectively, with posttreatment FOSS scores being significantly worse than pretreatment FOSS scores in the comparator group only. Conclusion Patients enrolled in the SPP demonstrated preserved swallowing function over the course of cancer treatment compared with a comparator group. This confirms the importance of early evaluation and intervention for dysphagia prior to and during CRT or RT alone. C1 [Peng, Kevin A.; Kuan, Edward C.; Wang, Marilene B.; Long, Jennifer L.] Univ Calif Los Angeles, Dept Head & Neck Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Unger, Lindsey] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Audiol & Speech Pathol, Los Angeles, CA USA. [Lorentz, William C.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA. [Wang, Marilene B.; Long, Jennifer L.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Long, Jennifer L.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. RP Peng, KA (reprint author), Univ Calif Los Angeles, Head & Neck Surg, 10833 Le Conte Ave,CHS 62-132, Los Angeles, CA 90095 USA. EM kap@ucla.edu OI Long, Jennifer/0000-0002-4185-2328; Kuan, Edward/0000-0003-3475-0718 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, Career Development Award [IK2BX001944] FX Funding source: This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, Career Development Award IK2BX001944 (Dr Jennifer L. Long). This work was supported with resources and facilities at the Greater Los Angeles VA Healthcare System. NR 25 TC 4 Z9 4 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD MAY PY 2015 VL 152 IS 5 BP 863 EP 867 DI 10.1177/0194599815575508 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA CH8BR UT WOS:000354261400017 PM 25829388 ER PT J AU Wang, EA McGinms, KA Goulet, J Bryant, K Gibert, C Leaf, DA Mattocks, K Fiellin, LE Vogenthaler, N Justice, AC Fiellin, DA AF Wang, Emily A. McGinms, Kathleen A. Goulet, Joseph Bryant, Kendall Gibert, Cynthia Leaf, David A. Mattocks, Kristin Fiellin, Lynn E. Vogenthaler, Nicholas Justice, Amy C. Fiellin, David A. CA Vet Aging Cohort Study Project Tea TI Food Insecurity and Health: Data from the Veterans Aging Cohort Study SO PUBLIC HEALTH REPORTS LA English DT Article ID HIV-INFECTED INDIVIDUALS; MENTAL-HEALTH; HOUSING INSTABILITY; WELFARE RECIPIENTS; INSUFFICIENCY; CARE; MORTALITY; ADULTS; CHILDREN; DISEASE AB Objective. Food insecurity may be a modifiable and independent risk factor for worse control of medical conditions, but it has not been explored among veterans. We determined the prevalence of, and factors independently associated with, food insecurity among veterans in the Veterans Aging Cohort Study (VACS). Methods. Using data from VACS from 2002-2008, we determined the prevalence of food insecurity among veterans who have accessed health care in the Veterans Health Administration (VA) as defined by "concern about having enough food for you or your family in the past month." We used multivariable logistic regression to determine factors independently associated with food insecurity and tests of trend to measure the association between food insecurity and control of hypertension, diabetes, HIV, and depression. Results. Of the 6,709 veterans enrolled in VACS, 1,624 (24%) reported being food insecure. Food insecurity was independently associated with being African American, earning <$25,000/year, recent homelessness, marijuana use, and depression. Being food insecure was also associated with worse control of hypertension, diabetes, HIV and depression (p<0.001). Conclusion. Food insecurity is prevalent and associated with worse control of medical conditions among veterans who have accessed care in the VA. C1 [Wang, Emily A.; Goulet, Joseph; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [McGinms, Kathleen A.; Goulet, Joseph; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Bryant, Kendall] NIAAA, NIH, Rockville, MD 20852 USA. [Gibert, Cynthia] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Mattocks, Kristin] VA Cent Western Massachusetts, Northampton, MA USA. [Mattocks, Kristin] Univ Massachusetts, Sch Med, Worcester, MA USA. [Vogenthaler, Nicholas] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06510 USA. RP Wang, EA (reprint author), Yale Univ, Sch Med, Gen Internal Med, Harkness Hall Bldg A,367 Cedar St,Ste 410A, New Haven, CT 06510 USA. EM emily.wang@yale.edu OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU National Institute on Alcohol Abuse and Alcoholism [U01-AA-13566, U10-AA-13566]; National Institute on Aging (NIA) [K23-AG00826]; Robert Wood Johnson Generalist Faculty Scholar Award; NIA, National Institute of Mental Health; Veterans Health Administration Health Services Research & Development Research Enhancement Award Program (REAP) PRIME Project [REA-08-266]; National Heart, Lung, and Blood Institute [K23-HL103720]; Yale Clinical Center of Investigation's Clinical & Translations Science Awards Grant [UL1 RR024139] FX The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The Veterans Aging Cohort Study (VACS) is funded by the National Institute on Alcohol Abuse and Alcoholism (#U01-AA-13566 and #U10-AA-13566); the National Institute on Aging (NIA) (#K23-AG00826); and the Robert Wood Johnson Generalist Faculty Scholar Award, an interagency agreement among the NIA, National Institute of Mental Health, and Veterans Health Administration Health Services Research & Development Research Enhancement Award Program (REAP) PRIME Project (#REA-08-266). Emily Wang receives salary support from a career development award from the National Heart, Lung, and Blood Institute (#K23-HL103720) and the Yale Clinical Center of Investigation's Clinical & Translations Science Awards Grant (#UL1 RR024139). The Institutional Review Boards at the Veterans Health Administrations in Atlanta, Georgia; Baltimore, Maryland; Bronx, New York; Manhattan/Brooklyn, New York; Houston, Texas; Los Angeles, California; Pittsburgh, Pennsylvania; and Washington, D.C., approved the study, and all participants provided written informed consent prior to enrollment. NR 33 TC 7 Z9 7 U1 2 U2 11 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAY-JUN PY 2015 VL 130 IS 3 BP 261 EP 268 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH5JJ UT WOS:000354071600013 PM 25931630 ER PT J AU Bao, YR Johansen, KL AF Bao, Yeran Johansen, Kirsten L. TI Diagnosis and Treatment of Low Testosterone among Patients with End-Stage Renal Disease SO SEMINARS IN DIALYSIS LA English DT Review ID TANDEM MASS-SPECTROMETRY; PLACEBO-CONTROLLED TRIALS; LATE-ONSET HYPOGONADISM; LOW SERUM TESTOSTERONE; BONE-MINERAL DENSITY; OLDER MEN; TRANSDERMAL TESTOSTERONE; MOBILITY LIMITATION; REFERENCE RANGES; MAINTENANCE HEMODIALYSIS AB The prevalence of low testosterone level is particularly high among patients with end-stage renal disease (ESRD) and has been associated with mortality. In populations without ESRD, low testosterone level has also been associated with a number of morbidities including cardiovascular disease, diabetes mellitus, low muscle mass, low bone mass, low physical performance, and frailty. However, there is controversy regarding what constitutes low testosterone level in the aging population and at what level replacement therapy with testosterone is indicated. There are no randomized controlled trials investigating long-term outcomes of testosterone replacement therapy in populations with or without ESRD. Available trial results suggest equivocal improvements in sexual function. Muscle mass and bone mineral density appear to improve, but results in physical function and performance are mixed and there are no data on fracture prevention. Some recent data suggest harm when testosterone was given to men with limited mobility. Finally, there is little evidence that testosterone adds to existing erythropoietin agents in the treatment of anemia in ESRD. Due to lack of evidence supporting long-term use of testosterone, the authors recommend against the routine use of testosterone in ESRD patients with low testosterone levels. Testosterone treatment can be considered in those with low bone mass and total testosterone level <200ng/dl, or in younger patients with sexual complaints with total testosterone level lower than the reference range. It is important to engage patients in discussion of risks and benefits before initiating testosterone therapy; testosterone therapy should be discontinued if the intended treatment effect is not observed after short-term use. C1 [Bao, Yeran] John Muir Med Grp, Walnut Creek, CA USA. [Johansen, Kirsten L.] San Francisco Gen Hosp, Div Nephrol, San Francisco, CA 94110 USA. [Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [K24 DK085153] NR 47 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD MAY-JUN PY 2015 VL 28 IS 3 BP 259 EP 265 DI 10.1111/sdi.12318 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA CH4BO UT WOS:000353976200012 PM 25376701 ER PT J AU Pelton, D Wangelin, B Tuerk, P AF Pelton, Dan Wangelin, Bethany Tuerk, Peter TI Utilizing Telehealth to Support Treatment of Acute Stress Disorder in a Theater of War: Prolonged Exposure via Clinical Videoconferencing SO TELEMEDICINE AND E-HEALTH LA English DT Article DE behavioral health; telepsychiatry; disaster medicine; military medicine ID THERAPY; TELEPSYCHIATRY; PSYCHOTHERAPY; SYMPTOMS; VETERANS; AFGHANISTAN; DEPRESSION; OUTCOMES; INJURY; TRIAL AB Background: Posttraumatic stress disorder (PTSD) and acute stress disorder are prevalent mental health diagnoses associated with the military operations in Iraq and Afghanistan and are especially significant in service members returning from combat. Prolonged exposure (PE) therapy is a highly effective behavioral treatment for these symptoms, and providing this treatment as soon as possible, even in the midst of a soldier's combat deployment, has strong potential benefits. Materials and Methods: In the current case study, telehealth technology was used to support the delivery of PE therapy to treat a service member diagnosed with acute stress disorder in a war zone. PE was conducted face-to-face on the relatively secure Forward Operating Base for the first half of therapy and via clinical videoconferencing (CV) to the service member's remote combat outpost during the later stages of therapy. The service member exhibited marked improvements in symptoms over 10 sessions. Results: Results are consistent with previous empirical findings and highlight the potential benefits of using telehealth to deliver evidenced-based treatment for traumatic stress disorders in a war zone. This case study provides a preliminary working model for delivering PE in a combat environment using multiple delivery systems. Conclusions: Benefits and clinical utility of CV-delivered exposure therapy are discussed, particularly for providers pending future operational deployments (e.g., including members of the military, independent government agencies, and first responders) and for those treating patients in remote locations. C1 [Pelton, Dan] Anxiety Solut LLC, Mclean, VA 22101 USA. [Wangelin, Bethany; Tuerk, Peter] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC USA. [Wangelin, Bethany; Tuerk, Peter] Med Univ S Carolina, Dept Psychiat & Behav Sci, Mil Sci Div, Charleston, SC 29425 USA. RP Pelton, D (reprint author), Anxiety Solut LLC, 1499 Chain Bridge Rd,Suite 201, Mclean, VA 22101 USA. EM dpelton@anxiety-solutions.com NR 39 TC 1 Z9 1 U1 3 U2 11 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD MAY 1 PY 2015 VL 21 IS 5 BP 382 EP 387 DI 10.1089/tmj.2014.0111 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA CH5UA UT WOS:000354099600006 PM 25764266 ER PT J AU Ramanathan, S Hill, JN Cameron, KA Safdar, N Guihan, M Evans, CT AF Ramanathan, Swetha Hill, Jennifer N. Cameron, Kenzie A. Safdar, Nasia Guihan, Marylou Evans, Charlesnika T. TI Relationship between knowledge and attitudes of methicillin-resistant Staphylococcus aureus and hand hygiene behavior in Veterans with spinal cord injury and disorder SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Methicillin-resistant Staphylococcus aureus; Veterans; Spinal cord injury; Knowledge; Attitudes; Hand hygiene behavior ID PERCEPTIONS; PATIENT AB The objective of this analysis was to understand the relationship between knowledge and attitudes regarding methicillin-resistant Staphylococcus aureus and hand hygiene behavior based on a baseline survey administered to Veterans with spinal cord injuries and disorders. Higher knowledge was associated with higher attitude scores (r = 0.35, P = .003), but knowledge and attitudes were not associated with behavior. Also, those with quadriplegia had higher knowledge scores (P = .03). Knowledge and attitudes, although related, do not appear to fully explain patients' hand hygiene behavior. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Ramanathan, Swetha; Hill, Jennifer N.; Guihan, Marylou; Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare, Dept Vet Affairs, Hines, IL 60141 USA. [Ramanathan, Swetha; Hill, Jennifer N.; Guihan, Marylou; Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA. [Cameron, Kenzie A.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Chicago, IL 60611 USA. [Cameron, Kenzie A.; Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Cameron, Kenzie A.; Evans, Charlesnika T.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Safdar, Nasia] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Univ Wisconsin Hosp & Clin, Dept Populat Hlth Sci, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Ramanathan, S (reprint author), Edward Hines Jr VA Hosp, 5th & Roosevelt Rd 151H,Room C306, Hines, IL 60141 USA. EM Swetha.Ramanathan@va.gov OI Cameron, Kenzie/0000-0002-3535-6459 FU Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Services, Quality Enhancement Research Initiative [RRP 09-125] FX This study was supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Services, Quality Enhancement Research Initiative (RRP 09-125). NR 10 TC 2 Z9 2 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAY 1 PY 2015 VL 43 IS 5 BP 537 EP 539 DI 10.1016/j.ajic.2015.01.030 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CH2XZ UT WOS:000353890100024 PM 25952051 ER PT J AU Paulson, D Horner, MD Bachman, D AF Paulson, Daniel Horner, Michael David Bachman, David TI A Comparison of Four Embedded Validity Indices for the RBANS in a Memory Disorders Clinic SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Assessment; Response validity; Effort testing; Aging; Malingering; Index validation; Cognitive evaluation ID TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL STATUS RBANS; POSTTRAUMATIC-STRESS-DISORDER; REPEATABLE BATTERY; COGNITIVELY INTACT; GERIATRIC SAMPLE; TEST-PERFORMANCE; NORMATIVE DATA; OLDER-ADULTS AB This examination of four embedded validity indices for the Repeated Battery for the Assessment of Neuropsychological Status (RBANS) explores the potential utility of integrating cognitive and self-reported depressive measures. Examined indices include the proposed RBANS Performance Validity Index (RBANS PVI) and the Charleston Revised Index of Effort for the RBANS (CRIER). The CRIER represented the novel integration of cognitive test performance and depression self-report information. The sample included 234 patients without dementia who could be identified as having demonstrated either valid or invalid responding, based on standardized criteria. Sensitivity and specificity for invalid responding varied widely, with the CRIER emerging as the best all-around index (sensitivity = 0.84, specificity = 0.90, AUC = 0.94). Findings support the use of embedded response validity indices, and suggest that the integration of cognitive and self-report depression data may optimize detection of invalid responding among older Veterans. C1 [Paulson, Daniel] Univ Cent Florida, Dept Psychol, Orlando, FL 32816 USA. [Paulson, Daniel; Horner, Michael David; Bachman, David] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Horner, Michael David; Bachman, David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Bachman, David] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Paulson, D (reprint author), Univ Cent Florida, Dept Psychol, Orlando, FL 32816 USA. EM daniel.paulson2@ucf.edu NR 40 TC 1 Z9 1 U1 2 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAY PY 2015 VL 30 IS 3 BP 207 EP 216 DI 10.1093/arclin/acv009 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA CH1ZO UT WOS:000353822600005 PM 25783523 ER PT J AU Fling, BW Nutt, JG Horak, FB AF Fling, Brett W. Nutt, John G. Horak, Fay B. TI Reply: Does dominant pedunculopontine nucleus exist? Probably not SO BRAIN LA English DT Letter ID MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; HEMIPARKINSONS-DISEASE; GAIT; DISTURBANCES; INHIBITION C1 [Fling, Brett W.; Nutt, John G.; Horak, Fay B.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA. [Fling, Brett W.; Horak, Fay B.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Fling, BW (reprint author), Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM fling@ohsu.edu FU NIA NIH HHS [R01 AG006457]; RRD VA [I01 RX001075] NR 22 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 EI 1460-2156 J9 BRAIN JI Brain PD MAY 1 PY 2015 VL 138 BP E347 EP U7 DI 10.1093/brain/awu317 PN 5 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CH2DB UT WOS:000353834100002 PM 25367026 ER PT J AU Klaassen, Z Singh, AA Howard, LE Feng, ZY Trock, B Terris, MK Aronson, WJ Cooperberg, MR Amling, CL Kane, CJ Partin, A Han, M Freedland, SJ AF Klaassen, Zachary Singh, Abhay A. Howard, Lauren E. Feng, Zhaoyong Trock, Bruce Terris, Martha K. Aronson, William J. Cooperberg, Matthew R. Amling, Christopher L. Kane, Christopher J. Partin, Alan Han, Misop Freedland, Stephen J. TI Is Clinical Stage T2c Prostate Cancer an Intermediate- or High-Risk Disease? SO CANCER LA English DT Article DE biochemical recurrence; clinical staging; D'Amico risk stratification; Gleason score; prostate cancer; prostate-specific antigen; radical prostatectomy ID ANDROGEN DEPRIVATION THERAPY; BEAM RADIATION-THERAPY; GROUP PROTOCOL 92-02; PHASE-III TRIAL; RADICAL PROSTATECTOMY; PREOPERATIVE NOMOGRAM; RANDOMIZED-TRIAL; RECURRENCE; VALIDATION; PROBABILITY AB BACKGROUNDClinical stage T2c (cT2c) is an indeterminate factor in prostate cancer (PC) risk stratification. According to the D'Amico grouping and American Urological Association guidelines, cT2c is a high risk, whereas the National Comprehensive Cancer Network and the European Urological Association classify cT2c as an intermediate risk. This study assessed whether cT2c tumors without other high-risk factors (clinical stage T2c, not otherwise specified [cT2c-NOS]) behaved as an intermediate or high risk through an analysis of biochemical recurrence (BCR) after radical prostatectomy. METHODSTwo thousand seven hundred fifty-nine men from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database and 12,900 men from Johns Hopkins Hospital (JHH) from 1988-2011 and 1982-2012, respectively, were analyzed. Patients were grouped into low-risk (prostate-specific antigen [PSA] < 10 ng/mL, Gleason sum 6, and cT1-T2a), intermediate-risk (PSA = 10-20 ng/mL, Gleason sum = 7, or cT2b), and high-risk PC categories (PSA > 20 ng/mL, Gleason sum = 8-10, or cT3). Men with cT2c tumors who were not otherwise at high risk (ie, PSA< 20 ng/mL and Gleason sum < 8) were placed into a separate category termed cT2c-NOS. Associations between cT2c-NOS and intermediate- and high-risk patients and BCR were tested with the log-rank test and Cox proportional analysis models. RESULTSNinety-nine men (4%) from SEARCH and 202 men (2%) from JHH had tumors classified as cT2c-NOS. The cT2c-NOS patients had a BCR risk similar to that of the intermediate-risk patients (SEARCH, P = .27; JHH, P = .23) but a significantly lower BCR risk in comparison with the high-risk patients (SEARCH, P < .001; JHH, P < .001). When they were specifically compared with intermediate- and high-risk patients, after adjustments for year and center, cT2c-NOS patients had outcomes comparable to those of intermediate-risk patients (SEARCH, P = .53; JHH, P = .54) but significantly better than those of high-risk patients (SEARCH, P = .003; JHH, P < .001). CONCLUSIONSPatients with cT2c disease without other high-risk features had outcomes similar to the outcomes of patients with intermediate-risk PC and significantly better than the outcomes of patients with high-risk PC. These findings suggest that men with cT2c disease should be considered to be at intermediate risk. Cancer 2015;121:1414-1421. (c) 2014 American Cancer Society. The risk of biochemical recurrence for patients with clinical stage T2c disease without other high-risk features is comparable to the risk for men with intermediate-risk prostate cancer and significantly better than the risk for men with high-risk prostate cancer. Men with clinical stage T2c prostate cancer should be offered treatment options for intermediate-risk disease. C1 [Klaassen, Zachary; Terris, Martha K.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Singh, Abhay A.; Howard, Lauren E.; Freedland, Stephen J.] Duke Univ, Med Ctr, Durham, NC 27710 USA. [Howard, Lauren E.; Freedland, Stephen J.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Feng, Zhaoyong; Trock, Bruce; Partin, Alan; Han, Misop] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Terris, Martha K.] Augusta Vet Affairs Med Ctr, Augusta, GA USA. [Aronson, William J.] West Los Angeles Vet Affairs Med Ctr, West Los Angeles, CA USA. [Aronson, William J.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Cooperberg, Matthew R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cooperberg, Matthew R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Amling, Christopher L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kane, Christopher J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Kane, Christopher J.] San Diego Vet Affairs Med Ctr, San Diego, CA USA. RP Freedland, SJ (reprint author), Duke Univ, Med Ctr, Dept Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU Department of Veterans Affairs; Georgia Cancer Coalition; National Institutes of Health [R01CA100938, K24CA160653]; Specialized Programs of Research Excellence (National Institutes of Health) [P50 CA92131-01A1] FX Research support was received from the Department of Veterans Affairs. Martha K. Terris reports a grant from the Georgia Cancer Coalition. William J. Aronson reports grant R01CA100938 from the National Institutes of Health and grant P50 CA92131-01A1 from the Specialized Programs of Research Excellence (National Institutes of Health). Stephen J. Freedland reports grant K24CA160653 from the National Institutes of Health. NR 30 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 1 PY 2015 VL 121 IS 9 BP 1414 EP 1421 DI 10.1002/cncr.29147 PG 8 WC Oncology SC Oncology GA CG5TE UT WOS:000353357000011 PM 25492369 ER PT J AU Heller, MT Shah, AB Bhargava, P Srivastava, U Sun, XM AF Heller, Matthew T. Shah, Amar B. Bhargava, Puneet Srivastava, Udayan Sun, Xiameng TI MDCT of endoleaks following endovascular repair of abdominal aortic aneurysms SO CLINICAL IMAGING LA English DT Article DE EVAR; AAA; MDCT; Aneurysm; Endoleak ID CT ANGIOGRAPHY; STENT-GRAFT; HELICAL CT; SURVEILLANCE; ENDOTENSION; MORTALITY; THERAPY; RUPTURE; DISEASE AB Endovascular aneurysm repair has been used to repair abdominal aortic aneurysms but necessitates surveillance to diagnose the delayed possibility of endoleak formation. Multi-detector computer tomography (MDCT) of the abdomen is one imaging technique used to diagnose enlargement of the aneurysm sac that may be indicative of endoleaks. MDCT has a role in identifying the initial endoleak formation and providing signs suggestive of the specific endoleak subtype; thus it is necessary for radiologists to be familiar with the findings of endoleak seen on MDCT. In this pictorial review, we explore the various types of endoleaks and their appearance on MDCT. (C) 2015 Elsevier Inc. All rights reserved. C1 [Heller, Matthew T.; Srivastava, Udayan; Sun, Xiameng] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA 15213 USA. [Shah, Amar B.] Westchester Cty Med Ctr, Dept Radiol, Valhalla, NY 10595 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Radiol S114, Seattle, WA 98108 USA. RP Srivastava, U (reprint author), Univ Pittsburgh, Sch Med, Dept Radiol, 200 Lothrop St,Suite 3950,PUH S Tower, Pittsburgh, PA 15213 USA. EM uds4@pitt.edu OI Bhargava, Puneet/0000-0002-3849-9666 NR 43 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD MAY-JUN PY 2015 VL 39 IS 3 BP 367 EP 373 DI 10.1016/j.clinimag.2015.01.004 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA CG9VT UT WOS:000353668900005 PM 25660322 ER PT J AU Murray, DE Durazzo, TC Mon, A Schmidt, TP Meyerhoff, DJ AF Murray, Donna E. Durazzo, Timothy C. Mon, Anderson Schmidt, Thomas P. Meyerhoff, Dieter J. TI Brain perfusion in polysubstance users: Relationship to substance and tobacco use, cognition, and self-regulation SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE MRI; Perfusion; Blood flow; Polysubstance; Alcohol; Smoking ID CEREBRAL-BLOOD-FLOW; ALCOHOL-DEPENDENT INDIVIDUALS; CHRONIC CIGARETTE-SMOKING; EMISSION COMPUTERIZED-TOMOGRAPHY; NATIONAL EPIDEMIOLOGIC SURVEY; BARRATT IMPULSIVENESS SCALE; TERM ABSTINENT ALCOHOLICS; DSM-IV ALCOHOL; DECISION-MAKING; PREFRONTAL CORTEX AB Background: Brain perfusion is altered in both alcohol dependence and stimulant dependence. Although most substance users also abuse/depend on alcohol concurrently (polysubstance users; PSU), rigorous perfusion research in PSU is limited. Also, the relationships of perfusion abnormalities with cognition, impulsivity, or decision making are not well known. Methods: Arterial spin labeling MRI and neuropsychological measures assessed perfusion levels and neurocognition in 20 alcohol-dependent individuals with comorbid-stimulant dependence (PSU), 26 individuals dependent on alcohol only (ALC), and 31 light/non-drinking controls (LD). The patient groups included smokers and non-smokers. Results: ALC had lower perfusion than LD in subcortical and cortical brain regions including the brain reward/executive oversight system (BREOS). Contrary to our hypothesis, regional perfusion was generally not lower in PSU than ALC. However, smoking PSU had lower perfusion than smoking ALC in several regions, including BREOS. Lower BREOS perfusion related to greater drinking severity in smoking substance users and to greater smoking severity in smoking ALC. Lower regional perfusion in ALC and PSU correlated with worse performance in different cognitive domains; smoking status affected perfusion-cognition relationships in ALC only. Lower BREOS perfusion in both substance using groups related to higher impulsivity. Conclusion: Although regional perfusion was not decreased in PSU as a group, the combination of cigarette smoking and polysubstance use is strongly related to hypoperfusion in important cortical and subcortical regions. As lower perfusion relates to greater smoking severity, worse cognition and higher impulsivity, smoking cessation is warranted for treatment-seeking PSU and ALC. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Murray, Donna E.; Durazzo, Timothy C.; Schmidt, Thomas P.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA. [Murray, Donna E.; Durazzo, Timothy C.; Schmidt, Thomas P.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Mon, Anderson] Koforidua Polytech, Sch Appl Sci & Stat, Koforidua, Ghana. RP Murray, DE (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM donna.murray@ucsf.edu FU National Institutes of Health [AA10788, DA025202, DA24136] FX This work was supported by grants AA10788, DA025202 (both to DJM) and DA24136 (to TCD) from the National Institutes of Health and by the use of resources at the SFVA Medical Center. The research has been administered by the Northern California Institute for Research and Education. Apart from funding, the centers did not contribute to this research or to the manuscript preparation. NR 80 TC 2 Z9 3 U1 2 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAY 1 PY 2015 VL 150 BP 120 EP 128 DI 10.1016/j.drugalcdep.2015.02.022 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA CG8YF UT WOS:000353600900016 PM 25772434 ER PT J AU Chen, YT Brennan-Minnella, AM Sheth, S El-Benna, J Swanson, RA AF Chen, Yanting Brennan-Minnella, Angela M. Sheth, Sunil El-Benna, Jamel Swanson, Raymond A. TI Tat-NR2B9c prevents excitotoxic neuronal superoxide production SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE DNA damage; glutamate; ischemia; nitric oxide; oxidative stress; stroke ID NMDA RECEPTOR ACTIVATION; NITRIC-OXIDE; NADPH OXIDASE; PROTEIN INTERACTIONS; MICE; NEUROPROTECTION; NEUROTOXICITY AB The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c is designed to prevent nitric oxide (NO) production by preventing postsynaptic density protein 95 (PSD-95) binding to N-methyl-D-aspartate (NMDA) receptors and neuronal nitric oxide synthase; however, PSD-95 is a scaffolding protein that also couples NMDA receptors to other downstream effects. Here, using neuronal cultures, we show that Tat-NR2B9c also prevents NMDA-induced activation of neuronal NADPH oxidase, thereby blocking superoxide production. Given that both superoxide and NO are required for excitotoxic injury, the neuroprotective effect of Tat-NR2B9c may alternatively be attributable to uncoupling neuronal NADPH oxidase from NMDA receptor activation. C1 [Chen, Yanting] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Neurol, Nanjing 210008, Jiangsu, Peoples R China. [Chen, Yanting; Brennan-Minnella, Angela M.; Sheth, Sunil; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. [El-Benna, Jamel] CNRS, Ctr Rech Inflammat Paris, INSERM, U1149,ERL8252, Paris, France. [El-Benna, Jamel] Univ Paris Diderot, Lab Excellence Inflamex, Sorbonne Paris Cite, Paris, France. RP Swanson, RA (reprint author), SFVAMC, Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM raymond.swanson@ucsf.edu FU US National Institutes of Health [NS081149]; Department of Veterans Affairs; China Scholarship Council FX This work was supported by the US National Institutes of Health (NS081149, RAS); Department of Veterans Affairs (RAS); and the China Scholarship Council (YC). NR 17 TC 6 Z9 6 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD MAY PY 2015 VL 35 IS 5 BP 739 EP 742 DI 10.1038/jcbfm.2015.16 PG 4 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA CH1GK UT WOS:000353769100006 PM 25669908 ER PT J AU Wald, HL Leykum, LK Mattison, MLP Vasilevskis, EE Meltzer, DO AF Wald, Heidi L. Leykum, Luci K. Mattison, Melissa L. P. Vasilevskis, Eduard E. Meltzer, David O. TI A Patient-Centered Research Agenda for the Care of the Acutely Ill Older Patient SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review ID MECHANICALLY VENTILATED PATIENTS; INAPPROPRIATE MEDICATION USE; GENERAL-HOSPITAL INPATIENTS; FACULTY-DEVELOPMENT PROGRAM; IMPROVE TRANSITIONAL CARE; DEPRESSIVE SYMPTOMS; COGNITIVE IMPAIRMENT; GERIATRICS EDUCATION; NURSING FACILITIES; MANAGEMENT PROGRAM AB Hospitalists and others acute-care providers are limited by gaps in evidence addressing the needs of the acutely ill older adult population. The Society of Hospital Medicine sponsored the Acute Care of Older Patients Priority Setting Partnership to develop a research agenda focused on bridging this gap. Informed by the Patient-Centered Outcomes Research Institute framework for identification and prioritization of research areas, we adapted a methodology developed by the James Lind Alliance to engage diverse stakeholders in the research agenda setting process. The work of the Partnership proceeded through 4 steps: convening, consulting, collating, and prioritizing. First, the steering committee convened a partnership of 18 stakeholder organizations in May 2013. Next, stakeholder organizations surveyed members to identify important unanswered questions in the acute care of older persons, receiving 1299 responses from 580 individuals. Finally, an extensive and structured process of collation and prioritization resulted in a final list of 10 research questions in the following areas: advanced-care planning, care transitions, delirium, dementia, depression, medications, models of care, physical function, surgery, and training. With the changing demographics of the hospitalized population, a workforce with limited geriatrics training, and gaps in evidence to inform clinical decision making for acutely ill older patients, the identified research questions deserve the highest priority in directing future research efforts to improve care for the older hospitalized patient and enrich training. Journal of Hospital Medicine 2015;10:318-327. (c) 2015 Society of Hospital Medicine C1 [Wald, Heidi L.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Mattison, Melissa L. P.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Sect Hosp Med, Boston, MA 02215 USA. [Vasilevskis, Eduard E.] Vanderbilt Univ, Sch Med, Sect Hosp Med, Div Gen Internal Med & Publ Hlth, Nashville, TN 37212 USA. [Vasilevskis, Eduard E.] Vanderbilt Univ, Sch Med, Ctr Qual Aging, Nashville, TN 37212 USA. [Vasilevskis, Eduard E.] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Meltzer, David O.] Univ Chicago, Dept Med, Sect Hosp Med, Chicago, IL 60637 USA. RP Wald, HL (reprint author), 13199 E Montview Blvd,Suite 400, Aurora, CO 80045 USA. EM heidi.wald@ucdenver.edu RI Meltzer, David/C-2926-2009 OI Meltzer, David/0000-0003-2790-7393 FU Association of Specialty Professors/American Society of Internal Medicine; John A. Hartford Foundation; National Institute on Aging of the National Institutes of Health [K23AG040157]; Veterans Affairs Clinical Research Center of Excellence; Geriatric Research, Education and Clinical Center (GRECC) FX This work was supported by the Association of Specialty Professors/American Society of Internal Medicine and the John A. Hartford Foundation. Dr. Vasilevskis was supported by the National Institute on Aging of the National Institutes of Health under award number K23AG040157 and the Veterans Affairs Clinical Research Center of Excellence, and the Geriatric Research, Education and Clinical Center (GRECC). Dr. Vasilevskis' institution receives grant funding for an aspect of submitted work. Dr. Meltzer is a PCORI Methodology Committee member. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans' Affairs. The authors report no conflicts of interest. NR 106 TC 1 Z9 1 U1 9 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD MAY PY 2015 VL 10 IS 5 BP 318 EP 327 DI 10.1002/jhm.2356 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CH3IV UT WOS:000353925100009 PM 25877486 ER PT J AU Bath, E Pope, K Ijadi-Maghsoodi, R Thomas, C AF Bath, Eraka Pope, Kayla Ijadi-Maghsoodi, Roya Thomas, Christopher TI Juvenile Life Without Parole: Updates on Legislative and Judicial Trends and on Facilitating Fair Sentencing SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article C1 [Bath, Eraka] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Pope, Kayla] Creighton Univ, Med Ctr, CHI Hlth, Boys Town Natl Res Hosp, Omaha, NE USA. [Pope, Kayla] Univ Nebraska Med Ctr, Omaha, NE USA. [Ijadi-Maghsoodi, Roya] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Thomas, Christopher] Univ Texas Med Branch, Galveston, TX 77555 USA. RP Bath, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Child Forens Serv, 300 Med Plaza,Room 1243, Los Angeles, CA 90024 USA. EM ebath@mednet.ucla.edu FU Office of Academic Affiliations through the VA Advanced Fellowship Program in Women's Health FX Dr Ijadi-Maghsoodi is supported by the Office of Academic Affiliations through the VA Advanced Fellowship Program in Women's Health. NR 5 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD MAY PY 2015 VL 54 IS 5 BP 343 EP 347 DI 10.1016/j.jaac.2015.02.011 PG 5 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA CG9WE UT WOS:000353670000002 PM 25901768 ER PT J AU Tardif, S Ross, C Bergman, P Fernandez, E Javors, M Salmon, A Spross, J Strong, R Richardson, A AF Tardif, Suzette Ross, Corinna Bergman, Phillip Fernandez, Elizabeth Javors, Marty Salmon, Adam Spross, Jennifer Strong, Randy Richardson, Arlan TI Testing Efficacy of Administration of the Antiaging Drug Rapamycin in a Nonhuman Primate, the Common Marmoset SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Rapamycin; mTOR; Marmoset; Nonhuman primate ID GENETICALLY HETEROGENEOUS MICE; EXTENDS LIFE-SPAN AB This report is the first description of dosing procedures, pharmacokinetics, biochemical action, and general tolerability of the antiaging drug rapamycin in the common marmoset, a small and short-lived monkey. Eudragit-encapsulated rapamycin was given orally to trained marmosets in a short-term (3 weeks) and a long-term (14 months) study. Circulating trough rapamycin levels (mean = 5.2 ng/mL; 1.93-10.73 ng/mL) achieved at roughly 1.0 mg/kg/day was comparable to those reported in studies of rodents and within the therapeutic range for humans. Long-term treated animals (6/8) indicated a reduction in mammalian target of rapamycin complex 1 signaling as noted by a decrease in the phospho rpS6 to total rpS6 ratio after 2 weeks of treatment. All long-term treated subjects had detectable concentrations of rapamycin in liver (4.7-19.9 pg/mg) and adipose tissue (2.2-32.8 pg/mg) with reduced mammalian target of rapamycin signaling in these tissues. There was no evidence of clinical anemia, fibrotic lung changes, or mouth ulcers. The observed death rate in the long-term study was as expected given the animals' ages. The ability to rapidly and reliably dose socially housed marmosets with an oral form of rapamycin that is well tolerated and that demonstrates a suppression of the mammalian target of rapamycin pathway leads us to conclude that this species offers a viable model for rapamycin testing to establish safety and efficacy for long-term antiaging intervention. C1 [Tardif, Suzette; Ross, Corinna; Bergman, Phillip; Fernandez, Elizabeth; Javors, Marty; Salmon, Adam; Spross, Jennifer; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Tardif, Suzette] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA. [Ross, Corinna; Strong, Randy] Texas A&M San Antonio, Dept Arts & Sci, San Antonio, TX USA. [Fernandez, Elizabeth; Salmon, Adam] South Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. [Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA. [Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Tardif, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM tardif@uthscsa.edu FU Barshop Institute for Longevity Aging Studies; Glenn Foundation; San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging FX This research was financially supported by the Barshop Institute for Longevity & Aging Studies, the Glenn Foundation, and the San Antonio Nathan Shock Center of Excellence in the Basic Biology of Aging. NR 19 TC 9 Z9 9 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2015 VL 70 IS 5 BP 577 EP 587 DI 10.1093/gerona/glu101 PG 11 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CH3AX UT WOS:000353899100005 PM 25038772 ER PT J AU Chen, DS Betz, J Yaffe, K Ayonayon, HN Kritchevsky, S Martin, KR Harris, TB Purchase-Helzner, E Satterfield, S Xue, QL Pratt, S Simonsick, EM Lin, FR AF Chen, David S. Betz, Joshua Yaffe, Kristine Ayonayon, Hilsa N. Kritchevsky, Stephen Martin, Kathryn R. Harris, Tamara B. Purchase-Helzner, Elizabeth Satterfield, Suzanne Xue, Qian-Li Pratt, Sheila Simonsick, Eleanor M. Lin, Frank R. CA Hlth ABC Study TI Association of Hearing Impairment with Declines in Physical Functioning and the Risk of Disability in Older Adults SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Physical function; Physical performance; Epidemiology ID LOWER-EXTREMITY FUNCTION; GAIT SPEED DECLINE; PERFORMANCE BATTERY; BODY-COMPOSITION; UNITED-STATES; SUBSEQUENT DISABILITY; VESTIBULAR FUNCTION; PROGNOSTIC VALUE; HEALTH; SURVIVAL AB Background: Identifying factors associated with functional declines in older adults is important given the aging of the population. We investigated if hearing impairment is independently associated with objectively measured declines in physical functioning in a community-based sample of older adults. Methods: Prospective observational study of 2,190 individuals from the Health, Aging, and Body Composition study. Participants were followed annually for up to 11 visits. Hearing was measured with pure-tone audiometry. Physical functioning and gait speed were measured with the Short Physical Performance Battery (SPPB). Incident disability and requirement for nursing care were assessed semiannually through self-report. Results: In a mixed-effects model, greater hearing impairment was associated with poorer physical functioning. At both Visit 1 and Visit 11, SPPB scores were lower in individuals with mild (10.14 [95% CI 10.04-10.25], p < .01; 7.35 [95% CI 7.12-7.58], p < .05) and moderate or greater hearing impairment (10.04 [95% CI 9.90-10.19], p < .01; 7.00 [95% CI 6.69-7.32], p < .01) than scores in normal hearing individuals (10.36 [95% CI 10.26-10.46]; 7.71 [95% CI 7.49-7.92]). We observed that women with moderate or greater hearing impairment had a 31% increased risk of incident disability (Hazard ratio [HR] = 1.31 [95% CI 1.08-1.60], p < .01) and a 31% increased risk of incident nursing care requirement (HR = 1.31 [95% CI 1.05-1.62], p = .02) compared to women with normal hearing. Conclusions: Hearing impairment is independently associated with poorer objective physical functioning in older adults, and a 31% increased risk for incident disability and need for nursing care in women. C1 [Chen, David S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Chen, David S.; Betz, Joshua; Xue, Qian-Li; Lin, Frank R.] Johns Hopkins Med Inst, Ctr Aging & Hlth, Baltimore, MD 21205 USA. [Yaffe, Kristine; Ayonayon, Hilsa N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kritchevsky, Stephen] Wake Forest Sch Med, Sticht Ctr Aging, Winston Salem, NC USA. [Martin, Kathryn R.; Harris, Tamara B.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Martin, Kathryn R.; Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Martin, Kathryn R.] Univ Aberdeen, Sch Med & Dent, Epidemiol Grp, Aberdeen, Scotland. [Purchase-Helzner, Elizabeth] Suny Downstate Med Ctr, Dept Epidemiol & Biostat, Brooklyn, NY 11203 USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Xue, Qian-Li] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Pratt, Sheila] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Pratt, Sheila] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA. [Lin, Frank R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Lin, FR (reprint author), Johns Hopkins Ctr Aging & Hlth, 2024 Monument St,Suite 2-700, Baltimore, MD 21287 USA. EM flin1@jhmi.edu OI Betz, Joshua/0000-0003-4488-9799 FU NIH [K23DC011279]; Eleanor Schwartz Charitable Foundation; Triological Society/American College of Surgeons; National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01NR012459]; NIH, National Institute on Aging FX This manuscript was supported in part by NIH K23DC011279, the Eleanor Schwartz Charitable Foundation, and a Triological Society/American College of Surgeons Clinician Scientist Award, as well as National Institute on Aging (NIA) Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant R01-AG028050, NINR grant R01NR012459, and the Intramural Research Program of the NIH, National Institute on Aging. NR 44 TC 14 Z9 15 U1 6 U2 17 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2015 VL 70 IS 5 BP 654 EP 661 DI 10.1093/gerona/glu207 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA CH3AX UT WOS:000353899100016 PM 25477427 ER PT J AU Wipf, JE AF Wipf, Joyce E. TI Women's Health Preface SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Editorial Material C1 Univ Washington, VA Puget Sound Hlth Care Syst, Seattle VA Ctr Excellence Primary Care Educ, Seattle, WA 98108 USA. RP Wipf, JE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle VA Ctr Excellence Primary Care Educ, 1660 South Columbian Way Mailstop S-123-COE, Seattle, WA 98108 USA. EM jwipf@uw.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP XVII EP XVIII DI 10.1016/j.mcna.2015.03.001 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700002 PM 25841608 ER PT J AU Evans, G Sutton, EL AF Evans, Ginger Sutton, Eliza L. TI Oral Contraception SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Oral contraception; Ethinyl estradiol; Levonorgestrel; Venous thromboembolism; Medical eligibility criteria ID COMBINED HORMONAL CONTRACEPTIVES; RANDOMIZED-CONTROLLED-TRIAL; POLYCYSTIC-OVARY-SYNDROME; UNITED-STATES; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; POSTPARTUM CONTRACEPTION; ETHINYL ESTRADIOL; FAMILY-HISTORY; BREAST-CANCER AB Oral contraception (OC) remains a popular noninvasive, readily reversible approach for pregnancy prevention and, largely off label, for control of acne, hirsutism, dysmenorrhea, irregular menstruation, menorrhagia, and other menstrual-related symptoms. Many OC formulations exist, with generics offering lower cost and comparable efficacy. Certain medical conditions, including hypertension, migraine, breast cancer, and risk of venous thromboembolism (VTE), present contraindications. Blood pressure measurement is the only physical examination or testing needed before prescription. Although no 00 is clearly superior to others, OCs containing the second-generation progestin levonorgestrel have been associated with lower VTE risk than those containing other progestins. C1 [Evans, Ginger] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Sutton, Eliza L.] Univ Washington, Womens Hlth Care Ctr, Seattle, WA 98105 USA. RP Evans, G (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-123 PCC, Seattle, WA 98108 USA. EM gingere@u.washington.edu NR 121 TC 6 Z9 7 U1 2 U2 17 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 479 EP + DI 10.1016/j.mcna.2015.01.004 PG 26 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700005 PM 25841596 ER PT J AU Allen, C Kolehmainen, C AF Allen, Caitlin Kolehmainen, Christine TI Intrauterine Devices and Other Forms of Contraception: Thinking Outside the Pack SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Contraception; Intrauterine devices; Subcutaneous implants; Barrier methods; Emergency contraception ID ACTING REVERSIBLE CONTRACEPTION; EMERGENCY CONTRACEPTION; ULIPRISTAL ACETATE; SEXUAL-BEHAVIOR; TUBAL-LIGATION; UNITED-STATES; VAGINAL RING; WOMEN; RISK; LEVONORGESTREL AB A variety of contraception options are available in addition to traditional combined oral contraceptive pills. Newer long-acting reversible contraceptive (LARC) methods such as intrauterine devices and subcutaneous implants are preferred because they do not depend on patient compliance. They are highly effective and appropriate for most women. Female and male sterilization are other effective but they are irreversible and require counseling to minimize regret. The contraceptive injection, patch, and ring do not require daily administration, but their typical efficacy rates are lower than LARC methods and similar to those for combined oral contraceptive pills. C1 [Allen, Caitlin] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Kolehmainen, Christine] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI 53703 USA. RP Allen, C (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, 5120 MFCB,1685 Highland Ave, Madison, WI 53705 USA. EM callen@uwhealth.org NR 64 TC 0 Z9 0 U1 2 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 505 EP + DI 10.1016/j.mcna.2015.01.005 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700006 PM 25841597 ER PT J AU Takahashi, TA Johnson, KM AF Takahashi, Traci A. Johnson, Kay M. TI Menopause SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Menopause; Hot flashes; Vulvovaginal atrophy; Vasomotor symptoms; Hormone therapy; Estrogen ID CONJUGATED EQUINE ESTROGENS; HEALTH INITIATIVE MEMORY; HYSTERECTOMIZED POSTMENOPAUSAL WOMEN; GLOBAL COGNITIVE FUNCTION; VULVO-VAGINAL ATROPHY; HORMONE-THERAPY; VASOMOTOR SYMPTOMS; MIDLIFE WOMEN; VENOUS THROMBOEMBOLISM; TRANSITION AB Women generally spend the last third of their lifetime in menopause, after their reproductive years have ended. During menopause, women experience a variety of predictable symptoms and conditions related to changes in sex hormone levels and aging. The menopausal transition precedes menopause by several years and is usually characterized by irregularity of the menstrual cycle and by hot flashes and night sweats. After menopause, genitourinary symptoms predominate, including vulvovaginal atrophy and dryness and lower urinary tract symptoms, including urinary frequency, urgency, and nocturia. Hormonal treatment is effective for vasomotor and genitourinary symptoms, but the understanding of its impact on cardiovascular disease, cognitive dysfunction, and depression continues to evolve. C1 [Takahashi, Traci A.; Johnson, Kay M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA. [Takahashi, Traci A.; Johnson, Kay M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Takahashi, TA (reprint author), Univ Washington, Sch Med, Dept Med, 1660 South Columbian Way,S-123 PCC, Seattle, WA 98108 USA. EM traci@u.washington.edu NR 51 TC 10 Z9 13 U1 5 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 521 EP + DI 10.1016/j.mcna.2015.01.006 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700007 PM 25841598 ER PT J AU Gill, SK AF Gill, Sharon K. TI Cardiovascular Risk Factors and Disease in Women SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE ASCVD; Heart disease; Stroke; Risk factors; Women; Prevention ID POLYCYSTIC-OVARY-SYNDROME; DENSITY-LIPOPROTEIN CHOLESTEROL; FORCE RECOMMENDATION STATEMENT; AMERICAN-HEART-ASSOCIATION; EXTENDED-RELEASE NIACIN; BLOOD-PRESSURE; PHYSICAL-ACTIVITY; STATIN THERAPY; ORAL-CONTRACEPTIVES; ATRIAL-FIBRILLATION AB Coronary artery disease and stroke predominantly affect older women as opposed to younger women, but the risk factors that contribute to atherosclerotic cardiovascular disease risk often start in young women. Young women with polycystic ovary syndrome (PCOS), with migraine, and who use oral contraceptive pills (OCPs) have short-term increases in thrombotic complications that can result in coronary events or stroke. Attention should be focused on risk reduction in women of all ages. Screening for and discussing diabetes, hypertension, obesity, smoking, migraine, PCOS, and pregnancy complication history and discussing the pros and cons of hormone and statin medications are part of reducing cardiovascular risk for women. C1 VA Puget Sound, Womens Hlth Program, Seattle, WA 98108 USA. RP Gill, SK (reprint author), VA Puget Sound, Womens Hlth Program, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Sharon.gill@va.gov NR 77 TC 3 Z9 3 U1 1 U2 15 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 535 EP + DI 10.1016/j.mcna.2015.01.007 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700008 PM 25841599 ER PT J AU Beste, LA Bondurant, HC Ioannou, GN AF Beste, Lauren A. Bondurant, Hollye C. Ioannou, George N. TI Prevalence and Management of Chronic Hepatitis C Virus Infection in Women SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Viral hepatitis; Women; Pregnancy; Antiviral therapy ID GENOTYPE 1 INFECTION; TREATMENT-NAIVE PATIENTS; INTERFERON-ALPHA 2A; PEGYLATED INTERFERON; NATURAL-HISTORY; PLUS RIBAVIRIN; UNITED-STATES; RISK-FACTORS; PERINATAL TRANSMISSION; FIBROSIS PROGRESSION AB Hepatitis C virus (HCV) is the most common blood-borne pathogen in the United States and is a leading cause of cirrhosis, need for liver transplantation, and liver-related mortality in women. Women should be offered testing if they fall in a high-risk group for exposure. Compared to men, women have higher rates of spontaneous HCV clearance after exposure and slower progression to cirrhosis but are more susceptible to liver damage from comorbid alcohol use. Premenopausal women with HCV should be counseled about the risks of antiviral treatment during pregnancy and the potential for vertical transmission of HCV to their offspring. C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Primary Care Serv, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Beste, Lauren A.] Univ Washington, Dept Internal Med, Div Gen Internal Med, Seattle, WA 98195 USA. [Bondurant, Hollye C.] VA Puget Sound Hlth Care Syst, Serv Pharm, Seattle, WA 98108 USA. [Ioannou, George N.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98108 USA. [Ioannou, George N.] Univ Washington, Dept Internal Med, Div Gastroenterol, Seattle, WA 98195 USA. RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, Primary Care Serv, Hlth Serv Res & Dev, 1660 South Columbian Way,5-111 GI, Seattle, WA 98108 USA. EM Lauren.beste@va.gov NR 49 TC 2 Z9 2 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 575 EP + DI 10.1016/j.mcna.2015.01.009 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700010 PM 25841601 ER PT J AU Golob, AL Laya, MB AF Golob, Anna L. Laya, Mary B. TI Osteoporosis Screening, Prevention, and Management SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Osteoporosis; Osteopenia; Fragility fractures; Prevention; Screening; Management ID SERVICES TASK-FORCE; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VITAMIN-D; RANDOMIZED-TRIAL; RECOMMENDATION STATEMENT; CALCIUM SUPPLEMENTATION; VERTEBRAL FRACTURE; SALMON-CALCITONIN; RISK AB Osteoporosis is characterized by low bone mineral density (BMD) and abnormal bone architecture. Common fracture sites are vertebrae, proximal femur, and distal forearm. Osteoporosis is underdiagnosed and undertreated. All women 65 and older should be screened. Consider screening younger postmenopausal women with elevated risk. Osteoporosis is diagnosed based on T score or a fragility fracture. Women with osteoporosis or who have a 10-year risk of any major fracture of 20% or hip fracture of 3% should be evaluated for causes of low bone density and treated with an osteoporosis-specific medication, lifestyle interventions, and calcium and vitamin D intake. C1 [Golob, Anna L.] Univ Washington, Dept Med, Div Gen Internal Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Laya, Mary B.] Univ Washington, Gen Internal Med Ctr, UW Med Ctr, Div Gen Internal Med,Dept Med, Seattle, WA 98105 USA. RP Golob, AL (reprint author), Univ Washington, Dept Med, Div Gen Internal Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Anna.Golob@va.gov NR 49 TC 24 Z9 29 U1 7 U2 39 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 587 EP + DI 10.1016/j.mcna.2015.01.010 PG 21 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700011 PM 25841602 ER PT J AU Levander, XA Overland, MK AF Levander, Ximena A. Overland, Maryann K. TI Care of Women Veterans SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Women veterans; Military cultural competency; Functional gastrointestinal disorders; Chronic pain syndromes; Post-traumatic stress disorder; Military sexual trauma; Veteran homelessness ID POSTTRAUMATIC-STRESS-DISORDER; IRRITABLE-BOWEL-SYNDROME; MILITARY SEXUAL TRAUMA; HEALTH-STATUS; PREVALENCE; RISK; FEMALE; HOMELESSNESS; ASSOCIATION; SYMPTOMS AB As more women have joined the US military, there has been a shift in the overall veteran population. Those who served in the US military, especially women, have undergone experiences that will impact their overall health and wellbeing. It is therefore critical for providers to better understand US military culture and be prepared on how to ask patients about their military experience. Health care providers need to be aware of the unique medical, psychiatric, and psychosocial needs of women veterans in order to best serve this patient population. C1 [Levander, Ximena A.; Overland, Maryann K.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Levander, XA (reprint author), 1959 Northeast Pacific St,Box 356421, Seattle, WA 98195 USA. EM Ximena@u.washington.edu NR 36 TC 4 Z9 4 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 651 EP + DI 10.1016/j.mcna.2015.01.013 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700014 PM 25841605 ER PT J AU Callegari, LS Ma, EW Schwarz, EB AF Callegari, Lisa S. Ma, Erica W. Schwarz, Eleanor Bimla TI Preconception Care and Reproductive Planning in Primary Care SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Preconception care; Reproductive life plan; Reproductive planning; Reproductive-aged women; Primary care ID GESTATIONAL DIABETES-MELLITUS; LIFE-STYLE INTERVENTIONS; LOW-BIRTH-WEIGHT; BODY-MASS INDEX; HEALTH-CARE; CLINICAL CONTENT; UNITED-STATES; SPONTANEOUS-ABORTIONS; CONGENITAL-ANOMALIES; BARIATRIC SURGERY AB Preconception care is designed to identify and reduce biomedical, behavioral, and social risks to the health of a woman or her baby before pregnancy occurs. Few women present requesting preconception care; however, 1 in 10 US women of childbearing age will become pregnant each year. As primary care physicians (PCPs) care for reproductive-aged women before, between, and after their pregnancies, they are ideally positioned to help women address health risks before conception, including optimizing chronic conditions, to prevent adverse pregnancy and longer-term health outcomes. PCPs can help women make informed decisions both about preparing for pregnancy and about using effective contraception when pregnancy is not desired. C1 [Callegari, Lisa S.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Callegari, Lisa S.; Ma, Erica W.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev HSR&D, Seattle, WA 98108 USA. [Schwarz, Eleanor Bimla] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA. RP Callegari, LS (reprint author), Univ Washington, Dept Vet Affairs, Hlth Serv Res & Dev HSR&D, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM lcallega@uw.edu FU VA Health Services Research and Development Postdoctoral Fellowship [TPM 61-041] FX L.S. Callegari was supported by a VA Health Services Research and Development Postdoctoral Fellowship (TPM 61-041). NR 97 TC 2 Z9 2 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAY PY 2015 VL 99 IS 3 BP 663 EP + DI 10.1016/j.mcna.2015.01.014 PG 21 WC Medicine, General & Internal SC General & Internal Medicine GA CG9VH UT WOS:000353667700015 PM 25841606 ER PT J AU Caruana, I Savoldo, B Hoyos, V Weber, G Liu, H Kim, ES Ittmann, MM Marchetti, D Dotti, G AF Caruana, Ignazio Savoldo, Barbara Hoyos, Valentina Weber, Gerrit Liu, Hao Kim, Eugene S. Ittmann, Michael M. Marchetti, Dario Dotti, Gianpietro TI Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes SO NATURE MEDICINE LA English DT Article ID METASTATIC BREAST-CANCER; ANTIGEN RECEPTOR; GENE-EXPRESSION; SULFATE; CELLS; GROWTH; MATRIX; ENDOGLYCOSIDASE; PROTEOGLYCANS; TRANSCRIPTION AB Adoptive transfer of chimeric antigen receptor (CAR)-redirected T lymphocytes (CAR-T cells) has had less striking therapeutic effects in solid tumors(1-3) than in lymphoid malignancies(4,5). Although active tumor-mediated immunosuppression may have a role in limiting the efficacy of CAR-T cells(6), functional changes in T lymphocytes after their ex vivo manipulation may also account for the reduced ability of cultured CAR-T cells to penetrate stroma-rich solid tumors compared with lymphoid tissues. We therefore studied the capacity of human in vitro-cultured CAR-T cells to degrade components of the extracellular matrix (ECM). In contrast to freshly isolated T lymphocytes, we found that in vitro-cultured T lymphocytes lack expression of the enzyme heparanase (HPSE), which degrades heparan sulfate proteoglycans, the main components of ECM. We found that HPSE mRNA is downregulated in in vitro-expanded T cells, which may be a consequence of p53 (officially known as TP53, encoding tumor protein 53) binding to the HPSE gene promoter. We therefore engineered CAR-T cells to express HPSE and showed their improved capacity to degrade the ECM, which promoted tumor T cell infiltration and antitumor activity. The use of this strategy may enhance the activity of CAR-T cells in individuals with stroma-rich solid tumors. C1 [Caruana, Ignazio; Savoldo, Barbara; Hoyos, Valentina; Weber, Gerrit; Dotti, Gianpietro] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Caruana, Ignazio; Savoldo, Barbara; Hoyos, Valentina; Weber, Gerrit; Dotti, Gianpietro] Houston Methodist Hosp, Houston, TX USA. [Savoldo, Barbara] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Liu, Hao] Baylor Coll Med, Biostat Shared Resource, Houston, TX 77030 USA. [Kim, Eugene S.] Texas Childrens Hosp, Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. [Ittmann, Michael M.; Marchetti, Dario; Dotti, Gianpietro] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Ittmann, Michael M.] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA. [Ittmann, Michael M.] Michael E DeBakey Dept Vet Affairs Med Ctr, Dan L Duncan Canc Ctr, Houston, TX USA. [Dotti, Gianpietro] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Dotti, G (reprint author), Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. EM gdotti@bcm.edu OI Caruana, Ignazio/0000-0002-9250-0605 FU US National Institutes of Health-National Cancer Institute [R01 CA142636]; Department of Defense; Technology and Therapeutic Development Award [W81XWH-10-10425] FX The authors would like to thank I. Vlodavsky and M. Brenner for the critical review of the manuscript and C. Gillespie for editing. This work was supported in part by the US National Institutes of Health-National Cancer Institute (G.D., no. R01 CA142636) and by a Department of Defense and Technology and Therapeutic Development Award (G.D., no. W81XWH-10-10425). L. Metelitsa kindly provided the CHLA-255 human NB cell line. NR 37 TC 39 Z9 42 U1 4 U2 31 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD MAY PY 2015 VL 21 IS 5 BP 524 EP U158 DI 10.1038/nm.3833 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA CH5IL UT WOS:000354068800022 PM 25849134 ER PT J AU Srinivasan, R Huang, BS Venugopal, S Johnston, AD Chai, H Zeng, HK Golshani, P Khakh, BS AF Srinivasan, Rahul Huang, Ben S. Venugopal, Sharmila Johnston, April D. Chai, Hua Zeng, Hongkui Golshani, Peyman Khakh, Baljit S. TI Ca2+ signaling in astrocytes from Ip3r2(-/-) mice in brain slices and during startle responses in vivo SO NATURE NEUROSCIENCE LA English DT Article ID NEURONAL-ACTIVITY; VISUAL-CORTEX; HIPPOCAMPAL ASTROCYTES; RECEPTOR ACTIVATION; CORTICAL ASTROCYTES; SYNAPTIC ACTIVITY; BEHAVIOR; MODULATION; PLASTICITY; GLIA AB Intracellular Ca2+ signaling is considered to be important for multiple astrocyte functions in neural circuits. However, mice devoid of inositol triphosphate type 2 receptors (IP3R2) reportedly lack all astrocyte Ca2+ signaling, but display no neuronal or neurovascular deficits, implying that astrocyte Ca2+ fluctuations are not involved in these functions. An assumption has been that the loss of somatic Ca2+ fluctuations also reflects a similar loss in astrocyte processes. We tested this assumption and found diverse types of Ca2+ fluctuations in astrocytes, with most occurring in processes rather than in somata. These fluctuations were preserved in Ip3r2(-/-) (also known as Itpr2(-/-)) mice in brain slices and in vivo, occurred in end feet, and were increased by G protein-coupled receptor activation and by startle-induced neuromodulatory responses. Our data reveal previously unknown Ca2+ fluctuations in astrocytes and highlight limitations of studies that used Ip3r2(-/-) mice to evaluate astrocyte contributions to neural circuit function and mouse behavior. C1 [Srinivasan, Rahul; Venugopal, Sharmila; Johnston, April D.; Chai, Hua; Khakh, Baljit S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Huang, Ben S.; Golshani, Peyman] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Zeng, Hongkui] Allen Inst Brain Sci, Seattle, WA USA. [Golshani, Peyman] Univ Calif Los Angeles, David Geffen Sch Med, Integrat Ctr Learning & Memory, Los Angeles, CA 90095 USA. [Golshani, Peyman] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Khakh, Baljit S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Khakh, BS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. EM bkhakh@mednet.ucla.edu OI Huang, Ben/0000-0003-2838-6315 FU US National Institutes of Health (NIH) [NS060677]; NIH [MH099559A, MH104069, MH101198-1]; CHDI Foundation; Simon's Foundation Circuits Grant FX The authors are grateful to current and past members of the laboratories for discussions and comments. Thanks also to M.V. Sofroniew for sharing equipment and to J. Chen for sharing mice. Special thanks to M.D. Haustein who helped with the initial testing of GECIquant and made valuable suggestions on its development. We thank C. Octeau for comments on the paper. Most of the work was supported by the US National Institutes of Health (NIH, NS060677). B.S.K., R.S. and S.V. were also supported by NIH grants (MH099559A, MH104069) and the CHDI Foundation. P.G. and B.S.H. were supported by NIH MH101198-1 and a Simon's Foundation Circuits Grant. NR 48 TC 50 Z9 51 U1 4 U2 26 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1097-6256 EI 1546-1726 J9 NAT NEUROSCI JI Nat. Neurosci. PD MAY PY 2015 VL 18 IS 5 BP 708 EP + DI 10.1038/nn.4001 PG 12 WC Neurosciences SC Neurosciences & Neurology GA CG9LN UT WOS:000353636900018 PM 25894291 ER PT J AU Barnett, PG Hamlett-Berry, K Sung, HY Max, W AF Barnett, Paul G. Hamlett-Berry, Kim Sung, Hai-Yen Max, Wendy TI Health Care Expenditures Attributable to Smoking in Military Veterans SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID CIGARETTE-SMOKING; UNITED-STATES; US MILITARY; TOBACCO USE; COSTS; PREVALENCE; BEHAVIOR; CALIFORNIA; SERVICE; IRAQ AB Introduction: The health effects of cigarette smoking have been estimated to account for between 6%-8% of U.S. health care expenditures. We estimated Veterans Health Administration (VHA) health care costs attributable to cigarette smoking. Methods: VHA survey and administrative data provided the number of Veteran enrollees, current and former smoking prevalence, and the cost of 4 types of care for groups defined by age, gender, and region. Cost and smoking status could not be linked at the enrollee level, so we used smoking attributable fractions estimated in sample of U.S. residents where the linkage could be made. Results: The 7.7 million Veterans enrolled in VHA received $40.2 billion in VHA provided health services in 2010. We estimated that $2.7 billion in VHA costs were attributable to the health effects of smoking. This was 7.6% of the $35.3 billion spent on the types of care for which smoking-attributable fractions could be determined. The fraction of inpatient costs that was attributable to smoking (11.4%) was greater than the fraction of ambulatory care cost attributable to smoking (5.3%). More cost was attributable to current smokers ($1.7 billion) than to former smokers ($ 983 million). Conclusions: The fraction of VHA costs attributable to smoking is similar to that of other health care systems. Smoking among Veterans is slowly decreasing, but prevalence remains high in Veterans with psychiatric and substance use disorders, and in younger and female Veterans. VHA has adopted a number of smoking cessation programs that have the potential for reducing future smoking-attributable costs. C1 [Barnett, Paul G.] US Dept Vet Affairs, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Hamlett-Berry, Kim] US Dept Vet Affairs, Publ Hlth Strateg Hlth Care Grp, Washington, DC USA. [Barnett, Paul G.] Univ Calif San Francisco, Treatment Res Ctr, San Francisco, CA 94143 USA. [Sung, Hai-Yen; Max, Wendy] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA. RP Barnett, PG (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152, Menlo Pk, CA 94025 USA. EM paul.barnett@va.gov FU Public Health Strategic Health Care Group; Health Services Research and Development Service of the U.S. Department of Veterans Affairs [ECN 99-017, RRP 11-266] FX This work was supported by funding from the Public Health Strategic Health Care Group and the Health Services Research and Development Service of the U.S. Department of Veterans Affairs, projects ECN 99-017 and RRP 11-266. NR 40 TC 5 Z9 5 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2015 VL 17 IS 5 BP 586 EP 591 DI 10.1093/ntr/ntu187 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CH3CL UT WOS:000353904000010 PM 25239960 ER PT J AU Saladin, ME Wray, JM Carpenter, MJ McClure, EA LaRowe, SD Upadhyaya, HP Gray, KM AF Saladin, Michael E. Wray, Jennifer M. Carpenter, Matthew J. McClure, Erin A. LaRowe, Steven D. Upadhyaya, Himanshu P. Gray, Kevin M. TI Menstrual Cycle Phase Effects in the Gender Dimorphic Stress Cue Reactivity of Smokers SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SMOKING STATUS; QUIT DATE; WITHDRAWAL; DEPENDENCE; NICOTINE; EMOTION; ADULTS; TRIAL; WOMEN; URGES AB Introduction: We previously reported that female smokers evidence greater subjective craving and stress/emotional reactivity to personalized stress cues than males. The present study employed the same dataset to assess whether females in the follicular versus luteal phase of the menstrual cycle accounted for the gender differences. Methods: Two objective criteria, onset of menses and luteinizing hormone surge (evaluated via home testing kits), were used to determine whether female smokers were in either the follicular (n = 22) or the luteal (n = 15) phase of their menstrual cycle, respectively. The females and a sample of male smokers (n = 53) were then administered a laboratory-based cue reactivity paradigm that involved assessment of craving, stress, and emotional reactivity in response to counterbalanced presentations of both a personalized stress script and neutral/relaxed script. Results: While there were no significant differences between females in the follicular versus luteal phase on any outcome measure, females in the luteal menstrual phase reported greater craving than males whereas females in the follicular phase reported greater stress and arousal than males and perceived the stress cues as more emotionally aversive than males. Conclusions: This preliminary investigation suggests that gender differences in craving versus affective responding to stress cues may, in part, be explained variation by menstrual cycle phase. Study limitations and implications of the findings for future research and treatment are briefly discussed. C1 [Saladin, Michael E.; Wray, Jennifer M.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Saladin, Michael E.; Wray, Jennifer M.; Carpenter, Matthew J.; McClure, Erin A.; LaRowe, Steven D.; Gray, Kevin M.] MUSC, Dept Psychiat & Behav Sci, Clin Neurosci Div, Charleston, SC USA. [Carpenter, Matthew J.] MUSC, Hollings Canc Ctr, Charleston, SC USA. [LaRowe, Steven D.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Subst Abuse Treatment Ctr, Charleston, SC USA. [Upadhyaya, Himanshu P.] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Gray, Kevin M.] MUSC, Youth Div, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Saladin, ME (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Room 224,MSC700, Charleston, SC 29425 USA. EM saladinm@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NIDA (Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health (SCOR) [P50 DA016511-11]; South Carolina Clinical & Translational Research (SCTR) Institute; NIH [UL1 RR029882, UL1 TR000062]; Pfizer, Inc. FX This research was supported by NIDA grants P50 DA016511-11 Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health (SCOR PI: K. T. Brady, and SCOR Component 4 PI's: MES and KMG), South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Numbers UL1 RR029882 and UL1 TR000062. Dr. KMG has received research support from Pfizer, Inc. (medication and placebo supply for NIH-funded research). NR 24 TC 2 Z9 2 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD MAY PY 2015 VL 17 IS 5 BP 607 EP 611 DI 10.1093/ntr/ntu203 PG 5 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CH3CL UT WOS:000353904000013 PM 25324432 ER PT J AU Bishwakarma, R Kinney, WH Honda, JR Mya, J Strand, MJ Gangavelli, A Bai, XY Ordway, DJ Iseman, MD Chan, ED AF Bishwakarma, Raju Kinney, William H. Honda, Jennifer R. Mya, Jenny Strand, Matthew J. Gangavelli, Avani Bai, Xiyuan Ordway, Diane J. Iseman, Michael D. Chan, Edward D. TI Epidemiologic link between tuberculosis and cigarette/biomass smoke exposure: Limitations despite the vast literature SO RESPIROLOGY LA English DT Review DE biomass fuel smoke; latent tuberculosis infection; Mycobacterium tuberculosis; tobacco smoke ID INDOOR AIR-POLLUTION; RISK-FACTORS; PULMONARY TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; SOLID-FUEL; ACTIVE TUBERCULOSIS; TOBACCO SMOKING; BIOMASS FUEL; HONG-KONG; ANTITUBERCULOSIS TREATMENT AB The geographic overlap between the prevalence of cigarette smoke (CS) exposure and tuberculosis (TB) in the world is striking. In recent years, relatively large number of studies has linked cigarette or biomass fuel smoke exposure and various aspects of TB. Our goals are to summarize the significance of the known published studies, graphically represent reports that quantified the association and discuss their potential limitations. PubMed searches were performed using the key words tuberculosis' with cigarette', tobacco', smoke' or biomass fuel smoke.' The references of relevant articles were examined for additional pertinent papers. A large number of mostly case-control and cross-sectional studies significantly associate both direct and second-hand smoke exposure with tuberculous infection, active TB, and/or more severe and lethal TB. Fewer link biomass fuel smoke exposure and TB. While a number of studies interpreted the association with multivariate analysis, other confounders are often not accounted for in these analyses. It is also important to emphasize that these retrospective studies can only show an association and not any causal link. We further explored the possibility that even if CS exposure is a risk factor for TB, several mechanisms may be responsible. Numerous studies associate cigarette and biomass smoke exposure with TB but the mechanism(s) remains largely unknown. While the associative link of these two health maladies is well established, more definitive, mechanistic studies are needed to cement the effect of smoke exposure on TB pathogenesis and to utilize this knowledge in empowering public health policies. C1 [Bishwakarma, Raju; Kinney, William H.; Mya, Jenny; Strand, Matthew J.; Gangavelli, Avani; Bai, Xiyuan; Iseman, Michael D.; Chan, Edward D.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. [Bishwakarma, Raju; Kinney, William H.; Mya, Jenny; Strand, Matthew J.; Gangavelli, Avani; Bai, Xiyuan; Iseman, Michael D.; Chan, Edward D.] Natl Jewish Hlth, Dept Acad Affairs, Denver, CO 80206 USA. [Honda, Jennifer R.; Iseman, Michael D.; Chan, Edward D.] Univ Colorado, Div Pulm Sci & Crit Care Med, Denver, CO 80202 USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Ordway, Diane J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Mycobacteria Res Labs, Ft Collins, CO 80523 USA. [Bishwakarma, Raju] Univ Texas Med Branch, Dept Med, Galveston, TX 77555 USA. RP Chan, ED (reprint author), Natl Jewish Hlth, Dept Med, D509,Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 93 TC 3 Z9 3 U1 3 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD MAY PY 2015 VL 20 IS 4 BP 556 EP 568 DI 10.1111/resp.12515 PG 13 WC Respiratory System SC Respiratory System GA CH2XW UT WOS:000353889700008 PM 25808744 ER PT J AU Sibila, O Laserna, E Maselli, DJ Fernandez, JF Mortensen, EM Anzueto, A Waterer, G Restrepo, MI AF Sibila, Oriol Laserna, Elena Maselli, Diego Jose Fernandez, Juan Felipe Mortensen, Eric M. Anzueto, Antonio Waterer, Grant Restrepo, Marcos I. TI Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia SO RESPIROLOGY LA English DT Article DE antibiotic treatment; community-acquired pneumonia; Pseudomonas aeruginosa; risk factor ID VENTILATOR-ASSOCIATED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; CARE-ASSOCIATED PNEUMONIA; GRAM-NEGATIVE BACILLI; PSEUDOMONAS-AERUGINOSA; OUTCOMES; SEVERITY; EXACERBATIONS; METAANALYSIS; MULTICENTER AB Background and objectiveCurrent guidelines recommend empirical treatment against Pseudomonas aeruginosa in community-acquired pneumonia (CAP) patients with specific risk factors. However, evidence to support these recommendations is limited. We evaluate the risk factors and the impact of antimicrobial therapy in patients hospitalized with CAP due to P.aeruginosa. MethodsWe performed a retrospective population-based study of >150 hospitals. Patients were included if they had a diagnosis of CAP and P.aeruginosa was identified as the causative pathogen. Univariate and multivariate analyses were performed using the presence of risk factors and 30-day mortality as the dependent measures. ResultsSeven hundred eighty-one patients with P.aeruginosa pneumonia were identified in a cohort of 62689 patients with pneumonia (1.1%). Of these, 402 patients (0.6%) were included in the study and 379 (0.5%) were excluded due to health care-associated pneumonia or immunosuppression. In patients with CAP due to P.aeruginosa, 272 (67.8%) had no documented risk factors. These patients had higher rates of dementia and cerebrovascular disease. Empirical antibiotic therapy against P.aeruginosa within the first 48h of presentation was independently associated with lower 30-day mortality in patients with CAP due to P.aeruginosa (hazard ratio (HR) 0.42, 95% confidence interval (CI): 0.23-0.76) and in patients without risk factors for P.aeruginosaCAP (HR 0.40, 95% CI: 0.21-0.76). ConclusionsRisk factor recommended by current guidelines only detect one third of the patients admitted with CAP due to P.aeruginosa. Risk factors did not define the whole benefit observed due to empirical therapy covering P.aeruginosa. Risk factors recommended by current guidelines only detect one third of the patients admitted with CAP due to P.aeruginosa.Not administrating antibiotics active against P.aeruginosa in the first 48h increases 30-day mortality. C1 [Sibila, Oriol] Hosp Santa Creu & Sant Pau, Resp Dept, Barcelona, Spain. [Sibila, Oriol] St Pau Biomed Res Inst IIB St Pau, Barcelona, Spain. [Laserna, Elena] Hosp Comarcal Mollet, Mollet Del Valles, Spain. [Sibila, Oriol; Laserna, Elena; Maselli, Diego Jose; Fernandez, Juan Felipe; Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care, San Antonio, TX 78229 USA. [Maselli, Diego Jose; Fernandez, Juan Felipe; Anzueto, Antonio; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Vet Evidence Based Res Disseminat & Implementat C, Med, San Antonio, TX USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Waterer, Grant] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Waterer, Grant] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia. RP Restrepo, MI (reprint author), South Texas Vet Hlth Care Syst ALMD, Vet Evidence Based Res Disseminat & Implementat C, Med, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM restrepom@uthscsa.edu OI Mortensen, Eric/0000-0002-3880-5563 FU National Institute of Nursing Research [R01NR010828]; Instituto de Salud Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia (SOCAP); Fundacio Catalana de Pneumologia (FUCAP); National Heart, Lung, and Blood Institute [K23HL096054] FX The project described was supported by Grant Number R01NR010828 from the National Institute of Nursing Research. Dr Sibila is supported by Instituto de Salud Carlos III (BAE11/00102). Dr Sibila and Dr Laserna are supported by Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), Societat Catalana de Pneumologia (SOCAP) and Fundacio Catalana de Pneumologia (FUCAP). Dr Restrepo's time is partially protected by Award Number K23HL096054 from the National Heart, Lung, and Blood Institute. NR 32 TC 9 Z9 10 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD MAY PY 2015 VL 20 IS 4 BP 660 EP 666 DI 10.1111/resp.12506 PG 7 WC Respiratory System SC Respiratory System GA CH2XW UT WOS:000353889700021 PM 25776134 ER PT J AU Hertzberg, L Katsel, P Roussos, P Haroutunian, V Domany, E AF Hertzberg, L. Katsel, P. Roussos, P. Haroutunian, V. Domany, E. TI Integration of gene expression and GWAS results supports involvement of calcium signaling in Schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE GWAS; Gene expression; Pathway analysis ID GENOME-WIDE ASSOCIATION; MULTIPLE BRAIN-REGIONS; RISK LOCI; IDENTIFICATION; METAANALYSIS; DATABASE AB The number of Genome Wide Association Studies (GWAS) of schizophrenia is rapidly growing. However, the small effect of individual genes limits the number of reliably implicated genes, which are too few and too diverse to perform reliable pathway analysis; hence the biological roles of the genes implicated in schizophrenia are unclear. To overcome these limitations we combine GWAS with genome-wide expression data from human post-mortem brain samples of schizophrenia patients and controls, taking these steps: 1) Identify 36 GWAS-based genes which are expressed in our dataset. 2) Find a cluster of 19 genes with highly correlated expression. We show that this correlation pattern is robust and statistically significant. 3) GO-enrichment analysis of these 19 genes reveals significant enrichment of ion channels and calcium-related processes. This finding (based on analyzing a small number of coherently expressed genes) is validated and enhanced in two ways: First, the emergence of calcium channels and calcium signaling is corroborated by identifying proteins that interact with those encoded by the cluster of 19. Second, extend the 19 cluster genes into 1028 genes, whose expression is highly correlated with the cluster's average profile. When GO-enrichment analysis is performed on this extended set, many schizophrenia related pathways appear, with calcium-related processes enriched with high statistical significance. Our results give further, expression-based validation to GWAS results, support a central role of calcium-signaling in the pathogenesis of schizophrenia, and point to additional pathways potentially related to the disease. (C) 2015 Elsevier B.V. All rights reserved. C1 [Hertzberg, L.; Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-7610001 Rehovot, Israel. [Hertzberg, L.] Tel Aviv Univ, Sackler Fac Med, Shalvata Mental Hlth Ctr, Emot Cognit Res Ctr, IL-69978 Tel Aviv, Israel. [Katsel, P.; Roussos, P.; Haroutunian, V.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Haroutunian, V.] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY USA. RP Domany, E (reprint author), Weizmann Inst Sci, Dept Phys Complex Syst, 234 Herzl St, IL-7610001 Rehovot, Israel. EM Eytan.domany@weizmann.ac.il RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU VA-MIRECC; NIH [MH066392, MH064673]; Leir Charitable Foundation FX The study was funded by VA-MIRECC, NIH MH066392 and MH064673 and the Leir Charitable Foundation. NR 33 TC 6 Z9 6 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2015 VL 164 IS 1-3 BP 92 EP 99 DI 10.1016/j.schres.2015.02.001 PG 8 WC Psychiatry SC Psychiatry GA CG5MX UT WOS:000353337100014 PM 25702973 ER PT J AU Vaez-Azizi, LM Ruby, E Dracxler, R Rothman, K Perrin, M Walsh-Messinger, J Antonius, D Goetz, RR Goetz, DM Keefe, DL Malaspina, D AF Vaez-Azizi, Leila M. Ruby, Eugene Dracxler, Roberta Rothman, Karen Perrin, Mary Walsh-Messinger, Julie Antonius, Daniel Goetz, Raymond R. Goetz, Deborah M. Keefe, David L. Malaspina, Dolores TI Telomere length variability is related to symptoms and cognition in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID AGE C1 [Vaez-Azizi, Leila M.; Ruby, Eugene; Dracxler, Roberta; Rothman, Karen; Antonius, Daniel; Goetz, Raymond R.; Keefe, David L.; Malaspina, Dolores] NYU, Sch Med, Dept Psychiat, Inst Social & Psychiat Initiat InSPIRES, New York, NY USA. [Dracxler, Roberta; Keefe, David L.] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA. [Perrin, Mary; Malaspina, Dolores] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA. [Walsh-Messinger, Julie] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC, Bronx, NY USA. [Walsh-Messinger, Julie] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Antonius, Daniel] SUNY Buffalo, Erie Cty Forens Mental Hlth Serv, Buffalo, NY 14260 USA. [Goetz, Raymond R.] New York State Psychiat Inst & Hosp, Div Clin Phenomenolgy, New York, NY 10032 USA. [Goetz, Deborah M.] New York State Off Mental Hlth, Nathan Kline Inst Psychiat Res, Orangeburg, NY USA. [Malaspina, Dolores] NY State Off Mental Hlth, Creedmoor Psychiat Ctr, Queens Village, NY 11427 USA. RP Vaez-Azizi, LM (reprint author), NYU, Sch Med, Dept Psychiat, 1 Pk Ave,8th Floor,Room 222, New York, NY 10016 USA. EM leila.vaez-azizi@med.nyu.edu; gene12586@gmail.com; roberta.dracxler@nyumc.org; Karen.rothman@nyumc.org; mary.perrin@nyumc.org; juliewmessinger@gmail.com; danantonius@gmail.com; goetzra@nyspi.columbia.edu; dgoetz@nki.rfmh.org; david.keefe@nyumc.org; dolores.malaspina@nyumc.org OI Goetz, Raymond/0000-0002-6797-2547 NR 10 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY PY 2015 VL 164 IS 1-3 BP 268 EP 269 DI 10.1016/j.schres.2015.03.011 PG 2 WC Psychiatry SC Psychiatry GA CG5MX UT WOS:000353337100040 PM 25841297 ER EF